<s> O None
Famotidine I Chemical
-associated I None
delirium I Disease
. I None
<eof> I None

<s> O None
A I None
series I None
of I None
six I None
cases I None
. I None
<eof> I None

<s> O None
Famotidine I Chemical
is I None
a I None
histamine I None
H2-receptor I None
antagonist I None
used I None
in I None
inpatient I None
settings I None
for I None
prevention I None
of I None
stress I None
ulcers I Disease
and I None
is I None
showing I None
increasing I None
popularity I None
because I None
of I None
its I None
low I None
cost I None
. I None
<eof> I None

<s> O None
Although I None
all I None
of I None
the I None
currently I None
available I None
H2-receptor I None
antagonists I None
have I None
shown I None
the I None
propensity I None
to I None
cause I None
delirium I Disease
, I None
only I None
two I None
previously I None
reported I None
cases I None
have I None
been I None
associated I None
with I None
famotidine I Chemical
. I None
<eof> I None

<s> O None
The I None
authors I None
report I None
on I None
six I None
cases I None
of I None
famotidine I Chemical
-associated I None
delirium I Disease
in I None
hospitalized I None
patients I None
who I None
cleared I None
completely I None
upon I None
removal I None
of I None
famotidine I Chemical
. I None
<eof> I None

<s> O None
The I None
pharmacokinetics I None
of I None
famotidine I Chemical
are I None
reviewed I None
, I None
with I None
no I None
change I None
in I None
its I None
metabolism I None
in I None
the I None
elderly I None
population I None
seen I None
. I None
<eof> I None

<s> O None
The I None
implications I None
of I None
using I None
famotidine I Chemical
in I None
elderly I None
persons I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Indomethacin I Chemical
induced I None
<eof> I None

<s> O None
hypotension I Disease
in I None
sodium I Chemical
and I None
volume I None
depleted I None
rats I None
. I None
<eof> I None

<s> O None
After I None
a I None
single I None
oral I None
dose I None
of I None
4 I None
mg I None
/ I None
kg I None
indomethacin I Chemical
<eof> I None

<s> O None
( I None
IDM I Chemical
) I None
to I None
<eof> I None

<s> O None
sodium I Chemical
and I None
volume I None
depleted I None
rats I None
plasma I None
renin I None
activity I None
( I None
PRA I None
) I None
and I None
<eof> I None

<s> O None
systolic I None
blood I None
pressure I None
fell I None
significantly I None
within I None
four I None
hours I None
. I None
<eof> I None

<s> O None
In I None
sodium I Chemical
repleted I None
animals I None
indomethacin I Chemical
did I None
not I None
change I None
systolic I None
blood I None
pressure I None
( I None
BP I None
) I None
although I None
plasma I None
renin I None
activity I None
was I None
decreased I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
indomethacin I Chemical
by I None
inhibition I None
of I None
prostaglandin I Chemical
synthesis I None
may I None
diminish I None
the I None
blood I None
pressure I None
maintaining I None
effect I None
of I None
the I None
stimulated I None
renin- I None
angiotensin I Chemical
system I None
in I None
sodium I Chemical
and I None
volume I None
depletion I None
. I None
<eof> I None

<s> O None
Late I None
- I None
onset I None
<eof> I None

<s> O None
scleroderma I Disease
renal O Disease
crisis O Disease
induced I None
by I None
tacrolimus I Chemical
and I None
prednisolone I Chemical
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
Scleroderma I Disease
renal O Disease
crisis O Disease
<eof> I None

<s> O None
( I None
SRC I Disease
) I None
is I None
a I None
rare I None
complication I None
of I None
systemic I Disease
sclerosis O Disease
<eof> I None

<s> O None
( I None
SSc I Disease
) I None
but I None
can I None
be I None
severe I None
enough I None
to I None
require I None
temporary I None
or I None
permanent I None
renal I None
replacement I None
therapy I None
. I None
<eof> I None

<s> O None
Moderate I None
to I None
high I None
dose I None
corticosteroid I Chemical
use I None
is I None
recognized I None
as I None
a I None
major I None
risk I None
factor I None
for I None
SRC I Disease
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
there I None
have I None
been I None
reports I None
of I None
thrombotic I Disease
microangiopathy O Disease
precipitated I None
by I None
cyclosporine I Chemical
in I None
patients I None
with I None
SSc I Disease
. I None
<eof> I None

<s> O None
In I None
this I None
article I None
, I None
we I None
report I None
a I None
patient I None
with I None
SRC I Disease
induced I None
by I None
tacrolimus I Chemical
and I None
corticosteroids I Chemical
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
work I None
is I None
to I None
call I None
attention I None
to I None
the I None
risk I None
of I None
tacrolimus I Chemical
use I None
in I None
patients I None
with I None
SSc I Disease
. I None
<eof> I None

<s> O None
The I None
risk I None
and I None
associated I None
factors I None
of I None
methamphetamine I Chemical
psychosis I Disease
in I None
methamphetamine I Chemical
-dependent I None
patients I None
in I None
Malaysia I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
study I None
was I None
to I None
determine I None
the I None
risk I None
of I None
lifetime I None
and I None
current I None
<eof> I None

<s> O None
methamphetamine I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
in I None
patients I None
with I None
methamphetamine I Chemical
dependence I None
. I None
<eof> I None

<s> O None
The I None
association I None
between I None
psychiatric I None
co I None
- I None
morbidity I None
and I None
methamphetamine I Chemical
-induced I None
psychosis I Disease
was I None
also I None
studied I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
was I None
a I None
cross I None
- I None
sectional I None
study I None
conducted I None
concurrently I None
at I None
a I None
teaching I None
hospital I None
and I None
a I None
drug I None
rehabilitation I None
center I None
in I None
Malaysia I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
the I None
diagnosis I None
of I None
methamphetamine I Chemical
based I None
on I None
DSM I None
- I None
IV I None
were I None
interviewed I None
using I None
the I None
Mini I None
International I None
Neuropsychiatric I None
Interview I None
( I None
M.I.N.I. I None
) I None
for I None
methamphetamine I Chemical
-induced I None
psychosis I Disease
and I None
other I None
Axis I None
<eof> I None

<s> O None
I I None
psychiatric I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
information I None
on I None
sociodemographic I None
background I None
and I None
drug I None
use I None
history I None
was I None
obtained I None
from I None
interview I None
or I None
medical I None
records I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
292 I None
subjects I None
, I None
47.9 I None
% I None
of I None
the I None
subjects I None
had I None
a I None
past I None
history I None
of I None
psychotic I Disease
symptoms O Disease
and I None
13.0 I None
% I None
of I None
the I None
patients I None
were I None
having I None
current I None
psychotic I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
Co I None
- I None
morbid I None
major I None
depressive I Disease
disorder O Disease
<eof> I None

<s> O None
( I None
OR=7.18 I None
, I None
95 I None
CI=2.612 I None
- I None
19.708 I None
) I None
, I None
bipolar I Disease
disorder O Disease
<eof> I None

<s> O None
( I None
OR=13.807 I None
, I None
95 I None
CI=5.194 I None
- I None
36.706 I None
) I None
, I None
antisocial I Disease
personality O Disease
disorder O Disease
<eof> I None

<s> O None
( I None
OR=12.619 I None
, I None
95 I None
CI=6.702 I None
- I None
23.759 I None
) I None
and I None
heavy I None
methamphetamine I Chemical
uses I None
were I None
significantly I None
associated I None
with I None
lifetime I None
<eof> I None

<s> O None
methamphetamine I Chemical
-induced I None
<eof> I None

<s> O None
psychosis I Disease
after I None
adjusted I None
for I None
other I None
factors I None
. I None
<eof> I None

<s> O None
Major I Disease
depressive O Disease
disorder O Disease
<eof> I None

<s> O None
( I None
OR=2.870 I None
, I None
CI=1.154 I None
- I None
7.142 I None
) I None
and I None
antisocial I Disease
personality O Disease
disorder O Disease
( I None
OR=3.299 I None
, I None
95 I None
CI=1.375 I None
- I None
7.914 I None
) I None
were I None
the I None
only I None
factors I None
associated I None
with I None
current I None
psychosis I Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
There I None
was I None
a I None
high I None
risk I None
of I None
psychosis I Disease
in I None
patients I None
with I None
methamphetamine I Chemical
dependence I None
. I None
<eof> I None

<s> O None
It I None
was I None
associated I None
with I None
co I None
- I None
morbid I None
affective I Disease
disorder O Disease
, I None
antisocial I Disease
personality O Disease
, I None
and I None
heavy I None
methamphetamine I Chemical
use I None
. I None
<eof> I None

<s> O None
It I None
is I None
recommended I None
that I None
all I None
cases I None
of I None
methamphetamine I Chemical
dependence I None
should I None
be I None
screened I None
for I None
psychotic I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
Cerebellar I None
sensory I None
processing I None
alterations I None
impact I None
motor I None
cortical I None
plasticity I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
: I None
clues I None
from I None
dyskinetic I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
plasticity I None
of I None
primary I None
motor I None
cortex I None
( I None
M1 I None
) I None
in I None
patients I None
with I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
and I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
( I None
LIDs I Disease
) I None
is I None
severely I None
impaired I None
. I None
<eof> I None

<s> O None
We I None
recently I None
reported I None
in I None
young I None
healthy I None
subjects I None
that I None
inhibitory I None
cerebellar I None
stimulation I None
enhanced I None
the I None
sensorimotor I None
plasticity I None
of I None
M1 I None
that I None
was I None
induced I None
by I None
paired I None
associative I None
stimulation I None
( I None
PAS I None
) I None
. I None
<eof> I None

<s> O None
This I None
study I None
demonstrates I None
that I None
the I None
deficient I None
sensorimotor I None
M1 I None
plasticity I None
in I None
16 I None
patients I None
with I None
LIDs I Disease
could I None
be I None
reinstated I None
by I None
a I None
single I None
session I None
of I None
real I None
inhibitory I None
cerebellar I None
stimulation I None
but I None
not I None
sham I None
stimulation I None
. I None
<eof> I None

<s> O None
This I None
was I None
evident I None
only I None
when I None
a I None
sensory I None
component I None
was I None
involved I None
in I None
the I None
induction I None
of I None
plasticity I None
, I None
indicating I None
that I None
cerebellar I None
sensory I None
processing I None
function I None
is I None
involved I None
in I None
the I None
resurgence I None
of I None
M1 I None
plasticity I None
. I None
<eof> I None

<s> O None
The I None
benefit I None
of I None
inhibitory I None
cerebellar I None
stimulation I None
on I None
LIDs I Disease
is I None
known I None
. I None
<eof> I None

<s> O None
To I None
explore I None
whether I None
this I None
benefit I None
is I None
linked I None
to I None
the I None
restoration I None
of I None
sensorimotor I None
plasticity I None
of I None
M1 I None
, I None
we I None
conducted I None
an I None
additional I None
study I None
looking I None
at I None
changes I None
in I None
LIDs I Disease
and I None
<eof> I None

<s> O None
PAS I None
- I None
induced I None
plasticity I None
after I None
10 I None
sessions I None
of I None
either I None
bilateral I None
, I None
real I None
inhibitory I None
cerebellar I None
stimulation I None
or I None
sham I None
stimulation I None
. I None
<eof> I None

<s> O None
Only I None
real I None
and I None
not I None
sham I None
stimulation I None
had I None
an I None
antidyskinetic I None
effect I None
and I None
it I None
was I None
paralleled I None
by I None
a I None
resurgence I None
in I None
the I None
sensorimotor I None
plasticity I None
of I None
M1 I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
alterations I None
in I None
cerebellar I None
sensory I None
processing I None
function I None
, I None
occurring I None
secondary I None
to I None
abnormal I None
basal I None
ganglia I None
signals I None
reaching I None
it I None
, I None
may I None
be I None
an I None
important I None
element I None
contributing I None
to I None
the I None
maladaptive I None
sensorimotor I None
plasticity I None
of I None
M1 I None
and I None
the I None
emergence I None
of I None
abnormal I Disease
involuntary O Disease
movements O Disease
. I None
<eof> I None

<s> O None
The I None
function I None
of I None
P2X3 I None
receptor I None
and I None
NK1 I None
receptor I None
antagonists I None
on I None
cyclophosphamide I Chemical
-induced I None
cystitis I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
study I None
is I None
to I None
explore I None
the I None
function I None
of I None
P2X3 I None
and I None
NK1 I None
receptors I None
antagonists I None
on I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYP I Chemical
) I None
-induced I None
<eof> I None

<s> O None
cystitis I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Sixty I None
female I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
rats I None
were I None
randomly I None
divided I None
into I None
three I None
groups I None
. I None
<eof> I None

<s> O None
The I None
rats I None
in I None
the I None
control I None
group I None
were I None
intraperitoneally I None
( I None
i.p I None
. I None
) I None
injected I None
with I None
0.9 I None
% I None
saline I None
( I None
4 I None
ml I None
/ I None
kg I None
) I None
; I None
the I None
rats I None
in I None
the I None
model I None
group I None
were I None
i.p I None
. I None
injected I None
with I None
CYP I Chemical
<eof> I None

<s> O None
( I None
150 I None
mg I None
/ I None
kg I None
) I None
; I None
and I None
the I None
rats I None
in I None
the I None
intervention I None
group I None
were I None
i.p I None
. I None
injected I None
with I None
CYP I Chemical
with I None
subsequently I None
perfusion I None
of I None
bladder I None
with I None
P2X3 I None
and I None
NK1 I None
receptors I None
' I None
antagonists I None
, I None
Suramin I Chemical
and I None
GR I Chemical
82334 O Chemical
. I None
<eof> I None

<s> O None
Spontaneous I None
pain I Disease
behaviors I None
following I None
the I None
administration I None
of I None
CYP I Chemical
were I None
observed I None
. I None
<eof> I None

<s> O None
Urodynamic I None
parameters I None
, I None
bladder I None
pressure I None
- I None
volume I None
curve I None
, I None
maximum I None
voiding I None
pressure I None
( I None
MVP I None
) I None
, I None
and I None
maximum I None
cystometric I None
capacity I None
( I None
MCC I None
) I None
, I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
Pathological I None
changes I None
in I None
bladder I None
tissue I None
were I None
observed I None
. I None
<eof> I None

<s> O None
Immunofluorescence I None
was I None
used I None
to I None
detect I None
the I None
expression I None
of I None
P2X3 I None
and I None
NK1 I None
receptors I None
in I None
bladder I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
treatment I None
increased I None
the I None
spontaneous I None
pain I Disease
behaviors I None
scores I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
bladder I None
instability I None
during I None
urine I None
storage I None
period I None
of I None
model I None
group I None
was I None
significantly I None
higher I None
than I None
intervention I None
group I None
( I None
X(2 I None
) I None
= I None
7.619 I None
, I None
P I None
= I None
0.007 I None
) I None
and I None
control I None
group I None
( I None
X(2 I None
) I None
<eof> I None

<s> O None
= I None
13.755 I None
, I None
P I None
= I None
0.000 I None
) I None
. I None
<eof> I None

<s> O None
MCC I None
in I None
the I None
model I None
group I None
was I None
lower I None
than I None
the I None
control I None
and I None
intervention I None
groups I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Histological I None
changes I None
evident I None
in I None
model I None
and I None
intervention I None
groups I None
rats I None
' I None
bladder I None
included I None
edema I Disease
, I None
vasodilation I None
, I None
and I None
infiltration I None
of I None
inflammatory I None
cells I None
. I None
<eof> I None

<s> O None
In I None
model I None
group I None
, I None
the I None
expression I None
of I None
P2X3 I None
receptor I None
increased I None
in I None
urothelium I None
and I None
suburothelium I None
, I None
and I None
NK1 I None
receptor I None
increased I None
in I None
suburothelium I None
, I None
while I None
the I None
expression I None
of I None
them I None
in I None
intervention I None
group I None
was I None
lower I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
CYP I Chemical
-induced I None
cystitis I Disease
, I None
the I None
expression I None
of I None
P2X3 I None
and I None
NK1 I None
receptors I None
increased I None
in I None
urothelium I None
and/or I None
suburothelium I None
. I None
<eof> I None

<s> O None
Perfusion I None
of I None
bladder I None
with I None
P2X3 I None
and I None
NK1 I None
receptors I None
antagonists I None
ameliorated I None
the I None
bladder I None
function I None
. I None
<eof> I None

<s> O None
Acute I None
hepatitis I Disease
associated I None
with I None
clopidogrel I Chemical
: I None
a I None
case I None
report I None
and I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
induced I None
<eof> I None

<s> O None
hepatotoxicity I Disease
is I None
a I None
common I None
cause I None
of I None
acute I None
hepatitis I Disease
, I None
and I None
the I None
recognition I None
of I None
the I None
responsible I None
drug I None
may I None
be I None
difficult I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
case I None
of I None
clopidogrel I Chemical
-related I None
acute I None
hepatitis I Disease
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
is I None
strongly I None
suggested I None
by I None
an I None
accurate I None
medical I None
history I None
and I None
liver I None
biopsy I None
. I None
<eof> I None

<s> O None
Reports I None
about I None
cases I None
of I None
hepatotoxicity I Disease
due I None
to I None
clopidogrel I Chemical
are I None
increasing I None
in I None
the I None
last I None
few I None
years I None
, I None
after I None
the I None
increased I None
use I None
of I None
this I None
drug I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
we I None
believe I None
that I None
physicians I None
should I None
carefully I None
consider I None
the I None
risk I None
of I None
drug I None
- I None
induced I None
hepatic I Disease
injury O Disease
when I None
clopidogrel I Chemical
is I None
prescribed I None
. I None
<eof> I None

<s> O None
Bortezomib I Chemical
and I None
dexamethasone I Chemical
as I None
salvage I None
therapy I None
in I None
patients I None
with I None
relapsed I None
/ I None
refractory I None
multiple I Disease
myeloma O Disease
: I None
analysis I None
of I None
long I None
- I None
term I None
clinical I None
outcomes I None
. I None
<eof> I None

<s> O None
Bortezomib I Chemical
( I None
bort I Chemical
) I None
- I None
dexamethasone I Chemical
<eof> I None

<s> O None
( I None
dex I Chemical
) I None
is I None
an I None
effective I None
therapy I None
for I None
relapsed I None
/ I None
refractory I None
( I None
R I None
/ I None
R I None
) I None
multiple I Disease
myeloma O Disease
<eof> I None

<s> O None
( I None
MM I Disease
) I None
. I None
<eof> I None

<s> O None
This I None
retrospective I None
study I None
investigated I None
the I None
combination I None
of I None
bort I Chemical
<eof> I None

<s> O None
( I None
1.3 I None
mg I None
/ I None
m(2 I None
) I None
on I None
days I None
1 I None
, I None
4 I None
, I None
8 I None
, I None
and I None
11 I None
every I None
3 I None
weeks I None
) I None
and I None
dex I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
on I None
the I None
day I None
of I None
and I None
the I None
day I None
after I None
bort I Chemical
) I None
as I None
salvage I None
treatment I None
in I None
85 I None
patients I None
with I None
R I None
/ I None
R I None
MM I Disease
after I None
prior I None
autologous I None
stem I None
cell I None
transplantation I None
or I None
conventional I None
chemotherapy I None
. I None
<eof> I None

<s> O None
The I None
median I None
number I None
of I None
prior I None
lines I None
of I None
therapy I None
was I None
2 I None
. I None
<eof> I None

<s> O None
Eighty I None
- I None
seven I None
percent I None
of I None
the I None
patients I None
had I None
received I None
immunomodulatory I None
drugs I None
included I None
in I None
some I None
line I None
of I None
therapy I None
before I None
bort I Chemical
- I None
dex I Chemical
. I None
<eof> I None

<s> O None
The I None
median I None
number I None
of I None
bort I Chemical
- I None
dex I Chemical
<eof> I None

<s> O None
cycles I None
was I None
6 I None
, I None
up I None
to I None
a I None
maximum I None
of I None
12 I None
cycles I None
. I None
<eof> I None

<s> O None
On I None
an I None
intention I None
- I None
to I None
- I None
treat I None
basis I None
, I None
55 I None
% I None
of I None
the I None
patients I None
achieved I None
at I None
least I None
partial I None
response I None
, I None
including I None
19 I None
% I None
CR I None
and I None
35 I None
% I None
achieved I None
at I None
least I None
very I None
good I None
partial I None
response I None
. I None
<eof> I None

<s> O None
Median I None
durations I None
of I None
response I None
, I None
time I None
to I None
next I None
therapy I None
and I None
treatment I None
- I None
free I None
interval I None
were I None
8 I None
, I None
11.2 I None
, I None
and I None
5.1 I None
months I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
most I None
relevant I None
adverse I None
event I None
was I None
peripheral I Disease
neuropathy O Disease
, I None
which I None
occurred I None
in I None
78 I None
% I None
of I None
the I None
patients I None
<eof> I None

<s> O None
( I None
grade I None
II I None
, I None
38 I None
% I None
; I None
grade I None
III I None
, I None
21 I None
% I None
) I None
and I None
led I None
to I None
treatment I None
discontinuation I None
in I None
6 I None
% I None
. I None
<eof> I None

<s> O None
With I None
a I None
median I None
follow I None
up I None
of I None
22 I None
months I None
, I None
median I None
time I None
to I None
progression I None
, I None
progression I None
- I None
free I None
survival I None
( I None
PFS I None
) I None
and I None
overall I None
survival I None
( I None
OS I None
) I None
were I None
8.9 I None
, I None
8.7 I None
, I None
and I None
22 I None
months I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Prolonged I None
PFS I None
and I None
OS I None
were I None
observed I None
in I None
patients I None
achieving I None
CR I None
and I None
receiving I None
bort I Chemical
- I None
dex I Chemical
<eof> I None

<s> O None
a I None
single I None
line I None
of I None
prior I None
therapy I None
. I None
<eof> I None

<s> O None
Bort I Chemical
- I None
dex I Chemical
was I None
an I None
effective I None
salvage I None
treatment I None
for I None
MM I Disease
patients I None
, I None
particularly I None
for I None
those I None
in I None
first I None
relapse I None
. I None
<eof> I None

<s> O None
Pubertal I None
exposure I None
to I None
Bisphenol I Chemical
A O Chemical
increases I None
<eof> I None

<s> O None
anxiety I Disease
-like I None
behavior I None
and I None
decreases I None
acetylcholinesterase I None
activity I None
of I None
hippocampus I None
in I None
adult I None
male I None
mice I None
. I None
<eof> I None

<s> O None
The I None
negative I None
effects I None
of I None
Bisphenol I Chemical
A O Chemical
<eof> I None

<s> O None
( I None
BPA I Chemical
) I None
on I None
neurodevelopment I None
and I None
behaviors I None
have I None
been I None
well I None
established I None
. I None
<eof> I None

<s> O None
Acetylcholinesterase I None
( I None
AChE I None
) I None
is I None
a I None
regulatory I None
enzyme I None
which I None
is I None
involved I None
in I None
<eof> I None

<s> O None
anxiety I Disease
-like I None
behavior I None
. I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
behavioral I None
phenotypes I None
and I None
AChE I None
activity I None
in I None
male I None
mice I None
following I None
BPA I Chemical
exposure I None
during I None
puberty I None
. I None
<eof> I None

<s> O None
On I None
postnatal I None
day I None
( I None
PND I None
) I None
35 I None
, I None
male I None
mice I None
were I None
exposed I None
to I None
50 I None
mg I None
<eof> I None

<s> O None
BPA I Chemical
/kg I None
diet I None
per I None
day I None
for I None
a I None
period I None
of I None
35 I None
days I None
. I None
<eof> I None

<s> O None
On I None
PND71 I None
, I None
a I None
behavioral I None
assay I None
was I None
performed I None
using I None
the I None
elevated I None
plus I None
maze I None
( I None
EPM I None
) I None
and I None
the I None
light I None
/ I None
dark I None
test I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
AChE I None
activity I None
was I None
measured I None
in I None
the I None
prefrontal I None
cortex I None
, I None
hypothalamus I None
, I None
cerebellum I None
and I None
hippocampus I None
. I None
<eof> I None

<s> O None
Results I None
from I None
our I None
behavioral I None
phenotyping I None
indicated I None
that I None
anxiety I Disease
-like I None
behavior I None
was I None
increased I None
in I None
mice I None
exposed I None
to I None
BPA I Chemical
. I None
<eof> I None

<s> O None
AChE I None
activity I None
was I None
significantly I None
decreased I None
in I None
the I None
hippocampus I None
of I None
mice I None
with I None
BPA I Chemical
compared I None
to I None
control I None
mice I None
, I None
whereas I None
no I None
difference I None
was I None
found I None
in I None
the I None
prefrontal I None
cortex I None
, I None
hypothalamus I None
and I None
cerebellum I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
showed I None
that I None
pubertal I None
BPA I Chemical
exposure I None
increased I None
anxiety I Disease
-like I None
behavior I None
, I None
which I None
may I None
be I None
associated I None
with I None
decreased I None
AChE I None
activity I None
of I None
the I None
hippocampus I None
in I None
adult I None
male I None
mice I None
. I None
<eof> I None

<s> O None
Further I None
studies I None
are I None
necessary I None
to I None
investigate I None
the I None
cholinergic I None
signaling I None
of I None
the I None
hippocampus I None
in I None
PBE I None
induced I None
anxiety I Disease
-like I None
behaviors I None
. I None
<eof> I None

<s> O None
Biochemical I None
effects I None
of I None
Solidago I None
virgaurea I None
extract I None
on I None
experimental I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Cardiovascular I Disease
diseases O Disease
<eof> I None

<s> O None
( I None
CVDs I Disease
) I None
are I None
the I None
major I None
health I None
problem I None
of I None
advanced I None
as I None
well I None
as I None
developing I None
countries I None
of I None
the I None
world I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
the I None
protective I None
effect I None
of I None
the I None
Solidago I None
virgaurea I None
extract I None
on I None
isoproterenol I Chemical
-induced I None
cardiotoxicity I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
subcutaneous I None
injection I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
30 I None
mg I None
/ I None
kg I None
) I None
into I None
rats I None
twice I None
at I None
an I None
interval I None
of I None
24 I None
h I None
, I None
for I None
two I None
consecutive I None
days I None
, I None
led I None
to I None
a I None
significant I None
increase I None
in I None
serum I None
lactate I Chemical
dehydrogenase I None
, I None
creatine I Chemical
phosphokinase I None
, I None
alanine I Chemical
transaminase I None
, I None
aspartate I Chemical
transaminase I None
, I None
and I None
angiotensin I Chemical
-converting I None
enzyme I None
activities I None
, I None
total I None
cholesterol I Chemical
, I None
triglycerides I Chemical
, I None
free I None
serum I None
<eof> I None

<s> O None
fatty I Chemical
acid O Chemical
, I None
cardiac I None
tissue I None
malondialdehyde I Chemical
<eof> I None

<s> O None
( I None
MDA I Chemical
) I None
, I None
and I None
nitric I Chemical
oxide O Chemical
levels I None
and I None
a I None
significant I None
decrease I None
in I None
levels I None
of I None
glutathione I Chemical
and I None
superoxide I Chemical
dismutase I None
in I None
cardiac I None
tissue I None
as I None
compared I None
to I None
the I None
normal I None
control I None
group I None
( I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
S. I None
virgaurea I None
extract I None
for I None
5 I None
weeks I None
at I None
a I None
dose I None
of I None
250 I None
mg I None
/ I None
kg I None
followed I None
by I None
isoproterenol I Chemical
injection I None
significantly I None
prevented I None
the I None
observed I None
alterations I None
. I None
<eof> I None

<s> O None
Captopril I Chemical
( I None
50 I None
mg I None
/ I None
kg I None
/ I None
day I None
, I None
given I None
orally I None
) I None
, I None
an I None
inhibitor I None
of I None
angiotensin I Chemical
<eof> I None

<s> O None
-converting I None
enzyme I None
used I None
as I None
a I None
standard I None
cardioprotective I None
drug I None
, I None
was I None
used I None
as I None
a I None
positive I None
control I None
in I None
this I None
study I None
. I None
<eof> I None

<s> O None
The I None
data I None
of I None
the I None
present I None
study I None
suggest I None
that I None
S. I None
virgaurea I None
extract I None
exerts I None
its I None
protective I None
effect I None
by I None
decreasing I None
MDA I Chemical
level I None
and I None
increasing I None
the I None
antioxidant I None
status I None
in I None
isoproterenol I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
The I None
study I None
emphasizes I None
the I None
beneficial I None
action I None
of I None
S. I None
virgaurea I None
extract I None
as I None
a I None
cardioprotective I None
agent I None
. I None
<eof> I None

<s> O None
" I None
Real I None
- I None
world I None
" I None
data I None
on I None
the I None
efficacy I None
and I None
safety I None
of I None
lenalidomide I Chemical
and I None
dexamethasone I Chemical
in I None
patients I None
with I None
relapsed I None
/ I None
refractory I None
multiple I Disease
myeloma O Disease
who I None
were I None
treated I None
according I None
to I None
the I None
standard I None
clinical I None
practice I None
: I None
a I None
study I None
of I None
the I None
Greek I None
Myeloma I Disease
Study I None
Group I None
. I None
<eof> I None

<s> O None
Lenalidomide I Chemical
and I None
dexamethasone I Chemical
<eof> I None

<s> O None
( I None
RD I Chemical
) I None
is I None
a I None
standard I None
of I None
care I None
for I None
relapsed I None
/ I None
refractory I None
multiple I Disease
myeloma O Disease
<eof> I None

<s> O None
( I None
RRMM I Disease
) I None
, I None
but I None
there I None
is I None
limited I None
published I None
data I None
on I None
its I None
efficacy I None
and I None
safety I None
in I None
the I None
" I None
real I None
world I None
" I None
( I None
RW I None
) I None
, I None
according I None
to I None
the I None
International I None
Society I None
of I None
Pharmacoeconomics I None
and I None
Outcomes I None
Research I None
definition I None
. I None
<eof> I None

<s> O None
We I None
studied I None
212 I None
RRMM I Disease
patients I None
who I None
received I None
RD I Chemical
in I None
RW I None
. I None
<eof> I None

<s> O None
Objective I None
response I None
( I None
> I None
PR I None
( I None
partial I None
response I None
) I None
) I None
rate I None
was I None
77.4 I None
% I None
( I None
complete I None
response I None
( I None
CR I None
) I None
, I None
20.2 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Median I None
time I None
to I None
first I None
and I None
best I None
response I None
was I None
2 I None
and I None
5 I None
months I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Median I None
time I None
to I None
CR I None
when I None
RD I Chemical
was I None
given I None
as I None
2nd I None
or I None
> I None
2(nd)-line I None
treatment I None
at I None
4 I None
and I None
11 I None
months I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Quality I None
of I None
response I None
was I None
independent I None
of I None
previous I None
lines I None
of I None
therapies I None
or I None
previous I None
exposure I None
to I None
thalidomide I Chemical
or I None
bortezomib I Chemical
. I None
<eof> I None

<s> O None
Median I None
duration I None
of I None
response I None
was I None
34.4 I None
months I None
, I None
and I None
it I None
was I None
higher I None
in I None
patients I None
who I None
received I None
RD I Chemical
until I None
progression I None
( I None
not I None
reached I None
versus I None
19 I None
months I None
, I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Improvement I None
of I None
humoral I None
immunity I None
occurred I None
in I None
60 I None
% I None
of I None
responders I None
( I None
p I None
< I None
0.001 I None
) I None
and I None
in I None
the I None
majority I None
of I None
patients I None
who I None
achieved I None
stable I None
disease I None
. I None
<eof> I None

<s> O None
Adverse I None
events I None
were I None
reported I None
in I None
68.9 I None
% I None
of I None
patients I None
( I None
myelosuppression I Disease
in I None
49.4 I None
% I None
) I None
and I None
12.7 I None
% I None
of I None
patients I None
needed I None
hospitalization I None
. I None
<eof> I None

<s> O None
Peripheral I Disease
neuropathy O Disease
was I None
observed I None
only I None
in I None
2.5 I None
% I None
of I None
patients I None
and I None
deep I Disease
vein O Disease
thrombosis O Disease
in I None
5.7 I None
% I None
. I None
<eof> I None

<s> O None
Dose I None
reductions I None
were I None
needed I None
in I None
31 I None
% I None
of I None
patients I None
and I None
permanent I None
discontinuation I None
in I None
38.9 I None
% I None
. I None
<eof> I None

<s> O None
Median I None
time I None
to I None
treatment I None
discontinuation I None
was I None
16.8 I None
months I None
. I None
<eof> I None

<s> O None
Performance I None
status I None
( I None
PS I None
) I None
and I None
initial I None
lenalidomide I Chemical
dose I None
predicted I None
for I None
treatment I None
discontinuation I None
. I None
<eof> I None

<s> O None
Extra I None
- I None
medullary I None
relapses I None
occurred I None
in I None
3.8 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Our I None
study I None
confirms I None
that I None
RD I Chemical
is I None
effective I None
and I None
safe I None
in I None
RRMM I Disease
in I None
the I None
RW I None
; I None
it I None
produces I None
durable I None
responses I None
especially I None
in I None
patients I None
who I None
continue I None
on I None
treatment I None
till I None
progression I None
and I None
improves I None
humoral I None
immunity I None
even I None
in I None
patients I None
with I None
stable I None
disease I None
. I None
<eof> I None

<s> O None
The I None
cytogenetic I None
action I None
of I None
ifosfamide I Chemical
, I None
mesna I Chemical
, I None
and I None
their I None
combination I None
on I None
peripheral I None
rabbit I None
lymphocytes I None
: I None
an I None
in I None
vivo I None
/ I None
in I None
vitro I None
cytogenetic I None
study I None
. I None
<eof> I None

<s> O None
Ifosfamide I Chemical
<eof> I None

<s> O None
( I None
IFO I Chemical
) I None
is I None
an I None
alkylating I None
nitrogen I Chemical
mustard I None
, I None
administrated I None
as I None
an I None
antineoplasmic I None
agent I None
. I None
<eof> I None

<s> O None
It I None
is I None
characterized I None
by I None
its I None
intense I None
urotoxic I None
action I None
, I None
leading I None
to I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
This I None
side I None
effect I None
of I None
IFO I Chemical
raises I None
the I None
requirement I None
for I None
the I None
co I None
- I None
administration I None
with I None
sodium I Chemical
2-sulfanylethanesulfonate O Chemical
<eof> I None

<s> O None
( I None
Mesna I Chemical
) I None
aiming I None
to I None
avoid I None
or I None
minimize I None
this I None
effect I None
. I None
<eof> I None

<s> O None
IFO I Chemical
and I None
Mesna I Chemical
were I None
administrated I None
separately I None
on I None
rabbit I None
's I None
lymphocytes I None
in I None
vivo I None
, I None
which I None
were I None
later I None
developed I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Cytogenetic I None
markers I None
for I None
sister I None
chromatid I None
exchanges I None
( I None
SCEs I None
) I None
, I None
proliferation I None
rate I None
index I None
( I None
PRI I None
) I None
and I None
Mitotic I None
Index I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
Mesna I Chemical
's I None
action I None
, I None
in I None
conjunction I None
with I None
IFO I Chemical
reduces I None
the I None
frequency I None
of I None
SCEs I None
, I None
in I None
comparison I None
with I None
the I None
SCEs I None
recordings I None
obtained I None
when I None
IFO I Chemical
is I None
administered I None
alone I None
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
this I None
, I None
when I None
high I None
concentrations I None
of I None
Mesna I Chemical
were I None
administered I None
alone I None
significant I None
reductions I None
of I None
the I None
PRI I None
were I None
noted I None
, I None
than I None
with I None
IFO I Chemical
acting I None
at I None
the I None
same I None
concentration I None
on I None
the I None
lymphocytes I None
. I None
<eof> I None

<s> O None
Mesna I Chemical
significantly I None
reduces I None
IFO I Chemical
's I None
genotoxicity I Disease
, I None
while I None
when I None
administered I None
in I None
high I None
concentrations I None
it I None
acts I None
in I None
an I None
inhibitory I None
fashion I None
on I None
the I None
cytostatic I None
action I None
of I None
the I None
drug I None
. I None
<eof> I None

<s> O None
Risk I None
factors I None
and I None
predictors I None
of I None
levodopa I Chemical
-induced I None
dyskinesia I Disease
among I None
multiethnic I None
Malaysians I None
with I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Chronic I None
pulsatile I None
levodopa I Chemical
therapy I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
leads I None
to I None
the I None
development I None
of I None
motor I None
fluctuations I None
and I None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
prevalence I None
and I None
predictors I None
of I None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesia I Disease
among I None
multiethnic I None
Malaysian I None
patients I None
with I None
PD I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
is I None
a I None
cross I None
- I None
sectional I None
study I None
involving I None
95 I None
patients I None
with I None
PD I Disease
on I None
uninterrupted I None
levodopa I Chemical
therapy I None
for I None
at I None
least I None
6 I None
months I None
. I None
<eof> I None

<s> O None
The I None
instrument I None
used I None
was I None
the I None
UPDRS I None
questionnaires I None
. I None
<eof> I None

<s> O None
The I None
predictors I None
of I None
dyskinesia I Disease
were I None
determined I None
using I None
multivariate I None
logistic I None
regression I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
mean I None
age I None
was I None
65.6 I None
+ I None
8.5 I None
years I None
. I None
<eof> I None

<s> O None
The I None
mean I None
onset I None
age I None
was I None
58.5 I None
+ I None
9.8 I None
years I None
. I None
<eof> I None

<s> O None
The I None
median I None
disease I None
duration I None
was I None
6 I None
( I None
7 I None
) I None
years I None
. I None
<eof> I None

<s> O None
Dyskinesia I Disease
was I None
present I None
in I None
44 I None
% I None
( I None
n I None
= I None
42 I None
) I None
with I None
median I None
levodopa I Chemical
therapy I None
of I None
3 I None
years I None
. I None
<eof> I None

<s> O None
There I None
were I None
64.3 I None
% I None
Chinese I None
, I None
31 I None
% I None
Malays I None
, I None
and I None
3.7 I None
% I None
Indians I None
and I None
other I None
ethnic I None
groups I None
. I None
<eof> I None

<s> O None
Eighty I None
- I None
one I None
percent I None
of I None
patients I None
with I None
dyskinesia I Disease
had I None
clinical I None
fluctuations I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
dyskinesia I Disease
had I None
lower I None
onset I None
age I None
( I None
p I None
< I None
0.001 I None
) I None
, I None
longer I None
duration I None
of I None
levodopa I Chemical
therapy I None
( I None
p I None
< I None
0.001 I None
) I None
, I None
longer I None
disease I None
duration I None
( I None
p I None
< I None
0.001 I None
) I None
, I None
higher I None
total I None
daily I None
levodopa I Chemical
dose I None
( I None
p I None
< I None
0.001 I None
) I None
, I None
and I None
higher I None
total I None
UPDRS I None
scores I None
( I None
p I None
= I None
0.005 I None
) I None
than I None
patients I None
without I None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
The I None
three I None
significant I None
predictors I None
of I None
dyskinesia I Disease
were I None
duration I None
of I None
levodopa I Chemical
therapy I None
, I None
onset I None
age I None
, I None
and I None
total I None
daily I None
levodopa I Chemical
dose I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
prevalence I None
of I None
levodopa I Chemical
-induced I None
dyskinesia I Disease
in I None
our I None
patients I None
was I None
44 I None
% I None
. I None
<eof> I None

<s> O None
The I None
most I None
significant I None
predictors I None
were I None
duration I None
of I None
levodopa I Chemical
therapy I None
, I None
total I None
daily I None
levodopa I Chemical
dose I None
, I None
and I None
onset I None
age I None
. I None
<eof> I None

<s> O None
An I None
unexpected I None
diagnosis I None
in I None
a I None
renal I None
- I None
transplant I None
patient I None
with I None
proteinuria I Disease
treated I None
with I None
everolimus I Chemical
: I None
AL I Disease
amyloidosis I Disease
. I None
<eof> I None

<s> O None
Proteinuria I Disease
is I None
an I None
expected I None
complication I None
in I None
transplant I None
patients I None
treated I None
with I None
mammalian I None
target I None
of I None
rapamycin I Chemical
inhibitors I None
( I None
mTOR I None
- I None
i I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
clinical I None
suspicion I None
should I None
always I None
be I None
supported I None
by I None
histological I None
evidence I None
in I None
order I None
to I None
investigate I None
potential I None
alternate I None
diagnoses I None
such I None
as I None
acute I None
or I None
chronic I None
rejection I None
, I None
interstitial I None
fibrosis I Disease
and I None
tubular I None
atrophy I Disease
, I None
or I None
recurrent I None
or I None
de I None
novo I None
glomerulopathy I Disease
. I None
<eof> I None

<s> O None
In I None
this I None
case I None
we I None
report I None
the I None
unexpected I None
diagnosis I None
of I None
amyloidosis I Disease
in I None
a I None
renal I None
- I None
transplant I None
patient I None
with I None
pre I None
- I None
transplant I None
monoclonal I None
gammapathy I None
of I None
undetermined I None
significance I None
who I None
developed I None
proteinuria I Disease
after I None
conversion I None
from I None
tacrolimus I Chemical
to I None
everolimus I Chemical
. I None
<eof> I None

<s> O None
An I None
investigation I None
of I None
the I None
pattern I None
of I None
kidney I Disease
injury O Disease
in I None
HIV I None
- I None
positive I None
persons I None
exposed I None
to I None
tenofovir I Chemical
disoproxil O Chemical
fumarate O Chemical
: I None
an I None
examination I None
of I None
a I None
large I None
population I None
database I None
( I None
MHRA I None
database I None
) I None
. I None
<eof> I None

<s> O None
The I None
potential I None
for I None
tenofovir I Chemical
to I None
cause I None
a I None
range I None
of I None
kidney I None
syndromes I None
has I None
been I None
established I None
from I None
mechanistic I None
and I None
randomised I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
exact I None
pattern I None
of I None
kidney I None
involvement I None
is I None
still I None
uncertain I None
. I None
<eof> I None

<s> O None
We I None
undertook I None
a I None
descriptive I None
analysis I None
of I None
Yellow I None
Card I None
records I None
of I None
407 I None
HIV I None
- I None
positive I None
persons I None
taking I None
tenofovir I Chemical
disoproxil O Chemical
fumarate O Chemical
<eof> I None

<s> O None
( I None
TDF I Chemical
) I None
as I None
part I None
of I None
their I None
antiretroviral I None
therapy I None
regimen I None
and I None
submitted I None
to I None
the I None
Medicines I None
and I None
Healthcare I None
Products I None
Regulatory I None
Agency I None
( I None
MHRA I None
) I None
with I None
suspected I None
kidney I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Reports I None
that I None
satisfy I None
defined I None
criteria I None
were I None
classified I None
as I None
acute I Disease
kidney O Disease
injury O Disease
, I None
kidney I Disease
tubular O Disease
dysfunction O Disease
and I None
Fanconi I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Of I None
the I None
407 I None
Yellow I None
Card I None
records I None
analysed I None
, I None
106 I None
satisfied I None
criteria I None
for I None
TDF I Chemical
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
kidney I Disease
disease O Disease
, I None
of I None
which I None
53 I None
( I None
50 I None
% I None
) I None
had I None
features I None
of I None
kidney I Disease
tubular O Disease
dysfunction O Disease
, I None
35 I None
( I None
33 I None
% I None
) I None
were I None
found I None
to I None
have I None
features I None
of I None
glomerular I Disease
dysfunction O Disease
and I None
18 I None
<eof> I None

<s> O None
( I None
17 I None
% I None
) I None
had I None
Fanconi I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
The I None
median I None
TDF I Chemical
exposure I None
was I None
316 I None
days I None
( I None
interquartile I None
range I None
120 I None
- I None
740 I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
hospitalisation I None
for I None
TDF I Chemical
<eof> I None

<s> O None
kidney I None
adverse I None
effects I None
was I None
high I None
, I None
particularly I None
amongst I None
patients I None
with I None
features I None
of I None
Fanconi I Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
The I None
pattern I None
of I None
kidney I None
syndromes I None
in I None
this I None
population I None
series I None
mirrors I None
that I None
reported I None
in I None
randomised I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
Cessation I None
of I None
TDF I Chemical
was I None
associated I None
with I None
complete I None
restoration I None
of I None
kidney I None
function I None
in I None
up I None
half I None
of I None
the I None
patients I None
in I None
this I None
report I None
. I None
<eof> I None

<s> O None
Incidence I None
of I None
postoperative I Disease
delirium O Disease
is I None
high I None
even I None
in I None
a I None
population I None
without I None
known I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Postoperative I Disease
delirium O Disease
is I None
a I None
recognized I None
complication I None
in I None
populations I None
at I None
risk I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
is I None
to I None
assess I None
the I None
prevalence I None
of I None
early I None
postoperative I Disease
delirium O Disease
in I None
a I None
population I None
without I None
known I None
risk I None
factors I None
admitted I None
to I None
the I None
ICU I None
for I None
postoperative I None
monitoring I None
after I None
elective I None
major I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
secondary I None
outcome I None
investigated I None
is I None
to I None
identify I None
eventual I None
independent I None
risk I None
factors I None
among I None
demographic I None
data I None
and I None
anesthetic I None
drugs I None
used I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
An I None
observational I None
, I None
prospective I None
study I None
was I None
conducted I None
on I None
a I None
consecutive I None
cohort I None
of I None
patients I None
admitted I None
to I None
our I None
ICU I None
within I None
and I None
for I None
at I None
least I None
24 I None
h I None
after I None
major I None
surgical I None
procedures I None
. I None
<eof> I None

<s> O None
Exclusion I None
criteria I None
were I None
any I None
preexisting I None
predisposing I None
factor I None
for I None
delirium I Disease
or I None
other I None
potentially I None
confounding I None
neurological I Disease
dysfunctions O Disease
. I None
<eof> I None

<s> O None
Patients I None
were I None
assessed I None
daily I None
using I None
the I None
confusion I Disease
assessment I None
method I None
for I None
the I None
ICU I None
scale I None
for I None
3 I None
days I None
after I None
the I None
surgical I None
procedure I None
. I None
<eof> I None

<s> O None
Early I None
postoperative I Disease
delirium O Disease
incidence I None
risk I None
factors I None
were I None
then I None
assessed I None
through I None
three I None
different I None
multiple I None
regression I None
models I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
According I None
to I None
the I None
confusion I None
assessment I None
method I None
for I None
the I None
ICU I None
scale I None
, I None
28 I None
% I None
of I None
patients I None
were I None
diagnosed I None
with I None
early I None
postoperative I Disease
delirium O Disease
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
thiopentone I Chemical
was I None
significantly I None
associated I None
with I None
an I None
eight I None
- I None
fold I None
- I None
higher I None
risk I None
for I None
delirium I Disease
compared I None
to I None
propofol I Chemical
( I None
57.1 I None
% I None
vs. I None
7.1 I None
% I None
, I None
RR I None
= I None
8.0 I None
, I None
X2 I None
<eof> I None

<s> O None
= I None
4.256 I None
; I None
df I None
= I None
1 I None
; I None
0.05 I None
< I None
p I None
< I None
0.02 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
this I None
study I None
early I None
postoperative I Disease
delirium O Disease
was I None
found I None
to I None
be I None
a I None
very I None
common I None
complication I None
after I None
major I None
surgery I None
, I None
even I None
in I None
a I None
population I None
without I None
known I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Thiopentone I Chemical
was I None
independently I None
associated I None
with I None
an I None
increase I None
in I None
its I None
relative I None
risk I None
. I None
<eof> I None

<s> O None
A I None
single I None
neurotoxic I Disease
dose I None
of I None
<eof> I None

<s> O None
methamphetamine I Chemical
induces I None
a I None
long I None
- I None
lasting I None
depressive I Disease
-like I None
behaviour I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Methamphetamine I Chemical
( I None
METH I Chemical
) I None
triggers I None
a I None
disruption I None
of I None
the I None
monoaminergic I None
system I None
and I None
METH I Chemical
abuse I None
leads I None
to I None
negative I None
emotional I None
states I None
including I None
depressive I Disease
symptoms O Disease
during I None
drug I None
withdrawal I None
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
is I None
currently I None
unknown I None
if I None
the I None
acute I None
toxic I None
dosage I None
of I None
METH I Chemical
also I None
causes I None
a I None
long I None
- I None
lasting I None
depressive I Disease
phenotype I None
and I None
persistent I None
monoaminergic I None
deficits I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
now I None
assessed I None
the I None
depressive I Disease
-like I None
behaviour I None
in I None
mice I None
at I None
early I None
and I None
long I None
- I None
term I None
periods I None
following I None
a I None
single I None
high I None
METH I Chemical
dose I None
( I None
30 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
METH I Chemical
did I None
not I None
alter I None
the I None
motor I None
function I None
and I None
procedural I None
memory I None
of I None
mice I None
as I None
assessed I None
by I None
swimming I None
speed I None
and I None
escape I None
latency I None
to I None
find I None
the I None
platform I None
in I None
a I None
cued I None
version I None
of I None
the I None
water I None
maze I None
task I None
. I None
<eof> I None

<s> O None
However I None
, I None
METH I Chemical
significantly I None
increased I None
the I None
immobility I None
time I None
in I None
the I None
tail I None
suspension I None
test I None
at I None
3 I None
and I None
49 I None
days I None
post I None
- I None
administration I None
. I None
<eof> I None

<s> O None
This I None
depressive I Disease
-like I None
profile I None
induced I None
by I None
METH I Chemical
was I None
accompanied I None
by I None
a I None
marked I None
depletion I None
of I None
frontostriatal I None
dopaminergic I None
and I None
serotonergic I None
neurotransmission I None
, I None
indicated I None
by I None
a I None
reduction I None
in I None
the I None
levels I None
of I None
dopamine I Chemical
, I None
DOPAC I Chemical
and I None
HVA I Chemical
, I None
tyrosine I Chemical
hydroxylase I None
and I None
serotonin I Chemical
, I None
observed I None
at I None
both I None
3 I None
and I None
49 I None
days I None
post I None
- I None
administration I None
. I None
<eof> I None

<s> O None
In I None
parallel I None
, I None
another I None
neurochemical I None
feature I None
of I None
depression I Disease
--astroglial I None
dysfunction I None
-- I None
was I None
unaffected I None
in I None
the I None
cortex I None
and I None
the I None
striatal I None
levels I None
of I None
the I None
astrocytic I None
protein I None
marker I None
, I None
glial I None
fibrillary I None
acidic I None
protein I None
, I None
were I None
only I None
transiently I None
increased I None
at I None
3 I None
days I None
. I None
<eof> I None

<s> O None
These I None
findings I None
demonstrate I None
for I None
the I None
first I None
time I None
that I None
a I None
single I None
high I None
dose I None
of I None
METH I Chemical
induces I None
long I None
- I None
lasting I None
depressive I Disease
-like I None
behaviour I None
in I None
mice I None
associated I None
with I None
a I None
persistent I None
disruption I None
of I None
frontostriatal I None
dopaminergic I None
and I None
serotonergic I None
homoeostasis I None
. I None
<eof> I None

<s> O None
Linezolid I Chemical
-induced I None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
Many I None
systemic I None
antimicrobials I None
have I None
been I None
implicated I None
to I None
cause I None
ocular I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
This I None
is I None
especially I None
relevant I None
in I None
multidrug I None
therapy I None
where I None
more I None
than I None
one I None
drug I None
can I None
cause I None
a I None
similar I None
ocular I None
adverse I None
effect I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
case I None
of I None
progressive I None
loss I Disease
of O Disease
vision O Disease
associated I None
with I None
linezolid I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
45-year I None
- I None
old I None
male I None
patient I None
who I None
was I None
on I None
treatment I None
with I None
multiple I None
second I None
- I None
line I None
anti I None
- I None
tuberculous I None
drugs I None
including I None
linezolid I Chemical
and I None
ethambutol I Chemical
for I None
extensively I Disease
drug O Disease
- O Disease
resistant O Disease
tuberculosis O Disease
<eof> I None

<s> O None
( I None
XDR I Disease
- O Disease
TB O Disease
) I None
presented I None
to I None
us I None
with I None
painless I None
progressive I None
loss I Disease
of O Disease
vision O Disease
in I None
both I None
eyes I None
. I None
<eof> I None

<s> O None
Color I None
vision I None
was I None
defective I None
and I None
fundus I None
examination I None
revealed I None
optic I Disease
disc O Disease
edema O Disease
in I None
both I None
eyes I None
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
-induced I None
<eof> I None

<s> O None
toxic I Disease
optic O Disease
neuropathy O Disease
was I None
suspected I None
and I None
tablet I None
ethambutol I Chemical
was I None
withdrawn I None
. I None
<eof> I None

<s> O None
Deterioration I Disease
of O Disease
vision O Disease
occurred I None
despite I None
withdrawal I None
of I None
ethambutol I Chemical
. I None
<eof> I None

<s> O None
Discontinuation I None
of I None
linezolid I Chemical
resulted I None
in I None
marked I None
improvement I None
of I None
vision I None
. I None
<eof> I None

<s> O None
Our I None
report I None
emphasizes I None
the I None
need I None
for I None
monitoring I None
of I None
visual I None
function I None
in I None
patients I None
on I None
long I None
- I None
term I None
linezolid I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Resuscitation I None
with I None
lipid I None
, I None
epinephrine I Chemical
, I None
or I None
both I None
in I None
levobupivacaine I Chemical
-induced I None
cardiac I Disease
toxicity O Disease
in I None
newborn I None
piglets I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
optimal I None
dosing I None
regimens I None
of I None
lipid I None
emulsion I None
, I None
epinephrine I Chemical
, I None
or I None
both I None
are I None
not I None
yet I None
determined I None
in I None
neonates I None
in I None
cases I None
of I None
local I None
anaesthetic I None
systemic I None
toxicity I Disease
<eof> I None

<s> O None
( I None
LAST I None
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Newborn I None
piglets I None
received I None
levobupivacaine I Chemical
until I None
cardiovascular I Disease
collapse O Disease
occurred I None
. I None
<eof> I None

<s> O None
Standard I None
cardiopulmonary I None
resuscitation I None
was I None
started I None
and I None
electrocardiogram I None
( I None
ECG I None
) I None
was I None
monitored I None
for I None
ventricular I Disease
tachycardia O Disease
, I None
fibrillation I Disease
, I None
or I None
QRS I None
prolongation I None
. I None
<eof> I None

<s> O None
Piglets I None
were I None
then I None
randomly I None
allocated I None
to I None
four I None
groups I None
: I None
control I None
( I None
saline I None
) I None
, I None
Intralipid I None
( I None
) I None
alone I None
, I None
epinephrine I Chemical
alone I None
, I None
or I None
a I None
combination I None
of I None
Intralipd I None
plus I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
Resuscitation I None
continued I None
for I None
30 I None
min I None
or I None
until I None
there I None
was I None
a I None
return I None
of I None
spontaneous I None
circulation I None
( I None
ROSC I None
) I None
accompanied I None
by I None
a I None
mean I None
arterial I None
pressure I None
at I None
or I None
superior I None
to I None
the I None
baseline I None
pressure I None
and I None
normal I None
sinus I None
rhythm I None
for I None
a I None
period I None
of I None
30 I None
min I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
ROSC I None
was I None
achieved I None
in I None
only I None
one I None
of I None
the I None
control I None
piglets I None
compared I None
with I None
most I None
of I None
the I None
treated I None
piglets I None
. I None
<eof> I None

<s> O None
Mortality I None
was I None
not I None
significantly I None
different I None
between I None
the I None
three I None
treatment I None
groups I None
, I None
but I None
was I None
significantly I None
lower I None
in I None
all I None
the I None
treatment I None
groups I None
compared I None
with I None
control I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
ECG I None
abnormalities I None
was I None
zero I None
in I None
the I None
Intralipid I None
only I None
group I None
, I None
but I None
14 I None
and I None
17 I None
, I None
respectively I None
, I None
in I None
the I None
epinephrine I Chemical
and I None
epinephrine I Chemical
plus I None
lipid I None
groups I None
( I None
P<0.05 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Lipid I None
emulsion I None
with I None
or I None
without I None
epinephrine I Chemical
, I None
or I None
epinephrine I Chemical
alone I None
were I None
equally I None
effective I None
in I None
achieving I None
a I None
return I None
to I None
spontaneous I None
circulation I None
in I None
this I None
model I None
of I None
LAST I None
. I None
<eof> I None

<s> O None
Epinephrine I Chemical
alone I None
or I None
in I None
combination I None
with I None
lipid I None
was I None
associated I None
with I None
an I None
increased I None
number I None
of I None
ECG I None
abnormalities I None
compared I None
with I None
lipid I None
emulsion I None
alone I None
. I None
<eof> I None

<s> O None
Incidence I None
of I None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
type O Disease
II O Disease
and I None
postoperative I None
recovery I None
of I None
platelet I None
count I None
in I None
liver I None
graft I None
recipients I None
: I None
a I None
retrospective I None
cohort I None
analysis I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Thrombocytopenia I Disease
in I None
patients I None
with I None
end I Disease
- O Disease
stage O Disease
liver O Disease
disease O Disease
is I None
a I None
common I None
disorder I None
caused I None
mainly I None
by I None
portal I Disease
hypertension O Disease
, I None
low I None
levels I None
of I None
thrombopoetin I None
, I None
and I None
endotoxemia I Disease
. I None
<eof> I None

<s> O None
The I None
impact I None
of I None
immune I None
- I None
mediated I None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
type O Disease
II O Disease
( I None
HIT I Disease
type O Disease
II O Disease
) I None
as I None
a I None
cause I None
of I None
thrombocytopenia I Disease
<eof> I None

<s> O None
after I None
liver I None
transplantation I None
is I None
not I None
yet I None
understood I None
, I None
with I None
few I None
literature I None
citations I None
reporting I None
contradictory I None
results I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
our I None
study I None
was I None
to I None
demonstrate I None
the I None
perioperative I None
course I None
of I None
thrombocytopenia I Disease
after I None
liver I None
transplantation I None
and I None
determine I None
the I None
occurrence I None
of I None
clinical I None
HIT I Disease
type O Disease
II O Disease
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
We I None
retrospectively I None
evaluated I None
the I None
medical I None
records I None
of I None
205 I None
consecutive I None
adult I None
patients I None
who I None
underwent I None
full I None
- I None
size I None
liver I None
transplantation I None
between I None
January I None
2006 I None
and I None
December I None
2010 I None
due I None
to I None
end I None
- I None
stage I None
or I None
malignant I None
liver I None
disease I None
. I None
<eof> I None

<s> O None
Preoperative I None
platelet I None
count I None
, I None
postoperative I None
course I None
of I None
platelets I None
, I None
and I None
clinical I None
signs I None
of I None
HIT I Disease
type O Disease
II O Disease
were I None
analyzed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
155 I None
( I None
75.6 I None
% I None
) I None
of I None
205 I None
patients I None
had I None
thrombocytopenia I Disease
before I None
transplantation I None
, I None
significantly I None
influenced I None
by I None
Model I None
of I None
End I Disease
- O Disease
Stage O Disease
Liver O Disease
Disease O Disease
score I None
and I None
liver I Disease
cirrhosis O Disease
. I None
<eof> I None

<s> O None
The I None
platelet I None
count I None
exceeded I None
100,000/uL I None
in I None
most I None
of I None
the I None
patients I None
( I None
n I None
= I None
193 I None
) I None
at I None
a I None
medium I None
of I None
7 I None
d. I None
Regarding I None
HIT I Disease
II O Disease
, I None
there I None
were I None
four I None
( I None
1.95 I None
% I None
) I None
patients I None
with I None
a I None
background I None
of I None
HIT I Disease
type O Disease
II O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
HIT I Disease
in I None
patients I None
with I None
end I Disease
- O Disease
stage O Disease
hepatic O Disease
failure O Disease
is I None
, I None
with I None
about I None
1.95 I None
% I None
, I None
rare I None
. I None
<eof> I None

<s> O None
For I None
further I None
reduction I None
of I None
HIT I Disease
type O Disease
II O Disease
, I None
the I None
use I None
of I None
intravenous I None
heparin I Chemical
should I None
be I None
avoided I None
and I None
the I None
prophylactic I None
anticoagulation I None
should I None
be I None
performed I None
with I None
low I None
- I None
molecular I None
- I None
weight I None
heparin I Chemical
after I None
normalization I None
of I None
platelet I None
count I None
. I None
<eof> I None

<s> O None
Takotsubo I Disease
syndrome O Disease
( I None
or I None
apical I Disease
ballooning O Disease
syndrome O Disease
) I None
secondary I None
to I None
Zolmitriptan I Chemical
. I None
<eof> I None

<s> O None
Takotsubo I Disease
syndrome O Disease
( I None
TS I Disease
) I None
, I None
also I None
known I None
as I None
broken I Disease
heart O Disease
syndrome O Disease
, I None
is I None
characterized I None
by I None
left I None
ventricle I None
apical I None
ballooning I None
with I None
elevated I None
cardiac I None
biomarkers I None
and I None
electrocardiographic I None
changes I None
suggestive I None
of I None
an I None
acute I Disease
coronary O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
ie I None
, I None
ST I None
- I None
segment I None
elevation I None
, I None
T I None
wave I None
inversions I None
, I None
and I None
pathologic I None
Q I None
waves I None
) I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
54-year I None
- I None
old I None
woman I None
with I None
medical I None
history I None
of I None
mitral I Disease
valve O Disease
prolapse O Disease
and I None
migraines I Disease
, I None
who I None
was I None
admitted I None
to I None
the I None
hospital I None
for I None
substernal I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
and I None
electrocardiogram I None
demonstrated I None
1/2 I None
mm I None
ST I None
- I None
segment I None
elevation I None
in I None
leads I None
II I None
, I None
III I None
, I None
aVF I None
, I None
V5 I None
, I None
and I None
V6 I None
and I None
positive I None
troponin I None
I. I None
Emergent I None
coronary I None
angiogram I None
revealed I None
normal I None
coronary I None
arteries I None
with I None
moderately I None
reduced I None
left I None
ventricular I None
ejection I None
fraction I None
with I None
wall I None
motion I None
abnormalities I None
consistent I None
with I None
TS I Disease
. I None
<eof> I None

<s> O None
Detailed I None
history I None
obtained I None
retrospectively I None
revealed I None
that I None
the I None
patient I None
took I None
zolmitriptan I Chemical
sparingly I None
only I None
when I None
she I None
had I None
migraines I Disease
. I None
<eof> I None

<s> O None
But I None
before I None
this I None
event I None
, I None
she I None
was I None
taking I None
<eof> I None

<s> O None
zolmitriptan I Chemical
2 I None
- I None
3 I None
times I None
daily I None
for I None
several I None
days I None
because I None
of I None
a I None
persistent I None
migraine I Disease
headache O Disease
. I None
<eof> I None

<s> O None
She I None
otherwise I None
reported I None
that I None
she I None
is I None
quite I None
active I None
, I None
rides I None
horses I None
, I None
and I None
does I None
show I None
jumping I None
without I None
any I None
limitations I None
in I None
her I None
physical I None
activity I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
evidence I None
of I None
any I None
recent I None
stress I None
or I None
status I Disease
migrainosus O Disease
. I None
<eof> I None

<s> O None
Extensive I None
literature I None
search I None
revealed I None
multiple I None
cases I None
of I None
coronary I Disease
artery O Disease
vasospasm O Disease
secondary I None
to I None
zolmitriptan I Chemical
, I None
but I None
none I None
of I None
the I None
cases I None
were I None
associated I None
with I None
TS I Disease
. I None
<eof> I None

<s> O None
Depression I Disease
, I None
impulsiveness I Disease
, I None
sleep I None
, I None
and I None
memory I None
in I None
past I None
and I None
present I None
polydrug I None
users I None
of I None
3,4-methylenedioxymethamphetamine I Chemical
<eof> I None

<s> O None
( I None
MDMA I Chemical
, I None
ecstasy I Chemical
) I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
Ecstasy I Chemical
<eof> I None

<s> O None
( I None
3,4-methylenedioxymethamphetamine I Chemical
, I None
MDMA I Chemical
) I None
is I None
a I None
worldwide I None
recreational I None
drug I None
of I None
abuse I None
. I None
<eof> I None

<s> O None
Unfortunately I None
, I None
the I None
results I None
from I None
human I None
research I None
investigating I None
its I None
psychological I None
effects I None
have I None
been I None
inconsistent I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
present I None
study I None
aimed I None
to I None
be I None
the I None
largest I None
to I None
date I None
in I None
sample I None
size I None
and I None
5HT I None
- I None
related I None
behaviors I None
; I None
the I None
first I None
to I None
compare I None
present I None
ecstasy I Chemical
users I None
with I None
past I None
users I None
after I None
an I None
abstinence I None
of I None
4 I None
or I None
more I None
years I None
, I None
and I None
the I None
first I None
to I None
include I None
robust I None
controls I None
for I None
other I None
recreational I None
substances I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
sample I None
of I None
997 I None
participants I None
( I None
52 I None
% I None
male I None
) I None
was I None
recruited I None
to I None
four I None
control I None
groups I None
( I None
non I None
- I None
drug I None
( I None
ND I None
) I None
, I None
alcohol I Chemical
/ I None
nicotine I Chemical
<eof> I None

<s> O None
( I None
AN I Chemical
) I None
, I None
cannabis I Chemical
/ I None
alcohol I Chemical
/ I None
nicotine I Chemical
<eof> I None

<s> O None
( I None
CAN I Chemical
) I None
, I None
non- I None
ecstasy I Chemical
polydrug I None
( I None
PD I None
) I None
) I None
, I None
and I None
two I None
ecstasy I Chemical
polydrug I None
groups I None
( I None
present I None
( I None
MDMA I Chemical
) I None
and I None
past I None
users I None
( I None
EX- I None
MDMA I Chemical
) I None
. I None
<eof> I None

<s> O None
Participants I None
completed I None
a I None
drug I None
history I None
questionnaire I None
, I None
Beck I None
Depression I Disease
Inventory I None
, I None
Barratt I None
Impulsiveness I Disease
Scale I None
, I None
Pittsburgh I None
Sleep I None
Quality I None
Index I None
, I None
and I None
Wechsler I None
Memory I None
Scale I None
<eof> I None

<s> O None
- I None
Revised I None
which I None
, I None
in I None
total I None
, I None
provided I None
13 I None
psychometric I None
measures I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
While I None
the I None
CAN I Chemical
and I None
PD I None
groups I None
tended I None
to I None
record I None
greater I None
deficits I None
than I None
the I None
non I None
- I None
drug I None
controls I None
, I None
the I None
MDMA I Chemical
and I None
EX- I None
MDMA I Chemical
groups I None
recorded I None
greater I None
deficits I None
than I None
all I None
the I None
control I None
groups I None
on I None
ten I None
of I None
the I None
13 I None
psychometric I None
measures I None
. I None
<eof> I None

<s> O None
Strikingly I None
, I None
despite I None
prolonged I None
abstinence I None
( I None
mean I None
, I None
4.98 I None
; I None
range I None
, I None
4 I None
- I None
9 I None
years I None
) I None
, I None
past I None
ecstasy I Chemical
users I None
showed I None
few I None
signs I None
of I None
recovery I None
. I None
<eof> I None

<s> O None
Compared I None
with I None
present I None
ecstasy I Chemical
users I None
, I None
the I None
past I None
users I None
showed I None
no I None
change I None
for I None
ten I None
measures I None
, I None
increased I None
impairment I None
for I None
two I None
measures I None
, I None
and I None
improvement I None
on I None
just I None
one I None
measure I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Given I None
this I None
record I None
of I None
impaired I Disease
memory O Disease
and I None
clinically I None
significant I None
levels I None
of I None
depression I Disease
, I None
impulsiveness I Disease
, I None
and I None
sleep I Disease
disturbance O Disease
, I None
the I None
prognosis I None
for I None
the I None
current I None
generation I None
of I None
ecstasy I Chemical
users I None
is I None
a I None
major I None
cause I None
for I None
concern I None
. I None
<eof> I None

<s> O None
Association I None
of I None
common I None
genetic I None
variants I None
of I None
HOMER1 I None
gene I None
with I None
levodopa I Chemical
adverse I None
effects I None
in I None
Parkinson I Disease
's O Disease
disease O Disease
patients I None
. I None
<eof> I None

<s> O None
Levodopa I Chemical
is I None
the I None
most I None
effective I None
symptomatic I None
therapy I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
, I None
but I None
its I None
chronic I None
use I None
could I None
lead I None
to I None
chronic I None
adverse I None
outcomes I None
, I None
such I None
as I None
motor I None
fluctuations I None
, I None
dyskinesia I Disease
and I None
visual I Disease
hallucinations O Disease
. I None
<eof> I None

<s> O None
HOMER1 I None
is I None
a I None
protein I None
with I None
pivotal I None
function I None
in I None
glutamate I Chemical
transmission I None
, I None
which I None
has I None
been I None
related I None
to I None
the I None
pathogenesis I None
of I None
these I None
complications I None
. I None
<eof> I None

<s> O None
This I None
study I None
investigates I None
whether I None
polymorphisms I None
in I None
the I None
HOMER1 I None
gene I None
promoter I None
region I None
are I None
associated I None
with I None
the I None
occurrence I None
of I None
the I None
chronic I None
complications I None
of I None
levodopa I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
205 I None
patients I None
with I None
idiopathic I Disease
Parkinson O Disease
's O Disease
disease O Disease
were I None
investigated I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
genotyped I None
for I None
rs4704559 I None
, I None
rs10942891 I None
and I None
rs4704560 I None
by I None
allelic I None
discrimination I None
with I None
Taqman I None
assays I None
. I None
<eof> I None

<s> O None
The I None
rs4704559 I None
G I None
allele I None
was I None
associated I None
with I None
a I None
lower I None
prevalence I None
of I None
dyskinesia I Disease
<eof> I None

<s> O None
( I None
prevalence I None
ratio I None
( I None
PR)=0.615 I None
, I None
95 I None
% I None
confidence I None
interval I None
( I None
CI I None
) I None
0.426 I None
- I None
0.887 I None
, I None
P=0.009 I None
) I None
and I None
visual I Disease
hallucinations O Disease
<eof> I None

<s> O None
( I None
PR=0.515 I None
, I None
95 I None
% I None
CI I None
0.295 I None
- I None
0.899 I None
, I None
P=0.020 I None
) I None
. I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
HOMER1 I None
rs4704559 I None
G I None
allele I None
has I None
a I None
protective I None
role I None
for I None
the I None
development I None
of I None
levodopa I Chemical
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Crocin I Chemical
improves I None
lipid I None
dysregulation I None
in I None
subacute I None
diazinon I Chemical
exposure I None
through I None
ERK1/2 I None
pathway I None
in I None
rat I None
liver I None
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
Diazinon I Chemical
<eof> I None

<s> O None
Yis I None
one I None
of I None
the I None
most I None
broadly I None
used I None
organophosphorus I Chemical
insecticides I None
in I None
agriculture I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
shown I None
that I None
exposure I None
to I None
diazinon I Chemical
may I None
interfere I None
with I None
lipid I None
metabolism I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
hypolipidemic I None
effect I None
of I None
crocin I Chemical
has I None
been I None
established I None
. I None
<eof> I None

<s> O None
Earlier I None
studies I None
revealed I None
the I None
major I None
role I None
of I None
Extracellular I None
signal I None
- I None
regulated I None
kinase I None
( I None
ERK I None
) I None
pathways I None
in I None
low I None
- I None
density I None
lipoprotein I None
receptor I None
( I None
LDLr I None
) I None
expression I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
evaluate I None
changes I None
in I None
the I None
regulation I None
of I None
lipid I None
metabolism I None
, I None
ERK I None
and I None
LDLr I None
expression I None
in I None
the I None
liver I None
of I None
rats I None
exposed I None
to I None
subacute I None
diazinon I Chemical
. I None
<eof> I None

<s> O None
Furthermore I None
ameliorating I None
effect I None
of I None
crocin I Chemical
on I None
diazinon I Chemical
induced I None
disturbed I None
cholesterol I Chemical
homeostasis I None
was I None
studied I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
24 I None
Rats I None
were I None
divided I None
into I None
4 I None
groups I None
and I None
received I None
following I None
treatments I None
for I None
4 I None
weeks I None
; I None
Corn I None
oil I None
( I None
control I None
) I None
, I None
diazinon I Chemical
( I None
15mg I None
/ I None
kg I None
per I None
day I None
, I None
orally I None
) I None
and I None
crocin I Chemical
( I None
12.5 I None
and I None
25mg I None
/ I None
kg I None
per I None
day I None
, I None
intraperitoneally I None
) I None
in I None
combination I None
with I None
diazinon I Chemical
<eof> I None

<s> O None
( I None
15 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
The I None
levels I None
of I None
cholesterol I Chemical
, I None
<eof> I None

<s> O None
triglyceride I Chemical
and I None
LDL I None
in I None
blood I None
of I None
rats I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
Moreover I None
mRNA I None
levels I None
of I None
LDLr I None
and I None
ERK1/2 I None
as I None
well I None
as I None
protein I None
levels I None
of I None
total I None
and I None
activated I None
forms I None
of I None
ERK1/2 I None
in I None
rat I None
liver I None
were I None
evaluated I None
by I None
Western I None
blotting I None
and I None
quantitative I None
real I None
time I None
polymerase I None
chain I None
reaction I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Our I None
data I None
showed I None
that I None
subacute I None
exposure I None
to I None
diazinon I Chemical
significantly I None
increased I None
concentrations I None
of I None
cholesterol I Chemical
, I None
triglyceride I Chemical
and I None
LDL I None
. I None
<eof> I None

<s> O None
Moreover I None
diazinon I Chemical
decreased I None
ERK1/2 I None
protein I None
phosphorylation I None
and I None
LDLr I None
transcript I None
. I None
<eof> I None

<s> O None
Crocin I Chemical
reduced I None
inhibition I None
of I None
ERK I None
activation I None
and I None
<eof> I None

<s> O None
diazinon I Chemical
-induced I None
<eof> I None

<s> O None
hyperlipemia I Disease
and I None
increased I None
levels I None
of I None
LDLr I None
transcript I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Crocin I Chemical
may I None
be I None
considered I None
as I None
a I None
novel I None
protective I None
agent I None
in I None
diazinon I Chemical
-induced I None
hyperlipemia I Disease
through I None
modulating I None
of I None
ERK I None
pathway I None
and I None
increase I None
of I None
LDLr I None
expression I None
. I None
<eof> I None

<s> O None
GEM I Chemical
-P I None
chemotherapy I None
is I None
active I None
in I None
the I None
treatment I None
of I None
relapsed I None
Hodgkin I Disease
lymphoma O Disease
. I None
<eof> I None

<s> O None
Hodgkin I Disease
lymphoma O Disease
<eof> I None

<s> O None
( I None
HL I Disease
) I None
is I None
a I None
relatively I None
chemosensitive I None
malignancy I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
for I None
those I None
who I None
relapse I None
, I None
high I None
- I None
dose I None
chemotherapy I None
with I None
autologous I None
stem I None
cell I None
transplant I None
is I None
the I None
treatment I None
of I None
choice I None
which I None
relies I None
on I None
adequate I None
disease I None
control I None
with I None
salvage I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Regimens I None
commonly I None
used I None
often I None
require I None
inpatient I None
administration I None
and I None
can I None
be I None
difficult I None
to I None
deliver I None
due I None
to I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Gemcitabine I Chemical
and I None
cisplatin I Chemical
have I None
activity I None
in I None
HL I Disease
, I None
non I None
- I None
overlapping I None
toxicity I Disease
with I None
first I None
- I None
line I None
chemotherapeutics I None
, I None
and I None
may I None
be I None
delivered I None
in I None
an I None
outpatient I None
setting I None
. I None
<eof> I None

<s> O None
In I None
this I None
retrospective I None
single I None
- I None
centre I None
analysis I None
, I None
patients I None
with I None
relapsed I None
or I None
refractory I None
HL I Disease
treated I None
with I None
gemcitabine I Chemical
1,000 I None
mg I None
/ I None
m(2 I None
<eof> I None

<s> O None
) I None
day I None
( I None
D)1 I None
, I None
D8 I None
and I None
D15 I None
; I None
methylprednisolone I Chemical
1,000 I None
mg I None
D1 I None
- I None
5 I None
; I None
and I None
cisplatin I Chemical
100 I None
mg I None
/ I None
m(2 I None
) I None
<eof> I None

<s> O None
D15 I None
, I None
every I None
28 I None
days I None
( I None
GEM I Chemical
-P I None
) I None
were I None
included I None
. I None
<eof> I None

<s> O None
Demographic I None
, I None
survival I None
, I None
response I None
and I None
toxicity I Disease
data I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
one I None
eligible I None
patients I None
were I None
identified I None
: I None
median I None
age I None
27 I None
. I None
<eof> I None

<s> O None
One I None
hundred I None
and I None
twenty I None
- I None
two I None
cycles I None
of I None
GEM I Chemical
-P I None
were I None
administered I None
in I None
total I None
( I None
median I None
3 I None
cycles I None
; I None
range I None
1 I None
- I None
6 I None
) I None
. I None
<eof> I None

<s> O None
Twenty I None
of I None
41 I None
( I None
48 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
received I None
GEM I Chemical
-P I None
as I None
second I None
- I None
line I None
treatment I None
and I None
11/41 I None
( I None
27 I None
% I None
) I None
as I None
third I None
- I None
line I None
therapy I None
. I None
<eof> I None

<s> O None
Overall I None
response I None
rate I None
( I None
ORR I None
) I None
to I None
GEM I Chemical
-P I None
in I None
the I None
entire I None
cohort I None
was I None
80 I None
% I None
( I None
complete I None
response I None
( I None
CR I None
) I None
37 I None
% I None
, I None
partial I None
response I None
44 I None
% I None
) I None
with I None
14/15 I None
CR I None
confirmed I None
as I None
a I None
metabolic I None
CR I None
on I None
PET I None
and I None
ORR I None
of I None
85 I None
% I None
in I None
the I None
20 I None
second I None
- I None
line I None
patients I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
grade I None
3/4 I None
toxicities I Disease
were I None
haematological I None
: I None
<eof> I None

<s> O None
neutropenia I Disease
54 I None
% I None
and I None
thrombocytopenia I Disease
51 I None
% I None
. I None
<eof> I None

<s> O None
Median I None
follow I None
- I None
up I None
from I None
the I None
start I None
of I None
GEM I Chemical
-P I None
was I None
4.5 I None
years I None
. I None
<eof> I None

<s> O None
Following I None
GEM I Chemical
-P I None
, I None
5-year I None
progression I None
- I None
free I None
survival I None
was I None
46 I None
% I None
( I None
95 I None
% I None
confidence I None
interval I None
( I None
CI I None
) I None
, I None
30 I None
- I None
62 I None
% I None
) I None
and I None
5-year I None
overall I None
survival I None
was I None
59 I None
% I None
( I None
95 I None
% I None
CI I None
, I None
43 I None
- I None
74 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Fourteen I None
of I None
41 I None
patients I None
proceeded I None
directly I None
to I None
autologous I None
transplant I None
. I None
<eof> I None

<s> O None
GEM I Chemical
-P I None
is I None
a I None
salvage I None
chemotherapy I None
with I None
relatively I None
high I None
response I None
rates I None
, I None
leading I None
to I None
successful I None
transplantation I None
in I None
appropriate I None
patients I None
, I None
in I None
the I None
treatment I None
of I None
relapsed I None
or I None
refractory I None
HL I Disease
. I None
<eof> I None

<s> O None
Basal I None
functioning I None
of I None
the I None
hypothalamic I None
- I None
pituitary I None
- I None
adrenal I None
( I None
HPA I None
) I None
axis I None
and I None
psychological I None
distress I None
in I None
recreational I None
ecstasy I Chemical
polydrug I None
users I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
Ecstasy I Chemical
<eof> I None

<s> O None
( I None
MDMA I Chemical
) I None
is I None
a I None
psychostimulant I None
drug I None
which I None
is I None
increasingly I None
associated I None
with I None
psychobiological I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
While I None
some I None
recent I None
studies I None
suggest I None
acute I None
changes I None
in I None
neuroendocrine I None
function I None
, I None
less I None
is I None
known I None
about I None
long I None
- I None
term I None
changes I None
in I None
HPA I None
functionality I None
in I None
recreational I None
users I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
current I None
study I None
is I None
the I None
first I None
to I None
explore I None
the I None
effects I None
of I None
ecstasy I Chemical
-polydrug I None
use I None
on I None
psychological I None
distress I None
and I None
basal I None
functioning I None
of I None
the I None
HPA I None
axis I None
through I None
assessing I None
the I None
secretion I None
of I None
cortisol I Chemical
across I None
the I None
diurnal I None
period I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Seventy I None
- I None
six I None
participants I None
( I None
21 I None
nonusers I None
, I None
29 I None
light I None
ecstasy I Chemical
-polydrug I None
users I None
, I None
26 I None
heavy I None
ecstasy I Chemical
-polydrug I None
users I None
) I None
completed I None
a I None
substance I None
use I None
inventory I None
and I None
measures I None
of I None
psychological I None
distress I None
at I None
baseline I None
, I None
then I None
two I None
consecutive I None
days I None
of I None
cortisol I Chemical
sampling I None
( I None
on I None
awakening I None
, I None
30 I None
min I None
post I None
awakening I None
, I None
between I None
1400 I None
and I None
1600 I None
hours I None
and I None
pre I None
bedtime I None
) I None
. I None
<eof> I None

<s> O None
On I None
day I None
2 I None
, I None
participants I None
also I None
attended I None
the I None
laboratory I None
to I None
complete I None
a I None
20-min I None
multitasking I None
stressor I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Both I None
user I None
groups I None
exhibited I None
significantly I None
greater I None
levels I None
of I None
anxiety I Disease
and I None
depression I Disease
than I None
nonusers I None
. I None
<eof> I None

<s> O None
On I None
day I None
1 I None
, I None
all I None
participants I None
exhibited I None
a I None
typical I None
cortisol I Chemical
profile I None
, I None
though I None
light I None
users I None
had I None
significantly I None
elevated I None
levels I None
pre I None
- I None
bed I None
. I None
<eof> I None

<s> O None
On I None
day I None
2 I None
, I None
heavy I None
users I None
demonstrated I None
elevated I None
levels I None
upon I None
awakening I None
and I None
all I None
ecstasy I Chemical
-polydrug I None
users I None
demonstrated I None
elevated I None
pre I None
- I None
bed I None
levels I None
compared I None
to I None
non I None
- I None
users I None
. I None
<eof> I None

<s> O None
Significant I None
between I None
group I None
differences I None
were I None
also I None
observed I None
in I None
afternoon I None
cortisol I Chemical
levels I None
and I None
in I None
overall I None
cortisol I Chemical
secretion I None
across I None
the I None
day I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
increases I None
in I None
anxiety I Disease
and I None
depression I Disease
are I None
in I None
line I None
with I None
previous I None
observations I None
in I None
recreational I None
ecstasy I Chemical
-polydrug I None
users I None
. I None
<eof> I None

<s> O None
Dysregulated I None
diurnal I None
<eof> I None

<s> O None
cortisol I Chemical
may I None
be I None
indicative I None
of I None
inappropriate I None
anticipation I None
of I None
forthcoming I None
demands I None
and I None
hypersecretion I None
may I None
lead I None
to I None
the I None
increased I None
psychological I None
and I None
physical I None
morbidity I None
associated I None
with I None
heavy I None
recreational I None
use I None
of I None
ecstasy I Chemical
. I None
<eof> I None

<s> O None
Ifosfamide I Chemical
related I None
encephalopathy I Disease
: I None
the I None
need I None
for I None
a I None
timely I None
EEG I None
evaluation I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Ifosfamide I Chemical
is I None
an I None
alkylating I None
agent I None
useful I None
in I None
the I None
treatment I None
of I None
a I None
wide I None
range I None
of I None
cancers I Disease
including I None
sarcomas I Disease
, I None
lymphoma I Disease
, I None
gynecologic I Disease
and O Disease
testicular O Disease
cancers O Disease
. I None
<eof> I None

<s> O None
Encephalopathy I Disease
has I None
been I None
reported I None
in I None
10 I None
- I None
40 I None
% I None
of I None
patients I None
receiving I None
high I None
- I None
dose I None
IV I None
ifosfamide I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
highlight I None
the I None
role I None
of I None
electroencephalogram I None
( I None
EEG I None
) I None
in I None
the I None
early I None
detection I None
and I None
management I None
of I None
<eof> I None

<s> O None
ifosfamide I Chemical
related I None
encephalopathy I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Retrospective I None
chart I None
review I None
including I None
clinical I None
data I None
and I None
EEG I None
recordings I None
was I None
done I None
on I None
five I None
patients I None
, I None
admitted I None
to I None
MD I None
Anderson I None
Cancer I Disease
Center I None
between I None
years I None
2009 I None
and I None
2012 I None
, I None
who I None
developed I None
ifosfamide I Chemical
related I None
acute I None
encephalopathy I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
five I None
patients I None
experienced I None
symptoms I None
of I None
encephalopathy I Disease
soon I None
after I None
( I None
within I None
12 I None
h-2 I None
days I None
) I None
receiving I None
ifosfamide I Chemical
. I None
<eof> I None

<s> O None
Two I None
patients I None
developed I None
generalized I None
convulsions I Disease
while I None
one I None
patient I None
developed I None
continuous I None
non I Disease
- O Disease
convulsive O Disease
status O Disease
epilepticus O Disease
<eof> I None

<s> O None
( I None
NCSE I Disease
) I None
that I None
required I None
ICU I None
admission I None
and I None
intubation I None
. I None
<eof> I None

<s> O None
Initial I None
EEG I None
showed I None
epileptiform I None
discharges I None
in I None
three I None
patients I None
; I None
run I None
of I None
triphasic I None
waves I None
in I None
one I None
patient I None
and I None
moderate I None
degree I None
diffuse I None
generalized I None
slowing I None
. I None
<eof> I None

<s> O None
Mixed I None
pattern I None
with I None
the I None
presence I None
of I None
both I None
sharps I None
and I None
triphasic I None
waves I None
were I None
also I None
noted I None
. I None
<eof> I None

<s> O None
Repeat I None
EEGs I None
within I None
24_h I None
of I None
symptom I None
onset I None
showed I None
marked I None
improvement I None
that I None
was I None
correlated I None
with I None
clinical I None
improvement I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Severity I None
of I None
ifosfamide I Chemical
related I None
encephalopathy I Disease
correlates I None
with I None
EEG I None
changes I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
a I None
timely I None
EEG I None
evaluation I None
for I None
patients I None
receiving I None
ifosfamide I Chemical
who I None
develop I None
features I None
of I None
encephalopathy I Disease
. I None
<eof> I None

<s> O None
Incidence I None
of I None
contrast I Chemical
-induced I None
nephropathy I Disease
in I None
hospitalised I None
patients I None
with I None
cancer I Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
frequency I None
of I None
and I None
possible I None
factors I None
related I None
to I None
contrast I Chemical
-induced I None
nephropathy I Disease
( I None
CIN I None
) I None
in I None
hospitalised I None
patients I None
with I None
cancer I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Ninety I None
adult I None
patients I None
were I None
enrolled I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
risk I None
factors I None
for I None
acute I Disease
renal O Disease
failure O Disease
were I None
excluded I None
. I None
<eof> I None

<s> O None
Blood I None
samples I None
were I None
examined I None
the I None
day I None
before I None
contrast I Chemical
-enhanced I None
computed I None
tomography I None
( I None
CT I None
) I None
and I None
serially I None
for I None
3 I None
days I None
thereafter I None
. I None
<eof> I None

<s> O None
CIN I None
was I None
defined I None
as I None
an I None
increase I None
in I None
serum I None
creatinine I Chemical
<eof> I None

<s> O None
( I None
Cr I Chemical
) I None
of I None
0.5 I None
mg I None
/ I None
dl I None
or I None
more I None
, I None
or I None
elevation I None
of I None
Cr I Chemical
to I None
25 I None
% I None
over I None
baseline I None
. I None
<eof> I None

<s> O None
Relationships I None
between I None
CIN I None
and I None
possible I None
risk I None
factors I None
were I None
investigated I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
CIN I None
was I None
detected I None
in I None
18/90 I None
( I None
20 I None
% I None
) I None
patients I None
. I None
<eof> I None

<s> O None
CIN I None
developed I None
in I None
25.5 I None
% I None
patients I None
who I None
underwent I None
chemotherapy I None
and I None
in I None
11 I None
% I None
patients I None
who I None
did I None
not I None
( I None
P I None
= I None
0.1 I None
) I None
. I None
<eof> I None

<s> O None
CIN I None
more I None
frequently I None
developed I None
in I None
patients I None
who I None
had I None
undergone I None
CT I None
within I None
45 I None
days I None
after I None
the I None
last I None
chemotherapy I None
( I None
P I None
= I None
0.005 I None
) I None
; I None
it I None
was I None
also I None
an I None
independent I None
risk I None
factor I None
( I None
P I None
= I None
0.017 I None
) I None
. I None
<eof> I None

<s> O None
CIN I None
was I None
significantly I None
more I None
after I None
treatment I None
with I None
bevacizumab I Chemical
/ I None
irinotecan I Chemical
( I None
P I None
= I None
0.021 I None
) I None
<eof> I None

<s> O None
and I None
in I None
patients I None
with I None
hypertension I Disease
<eof> I None

<s> O None
( I None
P I None
= I None
0.044 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
CIN I None
after I None
CT I None
in I None
hospitalised I None
oncological I None
patients I None
was I None
20 I None
% I None
. I None
<eof> I None

<s> O None
CIN I None
developed I None
4.5-times I None
more I None
frequently I None
in I None
patients I None
with I None
cancer I Disease
who I None
had I None
undergone I None
recent I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Hypertension I Disease
and I None
the I None
combination I None
of I None
bevacizumab I Chemical
/ I None
irinotecan I Chemical
may I None
be I None
additional I None
risk I None
factors I None
for I None
CIN I None
development I None
. I None
<eof> I None

<s> O None
KEY I None
POINTS I None
: I None
. I None
<eof> I None

<s> O None
Contrast I Chemical
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
<eof> I None

<s> O None
( I None
CIN I None
) I None
is I None
a I None
concern I None
for I None
oncological I None
patients I None
undergoing I None
CT I None
. I None
. I None
<eof> I None

<s> O None
CIN I None
occurs I None
more I None
often I None
when I None
CT I None
is I None
performed I None
< I None
45 I None
days I None
after I None
chemotherapy I None
. I None
. I None
<eof> I None

<s> O None
Hypertension I Disease
and I None
treatment I None
with I None
bevacizumab I Chemical
appear I None
to I None
be I None
additional I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Syndrome I Disease
of O Disease
inappropriate O Disease
antidiuretic O Disease
hormone O Disease
secretion I None
associated I None
with I None
desvenlafaxine I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
syndrome I Disease
of O Disease
inappropriate O Disease
anti O Disease
- O Disease
diuretic O Disease
hormone O Disease
<eof> I None

<s> O None
( I None
SIADH I Disease
) I None
secretion I None
associated I None
with I None
desvenlafaxine I Chemical
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
57-year I None
old I None
female I None
with I None
hyponatraemia I Disease
. I None
<eof> I None

<s> O None
Her I None
medications I None
included I None
desvenlafaxine I Chemical
, I None
and I None
symptoms I None
included I None
nausea I Disease
, I None
anxiety I Disease
and I None
confusion I Disease
. I None
<eof> I None

<s> O None
The I None
serum I None
sodium I Chemical
at I None
this I None
time I None
was I None
120 I None
mmol I None
/ I None
L I None
, I None
serum I None
osmolality I None
was I None
263 I None
mosmol I None
/ I None
kg I None
, I None
urine I None
osmolality I None
410 I None
mosmol I None
/ I None
kg I None
and I None
urine I None
sodium I Chemical
<eof> I None

<s> O None
63 I None
mmol I None
/ I None
L I None
, I None
consistent I None
with I None
a I None
diagnosis I None
of I None
SIADH I Disease
. I None
<eof> I None

<s> O None
Desvenlafaxine I Chemical
was I None
ceased I None
and I None
fluid I None
restriction I None
implemented I None
. I None
<eof> I None

<s> O None
After I None
4 I None
days I None
the I None
sodium I Chemical
increased I None
to I None
128 I None
mmol I None
/ I None
L I None
and I None
fluid I None
restriction I None
was I None
relaxed I None
. I None
<eof> I None

<s> O None
During I None
her I None
further I None
3 I None
weeks I None
inpatient I None
admission I None
the I None
serum I None
sodium I Chemical
ranged I None
from I None
134 I None
to I None
137 I None
mmol I None
/ I None
L I None
during I None
treatment I None
with I None
mirtazapine I Chemical
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
SIADH I Disease
has I None
been I None
widely I None
reported I None
with I None
a I None
range I None
of I None
antidepressants I None
. I None
<eof> I None

<s> O None
This I None
case I None
report I None
suggests I None
that I None
desvenlafaxine I Chemical
might I None
cause I None
clinically I None
significant I None
hyponatremia I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
aware I None
of I None
the I None
potential I None
for I None
antidepressants I None
to I None
cause I None
hyponatremia I Disease
, I None
and I None
take I None
appropriate I None
corrective I None
action I None
where I None
necessary I None
. I None
<eof> I None

<s> O None
Oxidative I None
stress I None
on I None
cardiotoxicity I Disease
after I None
treatment I None
with I None
single I None
and I None
multiple I None
doses I None
of I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
remains I None
controversial I None
. I None
<eof> I None

<s> O None
Wistar I None
rats I None
( I None
n I None
= I None
66 I None
) I None
received I None
DOX I Chemical
injections I None
intraperitoneally I None
and I None
were I None
randomly I None
assigned I None
to I None
2 I None
experimental I None
protocols I None
: I None
( I None
1 I None
) I None
rats I None
were I None
killed I None
before I None
( I None
-24 I None
h I None
, I None
n I None
= I None
8) I None
and I None
24 I None
h I None
after I None
( I None
+ I None
24 I None
h I None
, I None
n I None
= I None
8) I None
a I None
single I None
dose I None
of I None
DOX I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg I None
/ I None
kg I None
body I None
weight I None
) I None
to I None
determine I None
the I None
DOX I Chemical
acute I None
effect I None
and I None
( I None
2 I None
) I None
rats I None
( I None
n I None
= I None
58 I None
) I None
received I None
4 I None
injections I None
of I None
DOX I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg I None
/ I None
kg I None
body I None
weight I None
/ I None
week I None
) I None
and I None
were I None
killed I None
before I None
the I None
first I None
injection I None
( I None
M0 I None
) I None
and I None
1 I None
week I None
after I None
each I None
injection I None
( I None
M1 I None
, I None
M2 I None
, I None
M3 I None
, I None
and I None
M4 I None
) I None
to I None
determine I None
the I None
chronological I None
effects I None
. I None
<eof> I None

<s> O None
Animals I None
used I None
at I None
M0 I None
( I None
n I None
= I None
8) I None
were I None
also I None
used I None
at I None
moment I None
-24 I None
h I None
of I None
acute I None
study I None
. I None
<eof> I None

<s> O None
Cardiac I None
total I None
antioxidant I None
performance I None
( I None
TAP I None
) I None
, I None
DNA I None
damage I None
, I None
and I None
morphology I None
analyses I None
were I None
carried I None
out I None
at I None
each I None
time I None
point I None
. I None
<eof> I None

<s> O None
Single I None
dose I None
of I None
DOX I Chemical
was I None
associated I None
with I None
increased I None
cardiac I Disease
disarrangement O Disease
, I None
necrosis I Disease
, I None
and I None
DNA I None
damage I None
( I None
strand I None
breaks I None
( I None
SBs I None
) I None
and I None
oxidized I None
pyrimidines I None
) I None
and I None
decreased I None
TAP I None
. I None
<eof> I None

<s> O None
The I None
chronological I None
study I None
showed I None
an I None
effect I None
of I None
a I None
cumulative I None
dose I None
on I None
body I None
weight I None
( I None
R I None
= I None
-0.99 I None
, I None
p I None
= I None
0.011 I None
) I None
, I None
necrosis I Disease
<eof> I None

<s> O None
( I None
R I None
= I None
1.00 I None
, I None
p I None
= I None
0.004 I None
) I None
, I None
TAP I None
( I None
R I None
= I None
0.95 I None
, I None
<eof> I None

<s> O None
p I None
= I None
0.049 I None
) I None
, I None
and I None
DNA I None
SBs I None
( I None
R I None
= I None
-0.95 I None
, I None
p I None
= I None
0.049 I None
) I None
. I None
<eof> I None

<s> O None
DNA I None
SBs I None
damage I None
was I None
negatively I None
associated I None
with I None
TAP I None
( I None
R I None
= I None
-0.98 I None
, I None
p I None
= I None
0.018 I None
) I None
, I None
and I None
necrosis I Disease
( I None
R I None
= I None
-0.97 I None
, I None
p I None
= I None
0.027 I None
) I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
oxidative I None
damage I None
is I None
associated I None
with I None
acute I None
cardiotoxicity I Disease
induced I None
by I None
a I None
single I None
dose I None
of I None
DOX I Chemical
only I None
. I None
<eof> I None

<s> O None
Increased I None
resistance I None
to I None
the I None
oxidative I None
stress I None
is I None
plausible I None
for I None
the I None
multiple I None
dose I None
of I None
DOX I Chemical
. I None
<eof> I None

<s> O None
Thus I None
, I None
different I None
mechanisms I None
may I None
be I None
involved I None
in I None
acute I None
toxicity I Disease
versus I None
chronic I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Tacrolimus I Chemical
-related I None
seizure I Disease
after I None
pediatric I None
liver I None
transplantation I None
-- I None
a I None
single I None
- I None
center I None
experience I None
. I None
<eof> I None

<s> O None
To I None
identify I None
the I None
risk I None
factors I None
for I None
new I None
- I None
onset I None
seizures I Disease
after I None
pediatric I None
LT I None
and I None
to I None
assess I None
their I None
clinical I None
implications I None
and I None
long I None
- I None
term I None
prognosis I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
and I None
laboratory I None
data I None
of I None
27 I None
consecutive I None
children I None
who I None
underwent I None
LT I None
from I None
January I None
2007 I None
to I None
December I None
2010 I None
in I None
our I None
center I None
were I None
analyzed I None
retrospectively I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
divided I None
into I None
seizures I Disease
group I None
and I None
a I None
non- I None
seizures I Disease
group I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
operative I None
, I None
intra I None
- I None
operative I None
, I None
and I None
post I None
- I None
operative I None
data I None
were I None
collected I None
. I None
<eof> I None

<s> O None
Seizures I Disease
occurred I None
in I None
four I None
children I None
, I None
an I None
incidence I None
of I None
14.8 I None
% I None
. I None
<eof> I None

<s> O None
All I None
exhibited I None
generalized I None
tonic I Disease
- O Disease
clonic O Disease
seizures O Disease
within I None
the I None
first I None
two I None
wk I None
after I None
LT I None
. I None
<eof> I None

<s> O None
Univariate I None
analysis I None
showed I None
that I None
the I None
risk I None
factors I None
associated I None
with I None
seizures I Disease
<eof> I None

<s> O None
after I None
pediatric I None
LT I None
included I None
gender I None
, I None
pediatric I None
end I Disease
- O Disease
stage O Disease
liver O Disease
disease O Disease
score I None
before I None
surgery I None
, I None
Child I None
- I None
Pugh I None
score I None
before I None
surgery I None
, I None
serum I None
total I None
<eof> I None

<s> O None
bilirubin I Chemical
after I None
surgery I None
, I None
and I None
trough I None
TAC I Chemical
level I None
. I None
<eof> I None

<s> O None
Multivariate I None
analysis I None
showed I None
that I None
trough I None
TAC I Chemical
level I None
was I None
the I None
only I None
independent I None
risk I None
factor I None
associated I None
with I None
the I None
seizures I Disease
. I None
<eof> I None

<s> O None
All I None
children I None
who I None
experienced I None
seizures I Disease
survived I None
with I None
good I None
graft I None
function I None
and I None
remained I None
<eof> I None

<s> O None
seizure I Disease
-free I None
without I None
anti- I None
epileptic I Disease
drugs I None
over I None
a I None
mean I None
follow I None
- I None
up I None
period I None
of I None
33.7 I None
+ I None
14.6 I None
months I None
. I None
<eof> I None

<s> O None
High I None
trough I None
TAC I Chemical
<eof> I None

<s> O None
level I None
was I None
the I None
predominant I None
factor I None
that I None
contributed I None
to I None
seizures I Disease
in I None
the I None
early I None
post I None
- I None
operative I None
period I None
after I None
pediatric I None
LT I None
. I None
<eof> I None

<s> O None
High I None
PELD I None
and I None
Child I None
- I None
Pugh I None
scores I None
before I None
LT I None
and I None
high I None
post I None
- I None
operative I None
serum I None
Tbil I None
may I None
be I None
contributory I None
risk I None
factors I None
for I None
TAC I Chemical
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
The I None
flavonoid I Chemical
apigenin I Chemical
delays I None
forgetting I None
of I None
passive I None
avoidance I None
conditioning I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
present I None
experiments I None
were I None
performed I None
to I None
study I None
the I None
effect I None
of I None
the I None
flavonoid I Chemical
apigenin I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
intraperitoneally I None
( I None
i.p I None
. I None
) I None
, I None
1 I None
h I None
before I None
acquisition I None
) I None
, I None
on I None
24 I None
h I None
retention I None
performance I None
and I None
forgetting I None
of I None
a I None
step I None
- I None
through I None
passive I None
avoidance I None
task I None
, I None
in I None
young I None
male I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
differences I None
between I None
saline- I None
and I None
apigenin I Chemical
-treated I None
groups I None
in I None
the I None
24 I None
h I None
retention I None
trial I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
apigenin I Chemical
did I None
not I None
prevent I None
the I None
amnesia I Disease
induced I None
by I None
scopolamine I Chemical
<eof> I None

<s> O None
( I None
1mg I None
/ I None
kg I None
, I None
i.p I None
. I None
, I None
30 I None
min I None
before I None
the I None
acquisition I None
) I None
. I None
<eof> I None

<s> O None
The I None
saline- I None
and I None
apigenin I Chemical
-treated I None
rats I None
that I None
did I None
not I None
step I None
through I None
into I None
the I None
dark I None
compartment I None
during I None
the I None
cut I None
- I None
off I None
time I None
( I None
540 I None
s I None
) I None
were I None
retested I None
weekly I None
for I None
up I None
to I None
eight I None
weeks I None
. I None
<eof> I None

<s> O None
In I None
the I None
saline I None
treated I None
group I None
, I None
the I None
first I None
significant I None
decline I None
in I None
passive I None
avoidance I None
response I None
was I None
observed I None
at I None
four I None
weeks I None
, I None
and I None
complete I None
<eof> I None

<s> O None
memory I Disease
loss O Disease
was I None
found I None
five I None
weeks I None
after I None
the I None
acquisition I None
of I None
the I None
passive I None
avoidance I None
task I None
. I None
<eof> I None

<s> O None
At I None
the I None
end I None
of I None
the I None
experimental I None
period I None
, I None
60 I None
% I None
of I None
the I None
animals I None
treated I None
with I None
apigenin I Chemical
still I None
did I None
not I None
step I None
through I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
1 I None
) I None
apigenin I Chemical
delays I None
the I None
long I None
- I None
term I None
forgetting I None
but I None
did I None
not I None
modulate I None
the I None
24 I None
h I None
retention I None
of I None
fear I None
memory I None
and I None
2 I None
) I None
<eof> I None

<s> O None
the I None
obtained I None
beneficial I None
effect I None
of I None
apigenin I Chemical
on I None
the I None
passive I None
avoidance I None
conditioning I None
is I None
mediated I None
by I None
mechanisms I None
that I None
do I None
not I None
implicate I None
its I None
action I None
on I None
the I None
muscarinic I None
cholinergic I None
system I None
. I None
<eof> I None

<s> O None
Cholecystokinin I Chemical
- O Chemical
octapeptide O Chemical
restored I None
<eof> I None

<s> O None
morphine I Chemical
-induced I None
hippocampal I None
long I None
- I None
term I None
potentiation I None
impairment I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Cholecystokinin I Chemical
- O Chemical
octapeptide O Chemical
( I None
CCK-8 I Chemical
) I None
, I None
which I None
is I None
a I None
typical I None
brain I None
- I None
gut I None
peptide I None
, I None
exerts I None
a I None
wide I None
range I None
of I None
biological I None
activities I None
on I None
the I None
central I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
We I None
have I None
previously I None
reported I None
that I None
CCK-8 I Chemical
significantly I None
alleviated I None
morphine I Chemical
-induced I None
amnesia I Disease
and I None
reversed I None
spine I None
density I None
decreases I None
in I None
the I None
CA1 I None
region I None
of I None
the I None
hippocampus I None
in I None
<eof> I None

<s> O None
morphine I Chemical
-treated I None
animals I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
investigated I None
the I None
effects I None
of I None
CCK-8 I Chemical
on I None
long I None
- I None
term I None
potentiation I None
( I None
LTP I None
) I None
in I None
the I None
lateral I None
perforant I None
path I None
( I None
LPP)-granule I None
cell I None
synapse I None
of I None
rat I None
dentate I None
gyrus I None
( I None
DG I None
) I None
in I None
acute I None
saline I None
or I None
morphine I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Population I None
spikes I None
( I None
PS I None
) I None
, I None
which I None
were I None
evoked I None
by I None
stimulation I None
of I None
the I None
LPP I None
, I None
were I None
recorded I None
in I None
the I None
DG I None
region I None
. I None
<eof> I None

<s> O None
Acute I None
morphine I Chemical
<eof> I None

<s> O None
( I None
30mg I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
treatment I None
significantly I None
attenuated I None
hippocampal I None
LTP I None
and I None
CCK-8 I Chemical
( I None
1ug I None
, I None
i.c.v I None
. I None
) I None
restored I None
the I None
amplitude I None
of I None
PS I None
that I None
was I None
attenuated I None
by I None
morphine I Chemical
injection I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
microinjection I None
of I None
CCK-8 I Chemical
( I None
0.1 I None
and I None
1ug I None
, I None
i.c.v I None
. I None
) I None
<eof> I None

<s> O None
also I None
significantly I None
augmented I None
hippocampal I None
LTP I None
in I None
saline I None
- I None
treated I None
( I None
1ml I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
rats I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
treatment I None
of I None
the I None
CCK2 I None
receptor I None
antagonist I None
L-365,260 I None
( I None
10ug I None
, I None
i.c.v I None
) I None
reversed I None
the I None
effects I None
of I None
CCK-8 I Chemical
, I None
but I None
the I None
CCK1 I None
receptor I None
antagonist I None
L-364,718 I None
( I None
10ug I None
, I None
i.c.v I None
) I None
did I None
not I None
. I None
<eof> I None

<s> O None
The I None
present I None
results I None
demonstrate I None
that I None
CCK-8 I Chemical
attenuates I None
the I None
effect I None
of I None
morphine I Chemical
on I None
hippocampal I None
LTP I None
through I None
CCK2 I None
receptors I None
and I None
suggest I None
an I None
ameliorative I None
function I None
of I None
CCK-8 I Chemical
on I None
morphine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
memory I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
Glial I None
activation I None
and I None
post I None
- I None
synaptic I None
neurotoxicity I Disease
: I None
<eof> I None

<s> O None
the I None
key I None
events I None
in I None
Streptozotocin I Chemical
( I None
ICV I None
) I None
induced I None
memory I Disease
impairment O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
the I None
role I None
of I None
glial I None
activation I None
and I None
post I None
synaptic I None
toxicity I Disease
in I None
ICV I None
Streptozotocin I Chemical
<eof> I None

<s> O None
( I None
STZ I Chemical
) I None
induced I None
memory I Disease
impaired O Disease
rats I None
was I None
explored I None
. I None
<eof> I None

<s> O None
In I None
experiment I None
set I None
up I None
1 I None
: I None
Memory I Disease
deficit O Disease
was I None
found I None
in I None
Morris I None
water I None
maze I None
test I None
on I None
14 I None
- I None
16 I None
days I None
after I None
STZ I Chemical
( I None
ICV I None
; I None
3mg I None
/ I None
Kg I None
) I None
administration I None
. I None
<eof> I None

<s> O None
STZ I Chemical
causes I None
increased I None
expression I None
of I None
GFAP I None
, I None
CD11b I None
and I None
TNF I None
- I None
a I None
indicating I None
glial I None
activation I None
and I None
neuroinflammation I Disease
. I None
<eof> I None

<s> O None
STZ I Chemical
also I None
significantly I None
increased I None
the I None
level I None
of I None
ROS I None
, I None
nitrite I Chemical
, I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
and I None
reduced I None
the I None
mitochondrial I None
activity I None
in I None
synaptosomal I None
preparation I None
illustrating I None
free I None
radical I None
generation I None
and I None
excitotoxicity I Disease
. I None
<eof> I None

<s> O None
Increased I None
expression I None
and I None
activity I None
of I None
Caspase-3 I None
was I None
also I None
observed I None
in I None
STZ I Chemical
<eof> I None

<s> O None
treated I None
rat I None
which I None
specify I None
apoptotic I None
cell I None
death I None
in I None
hippocampus I None
and I None
cortex I None
. I None
<eof> I None

<s> O None
STZ I Chemical
treatment I None
showed I None
decrease I None
expression I None
of I None
post I None
synaptic I None
markers I None
CaMKIIa I None
and I None
PSD-95 I None
, I None
while I None
, I None
expression I None
of I None
pre I None
synaptic I None
markers I None
( I None
synaptophysin I None
and I None
SNAP-25 I None
) I None
remains I None
unaltered I None
indicating I None
selective I None
post I None
synaptic I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
Oral I None
treatment I None
with I None
Memantine I Chemical
<eof> I None

<s> O None
( I None
10mg I None
/ I None
kg I None
) I None
and I None
Ibuprofen I Chemical
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
kg I None
) I None
daily I None
for I None
13 I None
days I None
attenuated I None
<eof> I None

<s> O None
STZ I Chemical
induced I None
glial I None
activation I None
, I None
apoptotic I None
cell I None
death I None
and I None
post I None
synaptic I None
neurotoxicity I Disease
in I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
Further I None
, I None
in I None
experiment I None
set I None
up I None
2 I None
: I None
where I None
memory I None
function I None
was I None
not I None
affected I None
i.e. I None
7 I None
- I None
9 I None
days I None
after I None
STZ I Chemical
treatment I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
GFAP I None
, I None
CD11b I None
, I None
TNF I None
- I None
a I None
, I None
ROS I None
and I None
nitrite I Chemical
levels I None
were I None
increased I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
apoptotic I None
marker I None
, I None
synaptic I None
markers I None
, I None
mitochondrial I None
activity I None
and I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
levels I None
remained I None
unaffected I None
. I None
<eof> I None

<s> O None
Collective I None
data I None
indicates I None
that I None
neuroinflammatory I Disease
process I None
and I None
oxidative I None
stress I None
occurs I None
earlier I None
to I None
apoptosis I None
and I None
does I None
not I None
affect I None
memory I None
function I None
. I None
<eof> I None

<s> O None
Present I None
study I None
clearly I None
suggests I None
that I None
glial I None
activation I None
and I None
post I None
synaptic I None
neurotoxicity I Disease
are I None
the I None
key I None
factors I None
in I None
STZ I Chemical
induced I None
memory I Disease
impairment O Disease
and I None
neuronal I None
cell I None
death I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
effects I None
of I None
isotonic I None
sodium I Chemical
chloride O Chemical
with I None
diltiazem I Chemical
in I None
prevention I None
of I None
contrast I Chemical
-induced I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
INTRODUCTION I None
AND I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Contrast I Chemical
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
<eof> I None

<s> O None
( I None
CIN I None
) I None
significantly I None
increases I None
the I None
morbidity I None
and I None
mortality I None
of I None
patients I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
is I None
to I None
investigate I None
and I None
compare I None
the I None
protective I None
effects I None
of I None
isotonic I None
sodium I Chemical
chloride O Chemical
with I None
sodium I Chemical
bicarbonate O Chemical
infusion I None
and I None
isotonic I None
sodium I Chemical
chloride O Chemical
infusion I None
with I None
diltiazem I Chemical
, I None
a I None
calcium I Chemical
channel I None
blocker I None
, I None
in I None
preventing I None
CIN I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Our I None
study I None
included I None
patients I None
who I None
were I None
administered I None
30 I None
- I None
60 I None
mL I None
of I None
iodinated I None
contrast I Chemical
agent I None
for I None
percutaneous I None
coronary I None
angiography I None
( I None
PCAG I None
) I None
, I None
all I None
with I None
creatinine I Chemical
values I None
between I None
1.1 I None
and I None
3.1 I None
mg I None
/ I None
dL. I None
Patients I None
were I None
divided I None
into I None
three I None
groups I None
and I None
each I None
group I None
had I None
20 I None
patients I None
. I None
<eof> I None

<s> O None
The I None
first I None
group I None
of I None
patients I None
was I None
administered I None
isotonic I None
sodium I Chemical
chloride O Chemical
; I None
the I None
second I None
group I None
was I None
administered I None
a I None
solution I None
that I None
of I None
5 I None
% I None
dextrose I Chemical
and I None
sodium I Chemical
bicarbonate O Chemical
, I None
while I None
the I None
third I None
group I None
was I None
administered I None
isotonic I None
sodium I Chemical
chloride O Chemical
before I None
and I None
after I None
the I None
contrast I Chemical
injection I None
. I None
<eof> I None

<s> O None
The I None
third I None
group I None
received I None
an I None
additional I None
injection I None
of I None
diltiazem I Chemical
the I None
day I None
before I None
and I None
first I None
2 I None
days I None
after I None
the I None
contrast I Chemical
injection I None
. I None
<eof> I None

<s> O None
All I None
of I None
the I None
patients I None
' I None
plasma I None
blood I Chemical
urea O Chemical
nitrogen O Chemical
<eof> I None

<s> O None
( I None
BUN I Chemical
) I None
and I None
creatinine I Chemical
levels I None
were I None
measured I None
on I None
the I None
second I None
and I None
seventh I None
day I None
after I None
the I None
administration I None
of I None
intravenous I None
contrast I Chemical
material I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
basal I None
creatinine I Chemical
levels I None
were I None
similar I None
for I None
all I None
three I None
groups I None
( I None
p I None
> I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Among I None
a I None
total I None
of I None
60 I None
patients I None
included I None
in I None
the I None
study I None
, I None
16 I None
patients I None
developed I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
ARF I Disease
) I None
on I None
the I None
second I None
day I None
after I None
contrast I Chemical
material I None
was I None
injected I None
( I None
26.6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
patients I None
who I None
developed I None
ARF I Disease
on I None
the I None
second I None
day I None
after I None
the I None
injection I None
in I None
the I None
first I None
group I None
was I None
five I None
( I None
25 I None
% I None
) I None
, I None
in I None
the I None
second I None
group I None
was I None
six I None
( I None
30 I None
% I None
) I None
and I None
the I None
third I None
group I None
was I None
five I None
( I None
25 I None
% I None
) I None
( I None
p I None
> I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
There I None
was I None
no I None
significant I None
difference I None
between I None
isotonic I None
sodium I Chemical
chloride O Chemical
, I None
sodium I Chemical
bicarbonate O Chemical
and I None
isotonic I None
sodium I Chemical
chloride O Chemical
with I None
diltiazem I Chemical
application I None
in I None
prevention I None
of I None
CIN I None
. I None
<eof> I None

<s> O None
Neurocognitive I None
and I None
neuroradiologic I None
central I None
nervous I None
system I None
late I None
effects I None
in I None
children I None
treated I None
on I None
Pediatric I None
Oncology I None
Group I None
( I None
POG I None
) I None
<eof> I None

<s> O None
P9605 I None
( I None
standard I None
risk I None
) I None
and I None
P9201 I None
( I None
lesser I None
risk I None
) I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
protocols I None
( I None
ACCL0131 I None
) I None
: I None
a I None
methotrexate I Chemical
consequence I None
? I None
<eof> I None

<s> O None
A I None
report I None
from I None
the I None
Children I None
's I None
Oncology I None
Group I None
. I None
<eof> I None

<s> O None
Concerns I None
about I None
long I None
- I None
term I None
methotrexate I Chemical
<eof> I None

<s> O None
( I None
MTX I Chemical
) I None
<eof> I None

<s> O None
neurotoxicity I Disease
in I None
the I None
1990s I None
led I None
to I None
modifications I None
in I None
intrathecal I None
( I None
IT I None
) I None
therapy I None
, I None
leucovorin I None
rescue I None
, I None
and I None
frequency I None
of I None
systemic I None
MTX I Chemical
administration I None
in I None
children I None
with I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
neurocognitive I None
outcomes I None
and I None
neuroradiologic I None
evidence I None
of I None
leukoencephalopathy I Disease
were I None
compared I None
in I None
children I None
treated I None
with I None
intense I None
central I None
nervous I None
system I None
( I None
CNS)-directed I None
therapy I None
( I None
P9605 I None
) I None
versus I None
those I None
receiving I None
fewer I None
CNS I None
- I None
directed I None
treatment I None
days I None
during I None
intensive I None
consolidation I None
( I None
P9201 I None
) I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
66 I None
children I None
from I None
16 I None
Pediatric I None
Oncology I None
Group I None
institutions I None
with I None
" I None
standard I None
- I None
risk I None
" I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
, I None
1.00 I None
to I None
9.99 I None
years I None
at I None
diagnosis I None
, I None
without I None
evidence I None
of I None
CNS I None
leukemia I Disease
at I None
diagnosis I None
were I None
enrolled I None
on I None
ACCL0131 I None
: I None
28 I None
from I None
P9201 I None
and I None
38 I None
from I None
P9605 I None
. I None
<eof> I None

<s> O None
Magnetic I None
resonance I None
imaging I None
scans I None
and I None
standard I None
neuropsychological I None
tests I None
were I None
performed I None
> I None
2.6 I None
years I None
after I None
the I None
end I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Significantly I None
more I None
P9605 I None
patients I None
developed I None
<eof> I None

<s> O None
leukoencephalopathy I Disease
compared I None
with I None
P9201 I None
patients I None
( I None
68 I None
% I None
, I None
95 I None
% I None
confidence I None
interval I None
49%-83 I None
% I None
vs. I None
22 I None
% I None
, I None
95 I None
% I None
confidence I None
interval I None
5%-44 I None
% I None
; I None
P=0.001 I None
) I None
identified I None
as I None
late I None
as I None
7.7 I None
years I None
after I None
the I None
end I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
40 I None
% I None
of I None
patients I None
scored I None
< I None
85 I None
on I None
either I None
Verbal I None
or I None
Performance I None
IQ I None
. I None
<eof> I None

<s> O None
Children I None
on I None
both I None
studies I None
had I None
significant I None
attention I Disease
problems O Disease
, I None
but I None
P9605 I None
children I None
scored I None
below I None
average I None
on I None
more I None
neurocognitive I None
measures I None
than I None
those I None
treated I None
on I None
P9201 I None
( I None
82 I None
% I None
, I None
14/17 I None
measures I None
vs. I None
24 I None
% I None
, I None
4/17 I None
measures I None
) I None
. I None
<eof> I None

<s> O None
This I None
supports I None
ongoing I None
concerns I None
about I None
intensive I None
MTX I Chemical
exposure I None
as I None
a I None
major I None
contributor I None
to I None
CNS I None
late I None
effects I None
. I None
<eof> I None

<s> O None
Tranexamic I Chemical
acid O Chemical
overdosage I None
- I None
induced I None
generalized I None
seizure I Disease
in I None
renal I Disease
failure O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
45-year I None
- I None
old I None
lady I None
with I None
chronic I Disease
kidney O Disease
disease O Disease
stage I None
4 I None
due I None
to I None
chronic I None
tubulointerstial I Disease
disease O Disease
. I None
<eof> I None

<s> O None
She I None
was I None
admitted I None
to I None
our I None
center I None
for I None
severe I None
anemia I Disease
due I None
to I None
menorrhagia I Disease
and I None
deterioration I Disease
of O Disease
renal O Disease
function O Disease
. I None
<eof> I None

<s> O None
She I None
was I None
infused I None
three I None
units I None
of I None
packed I None
cells I None
during I None
a I None
session I None
of I None
hemodialysis I None
. I None
<eof> I None

<s> O None
Tranexamic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
TNA I Chemical
) I None
<eof> I None

<s> O None
1 I None
g I None
8-hourly I None
was I None
administered I None
to I None
her I None
to I None
control I None
bleeding I Disease
per I None
vaginum I None
. I None
<eof> I None

<s> O None
Two I None
hours I None
after I None
the I None
sixth I None
dose I None
of I None
TNA I Chemical
, I None
she I None
had I None
an I None
episode I None
of I None
generalized I None
tonic I Disease
clonic O Disease
convulsions O Disease
. I None
<eof> I None

<s> O None
TNA I Chemical
was I None
discontinued I None
. I None
<eof> I None

<s> O None
Investigations I None
of I None
the I None
patient I None
revealed I None
no I None
biochemical I None
or I None
structural I None
central I None
nervous I Disease
system O Disease
abnormalities O Disease
that I None
could I None
have I None
provoked I None
the I None
convulsions I Disease
. I None
<eof> I None

<s> O None
She I None
did I None
not I None
require I None
any I None
further I None
dialytic I None
support I None
. I None
<eof> I None

<s> O None
She I None
had I None
no I None
further I None
episodes I None
of I None
convulsion I Disease
till I None
dis I None
- I None
charge I None
and I None
during I None
the I None
two I None
months I None
of I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
precipitating I None
cause I None
of I None
convulsions I Disease
was I None
believed I None
to I None
be I None
an I None
overdose I Disease
of I None
TNA I Chemical
. I None
<eof> I None

<s> O None
Pre I None
- I None
treatment I None
of I None
bupivacaine I Chemical
-induced I None
cardiovascular I Disease
depression O Disease
using I None
different I None
lipid I None
formulations I None
of I None
propofol I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Pre I None
- I None
treatment I None
with I None
lipid I None
emulsions I None
has I None
been I None
shown I None
to I None
increase I None
lethal I None
doses I None
of I None
bupivacaine I Chemical
, I None
and I None
the I None
lipid I None
content I None
of I None
propofol I Chemical
may I None
alleviate I None
bupivacaine I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
is I None
to I None
investigate I None
the I None
effects I None
of I None
propofol I Chemical
in I None
intralipid I None
or I None
medialipid I None
emulsions I None
on I None
bupivacaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Rats I None
were I None
anaesthetised I None
with I None
ketamine I Chemical
and I None
were I None
given I None
0.5 I None
mg I None
/ I None
kg I None
/ I None
min I None
propofol I Chemical
in I None
intralipid I None
( I None
Group I None
P I None
) I None
, I None
propofol I Chemical
in I None
medialipid I None
<eof> I None

<s> O None
( I None
Group I None
L I None
) I None
, I None
or I None
saline I None
( I None
Group I None
C I None
) I None
over I None
20 I None
min I None
. I None
<eof> I None

<s> O None
Thereafter I None
, I None
2 I None
mg I None
/ I None
kg I None
/ I None
min I None
bupivacaine I Chemical
0.5 I None
% I None
was I None
infused I None
. I None
<eof> I None

<s> O None
We I None
recorded I None
time I None
to I None
first I None
dysrhythmia I Disease
occurrence I None
, I None
respective I None
times I None
to I None
25 I None
% I None
and I None
50 I None
% I None
reduction I None
of I None
the I None
heart I None
rate I None
( I None
HR I None
) I None
and I None
mean I None
arterial I None
pressure I None
, I None
and I None
time I None
to I None
asystole I Disease
and I None
total I None
amount I None
of I None
bupivacaine I Chemical
consumption I None
. I None
<eof> I None

<s> O None
Blood I None
and I None
tissue I None
samples I None
were I None
collected I None
following I None
asystole I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
time I None
to I None
first I None
dysrhythmia I Disease
occurrence I None
, I None
time I None
to I None
25 I None
% I None
and I None
50 I None
% I None
reductions I None
in I None
HR I None
, I None
and I None
time I None
to I None
asystole I Disease
were I None
longer I None
in I None
Group I None
P I None
than I None
the I None
other I None
groups I None
. I None
<eof> I None

<s> O None
The I None
cumulative I None
bupivacaine I Chemical
dose I None
given I None
at I None
those I None
time I None
points I None
was I None
higher I None
in I None
Group I None
P. I None
Plasma I None
bupivacaine I Chemical
levels I None
were I None
significantly I None
lower I None
in I None
Group I None
P I None
than I None
in I None
Group I None
C. I None
Bupivacaine I Chemical
levels I None
in I None
the I None
brain I None
and I None
heart I None
were I None
significantly I None
lower I None
in I None
Group I None
P I None
and I None
Group I None
L I None
<eof> I None

<s> O None
than I None
in I None
Group I None
C. I None
CONCLUSION I None
: I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
pre I None
- I None
treatment I None
with I None
propofol I Chemical
in I None
intralipid I None
, I None
compared I None
with I None
propofol I Chemical
in I None
medialipid I None
or I None
saline I None
, I None
delayed I None
the I None
onset I None
of I None
bupivacaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxic I Disease
effects I None
as I None
well I None
as I None
reduced I None
plasma I None
bupivacaine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Further I None
studies I None
are I None
needed I None
to I None
explore I None
tissue I None
bupivacaine I Chemical
levels I None
of I None
propofol I Chemical
in I None
medialipid I None
and I None
adapt I None
these I None
results I None
to I None
clinical I None
practice I None
. I None
<eof> I None

<s> O None
Drug I Disease
- O Disease
Induced O Disease
Acute O Disease
Liver O Disease
Injury O Disease
Within I None
12 I None
Hours I None
After I None
Fluvastatin I Chemical
Therapy I None
. I None
<eof> I None

<s> O None
Although I None
statins I Chemical
are I None
generally I None
well I None
- I None
tolerated I None
drugs I None
, I None
recent I None
cases I None
of I None
drug I Disease
- O Disease
induced O Disease
liver O Disease
injury O Disease
associated I None
with I None
their I None
use I None
have I None
been I None
reported I None
. I None
<eof> I None

<s> O None
A I None
52-year I None
- I None
old I None
Chinese I None
man I None
reported I None
with I None
liver I Disease
damage O Disease
, I None
which I None
appeared I None
12 I None
hours I None
after I None
beginning I None
treatment I None
with I None
fluvastatin I Chemical
. I None
<eof> I None

<s> O None
Patient I None
presented I None
with I None
complaints I None
of I None
increasing I None
nausea I Disease
, I None
anorexia I Disease
, I None
and I None
upper I None
abdominal I Disease
pain O Disease
. I None
<eof> I None

<s> O None
His I None
laboratory I None
values I None
showed I None
elevated I None
creatine I Chemical
kinase I None
and I None
transaminases I None
. I None
<eof> I None

<s> O None
Testing I None
for I None
autoantibodies I None
was I None
also I None
negative I None
. I None
<eof> I None

<s> O None
The I None
liver I None
biochemistries I None
eventually I None
normalized I None
within I None
3 I None
weeks I None
of I None
stopping I None
the I None
fluvastatin I Chemical
. I None
<eof> I None

<s> O None
Therefore I None
, I None
when I None
prescribing I None
statins I None
, I None
the I None
possibility I None
of I None
hepatic I Disease
damage O Disease
should I None
be I None
taken I None
into I None
account I None
. I None
<eof> I None

<s> O None
Fluconazole I Chemical
associated I None
<eof> I None

<s> O None
agranulocytosis I Disease
and I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
CASE I None
: I None
<eof> I None

<s> O None
We I None
describe I None
a I None
second I None
case I None
of I None
fluconazole I Chemical
associated I None
agranulocytosis I Disease
with I None
thrombocytopenia I Disease
and I None
recovery I None
upon I None
discontinuation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
patient I None
began I None
to I None
have I None
changes I None
in I None
white I None
blood I None
cells I None
and I None
platelets I None
within I None
48 I None
h I None
of I None
administration I None
of I None
fluconazole I Chemical
and I None
began I None
to I None
recover I None
with I None
48 I None
h I None
of I None
discontinuation I None
. I None
<eof> I None

<s> O None
This I None
case I None
highlights I None
that I None
drug I None
- I None
induced I None
blood I Disease
dyscrasias O Disease
can I None
occur I None
unexpectedly I None
as I None
a I None
result I None
of I None
treatment I None
with I None
a I None
commonly I None
used I None
drug I None
thought I None
to I None
be I None
" I None
safe I None
" I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
According I None
to I None
Naranjo I None
's I None
algorithm I None
the I None
likelihood I None
that I None
our I None
patient I None
's I None
agranulocytosis I Disease
and I None
thrombocytopenia I Disease
occurred I None
as I None
a I None
result I None
of I None
therapy I None
with I None
fluconazole I Chemical
is I None
probable I None
, I None
with I None
a I None
total I None
of I None
six I None
points I None
. I None
<eof> I None

<s> O None
We I None
feel I None
that I None
the I None
weight I None
of I None
the I None
overall I None
evidence I None
of I None
this I None
evidence I None
is I None
strong I None
. I None
<eof> I None

<s> O None
In I None
particular I None
the I None
temporal I None
relationship I None
of I None
bone I Disease
marrow O Disease
suppression O Disease
to I None
the I None
initiation I None
of I None
fluconazole I Chemical
and I None
the I None
abatement I None
of I None
symptoms I None
that I None
rapidly I None
reversed I None
immediately I None
following I None
discontinuation I None
. I None
<eof> I None

<s> O None
Two I None
- I None
dimensional I None
speckle I None
tracking I None
echocardiography I None
combined I None
with I None
high I None
- I None
sensitive I None
cardiac I None
troponin I None
T I None
in I None
early I None
detection I None
and I None
prediction I None
of I None
cardiotoxicity I Disease
during I None
epirubicine I Chemical
-based I None
chemotherapy I None
. I None
<eof> I None

<s> O None
AIMS I None
: I None
<eof> I None

<s> O None
To I None
investigate I None
whether I None
alterations I None
of I None
myocardial I Disease
strain O Disease
and I None
high I None
- I None
sensitive I None
cardiac I None
troponin I None
T I None
( I None
cTnT I None
) I None
could I None
predict I None
future I None
cardiac I Disease
dysfunction O Disease
in I None
patients I None
after I None
epirubicin I Chemical
exposure I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Seventy I None
- I None
five I None
patients I None
with I None
non I Disease
- O Disease
Hodgkin O Disease
lymphoma O Disease
treated I None
with I None
epirubicin I Chemical
were I None
studied I None
. I None
<eof> I None

<s> O None
Blood I None
collection I None
and I None
echocardiography I None
were I None
performed I None
at I None
baseline I None
, I None
1 I None
day I None
after I None
the I None
third I None
cycle I None
, I None
and I None
1 I None
day I None
after I None
completion I None
of I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
studied I None
using I None
echocardiography I None
during I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
Global I None
longitudinal I None
( I None
GLS I None
) I None
, I None
circumferential I None
( I None
GCS I None
) I None
, I None
and I None
radial I None
strain I None
( I None
GRS I None
) I None
were I None
calculated I None
using I None
speckle I None
tracking I None
echocardiography I None
. I None
<eof> I None

<s> O None
Left I None
ventricular I None
ejection I None
fraction I None
was I None
analysed I None
by I None
real I None
- I None
time I None
3D I None
echocardiography I None
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
was I None
defined I None
as I None
a I None
reduction I None
of I None
the I None
LVEF I None
of I None
> I None
5 I None
% I None
to I None
< I None
55 I None
% I None
with I None
symptoms I None
of I None
heart I Disease
failure O Disease
or I None
an I None
asymptomatic I None
reduction I None
of I None
the I None
LVEF I None
of I None
> I None
10 I None
% I None
to I None
< I None
55 I None
% I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Fourteen I None
patients I None
( I None
18.67 I None
% I None
) I None
developed I None
<eof> I None

<s> O None
cardiotoxicity I Disease
after I None
treatment I None
. I None
<eof> I None

<s> O None
GLS I None
( I None
-18.48 I None
+ I None
1.72 I None
% I None
vs. I None
-15.96 I None
+ I None
1.6 I None
% I None
) I None
, I None
GCS I None
( I None
-20.93 I None
+ I None
2.86 I None
% I None
vs. I None
-19.20 I None
+ I None
3.21 I None
% I None
) I None
, I None
and I None
GRS I None
( I None
39.23 I None
+ I None
6.44 I None
% I None
vs. I None
34.98 I None
+ I None
6.2 I None
% I None
) I None
were I None
markedly I None
reduced I None
and I None
cTnT I None
was I None
elevated I None
from I None
0.0010 I None
+ I None
0.0020 I None
to I None
0.0073 I None
+ I None
0.0038 I None
ng I None
/ I None
mL I None
( I None
P I None
all I None
< I None
0.01 I None
) I None
at I None
the I None
completion I None
of I None
chemotherapy I None
compared I None
with I None
baseline I None
values I None
. I None
<eof> I None

<s> O None
A I None
> I None
15.9 I None
% I None
decrease I None
in I None
GLS I None
[ I None
sensitivity I None
, I None
86 I None
% I None
; I None
specificity I None
, I None
75 I None
% I None
; I None
area I None
under I None
the I None
curve I None
( I None
AUC I None
) I None
= I None
0.815 I None
; I None
P I None
= I None
0.001 I None
] I None
and I None
a I None
> I None
0.004 I None
ng I None
/ I None
mL I None
elevation I None
in I None
cTnT I None
( I None
sensitivity I None
, I None
79 I None
% I None
; I None
specificity I None
, I None
64 I None
% I None
; I None
AUC I None
= I None
0.757 I None
; I None
P I None
= I None
0.005 I None
) I None
from I None
baseline I None
to I None
the I None
third I None
cycle I None
of I None
chemotherapy I None
predicted I None
later I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
decrease I None
in I None
GLS I None
remained I None
the I None
only I None
independent I None
predictor I None
of I None
cardiotoxicity I Disease
<eof> I None

<s> O None
( I None
P I None
= I None
0.000 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
GLS I None
combined I None
with I None
cTnT I None
may I None
provide I None
a I None
reliable I None
and I None
non I None
- I None
invasive I None
method I None
to I None
predict I None
cardiac I Disease
dysfunction O Disease
in I None
patients I None
receiving I None
anthracycline I Chemical
-based I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Prevention I None
of I None
etomidate I Chemical
-induced I None
myoclonus I Disease
: I None
which I None
is I None
superior I None
: I None
Fentanyl I Chemical
, I None
midazolam I Chemical
, I None
or I None
a I None
combination I None
? I None
<eof> I None

<s> O None
A I None
Retrospective I None
comparative I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
In I None
this I None
retrospective I None
comparative I None
study I None
, I None
we I None
aimed I None
to I None
compare I None
the I None
effectiveness I None
of I None
fentanyl I Chemical
, I None
midazolam I Chemical
, I None
and I None
a I None
combination I None
of I None
fentanyl I Chemical
and I None
midazolam I Chemical
to I None
prevent I None
etomidate I Chemical
-induced I None
myoclonus I Disease
. I None
<eof> I None

<s> O None
MATERIAL I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
study I None
was I None
performed I None
based I None
on I None
anesthesia I None
records I None
. I None
<eof> I None

<s> O None
Depending I None
on I None
the I None
drugs I None
that I None
would I None
be I None
given I None
before I None
the I None
induction I None
of I None
anesthesia I None
with I None
etomidate I Chemical
, I None
the I None
patients I None
were I None
separated I None
into I None
4 I None
groups I None
: I None
no I None
pretreatment I None
( I None
Group I None
NP I None
) I None
, I None
fentanyl I Chemical
<eof> I None

<s> O None
1 I None
ug.kg-1 I None
( I None
Group I None
F I None
) I None
, I None
midazolam I Chemical
0.03 I None
mg.kg-1 I None
( I None
Group I None
M I None
) I None
, I None
and I None
midazolam I Chemical
0.015 I None
mg.kg-1 I None
+ I None
<eof> I None

<s> O None
fentanyl I Chemical
0.5 I None
ug.kg-1 I None
<eof> I None

<s> O None
( I None
Group I None
FM I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
received I None
the I None
same I None
anesthetic I None
procedure I None
were I None
selected I None
: I None
2 I None
minutes I None
after I None
intravenous I None
injections I None
of I None
the I None
pretreatment I None
drugs I None
, I None
anesthesia I None
is I None
induced I None
with I None
0.3 I None
mg.kg-1 I None
etomidate I Chemical
injected I None
intravenously I None
over I None
a I None
period I None
of I None
20 I None
- I None
30 I None
seconds I None
. I None
<eof> I None

<s> O None
Myoclonic I Disease
movements O Disease
are I None
evaluated I None
, I None
which I None
were I None
observed I None
and I None
graded I None
according I None
to I None
clinical I None
severity I None
during I None
the I None
2 I None
minutes I None
after I None
etomidate I Chemical
injection I None
. I None
<eof> I None

<s> O None
The I None
severity I None
of I None
pain I Disease
due I None
to I None
etomidate I Chemical
injection I None
, I None
mean I None
arterial I None
pressure I None
, I None
heart I None
rate I None
, I None
and I None
adverse I None
effects I None
were I None
also I None
evaluated I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Study I None
results I None
showed I None
that I None
myoclonus I Disease
incidence I None
was I None
85 I None
% I None
, I None
40 I None
% I None
, I None
70 I None
% I None
, I None
and I None
25 I None
% I None
in I None
Group I None
NP I None
, I None
Group I None
F I None
, I None
Group I None
M I None
, I None
and I None
Group I None
FM I None
, I None
respectively I None
, I None
and I None
were I None
significantly I None
lower I None
in I None
Group I None
F I None
and I None
Group I None
FM I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
pretreatment I None
with I None
fentanyl I Chemical
or I None
combination I None
of I None
fentanyl I Chemical
and I None
midazolam I Chemical
was I None
effective I None
in I None
preventing I None
etomidate I Chemical
-induced I None
myoclonus I Disease
. I None
<eof> I None

<s> O None
Cholestatic I Disease
presentation I None
of I None
yellow I None
phosphorus I Chemical
poisoning I Disease
. I None
<eof> I None

<s> O None
Yellow I None
phosphorus I Chemical
, I None
a I None
component I None
of I None
certain I None
pesticide I None
pastes I None
and I None
fireworks I None
, I None
is I None
well I None
known I None
to I None
cause I None
hepatotoxicity I Disease
. I None
<eof> I None

<s> O None
Poisoning I Disease
with I None
yellow I None
phosphorus I Chemical
classically I None
manifests I None
with I None
acute I Disease
hepatitis O Disease
leading I None
to I None
acute I Disease
liver O Disease
failure O Disease
which I None
may I None
need I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
case I None
of I None
yellow I None
phosphorus I Chemical
poisoning I Disease
in I None
which I None
a I None
patient I None
presented I None
with I None
florid I None
clinical I None
features I None
of I None
cholestasis I Disease
highlighting I None
the I None
fact I None
that I None
cholestasis I Disease
can I None
rarely I None
be I None
a I None
presenting I None
feature I None
of I None
yellow I None
phosphorus I Chemical
hepatotoxicity I Disease
. I None
<eof> I None

<s> O None
Vasovagal I Disease
syncope O Disease
and I None
severe I None
bradycardia I Disease
following I None
intranasal I None
dexmedetomidine I Chemical
for I None
pediatric I None
procedural I None
sedation I None
. I None
<eof> I None

<s> O None
We I None
report I None
syncope I Disease
and I None
bradycardia I Disease
in I None
an I None
11-year I None
- I None
old I None
girl I None
following I None
administration I None
of I None
intranasal I None
dexmedetomidine I Chemical
for I None
sedation I None
for I None
a I None
voiding I None
cystourethrogram I None
. I None
<eof> I None

<s> O None
Following I None
successful I None
completion I None
of I None
VCUG I None
and I None
a I None
60-min I None
recovery I None
period I None
, I None
the I None
patient I None
's I None
level I None
of I None
consciousness I None
and I None
vital I None
signs I None
returned I None
to I None
presedation I None
levels I None
. I None
<eof> I None

<s> O None
Upon I None
leaving I None
the I None
sedation I None
area I None
, I None
the I None
patient I None
collapsed I None
, I None
with I None
no I None
apparent I None
inciting I None
event I None
. I None
<eof> I None

<s> O None
The I None
patient I None
quickly I None
regained I None
consciousness I None
and I None
no I None
injury I None
occurred I None
. I None
<eof> I None

<s> O None
The I None
primary I None
abnormality I None
found I None
was I None
persistent I None
bradycardia I Disease
, I None
and I None
she I None
was I None
admitted I None
to I None
the I None
hospital I None
for I None
telemetric I None
observation I None
. I None
<eof> I None

<s> O None
The I None
bradycardia I Disease
lasted I None
~2 I None
h I None
, I None
and I None
further I None
cardiac I None
workup I None
revealed I None
no I None
underlying I None
abnormality I None
. I None
<eof> I None

<s> O None
Unanticipated I None
and I None
previously I None
unreported I None
outcomes I None
may I None
be I None
witnessed I None
as I None
we I None
expand I None
the I None
use I None
of I None
certain I None
sedatives I None
to I None
alternative I None
routes I None
of I None
administration I None
. I None
<eof> I None

<s> O None
Paradoxical I None
severe I None
agitation I Disease
induced I None
by I None
add I None
- I None
on I None
high I None
- I None
doses I None
quetiapine I Chemical
in I None
schizo I Disease
- O Disease
affective O Disease
disorder O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
35-year I None
- I None
old I None
patient I None
suffering I None
from I None
schizo I Disease
- O Disease
affective O Disease
disorder O Disease
since I None
the I None
age I None
of I None
19 I None
years I None
, I None
treated I None
by I None
a I None
combination I None
of I None
first I None
- I None
generation I None
antipsychotics I None
, I None
<eof> I None

<s> O None
zuclopenthixol I Chemical
( I None
100 I None
mg I None
/ I None
day I None
) I None
and I None
lithium I Chemical
( I None
1200 I None
mg I None
/ I None
day I None
) I None
( I None
serum I None
<eof> I None

<s> O None
lithium I Chemical
<eof> I None

<s> O None
= I None
0.85 I None
mEq I None
/ I None
l I None
) I None
. I None
<eof> I None

<s> O None
This I None
patient I None
had I None
no I None
associated I None
personality I Disease
disorder O Disease
<eof> I None

<s> O None
( I None
particularly I None
no I None
antisocial I Disease
disorder O Disease
) I None
and I None
no I None
substance I Disease
abuse O Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Within I None
the I None
48 I None
h I None
following I None
the I None
gradual I None
introduction I None
of I None
quetiapine I Chemical
( I None
up I None
to I None
600 I None
mg I None
/ I None
day I None
) I None
, I None
the I None
patient I None
presented I None
severe I None
agitation I Disease
without I None
an I None
environmental I None
explanation I None
, I None
contrasting I None
with I None
the I None
absence I None
of I None
a I None
history I None
of I None
aggressiveness I Disease
or I None
personality I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
The I None
diagnoses I None
of I None
manic I Disease
shift I None
and I None
akathisia I Disease
were I None
dismissed I None
. I None
<eof> I None

<s> O None
The I None
withdrawal I None
and I None
the I None
gradual I None
reintroduction I None
of I None
quetiapine I Chemical
<eof> I None

<s> O None
2 I None
weeks I None
later I None
, I None
which I None
led I None
to I None
another I None
severe I None
agitation I Disease
, I None
enabled I None
us I None
to I None
attribute I None
the I None
agitation I Disease
specifically I None
to I None
quetiapine I Chemical
. I None
<eof> I None

<s> O None
Antioxidant I None
effects I None
of I None
bovine I None
lactoferrin I None
on I None
dexamethasone I Chemical
-induced I None
hypertension I Disease
in I None
rat I None
. I None
<eof> I None

<s> O None
Dexamethasone I Chemical
- I None
( I None
Dex I Chemical
- I None
) I None
induced I None
<eof> I None

<s> O None
hypertension I Disease
is I None
associated I None
with I None
enhanced I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
Lactoferrin I None
( I None
LF I None
) I None
is I None
an I None
iron I Chemical
-binding I None
glycoprotein I None
with I None
antihypertensive I None
properties I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
investigated I None
the I None
effect I None
of I None
chronic I None
administration I None
of I None
LF I None
on I None
oxidative I None
stress I None
and I None
hypertension I Disease
upon I None
Dex I Chemical
administration I None
. I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
treated I None
by I None
Dex I Chemical
<eof> I None

<s> O None
( I None
30 I None
u I None
g I None
/ I None
kg I None
/ I None
day I None
subcutaneously I None
) I None
or I None
saline I None
for I None
14 I None
days I None
. I None
<eof> I None

<s> O None
Oral I None
bovine I None
LF I None
( I None
30 I None
, I None
100 I None
, I None
300 I None
mg I None
/ I None
kg I None
) I None
was I None
given I None
from I None
day I None
8 I None
to I None
14 I None
in I None
a I None
reversal I None
study I None
. I None
<eof> I None

<s> O None
In I None
a I None
prevention I None
study I None
, I None
rats I None
received I None
4 I None
days I None
of I None
LF I None
treatment I None
followed I None
by I None
Dex I Chemical
and I None
continued I None
during I None
the I None
test I None
period I None
. I None
<eof> I None

<s> O None
Systolic I None
blood I None
pressure I None
( I None
SBP I None
) I None
was I None
measured I None
using I None
tail I None
- I None
cuff I None
method I None
. I None
<eof> I None

<s> O None
Thymus I None
weight I None
was I None
used I None
as I None
a I None
marker I None
of I None
glucocorticoid I None
activity I None
. I None
<eof> I None

<s> O None
Plasma I None
hydrogen I Chemical
peroxide O Chemical
<eof> I None

<s> O None
( I None
H2O2 I Chemical
) I None
concentration I None
and I None
ferric I None
reducing I None
antioxidant I None
power I None
( I None
FRAP I None
) I None
value I None
were I None
determined I None
. I None
<eof> I None

<s> O None
Dexamethasone I Chemical
significantly I None
increased I None
SBP I None
and I None
plasma I None
H2O2 I Chemical
level I None
and I None
decreased I None
thymus I None
and I None
body I None
weights I None
. I None
<eof> I None

<s> O None
LF I None
lowered I None
( I None
P I None
< I None
0.01 I None
) I None
and I None
dose I None
dependently I None
prevented I None
( I None
P I None
< I None
0.001 I None
) I None
<eof> I None

<s> O None
Dex I Chemical
-induced I None
hypertension I Disease
. I None
<eof> I None

<s> O None
LF I None
prevented I None
body I None
weight I Disease
loss O Disease
and I None
significantly I None
reduced I None
the I None
elevated I None
plasma I None
H2O2 I Chemical
and I None
increased I None
FRAP I None
values I None
. I None
<eof> I None

<s> O None
Chronic I None
administration I None
of I None
LF I None
strongly I None
reduced I None
the I None
blood I None
pressure I None
and I None
production I None
of I None
ROS I None
and I None
improved I None
antioxidant I None
capacity I None
in I None
Dex I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hypertension I Disease
, I None
suggesting I None
the I None
role I None
of I None
inhibition I None
of I None
oxidative I None
stress I None
as I None
another I None
mechanism I None
of I None
antihypertensive I None
action I None
of I None
LF I None
. I None
<eof> I None

<s> O None
The I None
association I None
between I None
tranexamic I Chemical
acid O Chemical
and I None
convulsive I Disease
seizures I Disease
after I None
cardiac I None
surgery I None
: I None
a I None
multivariate I None
analysis I None
in I None
11 I None
529 I None
patients I None
. I None
<eof> I None

<s> O None
Because I None
of I None
a I None
lack I None
of I None
contemporary I None
data I None
regarding I None
seizures I Disease
after I None
cardiac I None
surgery I None
, I None
we I None
undertook I None
a I None
retrospective I None
analysis I None
of I None
prospectively I None
collected I None
data I None
from I None
11 I None
529 I None
patients I None
in I None
whom I None
cardiopulmonary I None
bypass I None
was I None
used I None
from I None
January I None
2004 I None
to I None
December I None
2010 I None
. I None
<eof> I None

<s> O None
A I None
convulsive I Disease
seizure I Disease
was I None
defined I None
as I None
a I None
transient I None
episode I None
of I None
disturbed I None
brain I None
function I None
characterised I None
by I None
abnormal I Disease
involuntary O Disease
motor O Disease
movements O Disease
. I None
<eof> I None

<s> O None
Multivariate I None
regression I None
analysis I None
was I None
performed I None
to I None
identify I None
independent I None
predictors I None
of I None
postoperative I None
seizures I Disease
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
100 I None
( I None
0.9 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
developed I None
postoperative I None
convulsive I Disease
seizures I Disease
. I None
<eof> I None

<s> O None
Generalised I Disease
and O Disease
focal O Disease
seizures O Disease
were I None
identified I None
in I None
68 I None
and I None
32 I None
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
median I None
( I None
IQR I None
[ I None
range I None
] I None
) I None
time I None
after I None
surgery I None
when I None
the I None
seizure I Disease
occurred I None
was I None
7 I None
( I None
6 I None
- I None
12 I None
[ I None
1 I None
- I None
216 I None
] I None
) I None
<eof> I None

<s> O None
h I None
and I None
8 I None
( I None
6 I None
- I None
11 I None
[ I None
4 I None
- I None
18 I None
] I None
) I None
<eof> I None

<s> O None
h I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Epileptiform I None
findings I None
on I None
electroencephalography I None
were I None
seen I None
in I None
19 I None
patients I None
. I None
<eof> I None

<s> O None
Independent I None
predictors I None
of I None
postoperative I None
seizures I Disease
included I None
age I None
, I None
female I None
sex I None
, I None
redo I None
cardiac I None
surgery I None
, I None
calcification I None
of I None
ascending I None
aorta I None
, I None
congestive I Disease
heart O Disease
failure O Disease
, I None
deep I None
hypothermic I Disease
circulatory I None
arrest I None
, I None
duration I None
of I None
aortic I None
cross I None
- I None
clamp I None
and I None
tranexamic I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
When I None
tested I None
in I None
a I None
multivariate I None
regression I None
analysis I None
, I None
tranexamic I Chemical
acid O Chemical
was I None
a I None
strong I None
independent I None
predictor I None
of I None
seizures I Disease
( I None
OR I None
14.3 I None
, I None
95 I None
% I None
CI I None
5.5 I None
- I None
36.7 I None
; I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
convulsive I Disease
<eof> I None

<s> O None
seizures I Disease
had I None
2.5 I None
times I None
higher I None
in I None
- I None
hospital I None
mortality I None
rates I None
and I None
twice I None
the I None
length I None
of I None
hospital I None
stay I None
compared I None
with I None
patients I None
without I None
convulsive I Disease
seizures I Disease
. I None
<eof> I None

<s> O None
Mean I None
( I None
IQR I None
[ I None
range I None
] I None
) I None
length I None
of I None
stay I None
in I None
the I None
intensive I None
care I None
unit I None
was I None
115 I None
( I None
49 I None
- I None
228 I None
[ I None
32 I None
- I None
481 I None
] I None
) I None
<eof> I None

<s> O None
h I None
in I None
patients I None
with I None
convulsive I Disease
<eof> I None

<s> O None
seizures I Disease
compared I None
with I None
26 I None
( I None
22 I None
- I None
69 I None
[ I None
14 I None
- I None
1080 I None
] I None
) I None
<eof> I None

<s> O None
h I None
in I None
patients I None
without I None
seizures I Disease
<eof> I None

<s> O None
( I None
p I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Convulsive I Disease
<eof> I None

<s> O None
seizures I Disease
are I None
a I None
serious I None
postoperative I Disease
complication O Disease
after I None
cardiac I None
surgery I None
. I None
<eof> I None

<s> O None
As I None
tranexamic I Chemical
acid O Chemical
is I None
the I None
only I None
modifiable I None
factor I None
, I None
its I None
administration I None
, I None
particularly I None
in I None
doses I None
exceeding I None
80 I None
mg.kg(-1 I None
) I None
, I None
should I None
be I None
weighed I None
against I None
the I None
risk I None
of I None
postoperative I None
seizures I Disease
. I None
<eof> I None

<s> O None
Dysfunctional I Disease
overnight O Disease
memory O Disease
consolidation I None
in I None
ecstasy I Chemical
users I None
. I None
<eof> I None

<s> O None
Sleep I None
plays I None
an I None
important I None
role I None
in I None
the I None
consolidation I None
and I None
integration I None
of I None
memory I None
in I None
a I None
process I None
called I None
overnight I None
memory I None
consolidation I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
indicate I None
that I None
ecstasy I Chemical
users I None
have I None
marked I None
and I None
persistent I None
neurocognitive I None
and I None
sleep I Disease
- O Disease
related O Disease
impairments O Disease
. I None
<eof> I None

<s> O None
We I None
extend I None
past I None
research I None
by I None
examining I None
overnight I None
memory I None
consolidation I None
among I None
regular I None
ecstasy I Chemical
users I None
( I None
n=12 I None
) I None
and I None
drug I None
naive I None
healthy I None
controls I None
( I None
n=26 I None
) I None
. I None
<eof> I None

<s> O None
Memory I None
recall I None
of I None
word I None
pairs I None
was I None
evaluated I None
before I None
and I None
after I None
a I None
period I None
of I None
sleep I None
, I None
with I None
and I None
without I None
interference I None
prior I None
to I None
testing I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
assessed I None
neurocognitive I None
performances I None
across I None
tasks I None
of I None
learning I None
, I None
memory I None
and I None
executive I None
functioning I None
. I None
<eof> I None

<s> O None
Ecstasy I Chemical
users I None
demonstrated I None
impaired I Disease
overnight O Disease
memory O Disease
consolidation I None
, I None
a I None
finding I None
that I None
was I None
more I None
pronounced I None
following I None
associative I None
interference I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
ecstasy I Chemical
users I None
demonstrated I None
impairments I None
on I None
tasks I None
recruiting I None
frontostriatal I None
and I None
hippocampal I None
neural I None
circuitry I None
, I None
in I None
the I None
domains I None
of I None
proactive I None
interference I None
memory I None
, I None
long I None
- I None
term I None
memory I None
, I None
encoding I None
, I None
working I None
memory I None
and I None
complex I None
planning I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
ecstasy I Chemical
-associated I None
dysfunction I None
in I None
fronto I None
- I None
temporal I None
circuitry I None
may I None
underlie I None
overnight I None
consolidation I None
memory I Disease
impairments O Disease
in I None
regular I None
ecstasy I Chemical
users I None
. I None
<eof> I None

<s> O None
Normoammonemic I None
encephalopathy I Disease
: I None
solely I None
valproate I Chemical
induced I None
or I None
multiple I None
mechanisms I None
? I None
<eof> I None

<s> O None
A I None
77-year I None
- I None
old I None
woman I None
presented I None
with I None
subacute I None
onset I None
progressive I None
confusion I Disease
, I None
aggression I Disease
, I None
auditory I Disease
hallucinations O Disease
and I None
delusions I Disease
. I None
<eof> I None

<s> O None
In I None
the I None
preceding I None
months I None
, I None
the I None
patient I None
had I None
a I None
number I None
of I None
admissions I None
with I None
transient I None
unilateral I None
hemiparesis I Disease
with I None
facial I None
droop I None
, I None
and I None
had I None
been I None
started I None
on I None
valproate I Chemical
for I None
presumed I None
hemiplegic I Disease
migraine O Disease
. I None
<eof> I None

<s> O None
Valproate I Chemical
was I None
withdrawn I None
soon I None
after I None
admission I None
and I None
her I None
cognitive I None
abilities I None
have I None
gradually I None
improved I None
over I None
3 I None
months I None
of I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
Valproate I Chemical
levels I None
taken I None
prior I None
to I None
withdrawal I None
were I None
subtherapeutic I None
and I None
the I None
patient I None
was I None
normoammonaemic I None
. I None
<eof> I None

<s> O None
EEG I None
undertaken I None
during I None
inpatient I None
stay I None
showed I None
changes I None
consistent I None
with I None
encephalopathy I Disease
, I None
and I None
low I None
titre I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
) I None
receptor I None
antibodies I None
were I None
present I None
in I None
this I None
patient I None
. I None
<eof> I None

<s> O None
The I None
possible I None
aetiologies I None
of I None
valproate I Chemical
-induced I None
encephalopathy I Disease
and I None
NMDA I Chemical
receptor I None
- I None
associated I None
encephalitis I Disease
present I None
a I None
diagnostic I None
dilemma I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
putative I None
combinatorial I None
hypothesis I None
to I None
explain I None
this I None
patient I None
's I None
symptoms I None
. I None
<eof> I None

<s> O None
Cerebellar I None
and I None
oculomotor I None
dysfunction I None
induced I None
by I None
rapid I None
infusion I None
of I None
pethidine I Chemical
. I None
<eof> I None

<s> O None
Pethidine I Chemical
is I None
an I None
opioid I None
that I None
gains I None
its I None
popularity I None
for I None
the I None
effective I None
pain I Disease
control I None
through I None
acting I None
on I None
the I None
opioid I None
- I None
receptors I None
. I None
<eof> I None

<s> O None
However I None
, I None
rapid I None
pain I Disease
relief I None
sometimes I None
brings I None
about I None
unfavourable I None
side I None
effects I None
that I None
largely I None
limit I None
its I None
clinical I None
utility I None
. I None
<eof> I None

<s> O None
Common I None
side I None
effects I None
include I None
nausea I Disease
, I None
vomiting I Disease
and I None
hypotension I Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
impaired I None
renal I None
and I None
liver I None
function I None
, I None
and I None
those I None
who I None
need I None
long I None
- I None
term I None
pain I Disease
control I None
, I None
pethidine I Chemical
may I None
cause I None
excitatory I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
effects I None
through I None
its I None
neurotoxic I Disease
metabolite I None
, I None
norpethidine I Chemical
, I None
resulting I None
in I None
irritability I Disease
and I None
seizure I Disease
attack I None
. I None
<eof> I None

<s> O None
On I None
the I None
contrary I None
, I None
though I None
not I None
clinically I None
apparent I None
, I None
pethidine I Chemical
potentially I None
causes I None
inhibitory I None
impacts I None
on I None
the I None
CNS I None
and I None
impairs I None
normal I None
cerebellar I None
and I None
oculomotor I None
function I None
in I None
the I None
short I None
term I None
. I None
<eof> I None

<s> O None
In I None
this I None
case I None
report I None
, I None
we I None
highlight I None
opioid I None
's I None
inhibitory I None
side I None
effects I None
on I None
the I None
cerebellar I None
structure I None
that I None
causes I None
<eof> I None

<s> O None
dysmetria I Disease
, I None
dysarthria I Disease
, I None
reduced I None
smooth I None
pursuit I None
gain I None
and I None
decreased I None
saccadic I None
velocity I None
. I None
<eof> I None

<s> O None
Baboon I Disease
syndrome O Disease
induced I None
by I None
ketoconazole I Chemical
. I None
<eof> I None

<s> O None
A I None
27-year I None
- I None
old I None
male I None
patient I None
presented I None
with I None
a I None
maculopapular I Disease
eruption O Disease
on I None
the I None
flexural I None
areas I None
and I None
buttocks I None
after I None
using I None
oral I None
ketoconazole I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
diagnosed I None
with I None
drug I None
- I None
induced I None
baboon I Disease
syndrome O Disease
based I None
on I None
his I None
history I None
, I None
which I None
included I None
prior I None
sensitivity I None
to I None
topical I None
ketoconazole I Chemical
, I None
a I None
physical I None
examination I None
, I None
and I None
histopathological I None
findings I None
. I None
<eof> I None

<s> O None
Baboon I Disease
syndrome O Disease
is I None
a I None
drug- I None
or I None
contact I None
allergen I None
- I None
related I None
maculopapular I Disease
eruption O Disease
that I None
typically I None
involves I None
the I None
flexural I None
and I None
gluteal I None
areas I None
. I None
<eof> I None

<s> O None
To I None
the I None
best I None
of I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
first I None
reported I None
case I None
of I None
ketoconazole I Chemical
-induced I None
<eof> I None

<s> O None
baboon I Disease
syndrome O Disease
in I None
the I None
English I None
literature I None
. I None
<eof> I None

<s> O None
A I None
Case I None
of I None
Sudden I Disease
Cardiac O Disease
Death O Disease
due I None
to I None
Pilsicainide I Chemical
-Induced I None
Torsades I Disease
de O Disease
Pointes O Disease
. I None
<eof> I None

<s> O None
An I None
84-year I None
- I None
old I None
male I None
received I None
oral I None
pilsicainide I Chemical
, I None
a I None
pure I None
sodium I Chemical
channel I None
blocker I None
with I None
slow I None
recovery I None
kinetics I None
, I None
to I None
convert I None
his I None
paroxysmal I None
atrial I Disease
fibrillation O Disease
to I None
a I None
sinus I None
rhythm I None
; I None
the I None
patient I None
developed I None
sudden I Disease
cardiac O Disease
death O Disease
<eof> I None

<s> O None
two I None
days I None
later I None
. I None
<eof> I None

<s> O None
The I None
Holter I None
electrocardiogram I None
, I None
which I None
was I None
worn I None
by I None
chance I None
, I None
revealed I None
<eof> I None

<s> O None
torsade I Disease
de O Disease
pointes O Disease
with I None
gradually I None
prolonged I None
QT I None
intervals I None
. I None
<eof> I None

<s> O None
This I None
drug I None
is I None
rapidly I None
absorbed I None
from I None
the I None
gastrointestinal I None
tract I None
, I None
and I None
most I None
of I None
it I None
is I None
excreted I None
from I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
Although I None
the I None
patient I None
's I None
renal I None
function I None
was I None
not I None
highly I None
impaired I None
and I None
the I None
dose I None
of I None
pilsicainide I Chemical
was I None
low I None
, I None
the I None
plasma I None
concentration I None
of I None
pilsicainide I Chemical
may I None
have I None
been I None
high I None
, I None
which I None
can I None
produce I None
torsades I Disease
de O Disease
pointes O Disease
in I None
the I None
octogenarian I None
. I None
<eof> I None

<s> O None
Although I None
the I None
oral I None
administration I None
of I None
class I None
IC I None
drugs I None
, I None
including I None
pilsicainide I Chemical
, I None
is I None
effective I None
to I None
terminate I None
atrial I Disease
fibrillation O Disease
, I None
careful I None
consideration I None
must I None
be I None
taken I None
before I None
giving I None
these I None
drugs I None
to I None
octogenarians I None
. I None
<eof> I None

<s> O None
All I Chemical
- O Chemical
trans O Chemical
retinoic O Chemical
acid O Chemical
-induced I None
inflammatory I None
myositis I Disease
in I None
a I None
patient I None
with I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
All I Chemical
- O Chemical
trans O Chemical
retinoic O Chemical
acid O Chemical
( I None
ATRA I Chemical
) I None
, I None
a I None
component I None
of I None
standard I None
therapy I None
for I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
<eof> I None

<s> O None
( I None
APL I Disease
) I None
, I None
is I None
associated I None
with I None
potentially I None
serious I None
but I None
treatable I None
adverse I None
effects I None
involving I None
numerous I None
organ I None
systems I None
, I None
including I None
rare I None
skeletal I None
muscle I None
involvement I None
. I None
<eof> I None

<s> O None
Only I None
a I None
handful I None
of I None
cases I None
of I None
ATRA I Chemical
-induced I None
<eof> I None

<s> O None
myositis I Disease
in I None
children I None
have I None
been I None
reported I None
, I None
and I None
none I None
in I None
the I None
radiology I None
literature I None
. I None
<eof> I None

<s> O None
We I None
present I None
such I None
a I None
case I None
in I None
a I None
15-year I None
- I None
old I None
boy I None
with I None
APL I Disease
, I None
where I None
recognition I None
of I None
imaging I None
findings I None
played I None
a I None
crucial I None
role I None
in I None
making I None
the I None
diagnosis I None
and I None
facilitated I None
prompt I None
, I None
effective I None
treatment I None
. I None
<eof> I None

<s> O None
Tolerability I None
of I None
lomustine I Chemical
in I None
combination I None
with I None
cyclophosphamide I Chemical
in I None
dogs I None
with I None
lymphoma I Disease
. I None
<eof> I None

<s> O None
This I None
retrospective I None
study I None
describes I None
toxicity I Disease
associated I None
with I None
a I None
protocol I None
of I None
lomustine I Chemical
<eof> I None

<s> O None
( I None
CCNU I Chemical
) I None
and I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CTX I Chemical
) I None
in I None
dogs I None
with I None
lymphoma I Disease
. I None
<eof> I None

<s> O None
CCNU I Chemical
was I None
administered I None
per I None
os I None
( I None
PO I None
) I None
at I None
a I None
targeted I None
dosage I None
of I None
60 I None
mg I None
/ I None
m(2 I None
) I None
body I None
surface I None
area I None
on I None
day I None
0 I None
, I None
CTX I Chemical
was I None
administered I None
PO I None
at I None
a I None
targeted I None
dosage I None
of I None
250 I None
mg I None
/ I None
m(2 I None
) I None
divided I None
over I None
days I None
0 I None
through I None
4 I None
, I None
and I None
all I None
dogs I None
received I None
prophylactic I None
antibiotics I None
. I None
<eof> I None

<s> O None
Ninety I None
treatments I None
were I None
given I None
to I None
the I None
57 I None
dogs I None
included I None
in I None
the I None
study I None
. I None
<eof> I None

<s> O None
Neutropenia I Disease
was I None
the I None
principal I None
toxic I None
effect I None
, I None
and I None
the I None
overall I None
frequency I None
of I None
grade I None
4 I None
neutropenia I Disease
after I None
the I None
first I None
treatment I None
of I None
CCNU I Chemical
/ I None
CTX I Chemical
was I None
30 I None
% I None
( I None
95 I None
% I None
confidence I None
interval I None
, I None
19 I None
- I None
43 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
body I None
weight I None
of I None
dogs I None
with I None
grade I None
4 I None
neutropenia I Disease
( I None
19.7 I None
kg I None
+ I None
13.4 I None
kg I None
) I None
was I None
significantly I None
less I None
than I None
the I None
mean I None
body I None
weight I None
of I None
dogs I None
that I None
did I None
not I None
develop I None
grade I None
4 I None
neutropenia I Disease
( I None
31.7 I None
kg I None
+ I None
12.4 I None
kg I None
; I None
P I None
= I None
.005 I None
) I None
. I None
<eof> I None

<s> O None
One I None
dog I None
( I None
3 I None
% I None
) I None
developed I None
hematologic I None
changes I None
suggestive I None
of I None
hepatotoxicity I Disease
. I None
<eof> I None

<s> O None
No I None
dogs I None
had I None
evidence I None
of I None
either I None
renal I Disease
toxicity O Disease
or I None
hemorrhagic I None
cystitis I None
. I None
<eof> I None

<s> O None
Adverse I None
gastrointestinal I None
effects I None
were I None
uncommon I None
. I None
<eof> I None

<s> O None
On I None
the I None
basis I None
of I None
the I None
findings I None
reported I None
herein I None
, I None
a I None
dose I None
of I None
60 I None
mg I None
/ I None
m(2 I None
) I None
of I None
CCNU I Chemical
combined I None
with I None
250 I None
mg I None
/ I None
m(2 I None
) I None
of I None
CTX I Chemical
<eof> I None

<s> O None
( I None
divided I None
over I None
5 I None
days I None
) I None
<eof> I None

<s> O None
q I None
4 I None
wk I None
is I None
tolerable I None
in I None
tumor I Disease
-bearing I None
dogs I None
. I None
<eof> I None

<s> O None
Nelarabine I Chemical
<eof> I None

<s> O None
neurotoxicity I Disease
with I None
concurrent I None
intrathecal I None
chemotherapy I None
: I None
<eof> I None

<s> O None
Case I None
report I None
and I None
review I None
of I None
literature I None
. I None
<eof> I None

<s> O None
Severe I None
nelarabine I Chemical
neurotoxicity I Disease
in I None
a I None
patient I None
who I None
received I None
concurrent I None
intrathecal I None
( I None
IT I None
) I None
chemotherapy I None
is I None
reported I None
. I None
<eof> I None

<s> O None
A I None
37-year I None
- I None
old I None
Caucasian I None
woman I None
with I None
a I None
history I None
of I None
T I Disease
- O Disease
cell O Disease
lymphoblastic O Disease
lymphoma O Disease
was I None
admitted I None
for I None
relapsed I None
disease I None
. I None
<eof> I None

<s> O None
She I None
was I None
originally I None
treated I None
with I None
induction I None
chemotherapy I None
followed I None
by I None
an I None
autologous I None
transplant I None
. I None
<eof> I None

<s> O None
She I None
developed I None
relapsed I None
disease I None
10 I None
months I None
later I None
with I None
leukemic I Disease
involvement I None
. I None
<eof> I None

<s> O None
She I None
was I None
re I None
- I None
induced I None
with I None
nelarabine I Chemical
1500 I None
mg I None
/ I None
m(2 I None
) I None
on I None
days I None
1 I None
, I None
3 I None
, I None
and I None
5 I None
with I None
1 I None
dose I None
of I None
IT I None
cytarabine I Chemical
100 I None
mg I None
on I None
day I None
2 I None
as I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
prophylaxis I None
. I None
<eof> I None

<s> O None
At I None
the I None
time I None
of I None
treatment I None
, I None
she I None
was I None
on I None
continuous I None
renal I None
replacement I None
therapy I None
due I None
to I None
sequelae I None
of I None
tumor I Disease
lysis O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
TLS I Disease
) I None
. I None
<eof> I None

<s> O None
She I None
tolerated I None
therapy I None
well I None
, I None
entered I None
a I None
complete I None
remission I None
, I None
and I None
recovered I None
her I None
renal I None
function I None
. I None
<eof> I None

<s> O None
She I None
received I None
a I None
second I None
cycle I None
of I None
nelarabine I Chemical
without I None
additional I None
IT I None
prophylaxis I None
one I None
month I None
later I None
. I None
<eof> I None

<s> O None
A I None
week I None
after I None
this I None
second I None
cycle I None
, I None
she I None
noted I None
numbness I None
in I None
her I None
lower I None
extremities I None
. I None
<eof> I None

<s> O None
Predominantly I None
sensory I None
, I None
though I None
also I None
motor I None
and I None
autonomic I None
, I None
peripheral I Disease
neuropathy O Disease
started I None
in I None
her I None
feet I None
, I None
ascended I None
proximally I None
to I None
the I None
mid I None
- I None
thoracic I None
region I None
, I None
and I None
eventually I None
included I None
her I None
distal I None
upper I None
extremities I None
. I None
<eof> I None

<s> O None
A I None
magnetic I None
resonance I None
imaging I None
( I None
MRI I None
) I None
of I None
her I None
spine I None
demonstrated I None
changes I None
from I None
C2 I None
to I None
C6 I None
consistent I None
with I None
subacute I None
combined I None
degeneration I None
. I None
<eof> I None

<s> O None
Nelarabine I Chemical
was I None
felt I None
to I None
be I None
the I None
cause I None
of I None
her I None
symptoms I None
. I None
<eof> I None

<s> O None
Her I None
neuropathy I Disease
stabilized I None
and I None
showed I None
slight I None
improvement I None
and I None
ultimately I None
received I None
an I None
unrelated I None
, I None
reduced I None
- I None
intensity I None
allogeneic I None
transplant I None
while I None
in I None
complete I None
remission I None
, I None
but I None
relapsed I None
disease I None
10 I None
weeks I None
later I None
. I None
<eof> I None

<s> O None
She I None
is I None
currently I None
being I None
treated I None
with I None
best I None
supportive I None
care I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
first I None
published I None
case I None
report I None
of I None
severe I None
neurotoxicity I Disease
caused I None
by I None
nelarabine I Chemical
in I None
a I None
patient I None
who I None
received I None
concurrent I None
IT I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Valproate I Chemical
-induced I None
hyperammonemic I Disease
<eof> I None

<s> O None
encephalopathy I Disease
in I None
a I None
renal I None
transplanted I None
patient I None
. I None
<eof> I None

<s> O None
Neurological I Disease
complications O Disease
after I None
renal I None
transplantation I None
constitute I None
an I None
important I None
cause I None
of I None
morbidity I None
and I None
mortality I None
. I None
<eof> I None

<s> O None
Their I None
differential I None
diagnosis I None
is I None
difficult I None
and I None
essential I None
for I None
subsequent I None
patient I None
's I None
management I None
. I None
<eof> I None

<s> O None
Valproate I Chemical
-induced I None
hyperammonemic I Disease
<eof> I None

<s> O None
encephalopathy I Disease
is I None
an I None
uncommon I None
but I None
serious I None
effect I None
of I None
valproate I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
describe I None
the I None
case I None
of I None
a I None
15-year I None
- I None
old I None
girl I None
who I None
was I None
on I None
a I None
long I None
- I None
term I None
therapy I None
with I None
valproate I Chemical
due I None
to I None
epilepsy I Disease
and I None
revealed I None
impaired I Disease
consciousness O Disease
with I None
<eof> I None

<s> O None
hyperammonemia I Disease
12 I None
days I None
after I None
renal I None
transplantation I None
. I None
<eof> I None

<s> O None
After I None
withdraw I None
of I None
valproate I Chemical
, I None
patients I None
' I None
symptoms I None
resolved I None
within I None
24 I None
h. I None
Clinicians I None
should I None
increase I None
their I None
awareness I None
for I None
potential I None
complication I None
of I None
valproate I Chemical
, I None
especially I None
in I None
transplanted I None
patients I None
. I None
<eof> I None

<s> O None
Necrotising I Disease
fasciitis O Disease
after I None
bortezomib I Chemical
and I None
dexamethasone I Chemical
<eof> I None

<s> O None
-containing I None
regimen I None
in I None
an I None
elderly I None
patient I None
of I None
Waldenstrom I Disease
macroglobulinaemia O Disease
. I None
<eof> I None

<s> O None
Bortezomib I Chemical
and I None
high I None
- I None
dose I None
<eof> I None

<s> O None
dexamethasone I Chemical
<eof> I None

<s> O None
-containing I None
<eof> I None

<s> O None
regimens I None
are I None
considered I None
to I None
be I None
generally I None
tolerable I None
with I None
few I None
severe I None
bacterial I Disease
infections O Disease
in I None
patients I None
with I None
B I None
- I None
cell I None
malignancies I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
information I None
is I None
limited I None
concerning I None
the I None
safety I None
of I None
the I None
regimen I None
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
a I None
76-year I None
- I None
old I None
man I None
with I None
Waldenstrom I Disease
macroglobulinaemia O Disease
who I None
suffered I None
necrotising I Disease
fasciitis O Disease
without I None
neutropenia I Disease
after I None
the I None
combination I None
treatment I None
with I None
bortezomib I Chemical
, I None
high I None
- I None
dose I None
dexamethasone I Chemical
and I None
rituximab I None
. I None
<eof> I None

<s> O None
Despite I None
immediate I None
intravenous I None
antimicrobial I None
therapy I None
, I None
he I None
succumbed I None
23 I None
h I None
after I None
the I None
onset I None
. I None
<eof> I None

<s> O None
Physicians I None
should I None
recognise I None
the I None
possibility I None
of I None
fatal I None
bacterial I Disease
infections O Disease
related I None
to I None
bortezomib I Chemical
plus I None
high I None
- I None
dose I None
<eof> I None

<s> O None
dexamethasone I Chemical
in I None
elderly I None
patients I None
, I None
and I None
we I None
believe I None
this I None
case I None
warrants I None
further I None
investigation I None
. I None
<eof> I None

<s> O None
An I None
integrated I None
characterization I None
of I None
serological I None
, I None
pathological I None
, I None
and I None
functional I None
events I None
in I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Many I None
efficacious I None
cancer I Disease
treatments I None
cause I None
significant I None
cardiac I None
morbidity I None
, I None
yet I None
biomarkers I None
or I None
functional I None
indices I None
of I None
early I None
damage I None
, I None
which I None
would I None
allow I None
monitoring I None
and I None
intervention I None
, I None
are I None
lacking I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
have I None
utilized I None
a I None
rat I None
model I None
of I None
progressive I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
-induced I None
cardiomyopathy I Disease
, I None
applying I None
multiple I None
approaches I None
, I None
including I None
cardiac I None
magnetic I None
resonance I None
imaging I None
( I None
MRI I None
) I None
, I None
to I None
provide I None
the I None
most I None
comprehensive I None
characterization I None
to I None
date I None
of I None
the I None
timecourse I None
of I None
serological I None
, I None
pathological I None
, I None
and I None
functional I None
events I None
underlying I None
this I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Hannover I None
Wistar I None
rats I None
were I None
dosed I None
with I None
1.25 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
DOX I Chemical
weekly I None
for I None
8 I None
weeks I None
followed I None
by I None
a I None
4 I None
week I None
off I None
- I None
dosing I None
" I None
recovery I None
" I None
period I None
. I None
<eof> I None

<s> O None
Electron I None
microscopy I None
of I None
the I None
myocardium I None
revealed I None
<eof> I None

<s> O None
subcellular I Disease
degeneration O Disease
and I None
marked I None
mitochondrial I None
changes I None
after I None
a I None
single I None
dose I None
. I None
<eof> I None

<s> O None
Histopathological I None
analysis I None
revealed I None
progressive I None
cardiomyocyte I Disease
degeneration O Disease
, I None
hypertrophy I Disease
/cytomegaly I None
, I None
and I None
extensive I None
vacuolation I None
after I None
two I None
doses I None
. I None
<eof> I None

<s> O None
Extensive I None
replacement I None
fibrosis I Disease
( I None
quantified I None
by I None
Sirius I None
red I None
staining I None
) I None
developed I None
during I None
the I None
off I None
- I None
dosing I None
period I None
. I None
<eof> I None

<s> O None
Functional I None
indices I None
assessed I None
by I None
cardiac I None
MRI I None
( I None
including I None
left I None
ventricular I None
ejection I None
fraction I None
( I None
LVEF I None
) I None
, I None
cardiac I None
output I None
, I None
and I None
E I None
/ I None
A I None
ratio I None
) I None
declined I None
progressively I None
, I None
reaching I None
statistical I None
significance I None
after I None
two I None
doses I None
and I None
culminating I None
in I None
" I None
clinical I None
" I None
LV I Disease
dysfunction O Disease
by I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
Significant I None
increases I None
in I None
peak I None
myocardial I None
contrast I None
enhancement I None
and I None
serological I None
cardiac I None
troponin I None
I I None
( I None
cTnI I None
) I None
emerged I None
after I None
eight I None
doses I None
, I None
importantly I None
preceding I None
the I None
LVEF I None
decline I None
to I None
< I None
50 I None
% I None
. I None
<eof> I None

<s> O None
Troponin I None
I I None
levels I None
positively I None
correlated I None
with I None
delayed I None
and I None
peak I None
gadolinium I Chemical
contrast I None
enhancement I None
, I None
histopathological I None
grading I None
, I None
and I None
diastolic I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
subcellular I None
cardiomyocyte I Disease
degeneration O Disease
was I None
the I None
earliest I None
marker I None
, I None
followed I None
by I None
progressive I None
functional I None
decline I None
and I None
histopathological I None
manifestations I None
. I None
<eof> I None

<s> O None
Myocardial I None
contrast I None
enhancement I None
and I None
elevations I None
in I None
cTnI I None
occurred I None
later I None
. I None
<eof> I None

<s> O None
However I None
, I None
all I None
indices I None
predated I None
" I None
clinical I None
" I None
LV I Disease
dysfunction O Disease
and I None
thus I None
warrant I None
further I None
evaluation I None
as I None
predictive I None
biomarkers I None
. I None
<eof> I None

<s> O None
Intradermal I None
glutamate I Chemical
and I None
capsaicin I Chemical
injections I None
: I None
intra- I None
and I None
interindividual I None
variability I None
of I None
provoked I None
hyperalgesia I Disease
and I None
allodynia I Disease
. I None
<eof> I None

<s> O None
Intradermal I None
injections I None
of I None
glutamate I Chemical
and I None
capsaicin I Chemical
are I None
attractive I None
to I None
use I None
in I None
human I None
experimental I None
pain I Disease
models I None
because I None
hyperalgesia I Disease
and I None
allodynia I Disease
mimic I None
isolated I None
aspects I None
of I None
clinical I None
pain I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
the I None
reproducibility I None
of I None
these I None
models I None
. I None
<eof> I None

<s> O None
Twenty I None
healthy I None
male I None
volunteers I None
( I None
mean I None
age I None
24 I None
years I None
; I None
range I None
18 I None
- I None
38 I None
years I None
) I None
received I None
intradermal I None
injections I None
of I None
glutamate I Chemical
and I None
capsaicin I Chemical
in I None
the I None
volar I None
forearm I None
. I None
<eof> I None

<s> O None
Magnitudes I None
of I None
secondary I None
pinprick I None
hyperalgesia I Disease
and I None
brush I None
- I None
evoked I None
allodynia I Disease
were I None
investigated I None
using I None
von I None
Frey I None
filaments I None
( I None
gauges I None
10 I None
, I None
15 I None
, I None
60 I None
and I None
100 I None
g I None
) I None
and I None
brush I None
strokes I None
. I None
<eof> I None

<s> O None
Areas I None
of I None
secondary I Disease
hyperalgesia O Disease
and I None
allodynia I Disease
were I None
quantified I None
immediately I None
after I None
injection I None
and I None
after I None
15 I None
, I None
30 I None
and I None
60 I None
min I None
. I None
<eof> I None

<s> O None
Two I None
identical I None
experiments I None
separated I None
by I None
at I None
least I None
7 I None
days I None
were I None
performed I None
. I None
<eof> I None

<s> O None
Reproducibility I None
across I None
and I None
within I None
volunteers I None
( I None
inter- I None
and I None
intra I None
- I None
individual I None
variation I None
, I None
respectively I None
) I None
was I None
assessed I None
using I None
intraclass I None
correlation I None
coefficient I None
( I None
ICC I None
) I None
and I None
coefficient I None
of I None
variation I None
( I None
CV I None
) I None
. I None
<eof> I None

<s> O None
Secondary I None
pinprick I None
<eof> I None

<s> O None
hyperalgesia I Disease
was I None
observed I None
as I None
a I None
marked I None
increase I None
in I None
the I None
visual I None
analogue I None
scale I None
( I None
VAS I None
) I None
response I None
to I None
von I None
Frey I None
gauges I None
60 I None
and I None
100 I None
g I None
( I None
P I None
< I None
0.001 I None
) I None
after I None
glutamate I Chemical
injection I None
. I None
<eof> I None

<s> O None
For I None
capsaicin I Chemical
, I None
secondary I None
pinprick I None
hyperalgesia I Disease
was I None
detected I None
with I None
all I None
von I None
Frey I None
gauges I None
( I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Glutamate I Chemical
evoked I None
reproducible I None
VAS I None
response I None
to I None
all I None
von I None
Frey I None
gauges I None
( I None
ICC I None
> I None
0.60 I None
) I None
and I None
brush I None
strokes I None
( I None
ICC I None
> I None
0.83 I None
) I None
. I None
<eof> I None

<s> O None
Capsaicin I Chemical
injection I None
was I None
reproducible I None
for I None
secondary I Disease
hyperalgesia O Disease
<eof> I None

<s> O None
( I None
ICC I None
> I None
0.70 I None
) I None
and I None
allodynia I Disease
( I None
ICC I None
> I None
0.71 I None
) I None
. I None
<eof> I None

<s> O None
Intra I None
- I None
individual I None
variability I None
was I None
generally I None
lower I None
for I None
the I None
VAS I None
response I None
to I None
von I None
Frey I None
and I None
brush I None
compared I None
with I None
areas I None
of I None
secondary I Disease
hyperalgesia O Disease
and I None
allodynia I Disease
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
glutamate I Chemical
and I None
capsaicin I Chemical
yield I None
reproducible I None
hyperalgesic I Disease
and I None
<eof> I None

<s> O None
allodynic I Disease
responses I None
, I None
and I None
the I None
present I None
model I None
is I None
well I None
suited I None
for I None
basic I None
research I None
, I None
as I None
well I None
as I None
for I None
assessing I None
the I None
modulation I None
of I None
central I None
phenomena I None
. I None
<eof> I None

<s> O None
Ocular I None
- I None
specific I None
ER I None
stress I None
reduction I None
rescues I None
<eof> I None

<s> O None
glaucoma I Disease
in I None
murine I None
glucocorticoid I None
- I None
induced I None
glaucoma I Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
glucocorticoids I None
induces I None
ocular I Disease
hypertension O Disease
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
If I None
untreated I None
, I None
these I None
patients I None
can I None
develop I None
a I None
secondary I None
glaucoma I Disease
that I None
resembles I None
primary I Disease
open O Disease
- O Disease
angle O Disease
glaucoma O Disease
<eof> I None

<s> O None
( I None
POAG I Disease
) I None
. I None
<eof> I None

<s> O None
The I None
underlying I None
pathology I None
of I None
glucocorticoid I None
- I None
induced I None
glaucoma I Disease
is I None
not I None
fully I None
understood I None
, I None
due I None
in I None
part I None
to I None
lack I None
of I None
an I None
appropriate I None
animal I None
model I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
developed I None
a I None
murine I None
model I None
of I None
glucocorticoid I None
- I None
induced I None
glaucoma I Disease
that I None
exhibits I None
glaucoma I Disease
features I None
that I None
are I None
observed I None
in I None
patients I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
WT I None
mice I None
with I None
topical I None
ocular I None
0.1 I None
% I None
dexamethasone I Chemical
led I None
to I None
elevation I None
of I None
intraocular I None
pressure I None
( I None
IOP I None
) I None
, I None
functional I None
and I None
structural I None
loss I None
of I None
retinal I Disease
ganglion O Disease
cells I None
, I None
and I None
axonal I Disease
degeneration O Disease
, I None
resembling I None
glucocorticoid I None
- I None
induced I None
glaucoma I Disease
in I None
human I None
patients I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
dexamethasone I Chemical
-induced I None
<eof> I None

<s> O None
ocular I Disease
hypertension O Disease
was I None
associated I None
with I None
chronic I None
ER I None
stress I None
of I None
the I None
trabecular I None
meshwork I None
( I None
TM I None
) I None
. I None
<eof> I None

<s> O None
Similar I None
to I None
patients I None
, I None
withdrawal I None
of I None
dexamethasone I Chemical
treatment I None
reduced I None
elevated I None
IOP I None
and I None
ER I None
stress I None
in I None
this I None
animal I None
model I None
. I None
<eof> I None

<s> O None
Dexamethasone I Chemical
induced I None
the I None
transcriptional I None
factor I None
CHOP I None
, I None
a I None
marker I None
for I None
chronic I None
ER I None
stress I None
, I None
in I None
the I None
anterior I None
segment I None
tissues I None
, I None
and I None
Chop I None
deletion I None
reduced I None
ER I None
stress I None
in I None
these I None
tissues I None
and I None
prevented I None
<eof> I None

<s> O None
dexamethasone I Chemical
-induced I None
<eof> I None

<s> O None
ocular I Disease
hypertension O Disease
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
reduction I None
of I None
ER I None
stress I None
in I None
the I None
TM I None
with I None
sodium I Chemical
4-phenylbutyrate O Chemical
prevented I None
dexamethasone I Chemical
-induced I None
ocular I Disease
hypertension O Disease
in I None
WT I None
mice I None
. I None
<eof> I None

<s> O None
Our I None
data I None
indicate I None
that I None
ER I None
stress I None
contributes I None
to I None
glucocorticoid I None
- I None
induced I None
ocular I Disease
hypertension O Disease
and I None
suggest I None
that I None
reducing I None
ER I None
stress I None
has I None
potential I None
as I None
a I None
therapeutic I None
strategy I None
for I None
treating I None
glucocorticoid I None
- I None
induced I None
glaucoma I Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
ginsenosides I Chemical
on I None
opioid I None
- I None
induced I None
hyperalgesia I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Opioid I None
- I None
induced I None
hyperalgesia I Disease
<eof> I None

<s> O None
( I None
OIH I Disease
) I None
is I None
characterized I None
by I None
nociceptive I None
sensitization I None
caused I None
by I None
the I None
cessation I None
of I None
chronic I None
opioid I None
use I None
. I None
<eof> I None

<s> O None
OIH I Disease
can I None
limit I None
the I None
clinical I None
use I None
of I None
opioid I None
analgesics I None
and I None
complicate I None
withdrawal I None
from I None
opioid I Disease
addiction O Disease
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
investigated I None
the I None
effects I None
of I None
Re I None
, I None
Rg1 I None
, I None
and I None
Rb1 I None
ginsenosides I None
, I None
the I None
bioactive I None
components I None
of I None
ginseng I None
, I None
on I None
OIH I Disease
. I None
<eof> I None

<s> O None
OIH I Disease
was I None
achieved I None
in I None
mice I None
after I None
subcutaneous I None
administration I None
of I None
morphine I Chemical
for I None
7 I None
consecutive I None
days I None
three I None
times I None
per I None
day I None
. I None
<eof> I None

<s> O None
During I None
withdrawal I None
( I None
days I None
8 I None
and I None
9 I None
) I None
, I None
these I None
mice I None
were I None
administered I None
<eof> I None

<s> O None
Re I Chemical
, I None
Rg1 I Chemical
, I None
or I None
Rb1 I Chemical
intragastrically I None
two I None
times I None
per I None
day I None
. I None
<eof> I None

<s> O None
On I None
the I None
test I None
day I None
( I None
day I None
10 I None
) I None
, I None
mice I None
were I None
subjected I None
to I None
the I None
thermal I None
sensitivity I None
test I None
and I None
the I None
acetic I Chemical
acid O Chemical
-induced I None
writhing I None
test I None
. I None
<eof> I None

<s> O None
Re I Chemical
( I None
300 I None
mg I None
/ I None
kg I None
) I None
inhibited I None
<eof> I None

<s> O None
OIH I Disease
in I None
both I None
the I None
thermal I None
sensitivity I None
test I None
and I None
the I None
acetic I Chemical
acid O Chemical
-induced I None
writhing I None
test I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
Rg1 I None
and I None
Rb1 I None
ginsenosides I None
failed I None
to I None
prevent I None
OIH I Disease
in I None
either I None
test I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
Rg1 I Chemical
showed I None
a I None
tendency I None
to I None
aggravate I None
OIH I Disease
in I None
the I None
acetic I Chemical
acid O Chemical
-induced I None
writhing I None
test I None
. I None
<eof> I None

<s> O None
Our I None
data I None
suggested I None
that I None
the I None
ginsenoside I Chemical
Re O Chemical
, I None
but I None
not I None
Rg1 I Chemical
or I None
Rb1 I Chemical
, I None
may I None
contribute I None
toward I None
reversal I None
of I None
OIH I Disease
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
severe I None
hemodynamic I None
disturbances I None
between I None
dexmedetomidine I Chemical
and I None
propofol I Chemical
for I None
sedation I None
in I None
neurocritical I None
care I None
patients I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Dexmedetomidine I Chemical
and I None
propofol I Chemical
are I None
commonly I None
used I None
sedatives I None
in I None
neurocritical I None
care I None
as I None
they I None
allow I None
for I None
frequent I None
neurologic I None
examinations I None
. I None
<eof> I None

<s> O None
However I None
, I None
both I None
agents I None
are I None
associated I None
with I None
significant I None
hemodynamic I None
side I None
effects I None
. I None
<eof> I None

<s> O None
The I None
primary I None
objective I None
of I None
this I None
study I None
is I None
to I None
compare I None
the I None
prevalence I None
of I None
severe I None
hemodynamic I None
effects I None
in I None
neurocritical I None
care I None
patients I None
receiving I None
dexmedetomidine I Chemical
and I None
propofol I Chemical
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Multicenter I None
, I None
retrospective I None
, I None
propensity I None
- I None
matched I None
cohort I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Neurocritical I None
care I None
units I None
at I None
two I None
academic I None
medical I None
centers I None
with I None
dedicated I None
neurocritical I None
care I None
teams I None
and I None
board I None
- I None
certified I None
neurointensivists I None
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
<eof> I None

<s> O None
Neurocritical I None
care I None
patients I None
admitted I None
between I None
July I None
2009 I None
and I None
September I None
2012 I None
were I None
evaluated I None
and I None
then I None
matched I None
1:1 I None
based I None
on I None
propensity I None
scoring I None
of I None
baseline I None
characteristics I None
. I None
<eof> I None

<s> O None
INTERVENTIONS I None
: I None
<eof> I None

<s> O None
Continuous I None
sedation I None
with I None
dexmedetomidine I Chemical
or I None
propofol I Chemical
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
AND I None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
342 I None
patients I None
( I None
105 I None
dexmedetomidine I Chemical
and I None
237 I None
propofol I Chemical
) I None
were I None
included I None
in I None
the I None
analysis I None
, I None
with I None
190 I None
matched I None
( I None
95 I None
in I None
each I None
group I None
) I None
by I None
propensity I None
score I None
. I None
<eof> I None

<s> O None
The I None
primary I None
outcome I None
of I None
this I None
study I None
was I None
a I None
composite I None
of I None
severe I None
hypotension I Disease
<eof> I None

<s> O None
( I None
mean I None
arterial I None
pressure I None
< I None
60 I None
mm I None
Hg I None
) I None
and I None
bradycardia I Disease
<eof> I None

<s> O None
( I None
heart I None
rate I None
< I None
50 I None
beats I None
/ I None
min I None
) I None
during I None
sedative I None
infusion I None
. I None
<eof> I None

<s> O None
No I None
difference I None
in I None
the I None
primary I None
composite I None
outcome I None
in I None
both I None
the I None
unmatched I None
( I None
30 I None
% I None
vs I None
30 I None
% I None
, I None
p I None
= I None
0.94 I None
) I None
or I None
matched I None
cohorts I None
( I None
28 I None
% I None
vs I None
34 I None
% I None
, I None
p I None
= I None
0.35 I None
) I None
could I None
be I None
found I None
. I None
<eof> I None

<s> O None
When I None
analyzed I None
separately I None
, I None
no I None
differences I None
could I None
be I None
found I None
in I None
the I None
prevalence I None
of I None
severe I None
hypotension I Disease
or I None
bradycardia I Disease
in I None
either I None
the I None
unmatched I None
or I None
matched I None
cohorts I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Severe I None
hypotension I Disease
and I None
bradycardia I Disease
occur I None
at I None
similar I None
prevalence I None
in I None
neurocritical I None
care I None
patients I None
who I None
receive I None
dexmedetomidine I Chemical
or I None
propofol I Chemical
. I None
<eof> I None

<s> O None
Providers I None
should I None
similarly I None
consider I None
the I None
likelihood I None
of I None
hypotension I Disease
or I None
bradycardia I Disease
before I None
starting I None
either I None
sedative I None
. I None
<eof> I None

<s> O None
Hydroxytyrosol I Chemical
ameliorates I None
oxidative I None
stress I None
and I None
mitochondrial I Disease
dysfunction O Disease
in I None
doxorubicin I Chemical
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
in I None
rats I None
with I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Oxidative I None
stress I None
is I None
involved I None
in I None
several I None
processes I None
including I None
cancer I Disease
, I None
aging I None
and I None
cardiovascular I Disease
disease O Disease
, I None
and I None
has I None
been I None
shown I None
to I None
potentiate I None
the I None
therapeutic I None
effect I None
of I None
drugs I None
such I None
as I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
causes I None
significant I None
cardiotoxicity I Disease
characterized I None
by I None
marked I None
increases I None
in I None
oxidative I None
stress I None
and I None
mitochondrial I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
investigate I None
whether I None
doxorubicin I Chemical
-associated I None
chronic I None
<eof> I None

<s> O None
cardiac I Disease
toxicity O Disease
can I None
be I None
ameliorated I None
with I None
the I None
antioxidant I None
hydroxytyrosol I Chemical
in I None
rats I None
with I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Thirty I None
- I None
six I None
rats I None
bearing I None
<eof> I None

<s> O None
breast I Disease
tumors O Disease
induced I None
chemically I None
were I None
divided I None
into I None
4 I None
groups I None
: I None
control I None
, I None
hydroxytyrosol I Chemical
( I None
0.5mg I None
<eof> I None

<s> O None
/ I None
kg I None
, I None
5days I None
/ I None
week I None
) I None
, I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
1mg I None
/ I None
kg I None
/ I None
week I None
) I None
, I None
and I None
doxorubicin I Chemical
plus I None
hydroxytyrosol I Chemical
. I None
<eof> I None

<s> O None
Cardiac I Disease
disturbances O Disease
at I None
the I None
cellular I None
and I None
mitochondrial I None
level I None
, I None
mitochondrial I None
electron I None
transport I None
chain I None
complexes I None
I I None
- I None
IV I None
and I None
apoptosis I None
- I None
inducing I None
factor I None
, I None
and I None
oxidative I None
stress I None
markers I None
have I None
been I None
analyzed I None
. I None
<eof> I None

<s> O None
Hydroxytyrosol I Chemical
improved I None
the I None
cardiac I Disease
disturbances O Disease
enhanced I None
by I None
doxorubicin I Chemical
by I None
significantly I None
reducing I None
the I None
percentage I None
of I None
altered I None
mitochondria I None
and I None
oxidative I None
damage I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
hydroxytyrosol I Chemical
improve I None
the I None
mitochondrial I None
electron I None
transport I None
chain I None
. I None
<eof> I None

<s> O None
This I None
study I None
demonstrates I None
that I None
hydroxytyrosol I Chemical
protect I None
rat I None
heart I Disease
damage O Disease
provoked I None
by I None
doxorubicin I Chemical
decreasing I None
oxidative I None
damage I None
and I None
mitochondrial I None
alterations I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
-induced I None
myxoedema I None
coma I None
. I None
<eof> I None

<s> O None
A I None
62-year I None
- I None
old I None
man I None
was I None
found I None
to I None
have I None
bradycardia I Disease
, I None
<eof> I None

<s> O None
hypothermia I Disease
and I None
respiratory I Disease
failure O Disease
<eof> I None

<s> O None
3 I None
weeks I None
after I None
initiation I None
of I None
amiodarone I Chemical
therapy I None
for I None
atrial I Disease
fibrillation O Disease
. I None
<eof> I None

<s> O None
Thyroid I None
- I None
stimulating I None
hormone I None
was I None
found I None
to I None
be I None
168 I None
uIU I None
/ I None
mL I None
( I None
nl I None
. I None
0.3 I None
- I None
5 I None
uIU I None
/ I None
mL I None
) I None
and I None
free I None
thyroxine I Chemical
<eof> I None

<s> O None
( I None
FT4 I None
) I None
was I None
< I None
0.2 I None
ng I None
/ I None
dL I None
( I None
nl I None
. I None
0.8 I None
- I None
1.8 I None
ng I None
/ I None
dL I None
) I None
. I None
<eof> I None

<s> O None
He I None
received I None
intravenous I None
fluids I None
, I None
vasopressor I None
therapy I None
and I None
stress I None
dose I None
<eof> I None

<s> O None
steroids I Chemical
; I None
he I None
was I None
intubated I None
and I None
admitted I None
to I None
the I None
intensive I None
care I None
unit I None
. I None
<eof> I None

<s> O None
He I None
received I None
500 I None
ug I None
of I None
intravenous I None
levothyroxine I Chemical
in I None
the I None
first I None
18 I None
h I None
of I None
therapy I None
, I None
and I None
150 I None
ug I None
intravenous I None
daily I None
thereafter I None
. I None
<eof> I None

<s> O None
Haemodynamic I None
improvement I None
, I None
along I None
with I None
complete I None
recovery I None
of I None
mental I None
status I None
, I None
occurred I None
after I None
48 I None
h. I None
Twelve I None
hours I None
after I None
the I None
initiation I None
of I None
therapy I None
, I None
FT4 I None
was I None
0.96 I None
ng I None
/ I None
dL. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
maintained I None
on I None
levothyroxine I Chemical
175 I None
<eof> I None

<s> O None
( I None
g I None
POorally I None
daily I None
. I None
<eof> I None

<s> O None
A I None
thyroid I None
ultrasound I None
showed I None
diffuse I None
heterogeneity I None
. I None
<eof> I None

<s> O None
The I None
24 I None
hour I None
excretion I None
of I None
iodine I Chemical
was I None
3657 I None
( I None
mcg I None
( I None
25 I None
- I None
756 I None
( I None
mcg I None
) I None
. I None
<eof> I None

<s> O None
The I None
only I None
two I None
cases I None
of I None
amiodarone I Chemical
-induced I None
myxoedema I None
coma I None
in I None
the I None
literature I None
report I None
patient I None
death I None
despite I None
supportive I None
therapy I None
and I None
thyroid I None
hormone I None
replacement I None
. I None
<eof> I None

<s> O None
This I None
case I None
represents I None
the I None
most I None
thoroughly I None
investigated I None
case I None
of I None
amiodarone I Chemical
-induced I None
myxoedema I None
coma I None
with I None
a I None
history I None
significant I None
for I None
subclinical I None
thyroid I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Use I None
of I None
argatroban I Chemical
and I None
catheter I None
- I None
directed I None
thrombolysis I Disease
with I None
alteplase I None
in I None
an I None
oncology I None
patient I None
with I None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
with I None
thrombosis I Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
The I None
case I None
of I None
an I None
oncology I None
patient I None
who I None
developed I None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
with I None
thrombosis I Disease
<eof> I None

<s> O None
( I None
HITT I Disease
) I None
and I None
was I None
treated I None
with I None
argatroban I Chemical
plus I None
catheter I None
- I None
directed I None
thrombolysis I Disease
( I None
CDT I None
) I None
with I None
alteplase I None
is I None
presented I None
. I None
<eof> I None

<s> O None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
63-year I None
- I None
old I None
Caucasian I None
man I None
with I None
renal I None
amyloidosis I Disease
undergoing I None
peripheral I None
blood I None
stem I None
cell I None
collection I None
for I None
an I None
autologous I None
stem I None
cell I None
transplant I None
developed I None
extensive I None
bilateral I None
upper I Disease
- O Disease
extremity O Disease
deep O Disease
venous O Disease
thrombosis O Disease
<eof> I None

<s> O None
( I None
DVT I Disease
) I None
and I None
pulmonary I Disease
embolism O Disease
secondary I None
to I None
heparin I Chemical
<eof> I None

<s> O None
-induced I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
A I None
continuous I None
i.v I None
. I None
infusion I None
of I None
argatroban I Chemical
was I None
initiated I None
, I None
and I None
the I None
patient I None
was I None
managed I None
on I None
the I None
general I None
medical I None
floor I None
. I None
<eof> I None

<s> O None
After I None
one I None
week I None
of I None
therapy I None
, I None
he I None
was I None
transferred I None
to I None
the I None
intensive I None
care I None
unit I None
with I None
cardiopulmonary I None
compromise I None
related I None
to I None
superior I Disease
vena O Disease
cava O Disease
( O Disease
SVC O Disease
) O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
A I None
percutaneous I None
mechanical I None
thrombectomy I None
and I None
CDT I None
with I None
alteplase I None
were I None
attempted I None
, I None
but I None
the I None
procedure I None
was I None
aborted I None
due I None
to I None
epistaxis I Disease
. I None
<eof> I None

<s> O None
The I None
epistaxis I Disease
resolved I None
the I None
next I None
day I None
, I None
and I None
the I None
patient I None
was I None
restarted I None
on I None
argatroban I Chemical
. I None
<eof> I None

<s> O None
A I None
second I None
percutaneous I None
mechanical I None
thrombectomy I None
was I None
performed I None
six I None
days I None
later I None
and I None
resulted I None
in I None
partial I None
revascularization I None
of I None
the I None
SVC I None
and I None
central I None
veins I None
. I None
<eof> I None

<s> O None
Postthrombectomy I None
continuous I None
CDT I None
with I None
alteplase I None
was I None
commenced I None
while I None
argatroban I Chemical
was I None
withheld I None
, I None
and I None
complete I None
patency I None
of I None
the I None
SVC I None
and I None
central I None
veins I None
was I None
achieved I None
after I None
three I None
days I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Alteplase I None
was I None
discontinued I None
, I None
and I None
the I None
patient I None
was I None
reinitiated I None
on I None
argatroban I Chemical
; I None
ultimately I None
, I None
he I None
was I None
transitioned I None
to I None
warfarin I Chemical
for I None
long I None
- I None
term I None
anticoagulation I None
. I None
<eof> I None

<s> O None
Although I None
the I None
patient I None
recovered I None
, I None
he I None
experienced I None
permanent I None
vision I None
and I None
hearing I None
loss I None
, I None
as I None
well I None
as I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
A I None
63-year I None
- I None
old I None
man I None
with I None
renal I None
amyloidosis I Disease
and I None
SVC I Disease
syndrome O Disease
secondary I None
to I None
HITT I Disease
was I None
successfully I None
treated I None
with I None
argatroban I Chemical
and I None
CDT I None
with I None
alteplase I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
dehydroepiandrosterone I Chemical
in I None
amphetamine I Chemical
-induced I None
<eof> I None

<s> O None
schizophrenia I Disease
models I None
in I None
mice I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
examine I None
the I None
effects I None
of I None
dehydroepiandrosterone I Chemical
<eof> I None

<s> O None
( I None
DHEA I Chemical
) I None
on I None
animal I None
models I None
of I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Seventy I None
Swiss I None
albino I None
female I None
mice I None
( I None
25 I None
- I None
35 I None
g I None
) I None
were I None
divided I None
into I None
4 I None
groups I None
: I None
amphetamine I Chemical
-free I None
( I None
control I None
) I None
, I None
amphetamine I Chemical
, I None
50 I None
, I None
and I None
100 I None
mg I None
/ I None
kg I None
DHEA I Chemical
. I None
<eof> I None

<s> O None
The I None
DHEA I Chemical
was I None
administered I None
intraperitoneally I None
( I None
ip I None
) I None
for I None
5 I None
days I None
. I None
<eof> I None

<s> O None
Amphetamine I Chemical
<eof> I None

<s> O None
( I None
3 I None
mg I None
/ I None
kg I None
ip I None
) I None
induced I None
hyper I Disease
locomotion I None
, I None
apomorphine I Chemical
<eof> I None

<s> O None
( I None
1.5 I None
mg I None
/ I None
kg I None
subcutaneously I None
[ I None
sc I None
] I None
) I None
induced I None
climbing I None
, I None
and I None
haloperidol I Chemical
( I None
1.5 I None
mg I None
/ I None
kg I None
sc I None
) I None
induced I None
catalepsy I Disease
tests I None
were I None
used I None
as I None
animal I None
models I None
of I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
The I None
study I None
was I None
conducted I None
at I None
the I None
Animal I None
Experiment I None
Laboratories I None
, I None
Department I None
of I None
Pharmacology I None
, I None
Medical I None
School I None
, I None
Eskisehir I None
Osmangazi I None
University I None
, I None
Eskisehir I None
, I None
Turkey I None
between I None
March I None
and I None
May I None
2012 I None
. I None
<eof> I None

<s> O None
Statistical I None
analysis I None
was I None
carried I None
out I None
using I None
Kruskal I None
- I None
Wallis I None
test I None
for I None
hyper I Disease
locomotion I None
, I None
and I None
one I None
- I None
way I None
ANOVA I None
for I None
climbing I None
and I None
catalepsy I Disease
tests I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
the I None
amphetamine I Chemical
-induced I None
locomotion I None
test I None
, I None
there I None
were I None
significant I None
increases I None
in I None
all I None
movements I None
compared I None
with I None
the I None
amphetamine I Chemical
-free I None
group I None
. I None
<eof> I None

<s> O None
Both I None
DHEA I Chemical
<eof> I None

<s> O None
50 I None
mg I None
/ I None
kg I None
( I None
p<0.05 I None
) I None
, I None
and I None
100 I None
mg I None
/ I None
kg I None
( I None
p<0.01 I None
) I None
<eof> I None

<s> O None
significantly I None
decreased I None
all I None
movements I None
compared I None
with I None
the I None
amphetamine I Chemical
-induced I None
locomotion I None
group I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
difference I None
between I None
groups I None
in I None
the I None
haloperidol I Chemical
-induced I None
catalepsy I Disease
test I None
( I None
p<0.05 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
significant I None
difference I None
between I None
groups I None
in I None
terms I None
of I None
total I None
climbing I None
time I None
in I None
the I None
apomorphine I Chemical
-induced I None
climbing I None
test I None
( I None
p>0.05 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
<eof> I None

<s> O None
: I None
We I None
observed I None
that I None
DHEA I Chemical
reduced I None
locomotor I None
activity I None
and I None
increased I None
catalepsy I Disease
at I None
both I None
doses I None
, I None
while I None
it I None
had I None
no I None
effect I None
on I None
climbing I None
behavior I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
DHEA I Chemical
displays I None
typical I None
neuroleptic I None
- I None
like I None
effects I None
, I None
and I None
may I None
be I None
used I None
in I None
the I None
treatment I None
of I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
Availability I None
of I None
human I None
induced I None
pluripotent I None
stem I None
cell I None
- I None
derived I None
cardiomyocytes I None
in I None
assessment I None
of I None
drug I None
potential I None
for I None
QT I Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
Field I None
potential I None
duration I None
( I None
FPD I None
) I None
in I None
human I None
- I None
induced I None
pluripotent I None
stem I None
cell I None
- I None
derived I None
cardiomyocytes I None
( I None
hiPS I None
- I None
CMs I None
) I None
, I None
which I None
can I None
express I None
QT I None
interval I None
in I None
an I None
electrocardiogram I None
, I None
is I None
reported I None
to I None
be I None
a I None
useful I None
tool I None
to I None
predict I None
K I Chemical
( I None
+ I None
) I None
channel I None
and I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
channel I None
blocker I None
effects I None
on I None
QT I None
interval I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
is I None
no I None
report I None
showing I None
that I None
this I None
technique I None
can I None
be I None
used I None
to I None
predict I None
multichannel I None
blocker I None
potential I None
for I None
QT I Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
is I None
to I None
show I None
that I None
FPD I None
from I None
MEA I None
( I None
Multielectrode I None
array I None
) I None
of I None
hiPS I None
- I None
CMs I None
can I None
detect I None
QT I Disease
prolongation O Disease
induced I None
by I None
multichannel I None
blockers I None
. I None
<eof> I None

<s> O None
hiPS I None
- I None
CMs I None
were I None
seeded I None
onto I None
MEA I None
and I None
FPD I None
was I None
measured I None
for I None
2min I None
every I None
10min I None
for I None
30min I None
after I None
drug I None
exposure I None
for I None
the I None
vehicle I None
and I None
each I None
drug I None
concentration I None
. I None
<eof> I None

<s> O None
IKr I None
and I None
IKs I None
blockers I None
concentration I None
- I None
dependently I None
prolonged I None
corrected I None
FPD I None
( I None
FPDc I None
) I None
, I None
whereas I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
channel I None
blockers I None
concentration I None
- I None
dependently I None
shortened I None
FPDc I None
. I None
<eof> I None

<s> O None
Also I None
, I None
the I None
multichannel I None
blockers I None
Amiodarone I Chemical
, I None
Paroxetine I Chemical
, I None
Terfenadine I Chemical
and I None
Citalopram I Chemical
prolonged I None
FPDc I None
in I None
a I None
concentration I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
the I None
IKr I None
blockers I None
, I None
Terfenadine I Chemical
and I None
Citalopram I Chemical
, I None
which I None
are I None
reported I None
to I None
cause I None
Torsade I Disease
de O Disease
Pointes O Disease
<eof> I None

<s> O None
( I None
TdP I Disease
) I None
in I None
clinical I None
practice I None
, I None
produced I None
early I None
afterdepolarization I None
( I None
EAD I None
) I None
. I None
<eof> I None

<s> O None
hiPS I None
- I None
CMs I None
using I None
MEA I None
system I None
and I None
FPDc I None
can I None
predict I None
the I None
effects I None
of I None
drug I None
candidates I None
on I None
QT I None
interval I None
. I None
<eof> I None

<s> O None
This I None
study I None
also I None
shows I None
that I None
this I None
assay I None
can I None
help I None
detect I None
EAD I None
for I None
drugs I None
with I None
TdP I Disease
potential I None
. I None
<eof> I None

<s> O None
Dermal I None
developmental I None
<eof> I None

<s> O None
toxicity I Disease
of I None
N I None
- I None
phenylimide I None
herbicides I None
in I None
rats I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
S-53482 I Chemical
and I None
S-23121 I Chemical
are I None
N I None
- I None
phenylimide I None
herbicides I None
and I None
produced I None
embryolethality I Disease
, I None
<eof> I None

<s> O None
teratogenicity I Disease
( I None
mainly I None
ventricular I Disease
septal O Disease
defects O Disease
and I None
wavy I None
ribs I None
) I None
, I None
and I None
growth I Disease
retardation O Disease
in I None
rats I None
in I None
conventional I None
oral I None
developmental I None
<eof> I None

<s> O None
toxicity I Disease
studies I None
. I None
<eof> I None

<s> O None
Our I None
objective I None
in I None
this I None
study I None
was I None
to I None
investigate I None
whether I None
the I None
compounds I None
induce I None
developmental I None
toxicity I Disease
via I None
the I None
dermal I None
route I None
, I None
which I None
is I None
more I None
relevant I None
to I None
occupational I None
exposure I None
, I None
hence I None
better I None
addressing I None
human I None
health I None
risks I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
S-53482 I Chemical
was I None
administered I None
dermally I None
to I None
rats I None
at I None
30 I None
, I None
100 I None
, I None
and I None
300 I None
mg I None
/ I None
kg I None
during I None
organogenesis I None
, I None
and I None
S-23121 I Chemical
was I None
administered I None
at I None
200 I None
, I None
400 I None
, I None
and I None
800 I None
mg I None
/ I None
kg I None
( I None
the I None
maximum I None
applicable I None
dose I None
level I None
) I None
. I None
<eof> I None

<s> O None
Fetuses I None
were I None
obtained I None
by I None
a I None
Cesarean I None
section I None
and I None
examined I None
for I None
external I None
, I None
visceral I None
, I None
and I None
skeletal I None
alterations I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Dermal I None
exposure I None
of I None
rats I None
to I None
<eof> I None

<s> O None
S-53482 I Chemical
at I None
300 I None
mg I None
/ I None
kg I None
produced I None
patterns I None
of I None
developmental I None
toxicity I Disease
similar I None
to I None
those I None
resulting I None
from I None
oral I None
exposure I None
. I None
<eof> I None

<s> O None
Toxicity I Disease
included I None
<eof> I None

<s> O None
embryolethality I Disease
, I None
teratogenicity I Disease
, I None
and I None
growth I Disease
retardation O Disease
. I None
<eof> I None

<s> O None
Dermal I None
administration I None
of I None
S-23121 I Chemical
at I None
800 I None
mg I None
/ I None
kg I None
resulted I None
in I None
an I None
increased I None
incidence I None
of I None
embryonic I Disease
death O Disease
and I None
ventricular I Disease
septal O Disease
defect O Disease
, I None
but I None
retarded I None
fetal I None
growth I None
was I None
not I None
observed I None
as I None
it I None
was I None
following I None
oral I None
exposure I None
to I None
S-23121 I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Based I None
on I None
the I None
results I None
, I None
S-53482 I Chemical
and I None
S-23121 I Chemical
were I None
teratogenic I Disease
when I None
administered I None
dermally I None
to I None
pregnant I None
rats I None
as I None
were I None
the I None
compounds I None
administered I None
orally I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
investigation I None
of I None
the I None
mechanism I None
and I None
its I None
human I None
relevancy I None
become I None
more I None
important I None
. I None
<eof> I None

<s> O None
Rates I None
of I None
Renal I Disease
Toxicity O Disease
in I None
Cancer I Disease
Patients I None
Receiving I None
Cisplatin I Chemical
<eof> I None

<s> O None
With I None
and I None
Without I None
Mannitol I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Cisplatin I Chemical
is I None
a I None
widely I None
used I None
antineoplastic I None
. I None
<eof> I None

<s> O None
One I None
of I None
the I None
major I None
complications I None
of I None
cisplatin I Chemical
use I None
is I None
dose I None
- I None
limiting I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
There I None
are I None
many I None
strategies I None
to I None
prevent I None
this I None
toxicity I Disease
, I None
including I None
the I None
use I None
of I None
mannitol I Chemical
as I None
a I None
nephroprotectant I None
in I None
combination I None
with I None
hydration I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
We I None
aimed I None
to I None
evaluate I None
the I None
rates I None
of I None
cisplatin I Chemical
-induced I None
nephrotoxicity I Disease
in I None
cancer I Disease
patients I None
receiving I None
single I None
- I None
agent I None
cisplatin I Chemical
with I None
and I None
without I None
mannitol I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
single I None
- I None
center I None
retrospective I None
analysis I None
was I None
a I None
quasi I None
experiment I None
created I None
by I None
the I None
national I None
mannitol I Chemical
shortage I None
. I None
<eof> I None

<s> O None
Data I None
were I None
collected I None
on I None
adult I None
cancer I Disease
patients I None
receiving I None
single I None
- I None
agent I None
cisplatin I Chemical
as I None
an I None
outpatient I None
from I None
January I None
2011 I None
to I None
September I None
2012 I None
. I None
<eof> I None

<s> O None
The I None
primary I None
outcome I None
was I None
acute I Disease
kidney O Disease
injury O Disease
<eof> I None

<s> O None
( I None
AKI I Disease
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
We I None
evaluated I None
143 I None
patients I None
who I None
received I None
single I None
- I None
agent I None
cisplatin I Chemical
; I None
97.2 I None
% I None
of I None
patients I None
had I None
head I Disease
and O Disease
neck O Disease
cancer O Disease
as I None
their I None
primary I None
malignancy I Disease
. I None
<eof> I None

<s> O None
Patients I None
who I None
did I None
not I None
receive I None
mannitol I Chemical
were I None
more I None
likely I None
to I None
develop I None
nephrotoxicity I Disease
: I None
odds I None
ratio I None
[ I None
OR I None
] I None
= I None
2.646 I None
( I None
95 I None
% I None
CI I None
= I None
1.008 I None
, I None
6.944 I None
; I None
P I None
= I None
0.048 I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
received I None
the I None
100 I None
mg I None
/ I None
m(2 I None
) I None
dosing I None
and I None
patients I None
who I None
had I None
a I None
history I None
of I None
hypertension I Disease
also I None
had I None
a I None
higher I None
likelihood I None
of I None
developing I None
nephrotoxicity I Disease
: I None
<eof> I None

<s> O None
OR I None
= I None
11.494 I None
( I None
95 I None
% I None
CI I None
<eof> I None

<s> O None
= I None
4.149 I None
, I None
32.258 I None
; I None
P I None
< I None
0.0001 I None
) I None
and I None
OR I None
= I None
3.219 I None
( I None
95 I None
% I None
CI I None
= I None
1.228 I None
, I None
8.439 I None
; I None
P I None
= I None
0.017 I None
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
When I None
limited I None
quantities I None
of I None
mannitol I Chemical
are I None
available I None
, I None
it I None
should I None
preferentially I None
be I None
given I None
to I None
patients I None
at I None
particularly I None
high I None
risk I None
of I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Our I None
analysis I None
suggests I None
that I None
those I None
patients I None
receiving I None
the I None
dosing I None
schedule I None
of I None
100 I None
mg I None
/ I None
m(2 I None
) I None
<eof> I None

<s> O None
cisplatin I Chemical
every I None
3 I None
weeks I None
and I None
those I None
with I None
hypertension I Disease
are I None
at I None
the I None
greatest I None
risk I None
of I None
nephrotoxicity I Disease
and I None
would I None
benefit I None
from I None
the I None
addition I None
of I None
mannitol I Chemical
. I None
<eof> I None

<s> O None
Metformin I Chemical
protects I None
against I None
seizures I Disease
, I None
learning I None
and I None
memory I None
impairments I None
and I None
oxidative I None
damage I None
induced I None
by I None
pentylenetetrazole I Chemical
-induced I None
kindling I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Cognitive I Disease
impairment O Disease
, I None
the I None
most I None
common I None
and I None
severe I None
comorbidity I None
of I None
epilepsy I Disease
, I None
greatly I None
diminishes I None
the I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
However I None
, I None
current I None
therapeutic I None
interventions I None
for I None
epilepsy I Disease
can I None
also I None
cause I None
untoward I None
cognitive I None
effects I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
there I None
is I None
an I None
urgent I None
need I None
for I None
new I None
kinds I None
of I None
agents I None
targeting I None
both I None
seizures I Disease
and I None
cognition I Disease
deficits O Disease
. I None
<eof> I None

<s> O None
Oxidative I None
stress I None
is I None
considered I None
to I None
play I None
an I None
important I None
role I None
in I None
epileptogenesis I None
and I None
cognitive I Disease
deficits O Disease
, I None
and I None
antioxidants I None
have I None
a I None
putative I None
antiepileptic I None
potential I None
. I None
<eof> I None

<s> O None
Metformin I Chemical
, I None
the I None
most I None
commonly I None
prescribed I None
antidiabetic I None
oral I None
drug I None
, I None
has I None
antioxidant I None
properties I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
evaluate I None
the I None
ameliorative I None
effects I None
of I None
metformin I Chemical
on I None
seizures I Disease
, I None
cognitive I Disease
impairment O Disease
and I None
brain I None
oxidative I None
stress I None
markers I None
observed I None
in I None
pentylenetetrazole I Chemical
<eof> I None

<s> O None
-induced I None
kindling I None
animals I None
. I None
<eof> I None

<s> O None
Male I None
C57BL/6 I None
mice I None
were I None
administered I None
with I None
subconvulsive I None
dose I None
of I None
pentylenetetrazole I Chemical
<eof> I None

<s> O None
( I None
37 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
every I None
other I None
day I None
for I None
14 I None
injections I None
. I None
<eof> I None

<s> O None
Metformin I Chemical
was I None
injected I None
intraperitoneally I None
in I None
dose I None
of I None
200mg I None
/ I None
kg I None
along I None
with I None
alternate I None
- I None
day I None
PTZ I Chemical
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
metformin I Chemical
suppressed I None
the I None
progression I None
of I None
kindling I None
, I None
ameliorated I None
the I None
cognitive I Disease
impairment O Disease
and I None
decreased I None
brain I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
Thus I None
the I None
present I None
study I None
concluded I None
that I None
metformin I Chemical
may I None
be I None
a I None
potential I None
agent I None
for I None
the I None
treatment I None
of I None
epilepsy I Disease
as I None
well I None
as I None
a I None
protective I None
medicine I None
against I None
cognitive I Disease
impairment O Disease
induced I None
by I None
seizures I Disease
. I None
<eof> I None

<s> O None
P53 I None
inhibition I None
exacerbates I None
late I None
- I None
stage I None
anthracycline I Chemical
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
AIMS I None
: I None
Doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
is I None
an I None
effective I None
anti- I None
cancer I Disease
therapeutic I None
, I None
but I None
is I None
associated I None
with I None
both I None
acute I None
and I None
late I None
- I None
stage I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Children I None
are I None
particularly I None
sensitive I None
to I None
DOX I Chemical
-induced I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Here I None
, I None
the I None
impact I None
of I None
p53 I None
inhibition I None
on I None
acute I None
vs. I None
late I None
- I None
stage I None
DOX I Chemical
cardiotoxicity I Disease
was I None
examined I None
in I None
a I None
juvenile I None
model I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
Two I None
- I None
week I None
- I None
old I None
MHC I None
- I None
CB7 I None
mice I None
( I None
which I None
express I None
dominant I None
- I None
interfering I None
p53 I None
in I None
cardiomyocytes I None
) I None
and I None
their I None
non I None
- I None
transgenic I None
( I None
NON I None
- I None
TXG I None
) I None
<eof> I None

<s> O None
littermates I None
received I None
weekly I None
DOX I Chemical
injections I None
for I None
5 I None
weeks I None
( I None
25 I None
mg I None
/ I None
kg I None
cumulative I None
dose I None
) I None
. I None
<eof> I None

<s> O None
One I None
week I None
after I None
the I None
last I None
DOX I Chemical
treatment I None
( I None
acute I None
stage I None
) I None
, I None
MHC I None
- I None
CB7 I None
mice I None
exhibited I None
improved I None
cardiac I None
function I None
and I None
lower I None
levels I None
of I None
cardiomyocyte I None
apoptosis I None
when I None
compared I None
with I None
the I None
NON I None
- I None
TXG I None
mice I None
. I None
<eof> I None

<s> O None
Surprisingly I None
, I None
by I None
13 I None
weeks I None
following I None
the I None
last I None
DOX I Chemical
treatment I None
( I None
late I None
stage I None
) I None
, I None
MHC I None
- I None
CB7 I None
exhibited I None
a I None
progressive I None
decrease I None
in I None
cardiac I None
function I None
and I None
higher I None
rates I None
of I None
cardiomyocyte I None
apoptosis I None
when I None
compared I None
with I None
NON I None
- I None
TXG I None
mice I None
. I None
<eof> I None

<s> O None
p53 I None
inhibition I None
blocked I None
transient I None
<eof> I None

<s> O None
DOX I Chemical
-induced I None
<eof> I None

<s> O None
STAT3 I None
activation I None
in I None
MHC I None
- I None
CB7 I None
mice I None
, I None
which I None
was I None
associated I None
with I None
enhanced I None
induction I None
of I None
the I None
DNA I None
repair I None
proteins I None
Ku70 I None
and I None
Ku80 I None
. I None
<eof> I None

<s> O None
Mice I None
with I None
cardiomyocyte I None
- I None
restricted I None
deletion I None
of I None
STAT3 I None
exhibited I None
worse I None
cardiac I None
function I None
, I None
higher I None
levels I None
of I None
cardiomyocyte I None
apoptosis I None
, I None
and I None
a I None
greater I None
induction I None
of I None
Ku70 I None
and I None
Ku80 I None
in I None
response I None
to I None
DOX I Chemical
treatment I None
during I None
the I None
acute I None
stage I None
when I None
compared I None
with I None
control I None
animals I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
These I None
data I None
support I None
a I None
model I None
wherein I None
a I None
p53-dependent I None
cardioprotective I None
pathway I None
, I None
mediated I None
via I None
STAT3 I None
activation I None
, I None
mitigates I None
DOX I Chemical
<eof> I None

<s> O None
-induced I None
myocardial I None
stress I None
during I None
drug I None
delivery I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
these I None
data I None
suggest I None
an I None
explanation I None
as I None
to I None
how I None
p53 I None
inhibition I None
can I None
result I None
in I None
cardioprotection I None
during I None
drug I None
treatment I None
and I None
, I None
paradoxically I None
, I None
enhanced I None
cardiotoxicity I Disease
long I None
after I None
the I None
cessation I None
of I None
drug I None
treatment I None
. I None
<eof> I None

<s> O None
Metronidazole I Chemical
-induced I None
encephalopathy I Disease
: I None
an I None
uncommon I None
scenario I None
. I None
<eof> I None

<s> O None
Metronidazole I Chemical
can I None
produce I None
neurological I None
complications I None
although I None
it I None
is I None
not I None
a I None
common I None
scenario I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
case I None
where I None
a I None
patient I None
developed I None
features I None
of I None
encephalopathy I Disease
following I None
prolonged I None
metronidazole I Chemical
intake I None
. I None
<eof> I None

<s> O None
Magnetic I None
resonance I None
imaging I None
( I None
MRI I None
) I None
brain I None
showed I None
abnormal I None
signal I None
intensity I None
involving I None
both I None
dentate I None
nuclei I None
of I None
cerebellum I None
and I None
splenium I None
of I None
corpus I None
callosum I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
of I None
metronidazole I Chemical
toxicity I Disease
was I None
made I None
by I None
the I None
MRI I None
findings I None
and I None
supported I None
clinically I None
. I None
<eof> I None

<s> O None
Aconitine I Chemical
-induced I None
<eof> I None

<s> O None
Ca I Chemical
2 I None
+ I None
overload I None
causes I None
<eof> I None

<s> O None
arrhythmia I Disease
and I None
triggers I None
apoptosis I None
through I None
p38 I None
<eof> I None

<s> O None
MAPK I None
signaling I None
pathway I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Aconitine I Chemical
is I None
a I None
major I None
bioactive I None
diterpenoid I None
alkaloid I None
with I None
high I None
content I None
derived I None
from I None
herbal I None
aconitum I None
plants I None
. I None
<eof> I None

<s> O None
Emerging I None
evidence I None
indicates I None
that I None
voltage I None
- I None
dependent I None
Na I Chemical
( I None
+ I None
) I None
channels I None
have I None
pivotal I None
roles I None
in I None
the I None
cardiotoxicity I Disease
of I None
aconitine I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
no I None
reports I None
are I None
available I None
on I None
the I None
role I None
of I None
Ca I Chemical
<eof> I None

<s> O None
( I None
2 I None
+ I None
) I None
in I None
aconitine I Chemical
<eof> I None

<s> O None
poisoning I Disease
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
explored I None
the I None
importance I None
of I None
pathological I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
signaling I None
in I None
aconitine I Chemical
poisoning I Disease
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
overload I None
lead I None
to I None
accelerated I None
beating I None
rhythm I None
in I None
adult I None
rat I None
ventricular I None
myocytes I None
and I None
caused I None
arrhythmia I Disease
in I None
conscious I None
freely I None
moving I None
rats I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
effects I None
of I None
aconitine I Chemical
on I None
myocardial I Disease
injury O Disease
, I None
we I None
performed I None
cytotoxicity I Disease
assay I None
in I None
neonatal I None
rat I None
ventricular I None
myocytes I None
( I None
NRVMs I None
) I None
, I None
as I None
well I None
as I None
measured I None
lactate I Chemical
dehydrogenase I None
level I None
in I None
the I None
culture I None
medium I None
of I None
NRVMs I None
and I None
activities I None
of I None
serum I None
cardiac I None
enzymes I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
that I None
aconitine I Chemical
resulted I None
in I None
myocardial I Disease
injury O Disease
and I None
reduced I None
NRVMs I None
viability I None
dose I None
- I None
dependently I None
. I None
<eof> I None

<s> O None
To I None
confirm I None
the I None
pro I None
- I None
apoptotic I None
effects I None
, I None
we I None
performed I None
flow I None
cytometric I None
detection I None
, I None
cardiac I None
histology I None
, I None
transmission I None
electron I None
microscopy I None
and I None
terminal I None
deoxynucleotidyl I None
transferase I None
- I None
mediated I None
dUTP I Chemical
- I None
biotin I Chemical
nick I None
end I None
labeling I None
assay I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
that I None
aconitine I Chemical
stimulated I None
apoptosis I None
time I None
- I None
dependently I None
. I None
<eof> I None

<s> O None
The I None
expression I None
analysis I None
of I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
handling I None
proteins I None
demonstrated I None
that I None
aconitine I Chemical
promoted I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
overload I None
through I None
the I None
expression I None
regulation I None
of I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
handling I None
proteins I None
. I None
<eof> I None

<s> O None
The I None
expression I None
analysis I None
of I None
apoptosis I None
- I None
related I None
proteins I None
revealed I None
that I None
pro I None
- I None
apoptotic I None
protein I None
expression I None
was I None
upregulated I None
, I None
and I None
anti I None
- I None
apoptotic I None
protein I None
BCL-2 I None
expression I None
was I None
downregulated I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
increased I None
phosphorylation I None
of I None
MAPK I None
family I None
members I None
, I None
especially I None
the I None
P I None
- I None
P38/P38 I None
ratio I None
was I None
found I None
in I None
cardiac I None
tissues I None
. I None
<eof> I None

<s> O None
Hence I None
, I None
our I None
results I None
suggest I None
that I None
aconitine I Chemical
significantly I None
aggravates I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
overload I None
and I None
causes I None
arrhythmia I Disease
and I None
finally I None
promotes I None
apoptotic I None
development I None
via I None
phosphorylation I None
of I None
P38 I None
mitogen I None
- I None
activated I None
protein I None
kinase I None
. I None
<eof> I None

<s> O None
Chronic I None
treatment I None
with I None
metformin I Chemical
suppresses I None
toll I None
- I None
like I None
receptor I None
4 I None
signaling I None
and I None
attenuates I None
left I Disease
ventricular O Disease
dysfunction O Disease
following I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Acute I None
treatment I None
with I None
metformin I Chemical
has I None
a I None
protective I None
effect I None
in I None
myocardial I Disease
infarction O Disease
by I None
suppression I None
of I None
inflammatory I None
responses I None
due I None
to I None
activation I None
of I None
AMP I Chemical
<eof> I None

<s> O None
-activated I None
protein I None
kinase I None
( I None
AMPK I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
effect I None
of I None
chronic I None
pre I None
- I None
treatment I None
with I None
metformin I Chemical
on I None
cardiac I Disease
dysfunction O Disease
and I None
toll I None
- I None
like I None
receptor I None
4 I None
( I None
TLR4 I None
) I None
activities I None
following I None
myocardial I Disease
infarction O Disease
and I None
their I None
relation I None
with I None
AMPK I None
were I None
assessed I None
. I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
randomly I None
assigned I None
to I None
one I None
of I None
5 I None
groups I None
( I None
n=6 I None
) I None
: I None
normal I None
control I None
and I None
groups I None
were I None
injected I None
<eof> I None

<s> O None
isoproterenol I Chemical
after I None
chronic I None
pre I None
- I None
treatment I None
with I None
0 I None
, I None
25 I None
, I None
50 I None
, I None
or I None
100mg I None
/ I None
kg I None
of I None
<eof> I None

<s> O None
metformin I Chemical
twice I None
daily I None
for I None
14 I None
days I None
. I None
<eof> I None

<s> O None
Isoproterenol I Chemical
( I None
100mg I None
/ I None
kg I None
) I None
was I None
injected I None
subcutaneously I None
on I None
the I None
13th I None
and I None
14th I None
days I None
to I None
induce I None
acute I Disease
myocardial O Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Isoproterenol I Chemical
alone I None
decreased I None
left I None
ventricular I None
systolic I None
pressure I None
and I None
myocardial I None
contractility I None
indexed I None
as I None
LVdp I None
/ I None
dtmax I None
and I None
LVdp I None
/ I None
dtmin I None
. I None
<eof> I None

<s> O None
The I None
left I Disease
ventricular O Disease
dysfunction O Disease
was I None
significantly I None
lower I None
in I None
the I None
groups I None
treated I None
with I None
25 I None
and I None
50mg I None
/ I None
kg I None
of I None
metformin I Chemical
. I None
<eof> I None

<s> O None
Metfromin I None
markedly I None
lowered I None
isoproterenol I Chemical
-induced I None
elevation I None
in I None
the I None
levels I None
of I None
TLR4 I None
mRNA I None
, I None
myeloid I None
differentiation I None
protein I None
88 I None
( I None
MyD88 I None
) I None
, I None
tumor I Disease
necrosis I Disease
factor I None
- I None
alpha I None
( I None
TNF I None
- I None
a I None
) I None
, I None
and I None
interleukin I None
6 I None
( I None
IL-6 I None
) I None
in I None
the I None
heart I None
tissues I None
. I None
<eof> I None

<s> O None
Similar I None
changes I None
were I None
also I None
seen I None
in I None
the I None
serum I None
levels I None
of I None
TNF I None
- I None
a I None
and I None
IL-6 I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
lower I None
doses I None
of I None
25 I None
and I None
50mg I None
/ I None
kg I None
were I None
more I None
effective I None
than I None
100mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Phosphorylated I None
AMPKa I None
( I None
p I None
- I None
AMPK I None
) I None
in I None
the I None
myocardium I None
was I None
significantly I None
elevated I None
by I None
25mg I None
/ I None
kg I None
of I None
metformin I Chemical
, I None
slightly I None
by I None
50mg I None
/ I None
kg I None
, I None
but I None
not I None
by I None
100mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Chronic I None
pre I None
- I None
treatment I None
with I None
metformin I Chemical
reduces I None
post- I None
myocardial I Disease
infarction O Disease
cardiac I None
dysfunction I None
and I None
suppresses I None
inflammatory I None
responses I None
, I None
possibly I None
through I None
inhibition I None
of I None
TLR4 I None
activities I None
. I None
<eof> I None

<s> O None
This I None
mechanism I None
can I None
be I None
considered I None
as I None
a I None
target I None
to I None
protect I None
infarcted I None
myocardium I None
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
induced I None
by I None
combination I None
therapy I None
with I None
tetrabenazine I Chemical
and I None
tiapride I Chemical
in I None
a I None
Japanese I None
patient I None
with I None
Huntington I Disease
's O Disease
disease O Disease
at I None
the I None
terminal I None
stage I None
of I None
recurrent I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
We I None
herein I None
describe I None
the I None
case I None
of I None
an I None
81-year I None
- I None
old I None
Japanese I None
woman I None
with I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
that I None
occurred I None
36 I None
days I None
after I None
the I None
initiation I None
of I None
combination I None
therapy I None
with I None
tiapride I Chemical
<eof> I None

<s> O None
( I None
75 I None
mg I None
/ I None
day I None
) I None
and I None
tetrabenazine I Chemical
( I None
12.5 I None
mg I None
/ I None
day I None
) I None
for I None
Huntington I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
been I None
treated I None
with I None
tiapride I Chemical
or I None
tetrabenazine I Chemical
alone I None
without I None
any I None
adverse I None
effects I None
before I None
the I None
administration I None
of I None
the I None
combination I None
therapy I None
. I None
<eof> I None

<s> O None
She I None
also I None
had I None
advanced I None
<eof> I None

<s> O None
breast I Disease
cancer O Disease
when I None
the I None
combination I None
therapy I None
was I None
initiated I None
. I None
<eof> I None

<s> O None
To I None
the I None
best I None
of I None
our I None
knowledge I None
, I None
the I None
occurrence I None
of I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
due I None
to I None
combination I None
therapy I None
with I None
tetrabenazine I Chemical
and I None
tiapride I Chemical
has I None
not I None
been I None
previously I None
reported I None
. I None
<eof> I None

<s> O None
Tetrabenazine I Chemical
should I None
be I None
administered I None
very I None
carefully I None
in I None
combination I None
with I None
other I None
neuroleptic I Chemical
drugs O Chemical
, I None
particularly I None
in I None
patients I None
with I None
a I None
worsening I None
general I None
condition I None
. I None
<eof> I None

<s> O None
A I None
metoprolol I Chemical
- I None
terbinafine I Chemical
combination I None
induced I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
To I None
report I None
a I None
sinus I Disease
bradycardia O Disease
induced I None
by I None
metoprolol I Chemical
and I None
terbinafine I Chemical
drug I None
- I None
drug I None
interaction I None
and I None
its I None
management I None
. I None
<eof> I None

<s> O None
A I None
63 I None
year I None
- I None
old I None
Caucasian I None
man I None
on I None
metoprolol I Chemical
200 I None
mg I None
/ I None
day I None
for I None
stable I None
coronary I Disease
artery O Disease
disease O Disease
was I None
prescribed I None
a I None
90-day I None
course I None
of I None
oral I None
terbinafine I Chemical
250 I None
mg I None
/ I None
day I None
for I None
onychomycosis I Disease
. I None
<eof> I None

<s> O None
On I None
the I None
49th I None
day I None
of I None
terbinafine I Chemical
therapy I None
, I None
he I None
was I None
brought I None
to I None
the I None
emergency I None
room I None
for I None
a I None
decrease I None
of I None
his I None
global I None
health I None
status I None
, I None
confusion I Disease
and I None
falls I None
. I None
<eof> I None

<s> O None
The I None
electrocardiogram I None
revealed I None
a I None
37 I None
beats I None
/ I None
min I None
sinus I Disease
bradycardia O Disease
. I None
<eof> I None

<s> O None
A I None
score I None
of I None
7 I None
on I None
the I None
Naranjo I None
adverse I Disease
drug O Disease
reaction O Disease
probability I None
scale I None
indicates I None
a I None
probable I None
relationship I None
between I None
the I None
patient I None
's I None
sinus I Disease
bradycardia O Disease
and I None
the I None
drug I None
interaction I None
between I None
metoprolol I Chemical
and I None
terbinafine I Chemical
. I None
<eof> I None

<s> O None
The I None
heart I None
rate I None
ameliorated I None
first I None
with I None
a I None
decrease I None
in I None
the I None
dose I None
of I None
metoprolol I Chemical
. I None
<eof> I None

<s> O None
It I None
was I None
subsequently I None
changed I None
to I None
bisoprolol I Chemical
and I None
the I None
heart I None
rate I None
remained I None
normal I None
. I None
<eof> I None

<s> O None
By I None
inhibiting I None
the I None
cytochrome I None
P450 I None
2D6 I None
, I None
terbinafine I Chemical
had I None
decreased I None
metoprolol I Chemical
's I None
clearance I None
, I None
leading I None
in I None
metoprolol I Chemical
accumulation I None
which I None
has I None
resulted I None
in I None
clinically I None
significant I None
sinus I Disease
bradycardia O Disease
. I None
<eof> I None

<s> O None
Optochiasmatic I None
and I None
peripheral I Disease
neuropathy O Disease
due I None
to I None
ethambutol I Chemical
overtreatment I None
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
is I None
known I None
to I None
cause I None
optic I Disease
neuropathy O Disease
and I None
, I None
more I None
rarely I None
, I None
axonal I None
polyneuropathy I Disease
. I None
<eof> I None

<s> O None
We I None
characterize I None
the I None
clinical I None
, I None
neurophysiological I None
, I None
and I None
neuroimaging I None
findings I None
in I None
a I None
72-year I None
- I None
old I None
man I None
who I None
developed I None
visual I Disease
loss O Disease
and I None
paresthesias I Disease
after I None
11 I None
weeks I None
of I None
exposure I None
to I None
a I None
supratherapeutic I None
dose I None
of I None
ethambutol I Chemical
. I None
<eof> I None

<s> O None
This I None
case I None
demonstrates I None
the I None
selective I None
vulnerability I None
of I None
the I None
anterior I None
visual I None
pathways I None
and I None
peripheral I None
nerves I None
to I None
ethambutol I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Testosterone I Chemical
ameliorates I None
<eof> I None

<s> O None
streptozotocin I Chemical
-induced I None
<eof> I None

<s> O None
memory I Disease
impairment O Disease
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
study I None
the I None
effects I None
of I None
testosterone I Chemical
on I None
streptozotocin I Chemical
<eof> I None

<s> O None
( I None
STZ I Chemical
) I None
-induced I None
<eof> I None

<s> O None
memory I Disease
impairment O Disease
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Adult I None
male I None
Wistar I None
rats I None
were I None
intracerebroventricularly I None
( I None
icv I None
) I None
infused I None
with I None
STZ I Chemical
( I None
750 I None
ug I None
) I None
on I None
d I None
1 I None
and I None
d I None
3 I None
, I None
and I None
a I None
passive I None
avoidance I None
task I None
was I None
assessed I None
2 I None
weeks I None
after I None
the I None
first I None
injection I None
of I None
STZ I Chemical
. I None
<eof> I None

<s> O None
Castration I None
surgery I None
was I None
performed I None
in I None
another I None
group I None
of I None
rats I None
, I None
and I None
the I None
passive I None
avoidance I None
task I None
was I None
assessed I None
4 I None
weeks I None
after I None
the I None
operation I None
. I None
<eof> I None

<s> O None
Testosterone I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg.kg(-1).d(-1 I None
) I None
, I None
sc I None
) I None
, I None
the I None
androgen I Chemical
receptor I None
antagonist I None
flutamide I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg.kg(-1).d(-1 I None
) I None
, I None
ip I None
) I None
, I None
the I None
estrogen I Chemical
receptor I None
antagonist I None
tamoxifen I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg.kg(-1).d(-1 I None
) I None
, I None
ip I None
) I None
or I None
the I None
aromatase I None
inhibitor I None
letrozole I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg.kg(-1).d(-1 I None
) I None
, I None
ip I None
) I None
were I None
administered I None
for I None
6 I None
d I None
after I None
the I None
first I None
injection I None
of I None
STZ I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
STZ I Chemical
administration I None
and I None
castration I None
markedly I None
decreased I None
both I None
STL1 I None
( I None
the I None
short I None
memory I None
) I None
and I None
STL2 I None
( I None
the I None
long I None
memory I None
) I None
in I None
passive I None
avoidance I None
tests I None
. I None
<eof> I None

<s> O None
Testosterone I Chemical
replacement I None
almost I None
restored I None
the I None
STL1 I None
and I None
STL2 I None
in I None
castrated I None
rats I None
, I None
and I None
significantly I None
prolonged I None
the I None
STL1 I None
and I None
STL2 I None
in I None
STZ I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
flutamide I Chemical
, I None
letrozole I Chemical
or I None
tamoxifen I Chemical
significantly I None
impaired I Disease
the O Disease
memory O Disease
in I None
intact I None
rats I None
, I None
and I None
significantly I None
attenuated I None
the I None
testosterone I Chemical
replacement I None
in I None
improving I None
STZ I Chemical
- I None
and I None
castration I None
- I None
induced I None
memory I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Testosterone I Chemical
administration I None
ameliorates I None
STZ I Chemical
- I None
and I None
castration I None
- I None
induced I None
memory I Disease
impairment O Disease
in I None
male I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
Behavioral I None
and I None
neurochemical I None
studies I None
in I None
mice I None
pretreated I None
with I None
garcinielliptone I Chemical
FC O Chemical
in I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
seizures I Disease
. I None
<eof> I None

<s> O None
Garcinielliptone I Chemical
FC O Chemical
( I None
GFC I Chemical
) I None
isolated I None
from I None
hexanic I None
fraction I None
seed I None
extract I None
of I None
species I None
Platonia I None
insignis I None
Mart I None
. I None
<eof> I None

<s> O None
It I None
is I None
widely I None
used I None
in I None
folk I None
medicine I None
to I None
treat I None
skin I Disease
diseases O Disease
in I None
both I None
humans I None
and I None
animals I None
as I None
well I None
as I None
the I None
seed I None
decoction I None
has I None
been I None
used I None
to I None
treat I None
diarrheas I Disease
and I None
inflammatory I Disease
diseases O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
is I None
no I None
research I None
on I None
GFC I Chemical
effects I None
in I None
the I None
central I None
nervous I None
system I None
of I None
rodents I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
aimed I None
to I None
evaluate I None
the I None
GFC I Chemical
effects I None
at I None
doses I None
of I None
25 I None
, I None
50 I None
or I None
75 I None
mg I None
/ I None
kg I None
on I None
seizure I Disease
parameters I None
to I None
determine I None
their I None
anticonvulsant I None
activity I None
and I None
its I None
effects I None
on I None
amino I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
r I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
( I None
GABA I Chemical
) I None
, I None
glutamine I Chemical
, I None
aspartate I Chemical
and I None
glutathione I Chemical
) I None
levels I None
as I None
well I None
as I None
on I None
acetylcholinesterase I None
( I None
AChE I None
) I None
activity I None
in I None
mice I None
hippocampus I None
after I None
seizures I Disease
. I None
<eof> I None

<s> O None
GFC I Chemical
produced I None
an I None
increased I None
latency I None
to I None
first I None
seizure I Disease
, I None
at I None
doses I None
25mg I None
/ I None
kg I None
( I None
20.12 I None
+ I None
2.20 I None
min I None
) I None
, I None
50mg I None
/ I None
kg I None
( I None
20.95 I None
+ I None
2.21 I None
min I None
) I None
or I None
75 I None
mg I None
/ I None
kg I None
( I None
23.43 I None
+ I None
1.99 I None
min I None
) I None
when I None
compared I None
with I None
seized I None
mice I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
GABA I Chemical
content I None
of I None
mice I None
hippocampus I None
treated I None
with I None
GFC75 I None
plus I None
P400 I None
showed I None
an I None
increase I None
of I None
46.90 I None
% I None
when I None
compared I None
with I None
seized I None
mice I None
. I None
<eof> I None

<s> O None
In I None
aspartate I Chemical
, I None
glutamine I Chemical
and I None
glutamate I Chemical
levels I None
detected I None
a I None
decrease I None
of I None
5.21 I None
% I None
, I None
13.55 I None
% I None
and I None
21.80 I None
% I None
, I None
respectively I None
in I None
mice I None
hippocampus I None
treated I None
with I None
GFC75 I None
plus I None
P400 I None
when I None
compared I None
with I None
seized I None
mice I None
. I None
<eof> I None

<s> O None
Hippocampus I None
mice I None
treated I None
with I None
GFC75 I None
plus I None
P400 I None
showed I None
an I None
increase I None
in I None
AChE I None
activity I None
( I None
63.30 I None
% I None
) I None
when I None
compared I None
with I None
seized I None
mice I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
GFC I Chemical
can I None
exert I None
anticonvulsant I None
activity I None
and I None
reduce I None
the I None
frequency I None
of I None
installation I None
of I None
pilocarpine I Chemical
-induced I None
status I Disease
epilepticus O Disease
, I None
as I None
demonstrated I None
by I None
increase I None
in I None
latency I None
to I None
first I None
seizure I Disease
and I None
decrease I None
in I None
mortality I None
rate I None
of I None
animals I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
our I None
data I None
suggest I None
that I None
GFC I Chemical
may I None
influence I None
in I None
epileptogenesis I None
and I None
promote I None
anticonvulsant I None
actions I None
in I None
pilocarpine I Chemical
model I None
by I None
modulating I None
the I None
GABA I Chemical
and I None
glutamate I Chemical
contents I None
and I None
of I None
AChE I None
activity I None
in I None
seized I None
mice I None
hippocampus I None
. I None
<eof> I None

<s> O None
This I None
compound I None
may I None
be I None
useful I None
to I None
produce I None
neuronal I None
protection I None
and I None
it I None
can I None
be I None
considered I None
as I None
an I None
anticonvulsant I None
agent I None
. I None
<eof> I None

<s> O None
Standard I None
operating I None
procedures I None
for I None
antibiotic I None
therapy I None
and I None
the I None
occurrence I None
of I None
acute I Disease
kidney O Disease
injury O Disease
: I None
a I None
prospective I None
, I None
clinical I None
, I None
non I None
- I None
interventional I None
, I None
observational I None
study I None
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
Acute I Disease
kidney O Disease
injury O Disease
<eof> I None

<s> O None
( I None
AKI I Disease
) I None
occurs I None
in I None
7 I None
% I None
of I None
hospitalized I None
and I None
66 I None
% I None
of I None
Intensive I None
Care I None
Unit I None
( I None
ICU I None
) I None
patients I None
. I None
<eof> I None

<s> O None
It I None
increases I None
mortality I None
, I None
hospital I None
length I None
of I None
stay I None
, I None
and I None
costs I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
investigate I None
, I None
whether I None
there I None
is I None
an I None
association I None
between I None
adherence I None
to I None
guidelines I None
( I None
standard I None
operating I None
procedures I None
( I None
SOP I None
) I None
) I None
for I None
potentially I None
nephrotoxic I Disease
antibiotics I None
and I None
the I None
occurrence I None
of I None
AKI I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
study I None
was I None
carried I None
out I None
as I None
a I None
prospective I None
, I None
clinical I None
, I None
non I None
- I None
interventional I None
, I None
observational I None
study I None
. I None
<eof> I None

<s> O None
Data I None
collection I None
was I None
performed I None
over I None
a I None
total I None
of I None
170 I None
days I None
in I None
three I None
ICUs I None
at I None
Charite I None
- I None
Universitaetsmedizin I None
Berlin I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
675 I None
patients I None
were I None
included I None
; I None
163 I None
of I None
these I None
had I None
therapy I None
with I None
vancomycin I Chemical
, I None
gentamicin I Chemical
, I None
or I None
tobramycin I Chemical
; I None
were I None
> I None
18 I None
years I None
; I None
and I None
treated I None
in I None
the I None
ICU I None
for I None
> I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
an I None
adherence I None
to I None
SOP I None
> I None
70 I None
% I None
were I None
classified I None
into I None
the I None
high I None
adherence I None
group I None
( I None
HAG I None
) I None
and I None
patients I None
with I None
an I None
adherence I None
of I None
< I None
70 I None
% I None
into I None
the I None
low I None
adherence I None
group I None
( I None
LAG I None
) I None
. I None
<eof> I None

<s> O None
AKI I Disease
was I None
defined I None
according I None
to I None
RIFLE I None
criteria I None
. I None
<eof> I None

<s> O None
Adherence I None
to I None
SOPs I None
was I None
evaluated I None
by I None
retrospective I None
expert I None
audit I None
. I None
<eof> I None

<s> O None
Development I None
of I None
AKI I Disease
was I None
compared I None
between I None
groups I None
with I None
exact I None
Chi2-test I None
and I None
multivariate I None
logistic I None
regression I None
analysis I None
( I None
two I None
- I None
sided I None
P I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
LAG I None
consisted I None
of I None
75 I None
patients I None
( I None
46 I None
% I None
) I None
versus I None
88 I None
HAG I None
patients I None
( I None
54 I None
% I None
) I None
. I None
<eof> I None

<s> O None
AKI I Disease
occurred I None
significantly I None
more I None
often I None
in I None
LAG I None
with I None
36 I None
% I None
versus I None
21 I None
% I None
in I None
HAG I None
( I None
P I None
= I None
0.035 I None
) I None
. I None
<eof> I None

<s> O None
Basic I None
characteristics I None
were I None
comparable I None
, I None
except I None
an I None
increased I None
rate I None
of I None
soft I None
tissue I None
infections I Disease
in I None
LAG I None
. I None
<eof> I None

<s> O None
Multivariate I None
analysis I None
revealed I None
an I None
odds I None
ratio I None
of I None
2.5-fold I None
for I None
LAG I None
to I None
develop I None
AKI I Disease
compared I None
with I None
HAG I None
( I None
95 I None
% I None
confidence I None
interval I None
1.195 I None
to I None
5.124 I None
, I None
P I None
= I None
0.039 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Low I None
adherence I None
to I None
SOPs I None
for I None
potentially I None
nephrotoxic I Disease
antibiotics I None
was I None
associated I None
with I None
a I None
higher I None
occurrence I None
of I None
AKI I Disease
. I None
<eof> I None

<s> O None
TRIAL I None
REGISTRATION I None
: I None
<eof> I None

<s> O None
Current I None
Controlled I None
Trials I None
ISRCTN54598675 I None
. I None
<eof> I None

<s> O None
Registered I None
17 I None
August I None
2007 I None
. I None
<eof> I None

<s> O None
Rhabdomyolysis I Disease
in I None
a I None
hepatitis I Disease
C O Disease
virus O Disease
infected O Disease
patient I None
treated I None
with I None
telaprevir I Chemical
and I None
simvastatin I Chemical
. I None
<eof> I None

<s> O None
A I None
46-year I None
old I None
man I None
with I None
a I None
chronic I None
hepatitis I Disease
C O Disease
virus O Disease
infection O Disease
received I None
triple I None
therapy I None
with I None
ribavirin I Chemical
, I None
pegylated I Chemical
interferon O Chemical
and I None
telaprevir I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
also I None
received I None
simvastatin I Chemical
. I None
<eof> I None

<s> O None
One I None
month I None
after I None
starting I None
the I None
antiviral I None
therapy I None
, I None
the I None
patient I None
was I None
admitted I None
to I None
the I None
hospital I None
because I None
he I None
developed I None
rhabdomyolysis I Disease
. I None
<eof> I None

<s> O None
At I None
admission I None
simvastatin I Chemical
and I None
all I None
antiviral I None
drugs I None
were I None
discontinued I None
because I None
toxicity I Disease
due I None
to I None
a I None
drug I None
- I None
drug I None
interaction I None
was I None
suspected I None
. I None
<eof> I None

<s> O None
The I None
creatine I Chemical
kinase I None
peaked I None
at I None
62,246 I None
IU I None
/ I None
L I None
and I None
the I None
patient I None
was I None
treated I None
with I None
intravenous I None
normal I None
saline I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
renal I None
function I None
remained I None
unaffected I None
. I None
<eof> I None

<s> O None
Fourteen I None
days I None
after I None
hospitalization I None
, I None
creatine I Chemical
kinase I None
level I None
had I None
returned I None
to I None
230 I None
IU I None
/ I None
L I None
and I None
the I None
patient I None
was I None
discharged I None
. I None
<eof> I None

<s> O None
Telaprevir I Chemical
was I None
considered I None
the I None
probable I None
causative I None
agent I None
of I None
an I None
interaction I None
with I None
simvastatin I Chemical
according I None
to I None
the I None
Drug I None
Interaction I None
Probability I None
Scale I None
. I None
<eof> I None

<s> O None
The I None
interaction I None
is I None
due I None
to I None
inhibition I None
of I None
CYP3A4-mediated I None
simvastatin I Chemical
clearance I None
. I None
<eof> I None

<s> O None
Simvastatin I Chemical
plasma I None
concentration I None
increased I None
30 I None
times I None
in I None
this I None
patient I None
and I None
statin I Chemical
induced I None
<eof> I None

<s> O None
muscle I Disease
toxicity O Disease
is I None
related I None
to I None
the I None
concentration I None
of I None
the I None
statin I Chemical
in I None
blood I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
with I None
this I None
case I None
we I None
illustrate I None
that I None
telaprevir I Chemical
as I None
well I None
as I None
statins I Chemical
are I None
susceptible I None
to I None
clinical I None
relevant I None
drug I None
- I None
drug I None
interactions I None
. I None
<eof> I None

<s> O None
Combination I None
of I None
bortezomib I Chemical
, I None
thalidomide I Chemical
, I None
and I None
dexamethasone I Chemical
( I None
VTD I None
) I None
as I None
a I None
consolidation I None
therapy I None
after I None
autologous I None
stem I None
cell I None
transplantation I None
for I None
symptomatic I None
multiple I Disease
myeloma O Disease
in I None
Japanese I None
patients I None
. I None
<eof> I None

<s> O None
Consolidation I None
therapy I None
for I None
patients I None
with I None
multiple I Disease
myeloma O Disease
<eof> I None

<s> O None
( I None
MM I Disease
) I None
has I None
been I None
widely I None
adopted I None
to I None
improve I None
treatment I None
response I None
following I None
autologous I None
stem I None
cell I None
transplantation I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
retrospectively I None
analyzed I None
the I None
safety I None
and I None
efficacy I None
of I None
combination I None
regimen I None
of I None
bortezomib I Chemical
, I None
thalidomide I Chemical
, I None
and I None
dexamethasone I Chemical
( I None
VTD I None
) I None
as I None
consolidation I None
therapy I None
in I None
24 I None
Japanese I None
patients I None
with I None
newly I None
diagnosed I None
MM I Disease
. I None
<eof> I None

<s> O None
VTD I None
consisted I None
of I None
bortezomib I Chemical
at I None
a I None
dose I None
of I None
1.3 I None
mg I None
/ I None
m(2 I None
) I None
and I None
dexamethasone I Chemical
at I None
a I None
dose I None
of I None
40 I None
mg I None
/ I None
day I None
on I None
days I None
1 I None
, I None
8 I None
, I None
15 I None
, I None
and I None
22 I None
of I None
a I None
35-day I None
cycle I None
, I None
with I None
daily I None
oral I None
thalidomide I Chemical
at I None
a I None
dose I None
of I None
100 I None
mg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Grade I None
3 I None
- I None
4 I None
neutropenia I Disease
and I None
thrombocytopenia I Disease
were I None
documented I None
in I None
four I None
and I None
three I None
patients I None
( I None
17 I None
and I None
13 I None
% I None
) I None
, I None
respectively I None
, I None
but I None
drug I None
dose I None
reduction I None
due I None
to I None
cytopenia I Disease
was I None
not I None
required I None
in I None
any I None
case I None
. I None
<eof> I None

<s> O None
Peripheral I Disease
neuropathy O Disease
was I None
common I None
( I None
63 I None
% I None
) I None
, I None
but I None
severe I None
grade I None
3 I None
- I None
4 I None
peripheral I Disease
neuropathy O Disease
was I None
not I None
observed I None
. I None
<eof> I None

<s> O None
Very I None
good I None
partial I None
response I None
or I None
better I None
response I None
( I None
> I None
VGPR I None
) I None
rates I None
before I None
and I None
after I None
consolidation I None
therapy I None
were I None
54 I None
and I None
79 I None
% I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Patients I None
had I None
a I None
significant I None
probability I None
of I None
improving I None
from I None
< I None
VGPR I None
before I None
consolidation I None
therapy I None
to I None
> I None
VGPR I None
after I None
consolidation I None
therapy I None
( I None
p I None
= I None
0.041 I None
) I None
. I None
<eof> I None

<s> O None
The I None
VTD I None
regimen I None
may I None
be I None
safe I None
and I None
effective I None
as I None
a I None
consolidation I None
therapy I None
in I None
the I None
treatment I None
of I None
MM I None
in I None
Japanese I None
population I None
. I None
<eof> I None

<s> O None
Conversion I None
to I None
sirolimus I Chemical
ameliorates I None
<eof> I None

<s> O None
cyclosporine I Chemical
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
in I None
the I None
rat I None
: I None
focus I None
on I None
serum I None
, I None
urine I None
, I None
gene I None
, I None
and I None
protein I None
renal I None
expression I None
biomarkers I None
. I None
<eof> I None

<s> O None
Protocols I None
of I None
conversion I None
from I None
cyclosporin I Chemical
A O Chemical
<eof> I None

<s> O None
( I None
CsA I Chemical
) I None
to I None
sirolimus I Chemical
<eof> I None

<s> O None
( I None
SRL I Chemical
) I None
have I None
been I None
widely I None
used I None
in I None
immunotherapy I None
after I None
transplantation I None
to I None
prevent I None
CsA I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
, I None
but I None
the I None
molecular I None
mechanisms I None
underlying I None
these I None
protocols I None
remain I None
nuclear I None
. I None
<eof> I None

<s> O None
This I None
study I None
aimed I None
to I None
identify I None
the I None
molecular I None
pathways I None
and I None
putative I None
biomarkers I None
of I None
<eof> I None

<s> O None
CsA I Chemical
-to- I None
SRL I Chemical
conversion I None
in I None
a I None
rat I None
model I None
. I None
<eof> I None

<s> O None
Four I None
animal I None
groups I None
( I None
n I None
= I None
6 I None
) I None
were I None
tested I None
during I None
9 I None
weeks I None
: I None
control I None
, I None
CsA I Chemical
, I None
SRL I Chemical
, I None
and I None
conversion I None
( I None
CsA I Chemical
for I None
3 I None
weeks I None
followed I None
by I None
SRL I Chemical
for I None
6 I None
weeks I None
) I None
. I None
<eof> I None

<s> O None
Classical I None
and I None
emergent I None
serum I None
, I None
urinary I None
, I None
and I None
kidney I None
tissue I None
( I None
gene I None
and I None
protein I None
expression I None
) I None
<eof> I None

<s> O None
markers I None
were I None
assessed I None
. I None
<eof> I None

<s> O None
Renal I Disease
lesions O Disease
were I None
analyzed I None
in I None
hematoxylin I Chemical
and I None
eosin I Chemical
, I None
periodic I None
acid I None
- I None
Schiff I None
, I None
and I None
Masson I None
's I None
trichrome I None
stains I None
. I None
<eof> I None

<s> O None
SRL I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
presented I None
proteinuria I Disease
and I None
NGAL I None
( I None
serum I None
and I None
urinary I None
) I None
as I None
the I None
best I None
markers I None
of I None
renal I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
Short I None
CsA I Chemical
treatment I None
presented I None
slight I None
or I None
even I None
absent I None
kidney I Disease
lesions O Disease
and I None
TGF I None
- I None
b I None
, I None
NF- I None
kb I None
, I None
mTOR I None
, I None
PCNA I None
, I None
TP53 I None
, I None
KIM-1 I None
, I None
and I None
CTGF I None
as I None
relevant I None
gene I None
and I None
protein I None
changes I None
. I None
<eof> I None

<s> O None
Prolonged I None
CsA I Chemical
exposure I None
aggravated I None
renal I Disease
damage O Disease
, I None
without I None
clear I None
changes I None
on I None
the I None
traditional I None
markers I None
, I None
but I None
with I None
changes I None
in I None
serums I None
TGF- I None
b I None
and I None
IL-7 I None
, I None
TBARs I None
clearance I None
, I None
and I None
kidney I None
TGF I None
- I None
b I None
and I None
mTOR I None
<eof> I None

<s> O None
. I None
Conversion I None
to I None
SRL I Chemical
prevented I None
CsA I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
renal I Disease
damage O Disease
evolution I None
( I None
absent I None
/ I None
mild I None
grade I None
lesions I None
) I None
, I None
while I None
NGAL I None
( I None
serum I None
versus I None
urine I None
) I None
seems I None
to I None
be I None
a I None
feasible I None
biomarker I None
of I None
CsA I Chemical
replacement I None
to I None
SRL I Chemical
. I None
<eof> I None

<s> O None
Kinin I None
B2 I None
receptor I None
deletion I None
and I None
blockage I None
ameliorates I None
<eof> I None

<s> O None
cisplatin I Chemical
-induced I None
<eof> I None

<s> O None
acute I Disease
renal O Disease
injury O Disease
. I None
<eof> I None

<s> O None
Cisplatin I Chemical
treatment I None
has I None
been I None
adopted I None
in I None
some I None
chemotherapies I None
; I None
however I None
, I None
this I None
drug I None
can I None
induce I None
acute I Disease
kidney O Disease
injury O Disease
due I None
its I None
ability I None
to I None
negatively I None
affect I None
renal I None
function I None
, I None
augment I None
serum I None
levels I None
of I None
creatinine I Chemical
and I None
urea I Chemical
, I None
increase I None
the I None
acute I Disease
tubular O Disease
necrosis O Disease
score I None
and I None
up I None
- I None
regulate I None
cytokines I None
( I None
e.g. I None
, I None
IL-1b I None
and I None
TNF I None
- I None
a I None
) I None
. I None
<eof> I None

<s> O None
The I None
kinin I None
B2 I None
receptor I None
has I None
been I None
associated I None
with I None
the I None
inflammation I Disease
process I None
, I None
as I None
well I None
as I None
the I None
regulation I None
of I None
cytokine I None
expression I None
, I None
and I None
its I None
deletion I None
resulted I None
in I None
an I None
improvement I None
in I None
the I None
diabetic I Disease
nephropathy O Disease
status I None
. I None
<eof> I None

<s> O None
To I None
examine I None
the I None
role I None
of I None
the I None
kinin I None
B2 I None
receptor I None
in I None
cisplatin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
kidney O Disease
injury O Disease
, I None
kinin I None
B2 I None
receptor I None
knockout I None
mice I None
were I None
challenged I None
with I None
cisplatin I Chemical
. I None
<eof> I None

<s> O None
Additionally I None
, I None
WT I None
mice I None
were I None
treated I None
with I None
a I None
B2 I None
receptor I None
antagonist I None
after I None
cisplatin I Chemical
administration I None
. I None
<eof> I None

<s> O None
B2 I None
receptor I None
- I None
deficient I None
mice I None
were I None
less I None
sensitive I None
to I None
this I None
drug I None
than I None
the I None
WT I None
mice I None
, I None
as I None
shown I None
by I None
reduced I None
weight I Disease
loss O Disease
, I None
better I None
preservation I None
of I None
kidney I None
function I None
, I None
down I None
regulation I None
of I None
inflammatory I None
cytokines I None
and I None
less I None
acute I Disease
tubular O Disease
necrosis O Disease
. I None
<eof> I None

<s> O None
Moreover I None
, I None
treatment I None
with I None
the I None
kinin I None
B2 I None
receptor I None
antagonist I None
effectively I None
reduced I None
the I None
levels I None
of I None
serum I None
creatinine I Chemical
and I None
blood I None
urea I Chemical
after I None
cisplatin I Chemical
administration I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
our I None
data I None
suggest I None
that I None
the I None
kinin I None
B2 I None
receptor I None
is I None
involved I None
in I None
cisplatin I Chemical
-induced I None
acute I Disease
kidney O Disease
injury O Disease
by I None
mediating I None
the I None
necrotic I Disease
process I None
and I None
the I None
expression I None
of I None
inflammatory I None
cytokines I None
, I None
thus I None
resulting I None
in I None
declined I None
renal I None
function I None
. I None
<eof> I None

<s> O None
These I None
results I None
highlight I None
the I None
kinin I None
B2 I None
receptor I None
antagonist I None
treatment I None
in I None
amelioration I None
of I None
nephrotoxicity I Disease
induced I None
by I None
cisplatin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Safety I None
and I None
efficacy I None
of I None
fluocinolone I Chemical
acetonide O Chemical
intravitreal I None
implant I None
( I None
0.59 I None
mg I None
) I None
in I None
birdshot I Disease
retinochoroidopathy O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
report I None
the I None
treatment I None
outcomes I None
of I None
the I None
fluocinolone I Chemical
acetonide O Chemical
intravitreal I None
implant I None
( I None
0.59 I None
mg I None
) I None
in I None
patients I None
with I None
birdshot I Disease
retinochoroidopathy O Disease
whose I None
disease I None
is I None
refractory I None
or I None
intolerant I None
to I None
conventional I None
immunomodulatory I None
therapy I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
retrospective I None
case I None
series I None
involving I None
11 I None
birdshot I Disease
retinochoroidopathy O Disease
patients I None
( I None
11 I None
eyes I None
) I None
. I None
<eof> I None

<s> O None
Eleven I None
patients I None
( I None
11 I None
eyes I None
) I None
underwent I None
surgery I None
for I None
fluocinolone I Chemical
acetonide O Chemical
implant I None
( I None
0.59 I None
mg I None
) I None
. I None
<eof> I None

<s> O None
Treatment I None
outcomes I None
of I None
interest I None
were I None
noted I None
at I None
baseline I None
, I None
before I None
fluocinolone I Chemical
acetonide O Chemical
implant I None
, I None
and I None
then I None
at I None
6 I None
months I None
, I None
1 I None
year I None
, I None
2 I None
years I None
, I None
3 I None
years I None
, I None
and I None
beyond I None
3 I None
years I None
. I None
<eof> I None

<s> O None
Disease I None
activity I None
markers I None
, I None
including I None
signs I None
of I None
ocular I None
inflammation I Disease
, I None
evidence I None
of I None
retinal I Disease
vasculitis O Disease
, I None
Swedish I None
interactive I None
threshold I None
algorithm I None
- I None
short I None
wavelength I None
automated I None
perimetry I None
Humphrey I None
visual I None
field I None
analysis I None
, I None
electroretinographic I None
parameters I None
, I None
and I None
optical I None
coherence I None
tomography I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
Data I None
on I None
occurrence I None
of I None
cataract I Disease
and I None
raised I Disease
intraocular O Disease
pressure O Disease
were I None
collected I None
in I None
all I None
eyes I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Intraocular I None
inflammation I Disease
was I None
present I None
in I None
54.5 I None
, I None
9.9 I None
, I None
11.1 I None
, I None
and I None
0 I None
% I None
of I None
patients I None
at I None
baseline I None
, I None
6 I None
months I None
, I None
1 I None
year I None
, I None
2 I None
years I None
, I None
3 I None
years I None
, I None
and I None
beyond I None
3 I None
years I None
after I None
receiving I None
the I None
implant I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Active I None
vasculitis I Disease
was I None
noted I None
in I None
36.3 I None
% I None
patients I None
at I None
baseline I None
and I None
0 I None
% I None
at I None
3 I None
years I None
of I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
More I None
than I None
20 I None
% I None
( I None
47.61 I None
- I None
67.2 I None
% I None
) I None
reduction I None
in I None
central I None
retinal I None
thickness I None
was I None
noted I None
in I None
all I None
patients I None
with I None
cystoid I Disease
macular O Disease
edema O Disease
at I None
6 I None
months I None
, I None
1 I None
year I None
, I None
2 I None
years I None
, I None
and I None
3 I None
years I None
postimplant I None
. I None
<eof> I None

<s> O None
At I None
baseline I None
, I None
54.5 I None
% I None
patients I None
were I None
on I None
immunomodulatory I None
agents I None
. I None
<eof> I None

<s> O None
This I None
percentage I None
decreased I None
to I None
45.45 I None
, I None
44.4 I None
, I None
and I None
14.28 I None
% I None
at I None
1 I None
year I None
, I None
2 I None
years I None
, I None
and I None
3 I None
years I None
postimplant I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Adverse I None
events I None
included I None
increased I Disease
intraocular O Disease
pressure O Disease
( I None
54.5 I None
% I None
) I None
and I None
cataract I Disease
formation I None
( I None
100 I None
% I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
fluocinolone I Chemical
acetonide O Chemical
implant I None
( I None
0.59 I None
mg I None
) I None
helps I None
to I None
control I None
inflammation I Disease
in I None
otherwise I None
treatment I None
- I None
refractory I None
cases I None
of I None
birdshot I Disease
retinochoroidopathy O Disease
. I None
<eof> I None

<s> O None
It I None
is I None
associated I None
with I None
significant I None
side I None
effects I None
of I None
cataract I Disease
and I None
ocular I Disease
hypertension O Disease
requiring I None
treatment I None
. I None
<eof> I None

<s> O None
Optimal I None
precurarizing I None
dose I None
of I None
rocuronium I Chemical
to I None
decrease I None
<eof> I None

<s> O None
fasciculation I Disease
and I None
myalgia I Disease
following I None
succinylcholine I Chemical
administration I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Succinylcholine I Chemical
commonly I None
produces I None
frequent I None
adverse I None
effects I None
, I None
including I None
muscle I Disease
fasciculation O Disease
and I None
myalgia I Disease
. I None
<eof> I None

<s> O None
The I None
current I None
study I None
identified I None
the I None
optimal I None
dose I None
of I None
rocuronium I Chemical
to I None
prevent I None
succinylcholine I Chemical
-induced I None
fasciculation I Disease
and I None
myalgia I Disease
and I None
evaluated I None
the I None
influence I None
of I None
rocuronium I Chemical
on I None
the I None
speed I None
of I None
onset I None
produced I None
by I None
succinylcholine I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
randomized I None
, I None
double I None
- I None
blinded I None
study I None
was I None
conducted I None
in I None
100 I None
patients I None
randomly I None
allocated I None
into I None
five I None
groups I None
of I None
20 I None
patients I None
each I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
randomized I None
to I None
receive I None
0.02 I None
, I None
0.03 I None
, I None
0.04 I None
, I None
0.05 I None
and I None
0.06 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
rocuronium I Chemical
as I None
a I None
precurarizing I None
dose I None
. I None
<eof> I None

<s> O None
Neuromuscular I None
monitoring I None
after I None
each I None
precurarizing I None
dose I None
was I None
recorded I None
from I None
the I None
adductor I None
pollicis I None
muscle I None
using I None
acceleromyography I None
with I None
train I None
- I None
of I None
- I None
four I None
stimulation I None
of I None
the I None
ulnar I None
nerve I None
. I None
<eof> I None

<s> O None
All I None
patients I None
received I None
<eof> I None

<s> O None
succinylcholine I Chemical
1.5 I None
mg I None
/ I None
kg I None
at I None
2 I None
minutes I None
after I None
the I None
precurarization I None
, I None
and I None
were I None
assessed I None
the I None
incidence I None
and I None
severity I None
of I None
fasciculations I Disease
, I None
while I None
myalgia I Disease
was I None
assessed I None
at I None
24 I None
hours I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
incidence I None
and I None
severity I None
of I None
visible I None
muscle I Disease
fasciculation O Disease
was I None
significantly I None
less I None
with I None
increasing I None
the I None
amount I None
of I None
precurarizing I None
dose I None
of I None
rocuronium I Chemical
<eof> I None

<s> O None
( I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Those I None
of I None
myalgia I Disease
tend I None
to I None
decrease I None
according I None
to I None
increasing I None
the I None
amount I None
of I None
precurarizing I None
dose I None
of I None
rocuronium I Chemical
, I None
but I None
there I None
was I None
no I None
significance I None
( I None
P I None
= I None
0.072 I None
) I None
. I None
<eof> I None

<s> O None
The I None
onset I None
time I None
of I None
succinylcholine I Chemical
was I None
significantly I None
longer I None
with I None
increasing I None
the I None
amount I None
of I None
precurarizing I None
dose I None
of I None
rocuronium I Chemical
<eof> I None

<s> O None
( I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Precurarization I None
with I None
0.04 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
rocuronium I Chemical
was I None
the I None
optimal I None
dose I None
considering I None
the I None
reduction I None
in I None
the I None
incidence I None
and I None
severity I None
of I None
fasciculation I Disease
and I None
myalgia I Disease
with I None
acceptable I None
onset I None
time I None
, I None
and I None
the I None
safe I None
and I None
effective I None
precurarization I None
. I None
<eof> I None

<s> O None
Absence I None
of I None
PKC I None
- I None
alpha I None
attenuates I None
lithium I Chemical
-induced I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
. I None
<eof> I None

<s> O None
Lithium I Chemical
, I None
an I None
effective I None
antipsychotic I None
, I None
induces I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
<eof> I None

<s> O None
( I None
NDI I Disease
) I None
in I None
40 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
The I None
decreased I None
capacity I None
to I None
concentrate I None
urine I None
is I None
likely I None
due I None
to I None
lithium I Chemical
acutely I None
disrupting I None
the I None
cAMP I Chemical
pathway I None
and I None
chronically I None
reducing I None
urea I Chemical
transporter I None
( I None
UT I None
- I None
A1 I None
) I None
and I None
water I None
channel I None
( I None
AQP2 I None
) I None
expression I None
in I None
the I None
inner I None
medulla I None
. I None
<eof> I None

<s> O None
Targeting I None
an I None
alternative I None
signaling I None
pathway I None
, I None
such I None
as I None
PKC I None
- I None
mediated I None
signaling I None
, I None
may I None
be I None
an I None
effective I None
method I None
of I None
treating I None
lithium I Chemical
-induced I None
<eof> I None

<s> O None
polyuria I Disease
. I None
<eof> I None

<s> O None
PKC I None
- I None
alpha I None
null I None
mice I None
( I None
PKCa I None
KO I None
) I None
and I None
strain I None
- I None
matched I None
wild I None
type I None
( I None
WT I None
) I None
controls I None
were I None
treated I None
with I None
lithium I Chemical
for I None
0 I None
, I None
3 I None
or I None
5 I None
days I None
. I None
<eof> I None

<s> O None
WT I None
mice I None
had I None
increased I None
urine I None
output I None
and I None
lowered I None
urine I None
osmolality I None
after I None
3 I None
and I None
5 I None
days I None
of I None
treatment I None
whereas I None
PKCa I None
KO I None
mice I None
had I None
no I None
change I None
in I None
urine I None
output I None
or I None
concentration I None
. I None
<eof> I None

<s> O None
Western I None
blot I None
analysis I None
revealed I None
that I None
AQP2 I None
expression I None
in I None
medullary I None
tissues I None
was I None
lowered I None
after I None
3 I None
and I None
5 I None
days I None
in I None
WT I None
mice I None
; I None
however I None
, I None
AQP2 I None
was I None
unchanged I None
in I None
PKCa I None
KO I None
. I None
<eof> I None

<s> O None
Similar I None
results I None
were I None
observed I None
with I None
UT I None
- I None
A1 I None
expression I None
. I None
<eof> I None

<s> O None
Animals I None
were I None
also I None
treated I None
with I None
lithium I Chemical
for I None
6 I None
weeks I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
<eof> I None

<s> O None
-treated I None
WT I None
mice I None
had I None
19-fold I None
increased I None
urine I None
output I None
whereas I None
treated I None
PKCa I None
KO I None
animals I None
had I None
a I None
4-fold I None
increase I None
in I None
output I None
. I None
<eof> I None

<s> O None
AQP2 I None
and I None
UT I None
- I None
A1 I None
expression I None
was I None
lowered I None
in I None
6 I None
week I None
lithium I Chemical
<eof> I None

<s> O None
-treated I None
WT I None
animals I None
whereas I None
in I None
treated I None
PKCa I None
KO I None
mice I None
, I None
AQP2 I None
was I None
only I None
reduced I None
by I None
2-fold I None
and I None
UT I None
- I None
A1 I None
expression I None
was I None
unaffected I None
. I None
<eof> I None

<s> O None
Urinary I None
sodium I Chemical
, I None
potassium I Chemical
and I None
calcium I Chemical
were I None
elevated I None
in I None
lithium I Chemical
<eof> I None

<s> O None
-fed I None
WT I None
but I None
not I None
in I None
<eof> I None

<s> O None
lithium I Chemical
-fed I None
PKCa I None
KO I None
mice I None
. I None
<eof> I None

<s> O None
Our I None
data I None
show I None
that I None
ablation I None
of I None
PKCa I None
preserves I None
AQP2 I None
and I None
UT I None
- I None
A1 I None
protein I None
expression I None
and I None
localization I None
in I None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
NDI I Disease
, I None
and I None
prevents I None
the I None
development I None
of I None
the I None
severe I None
polyuria I Disease
associated I None
with I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Is I None
Dysguesia I Disease
<eof> I None

<s> O None
Going I None
to I None
be I None
a I None
Rare I None
or I None
a I None
Common I None
Side I None
- I None
effect I None
of I None
Amlodipine I Chemical
? I None
<eof> I None

<s> O None
A I None
very I None
rare I None
side I None
- I None
effect I None
of I None
amlodipine I Chemical
is I None
dysguesia I Disease
. I None
<eof> I None

<s> O None
A I None
review I None
of I None
the I None
literature I None
produced I None
only I None
one I None
case I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
about I None
a I None
female I None
with I None
essential I None
hypertension I Disease
on I None
drug I None
treatment I None
with I None
amlodipine I Chemical
developed I None
loss I Disease
of O Disease
taste O Disease
sensation O Disease
. I None
<eof> I None

<s> O None
Condition I None
moderately I None
improved I None
on I None
stoppage I None
of I None
the I None
drug I None
for I None
25 I None
days I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
amlodipine I Chemical
can I None
cause I None
dysguesia I Disease
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
describe I None
the I None
clinical I None
presentation I None
and I None
review I None
the I None
relevant I None
literature I None
on I None
amlodipine I Chemical
and I None
dysguesia I Disease
. I None
<eof> I None

<s> O None
Rhabdomyolysis I Disease
in I None
association I None
with I None
simvastatin I Chemical
and I None
dosage I None
increment I None
in I None
clarithromycin I Chemical
. I None
<eof> I None

<s> O None
Clarithromycin I Chemical
is I None
the I None
most I None
documented I None
cytochrome I None
P450 I None
3A4 I None
( I None
CYP3A4 I None
) I None
inhibitor I None
to I None
cause I None
an I None
adverse I None
interaction I None
with I None
simvastatin I Chemical
. I None
<eof> I None

<s> O None
This I None
particular I None
case I None
is I None
of I None
interest I None
as I None
rhabdomyolysis I Disease
only I None
occurred I None
after I None
an I None
increase I None
in I None
the I None
dose I None
of I None
clarithromycin I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
developed I None
raised I None
cardiac I None
biomarkers I None
without I None
any I None
obvious I None
cardiac I None
issues I None
, I None
a I None
phenomenon I None
that I None
has I None
been I None
linked I None
to I None
rhabdomyolysis I Disease
previously I None
. I None
<eof> I None

<s> O None
To I None
date I None
, I None
there I None
has I None
been I None
no I None
reported I None
effect I None
of I None
rhabdomyolysis I Disease
on I None
the I None
structure I None
and I None
function I None
of I None
cardiac I None
muscle I None
. I None
<eof> I None

<s> O None
Clinicians I None
need I None
to I None
be I None
aware I None
of I None
prescribing I None
concomitant I None
medications I None
that I None
increase I None
the I None
risk I None
of I None
myopathy I Disease
or I None
inhibit I None
the I None
CYP3A4 I None
enzyme I None
. I None
<eof> I None

<s> O None
Our I None
case I None
suggests I None
that I None
troponin I None
elevation I None
could I None
be I None
associated I None
with I None
statin I Chemical
induced I None
rhabdomyolysis I Disease
, I None
which I None
may I None
warrant I None
further I None
studies I None
. I None
<eof> I None

<s> O None
Characterization I None
of I None
a I None
novel I None
BCHE I None
" I None
silent I None
" I None
allele I None
: I None
point I None
mutation I None
( I None
p I None
. I None
<eof> I None

<s> O None
Val204Asp I None
) I None
causes I None
loss I None
of I None
activity I None
and I None
prolonged I None
apnea I Disease
with I None
suxamethonium I Chemical
. I None
<eof> I None

<s> O None
Butyrylcholinesterase I Disease
deficiency O Disease
is I None
characterized I None
by I None
prolonged I None
apnea I Disease
after I None
the I None
use I None
of I None
muscle I None
relaxants I None
( I None
suxamethonium I Chemical
or I None
mivacurium I Chemical
) I None
in I None
patients I None
who I None
have I None
mutations I None
in I None
the I None
BCHE I None
gene I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
a I None
case I None
of I None
prolonged I None
neuromuscular I None
block I None
after I None
administration I None
of I None
suxamethonium I Chemical
leading I None
to I None
the I None
discovery I None
of I None
a I None
novel I None
BCHE I None
variant I None
( I None
c.695T I None
> I None
A I None
, I None
p I None
. I None
<eof> I None

<s> O None
Val204Asp I None
) I None
. I None
<eof> I None

<s> O None
Inhibition I None
studies I None
, I None
kinetic I None
analysis I None
and I None
molecular I None
dynamics I None
were I None
undertaken I None
to I None
understand I None
how I None
this I None
mutation I None
disrupts I None
the I None
catalytic I None
triad I None
and I None
determines I None
a I None
" I None
silent I None
" I None
phenotype I None
. I None
<eof> I None

<s> O None
Low I None
activity I None
of I None
patient I None
plasma I None
butyrylcholinesterase I None
with I None
butyrylthiocholine I Chemical
<eof> I None

<s> O None
( I None
BTC I Chemical
) I None
and I None
benzoylcholine I Chemical
, I None
and I None
values I None
of I None
<eof> I None

<s> O None
dibucaine I Chemical
and I None
fluoride I Chemical
numbers I None
fit I None
with I None
heterozygous I None
atypical I None
silent I None
genotype I None
. I None
<eof> I None

<s> O None
Electrophoretic I None
analysis I None
of I None
plasma I None
BChE I None
of I None
the I None
proband I None
and I None
his I None
mother I None
showed I None
that I None
patient I None
has I None
a I None
reduced I None
amount I None
of I None
tetrameric I None
enzyme I None
in I None
plasma I None
and I None
that I None
minor I None
fast I None
- I None
moving I None
BChE I None
components I None
: I None
monomer I None
, I None
dimer I None
, I None
and I None
monomer I None
- I None
albumin I None
conjugate I None
are I None
missing I None
. I None
<eof> I None

<s> O None
Kinetic I None
analysis I None
showed I None
that I None
the I None
p I None
. I None
<eof> I None

<s> O None
Val204Asp I None
/ I None
<eof> I None

<s> O None
p I None
. I None
<eof> I None

<s> O None
Asp70Gly I None
- I None
p I None
<eof> I None

<s> O None
. I None
Ala539Thr I None
BChE I None
displays I None
a I None
pure I None
Michaelian I None
behavior I None
with I None
BTC I Chemical
as I None
the I None
substrate I None
. I None
<eof> I None

<s> O None
Both I None
catalytic I None
parameters I None
Km I None
= I None
265 I None
uM I None
for I None
BTC I Chemical
, I None
two I None
times I None
higher I None
than I None
that I None
of I None
the I None
atypical I None
enzyme I None
, I None
and I None
a I None
low I None
Vmax I None
are I None
consistent I None
with I None
the I None
absence I None
of I None
activity I None
against I None
suxamethonium I Chemical
. I None
<eof> I None

<s> O None
Molecular I None
dynamic I None
( I None
MD I None
) I None
simulations I None
showed I None
that I None
the I None
overall I None
effect I None
of I None
the I None
mutation I None
p I None
. I None
<eof> I None

<s> O None
Val204Asp I None
is I None
disruption I None
of I None
hydrogen I Chemical
bonding I None
between I None
Gln223 I None
and I None
Glu441 I None
, I None
leading I None
Ser198 I None
and I None
His438 I None
to I None
move I None
away I None
from I None
each I None
other I None
with I None
subsequent I None
disruption I None
of I None
the I None
catalytic I None
triad I None
functionality I None
regardless I None
of I None
the I None
type I None
of I None
substrate I None
. I None
<eof> I None

<s> O None
MD I None
also I None
showed I None
that I None
the I None
enzyme I None
volume I None
is I None
increased I None
, I None
suggesting I None
a I None
pre I None
- I None
denaturation I None
state I None
. I None
<eof> I None

<s> O None
This I None
fits I None
with I None
the I None
reduced I None
concentration I None
of I None
p I None
. I None
<eof> I None

<s> O None
Ala204Asp I None
/ I None
p I None
. I None
<eof> I None

<s> O None
Asp70Gly I None
- I None
p I None
. I None
Ala539Thr I None
tetrameric I None
enzyme I None
in I None
the I None
plasma I None
and I None
non I None
- I None
detectable I None
fast I None
moving I None
- I None
bands I None
on I None
electrophoresis I None
gels I None
. I None
<eof> I None

<s> O None
Delayed I None
anemia I Disease
after I None
treatment I None
with I None
injectable I None
artesunate I Chemical
in I None
the I None
Democratic I None
Republic I None
of I None
the I None
Congo I None
: I None
a I None
manageable I None
issue I None
. I None
<eof> I None

<s> O None
Cases I None
of I None
delayed I None
hemolytic I Disease
anemia O Disease
have I None
been I None
described I None
after I None
treatment I None
with I None
injectable I None
artesunate I Chemical
, I None
the I None
current I None
World I None
Health I None
Organization I None
( I None
WHO)-recommended I None
first I None
- I None
line I None
drug I None
for I None
the I None
treatment I None
of I None
severe I None
malaria I Disease
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
350 I None
patients I None
( I None
215 I None
[ I None
61.4 I None
% I None
] I None
< I None
5 I None
years I None
of I None
age I None
and I None
135 I None
[ I None
38.6 I None
% I None
] I None
> I None
5 I None
years I None
of I None
age I None
) I None
were I None
followed I None
- I None
up I None
after I None
treatment I None
with I None
injectable I None
artesunate I Chemical
for I None
severe I None
malaria I Disease
in I None
hospitals I None
and I None
health I None
centers I None
of I None
the I None
Democratic I None
Republic I None
of I None
the I None
Congo I None
. I None
<eof> I None

<s> O None
Complete I None
series I None
of I None
hemoglobin I None
( I None
Hb I None
) I None
measurements I None
were I None
available I None
for I None
201 I None
patients I None
. I None
<eof> I None

<s> O None
A I None
decrease I None
in I None
Hb I None
levels I None
between I None
2 I None
and I None
5 I None
g I None
/ I None
dL I None
was I None
detected I None
in I None
23 I None
( I None
11.4 I None
% I None
) I None
patients I None
during I None
the I None
follow I None
- I None
up I None
period I None
. I None
<eof> I None

<s> O None
For I None
five I None
patients I None
, I None
Hb I None
levels I None
decreased I None
below I None
5 I None
g I None
/ I None
dL I None
during I None
at I None
least I None
one I None
follow I None
- I None
up I None
visit I None
. I None
<eof> I None

<s> O None
All I None
cases I None
of I None
delayed I None
anemia I Disease
were I None
clinically I None
manageable I None
and I None
resolved I None
within I None
one I None
month I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
signal I None
transducer I None
and I None
activator I None
of I None
transcription I None
3 I None
and I None
apoptotic I None
pathways I None
by I None
betaine I Chemical
attenuates I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
acute I None
myocardial I Disease
injury O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
designed I None
to I None
investigate I None
the I None
cardioprotective I None
effects I None
of I None
betaine I Chemical
on I None
acute I None
myocardial I Disease
ischemia O Disease
induced I None
experimentally I None
in I None
rats I None
focusing I None
on I None
regulation I None
of I None
signal I None
transducer I None
and I None
activator I None
of I None
transcription I None
3 I None
( I None
STAT3 I None
) I None
and I None
apoptotic I None
pathways I None
as I None
the I None
potential I None
mechanism I None
underlying I None
the I None
drug I None
effect I None
. I None
<eof> I None

<s> O None
Male I None
Sprague I None
Dawley I None
rats I None
were I None
treated I None
with I None
betaine I Chemical
<eof> I None

<s> O None
( I None
100 I None
, I None
200 I None
, I None
and I None
400 I None
mg I None
/ I None
kg I None
) I None
orally I None
for I None
40 I None
days I None
. I None
<eof> I None

<s> O None
Acute I None
myocardial I Disease
ischemic O Disease
injury O Disease
was I None
induced I None
in I None
rats I None
by I None
subcutaneous I None
injection I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
85 I None
mg I None
/ I None
kg I None
) I None
, I None
for I None
two I None
consecutive I None
days I None
. I None
<eof> I None

<s> O None
Serum I None
cardiac I None
marker I None
enzyme I None
, I None
histopathological I None
variables I None
and I None
expression I None
of I None
protein I None
levels I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
Oral I None
administration I None
of I None
betaine I Chemical
<eof> I None

<s> O None
( I None
200 I None
and I None
400 I None
mg I None
/ I None
kg I None
) I None
significantly I None
reduced I None
the I None
level I None
of I None
cardiac I None
marker I None
enzyme I None
in I None
the I None
serum I None
and I None
prevented I None
left I None
ventricular I Disease
remodeling O Disease
. I None
<eof> I None

<s> O None
Western I None
blot I None
analysis I None
showed I None
that I None
isoproterenol I Chemical
-induced I None
phosphorylation I None
of I None
STAT3 I None
was I None
maintained I None
or I None
further I None
enhanced I None
by I None
betaine I Chemical
treatment I None
in I None
myocardium I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
betaine I Chemical
( I None
200 I None
and I None
400 I None
mg I None
/ I None
kg I None
) I None
treatment I None
increased I None
the I None
ventricular I None
expression I None
of I None
Bcl-2 I None
and I None
reduced I None
the I None
level I None
of I None
Bax I None
, I None
therefore I None
causing I None
a I None
significant I None
increase I None
in I None
the I None
ratio I None
of I None
Bcl-2/Bax I None
. I None
<eof> I None

<s> O None
The I None
protective I None
role I None
of I None
betaine I Chemical
on I None
myocardial I Disease
damage O Disease
was I None
further I None
confirmed I None
by I None
histopathological I None
examination I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
our I None
results I None
showed I None
that I None
betaine I Chemical
pretreatment I None
attenuated I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
acute I None
myocardial I Disease
ischemia O Disease
via I None
the I None
regulation I None
of I None
STAT3 I None
and I None
apoptotic I None
pathways I None
. I None
<eof> I None

<s> O None
Quetiapine I Chemical
-induced I None
neutropenia I Disease
in I None
a I None
bipolar I Disease
patient I None
with I None
hepatocellular I Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Quetiapine I Chemical
is I None
a I None
dibenzothiazepine I None
derivative I None
, I None
similar I None
to I None
clozapine I Chemical
, I None
which I None
has I None
the I None
highest I None
risk I None
of I None
causing I None
blood I Disease
dyscrasias O Disease
, I None
especially I None
neutropenia I Disease
. I None
<eof> I None

<s> O None
There I None
are I None
some I None
case I None
reports I None
about I None
this I None
side I None
effect I None
of I None
quetiapine I Chemical
, I None
but I None
possible I None
risk I None
factors I None
are I None
seldom I None
discussed I None
and I None
identified I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
a I None
patient I None
with I None
hepatocellular I Disease
carcinoma O Disease
that I None
developed I None
neutropenia I Disease
after I None
treatment I None
with I None
quetiapine I Chemical
is I None
described I None
here I None
. I None
<eof> I None

<s> O None
CASE I None
REPORT I None
: I None
<eof> I None

<s> O None
A I None
62-year I None
- I None
old I None
Taiwanese I None
widow I None
with I None
bipolar I Disease
disorder O Disease
was I None
diagnosed I None
with I None
hepatocellular I Disease
carcinoma O Disease
at I None
age I None
60 I None
. I None
<eof> I None

<s> O None
She I None
developed I None
leucopenia I Disease
after I None
being I None
treated I None
with I None
quetiapine I Chemical
. I None
<eof> I None

<s> O None
After I None
quetiapine I Chemical
was I None
discontinued I None
, I None
her I None
white I None
blood I None
cell I None
count I None
returned I None
to I None
normal I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Although I None
neutropenia I Disease
is I None
not I None
a I None
common I None
side I None
effect I None
of I None
quetiapine I Chemical
, I None
physicians I None
should I None
be I None
cautious I None
about I None
its I None
presentation I None
and I None
associated I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Hepatic I Disease
dysfunction O Disease
may I None
be I None
one I None
of I None
the I None
possible I None
risk I None
factors I None
, I None
and I None
concomitant I None
fever I Disease
may I None
be I None
a I None
diagnostic I None
marker I None
for I None
adverse I None
reaction I None
to I None
quetiapine I Chemical
. I None
<eof> I None

<s> O None
Lateral I None
antebrachial I None
cutaneous I None
neuropathy I Disease
after I None
steroid I Chemical
injection I None
at I None
lateral I None
epicondyle I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
AND I None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
This I None
report I None
aimed I None
to I None
present I None
a I None
case I None
of I None
lateral I None
antebrachial I None
cutaneous I None
neuropathy I Disease
<eof> I None

<s> O None
( I None
LACNP I None
) I None
that I None
occurred I None
after I None
a I None
steroid I Chemical
injection I None
in I None
the I None
lateral I None
epicondyle I None
to I None
treat I None
lateral I Disease
epicondylitis O Disease
in I None
a I None
40-year I None
- I None
old I None
woman I None
. I None
<eof> I None

<s> O None
MATERIAL I None
AND I None
METHOD I None
: I None
<eof> I None

<s> O None
A I None
40-year I None
- I None
old I None
woman I None
presented I None
with I None
decreased I None
sensation I None
and I None
paresthesia I Disease
over I None
her I None
right I None
lateral I None
forearm I None
; I None
the I None
paresthesia I Disease
had I None
occurred I None
after I None
a I None
steroid I Chemical
injection I None
in I None
the I None
right I None
lateral I None
epicondyle I None
3 I None
months I None
before I None
. I None
<eof> I None

<s> O None
Her I None
sensation I None
of I None
light I None
touch I None
and I None
pain I Disease
was I None
diminished I None
over I None
the I None
lateral I None
side I None
of I None
the I None
right I None
forearm I None
and I None
wrist I None
area I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
sensory I None
action I None
potential I None
amplitude I None
of I None
the I None
right I None
lateral I None
antebrachial I None
cutaneous I None
nerve I None
( I None
LACN I None
) I None
( I None
6.2 I None
uV I None
) I None
was I None
lower I None
than I None
that I None
of I None
the I None
left I None
( I None
13.1 I None
uV I None
) I None
. I None
<eof> I None

<s> O None
The I None
difference I None
of I None
amplitude I None
between I None
both I None
sides I None
was I None
significant I None
because I None
there I None
was I None
more I None
than I None
a I None
50 I None
% I None
reduction I None
. I None
<eof> I None

<s> O None
She I None
was I None
diagnosed I None
with I None
right I None
LACNP I None
( I None
mainly I None
axonal I None
involvement I None
) I None
on I None
the I None
basis I None
of I None
the I None
clinical I None
manifestation I None
and I None
the I None
electrodiagnostic I None
findings I None
. I None
<eof> I None

<s> O None
Her I None
symptoms I None
improved I None
through I None
physical I None
therapy I None
but I None
persisted I None
to I None
some I None
degree I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
report I None
describes I None
the I None
case I None
of I None
a I None
woman I None
with I None
LACNP I None
that I None
developed I None
after I None
a I None
steroid I Chemical
injection I None
for I None
the I None
treatment I None
of I None
lateral I Disease
epicondylitis O Disease
. I None
<eof> I None

<s> O None
An I None
electrodiagnostic I None
study I None
, I None
including I None
a I None
nerve I None
conduction I None
study I None
of I None
the I None
LACN I None
, I None
was I None
helpful I None
to I None
diagnose I None
right I None
LACNP I None
and I None
to I None
find I None
the I None
passage I None
of I None
the I None
LACN I None
on I None
the I None
lateral I None
epicondyle I None
. I None
<eof> I None

<s> O None
Curcumin I Chemical
prevents I None
maleate I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
: I None
relation I None
to I None
hemodynamic I None
alterations I None
, I None
oxidative I None
stress I None
, I None
mitochondrial I None
oxygen I Chemical
consumption I None
and I None
activity I None
of I None
respiratory I None
complex I None
I. I None
<eof> I None

<s> O None
The I None
potential I None
protective I None
effect I None
of I None
the I None
dietary I None
antioxidant I None
curcumin I Chemical
<eof> I None

<s> O None
( I None
120 I None
mg I None
/ I None
Kg I None
/ I None
day I None
for I None
6 I None
days I None
) I None
against I None
the I None
renal I Disease
injury O Disease
induced I None
by I None
maleate I Chemical
was I None
evaluated I None
. I None
<eof> I None

<s> O None
Tubular I None
proteinuria I Disease
and I None
<eof> I None

<s> O None
oxidative I None
stress I None
were I None
induced I None
by I None
a I None
single I None
injection I None
of I None
maleate I Chemical
<eof> I None

<s> O None
( I None
400 I None
mg I None
/ I None
kg I None
) I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Maleate I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
injury O Disease
included I None
increase I None
in I None
renal I None
vascular I None
resistance I None
and I None
in I None
the I None
urinary I None
excretion I None
of I None
total I None
protein I None
, I None
glucose I Chemical
, I None
sodium I Chemical
, I None
neutrophil I None
gelatinase I None
- I None
associated I None
lipocalin I None
( I None
NGAL I None
) I None
and I None
N I None
- I None
acetyl I None
b I None
- I None
D I None
- I None
glucosaminidase I None
( I None
NAG I None
) I None
, I None
upregulation I None
of I None
kidney I Disease
injury O Disease
molecule I None
( I None
KIM)-1 I None
, I None
decrease I None
in I None
renal I None
blood I None
flow I None
and I None
claudin-2 I None
expression I None
besides I None
of I None
necrosis I Disease
and I None
apoptosis I None
of I None
tubular I None
cells I None
on I None
24 I None
h. I None
Oxidative I None
stress I None
was I None
determined I None
by I None
measuring I None
the I None
oxidation I None
of I None
lipids I None
and I None
proteins I None
and I None
diminution I None
in I None
renal I None
Nrf2 I None
levels I None
. I None
<eof> I None

<s> O None
Studies I None
were I None
also I None
conducted I None
in I None
renal I None
epithelial I None
LLC I None
- I None
PK1 I None
cells I None
and I None
in I None
mitochondria I None
isolated I None
from I None
kidneys I None
of I None
all I None
the I None
experimental I None
groups I None
. I None
<eof> I None

<s> O None
Maleate I Chemical
induced I None
cell I None
damage I None
and I None
reactive I None
oxygen I Chemical
species I None
( I None
ROS I None
) I None
production I None
in I None
LLC I None
- I None
PK1 I None
cells I None
in I None
culture I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
maleate I Chemical
treatment I None
reduced I None
oxygen I Chemical
consumption I None
in I None
ADP I Chemical
<eof> I None

<s> O None
-stimulated I None
mitochondria I None
and I None
diminished I None
respiratory I None
control I None
index I None
when I None
using I None
malate I Chemical
/ I None
glutamate I Chemical
as I None
substrate I None
. I None
<eof> I None

<s> O None
The I None
activities I None
of I None
both I None
complex I None
I I None
and I None
aconitase I None
were I None
also I None
diminished I None
. I None
<eof> I None

<s> O None
All I None
the I None
above I None
- I None
described I None
alterations I None
were I None
prevented I None
by I None
curcumin I Chemical
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
curcumin I Chemical
is I None
able I None
to I None
attenuate I None
in I None
vivo I None
maleate I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
and I None
in I None
vitro I None
cell I None
damage I None
. I None
<eof> I None

<s> O None
The I None
in I None
vivo I None
protection I None
was I None
associated I None
to I None
the I None
prevention I None
of I None
oxidative I None
stress I None
and I None
preservation I None
of I None
mitochondrial I None
oxygen I Chemical
consumption I None
and I None
activity I None
of I None
respiratory I None
complex I None
I I None
, I None
and I None
the I None
in I None
vitro I None
protection I None
was I None
associated I None
to I None
the I None
prevention I None
of I None
ROS I None
production I None
. I None
<eof> I None

<s> O None
Incidence I None
of I None
solid I None
tumours I Disease
among I None
pesticide I None
applicators I None
exposed I None
to I None
the I None
organophosphate I Chemical
insecticide I None
diazinon I Chemical
in I None
the I None
Agricultural I None
Health I None
Study I None
: I None
an I None
updated I None
analysis I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Diazinon I Chemical
, I None
a I None
common I None
organophosphate I Chemical
insecticide I None
with I None
genotoxic I None
properties I None
, I None
was I None
previously I None
associated I None
with I None
lung I Disease
cancer O Disease
in I None
the I None
Agricultural I None
Health I None
Study I None
( I None
AHS I None
) I None
cohort I None
, I None
but I None
few I None
other I None
epidemiological I None
studies I None
have I None
examined I None
diazinon I Chemical
-associated I None
cancer I Disease
risk I None
. I None
<eof> I None

<s> O None
We I None
used I None
updated I None
diazinon I Chemical
exposure I None
and I None
cancer I Disease
incidence I None
information I None
to I None
evaluate I None
solid I None
tumour I Disease
risk I None
in I None
the I None
AHS I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
pesticide I None
applicators I None
in I None
Iowa I None
and I None
North I None
Carolina I None
reported I None
lifetime I None
diazinon I Chemical
use I None
at I None
enrolment I None
( I None
1993 I None
- I None
1997 I None
) I None
and I None
follow I None
- I None
up I None
( I None
1998 I None
- I None
2005 I None
) I None
; I None
<eof> I None

<s> O None
cancer I Disease
incidence I None
was I None
assessed I None
through I None
2010(North I None
Carolina)/2011(Iowa I None
) I None
. I None
<eof> I None

<s> O None
Among I None
applicators I None
with I None
usage I None
information I None
sufficient I None
to I None
evaluate I None
exposure I None
- I None
response I None
patterns I None
, I None
we I None
used I None
Poisson I None
regression I None
to I None
estimate I None
adjusted I None
rate I None
ratios I None
( I None
RRs I None
) I None
and I None
95 I None
% I None
CI I None
for I None
cancer I Disease
<eof> I None

<s> O None
sites I None
with I None
> I None
10 I None
exposed I None
cases I None
for I None
both I None
lifetime I None
( I None
LT I None
) I None
exposure I None
days I None
and I None
intensity I None
- I None
weighted I None
( I None
IW I None
) I None
lifetime I None
exposure I None
days I None
( I None
accounting I None
for I None
factors I None
impacting I None
exposure I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
We I None
observed I None
elevated I None
lung I Disease
cancer O Disease
risks I None
( I None
N=283 I None
) I None
among I None
applicators I None
with I None
the I None
greatest I None
number I None
of I None
LT I None
( I None
RR=1.60 I None
; I None
95 I None
% I None
CI I None
1.11 I None
to I None
2.31 I None
; I None
Ptrend=0.02 I None
) I None
and I None
IW I None
days I None
of I None
diazinon I Chemical
use I None
( I None
RR=1.41 I None
; I None
95 I None
% I None
CI I None
0.98 I None
to I None
2.04 I None
; I None
Ptrend=0.08 I None
) I None
. I None
<eof> I None

<s> O None
Kidney I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
N=94 I None
) I None
risks I None
were I None
non I None
- I None
significantly I None
elevated I None
( I None
RRLT I None
days=1.77 I None
; I None
95 I None
% I None
CI I None
0.90 I None
to I None
3.51 I None
; I None
Ptrend=0.09 I None
; I None
RRIW I None
days I None
1.37 I None
; I None
95 I None
% I None
CI I None
0.64 I None
to I None
2.92 I None
; I None
Ptrend=0.50 I None
) I None
, I None
as I None
were I None
risks I None
for I None
aggressive I None
prostate I Disease
cancer O Disease
( I None
N=656 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Our I None
updated I None
evaluation I None
of I None
diazinon I Chemical
provides I None
additional I None
evidence I None
of I None
an I None
association I None
with I None
lung I Disease
cancer O Disease
risk I None
. I None
<eof> I None

<s> O None
Newly I None
identified I None
links I None
to I None
kidney I Disease
cancer O Disease
and I None
associations I None
with I None
aggressive I None
prostate I Disease
cancer O Disease
require I None
further I None
evaluation I None
. I None
<eof> I None

<s> O None
Associations I None
of I None
Ozone I Chemical
and I None
PM2.5 I None
Concentrations I None
With I None
Parkinson I Disease
's O Disease
Disease O Disease
<eof> I None

<s> O None
Among I None
Participants I None
in I None
the I None
Agricultural I None
Health I None
Study I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
This I None
study I None
describes I None
associations I None
of I None
ozone I Chemical
and I None
fine I None
particulate I Chemical
matter O Chemical
with I None
Parkinson I Disease
's O Disease
disease O Disease
observed I None
among I None
farmers I None
in I None
North I None
Carolina I None
and I None
Iowa I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
used I None
logistic I None
regression I None
to I None
determine I None
the I None
associations I None
of I None
these I None
pollutants I None
with I None
self I None
- I None
reported I None
, I None
doctor I None
- I None
diagnosed I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Daily I None
predicted I None
pollutant I None
concentrations I None
were I None
used I None
to I None
derive I None
surrogates I None
of I None
long I None
- I None
term I None
exposure I None
and I None
link I None
them I None
to I None
study I None
participants I None
' I None
geocoded I None
addresses I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
We I None
observed I None
positive I None
associations I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
with I None
ozone I Chemical
<eof> I None

<s> O None
( I None
odds I None
ratio I None
= I None
1.39 I None
; I None
95 I None
% I None
CI I None
: I None
0.98 I None
to I None
1.98 I None
) I None
and I None
fine I None
particulate I Chemical
matter O Chemical
<eof> I None

<s> O None
( I None
odds I None
ratio I None
= I None
1.34 I None
; I None
95 I None
% I None
CI I None
: I None
0.93 I None
to I None
1.93 I None
) I None
in I None
North I None
Carolina I None
but I None
not I None
in I None
Iowa I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
plausibility I None
of I None
an I None
effect I None
of I None
ambient I None
concentrations I None
of I None
these I None
pollutants I None
on I None
Parkinson I Disease
's O Disease
disease O Disease
risk I None
is I None
supported I None
by I None
experimental I None
data I None
demonstrating I None
damage I None
to I None
dopaminergic I None
neurons I None
at I None
relevant I None
concentrations I None
. I None
<eof> I None

<s> O None
Additional I None
studies I None
are I None
needed I None
to I None
address I None
uncertainties I None
related I None
to I None
confounding I None
and I None
to I None
examine I None
temporal I None
aspects I None
of I None
the I None
associations I None
we I None
observed I None
. I None
<eof> I None

<s> O None
Low I None
functional I None
programming I None
of I None
renal I None
AT2R I None
mediates I None
the I None
developmental I None
origin I None
of I None
glomerulosclerosis I Disease
in I None
adult I None
offspring I None
induced I None
by I None
prenatal I None
caffeine I Chemical
exposure I None
. I None
<eof> I None

<s> O None
UNASSIGNED I None
: I None
<eof> I None

<s> O None
Our I None
previous I None
study I None
has I None
indicated I None
that I None
prenatal I None
<eof> I None

<s> O None
caffeine I Chemical
exposure I None
( I None
PCE I None
) I None
could I None
induce I None
intrauterine I Disease
growth O Disease
retardation O Disease
<eof> I None

<s> O None
( I None
IUGR I Disease
) I None
of I None
offspring I None
. I None
<eof> I None

<s> O None
Recent I None
research I None
suggested I None
that I None
IUGR I Disease
is I None
a I None
risk I None
factor I None
for I None
glomerulosclerosis I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
whether I None
PCE I None
could I None
induce I None
<eof> I None

<s> O None
glomerulosclerosis I Disease
and I None
its I None
underlying I None
mechanisms I None
remain I None
unknown I None
. I None
<eof> I None

<s> O None
This I None
study I None
aimed I None
to I None
demonstrate I None
the I None
induction I None
to I None
glomerulosclerosis I Disease
in I None
adult I None
offspring I None
by I None
PCE I None
and I None
its I None
intrauterine I None
programming I None
mechanisms I None
. I None
<eof> I None

<s> O None
A I None
rat I None
model I None
of I None
IUGR I Disease
was I None
established I None
by I None
PCE I None
, I None
male I None
fetuses I None
and I None
adult I None
offspring I None
at I None
the I None
age I None
of I None
postnatal I None
week I None
24 I None
were I None
euthanized I None
. I None
<eof> I None

<s> O None
The I None
results I None
revealed I None
that I None
the I None
adult I None
offspring I None
kidneys I None
in I None
the I None
PCE I None
group I None
exhibited I None
glomerulosclerosis I Disease
as I None
well I None
as I None
interstitial I Disease
fibrosis O Disease
, I None
accompanied I None
by I None
elevated I None
levels I None
of I None
serum I None
creatinine I Chemical
and I None
urine I None
protein I None
. I None
<eof> I None

<s> O None
Renal I None
angiotensin I Chemical
II O Chemical
<eof> I None

<s> O None
receptor I None
type I None
2 I None
( I None
AT2R I None
) I None
gene I None
expression I None
in I None
adult I None
offspring I None
was I None
reduced I None
by I None
PCE I None
, I None
whereas I None
the I None
renal I None
angiotensin I Chemical
II O Chemical
receptor I None
type I None
1a I None
( I None
AT1aR)/AT2R I None
expression I None
ratio I None
was I None
increased I None
. I None
<eof> I None

<s> O None
The I None
fetal I None
kidneys I None
in I None
the I None
PCE I None
group I None
displayed I None
an I None
enlarged I None
Bowman I None
's I None
space I None
and I None
a I None
shrunken I None
glomerular I None
tuft I None
, I None
accompanied I None
by I None
a I None
reduced I None
cortex I None
width I None
and I None
an I None
increase I None
in I None
the I None
nephrogenic I None
zone I None
/ I None
cortical I None
zone I None
ratio I None
. I None
<eof> I None

<s> O None
Observation I None
by I None
electronic I None
microscope I None
revealed I None
structural I None
damage I None
of I None
podocytes I None
; I None
the I None
reduced I None
expression I None
level I None
of I None
podocyte I None
marker I None
genes I None
, I None
nephrin I None
and I None
podocin I None
, I None
was I None
also I None
detected I None
by I None
q I None
- I None
PCR I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
AT2R I None
gene I None
and I None
protein I None
expressions I None
in I None
fetal I None
kidneys I None
were I None
inhibited I None
by I None
PCE I None
, I None
associated I None
with I None
the I None
repression I None
of I None
the I None
gene I None
expression I None
of I None
glial I None
- I None
cell I None
- I None
line I None
- I None
derived I None
neurotrophic I None
factor I None
( I None
GDNF)/ I None
tyrosine I Chemical
kinase I None
receptor I None
( I None
c I None
- I None
Ret I None
) I None
signaling I None
pathway I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrated I None
that I None
PCE I None
could I None
induce I None
dysplasia I Disease
of O Disease
fetal O Disease
kidneys O Disease
as I None
well I None
as I None
glomerulosclerosis I Disease
of I None
adult I None
offspring I None
, I None
and I None
the I None
low I None
functional I None
programming I None
of I None
renal I None
AT2R I None
might I None
mediate I None
the I None
developmental I None
origin I None
of I None
adult I None
glomerulosclerosis I Disease
. I None
<eof> I None

<s> O None
1,3-Butadiene I Chemical
, I None
CML I Disease
and I None
the I None
t(9:22 I None
) I None
<eof> I None

<s> O None
translocation I None
: I None
<eof> I None

<s> O None
A I None
reality I None
check I None
. I None
<eof> I None

<s> O None
UNASSIGNED I None
: I None
<eof> I None

<s> O None
Epidemiological I None
studies I None
of I None
1,3-butadiene I Chemical
have I None
suggest I None
that I None
exposures I None
to I None
humans I None
are I None
associated I None
with I None
chronic I Disease
myeloid O Disease
leukemia O Disease
<eof> I None

<s> O None
( I None
CML I Disease
) I None
. I None
<eof> I None

<s> O None
CML I Disease
has I None
a I None
well I None
- I None
documented I None
association I None
with I None
ionizing I None
radiation I None
, I None
but I None
reports I None
of I None
associations I None
with I None
chemical I None
exposures I None
have I None
been I None
questioned I None
. I None
<eof> I None

<s> O None
Ionizing I None
radiation I None
is I None
capable I None
of I None
inducing I None
the I None
requisite I None
CML I Disease
-associated I None
t(9:22 I None
) I None
<eof> I None

<s> O None
translocation I None
( I None
Philadelphia I Disease
chromosome O Disease
) I None
in I None
appropriate I None
cells I None
in I None
vitro I None
but I None
, I None
thus I None
far I None
, I None
chemicals I None
have I None
not I None
shown I None
this I None
capacity I None
. I None
<eof> I None

<s> O None
We I None
have I None
proposed I None
that I None
1,3-butadiene I Chemical
<eof> I None

<s> O None
metabolites I None
be I None
so I None
tested I None
as I None
a I None
reality I None
check I None
on I None
the I None
epidemiological I None
reports I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
conduct I None
reliable I None
testing I None
in I None
this I None
regard I None
, I None
it I None
is I None
essential I None
that I None
a I None
positive I None
control I None
for I None
induction I None
be I None
available I None
. I None
<eof> I None

<s> O None
We I None
have I None
used I None
ionizing I None
radiation I None
to I None
develop I None
such I None
a I None
control I None
. I None
<eof> I None

<s> O None
Results I None
described I None
here I None
demonstrate I None
that I None
this I None
agent I None
does I None
in I None
fact I None
induce I None
pathogenic I None
t(9:22 I None
) I None
<eof> I None

<s> O None
translocations I None
in I None
a I None
human I None
myeloid I None
cell I None
line I None
in I None
vitro I None
, I None
but I None
does I None
so I None
at I None
low I None
frequencies I None
. I None
<eof> I None

<s> O None
Conditions I None
that I None
will I None
be I None
required I None
for I None
studies I None
of I None
1,3-butadiene I Chemical
are I None
discussed I None
. I None
<eof> I None

<s> O None
Cancer I Disease
incidence I None
and I None
metolachlor I Chemical
use I None
in I None
the I None
Agricultural I None
Health I None
Study I None
: I None
An I None
update I None
. I None
<eof> I None

<s> O None
UNASSIGNED I None
: I None
<eof> I None

<s> O None
Metolachlor I Chemical
, I None
a I None
widely I None
used I None
herbicide I None
, I None
is I None
classified I None
as I None
a I None
Group I None
C I None
carcinogen I None
by I None
the I None
U.S. I None
Environmental I None
Protection I None
Agency I None
based I None
on I None
increased I None
liver I Disease
neoplasms O Disease
in I None
female I None
rats I None
. I None
<eof> I None

<s> O None
Epidemiologic I None
studies I None
of I None
the I None
health I None
effects I None
of I None
metolachlor I Chemical
have I None
been I None
limited I None
. I None
<eof> I None

<s> O None
The I None
Agricultural I None
Health I None
Study I None
( I None
AHS I None
) I None
is I None
a I None
prospective I None
cohort I None
study I None
including I None
licensed I None
private I None
and I None
commercial I None
pesticide I None
applicators I None
in I None
Iowa I None
and I None
North I None
Carolina I None
enrolled I None
1993 I None
- I None
1997 I None
. I None
<eof> I None

<s> O None
We I None
evaluated I None
cancer I Disease
incidence I None
through I None
2010/2011 I None
( I None
NC I None
/ I None
IA I None
) I None
for I None
49,616 I None
applicators I None
, I None
53 I None
% I None
of I None
whom I None
reported I None
ever I None
using I None
metolachlor I Chemical
. I None
<eof> I None

<s> O None
We I None
used I None
Poisson I None
regression I None
to I None
evaluate I None
relations I None
between I None
two I None
metrics I None
of I None
metolachlor I Chemical
use I None
( I None
lifetime I None
days I None
, I None
intensity I None
- I None
weighted I None
lifetime I None
days I None
) I None
and I None
cancer I Disease
incidence I None
. I None
<eof> I None

<s> O None
We I None
saw I None
no I None
association I None
between I None
metolachlor I Chemical
use I None
and I None
incidence I None
of I None
all I None
cancers I Disease
combined I None
( I None
n I None
= I None
5,701 I None
with I None
a I None
5-year I None
lag I None
) I None
or I None
most I None
site I None
- I None
specific I None
cancers I Disease
. I None
<eof> I None

<s> O None
For I None
liver I Disease
cancer O Disease
, I None
in I None
analyses I None
restricted I None
to I None
exposed I None
workers I None
, I None
elevations I None
observed I None
at I None
higher I None
categories I None
of I None
use I None
were I None
not I None
statistically I None
significant I None
. I None
<eof> I None

<s> O None
However I None
, I None
trends I None
for I None
both I None
lifetime I None
and I None
intensity I None
- I None
weighted I None
lifetime I None
days I None
of I None
metolachor I Chemical
use I None
were I None
positive I None
and I None
statistically I None
significant I None
with I None
an I None
unexposed I None
reference I None
group I None
. I None
<eof> I None

<s> O None
A I None
similar I None
pattern I None
was I None
observed I None
for I None
follicular I Disease
cell O Disease
lymphoma O Disease
, I None
but I None
no I None
other I None
lymphoma I Disease
subtypes I None
. I None
<eof> I None

<s> O None
An I None
earlier I None
suggestion I None
of I None
increased I None
lung I Disease
cancer O Disease
risk I None
at I None
high I None
levels I None
of I None
metolachlor I Chemical
use I None
in I None
this I None
cohort I None
was I None
not I None
confirmed I None
in I None
this I None
update I None
. I None
<eof> I None

<s> O None
This I None
suggestion I None
of I None
an I None
association I None
between I None
metolachlor I Chemical
and I None
liver I Disease
cancer O Disease
among I None
pesticide I None
applicators I None
is I None
a I None
novel I None
finding I None
and I None
echoes I None
observation I None
of I None
increased I None
liver I Disease
neoplasms O Disease
in I None
some I None
animal I None
studies I None
. I None
<eof> I None

<s> O None
However I None
, I None
our I None
findings I None
for I None
both I None
liver I Disease
cancer O Disease
and I None
follicular I None
cell I None
lymphoma I Disease
warrant I None
follow I None
- I None
up I None
to I None
better I None
differentiate I None
effects I None
of I None
metolachlor I Chemical
use I None
from I None
other I None
factors I None
. I None
<eof> I None

<s> O None
Mechanisms I None
Underlying I None
Latent I None
Disease I None
Risk I None
Associated I None
with I None
Early I None
- I None
Life I None
<eof> I None

<s> O None
Arsenic I Chemical
Exposure I None
: I None
Current I None
Research I None
Trends I None
and I None
Scientific I None
Gaps I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Millions I None
of I None
individuals I None
worldwide I None
, I None
particularly I None
those I None
living I None
in I None
rural I None
and I None
developing I None
areas I None
, I None
are I None
exposed I None
to I None
harmful I None
levels I None
of I None
inorganic I Chemical
arsenic O Chemical
<eof> I None

<s> O None
( I None
iAs I Chemical
) I None
in I None
their I None
drinking I None
water I None
. I None
<eof> I None

<s> O None
Inorganic I Chemical
As O Chemical
exposure I None
during I None
key I None
developmental I None
periods I None
is I None
associated I None
with I None
a I None
variety I None
of I None
adverse I None
health I None
effects I None
including I None
those I None
that I None
are I None
evident I None
in I None
adulthood I None
. I None
<eof> I None

<s> O None
There I None
is I None
considerable I None
interest I None
in I None
identifying I None
the I None
molecular I None
mechanisms I None
that I None
relate I None
early I None
- I None
life I None
iAs I Chemical
exposure I None
to I None
the I None
development I None
of I None
these I None
latent I None
diseases I None
, I None
particularly I None
in I None
relationship I None
to I None
cancer I Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
This I None
work I None
summarizes I None
research I None
on I None
the I None
molecular I None
mechanisms I None
that I None
underlie I None
the I None
increased I None
risk I None
of I None
cancer I Disease
development I None
in I None
adulthood I None
that I None
is I None
associated I None
with I None
early I None
- I None
life I None
iAs I Chemical
exposure I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Epigenetic I None
reprogramming I None
that I None
imparts I None
functional I None
changes I None
in I None
gene I None
expression I None
, I None
the I None
development I None
of I None
cancer I Disease
stem I None
cells I None
, I None
and I None
immunomodulation I None
are I None
plausible I None
underlying I None
mechanisms I None
by I None
which I None
early I None
- I None
life I None
iAs I Chemical
exposure I None
elicits I None
latent I None
carcinogenic I None
effects I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Evidence I None
is I None
mounting I None
that I None
relates I None
early I None
- I None
life I None
iAs I Chemical
exposure I None
and I None
cancer I Disease
development I None
later I None
in I None
life I None
. I None
<eof> I None

<s> O None
Future I None
research I None
should I None
include I None
animal I None
studies I None
that I None
address I None
mechanistic I None
hypotheses I None
and I None
studies I None
of I None
human I None
populations I None
that I None
integrate I None
early I None
- I None
life I None
exposure I None
, I None
molecular I None
alterations I None
, I None
and I None
latent I None
disease I None
outcomes I None
. I None
<eof> I None

<s> O None
On I None
the I None
antiarrhythmic I None
activity I None
of I None
one I None
N I None
- I None
substituted I None
piperazine I Chemical
derivative I None
of I None
trans-2-amino-3-hydroxy-1 I Chemical
, O Chemical
2 O Chemical
, O Chemical
3 O Chemical
, O Chemical
4-tetrahydroanaphthalene O Chemical
. I None
<eof> I None

<s> O None
The I None
antiarrhythmic I None
activity I None
of I None
the I None
compound I None
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine I Chemical
hydrochloride O Chemical
, I None
referred I None
to I None
as I None
P11 I Chemical
, I None
is I None
studied I None
on I None
anaesthesized I None
cats I None
and I None
Wistar I None
albino I None
rats I None
, I None
as I None
well I None
as I None
on I None
non I None
- I None
anaesthesized I None
rabbits I None
. I None
<eof> I None

<s> O None
Four I None
types I None
of I None
experimental I None
arrhythmia I Disease
are I None
used I None
-- I None
with I None
BaCl2 I Chemical
, I None
with I None
chloroform I Chemical
- I None
adrenaline I Chemical
, I None
with I None
strophantine I Chemical
G O Chemical
and I None
with I None
aconitine I Chemical
. I None
<eof> I None

<s> O None
The I None
compound I None
P11 I Chemical
is I None
introduced I None
in I None
doses I None
of I None
0.25 I None
and I None
0.50 I None
mg I None
/ I None
kg I None
intravenously I None
and I None
10 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
orally I None
. I None
<eof> I None

<s> O None
The I None
compound I None
manifests I None
antiarrhythmic I None
activity I None
in I None
all I None
models I None
of I None
experimental I None
arrhythmia I Disease
used I None
, I None
causing I None
greatest I None
inhibition I None
on I None
the I None
arrhythmia I Disease
induced I None
by I None
chloroform I Chemical
- I None
adrenaline I Chemical
<eof> I None

<s> O None
( I None
in I None
90 I None
per I None
cent I None
) I None
and I None
with I None
BaCl2 I Chemical
( I None
in I None
84 I None
per I None
cent I None
) I None
. I None
<eof> I None

<s> O None
The I None
results I None
obtained I None
are I None
associated I None
with I None
the I None
beta I None
- I None
adrenoblocking I None
and I None
with I None
the I None
membrane I None
- I None
stabilizing I None
action I None
of I None
the I None
compound I None
. I None
<eof> I None

<s> O None
Experimental I None
progressive I None
muscular I Disease
dystrophy O Disease
and I None
its I None
treatment I None
with I None
high I None
doses I None
anabolizing I None
agents I None
. I None
<eof> I None

<s> O None
We I None
are I None
still I None
a I None
long I None
way I None
from I None
discovering I None
an I None
unequivocal I None
pathogenetic I None
interpretation I None
of I None
progressive I None
muscular I Disease
dystrophy O Disease
in I None
man I None
. I None
<eof> I None

<s> O None
Noteworthy I None
efforts I None
have I None
been I None
made I None
in I None
the I None
experimental I None
field I None
; I None
a I None
recessive I None
autosomic I None
form I None
found I None
in I None
the I None
mouse I None
seems I None
to I None
bear I None
the I None
closest I None
resemblance I None
to I None
the I None
human I None
form I None
from I None
the I None
genetic I None
point I None
of I None
view I None
. I None
<eof> I None

<s> O None
Myopathy I Disease
due I None
to I None
lack I None
of I None
vitamin I Chemical
E O Chemical
and I None
myopathy I Disease
induced I None
by I None
certain I None
viruses I None
have I None
much I None
in I None
common I None
anatomically I None
and I None
pathologically I None
with I None
the I None
human I None
form I None
. I None
<eof> I None

<s> O None
The I None
authors I None
induced I None
myodystrophy I Disease
in I None
the I None
rat I None
by I None
giving I None
it I None
a I None
diet I None
lacking I None
in I None
vitamin I Chemical
E O Chemical
. I None
<eof> I None

<s> O None
The I None
pharmacological I None
characteristics I None
of I None
vitamin I Chemical
E O Chemical
and I None
the I None
degenerative I None
changes I None
brought I None
about I None
by I None
its I None
deficiency I None
, I None
especially I None
in I None
the I None
muscles I None
, I None
are I None
illustrated I None
. I None
<eof> I None

<s> O None
It I None
is I None
thus I None
confirmed I None
that I None
the I None
histological I None
characteristics I None
of I None
myopathic I Disease
rat I None
muscle I None
induced I None
experimentally I None
are I None
extraordinarily I None
similar I None
to I None
those I None
of I None
human I None
myopathy I Disease
as I None
confirmed I None
during I None
biopsies I None
performed I None
at I None
the I None
Orthopaedic I None
Traumatological I None
Centre I None
, I None
Florence I None
. I None
<eof> I None

<s> O None
The I None
encouraging I None
results I None
obtained I None
in I None
various I None
authoratative I None
departments I None
in I None
myopathic I Disease
patients I None
by I None
using I None
anabolizing I None
steroids I Chemical
have I None
encouraged I None
the I None
authors I None
to I None
investigate I None
the I None
beneficial I None
effects I None
of I None
one I None
anabolizing I None
agent I None
( I None
Dianabol I Chemical
, I None
CIBA I Chemical
) I None
at I None
high I None
doses I None
in I None
rats I None
rendered I None
myopathic I Disease
by I None
a I None
diet I None
deficient I None
in I None
vitamin I Chemical
E O Chemical
. I None
<eof> I None

<s> O None
In I None
this I None
way I None
they I None
obtained I None
appreciable I None
changes I None
in I None
body I None
weight I None
( I None
increased I None
from I None
50 I None
to I None
70 I None
g I None
after I None
forty I None
days I None
at I None
a I None
dose I None
of I None
5 I None
mg I None
per I None
day I None
of I None
anabolizing I None
agent I None
) I None
, I None
but I None
most I None
of I None
all I None
they I None
found I None
histological I None
changes I None
due I None
to I None
" I None
regenerative I None
" I None
changes I None
in I None
the I None
muscle I None
tissue I None
, I None
which I None
however I None
maintained I None
its I None
myopathic I Disease
characteristics I None
in I None
the I None
control I None
animals I None
that I None
were I None
not I None
treated I None
with I None
the I None
anabolizing I None
agent I None
. I None
<eof> I None

<s> O None
The I None
authors I None
conclude I None
by I None
affirming I None
the I None
undoubted I None
efficacy I None
of I None
the I None
anabolizing I None
steroids I Chemical
in I None
experimental I None
myopathic I Disease
disease O Disease
, I None
but I None
they I None
have I None
reservations I None
as I None
to I None
the I None
transfer I None
of I None
the I None
results I None
into I None
the I None
human I None
field I None
, I None
where I None
high I None
dosage I None
can I None
not I None
be I None
carried I None
out I None
continuously I None
because I None
of I None
the I None
effects I None
of I None
the I None
drug I None
on I None
virility I None
; I None
because I None
the I None
tissue I None
injury I None
too I None
often I None
occurs I None
at I None
an I None
irreversible I None
stage I None
vis I None
- I None
a I None
- I None
vis I None
the I None
" I None
regeneration I None
" I None
of I None
the I None
muscle I None
tissue I None
; I None
and I None
finally I None
because I None
the I None
dystrophic I None
injurious I None
agent I None
is I None
certainly I None
not I None
the I None
lack I None
of I None
vitamin I Chemical
E O Chemical
but I None
something I None
as I None
yet I None
unknown I None
. I None
<eof> I None

<s> O None
Fetal I None
risks I None
due I None
to I None
warfarin I Chemical
therapy I None
during I None
pregnancy I None
. I None
<eof> I None

<s> O None
Two I None
mothers I None
with I None
heart I None
valve I None
prosthesis I None
were I None
treated I None
with I None
warfarin I Chemical
during I None
pregnancy I None
. I None
<eof> I None

<s> O None
In I None
the I None
first I None
case I None
a I None
caesarean I None
section I None
was I None
done I None
one I None
week I None
after I None
replacement I None
of I None
warfarin I Chemical
with I None
heparin I Chemical
. I None
<eof> I None

<s> O None
The I None
baby I None
died I None
of I None
cerebral I None
and I None
pulmonary I None
hemorrhage I None
. I None
<eof> I None

<s> O None
The I None
second I None
mother I None
had I None
a I None
male I None
infant I None
by I None
caesarean I None
section I None
. I None
<eof> I None

<s> O None
The I None
baby I None
showed I None
warfarin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
embryopathy I Disease
with I None
nasal I Disease
hypoplasia O Disease
and I None
stippled I Disease
epiphyses O Disease
<eof> I None

<s> O None
( I None
chondrodysplasia I Disease
punctata O Disease
) I None
. I None
<eof> I None

<s> O None
Nasal I Disease
hypoplasia O Disease
with I None
or I None
without I None
stippled I Disease
epiphyses O Disease
has I None
now I None
been I None
reported I None
in I None
11 I None
infants I None
born I None
to I None
mothers I None
treated I None
with I None
warfarin I Chemical
during I None
the I None
first I None
trimester I None
, I None
and I None
a I None
causal I None
association I None
is I None
probable I None
. I None
<eof> I None

<s> O None
In I None
view I None
of I None
the I None
risks I None
to I None
both I None
mother I None
and I None
fetus I None
in I None
women I None
with I None
prosthetic I None
cardiac I None
valves I None
it I None
is I None
recommended I None
that I None
therapeutic I None
abortion I None
be I None
advised I None
as I None
the I None
first I None
alternative I None
. I None
<eof> I None

<s> O None
Isradipine I Chemical
treatment I None
for I None
hypertension I Disease
in I None
general I None
practice I None
in I None
Hong I None
Kong I None
. I None
<eof> I None

<s> O None
A I None
6-week I None
open I None
study I None
of I None
the I None
introduction I None
of I None
isradipine I Chemical
treatment I None
was I None
conducted I None
in I None
general I None
practice I None
in I None
Hong I None
Kong I None
. I None
<eof> I None

<s> O None
303 I None
Chinese I None
patients I None
with I None
mild I None
to I None
moderate I None
hypertension I Disease
entered I None
the I None
study I None
. I None
<eof> I None

<s> O None
Side I None
effects I None
were I None
reported I None
in I None
21 I None
% I None
of I None
patients I None
and I None
caused I None
withdrawal I None
from I None
the I None
study I None
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
The I None
main I None
side I None
- I None
effects I None
were I None
headache I Disease
, I None
dizziness I Disease
, I None
palpitation I Disease
and I None
flushing I Disease
and I None
these I None
were I None
not I None
more I None
frequent I None
than I None
reported I None
in I None
other I None
studies I None
with I None
isradipine I Chemical
or I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
Supine I None
blood I None
pressure I None
was I None
reduced I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
from I None
170 I None
+ I None
/- I None
<eof> I None

<s> O None
20/102 I None
<eof> I None

<s> O None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
mmHg I None
to I None
153 I None
+ I None
/- I None
<eof> I None

<s> O None
19/92 I None
+ I None
/- I None
8 I None
, I None
147 I None
+ I None
/- I None
<eof> I None

<s> O None
18/88 I None
+ I None
/- I None
7 I None
and I None
144 I None
+ I None
<eof> I None

<s> O None
/- I None
14/87 I None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
mmHg I None
at I None
2 I None
, I None
4 I None
and I None
6 I None
weeks I None
respectively I None
in I None
evaluable I None
patients I None
. I None
<eof> I None

<s> O None
Similar I None
reductions I None
occurred I None
in I None
standing I None
blood I None
pressure I None
and I None
there I None
was I None
no I None
evidence I None
of I None
postural I Disease
hypotension O Disease
. I None
<eof> I None

<s> O None
Normalization I None
and I None
responder I None
rates I None
at I None
6 I None
weeks I None
were I None
86 I None
% I None
and I None
69 I None
% I None
respectively I None
. I None
<eof> I None

<s> O None
Dosage I None
was I None
increased I None
from I None
2.5 I None
mg I None
b.d I None
. I None
<eof> I None

<s> O None
to I None
5 I None
mg I None
b.d I None
. I None
<eof> I None

<s> O None
at I None
4 I None
weeks I None
in I None
patients I None
with I None
diastolic I None
blood I None
pressure I None
greater I None
than I None
90 I None
mmHg I None
and I None
their I None
further I None
response I None
was I None
greater I None
than I None
those I None
remaining I None
on I None
2.5 I None
mg I None
b.d I None
. I None
<eof> I None

<s> O None
Tachyphylaxis I None
to I None
systemic I None
but I None
not I None
to I None
airway I None
responses I None
during I None
prolonged I None
therapy I None
with I None
high I None
dose I None
inhaled I None
salbutamol I Chemical
in I None
asthmatics I Disease
. I None
<eof> I None

<s> O None
High I None
doses I None
of I None
inhaled I None
<eof> I None

<s> O None
salbutamol I Chemical
produce I None
substantial I None
improvements I None
in I None
airway I None
response I None
in I None
patients I None
with I None
asthma I Disease
, I None
and I None
are I None
associated I None
with I None
dose I None
- I None
dependent I None
systemic I None
beta I None
- I None
adrenoceptor I None
responses I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
whether I None
tachyphylaxis I None
occurs I None
during I None
prolonged I None
treatment I None
with I None
high I None
dose I None
inhaled I None
salbutamol I Chemical
. I None
<eof> I None

<s> O None
Twelve I None
<eof> I None

<s> O None
asthmatic I Disease
patients I None
( I None
FEV1 I None
, I None
81 I None
+ I None
/- I None
4 I None
% I None
predicted I None
) I None
, I None
requiring I None
only I None
occasional I None
inhaled I None
beta I None
- I None
agonists I None
as I None
their I None
sole I None
therapy I None
, I None
were I None
given I None
a I None
14-day I None
treatment I None
with I None
high I None
dose I None
inhaled I None
salbutamol I Chemical
<eof> I None

<s> O None
( I None
HDS I None
) I None
, I None
4,000 I None
micrograms I None
daily I None
, I None
low I None
dose I None
inhaled I None
salbutamol I Chemical
<eof> I None

<s> O None
( I None
LDS I None
) I None
, I None
800 I None
micrograms I None
daily I None
, I None
or I None
placebo I None
( I None
PI I None
) I None
by I None
metered I None
- I None
dose I None
inhaler I None
in I None
a I None
double I None
- I None
blind I None
, I None
randomized I None
crossover I None
design I None
. I None
<eof> I None

<s> O None
During I None
the I None
14-day I None
run I None
- I None
in I None
and I None
during I None
washout I None
periods I None
, I None
inhaled I None
beta I None
- I None
agonists I None
were I None
withheld I None
and I None
ipratropium I Chemical
bromide O Chemical
was I None
substituted I None
for I None
rescue I None
purposes I None
. I None
<eof> I None

<s> O None
At I None
the I None
end I None
of I None
each I None
14-day I None
treatment I None
, I None
a I None
dose I None
- I None
response I None
curve I None
( I None
DRC I None
) I None
was I None
performed I None
, I None
and I None
airway I None
( I None
FEV1 I None
, I None
FEF25 I None
- I None
75 I None
) I None
chronotropic I None
( I None
HR I None
) I None
, I None
tremor I Disease
, I None
and I None
metabolic I None
( I None
K I Chemical
, I None
Glu I Chemical
) I None
responses I None
were I None
measured I None
at I None
each I None
step I None
( I None
from I None
100 I None
to I None
4,000 I None
micrograms I None
) I None
. I None
<eof> I None

<s> O None
Treatment I None
had I None
no I None
significant I None
effect I None
on I None
baseline I None
values I None
. I None
<eof> I None

<s> O None
There I None
were I None
dose I None
- I None
dependent I None
increases I None
in I None
FEV1 I None
and I None
FEF25 I None
- I None
75 I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
and I None
pretreatment I None
with I None
HDS I None
did I None
not I None
displace I None
the I None
DRC I None
to I None
the I None
right I None
. I None
<eof> I None

<s> O None
DRC I None
for I None
HR I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
K I Chemical
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
and I None
Glu I Chemical
( I None
p I None
less I None
than I None
0.005 I None
) I None
were I None
attenuated I None
after I None
treatment I None
with I None
HDS I None
compared I None
with I None
PI I None
. I None
<eof> I None

<s> O None
There I None
were I None
also I None
differences I None
between I None
HDS I None
and I None
LDS I None
for I None
HR I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
and I None
Glu I Chemical
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.05 I None
) I None
responses I None
. I None
<eof> I None

<s> O None
Frequency I None
and I None
severity I None
of I None
subjective I None
adverse I None
effects I None
were I None
also I None
reduced I None
after I None
HDS I None
: I None
<eof> I None

<s> O None
tremor I Disease
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
palpitations I Disease
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.001).(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Increased I None
anxiogenic I None
effects I None
of I None
caffeine I Chemical
in I None
panic I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
oral I None
administration I None
of I None
caffeine I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
) I None
on I None
behavioral I None
ratings I None
, I None
somatic I None
symptoms I None
, I None
blood I None
pressure I None
and I None
plasma I None
levels I None
of I None
3-methoxy-4-hydroxyphenethyleneglycol I Chemical
<eof> I None

<s> O None
( I None
MHPG I Chemical
) I None
and I None
cortisol I Chemical
were I None
determined I None
in I None
17 I None
healthy I None
subjects I None
and I None
21 I None
patients I None
meeting I None
DSM I None
- I None
III I None
criteria I None
for I None
agoraphobia I Disease
with I None
panic I Disease
attacks O Disease
or I None
panic I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Caffeine I Chemical
produced I None
significantly I None
greater I None
increases I None
in I None
subject I None
- I None
rated I None
anxiety I Disease
, I None
nervousness I None
, I None
fear I None
, I None
nausea I Disease
, I None
palpitations I Disease
, I None
restlessness I Disease
, I None
and I None
tremors I Disease
in I None
the I None
patients I None
compared I None
with I None
healthy I None
subjects I None
. I None
<eof> I None

<s> O None
In I None
the I None
patients I None
, I None
but I None
not I None
the I None
healthy I None
subjects I None
, I None
these I None
symptoms I None
were I None
significantly I None
correlated I None
with I None
plasma I None
caffeine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Seventy I None
- I None
one I None
percent I None
of I None
the I None
patients I None
reported I None
that I None
the I None
behavioral I None
effects I None
of I None
caffeine I Chemical
were I None
similar I None
to I None
those I None
experienced I None
during I None
panic I Disease
attacks O Disease
. I None
<eof> I None

<s> O None
Caffeine I Chemical
did I None
not I None
alter I None
plasma I None
MHPG I Chemical
levels I None
in I None
either I None
the I None
healthy I None
subjects I None
or I None
patients I None
. I None
<eof> I None

<s> O None
Caffeine I Chemical
increased I None
plasma I None
cortisol I Chemical
levels I None
equally I None
in I None
the I None
patient I None
and I None
healthy I None
groups I None
. I None
<eof> I None

<s> O None
Because I None
caffeine I Chemical
is I None
an I None
adenosine I Chemical
receptor I None
antagonist I None
, I None
these I None
results I None
suggest I None
that I None
some I None
panic I Disease
disorder O Disease
patients I None
may I None
have I None
abnormalities I Disease
in O Disease
neuronal O Disease
systems O Disease
involving I None
adenosine I Chemical
. I None
<eof> I None

<s> O None
Patients I None
with I None
anxiety I Disease
disorders O Disease
may I None
benefit I None
by I None
avoiding I None
caffeine I Chemical
-containing I None
foods I None
and I None
beverages I None
. I None
<eof> I None

<s> O None
Human I None
and I None
canine I None
ventricular I None
vasoactive I None
intestinal I None
polypeptide I None
: I None
decrease I None
with I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Vasoactive I None
intestinal I None
polypeptide I None
( I None
VIP I None
) I None
is I None
a I None
systemic I None
and I None
coronary I None
vasodilator I None
that I None
may I None
have I None
positive I None
inotropic I None
properties I None
. I None
<eof> I None

<s> O None
Myocardial I None
levels I None
of I None
VIP I None
were I None
assayed I None
before I None
and I None
after I None
the I None
development I None
of I None
heart I Disease
failure O Disease
in I None
two I None
canine I None
models I None
. I None
<eof> I None

<s> O None
In I None
the I None
first I None
, I None
cobalt I Chemical
<eof> I None

<s> O None
cardiomyopathy I Disease
was I None
induced I None
in I None
eight I None
dogs I None
; I None
VIP I None
( I None
by I None
radioimmunoassay I None
) I None
decreased I None
from I None
35 I None
+ I None
/- I None
<eof> I None

<s> O None
11 I None
pg I None
/ I None
mg I None
protein I None
( I None
mean I None
+ I None
/- I None
SD I None
) I None
to I None
5 I None
+ I None
/- I None
4 I None
<eof> I None

<s> O None
pg I None
/ I None
mg I None
protein I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
six I None
dogs I None
with I None
doxorubicin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
heart I Disease
failure O Disease
, I None
VIP I None
decreased I None
from I None
31 I None
+ I None
/- I None
7 I None
to I None
11 I None
+ I None
/- I None
<eof> I None

<s> O None
4 I None
<eof> I None

<s> O None
pg I None
/ I None
mg I None
protein I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
VIP I None
content I None
of I None
left I None
ventricular I None
muscle I None
of I None
resected I None
failing I None
hearts I None
in I None
10 I None
patients I None
receiving I None
a I None
heart I None
transplant I None
was I None
compared I None
with I None
the I None
papillary I None
muscles I None
in I None
14 I None
patients I None
( I None
five I None
with I None
rheumatic I Disease
disease O Disease
, I None
nine I None
with I None
myxomatous I Disease
degeneration O Disease
) I None
receiving I None
mitral I None
valve I None
prostheses I None
. I None
<eof> I None

<s> O None
The I None
lowest I None
myocardial I None
VIP I None
concentration I None
was I None
found I None
in I None
the I None
hearts I None
of I None
patients I None
with I None
coronary I Disease
disease O Disease
<eof> I None

<s> O None
( I None
one I None
patient I None
receiving I None
a I None
transplant I None
and I None
three I None
receiving I None
mitral I None
prostheses I None
) I None
( I None
6.3 I None
+ I None
/- I None
1.9 I None
pg I None
/ I None
mg I None
protein I None
) I None
. I None
<eof> I None

<s> O None
The I None
other I None
patients I None
undergoing I None
transplantation I None
had I None
an I None
average I None
ejection I None
fraction I None
of I None
17 I None
% I None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
% I None
and I None
a I None
VIP I None
level I None
of I None
8.8 I None
+ I None
/- I None
3.9 I None
pg I None
/ I None
mg I None
protein I None
. I None
<eof> I None

<s> O None
The I None
hearts I None
without I None
coronary I Disease
artery O Disease
disease O Disease
<eof> I None

<s> O None
( I None
average I None
ejection I None
fraction I None
of I None
this I None
group I None
62 I None
% I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
% I None
) I None
had I None
a I None
VIP I None
concentration I None
of I None
14.1 I None
+ I None
/- I None
<eof> I None

<s> O None
7.9 I None
<eof> I None

<s> O None
pg I None
/ I None
mg I None
protein I None
, I None
and I None
this I None
was I None
greater I None
than I None
in I None
hearts I None
of I None
the I None
patients I None
with I None
coronary I Disease
disease O Disease
and I None
the I None
hearts I None
of I None
patients I None
receiving I None
a I None
transplant I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Myocardial I None
catecholamines I Chemical
were I None
also I None
determined I None
in I None
14 I None
subjects I None
; I None
a I None
weak I None
correlation I None
( I None
r I None
= I None
0.57 I None
, I None
P I None
less I None
than I None
0.05 I None
) I None
between I None
the I None
tissue I None
concentrations I None
of I None
VIP I None
and I None
norepinephrine I Chemical
was I None
noted.(ABSTRACT I None
TRUNCATED I None
<eof> I None

<s> O None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Interstrain I None
variation I None
in I None
acute I None
toxic I None
response I None
to I None
caffeine I Chemical
among I None
inbred I None
mice I None
. I None
<eof> I None

<s> O None
Acute I None
toxic I None
dosage I None
- I None
dependent I None
behavioral I None
effects I None
of I None
caffeine I Chemical
were I None
compared I None
in I None
adult I None
males I None
from I None
seven I None
inbred I None
mouse I None
strains I None
( I None
A I None
/ I None
J I None
, I None
BALB I None
/ I None
cJ I None
, I None
CBA I None
/ I None
J I None
, I None
C3H I None
/ I None
HeJ I None
, I None
C57BL/6J I None
, I None
DBA/2J I None
, I None
SWR I None
/ I None
J I None
) I None
. I None
<eof> I None

<s> O None
C57BL/6J I None
, I None
chosen I None
as I None
a I None
" I None
prototypic I None
" I None
mouse I None
strain I None
, I None
was I None
used I None
to I None
determine I None
behavioral I None
responses I None
to I None
a I None
broad I None
range I None
( I None
5 I None
- I None
500 I None
mg I None
/ I None
kg I None
) I None
of I None
caffeine I Chemical
doses I None
. I None
<eof> I None

<s> O None
Five I None
phenotypic I None
characteristics I None
-- I None
locomotor I None
activity I None
, I None
righting I None
ability I None
, I None
clonic I Disease
seizure O Disease
induction I None
, I None
stress I None
- I None
induced I None
lethality I None
, I None
death I None
without I None
external I None
stress I None
-- I None
were I None
scored I None
at I None
various I None
caffeine I Chemical
doses I None
in I None
drug I None
- I None
naive I None
animals I None
under I None
empirically I None
optimized I None
, I None
rigidly I None
constant I None
experimental I None
conditions I None
. I None
<eof> I None

<s> O None
Mice I None
( I None
n I None
= I None
12 I None
for I None
each I None
point I None
) I None
received I None
single I None
IP I None
injections I None
of I None
a I None
fixed I None
volume I None
/ I None
g I None
body I None
weight I None
of I None
physiological I None
saline I None
carrier I None
with I None
or I None
without I None
caffeine I Chemical
in I None
doses I None
ranging I None
from I None
125 I None
- I None
500 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Loss I None
of I None
righting I None
ability I None
was I None
scored I None
at I None
1 I None
, I None
3 I None
, I None
5 I None
min I None
post I None
dosing I None
and I None
at I None
5 I None
min I None
intervals I None
thereafter I None
for I None
20 I None
min I None
. I None
<eof> I None

<s> O None
In I None
the I None
same I None
animals I None
the I None
occurrence I None
of I None
clonic I Disease
seizures O Disease
was I None
scored I None
as I None
to I None
time I None
of I None
onset I None
and I None
severity I None
for I None
20 I None
min I None
after I None
drug I None
administration I None
. I None
<eof> I None

<s> O None
When I None
these I None
proceeded I None
to I None
tonic I Disease
seizures O Disease
, I None
death I None
occurred I None
in I None
less I None
than I None
20 I None
min I None
. I None
<eof> I None

<s> O None
Animals I None
surviving I None
for I None
20 I None
min I None
were I None
immediately I None
stressed I None
by I None
a I None
swim I None
test I None
in I None
25 I None
degrees I None
C I None
water I None
, I None
and I None
death I None
- I None
producing I None
tonic I Disease
seizures O Disease
were I None
scored I None
for I None
2 I None
min I None
. I None
<eof> I None

<s> O None
In I None
other I None
animals I None
locomotor I None
activity I None
was I None
measured I None
15 I None
or I None
60 I None
min I None
after I None
caffeine I Chemical
administration I None
. I None
<eof> I None

<s> O None
By I None
any I None
single I None
behavioral I None
criterion I None
or I None
a I None
combination I None
of I None
these I None
criteria I None
, I None
marked I None
differences I None
in I None
response I None
to I None
toxic I None
caffeine I Chemical
doses I None
were I None
observed I None
between I None
strains I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
behavioral I None
toxicity I Disease
testing I None
of I None
alkylxanthines I Chemical
in I None
a I None
single I None
mouse I None
strain I None
may I None
be I None
misleading I None
and I None
suggest I None
that I None
toxic I None
responses I None
of I None
the I None
central I None
nervous I None
system I None
to I None
this I None
class I None
of I None
compounds I None
are I None
genetically I None
influenced I None
in I None
mammals I None
. I None
<eof> I None

<s> O None
Invasive I None
carcinoma I Disease
of O Disease
the O Disease
renal O Disease
pelvis O Disease
following I None
cyclophosphamide I Chemical
therapy I None
for I None
nonmalignant I None
disease I None
. I None
<eof> I None

<s> O None
A I None
47-year I None
- I None
old I None
woman I None
with I None
right I None
hydroureteronephrosis I Disease
due I None
to I None
ureterovesical I None
junction I None
obstruction I None
had I None
gross I None
hematuria I Disease
after I None
being I None
treated I None
for I None
five I None
years I None
wtih I None
cyclophosphamide I Chemical
for I None
cerebral I Disease
vasculitis O Disease
. I None
<eof> I None

<s> O None
A I None
right I None
nephroureterectomy I None
was I None
required I None
for I None
control I None
of I None
bleeding I Disease
. I None
<eof> I None

<s> O None
The I None
pathology I None
specimen I None
contained I None
clinically I None
occult I None
invasive I None
carcinoma I Disease
of O Disease
the O Disease
renal O Disease
pelvis O Disease
. I None
<eof> I None

<s> O None
Although I None
the I None
ability I None
of I None
cyclophosphamide I Chemical
to I None
cause I None
hemorrhagic I None
cystitis I None
and I None
urine I None
cytologic I None
abnormalities I None
indistinguishable I None
from I None
high I None
grade I None
<eof> I None

<s> O None
carcinoma I Disease
is I None
well I None
known I None
, I None
it I None
is I None
less I None
widely I None
appreciated I None
that I None
it I None
is I None
also I None
associated I None
with I None
carcinoma I Disease
of O Disease
the O Disease
urinary O Disease
tract O Disease
. I None
<eof> I None

<s> O None
Twenty I None
carcinomas I Disease
of O Disease
the O Disease
urinary O Disease
bladder O Disease
and I None
one I None
carcinoma I Disease
of O Disease
the O Disease
prostate O Disease
have I None
been I None
reported I None
in I None
association I None
with I None
its I None
use I None
. I None
<eof> I None

<s> O None
The I None
present I None
case I None
is I None
the I None
first I None
carcinoma I Disease
of O Disease
the O Disease
renal O Disease
pelvis O Disease
reported I None
in I None
association I None
with I None
cyclophosphamide I Chemical
treatment I None
. I None
<eof> I None

<s> O None
It I None
is I None
the I None
third I None
urinary I Disease
tract O Disease
cancer O Disease
reported I None
in I None
association I None
with I None
cyclophosphamide I Chemical
treatment I None
for I None
nonmalignant I None
disease I None
. I None
<eof> I None

<s> O None
The I None
association I None
of I None
the I None
tumor I Disease
with I None
preexisting I None
hydroureteronephrosis I Disease
suggests I None
that I None
stasis I None
prolonged I None
and I None
intensified I None
exposure I None
of I None
upper I None
urinary I None
tract I None
epithelium I None
to I None
cyclophosphamide I Chemical
. I None
<eof> I None

<s> O None
Patients I None
who I None
are I None
candidates I None
for I None
long I None
- I None
term I None
cyclophosphamide I Chemical
treatment I None
should I None
be I None
routinely I None
evaluated I None
for I None
obstructive I Disease
uropathy O Disease
. I None
<eof> I None

<s> O None
Ascending I None
dose I None
tolerance I None
study I None
of I None
intramuscular I None
carbetocin I Chemical
administered I None
after I None
normal I None
vaginal I None
birth I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
maximum I None
tolerated I None
dose I None
( I None
MTD I None
) I None
of I None
carbetocin I Chemical
<eof> I None

<s> O None
( I None
a I None
long I None
- I None
acting I None
synthetic I None
analogue I None
of I None
oxytocin I Chemical
) I None
, I None
when I None
administered I None
immediately I None
after I None
vaginal I None
delivery I None
at I None
term I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Carbetocin I Chemical
was I None
given I None
as I None
an I None
intramuscular I None
injection I None
immediately I None
after I None
the I None
birth I None
of I None
the I None
infant I None
in I None
45 I None
healthy I None
women I None
with I None
normal I None
singleton I None
pregnancies I None
who I None
delivered I None
vaginally I None
at I None
term I None
. I None
<eof> I None

<s> O None
Dosage I None
groups I None
of I None
15 I None
, I None
30 I None
, I None
50 I None
, I None
75 I None
, I None
100 I None
, I None
125 I None
, I None
150 I None
, I None
175 I None
or I None
200 I None
microg I None
<eof> I None

<s> O None
carbetocin I Chemical
were I None
assigned I None
to I None
blocks I None
of I None
three I None
women I None
according I None
to I None
the I None
continual I None
reassessment I None
method I None
( I None
CRM I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
dosage I None
groups I None
consisted I None
of I None
three I None
women I None
, I None
except I None
those I None
with I None
100 I None
microg I None
( I None
n=6 I None
) I None
and I None
200 I None
microg I None
( I None
n=18 I None
) I None
. I None
<eof> I None

<s> O None
Recorded I None
were I None
dose I None
- I None
limiting I None
adverse I None
events I None
: I None
<eof> I None

<s> O None
hyper- I Disease
or O Disease
hypotension O Disease
( I None
three I None
) I None
, I None
severe I None
abdominal I Disease
pain O Disease
( I None
0 I None
) I None
, I None
vomiting I Disease
( I None
0 I None
) I None
and I None
retained I Disease
placenta O Disease
( I None
four I None
) I None
. I None
<eof> I None

<s> O None
Serious I None
adverse I None
events I None
occurred I None
in I None
seven I None
women I None
: I None
six I None
cases I None
with I None
blood I Disease
loss O Disease
<eof> I None

<s> O None
> I None
or I None
= I None
1000 I None
ml I None
, I None
four I None
cases I None
of I None
manual I None
placenta I None
removal I None
, I None
five I None
cases I None
of I None
additional I None
oxytocics I None
administration I None
and I None
five I None
cases I None
of I None
blood I None
transfusion I None
. I None
<eof> I None

<s> O None
Maximum I None
blood I Disease
loss O Disease
was I None
greatest I None
at I None
the I None
upper I None
and I None
lower I None
dose I None
levels I None
, I None
and I None
lowest I None
in I None
the I None
70 I None
- I None
125 I None
microg I None
dose I None
range I None
. I None
<eof> I None

<s> O None
Four I None
out I None
of I None
six I None
cases I None
with I None
blood I Disease
loss O Disease
<eof> I None

<s> O None
> I None
or I None
= I None
1000 I None
ml I None
occurred I None
in I None
the I None
200 I None
microg I None
group I None
. I None
<eof> I None

<s> O None
The I None
majority I None
of I None
additional I None
administration I None
of I None
oxytocics I None
( I None
4/5 I None
) I None
and I None
blood I None
transfusion I None
( I None
3/5 I None
) I None
occurred I None
in I None
the I None
dose I None
groups I None
of I None
200 I None
microg I None
. I None
<eof> I None

<s> O None
All I None
retained I None
placentae I None
were I None
found I None
in I None
the I None
group I None
of I None
200 I None
microg I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
MTD I None
was I None
calculated I None
to I None
be I None
at I None
200 I None
microg I None
carbetocin I Chemical
. I None
<eof> I None

<s> O None
A I None
pilot I None
study I None
to I None
assess I None
the I None
safety I None
of I None
<eof> I None

<s> O None
dobutamine I Chemical
stress I None
echocardiography I None
in I None
the I None
emergency I None
department I None
evaluation I None
of I None
cocaine I Chemical
-associated I None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
STUDY I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Chest I Disease
pain O Disease
in I None
the I None
setting I None
of I None
cocaine I Chemical
use I None
poses I None
a I None
diagnostic I None
dilemma I None
. I None
<eof> I None

<s> O None
Dobutamine I Chemical
stress I None
echocardiography I None
( I None
DSE I None
) I None
is I None
a I None
widely I None
available I None
and I None
sensitive I None
test I None
for I None
evaluating I None
cardiac I None
ischemia I Disease
. I None
<eof> I None

<s> O None
Because I None
of I None
the I None
theoretical I None
concern I None
regarding I None
administration I None
of I None
dobutamine I Chemical
in I None
the I None
setting I None
of I None
cocaine I Chemical
use I None
, I None
we I None
conducted I None
a I None
pilot I None
study I None
to I None
assess I None
the I None
safety I None
of I None
DSE I None
in I None
emergency I None
department I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
prospective I None
case I None
series I None
was I None
conducted I None
in I None
the I None
intensive I None
diagnostic I None
and I None
treatment I None
unit I None
in I None
the I None
ED I None
of I None
an I None
urban I None
tertiary I None
- I None
care I None
teaching I None
hospital I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
eligible I None
for I None
DSE I None
if I None
they I None
had I None
used I None
cocaine I Chemical
within I None
24 I None
hours I None
preceding I None
the I None
onset I None
of I None
chest I Disease
pain O Disease
and I None
had I None
a I None
normal I None
ECG I None
and I None
tropinin I None
<eof> I None

<s> O None
I I None
level I None
. I None
<eof> I None

<s> O None
Patients I None
exhibiting I None
signs I None
of I None
continuing I None
cocaine I Chemical
toxicity I Disease
were I None
excluded I None
from I None
the I None
study I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
admitted I None
to I None
the I None
hospital I None
for I None
serial I None
testing I None
after I None
the I None
DSE I None
testing I None
in I None
the I None
intensive I None
diagnostic I None
and I None
treatment I None
unit I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
four I None
patients I None
were I None
enrolled I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
had I None
inadequate I None
resting I None
images I None
, I None
one I None
DSE I None
was I None
terminated I None
because I None
of I None
inferior I None
hypokinesis I Disease
, I None
another I None
DSE I None
was I None
terminated I None
because I None
of I None
a I None
rate I None
- I None
related I None
atrial I None
conduction I None
deficit I None
, I None
and I None
1 I None
patient I None
did I None
not I None
reach I None
the I None
target I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
19 I None
patients I None
completed I None
a I None
DSE I None
and I None
reached I None
their I None
target I None
heart I None
rates I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
patients I None
experienced I None
signs I None
of I None
exaggerated I None
adrenergic I None
response I None
, I None
which I None
was I None
defined I None
as I None
a I None
systolic I None
blood I None
pressure I None
of I None
greater I None
than I None
200 I None
mm I None
Hg I None
or I None
the I None
occurrence I None
of I None
tachydysrhythmias I Disease
( I None
excluding I None
sinus I Disease
tachycardia O Disease
) I None
. I None
<eof> I None

<s> O None
Further I None
suggesting I None
lack I None
of I None
exaggerated I None
adrenergic I None
response I None
, I None
13 I None
( I None
65 I None
% I None
) I None
of I None
20 I None
patients I None
required I None
supplemental I None
atropine I Chemical
to I None
reach I None
their I None
target I None
heart I None
rates I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
No I None
exaggerated I None
adrenergic I None
response I None
was I None
detected I None
when I None
dobutamine I Chemical
was I None
administered I None
to I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
-induced I None
torsade I Disease
de O Disease
pointes O Disease
during I None
bladder I None
irrigation I None
: I None
an I None
unusual I None
presentation I None
-- I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
The I None
authors I None
present I None
a I None
case I None
of I None
early I None
( I None
within I None
4 I None
days I None
) I None
development I None
of I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
TdP I Disease
) I None
associated I None
with I None
oral I None
amiodarone I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Consistent I None
with I None
other I None
reports I None
this I None
case I None
of I None
TdP I Disease
occurred I None
in I None
the I None
context I None
of I None
multiple I None
exacerbating I None
factors I None
including I None
hypokalemia I Disease
and I None
digoxin I Chemical
excess I None
. I None
<eof> I None

<s> O None
Transient I None
prolongation I None
of I None
the I None
QT I None
during I None
bladder I None
irrigation I None
prompted I None
the I None
episode I None
of I None
TdP I Disease
. I None
<eof> I None

<s> O None
It I None
is I None
well I None
known I None
that I None
bradycardia I Disease
exacerbates I None
acquired I None
TdP I Disease
. I None
<eof> I None

<s> O None
The I None
authors I None
speculate I None
that I None
the I None
increased I None
vagal I None
tone I None
during I None
bladder I None
irrigation I None
, I None
a I None
vagal I None
maneuver I None
, I None
in I None
the I None
context I None
of I None
amiodarone I Chemical
therapy I None
resulted I None
in I None
amiodarone I Chemical
-induced I None
proarrhythmia I Disease
. I None
<eof> I None

<s> O None
In I None
the I None
absence I None
of I None
amiodarone I Chemical
therapy I None
, I None
a I None
second I None
bladder I None
irrigation I None
did I None
not I None
induce I None
TdP I Disease
despite I None
hypokalemia I Disease
and I None
hypomagnesemia I Disease
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
insufficiency O Disease
after I None
high I None
- I None
dose I None
melphalan I Chemical
in I None
patients I None
with I None
primary I Disease
systemic O Disease
amyloidosis O Disease
during I None
stem I None
cell I None
transplantation I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Patients I None
with I None
primary I Disease
systemic O Disease
amyloidosis O Disease
<eof> I None

<s> O None
( I None
AL I Disease
) I None
have I None
a I None
poor I None
prognosis I None
. I None
<eof> I None

<s> O None
Median I None
survival I None
time I None
from I None
standard I None
treatments I None
is I None
only I None
17 I None
months I None
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
intravenous I None
melphalan I Chemical
followed I None
by I None
peripheral I None
blood I None
stem I None
cell I None
transplant I None
( I None
PBSCT I None
) I None
appears I None
to I None
be I None
the I None
most I None
promising I None
therapy I None
, I None
but I None
treatment I None
mortality I None
can I None
be I None
high I None
. I None
<eof> I None

<s> O None
The I None
authors I None
have I None
noted I None
the I None
development I None
of I None
acute I Disease
renal O Disease
insufficiency O Disease
immediately I None
after I None
melphalan I Chemical
conditioning I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
further I None
examine I None
its I None
risk I None
factors I None
and I None
impact I None
on I None
posttransplant I None
mortality I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Consecutive I None
AL I Disease
patients I None
who I None
underwent I None
PBSCT I None
were I None
studied I None
retrospectively I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
insufficiency O Disease
<eof> I None

<s> O None
( I None
ARI I Disease
) I None
after I None
high I None
- I None
dose I None
melphalan I Chemical
was I None
defined I None
by I None
a I None
minimum I None
increase I None
of I None
0.5 I None
mg I None
/ I None
dL I None
( I None
44 I None
micromol I None
/ I None
L I None
) I None
in I None
the I None
serum I None
creatinine I Chemical
level I None
that I None
is I None
greater I None
than I None
50 I None
% I None
of I None
baseline I None
immediately I None
after I None
conditioning I None
. I None
<eof> I None

<s> O None
Urine I None
sediment I None
score I None
was I None
the I None
sum I None
of I None
the I None
individual I None
types I None
of I None
sediment I None
identified I None
on I None
urine I None
microscopy I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
the I None
80 I None
patients I None
studied I None
, I None
ARI I Disease
developed I None
in I None
18.8 I None
% I None
of I None
the I None
patients I None
after I None
high I None
- I None
dose I None
melphalan I Chemical
. I None
<eof> I None

<s> O None
Univariate I None
analysis I None
identified I None
age I None
, I None
hypoalbuminemia I Disease
, I None
heavy I None
proteinuria I Disease
, I None
diuretic I None
use I None
, I None
and I None
urine I None
sediment I None
score I None
( I None
> I None
3 I None
) I None
as I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Age I None
and I None
urine I None
sediment I None
score I None
remained I None
independently I None
significant I None
risk I None
factors I None
in I None
the I None
multivariate I None
analysis I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
had I None
ARI I Disease
after I None
high I None
- I None
dose I None
melphalan I Chemical
underwent I None
dialysis I None
more I None
often I None
( I None
P I None
= I None
0.007 I None
) I None
, I None
and I None
had I None
a I None
worse I None
1-year I None
survival I None
( I None
P I None
= I None
0.03 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
timing I None
of I None
renal I Disease
injury O Disease
strongly I None
suggests I None
melphalan I Chemical
as I None
the I None
causative I None
agent I None
. I None
<eof> I None

<s> O None
Ongoing I None
<eof> I None

<s> O None
tubular I Disease
injury O Disease
may I None
be I None
a I None
prerequisite I None
for I None
renal I Disease
injury O Disease
by I None
melphalan I Chemical
as I None
evidenced I None
by I None
the I None
active I None
urinary I None
sediment I None
. I None
<eof> I None

<s> O None
Development I None
of I None
ARI I Disease
adversely I None
affected I None
the I None
outcome I None
after I None
PBSCT I None
. I None
<eof> I None

<s> O None
Effective I None
preventive I None
measures I None
may I None
help I None
decrease I None
the I None
treatment I None
mortality I None
of I None
PBSCT I None
in I None
AL I Disease
patients I None
. I None
<eof> I None

<s> O None
Impaired I Disease
fear O Disease
recognition O Disease
in I None
regular I None
recreational I None
cocaine I Chemical
users I None
. I None
<eof> I None

<s> O None
INTRODUCTION I None
: I None
<eof> I None

<s> O None
The I None
ability I None
to I None
read I None
facial I None
expressions I None
is I None
essential I None
for I None
normal I None
human I None
social I None
interaction I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
conduct I None
the I None
first I None
investigation I None
of I None
facial I None
expression I None
recognition I None
performance I None
in I None
recreational I None
cocaine I Chemical
users I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
Three I None
groups I None
, I None
comprised I None
of I None
21 I None
cocaine I Chemical
naive I None
participants I None
( I None
CN I None
) I None
, I None
30 I None
occasional I None
cocaine I Chemical
<eof> I None

<s> O None
( I None
OC I None
) I None
, I None
and I None
48 I None
regular I None
recreational I None
cocaine I Chemical
<eof> I None

<s> O None
( I None
RC I None
) I None
users I None
, I None
were I None
compared I None
. I None
<eof> I None

<s> O None
An I None
emotional I None
facial I None
expression I None
( I None
EFE I None
) I None
task I None
consisting I None
of I None
a I None
male I None
and I None
female I None
face I None
expressing I None
six I None
basic I None
emotions I None
( I None
happiness I None
, I None
surprise I None
, I None
sadness I None
, I None
anger I None
, I None
fear I None
, I None
and I None
disgust I None
) I None
was I None
administered I None
. I None
<eof> I None

<s> O None
Mean I None
percent I None
accuracy I None
and I None
latencies I None
for I None
correct I None
responses I None
across I None
eight I None
presentations I None
of I None
each I None
basic I None
emotion I None
were I None
derived I None
. I None
<eof> I None

<s> O None
Participants I None
were I None
also I None
assessed I None
with I None
the I None
" I None
Eyes I None
task I None
" I None
to I None
investigate I None
their I None
ability I None
to I None
recognize I None
more I None
complex I None
emotional I None
states I None
and I None
the I None
Symptom I None
CheckList-90-Revised I None
to I None
measure I None
psychopathology I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
There I None
were I None
no I None
group I None
differences I None
in I None
psychopathology I None
or I None
" I None
eyes I None
task I None
" I None
performance I None
, I None
but I None
the I None
RC I None
group I None
, I None
who I None
otherwise I None
had I None
similar I None
illicit I None
substance I None
use I None
histories I None
to I None
the I None
OC I None
group I None
, I None
exhibited I None
impaired I Disease
fear O Disease
recognition O Disease
accuracy I None
compared I None
to I None
the I None
OC I None
and I None
CN I None
groups I None
. I None
<eof> I None

<s> O None
The I None
RC I None
group I None
also I None
correctly I None
identified I None
anger I None
, I None
fear I None
, I None
happiness I None
, I None
and I None
surprise I None
, I None
more I None
slowly I None
than I None
CN I None
, I None
but I None
not I None
OC I None
participants I None
. I None
<eof> I None

<s> O None
The I None
OC I None
group I None
was I None
slower I None
than I None
CN I None
when I None
correctly I None
identifying I None
disgust I None
. I None
<eof> I None

<s> O None
The I None
selective I None
deficit I Disease
in O Disease
fear O Disease
recognition O Disease
accuracy I None
manifested I None
by I None
the I None
RC I None
group I None
can I None
not I None
be I None
explained I None
by I None
the I None
subacute I None
effects I None
of I None
cocaine I Chemical
, I None
or I None
ecstasy I Chemical
, I None
because I None
recent I None
and I None
less I None
recent I None
users I None
of I None
these I None
drugs I None
within I None
this I None
group I None
were I None
similarly I None
impaired I None
. I None
<eof> I None

<s> O None
Possible I None
parallels I None
between I None
RC I None
users I None
and I None
psychopaths I Disease
with I None
respect I None
to I None
impaired I Disease
fear O Disease
recognition O Disease
, I None
amygdala I Disease
dysfunction O Disease
, I None
and I None
etiology I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Corneal I Disease
ulcers O Disease
associated I None
with I None
aerosolized I None
crack I Chemical
cocaine O Chemical
use I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
We I None
report I None
4 I None
cases I None
of I None
corneal I Disease
ulcers O Disease
associated I None
with I None
drug I Disease
abuse O Disease
. I None
<eof> I None

<s> O None
The I None
pathogenesis I None
of I None
these I None
ulcers I Disease
and I None
management I None
of I None
these I None
patients I None
are I None
also I None
reviewed I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Review I None
of I None
all I None
cases I None
of I None
corneal I Disease
ulcers O Disease
associated I None
with I None
drug I Disease
abuse O Disease
<eof> I None

<s> O None
seen I None
at I None
our I None
institution I None
from I None
July I None
2006 I None
to I None
December I None
2006 I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Four I None
patients I None
with I None
corneal I Disease
ulcers O Disease
associated I None
with I None
crack I Chemical
cocaine O Chemical
use I None
were I None
reviewed I None
. I None
<eof> I None

<s> O None
All I None
corneal I Disease
ulcers O Disease
were I None
cultured I None
, I None
and I None
the I None
patients I None
were I None
admitted I None
to I None
the I None
hospital I None
for I None
intensive I None
topical I None
antibiotic I None
treatment I None
. I None
<eof> I None

<s> O None
Each I None
patient I None
received I None
comprehensive I None
health I None
care I None
, I None
including I None
medical I None
and I None
substance I Disease
abuse O Disease
consultations I None
. I None
<eof> I None

<s> O None
Streptococcal I None
organisms I None
were I None
found I None
in I None
3 I None
cases I None
and I None
Capnocytophaga I None
and I None
Brevibacterium I None
casei I None
in I None
1 I None
patient I None
. I None
<eof> I None

<s> O None
The I None
infections I Disease
responded I None
to I None
antibiotic I None
treatment I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
needed I None
a I None
lateral I None
tarsorrhaphy I None
for I None
persistent I None
epithelial I Disease
defects O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Aerosolized I None
crack I Chemical
cocaine O Chemical
use I None
can I None
be I None
associated I None
with I None
the I None
development I None
of I None
corneal I Disease
ulcers O Disease
. I None
<eof> I None

<s> O None
Drug I Disease
abuse O Disease
provides I None
additional I None
challenges I None
for I None
management I None
. I None
<eof> I None

<s> O None
Not I None
only I None
treatment I None
of I None
their I None
infections I Disease
but I None
also I None
the I None
overall I None
poor I None
health I None
of I None
the I None
patients I None
and I None
increased I None
risk I None
of I None
noncompliance I None
need I None
to I None
be I None
addressed I None
. I None
<eof> I None

<s> O None
Comprehensive I None
care I None
may I None
provide I None
the I None
patient I None
the I None
opportunity I None
to I None
discontinue I None
their I None
substance I Disease
abuse O Disease
, I None
improve I None
their I None
overall I None
health I None
, I None
and I None
prevent I None
future I None
corneal I None
complications I None
. I None
<eof> I None

<s> O None
Levetiracetam I Chemical
as I None
an I None
adjunct I None
to I None
phenobarbital I Chemical
treatment I None
in I None
cats I None
with I None
suspected I None
idiopathic I Disease
epilepsy O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
assess I None
pharmacokinetics I None
, I None
efficacy I None
, I None
and I None
tolerability I None
of I None
oral I None
levetiracetam I Chemical
administered I None
as I None
an I None
adjunct I None
to I None
phenobarbital I Chemical
treatment I None
in I None
cats I None
with I None
poorly I None
controlled I None
suspected I None
idiopathic I Disease
epilepsy O Disease
. I None
<eof> I None

<s> O None
DESIGN I None
- I None
Open I None
- I None
label I None
, I None
noncomparative I None
clinical I None
trial I None
. I None
<eof> I None

<s> O None
ANIMALS I None
: I None
12 I None
cats I None
suspected I None
to I None
have I None
idiopathic I Disease
epilepsy O Disease
<eof> I None

<s> O None
that I None
was I None
poorly I None
controlled I None
with I None
phenobarbital I Chemical
or I None
that I None
had I None
unacceptable I None
adverse I None
effects I None
when I None
treated I None
with I None
phenobarbital I Chemical
. I None
<eof> I None

<s> O None
PROCEDURES I None
: I None
<eof> I None

<s> O None
Cats I None
were I None
treated I None
with I None
levetiracetam I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
[ I None
9.1 I None
mg I None
/ I None
lb I None
] I None
, I None
<eof> I None

<s> O None
PO I None
, I None
q I None
8 I None
h I None
) I None
. I None
<eof> I None

<s> O None
After I None
a I None
minimum I None
of I None
1 I None
week I None
of I None
treatment I None
, I None
serum I None
levetiracetam I Chemical
<eof> I None

<s> O None
concentrations I None
were I None
measured I None
before I None
and I None
2 I None
, I None
4 I None
, I None
and I None
6 I None
hours I None
after I None
drug I None
administration I None
, I None
and I None
maximum I None
and I None
minimum I None
serum I None
concentrations I None
and I None
elimination I None
half I None
- I None
life I None
were I None
calculated I None
. I None
<eof> I None

<s> O None
Seizure I Disease
frequencies I None
before I None
and I None
after I None
initiation I None
of I None
levetiracetam I Chemical
treatment I None
were I None
compared I None
, I None
and I None
adverse I None
effects I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Median I None
maximum I None
serum I None
levetiracetam I Chemical
<eof> I None

<s> O None
concentration I None
was I None
25.5 I None
microg I None
/ I None
mL I None
, I None
median I None
minimum I None
serum I None
levetiracetam I Chemical
<eof> I None

<s> O None
concentration I None
was I None
8.3 I None
microg I None
/ I None
mL I None
, I None
and I None
median I None
elimination I None
half I None
- I None
life I None
was I None
2.9 I None
hours I None
. I None
<eof> I None

<s> O None
Median I None
seizure I Disease
frequency I None
prior I None
to I None
treatment I None
with I None
levetiracetam I Chemical
( I None
2.1 I None
seizures I Disease
/mo I None
) I None
was I None
significantly I None
higher I None
than I None
median I None
seizure I Disease
frequency I None
after I None
initiation I None
of I None
levetiracetam I Chemical
treatment I None
( I None
0.42 I None
seizures I Disease
/mo I None
) I None
, I None
and I None
7 I None
of I None
10 I None
cats I None
were I None
classified I None
as I None
having I None
responded I None
to I None
levetiracetam I Chemical
treatment I None
( I None
ie I None
, I None
reduction I None
in I None
seizure I Disease
frequency I None
of I None
> I None
or=50 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Two I None
cats I None
had I None
transient I None
<eof> I None

<s> O None
lethargy I Disease
and I None
inappetence I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
AND I None
CLINICAL I None
RELEVANCE I None
: I None
<eof> I None

<s> O None
Results I None
suggested I None
that I None
levetiracetam I Chemical
is I None
well I None
tolerated I None
in I None
cats I None
and I None
may I None
be I None
useful I None
as I None
an I None
adjunct I None
to I None
phenobarbital I Chemical
treatment I None
in I None
cats I None
with I None
idiopathic I Disease
epilepsy O Disease
. I None
<eof> I None

<s> O None
Bilateral I None
haemorrhagic I None
infarction I None
of I None
the I None
globus I None
pallidus I None
after I None
cocaine I Chemical
and I None
alcohol I Chemical
intoxication I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
is I None
a I None
risk I None
factor I None
for I None
both I None
ischemic I None
and I None
haemorrhagic I None
stroke I None
. I None
<eof> I None

<s> O None
We I None
present I None
the I None
case I None
of I None
a I None
31-year I None
- I None
old I None
man I None
with I None
bilateral I None
ischemia I Disease
of O Disease
the O Disease
globus O Disease
pallidus O Disease
after I None
excessive I None
alcohol I Chemical
and I None
intranasal I None
cocaine I Chemical
use I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
related I None
<eof> I None

<s> O None
globus I Disease
pallidus O Disease
infarctions O Disease
are I None
most I None
often I None
associated I None
with I None
heroin I Chemical
. I None
<eof> I None

<s> O None
Bilateral I None
basal I Disease
ganglia O Disease
infarcts O Disease
after I None
the I None
use I None
of I None
cocaine I Chemical
, I None
without I None
concurrent I None
heroin I Chemical
use I None
, I None
have I None
never I None
been I None
reported I None
. I None
<eof> I None

<s> O None
In I None
our I None
patient I None
, I None
transient I None
cardiac I Disease
arrhythmia O Disease
or I None
respiratory I Disease
dysfunction O Disease
related I None
to I None
cocaine I Chemical
and/or I None
ethanol I Chemical
use I None
were I None
the I None
most I None
likely I None
causes I None
of I None
cerebral I Disease
hypoperfusion O Disease
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
after I None
high I None
- I None
dose I None
methotrexate I Chemical
therapy I None
in I None
a I None
patient I None
with I None
ileostomy I None
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
methotrexate I Chemical
<eof> I None

<s> O None
( I None
HD- I None
MTX I Chemical
) I None
is I None
an I None
important I None
treatment I None
for I None
Burkitt I Disease
lymphoma O Disease
, I None
but I None
can I None
cause I None
hepatic I None
and I None
renal I None
toxicity I None
when I None
its I None
clearance I None
is I None
delayed I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
after I None
HD- I None
MTX I Chemical
therapy I None
in I None
a I None
patient I None
with I None
ileostomy I None
, I None
The I None
patient I None
was I None
a I None
3-year I None
- I None
old I None
boy I None
who I None
had I None
received I None
a I None
living I None
- I None
related I None
liver I None
transplantation I None
for I None
congenital I None
biliary I Disease
atresia O Disease
. I None
<eof> I None

<s> O None
At I None
day I None
833 I None
after I None
the I None
transplantation I None
, I None
he I None
was I None
diagnosed I None
with I None
PTLD I Disease
<eof> I None

<s> O None
( I None
post I Disease
- O Disease
transplantation O Disease
lymphoproliferative O Disease
disorder O Disease
, I None
Burkitt I Disease
- O Disease
type O Disease
malignant O Disease
lymphoma O Disease
) I None
. I None
<eof> I None

<s> O None
During I None
induction I None
therapy I None
, I None
he I None
suffered I None
ileal I None
perforation I None
and I None
ileostomy I None
was I None
performed I None
. I None
<eof> I None

<s> O None
Subsequent I None
HD- I None
MTX I Chemical
therapy I None
caused I None
acute I Disease
renal O Disease
failure O Disease
that I None
required I None
continuous I None
hemodialysis I None
. I None
<eof> I None

<s> O None
We I None
supposed I None
that I None
intravascular I None
hypovolemia I Disease
due I None
to I None
substantial I None
drainage I None
from I None
the I None
ileostoma I None
caused I None
acute I Disease
prerenal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
After I None
recovery I None
of I None
his I None
renal I None
function I None
, I None
we I None
could I None
safely I None
treat I None
the I None
patient I None
with I None
HD- I None
MTX I Chemical
therapy I None
by I None
controlling I None
drainage I None
from I None
ileostoma I None
with I None
total I None
parenteral I None
nutrition I None
. I None
<eof> I None

<s> O None
Antithrombotic I None
drug I None
use I None
, I None
cerebral I Disease
microbleeds O Disease
, I None
and I None
intracerebral I Disease
hemorrhage O Disease
: I None
a I None
systematic I None
review I None
of I None
published I None
and I None
unpublished I None
studies I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
AND I None
PURPOSE I None
: I None
<eof> I None

<s> O None
Cerebral I Disease
microbleeds O Disease
<eof> I None

<s> O None
( I None
MB I Disease
) I None
are I None
potential I None
risk I None
factors I None
for I None
intracerebral I Disease
hemorrhage O Disease
<eof> I None

<s> O None
( I None
ICH I Disease
) I None
, I None
but I None
it I None
is I None
unclear I None
if I None
they I None
are I None
a I None
contraindication I None
to I None
using I None
antithrombotic I None
drugs I None
. I None
<eof> I None

<s> O None
Insights I None
could I None
be I None
gained I None
by I None
pooling I None
data I None
on I None
MB I Disease
frequency I None
stratified I None
by I None
antithrombotic I None
use I None
in I None
cohorts I None
with I None
ICH I Disease
and I None
ischemic I Disease
stroke O Disease
<eof> I None

<s> O None
( I None
IS I Disease
) I None
/ I None
<eof> I None

<s> O None
transient I Disease
ischemic O Disease
attack O Disease
<eof> I None

<s> O None
( I None
TIA I Disease
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
performed I None
a I None
systematic I None
review I None
of I None
published I None
and I None
unpublished I None
data I None
from I None
cohorts I None
with I None
stroke I Disease
or I None
TIA I Disease
to I None
compare I None
the I None
presence I None
of I None
MB I Disease
in I None
: I None
( I None
1 I None
) I None
antithrombotic I None
users I None
vs I None
nonantithrombotic I None
users I None
with I None
ICH I Disease
; I None
( I None
2 I None
) I None
antithrombotic I None
users I None
vs I None
nonusers I None
with I None
IS I Disease
/ I None
TIA I Disease
; I None
and I None
( I None
3 I None
) I None
ICH I Disease
vs I None
ischemic I Disease
events I None
stratified I None
by I None
antithrombotic I None
use I None
. I None
<eof> I None

<s> O None
We I None
also I None
analyzed I None
published I None
and I None
unpublished I None
follow I None
- I None
up I None
data I None
to I None
determine I None
the I None
risk I None
of I None
ICH I Disease
in I None
antithrombotic I None
users I None
with I None
MB I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
a I None
pooled I None
analysis I None
of I None
1460 I None
ICH I Disease
and I None
3817 I None
<eof> I None

<s> O None
IS I Disease
/ I None
TIA I Disease
, I None
<eof> I None

<s> O None
MB I Disease
were I None
more I None
frequent I None
in I None
ICH I Disease
vs I None
IS I Disease
/ I None
TIA I Disease
in I None
all I None
treatment I None
groups I None
, I None
but I None
the I None
excess I None
increased I None
from I None
2.8 I None
( I None
odds I None
ratio I None
; I None
range I None
, I None
2.3 I None
- I None
3.5 I None
) I None
in I None
nonantithrombotic I None
users I None
to I None
5.7 I None
( I None
range I None
, I None
3.4 I None
- I None
9.7 I None
) I None
in I None
antiplatelet I None
users I None
and I None
8.0 I None
( I None
range I None
, I None
3.5 I None
- I None
17.8 I None
) I None
in I None
warfarin I Chemical
users I None
( I None
P I None
difference=0.01 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
also I None
an I None
excess I None
of I None
MB I Disease
in I None
warfarin I Chemical
users I None
vs I None
nonusers I None
with I None
ICH I Disease
<eof> I None

<s> O None
( I None
OR I None
, I None
2.7 I None
; I None
95 I None
% I None
CI I None
, I None
1.6 I None
- I None
4.4 I None
; I None
P<0.001 I None
) I None
but I None
none I None
in I None
warfarin I Chemical
users I None
with I None
IS I Disease
/ I None
TIA I Disease
<eof> I None

<s> O None
( I None
OR I None
, I None
1.3 I None
; I None
95 I None
% I None
CI I None
, I None
0.9 I None
- I None
1.7 I None
; I None
P=0.33 I None
; I None
P I None
difference=0.01 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
smaller I None
excess I None
of I None
MB I Disease
in I None
antiplatelet I None
users I None
vs I None
nonusers I None
with I None
ICH I Disease
<eof> I None

<s> O None
( I None
OR I None
, I None
1.7 I None
; I None
95 I None
% I None
CI I None
, I None
1.3 I None
- I None
2.3 I None
; I None
P<0.001 I None
) I None
, I None
but I None
<eof> I None

<s> O None
findings I None
were I None
similar I None
for I None
antiplatelet I None
users I None
with I None
IS I Disease
/ I None
TIA I Disease
<eof> I None

<s> O None
( I None
OR I None
, I None
1.4 I None
; I None
95 I None
% I None
CI I None
, I None
1.2 I None
- I None
1.7 I None
; I None
P<0.001 I None
; I None
P I None
difference=0.25 I None
) I None
. I None
<eof> I None

<s> O None
In I None
pooled I None
follow I None
- I None
up I None
data I None
for I None
768 I None
antithrombotic I None
users I None
, I None
presence I None
of I None
MB I Disease
at I None
baseline I None
was I None
associated I None
with I None
a I None
substantially I None
increased I None
risk I None
of I None
subsequent I None
ICH I Disease
<eof> I None

<s> O None
( I None
OR I None
, I None
12.1 I None
; I None
95 I None
% I None
CI I None
, I None
3.4 I None
- I None
42.5 I None
; I None
P<0.001 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
excess I None
of I None
MB I Disease
in I None
warfarin I Chemical
users I None
with I None
ICH I Disease
compared I None
to I None
other I None
groups I None
suggests I None
that I None
MB I Disease
increase I None
the I None
risk I None
of I None
warfarin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
ICH I Disease
. I None
<eof> I None

<s> O None
Limited I None
prospective I None
data I None
corroborate I None
these I None
findings I None
, I None
but I None
larger I None
prospective I None
studies I None
are I None
urgently I None
required I None
. I None
<eof> I None

<s> O None
Verapamil I Chemical
stimulation I None
test I None
in I None
hyperprolactinemia I Disease
: I None
loss I None
of I None
prolactin I None
response I None
in I None
anatomic I None
or I None
functional I None
stalk I None
effect I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
Verapamil I Chemical
stimulation I None
test I None
was I None
previously I None
investigated I None
as I None
a I None
tool I None
for I None
differential I None
diagnosis I None
of I None
hyperprolactinemia I Disease
, I None
but I None
with I None
conflicting I None
results I None
. I None
<eof> I None

<s> O None
Macroprolactinemia I Disease
was I None
never I None
considered I None
in I None
those I None
previous I None
studies I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
aimed I None
to I None
re I None
- I None
investigate I None
the I None
diagnostic I None
value I None
of I None
verapamil I Chemical
in I None
a I None
population I None
who I None
were I None
all I None
screened I None
for I None
macroprolactinemia I Disease
. I None
<eof> I None

<s> O None
Prolactin I None
responses I None
to I None
verapamil I Chemical
in I None
65 I None
female I None
patients I None
( I None
age I None
: I None
29.9 I None
+ I None
/- I None
<eof> I None

<s> O None
8.1 I None
years I None
) I None
with I None
hyperprolactinemia I Disease
were I None
tested I None
in I None
a I None
descriptive I None
, I None
matched I None
case I None
- I None
control I None
study I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Verapamil I Chemical
<eof> I None

<s> O None
80 I None
mg I None
, I None
p.o I None
. I None
<eof> I None

<s> O None
was I None
administered I None
, I None
and I None
then I None
PRL I None
levels I None
were I None
measured I None
at I None
8th I None
and I None
16th I None
hours I None
, I None
by I None
immunometric I None
chemiluminescence I None
. I None
<eof> I None

<s> O None
Verapamil I Chemical
responsiveness I None
was I None
determined I None
by I None
peak I None
percent I None
change I None
in I None
basal I None
prolactin I None
levels I None
( I None
PRL I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Verapamil I Chemical
significantly I None
increased I None
PRL I None
levels I None
in I None
healthy I None
controls I None
( I None
N. I None
8 I None
, I None
PRL I None
: I None
183 I None
% I None
) I None
, I None
macroprolactinoma I Disease
<eof> I None

<s> O None
( I None
N. I None
8 I None
, I None
PRL I None
: I None
7 I None
% I None
) I None
, I None
microprolactinoma I Disease
<eof> I None

<s> O None
( I None
N. I None
19 I None
, I None
PRL I None
: I None
21 I None
% I None
) I None
, I None
macroprolactinemia I Disease
<eof> I None

<s> O None
( I None
N. I None
23 I None
, I None
PRL I None
: I None
126 I None
% I None
) I None
, I None
but I None
not I None
in I None
pseudoprolactinoma I Disease
<eof> I None

<s> O None
( I None
N. I None
8 I None
, I None
PRL I None
: I None
0.8 I None
% I None
) I None
, I None
and I None
risperidone I Chemical
-induced I None
hyperprolactinemia I Disease
( I None
N. I None
7 I None
, I None
PRL I None
: I None
3 I None
% I None
) I None
. I None
<eof> I None

<s> O None
ROC I None
curve I None
analysis I None
revealed I None
that I None
unresponsiveness I None
to I None
verapamil I Chemical
defined I None
as I None
PRL I None
< I None
7 I None
% I None
, I None
discriminated I None
anatomical I None
or I None
functional I None
stalk I None
effect I None
( I None
sensitivity I None
: I None
74 I None
% I None
, I None
specificity I None
: I None
73 I None
% I None
, I None
AUC I None
: I None
0.855+/-0.04 I None
, I None
P I None
< I None
0.001 I None
, I None
CI I None
: I None
0.768 I None
- I None
0.942 I None
) I None
associated I None
with I None
pseudoprolactinoma I Disease
or I None
risperidone I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
, I None
respectively I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Verapamil I Chemical
responsiveness I None
is I None
not I None
a I None
reliable I None
finding I None
for I None
the I None
differential I None
diagnosis I None
of I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
verapamil I Chemical
unresponsiveness I None
discriminates I None
stalk I None
effect I None
( I None
i.e. I None
, I None
anatomically I None
or I None
functionally I None
inhibited I None
dopaminergic I None
tonus I None
) I None
from I None
other I None
causes I None
of I None
hyperprolactinemia I Disease
with I None
varying I None
degrees I None
of I None
responsiveness I None
. I None
<eof> I None

<s> O None
Central I None
action I None
of I None
narcotic I None
analgesics I None
. I None
<eof> I None

<s> O None
Part I None
IV I None
. I None
<eof> I None

<s> O None
Noradrenergic I None
influences I None
on I None
the I None
activity I None
of I None
analgesics I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
clonidine I Chemical
, I None
naphazoline I Chemical
and I None
xylometazoline I Chemical
on I None
analgesia I None
induced I None
by I None
morphine I Chemical
, I None
codeine I Chemical
, I None
fentanyl I Chemical
and I None
pentazocine I Chemical
, I None
and I None
on I None
cataleptic I Disease
effect I None
of I None
morphine I Chemical
, I None
codine I Chemical
and I None
fentanyl I Chemical
was I None
studied I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
biochemical I None
assays I None
on I None
the I None
influence I None
of I None
four I None
analgesics I None
on I None
the I None
brain I None
concentration I None
and I None
turnover I None
of I None
noradrenaline I Chemical
<eof> I None

<s> O None
( I None
NA I Chemical
) I None
were I None
also I None
performed I None
. I None
<eof> I None

<s> O None
It I None
was I None
found I None
that I None
three I None
drugs I None
stimulating I None
central I None
NA I Chemical
receptors I None
failed I None
to I None
affect I None
the I None
analgesic I None
ED50 I None
of I None
all I None
antinociceptive I None
agents I None
and I None
they I None
enhanced I None
catalepsy I Disease
induced I None
by I None
morphine I Chemical
and I None
fentanyl I Chemical
. I None
<eof> I None

<s> O None
Codeine I Chemical
<eof> I None

<s> O None
catalepsy I Disease
was I None
increased I None
by I None
clonidine I Chemical
and I None
decreased I None
by I None
naphazoline I Chemical
and I None
xylometazoline I Chemical
. I None
<eof> I None

<s> O None
The I None
brain I None
concentration I None
of I None
NA I Chemical
was I None
not I None
changed I None
by I None
morphine I Chemical
and I None
fentanyl I Chemical
, I None
but I None
one I None
of I None
the I None
doses I None
of I None
codeine I Chemical
<eof> I None

<s> O None
( I None
45 I None
mg I None
/ I None
kg I None
) I None
slightly I None
enhanced I None
it I None
. I None
<eof> I None

<s> O None
Pentazocine I Chemical
<eof> I None

<s> O None
dose I None
- I None
dependently I None
decreased I None
the I None
brain I None
level I None
of I None
NA I Chemical
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
NA I Chemical
turnover I None
was I None
not I None
altered I None
by I None
analgesics I None
except I None
for I None
the I None
higher I None
dose I None
of I None
fentanyl I Chemical
<eof> I None

<s> O None
( I None
0.2 I None
mg I None
/ I None
kg I None
) I None
following I None
which I None
the I None
disappearance I None
of I None
NA I Chemical
from I None
the I None
brain I None
was I None
diminished I None
. I None
<eof> I None

<s> O None
The I None
results I None
are I None
discussed I None
in I None
the I None
light I None
of I None
various I None
and I None
non I None
- I None
uniform I None
data I None
from I None
the I None
literature I None
. I None
<eof> I None

<s> O None
It I None
is I None
suggested I None
that I None
in I None
rats I None
the I None
brain I None
<eof> I None

<s> O None
NA I Chemical
plays I None
a I None
less I None
important I None
function I None
than I None
the I None
other I None
monoamines I Chemical
in I None
the I None
behavioural I None
activity I None
of I None
potent I None
analgesics I None
. I None
<eof> I None

<s> O None
Modification I None
by I None
propranolol I Chemical
of I None
cardiovascular I None
effects I None
of I None
induced I None
hypoglycaemia I Disease
. I None
<eof> I None

<s> O None
The I None
cardiovascular I None
effects I None
of I None
hypoglycaemia I Disease
, I None
with I None
and I None
without I None
beta I None
- I None
blockade I None
, I None
were I None
compared I None
in I None
fourteen I None
healthy I None
men I None
. I None
<eof> I None

<s> O None
Eight I None
received I None
insulin I None
alone I None
, I None
and I None
eight I None
, I None
including I None
two I None
of I None
the I None
original I None
insulin I None
- I None
only I None
group I None
, I None
were I None
given I None
propranolol I Chemical
and I None
insulin I None
. I None
<eof> I None

<s> O None
In I None
the I None
insulin I None
- I None
group I None
the I None
period I None
of I None
hypoglycaemia I Disease
was I None
associated I None
with I None
an I None
increase I None
in I None
heart I None
- I None
rate I None
and I None
a I None
fall I None
in I None
diastolic I None
blood I None
- I None
pressure I None
. I None
<eof> I None

<s> O None
In I None
the I None
propranolol I Chemical
-insulin I None
group I None
there I None
was I None
a I None
significant I None
fall I None
in I None
heart I None
- I None
rate I None
in I None
most I None
subjects I None
and I None
an I None
increase I None
in I None
diastolic I None
pressure I None
. I None
<eof> I None

<s> O None
Typical I None
S I None
- I None
T I None
/ I None
T I None
changes I None
occurred I None
in I None
the I None
insulin I None
- I None
group I None
but I None
in I None
none I None
of I None
the I None
propranolol I Chemical
-insulin I None
group I None
. I None
<eof> I None

<s> O None
Hypertension I Disease
in I None
diabetics I Disease
prone I None
to I None
hypoglycaemia I Disease
attacks I None
should I None
not I None
be I None
treated I None
with I None
beta I None
- I None
blockers I None
because I None
these I None
drugs I None
may I None
cause I None
a I None
sharp I None
rise I None
in I None
blood I None
- I None
pressure I None
in I None
such I None
patients I None
. I None
<eof> I None

<s> O None
Prevention I None
and I None
treatment I None
of I None
endometrial I Disease
disease O Disease
in I None
climacteric I None
women I None
receiving I None
oestrogen I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
treatment I None
regimens I None
are I None
described I None
in I None
74 I None
patients I None
with I None
endometrial I Disease
disease O Disease
among I None
850 I None
climacteric I None
women I None
receiving I None
oestrogen I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Cystic I None
hyperplasia I Disease
was I None
associated I None
with I None
unopposed I None
oestrogen I Chemical
therapy I None
without I None
progestagen I Chemical
. I None
<eof> I None

<s> O None
Two I None
courses I None
of I None
21 I None
days I None
of I None
5 I None
mg I None
norethisterone I Chemical
daily I None
caused I None
reversion I None
to I None
normal I None
in I None
all I None
57 I None
cases I None
of I None
cystic I None
hyperplasia I Disease
and I None
6 I None
of I None
the I None
8 I None
cases I None
of I None
atypical I None
hyperplasia I Disease
. I None
<eof> I None

<s> O None
4 I None
cases I None
of I None
endometrial I Disease
carcinoma O Disease
referred I None
from I None
elsewhere I None
demonstrated I None
the I None
problems I None
of I None
inappropriate I None
and I None
unsupervised I None
unopposed I None
<eof> I None

<s> O None
oestrogen I Chemical
therapy I None
and I None
the I None
difficulty I None
in I None
distinguishing I None
severe I None
hyperplasia I Disease
from I None
malignancy I Disease
. I None
<eof> I None

<s> O None
Cyclical I None
low I None
- I None
dose I None
<eof> I None

<s> O None
oestrogen I Chemical
therapy I None
with I None
7 I None
- I None
-13 I None
days I None
of I None
progestagen I Chemical
does I None
not I None
seem I None
to I None
increase I None
the I None
risk I None
of I None
endometrial I Disease
hyperplasia O Disease
or I None
carcinoma I Disease
. I None
<eof> I None

<s> O None
Pure I Disease
red O Disease
cell O Disease
aplasia O Disease
, I None
toxic I Disease
dermatitis O Disease
and I None
lymphadenopathy I Disease
in I None
a I None
patient I None
taking I None
diphenylhydantoin I Chemical
. I None
<eof> I None

<s> O None
A I None
patient I None
taking I None
diphenylhydantoin I Chemical
for I None
3 I None
weeks I None
developed I None
a I None
generalized I None
skin I Disease
rash O Disease
, I None
lymphadenopathy I Disease
and I None
pure I Disease
red O Disease
cell O Disease
aplasia O Disease
. I None
<eof> I None

<s> O None
After I None
withdrawal I None
of I None
the I None
pharmacon I None
all I None
symptoms I None
disappeared I None
spontaneously I None
. I None
<eof> I None

<s> O None
Skin I Disease
rash O Disease
is I None
a I None
well I None
- I None
known I None
complication I None
of I None
diphenylhydantoin I Chemical
treatment I None
as I None
is I None
benign I None
and I None
malignant I None
lymphadenopathy I Disease
. I None
<eof> I None

<s> O None
Pure I Disease
red O Disease
cell O Disease
aplasia O Disease
associated I None
with I None
diphenylhydantoin I Chemical
medication I None
has I None
been I None
reported I None
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
The I None
exact I None
mechanism I None
by I None
which I None
diphenylhydantoin I Chemical
exerts I None
its I None
toxic I None
effects I None
is I None
not I None
known I None
. I None
<eof> I None

<s> O None
In I None
this I None
patient I None
the I None
time I None
relation I None
between I None
the I None
ingestion I None
of I None
diphenylhydantoin I Chemical
and I None
the I None
occurrence I None
of I None
the I None
skin I Disease
rash O Disease
, I None
lymphadenopathy I Disease
and I None
pure I Disease
red O Disease
cell O Disease
aplasia O Disease
is I None
very I None
suggestive I None
of I None
a I None
direct I None
connection I None
. I None
<eof> I None

<s> O None
Continuous I None
infusion I None
<eof> I None

<s> O None
tobramycin I Chemical
combined I None
with I None
carbenicillin I Chemical
for I None
infections I Disease
in I None
cancer I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
cure I None
rate I None
of I None
infections I Disease
in I None
cancer I Disease
<eof> I None

<s> O None
patients I None
is I None
adversely I None
affected I None
by I None
neutropenia I Disease
<eof> I None

<s> O None
( I None
less I None
than I None
1,000/mm3 I None
) I None
. I None
<eof> I None

<s> O None
In I None
particular I None
, I None
patients I None
with I None
severe I None
neutropenia I Disease
<eof> I None

<s> O None
( I None
less I None
than I None
100/mm3 I None
) I None
have I None
shown I None
a I None
poor I None
response I None
to I None
antibiotics I None
. I None
<eof> I None

<s> O None
To I None
overcome I None
the I None
adverse I None
effects I None
of I None
neutropenia I Disease
, I None
tobramycin I Chemical
was I None
given I None
by I None
continuous I None
infusion I None
and I None
combined I None
with I None
intermittent I None
carbenicillin I Chemical
. I None
<eof> I None

<s> O None
Tobramycin I Chemical
was I None
given I None
to I None
a I None
total I None
daily I None
dose I None
of I None
300 I None
mg I None
/ I None
m2 I None
and I None
carbenicillin I Chemical
was I None
given I None
at I None
a I None
dose I None
of I None
5 I None
gm I None
every I None
four I None
hours I None
. I None
<eof> I None

<s> O None
There I None
were I None
125 I None
infectious I None
episodes I None
in I None
116 I None
cancer I Disease
patients I None
receiving I None
myelosuppressive I None
chemotherapy I None
. I None
<eof> I None

<s> O None
The I None
overall I None
cure I None
rate I None
was I None
70 I None
% I None
. I None
<eof> I None

<s> O None
Pneumonia I Disease
was I None
the I None
most I None
common I None
infection I Disease
and I None
61 I None
% I None
of I None
59 I None
episodes I None
were I None
cured I None
. I None
<eof> I None

<s> O None
Gram I None
- I None
negative I None
bacilli I None
were I None
the I None
most I None
common I None
causative I None
organisms I None
and I None
69 I None
% I None
of I None
these I None
infections I Disease
were I None
cured I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
pathogen I None
was I None
Klebsiella I None
pneumoniae I Disease
and I None
this I None
, I None
together I None
with I None
Escherichia I None
coli I None
and I None
Pseudomonas I None
aeruginosa I None
, I None
accounted I None
for I None
74 I None
% I None
of I None
all I None
gram I Disease
- O Disease
negative O Disease
bacillary O Disease
infections O Disease
. I None
<eof> I None

<s> O None
Response I None
was I None
not I None
influenced I None
by I None
the I None
initial I None
neutrophil I None
count I None
, I None
with I None
a I None
62 I None
% I None
cure I None
rate I None
for I None
39 I None
episodes I None
associated I None
with I None
severe I None
neutropenia I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
failure I None
of I None
the I None
neutrophil I None
count I None
to I None
increase I None
during I None
therapy I None
adversely I None
affected I None
response I None
. I None
<eof> I None

<s> O None
Azotemia I Disease
was I None
the I None
major I None
side I None
effect I None
recognized I None
, I None
and I None
it I None
occurred I None
in I None
11 I None
% I None
of I None
episodes I None
. I None
<eof> I None

<s> O None
Major I None
azotemia I Disease
<eof> I None

<s> O None
( I None
serum I None
<eof> I None

<s> O None
creatinine I Chemical
greater I None
than I None
2.5 I None
mg I None
/ I None
dl I None
or I None
BUN I None
greater I None
than I None
50 I None
mg I None
/ I None
dl I None
) I None
occurred I None
in I None
only I None
2 I None
% I None
. I None
<eof> I None

<s> O None
Azotemia I Disease
was I None
not I None
related I None
to I None
duration I None
of I None
therapy I None
or I None
serum I None
tobramycin I Chemical
concentration I None
. I None
<eof> I None

<s> O None
This I None
antibiotic I None
regimen I None
showed I None
both I None
therapeutic I None
efficacy I None
and I None
acceptable I None
renal I Disease
toxicity O Disease
for I None
these I None
patients I None
. I None
<eof> I None

<s> O None
Recurrent I None
subarachnoid I Disease
hemorrhage O Disease
associated I None
with I None
aminocaproic I Chemical
acid O Chemical
therapy I None
and I None
acute I Disease
renal O Disease
artery O Disease
thrombosis O Disease
. I None
<eof> I None

<s> O None
Case I None
report I None
. I None
<eof> I None

<s> O None
Epsilon I Chemical
aminocaproic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
EACA I Chemical
) I None
has I None
been I None
used I None
to I None
prevent I None
rebleeding I None
in I None
patients I None
with I None
subarachnoid I Disease
hemorrhage O Disease
<eof> I None

<s> O None
( I None
SAH I Disease
) I None
. I None
<eof> I None

<s> O None
Although I None
this I None
agent I None
does I None
decrease I None
the I None
frequency I None
of I None
rebleeding I None
, I None
several I None
reports I None
have I None
described I None
thrombotic I Disease
complications I None
of I None
EACA I Chemical
therapy I None
. I None
<eof> I None

<s> O None
These I None
complications I None
have I None
included I None
clinical I None
deterioration I None
and I None
intracranial I Disease
vascular O Disease
thrombosis O Disease
in I None
patients I None
with I None
SAH I Disease
, I None
arteriolar I None
and I None
capillary I None
fibrin I None
thrombi I Disease
in I None
patients I None
with I None
fibrinolytic I None
syndromes I None
treated I None
with I None
EACA I Chemical
, I None
or I None
other I None
thromboembolic I Disease
phenomena O Disease
. I None
<eof> I None

<s> O None
Since I None
intravascular I None
fibrin I None
thrombi I Disease
are I None
often I None
observed I None
in I None
patients I None
with I None
fibrinolytic I None
disorders I None
, I None
EACA I Chemical
should I None
not I None
be I None
implicated I None
in I None
the I None
pathogenesis I None
of I None
fibrin I None
thrombi I Disease
in I None
patients I None
with I None
disseminated I Disease
intravascular O Disease
coagulation O Disease
or I None
other I None
" I None
consumption I Disease
coagulopathies O Disease
. I None
<eof> I None

<s> O None
" I None
<eof> I None

<s> O None
This I None
report I None
describes I None
subtotal I None
infarction I Disease
of I None
the I None
kidney I None
due I None
to I None
thrombosis I Disease
of O Disease
a O Disease
normal O Disease
renal O Disease
artery O Disease
. I None
<eof> I None

<s> O None
This I None
occlusion I None
occurred I None
after I None
EACA I Chemical
therapy I None
in I None
a I None
patient I None
with I None
SAH I Disease
and I None
histopathological I None
documentation I None
of I None
recurrent I None
SAH I Disease
. I None
<eof> I None

<s> O None
The I None
corresponding I None
clinical I None
event I None
was I None
characterized I None
by I None
marked I None
hypertension I Disease
and I None
abrupt I None
neurological I None
deterioration I None
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
propranolol I Chemical
therapy I None
in I None
pregnancy I None
: I None
maternal I None
and I None
fetal I None
outcome I None
. I None
<eof> I None

<s> O None
Propranolol I Chemical
, I None
a I None
beta I None
- I None
adrenergic I None
blocking I None
agent I None
, I None
has I None
found I None
an I None
important I None
position I None
in I None
the I None
practice I None
of I None
medicine I None
. I None
<eof> I None

<s> O None
Its I None
use I None
in I None
pregnancy I None
, I None
however I None
, I None
is I None
an I None
open I None
question I None
as I None
a I None
number I None
of I None
detrimental I None
side I None
effects I None
have I None
been I None
reported I None
in I None
the I None
fetus I None
and I None
neonate I None
. I None
<eof> I None

<s> O None
Ten I None
patients I None
and I None
12 I None
pregnancies I None
are I None
reported I None
where I None
chronic I None
propranolol I Chemical
has I None
been I None
administered I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
with I None
serial I None
pregnancies I None
with I None
and I None
without I None
<eof> I None

<s> O None
propranolol I Chemical
therapy I None
are I None
also I None
examined I None
. I None
<eof> I None

<s> O None
Maternal I None
, I None
fetal I None
, I None
and I None
neonatal I None
complications I None
are I None
examined I None
. I None
<eof> I None

<s> O None
An I None
attempt I None
is I None
made I None
to I None
differentiate I None
drug I None
- I None
related I None
complications I None
from I None
maternal I None
disease I None
-- I None
related I None
complications I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
previously I None
reported I None
hypoglycemia I Disease
, I None
hyperbilirubinemia I Disease
, I None
polycythemia I Disease
, I None
neonatal I Disease
apnea O Disease
, I None
and I None
bradycardia I Disease
are I None
not I None
invariable I None
and I None
can I None
not I None
be I None
statistically I None
correlated I None
with I None
chronic I None
propranolol I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Growth I Disease
retardation O Disease
, I None
however I None
, I None
appears I None
to I None
be I None
significant I None
in I None
both I None
of I None
our I None
series I None
. I None
<eof> I None

<s> O None
Use I None
of I None
propranolol I Chemical
in I None
the I None
treatment I None
of I None
idiopathic I Disease
orthostatic O Disease
hypotension O Disease
. I None
<eof> I None

<s> O None
Five I None
patients I None
with I None
idiopathic I Disease
orthostatic O Disease
hypotension O Disease
who I None
had I None
physiologic I None
and I None
biochemical I None
evidence I None
of I None
severe I None
autonomic I None
dysfunction I None
were I None
included I None
in I None
the I None
study I None
. I None
<eof> I None

<s> O None
They I None
all I None
exhibited I None
markedly I None
reduced I None
plasma I None
catecholamines I Chemical
and I None
plasma I None
renin I None
activity I None
in I None
both I None
recumbent I None
and I None
upright I None
positions I None
and I None
had I None
marked I None
hypersensitivity I Disease
to I None
the I None
pressor I None
effects I None
of I None
infused I None
norepinephrine I Chemical
. I None
<eof> I None

<s> O None
Treatment I None
with I None
propanolol I Chemical
<eof> I None

<s> O None
administered I None
intravenously I None
( I None
1 I None
- I None
5 I None
mg I None
) I None
produced I None
increases I None
in I None
supine I None
and I None
upright I None
blood I None
pressure I None
in I None
4 I None
of I None
the I None
5 I None
individuals I None
with I None
rises I None
ranging I None
from I None
11/6 I None
to I None
22/11 I None
mmHg I None
. I None
<eof> I None

<s> O None
Chronic I None
oral I None
administration I None
of I None
propranolol I Chemical
<eof> I None

<s> O None
( I None
40 I None
- I None
160 I None
mg I None
/ I None
day I None
) I None
also I None
elevated I None
the I None
blood I None
pressures I None
of I None
these I None
individuals I None
with I None
increases I None
in I None
the I None
order I None
of I None
20 I None
- I None
35/15 I None
- I None
25 I None
mmg I None
being I None
observed I None
. I None
<eof> I None

<s> O None
In I None
1 I None
patient I None
, I None
marked I None
hypertension I Disease
was I None
induced I None
by I None
propranolol I Chemical
and I None
the I None
drug I None
had I None
to I None
be I None
withdrawn I None
. I None
<eof> I None

<s> O None
It I None
otherwise I None
was I None
well I None
tolerated I None
and I None
no I None
important I None
side I None
effects I None
were I None
observed I None
. I None
<eof> I None

<s> O None
Treatment I None
has I None
been I None
continued I None
in I None
3 I None
individuals I None
for I None
6 I None
- I None
13 I None
months I None
with I None
persistence I None
of I None
the I None
pressor I None
effect I None
, I None
although I None
there I None
appears I None
to I None
have I None
been I None
some I None
decrease I None
in I None
the I None
degree I None
of I None
response I None
with I None
time I None
. I None
<eof> I None

<s> O None
Hemodynamic I None
measurements I None
in I None
1 I None
of I None
the I None
patients I None
demonstrated I None
an I None
increase I None
in I None
total I None
peripheral I None
resistance I None
and I None
essentially I None
no I None
change I None
in I None
cardiac I None
output I None
following I None
propranolol I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
studies I None
suggest I None
that I None
propranolol I Chemical
is I None
a I None
useful I None
drug I None
in I None
selected I None
patients I None
with I None
severe I None
idiopathic I Disease
orthostatic O Disease
hypotension O Disease
. I None
<eof> I None

<s> O None
Total I None
intravenous I None
anesthesia I None
with I None
etomidate I Chemical
. I None
<eof> I None

<s> O None
III I None
. I None
<eof> I None

<s> O None
Some I None
observations I None
in I None
adults I None
. I None
<eof> I None

<s> O None
An I None
investigation I None
was I None
undertaken I None
to I None
determine I None
the I None
dosage I None
of I None
etomidate I Chemical
required I None
to I None
maintain I None
sleep I None
in I None
adults I None
undergoing I None
surgery I None
under I None
regional I None
local I None
anesthesia I None
. I None
<eof> I None

<s> O None
Premedication I None
of I None
<eof> I None

<s> O None
diazepam I Chemical
10 I None
mg I None
and I None
atropine I Chemical
0.5 I None
mg I None
was I None
given I None
, I None
and I None
sleep I None
was I None
induced I None
and I None
maintained I None
by I None
intermittent I None
intravenous I None
injections I None
of I None
etomidate I Chemical
<eof> I None

<s> O None
0.1/mg I None
/ I None
kg I None
, I None
given I None
whenever I None
the I None
patient I None
would I None
open I None
his I None
eyes I None
on I None
request I None
. I None
<eof> I None

<s> O None
A I None
mean I None
overall I None
dose I None
of I None
<eof> I None

<s> O None
etomidate I Chemical
17.4 I None
microgram I None
/ I None
kg I None
/ I None
min I None
. I None
was I None
required I None
to I None
maintain I None
sleep I None
, I None
but I None
great I None
individual I None
variation I None
occurred I None
, I None
with I None
older I None
patients I None
requiring I None
less I None
drug I None
. I None
<eof> I None

<s> O None
The I None
investigation I None
was I None
discontinued I None
after I None
18 I None
patients I None
because I None
of I None
the I None
frequency I None
and I None
intensity I None
of I None
side I None
- I None
effects I None
, I None
particularly I None
pain I Disease
and I None
myoclonia I Disease
, I None
which I None
caused I None
the I None
technique I None
to I None
be I None
abandoned I None
in I None
two I None
cases I None
. I None
<eof> I None

<s> O None
It I None
is I None
considered I None
unlikely I None
that I None
etomidate I Chemical
will I None
prove I None
to I None
be I None
the I None
hypnotic I None
of I None
choice I None
for I None
a I None
totally I None
intravenous I None
anesthetic I None
technique I None
in I None
adults I None
because I None
of I None
the I None
high I None
incidence I None
of I None
myoclonia I Disease
after I None
prolonged I None
administration I None
. I None
<eof> I None

<s> O None
In I None
several I None
patients I None
uncontrollable I None
muscle I None
movements I None
persisted I None
for I None
many I None
minutes I None
after I None
complete I None
recovery I None
of I None
consciousness I None
. I None
<eof> I None

<s> O None
A I None
method I None
for I None
the I None
measurement I None
of I None
tremor I Disease
, I None
and I None
a I None
comparison I None
of I None
the I None
effects I None
of I None
tocolytic I None
beta I None
- I None
mimetics I None
. I None
<eof> I None

<s> O None
A I None
method I None
permitting I None
measurement I None
of I None
finger I None
tremor I Disease
as I None
a I None
displacement I None
- I None
time I None
curve I None
is I None
described I None
, I None
using I None
a I None
test I None
system I None
with I None
simple I None
amplitude I None
calibration I None
. I None
<eof> I None

<s> O None
The I None
coordinates I None
of I None
the I None
inversion I None
points I None
of I None
the I None
displacement I None
- I None
time I None
curves I None
were I None
transferred I None
through I None
graphical I None
input I None
equipment I None
to I None
punched I None
tape I None
. I None
<eof> I None

<s> O None
By I None
means I None
of I None
a I None
computer I None
program I None
, I None
periods I None
and I None
amplitudes I None
of I None
tremor I Disease
oscillations I None
were I None
calculated I None
and I None
classified I None
. I None
<eof> I None

<s> O None
The I None
event I None
frequency I None
for I None
each I None
class I None
of I None
periods I None
and I None
amplitudes I None
was I None
determined I None
. I None
<eof> I None

<s> O None
The I None
actions I None
of I None
fenoterol I Chemical
- O Chemical
hydrobromide O Chemical
, I None
ritodrin I Chemical
- O Chemical
HCl O Chemical
and I None
placebo I None
given I None
to I None
10 I None
healthy I None
subjects I None
by I None
intravenous I None
infusion I None
in I None
a I None
double I None
- I None
blind I None
crossover I None
study I None
were I None
tested I None
by I None
this I None
method I None
. I None
<eof> I None

<s> O None
At I None
therapeutic I None
doses I None
both I None
substances I None
raised I None
the I None
mean I None
tremor I Disease
amplitude I None
to I None
about I None
three I None
times I None
the I None
control I None
level I None
. I None
<eof> I None

<s> O None
At I None
the I None
same I None
time I None
, I None
the I None
mean I None
period I None
within I None
each I None
class I None
of I None
amplitudes I None
shortened I None
by I None
10 I None
- I None
-20 I None
ms I None
, I None
whereas I None
the I None
mean I None
periods I None
calculated I None
from I None
all I None
oscillations I None
together I None
did I None
not I None
change I None
significantly I None
. I None
<eof> I None

<s> O None
After I None
the I None
end I None
of I None
fenoterol I Chemical
- O Chemical
hydrobromide O Chemical
infusion I None
, I None
tremor I Disease
amplitudes I None
decreased I None
significantly I None
faster I None
than I None
those I None
following I None
ritodrin I Chemical
- O Chemical
HCl O Chemical
infusion I None
. I None
<eof> I None

<s> O None
Bilateral I None
retinal I Disease
artery O Disease
and O Disease
choriocapillaris O Disease
occlusion O Disease
following I None
the I None
injection I None
of I None
long I None
- I None
acting I None
corticosteroid I Chemical
suspensions I None
in I None
combination I None
with I None
other I None
drugs I None
: I None
I. I None
Clinical I None
studies I None
. I None
<eof> I None

<s> O None
Two I None
well I None
- I None
documented I None
cases I None
of I None
bilateral I None
retinal I Disease
artery O Disease
and O Disease
choriocapillaris O Disease
occlusions O Disease
with I None
blindness I Disease
following I None
head I None
and I None
neck I None
soft I None
- I None
tissue I None
injection I None
with I None
methylprednisolone I Chemical
acetate O Chemical
in I None
combination I None
with I None
lidocaine I Chemical
, I None
epinephrine I Chemical
, I None
or I None
penicillin I Chemical
are I None
reported I None
. I None
<eof> I None

<s> O None
One I None
case I None
had I None
only I None
a I None
unilateral I None
injection I None
. I None
<eof> I None

<s> O None
The I None
acute I None
observations I None
included I None
hazy I None
sensorium I None
, I None
superior I None
gaze I None
palsy I Disease
, I None
pupillary I Disease
abnormalities O Disease
, I None
and I None
conjunctival I None
hemorrhages I Disease
with I None
edema I Disease
. I None
<eof> I None

<s> O None
Follow I None
- I None
up I None
changes I None
showed I None
marked I None
visual I Disease
loss O Disease
, I None
constricted I None
visual I None
fields I None
, I None
optic I None
nerve I None
pallor I None
, I None
vascular I None
attenuation I None
, I None
and I None
chorioretinal I Disease
atrophy O Disease
. I None
<eof> I None

<s> O None
The I None
literature I None
is I None
reviewed I None
, I None
and I None
possible I None
causes I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Cephalothin I Chemical
-induced I None
immune I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
A I None
patient I None
with I None
renal I Disease
disease O Disease
developed I None
Coombs I None
- I None
positive I None
hemolytic I Disease
anemia O Disease
while I None
receiving I None
cephalothin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
An I None
anti- I None
cephalothin I Chemical
IgG I None
antibody I None
was I None
detected I None
in I None
the I None
patient I None
's I None
serum I None
and I None
in I None
the I None
eluates I None
from I None
her I None
erythrocytes I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
nonimmunologic I None
binding I None
of I None
normal I None
and I None
patient I None
's I None
serum I None
proteins I None
to I None
her I None
own I None
and I None
cephalothin I Chemical
-coated I None
normal I None
red I None
cells I None
was I None
demonstrated I None
. I None
<eof> I None

<s> O None
Skin I None
tests I None
and I None
in I None
vitro I None
lymphocyte I None
stimulation I None
revealed I None
that I None
the I None
patient I None
was I None
sensitized I None
to I None
cephalothin I Chemical
and I None
also I None
to I None
ampicillin I Chemical
. I None
<eof> I None

<s> O None
Careful I None
investigation I None
of I None
drug I None
- I None
induced I None
hemolytic I Disease
anemias O Disease
reveals I None
the I None
complexity I None
of I None
the I None
immune I None
mechanisms I None
involved I None
. I None
<eof> I None

<s> O None
Kaliuretic I None
effect I None
of I None
L I Chemical
- O Chemical
dopa O Chemical
treatment I None
in I None
parkinsonian I Disease
patients I None
. I None
<eof> I None

<s> O None
Hypokalemia I Disease
, I None
sometimes I None
severe I None
, I None
was I None
observed I None
in I None
some I None
L I Chemical
- O Chemical
dopa O Chemical
-treated I None
<eof> I None

<s> O None
parkinsonian I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
influence I None
of I None
L I Chemical
- O Chemical
dopa O Chemical
on I None
the I None
renal I None
excretion I None
of I None
potassium I Chemical
was I None
studied I None
in I None
3 I None
patients I None
with I None
hypokalemia I Disease
and I None
in I None
5 I None
normokalemic I None
patients I None
by I None
determination I None
of I None
renal I None
plasma I None
flow I None
, I None
glomerular I None
filtration I None
rate I None
, I None
plasma I None
concentration I None
of I None
potassium I Chemical
and I None
sodium I Chemical
as I None
well I None
as I None
urinary I None
excretion I None
of I None
potassium I Chemical
, I None
sodium I Chemical
and I None
aldosterone I Chemical
. I None
<eof> I None

<s> O None
L I Chemical
- O Chemical
Dopa O Chemical
intake I None
was I None
found I None
to I None
cause I None
an I None
increased I None
excretion I None
of I None
potassium I Chemical
, I None
and I None
sometimes I None
also I None
of I None
sodium I Chemical
, I None
in I None
the I None
hypokalemic I None
but I None
not I None
in I None
the I None
normokalemic I None
patients I None
. I None
<eof> I None

<s> O None
This I None
effect I None
on I None
the I None
renal I None
function I None
could I None
be I None
prohibited I None
by I None
the I None
administration I None
of I None
a I None
peripheral I None
dopa I None
decarbodylase I None
inhibitor I None
. I None
<eof> I None

<s> O None
It I None
is I None
not I None
known I None
why I None
this I None
effect I None
occurred I None
in I None
some I None
individuals I None
but I None
not I None
in I None
others I None
, I None
but I None
our I None
results I None
indicate I None
a I None
correlation I None
between I None
aldosterone I Chemical
production I None
and I None
this I None
renal I None
effect I None
of I None
L I Chemical
- O Chemical
dopa O Chemical
. I None
<eof> I None

<s> O None
Phenytoin I Chemical
<eof> I None

<s> O None
encephalopathy I Disease
as I None
probable I None
idiosyncratic I None
reaction I None
: I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
phenytoin I Chemical
<eof> I None

<s> O None
( I None
DPH I Chemical
) I None
encephalopathy I Disease
with I None
increasing I None
seizures I Disease
and I None
EEG I None
and I None
mental I None
changes I None
is I None
described I None
. I None
<eof> I None

<s> O None
Despite I None
adequate I None
oral I None
dosage I None
of I None
DPH I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
/ I None
daily I None
) I None
<eof> I None

<s> O None
the I None
plasma I None
level I None
was I None
very I None
low I None
( I None
2.8 I None
microgramg I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
The I None
encephalopathy I Disease
was I None
probably I None
an I None
idiosyncratic I None
and I None
not I None
toxic I None
or I None
allergic I None
reaction I None
. I None
<eof> I None

<s> O None
In I None
fact I None
the I None
concentration I None
of I None
free I None
DPH I Chemical
was I None
normal I None
, I None
the I None
patient I None
presented I None
a I None
retarded I None
morbilliform I None
rash I Disease
during I None
DPH I Chemical
treatment I None
, I None
the I None
protidogram I None
was I None
normal I None
, I None
and I None
an I None
intradermic I None
DPH I Chemical
injection I None
had I None
no I None
local I None
effect I None
. I None
<eof> I None

<s> O None
The I None
authors I None
conclude I None
that I None
in I None
a I None
patient I None
starting I None
DPH I Chemical
treatment I None
an I None
unexpected I None
increase I None
in I None
seizures I Disease
, I None
with I None
EEG I None
and I None
mental I None
changes I None
occurring I None
simultaneously I None
, I None
should I None
alert I None
the I None
physician I None
to I None
the I None
possible I None
need I None
for I None
eliminating I None
DPH I Chemical
from I None
the I None
therapeutic I None
regimen I None
, I None
even I None
if I None
plasma I None
concentrations I None
are I None
low I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
exercise I None
on I None
the I None
severity I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
exercise I None
on I None
the I None
severity I None
of I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
was I None
studied I None
in I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Ninety I None
- I None
three I None
rats I None
were I None
randomly I None
divided I None
into I None
three I None
groups I None
. I None
<eof> I None

<s> O None
The I None
exercise- I None
<eof> I None

<s> O None
isoproterenol I Chemical
( I None
E-1 I None
) I None
and I None
exercise I None
control I None
( I None
EC I None
) I None
groups I None
exercised I None
daily I None
for I None
thirty I None
days I None
on I None
a I None
treadmill I None
at I None
1 I None
mph I None
, I None
2 I None
% I None
grade I None
while I None
animals I None
of I None
the I None
sedentary- I None
isoproterenol I Chemical
( I None
S I None
- I None
I I None
) I None
group I None
remained I None
sedentary I None
. I None
<eof> I None

<s> O None
Eight I None
animals I None
were I None
assigned I None
to I None
the I None
sedentary I None
control I None
( I None
SC I None
) I None
group I None
which I None
remained I None
sedentary I None
throughout I None
the I None
experimental I None
period I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
eight I None
hours I None
after I None
the I None
final I None
exercise I None
period I None
, I None
S I None
- I None
I I None
and I None
E I None
- I None
I I None
animals I None
received I None
a I None
single I None
subcutaneous I None
injection I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
250 I None
mg I None
/ I None
kg I None
body I None
weight I None
) I None
. I None
<eof> I None

<s> O None
Animals I None
of I None
the I None
S I None
- I None
I I None
group I None
exhibited I None
significantly I None
( I None
Pp I None
less I None
than I None
0.05 I None
) I None
greater I None
mortality I None
from I None
the I None
effects I None
of I None
isoproterenol I Chemical
than I None
animals I None
of I None
the I None
E I None
- I None
I I None
group I None
. I None
<eof> I None

<s> O None
Serum I None
CPK I None
activity I None
for I None
E I None
- I None
I I None
animals I None
was I None
significantly I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
greater I None
than I None
for I None
animals I None
in I None
the I None
S I None
- I None
I I None
and I None
EC I None
groups I None
twenty I None
hours I None
following I None
isoproterenol I Chemical
injection I None
. I None
<eof> I None

<s> O None
No I None
statistically I None
significant I None
differences I None
were I None
observed I None
between I None
the I None
two I None
isoproterenol I Chemical
treated I None
groups I None
for I None
severity I None
of I None
the I None
induced I None
lesions I None
, I None
changes I None
in I None
heart I None
weight I None
, I None
or I None
heart I None
weight I None
to I None
body I None
weight I None
ratios I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicated I None
that I None
exercise I None
reduced I None
the I None
mortality I None
associated I None
with I None
the I None
effects I None
of I None
large I None
dosages I None
of I None
isoproterenol I Chemical
but I None
had I None
little I None
on I None
the I None
severity I None
of I None
the I None
infarction I Disease
. I None
<eof> I None

<s> O None
Effect I None
of I None
D I Chemical
- O Chemical
Glucarates O Chemical
on I None
basic I None
antibiotic I None
- I None
induced I None
renal I Disease
damage O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Dehydrated I Disease
rats I None
regularly I None
develop I None
<eof> I None

<s> O None
acute I Disease
renal O Disease
failure O Disease
following I None
single I None
injection I None
of I None
aminoglycoside I Chemical
antibiotics I None
combined I None
with I None
dextran I None
or I None
of I None
antibiotics I None
only I None
. I None
<eof> I None

<s> O None
Oral I None
administration I None
of I None
2,5-di I Chemical
- O Chemical
O O Chemical
- O Chemical
acetyl O Chemical
- O Chemical
D O Chemical
- O Chemical
glucaro-1,4 O Chemical
- O Chemical
6,3-dilactone O Chemical
protected I None
rats I None
against I None
renal I Disease
failure O Disease
induced I None
by I None
<eof> I None

<s> O None
kanamycin I Chemical
-dextran I None
. I None
<eof> I None

<s> O None
The I None
protective I None
effect I None
was I None
prevalent I None
among I None
D I Chemical
- O Chemical
glucarates O Chemical
, I None
and I None
also I None
to I None
other I None
saccharic I Chemical
acid O Chemical
, I None
hexauronic I Chemical
acids O Chemical
and I None
hexaaldonic I Chemical
acids O Chemical
, I None
although I None
to I None
a I None
lesser I None
degree I None
, I None
but I None
not I None
to I None
a I None
hexaaldose I None
, I None
sugar I Chemical
alcohols O Chemical
, I None
substances I None
inthe I None
TCA I Chemical
cycle I None
and I None
other I None
acidic I None
compounds I None
. I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
Glucarates O Chemical
were I None
effective I None
against I None
renal I Disease
damage O Disease
induced I None
by I None
peptide I None
antibiotics I None
as I None
well I None
as I None
various I None
aminoglycoside I Chemical
antibitocis I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
responses I None
were I None
observed I None
in I None
the I None
protective I None
effect I None
of I None
D I Chemical
- O Chemical
Glucarates O Chemical
. I None
<eof> I None

<s> O None
With I None
a I None
D I Chemical
- O Chemical
glucarate O Chemical
of I None
a I None
fixed I None
size I None
of I None
dose I None
, I None
approximately I None
the I None
same I None
degree I None
of I None
protection I None
was I None
obtained I None
against I None
renal I Disease
damages O Disease
induced I None
by I None
different I None
basic I None
antibiotics I None
despite I None
large I None
disparities I None
in I None
administration I None
doses I None
of I None
different I None
antibiotics I None
. I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
Glucarates O Chemical
had I None
the I None
ability I None
to I None
prevent I None
renal I Disease
damage O Disease
but I None
not I None
to I None
cure I None
it I None
. I None
<eof> I None

<s> O None
Rats I None
excreted I None
acidic I None
urine I None
when I None
they I None
were I None
spared I None
from I None
renal I Disease
lesions O Disease
by I None
monosaccharides I Chemical
. I None
<eof> I None

<s> O None
The I None
reduction I None
effect I None
of I None
D I Chemical
- O Chemical
glucarates O Chemical
against I None
nephrotoxicity I Disease
of I None
basic I None
antibiotics I None
was I None
discussed I None
. I None
<eof> I None

<s> O None
Paraplegia I Disease
following I None
intrathecal I None
methotrexate I Chemical
: I None
report I None
of I None
a I None
case I None
and I None
review I None
of I None
the I None
literature I None
. I None
<eof> I None

<s> O None
A I None
patient I None
who I None
developed I None
paraplegia I Disease
following I None
the I None
intrathecal I None
instillation I None
of I None
methotrexate I Chemical
is I None
discribed I None
. I None
<eof> I None

<s> O None
The I None
ten I None
previously I None
reported I None
cases I None
of I None
this I None
unusual I None
complication I None
are I None
reviewed I None
. I None
<eof> I None

<s> O None
The I None
following I None
factors I None
appear I None
to I None
predispose I None
to I None
the I None
development I None
of I None
this I None
complication I None
: I None
abnormal I None
cerebrospinal I None
dynamics I None
related I None
to I None
the I None
presence I None
of I None
central I Disease
nervous O Disease
system O Disease
leukemia O Disease
, I None
and I None
epidural I None
cerebrospinal I None
leakage I None
; I None
elevated I None
cerebrospinal I None
fluid I None
methothexate I Chemical
concentration I None
related I None
to I None
abnormal I None
cerebrospinal I None
fluid I None
dynamics I None
and I None
to I None
inappropriately I None
high I None
methotrexate I Chemical
doses I None
based I None
on I None
body I None
surface I None
area I None
calculations I None
in I None
older I None
children I None
and I None
adults I None
; I None
the I None
presence I None
of I None
neurotoxic I Disease
preservatives I None
in I None
commercially I None
available I None
methotrexate I Chemical
preparations I None
and I None
diluents I None
; I None
and I None
the I None
use I None
of I None
methotrexate I Chemical
diluents I None
of I None
unphysiologic I None
pH I None
, I None
ionic I None
content I None
and I None
osmolarity I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
methotrexate I Chemical
contaminants I None
, I None
local I None
folate I Disease
deficiency O Disease
, I None
and I None
cranial I None
irradiation I None
in I None
the I None
pathogenesis I None
of I None
intrathecal I None
methotrexate I Chemical
<eof> I None

<s> O None
toxicity I Disease
is I None
unclear I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
neurotoxicity I Disease
may I None
be I None
reduced I None
by I None
employing I None
lower I None
doses I None
of I None
methotrexate I Chemical
in I None
the I None
presence I None
of I None
central I Disease
nervous O Disease
system O Disease
leukemia O Disease
, I None
in I None
older I None
children I None
and I None
adults I None
, I None
and I None
in I None
the I None
presence I None
of I None
epidural I None
leakage I None
. I None
<eof> I None

<s> O None
Only I None
preservative I None
- I None
free I None
methotrexate I Chemical
in I None
Elliott I None
's I None
B I None
Solution I None
at I None
a I None
concentration I None
of I None
not I None
more I None
than I None
1 I None
mg I None
/ I None
ml I None
should I None
be I None
used I None
for I None
intrathecal I None
administration I None
. I None
<eof> I None

<s> O None
Periodic I None
monitoring I None
of I None
cerebruspinal I None
fluid I None
methotrexate I Chemical
levels I None
may I None
be I None
predictive I None
of I None
the I None
development I None
of I None
serious I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
Centrally I None
mediated I None
cardiovascular I None
effects I None
of I None
intracisternal I None
application I None
of I None
carbachol I Chemical
in I None
anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
The I None
pressor I None
response I None
to I None
the I None
intracisternal I None
( I None
i.c I None
. I None
) I None
<eof> I None

<s> O None
injection I None
of I None
carbachol I Chemical
<eof> I None

<s> O None
( I None
1 I None
mug I None
) I None
in I None
anesthetized I None
rats I None
was I None
analyzed I None
. I None
<eof> I None

<s> O None
This I None
response I None
was I None
significantly I None
reduced I None
by I None
the I None
intravenous I None
( I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
injection I None
of I None
guanethidine I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
) I None
, I None
hexamethonium I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
) I None
or I None
phentolamine I Chemical
( I None
5 I None
mg I None
) I None
, I None
and I None
conversely I None
, I None
potentiated I None
by I None
i.v I None
. I None
<eof> I None

<s> O None
desmethylimipramine I Chemical
( I None
0.3 I None
mg I None
) I None
, I None
<eof> I None

<s> O None
while I None
propranolol I Chemical
( I None
0.5 I None
mg I None
) I None
i.v I None
. I None
<eof> I None

<s> O None
selectively I None
inhibited I None
the I None
enlargement I Disease
of O Disease
pulse O Disease
pressure O Disease
and I None
the I None
tachycardia I Disease
following I None
i.c I None
. I None
<eof> I None

<s> O None
carbachol I Chemical
( I None
1 I None
mug I None
) I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
pressor I None
response I None
to I None
i.c I None
. I None
<eof> I None

<s> O None
carbachol I Chemical
( I None
1 I None
mug I None
) I None
was I None
almost I None
completely I None
blocked I None
by I None
i.c I None
. I None
<eof> I None

<s> O None
atropine I Chemical
( I None
3 I None
mug I None
) I None
or I None
hexamethonium I Chemical
( I None
500 I None
mug I None
) I None
, I None
and I None
significantly I None
reduced I None
by I None
i.c I None
. I None
<eof> I None

<s> O None
chlorpromazine I Chemical
( I None
50 I None
mug I None
) I None
but I None
significantly I None
potentiated I None
by I None
i.c I None
. I None
<eof> I None

<s> O None
desmethylimipramine I Chemical
( I None
30 I None
mug I None
) I None
. I None
<eof> I None

<s> O None
The I None
pressor I None
response I None
to I None
i.c I None
. I None
<eof> I None

<s> O None
carbachol I Chemical
( I None
1 I None
mug I None
) I None
remained I None
unchanged I None
after I None
sectioning I None
of I None
the I None
bilateral I None
cervical I None
vagal I None
nerves I None
but I None
disappeared I None
after I None
sectioning I None
of I None
the I None
spinal I None
cord I None
( I None
C7-C8 I None
) I None
. I None
<eof> I None

<s> O None
From I None
the I None
above I None
result I None
it I None
is I None
suggested I None
that I None
the I None
pressor I None
response I None
to I None
i.c I None
. I None
<eof> I None

<s> O None
carbachol I Chemical
ortral I None
and I None
peripheral I None
adrenergic I None
mechanisms I None
, I None
and I None
that I None
the I None
sympathetic I None
trunk I None
is I None
the I None
main I None
pathway I None
. I None
<eof> I None

<s> O None
Hyperglycemic I Disease
effect I None
of I None
amino I Chemical
compounds I None
structurally I None
related I None
to I None
caproate I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
chronic I None
feeding I None
of I None
small I None
amounts I None
( I None
0.3 I None
- I None
3 I None
% I None
of I None
diet I None
weight I None
) I None
of I None
certain I None
amino I Chemical
derivatives I None
of I None
caproate I Chemical
resulted I None
in I None
hyperglycemia I Disease
, I None
an I None
elevated I None
glucose I Chemical
tolerance I None
curve I None
and I None
, I None
occasionally I None
, I None
glucosuria I Disease
. I None
<eof> I None

<s> O None
Effective I None
compounds I None
included I None
norleucine I Chemical
, I None
norvaline I Chemical
, I None
glutamate I Chemical
, I None
epsilon I Chemical
- O Chemical
aminocaproate O Chemical
, I None
methionine I Chemical
, I None
and I None
leucine I Chemical
. I None
<eof> I None

<s> O None
Fatty I Disease
liver O Disease
induced I None
by I None
tetracycline I Chemical
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
response I None
relationships I None
and I None
effect I None
of I None
sex I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
response I None
relationships I None
, I None
biochemical I None
mechanisms I None
, I None
and I None
sex I None
differences I None
in I None
the I None
experimental I None
fatty I Disease
liver O Disease
induced I None
by I None
tetracycline I Chemical
were I None
studied I None
in I None
the I None
intact I None
rat I None
and I None
with I None
the I None
isolated I None
perfused I None
rat I None
liver I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
In I None
the I None
intact I None
male I None
and I None
female I None
rat I None
, I None
no I None
direct I None
relationship I None
was I None
observed I None
between I None
dose I None
of I None
tetracycline I Chemical
and I None
hepatic I None
accumulation I None
of I None
triglyceride I Chemical
. I None
<eof> I None

<s> O None
With I None
provision I None
of I None
adequate I None
oleic I Chemical
acid O Chemical
as I None
a I None
substrate I None
for I None
the I None
isolated I None
perfused I None
liver I None
, I None
a I None
direct I None
relationship I None
was I None
observed I None
between I None
dose I None
of I None
tetracycline I Chemical
and I None
both I None
accumulation I None
of I None
triglyceride I Chemical
in I None
the I None
liver I None
and I None
depression I Disease
of I None
output I None
of I None
triglyceride I Chemical
by I None
livers I None
from I None
male I None
and I None
female I None
rats I None
. I None
<eof> I None

<s> O None
Marked I None
differences I None
were I None
observed I None
between I None
female I None
and I None
male I None
rats I None
with I None
regard I None
to I None
base I None
line I None
( I None
control I None
) I None
hepatic I None
concentration I None
of I None
triglyceride I Chemical
and I None
output I None
of I None
triglyceride I Chemical
. I None
<eof> I None

<s> O None
Accumulation I None
of I None
hepatic I None
triglyceride I Chemical
, I None
as I None
a I None
per I None
cent I None
of I None
control I None
values I None
, I None
in I None
response I None
to I None
graded I None
doses I None
of I None
tetracycline I Chemical
, I None
did I None
not I None
differ I None
significantly I None
between I None
male I None
, I None
female I None
and I None
pregnant I None
rat I None
livers I None
. I None
<eof> I None

<s> O None
However I None
, I None
livers I None
from I None
female I None
, I None
and I None
especially I None
pregnant I None
female I None
rats I None
, I None
were I None
strikingly I None
resistant I None
to I None
the I None
effects I None
of I None
tetracycline I Chemical
on I None
depression I Disease
of I None
output I None
of I None
triglyceride I Chemical
under I None
these I None
experimental I None
conditions I None
. I None
<eof> I None

<s> O None
These I None
differences I None
between I None
the I None
sexes I None
could I None
not I None
be I None
related I None
to I None
altered I None
disposition I None
of I None
tetracycline I Chemical
or I None
altered I None
uptake I None
of I None
oleic I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
Depressed I None
hepatic I None
secretion I None
of I None
triglyceride I Chemical
accounted I None
only I None
for I None
30 I None
to I None
50 I None
% I None
of I None
accumulated I None
hepatic I None
triglyceride I Chemical
, I None
indicating I None
that I None
additional I None
mechanisms I None
must I None
be I None
involved I None
in I None
the I None
production I None
of I None
the I None
triglyceride I Chemical
-rich I None
fatty I Disease
liver O Disease
in I None
response I None
to I None
tetracycline I Chemical
. I None
<eof> I None

<s> O None
Fatal I None
myeloencephalopathy I Disease
due I None
to I None
intrathecal I None
vincristine I Chemical
administration I None
. I None
<eof> I None

<s> O None
Vincristine I Chemical
was I None
accidentally I None
given I None
intrathecally I None
to I None
a I None
child I None
with I None
leukaemia I Disease
, I None
producing I None
sensory I Disease
and O Disease
motor O Disease
dysfunction O Disease
followed I None
by I None
encephalopathy I Disease
and I None
death I None
. I None
<eof> I None

<s> O None
Separate I None
times I None
for I None
administering I None
vincristine I Chemical
and I None
intrathecal I None
therapy I None
is I None
recommended I None
. I None
<eof> I None

<s> O None
Progesterone I Chemical
potentiation I None
of I None
bupivacaine I Chemical
arrhythmogenicity I None
in I None
pentobarbital I Chemical
<eof> I None

<s> O None
-anesthetized I None
rats I None
and I None
beating I None
rat I None
heart I None
cell I None
cultures I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
progesterone I Chemical
treatment I None
on I None
bupivacaine I Chemical
arrhythmogenicity I None
in I None
beating I None
rat I None
heart I None
myocyte I None
cultures I None
and I None
on I None
anesthetized I None
rats I None
were I None
determined I None
. I None
<eof> I None

<s> O None
After I None
determining I None
the I None
bupivacaine I Chemical
AD50 I None
( I None
the I None
concentration I None
of I None
bupivacaine I Chemical
that I None
caused I None
50 I None
% I None
of I None
all I None
beating I None
rat I None
heart I None
myocyte I None
cultures I None
to I None
become I None
arrhythmic I Disease
) I None
, I None
we I None
determined I None
the I None
effect I None
of I None
1-hour I None
progesterone I Chemical
HCl I Chemical
exposure I None
on I None
myocyte I None
contractile I None
rhythm I None
. I None
<eof> I None

<s> O None
Each I None
concentration I None
of I None
progesterone I Chemical
( I None
6.25 I None
, I None
12.5 I None
, I None
25 I None
, I None
and I None
50 I None
micrograms I None
/ I None
ml I None
) I None
caused I None
a I None
significant I None
and I None
concentration I None
- I None
dependent I None
reduction I None
in I None
the I None
AD50 I None
for I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
Estradiol I Chemical
treatment I None
also I None
increased I None
the I None
arrhythmogenicity I None
of I None
bupivacaine I Chemical
in I None
myocyte I None
cultures I None
, I None
but I None
was I None
only I None
one I None
fourth I None
as I None
potent I None
as I None
progesterone I Chemical
. I None
<eof> I None

<s> O None
Neither I None
progesterone I Chemical
nor I None
estradiol I Chemical
effects I None
on I None
bupivacaine I Chemical
arrhythmogenicity I None
were I None
potentiated I None
by I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
Chronic I None
progesterone I Chemical
pretreatment I None
( I None
5 I None
mg I None
/ I None
kg I None
/ I None
day I None
for I None
21 I None
days I None
) I None
caused I None
a I None
significant I None
increase I None
in I None
bupivacaine I Chemical
arrhythmogenicity I None
in I None
intact I None
pentobarbital I Chemical
-anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
decrease I None
in I None
the I None
time I None
to I None
onset I None
of I None
arrhythmia I Disease
as I None
compared I None
with I None
control I None
nonprogesterone I None
- I None
treated I None
rats I None
( I None
6.2 I None
+ I None
/- I None
1.3 I None
vs. I None
30.8 I None
+ I None
/- I None
<eof> I None

<s> O None
2.5 I None
min I None
, I None
mean I None
<eof> I None

<s> O None
+ I None
/- I None
SE I None
) I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
this I None
study I None
indicate I None
that I None
progesterone I Chemical
can I None
potentiate I None
bupivacaine I Chemical
arrhythmogenicity I None
both I None
in I None
vivo I None
and I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Potentiation I None
of I None
bupivacaine I Chemical
arrhythmia I Disease
in I None
myocyte I None
cultures I None
suggests I None
that I None
this I None
effect I None
is I None
at I None
least I None
partly I None
mediated I None
at I None
the I None
myocyte I None
level I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
occurring I None
during I None
intravenous I None
desferrioxamine I Chemical
therapy I None
: I None
recovery I None
after I None
haemodialysis I None
. I None
<eof> I None

<s> O None
A I None
patient I None
with I None
transfusion I None
- I None
dependent I None
thalassemia I Disease
was I None
undergoing I None
home I None
intravenous I None
desferrioxamine I Chemical
<eof> I None

<s> O None
( I None
DFX I Chemical
) I None
treatment I None
by I None
means I None
of I None
a I None
totally I None
implanted I None
system I None
because I None
of I None
his I None
poor I None
compliance I None
with I None
the I None
nightly I None
subcutaneous I None
therapy I None
. I None
<eof> I None

<s> O None
Due I None
to I None
an I None
accidental I None
malfunctioning I None
of I None
the I None
infusion I None
pump I None
, I None
the I None
patient I None
was I None
inadvertently I None
administered I None
a I None
toxic I None
dosage I None
of I None
the I None
drug I None
which I None
caused I None
renal I Disease
insufficiency O Disease
. I None
<eof> I None

<s> O None
Given I None
the I None
progressive I None
deterioration I None
of I None
the I None
symptoms I None
and I None
of I None
the I None
laboratory I None
values I None
, I None
despite I None
adequate I None
medical I None
treatment I None
, I None
a I None
decision I None
was I None
made I None
to I None
introduce I None
haemodialytical I None
therapy I None
in I None
order I None
to I None
remove I None
the I None
drug I None
and I None
therapy I None
reduce I None
the I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
From I None
the I None
results I None
obtained I None
, I None
haemodialysis I None
can I None
therefore I None
be I None
suggested I None
as I None
a I None
useful I None
therapy I None
in I None
rare I None
cases I None
of I None
progressive I None
acute I Disease
renal O Disease
failure O Disease
caused I None
by I None
desferrioxamine I Chemical
. I None
<eof> I None

<s> O None
Neuroleptic I Chemical
-associated I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
Can I None
it I None
be I None
treated I None
with I None
bromocriptine I Chemical
? I None
<eof> I None

<s> O None
Six I None
stable I None
psychiatric I None
outpatients I None
with I None
hyperprolactinemia I Disease
and I None
amenorrhea I Disease
/ I None
oligomenorrhea I Disease
associated I None
with I None
their I None
neuroleptic I Chemical
medications O Chemical
were I None
treated I None
with I None
bromocriptine I Chemical
. I None
<eof> I None

<s> O None
Daily I None
dosages I None
of I None
5 I None
- I None
10 I None
mg I None
corrected I None
the I None
hyperprolactinemia I Disease
and I None
restored I None
menstruation I None
in I None
four I None
of I None
the I None
six I None
patients I None
. I None
<eof> I None

<s> O None
One I None
woman I None
, I None
however I None
, I None
developed I None
worsened I None
psychiatric I Disease
symptoms O Disease
while I None
taking I None
bromocriptine I Chemical
, I None
and I None
it I None
was I None
discontinued I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
three I None
of I None
six I None
patients I None
had I None
their I None
menstrual I None
irregularity I None
successfully I None
corrected I None
with I None
bromocriptine I Chemical
. I None
<eof> I None

<s> O None
This I None
suggests I None
that I None
bromocriptine I Chemical
should I None
be I None
further I None
evaluated I None
as I None
potential I None
therapy I None
for I None
neuroleptic I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
and I None
amenorrhea I Disease
/ I None
galactorrhea I Disease
. I None
<eof> I None

<s> O None
Ethacrynic I Chemical
acid O Chemical
-induced I None
convulsions I Disease
and I None
brain I None
neurotransmitters I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Intracerebroventricular I None
injection I None
of I None
ethacrynic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
50 I None
% I None
<eof> I None

<s> O None
convulsive I Disease
dose I None
; I None
50 I None
micrograms I None
/ I None
mouse I None
) I None
accelerated I None
the I None
synthesis I None
/ I None
turnover I None
of I None
5-hydroxytryptamine I Chemical
<eof> I None

<s> O None
( I None
5-HT I Chemical
) I None
but I None
suppressed I None
the I None
synthesis I None
of I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
and I None
acetylcholine I Chemical
in I None
mouse I None
brain I None
. I None
<eof> I None

<s> O None
These I None
effects I None
were I None
completely I None
antagonized I None
by I None
pretreatment I None
with I None
a I None
glutamate I Chemical
/ I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
antagonist I None
, I None
aminophosphonovaleric I Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
In I None
ethacrynic I Chemical
acid O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
convulsions I Disease
, I None
these I None
neurotransmitter I None
systems I None
may I None
be I None
differentially I None
modulated I None
, I None
probably I None
through I None
activation I None
of I None
glutaminergic I None
neurons I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Pharmacology I None
of I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
<eof> I None

<s> O None
A I None
receptor I None
complex I None
after I None
the I None
in I None
vivo I None
administration I None
of I None
the I None
anxioselective I None
and I None
anticonvulsant I None
beta I Chemical
- O Chemical
carboline O Chemical
derivative I None
abecarnil I Chemical
. I None
<eof> I None

<s> O None
In I None
rodents I None
, I None
the I None
effect I None
of I None
the I None
beta I Chemical
- O Chemical
carboline O Chemical
derivative I None
isopropyl-6- I Chemical
benzyloxy-4-methoxymethyl O Chemical
- O Chemical
beta O Chemical
- O Chemical
carboline-3-carboxylate O Chemical
<eof> I None

<s> O None
( I None
abecarrnil I Chemical
) I None
, I None
a I None
new I None
ligand I None
for I None
benzodiazepine I Chemical
receptors I None
possessing I None
anxiolytic I None
and I None
anticonvulsant I None
properties I None
, I None
was I None
evaluated I None
on I None
the I None
function I None
of I None
central I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
GABA I Chemical
) I None
<eof> I None

<s> O None
A I None
receptor I None
complex I None
, I None
both I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Added I None
in I None
vitro I None
to I None
rat I None
cortical I None
membrane I None
preparation I None
, I None
<eof> I None

<s> O None
abecarnil I Chemical
increased I None
[ I None
3H I None
] I None
GABA I Chemical
binding I None
, I None
enhanced I None
<eof> I None

<s> O None
muscimol I Chemical
-stimulated I None
36Cl- I None
uptake I None
and I None
reduced I None
the I None
binding I None
of I None
t-[35S]butylbicyclophosphorothionate I Chemical
<eof> I None

<s> O None
( I None
[ I Chemical
35S]TBPS O Chemical
) I None
. I None
<eof> I None

<s> O None
These I None
effects I None
were I None
similar I None
to I None
those I None
induced I None
by I None
diazepam I Chemical
, I None
whereas I None
the I None
partial I None
agonist I None
Ro I Chemical
16 O Chemical
- O Chemical
6028 O Chemical
<eof> I None

<s> O None
( I None
tert I Chemical
- O Chemical
butyl-(S)-8-bromo-11,12,13,13a O Chemical
- O Chemical
tetrahydro-9-oxo-9H- O Chemical
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate O Chemical
) I None
showed I None
very I None
weak I None
efficacy I None
in I None
these I None
biochemical I None
tests I None
. I None
<eof> I None

<s> O None
After I None
i.p I None
. I None
<eof> I None

<s> O None
injection I None
to I None
rats I None
, I None
abecarnil I Chemical
and I None
diazepam I Chemical
decreased I None
in I None
a I None
time I None
- I None
dependent I None
and I None
dose I None
- I None
related I None
( I None
0.25 I None
- I None
20 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
manner I None
[ I Chemical
35S]TBPS O Chemical
<eof> I None

<s> O None
binding I None
measured I None
ex I None
vivo I None
in I None
the I None
cerebral I None
cortex I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
both I None
drugs I None
at I None
the I None
dose I None
of I None
0.5 I None
mg I None
/ I None
kg I None
antagonized I None
completely I None
the I None
convulsant I None
activity I None
and I None
the I None
increase I None
of I None
[ I Chemical
35S]TBPS O Chemical
binding I None
induced I None
by I None
isoniazide I Chemical
<eof> I None

<s> O None
( I None
350 I None
mg I None
/ I None
kg I None
s.c I None
. I None
) I None
as I None
well I None
as I None
the I None
increase I None
of I None
[ I Chemical
35S]TBPS O Chemical
binding I None
induced I None
by I None
foot I None
- I None
shock I None
stress I None
. I None
<eof> I None

<s> O None
To I None
better I None
correlate I None
the I None
biochemical I None
and I None
the I None
pharmacological I None
effects I None
, I None
we I None
studied I None
the I None
action I None
of I None
abecarnil I Chemical
on I None
[ I Chemical
35S]TBPS O Chemical
<eof> I None

<s> O None
binding I None
, I None
exploratory I None
motility I None
and I None
on I None
isoniazid I Chemical
-induced I None
biochemical I None
and I None
pharmacological I None
effects I None
in I None
mice I None
. I None
<eof> I None

<s> O None
In I None
these I None
animals I None
, I None
abecarnil I Chemical
produced I None
a I None
paralleled I None
dose I None
- I None
dependent I None
( I None
0.05 I None
- I None
1 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
reduction I None
of I None
both I None
motor I None
behavior I None
and I None
cortical I None
[ I None
35S]TBPS I None
binding I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
0.05 I None
mg I None
/ I None
kg I None
of I None
this I None
beta I Chemical
- O Chemical
carboline O Chemical
reduced I None
markedly I None
the I None
increase I None
of I None
[ I Chemical
35S]TBPS O Chemical
binding I None
and I None
the I None
convulsions I Disease
induced I None
by I None
isoniazid I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
/ I None
kg I None
s.c.).(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Recurrent I None
myocardial I Disease
infarction O Disease
in I None
a I None
postpartum I None
patient I None
receiving I None
bromocriptine I Chemical
. I None
<eof> I None

<s> O None
Myocardial I Disease
infarction O Disease
in I None
puerperium I None
is I None
infrequently I None
reported I None
. I None
<eof> I None

<s> O None
Spasm I Disease
, I None
coronary I None
dissection I None
, I None
or I None
atheromatous I None
etiology I None
has I None
been I None
described I None
. I None
<eof> I None

<s> O None
Bromocriptine I Chemical
has I None
been I None
implicated I None
in I None
several I None
previous I None
case I None
reports I None
of I None
myocardial I Disease
infarction O Disease
in I None
the I None
puerperium I None
. I None
<eof> I None

<s> O None
Our I None
case I None
( I None
including I None
an I None
inadvertent I None
rechallenge I None
) I None
suggests I None
such I None
a I None
relationship I None
. I None
<eof> I None

<s> O None
Although I None
generally I None
regarded I None
as I None
" I None
safe I None
, I None
" I None
possible I None
serious I None
cardiac I None
effects I None
of I None
bromocriptine I Chemical
should I None
be I None
acknowledged I None
. I None
<eof> I None

<s> O None
Asterixis I Disease
induced I None
by I None
carbamazepine I Chemical
therapy I None
. I None
<eof> I None

<s> O None
There I None
are I None
very I None
few I None
reports I None
about I None
asterixis I Disease
as I None
a I None
side I None
effect I None
of I None
treatment I None
with I None
psychopharmacologic I None
agents I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
we I None
present I None
four I None
patients I None
treated I None
with I None
a I None
combination I None
of I None
different I None
psychotropic I None
drugs I None
, I None
in I None
whom I None
asterixis I Disease
was I None
triggered I None
either I None
by I None
adding I None
carbamazepine I Chemical
<eof> I None

<s> O None
( I None
CBZ I Chemical
) I None
to I None
a I None
treatment I None
regimen I None
, I None
or I None
by I None
increasing I None
its I None
dosage I None
. I None
<eof> I None

<s> O None
Neither I None
dosage I None
nor I None
serum I None
levels I None
of I None
CBZ I Chemical
were I None
in I None
a I None
higher I None
range I None
. I None
<eof> I None

<s> O None
We I None
consider I None
asterixis I Disease
to I None
be I None
an I None
easily I None
overlooked I None
sign I None
of I None
neurotoxicity I Disease
, I None
which I None
may I None
occur I None
even I None
at I None
low I None
or I None
moderate I None
dosage I None
levels I None
, I None
if I None
certain I None
drugs I None
as I None
lithium I Chemical
or I None
clozapine I Chemical
are I None
used I None
in I None
combination I None
with I None
CBZ I Chemical
. I None
<eof> I None

<s> O None
Pharmacodynamics I None
of I None
the I None
hypotensive I Disease
effect I None
of I None
levodopa I Chemical
in I None
parkinsonian I Disease
patients I None
. I None
<eof> I None

<s> O None
Blood I None
pressure I None
effects I None
of I None
i.v I None
. I None
<eof> I None

<s> O None
levodopa I Chemical
were I None
examined I None
in I None
parkinsonian I Disease
patients I None
with I None
stable I None
and I None
fluctuating I None
responses I None
to I None
levodopa I Chemical
. I None
<eof> I None

<s> O None
The I None
magnitude I None
of I None
the I None
hypotensive I Disease
effect I None
of I None
levodopa I Chemical
was I None
concentration I None
dependent I None
and I None
was I None
fit I None
to I None
an I None
Emax I None
model I None
in I None
fluctuating I None
responders I None
. I None
<eof> I None

<s> O None
Stable I None
responders I None
demonstrated I None
a I None
small I None
hypotensive I Disease
response I None
. I None
<eof> I None

<s> O None
Baseline I None
blood I None
pressures I None
were I None
higher I None
in I None
fluctuating I None
patients I None
; I None
a I None
higher I None
baseline I None
blood I None
pressure I None
correlated I None
with I None
greater I None
hypotensive I Disease
effects I None
. I None
<eof> I None

<s> O None
Antiparkinsonian I None
effects I None
of I None
levodopa I Chemical
temporally I None
correlated I None
with I None
blood I None
pressure I None
changes I None
. I None
<eof> I None

<s> O None
Phenylalanine I Chemical
, I None
a I None
large I None
neutral I None
amino I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
LNAA I None
) I None
competing I None
with I None
levodopa I Chemical
for I None
transport I None
across I None
the I None
blood I None
- I None
brain I None
barrier I None
, I None
reduced I None
the I None
hypotensive I Disease
and I None
antiparkinsonian I None
effects I None
of I None
levodopa I Chemical
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
levodopa I Chemical
has I None
a I None
central I None
hypotensive I Disease
action I None
that I None
parallels I None
the I None
motor I None
effects I None
in I None
fluctuating I None
patients I None
. I None
<eof> I None

<s> O None
The I None
hypotensive I Disease
effect I None
appears I None
to I None
be I None
related I None
to I None
the I None
higher I None
baseline I None
blood I None
pressure I None
we I None
observed I None
in I None
fluctuating I None
patients I None
relative I None
to I None
stable I None
patients I None
. I None
<eof> I None

<s> O None
Syndrome I Disease
of O Disease
inappropriate O Disease
secretion O Disease
of O Disease
antidiuretic O Disease
hormone O Disease
after I None
infusional I None
vincristine I Chemical
. I None
<eof> I None

<s> O None
A I None
77-year I None
- I None
old I None
woman I None
with I None
refractory I None
multiple I Disease
myeloma O Disease
was I None
treated I None
with I None
a I None
4-day I None
continuous I None
intravenous I None
infusion I None
of I None
vincristine I Chemical
and I None
doxorubicin I Chemical
and I None
4 I None
days I None
of I None
oral I None
dexamethasone I Chemical
. I None
<eof> I None

<s> O None
Nine I None
days I None
after I None
her I None
second I None
cycle I None
she I None
presented I None
with I None
lethargy I Disease
and I None
weakness I Disease
associated I None
with I None
hyponatremia I Disease
. I None
<eof> I None

<s> O None
Evaluation I None
revealed I None
the I None
syndrome I Disease
of O Disease
inappropriate O Disease
secretion O Disease
of O Disease
antidiuretic O Disease
hormone O Disease
, I None
which I None
was I None
attributed I None
to I None
the I None
vincristine I Chemical
infusion I None
. I None
<eof> I None

<s> O None
After I None
normal I None
serum I None
sodium I Chemical
levels I None
returned I None
, I None
further I None
doxorubicin I Chemical
and I None
dexamethasone I Chemical
chemotherapy I None
without I None
vincristine I Chemical
did I None
not I None
produce I None
this I None
complication I None
. I None
<eof> I None

<s> O None
Heart I Disease
failure O Disease
: I None
to I None
digitalise I None
or I None
not I None
? I None
<eof> I None

<s> O None
The I None
view I None
against I None
. I None
<eof> I None

<s> O None
Despite I None
extensive I None
clinical I None
experience I None
the I None
role I None
of I None
digoxin I Chemical
is I None
still I None
not I None
well I None
defined I None
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
atrial I Disease
fibrillation O Disease
<eof> I None

<s> O None
digoxin I Chemical
is I None
beneficial I None
for I None
ventricular I None
rate I None
control I None
. I None
<eof> I None

<s> O None
For I None
patients I None
in I None
sinus I None
rhythm I None
and I None
heart I Disease
failure O Disease
<eof> I None

<s> O None
the I None
situation I None
is I None
less I None
clear I None
. I None
<eof> I None

<s> O None
Digoxin I Chemical
has I None
a I None
narrow I None
therapeutic I None
: I None
<eof> I None

<s> O None
toxic I None
ratio I None
and I None
concentrations I None
are I None
affected I None
by I None
a I None
number I None
of I None
drugs I None
. I None
<eof> I None

<s> O None
Also I None
, I None
digoxin I Chemical
has I None
undesirable I None
effects I None
such I None
as I None
increasing I None
peripheral I None
resistance I None
and I None
myocardial I None
demands I None
, I None
and I None
causing I None
arrhythmias I Disease
. I None
<eof> I None

<s> O None
There I None
is I None
a I None
paucity I None
of I None
data I None
from I None
well I None
- I None
designed I None
trials I None
. I None
<eof> I None

<s> O None
The I None
trials I None
that I None
are I None
available I None
are I None
generally I None
small I None
with I None
limitations I None
in I None
design I None
and I None
these I None
show I None
variation I None
in I None
patient I None
benefit I None
. I None
<eof> I None

<s> O None
More I None
convincing I None
evidence I None
is I None
required I None
showing I None
that I None
digoxin I Chemical
improves I None
symptoms I None
or I None
exercise I None
capacity I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
no I None
trial I None
has I None
had I None
sufficient I None
power I None
to I None
evaluate I None
mortality I None
. I None
<eof> I None

<s> O None
Pooled I None
analysis I None
of I None
the I None
effects I None
of I None
other I None
inotropic I None
drugs I None
shows I None
an I None
excess I None
mortality I None
and I None
there I None
is I None
a I None
possibility I None
that I None
digoxin I Chemical
may I None
increase I None
mortality I None
after I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
. I None
<eof> I None

<s> O None
Angiotensin I Chemical
-converting I None
enzyme I None
( I None
ACE I None
) I None
inhibitors I None
should I None
be I None
used I None
first I None
as I None
they I None
are I None
safer I None
, I None
do I None
not I None
require I None
blood I None
level I None
monitoring I None
, I None
modify I None
progression I None
of I None
disease I None
, I None
relieve I None
symptoms I None
, I None
improve I None
exercise I None
tolerance I None
and I None
reduce I None
mortality I None
. I None
<eof> I None

<s> O None
Caution I None
should I None
be I None
exercised I None
in I None
using I None
digoxin I Chemical
until I None
large I None
mortality I None
trials I None
are I None
completed I None
showing I None
either I None
benefit I None
or I None
harm I None
. I None
<eof> I None

<s> O None
Until I None
then I None
digoxin I Chemical
should I None
be I None
considered I None
a I None
third I None
- I None
line I None
therapy I None
. I None
<eof> I None

<s> O None
Intravascular I None
hemolysis I Disease
and I None
acute I Disease
renal O Disease
failure O Disease
following I None
intermittent I None
rifampin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Renal I Disease
failure O Disease
is I None
a I None
rare I None
complication I None
associated I None
with I None
the I None
use I None
of I None
rifampin I Chemical
. I None
<eof> I None

<s> O None
Intravascular I None
<eof> I None

<s> O None
hemolysis I Disease
leading I None
to I None
acute I Disease
renal O Disease
failure O Disease
following I None
rifampin I Chemical
therapy I None
is I None
extremely I None
rare I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
with I None
leprosy I Disease
who I None
developed I None
hemolysis I Disease
and I None
acute I Disease
renal O Disease
failure O Disease
following I None
rifampin I Chemical
are I None
reported I None
. I None
<eof> I None

<s> O None
Zidovudine I Chemical
-induced I None
hepatitis I Disease
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
acute I None
hepatitis I Disease
induced I None
by I None
zidovudine I Chemical
in I None
a I None
38-year I None
- I None
old I None
patient I None
with I None
<eof> I None

<s> O None
AIDS I Disease
is I None
presented I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
whereby I None
the I None
hepatitis I Disease
was I None
induced I None
is I None
not I None
known I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
patient I None
tolerated I None
well I None
an I None
alternative I None
reverse I None
transcriptase I None
inhibitor I None
, I None
2'3 I Chemical
' O Chemical
dideoxyinosine O Chemical
. I None
<eof> I None

<s> O None
Physicians I None
caring I None
for I None
patients I None
with I None
AIDS I Disease
should I None
be I None
aware I None
of I None
this I None
hitherto I None
rarely I None
reported I None
complication I None
. I None
<eof> I None

<s> O None
Thoracic I Disease
hematomyelia O Disease
secondary I None
to I None
coumadin I Chemical
anticoagulant I None
therapy I None
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
thoracic I Disease
hematomyelia O Disease
secondary I None
to I None
anticoagulant I None
therapy I None
is I None
presented I None
. I None
<eof> I None

<s> O None
Clinical I None
features I None
, I None
similar I None
to I None
2 I None
other I None
previously I None
reported I None
cases I None
, I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
A I None
high I None
index I None
of I None
suspicion I None
may I None
lead I None
to I None
a I None
quick I None
diagnostic I None
procedure I None
and I None
successful I None
decompressive I None
surgery I None
. I None
<eof> I None

<s> O None
Mania I Disease
associated I None
with I None
fluoxetine I Chemical
treatment I None
in I None
adolescents I None
. I None
<eof> I None

<s> O None
Fluoxetine I Chemical
, I None
a I None
selective I None
serotonin I Chemical
reuptake I None
inhibitor I None
, I None
is I None
gaining I None
increased I None
acceptance I None
in I None
the I None
treatment I None
of I None
adolescent I None
depression I Disease
. I None
<eof> I None

<s> O None
Generally I None
safe I None
and I None
well I None
tolerated I None
by I None
adults I None
, I None
fluoxetine I Chemical
has I None
been I None
reported I None
to I None
induce I None
mania I Disease
. I None
<eof> I None

<s> O None
The I None
cases I None
of I None
five I None
depressed I Disease
adolescents I None
, I None
14 I None
- I None
16 I None
years I None
of I None
age I None
, I None
who I None
developed I None
mania I Disease
during I None
pharmacotherapy I None
with I None
fluoxetine I Chemical
, I None
are I None
reported I None
here I None
. I None
<eof> I None

<s> O None
Apparent I None
risk I None
factors I None
for I None
the I None
development I None
of I None
mania I Disease
or I None
hypomania I Disease
during I None
fluoxetine I Chemical
pharmacotherapy I None
in I None
this I None
population I None
were I None
the I None
combination I None
of I None
attention I Disease
- O Disease
deficit O Disease
hyperactivity O Disease
disorder O Disease
and I None
affective I None
instability I None
; I None
major I None
depression I Disease
with I None
psychotic I Disease
features I None
; I None
a I None
family I None
history I None
of I None
affective I Disease
disorder O Disease
, I None
especially I None
bipolar I Disease
disorder O Disease
; I None
and I None
a I None
diagnosis I None
of I None
bipolar I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Further I None
study I None
is I None
needed I None
to I None
determine I None
the I None
optimal I None
dosage I None
and I None
to I None
identify I None
risk I None
factors I None
that I None
increase I None
individual I None
vulnerability I None
to I None
fluoxetine I Chemical
induced I None
mania I Disease
in I None
adolescents I None
. I None
<eof> I None

<s> O None
Gemfibrozil I Chemical
- I None
lovastatin I Chemical
therapy I None
for I None
primary I None
hyperlipoproteinemias I Disease
. I None
<eof> I None

<s> O None
The I None
specific I None
aim I None
of I None
this I None
retrospective I None
, I None
observational I None
study I None
was I None
to I None
assess I None
safety I None
and I None
efficacy I None
of I None
long I None
- I None
term I None
( I None
21 I None
months I None
/ I None
patient I None
) I None
, I None
open I None
- I None
label I None
, I None
gemfibrozil I Chemical
- I None
lovastatin I Chemical
treatment I None
in I None
80 I None
patients I None
with I None
primary I None
mixed I None
hyperlipidemia I Disease
( I None
68 I None
% I None
of I None
whom I None
had I None
atherosclerotic I Disease
vascular O Disease
disease O Disease
) I None
. I None
<eof> I None

<s> O None
Because I None
ideal I None
lipid I None
targets I None
were I None
not I None
reached I None
( I None
low I None
- I None
density I None
lipoprotein I None
( I None
LDL I None
) I None
<eof> I None

<s> O None
cholesterol I Chemical
less I None
than I None
130 I None
mg I None
/ I None
dl I None
, I None
high I None
- I None
density I None
lipoprotein I None
( I None
HDL I None
) I None
<eof> I None

<s> O None
cholesterol I Chemical
greater I None
than I None
35 I None
mg I None
/ I None
dl I None
, I None
or I None
total I None
cholesterol I Chemical
/HDL I None
<eof> I None

<s> O None
cholesterol I Chemical
less I None
than I None
4.5 I None
mg I None
/ I None
dl I None
) I None
with I None
diet I None
plus I None
a I None
single I None
drug I None
, I None
<eof> I None

<s> O None
gemfibrozil I Chemical
( I None
1.2 I None
g I None
/ I None
day)- I None
lovastatin I Chemical
( I None
primarily I None
20 I None
or I None
40 I None
mg I None
) I None
treatment I None
was I None
given I None
. I None
<eof> I None

<s> O None
Follow I None
- I None
up I None
visits I None
were I None
scheduled I None
with I None
2-drug I None
therapy I None
every I None
6 I None
to I None
8 I None
weeks I None
, I None
an I None
average I None
of I None
10.3 I None
visits I None
per I None
patient I None
, I None
with I None
741 I None
batteries I None
of I None
6 I None
liver I None
function I None
tests I None
and I None
714 I None
creatine I Chemical
phosphokinase I None
levels I None
measured I None
. I None
<eof> I None

<s> O None
Only I None
1 I None
of I None
the I None
4,446 I None
liver I None
function I None
tests I None
( I None
0.02 I None
% I None
) I None
, I None
a I None
gamma I None
glutamyl I None
transferase I None
, I None
was I None
greater I None
than I None
or I None
equal I None
to I None
3 I None
times I None
the I None
upper I None
normal I None
limit I None
. I None
<eof> I None

<s> O None
Of I None
the I None
714 I None
creatine I Chemical
phosphokinase I None
levels I None
, I None
9 I None
% I None
were I None
high I None
; I None
only I None
1 I None
( I None
0.1 I None
% I None
) I None
was I None
greater I None
than I None
or I None
equal I None
to I None
3 I None
times I None
the I None
upper I None
normal I None
limit I None
. I None
<eof> I None

<s> O None
With I None
2-drug I None
therapy I None
, I None
mean I None
total I None
<eof> I None

<s> O None
cholesterol I Chemical
decreased I None
22 I None
% I None
from I None
255 I None
to I None
200 I None
mg I None
/ I None
dl I None
, I None
triglyceride I Chemical
levels I None
decreased I None
35 I None
% I None
from I None
236 I None
to I None
154 I None
mg I None
/ I None
dl I None
, I None
LDL I None
cholesterol I Chemical
decreased I None
26 I None
% I None
from I None
176 I None
to I None
131 I None
mg I None
/ I None
dl I None
, I None
and I None
the I None
total I None
cholesterol I Chemical
/HDL I None
<eof> I None

<s> O None
cholesterol I Chemical
ratio I None
decreased I None
24 I None
% I None
from I None
7.1 I None
to I None
5.4 I None
, I None
all I None
p I None
less I None
than I None
or I None
equal I None
to I None
0.0001 I None
. I None
<eof> I None

<s> O None
Myositis I Disease
, I None
attributable I None
to I None
the I None
drug I None
combination I None
and I None
symptomatic I None
enough I None
to I None
discontinue I None
it I None
, I None
occurred I None
in I None
3 I None
% I None
of I None
patients I None
, I None
and I None
in I None
1 I None
% I None
with I None
concurrent I None
high I None
creatine I Chemical
phosphokinase I None
<eof> I None

<s> O None
( I None
769 I None
U I None
/ I None
liter I None
) I None
; I None
no I None
patients I None
had I None
<eof> I None

<s> O None
rhabdomyolysis I Disease
or I None
myoglobinuria I Disease
.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Hepatocellular I Disease
carcinoma O Disease
in I None
<eof> I None

<s> O None
Fanconi I Disease
's O Disease
anemia O Disease
treated I None
with I None
androgen I Chemical
and I None
corticosteroid I Chemical
. I None
<eof> I None

<s> O None
The I None
case I None
of I None
an I None
11-year I None
- I None
old I None
boy I None
is I None
reported I None
who I None
was I None
known I None
to I None
have I None
Fanconi I Disease
's O Disease
anemia O Disease
for I None
3 I None
years I None
and I None
was I None
treated I None
with I None
androgens I Chemical
, I None
corticosteroids I Chemical
and I None
transfusions I None
. I None
<eof> I None

<s> O None
Two I None
weeks I None
before I None
his I None
death I None
he I None
was I None
readmitted I None
because I None
of I None
aplastic I None
crisis I None
with I None
septicemia I Disease
and I None
marked I None
abnormalities I None
in I None
liver I None
function I None
and I None
died I None
of I None
hemorrhagic I Disease
bronchopneumonia O Disease
. I None
<eof> I None

<s> O None
At I None
autopsy I None
peliosis I Disease
and I None
multiple I None
hepatic I Disease
tumors O Disease
were I None
found I None
which I None
histologically I None
proved I None
to I None
be I None
well I None
- I None
differentiated I None
hepatocellular I Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
This I None
case I None
contributes I None
to I None
the I None
previous I None
observations I None
that I None
non I None
- I None
metastasizing I None
hepatic I Disease
neoplasms O Disease
and I None
peliosis I Disease
can I None
develop I None
in I None
patients I None
with I None
androgen I Chemical
- I None
and I None
corticosteroid I Chemical
-treated I None
Fanconi I Disease
's O Disease
anemia O Disease
. I None
<eof> I None

<s> O None
Chronic I None
lesion I None
of I None
rostral I None
ventrolateral I None
medulla I None
in I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
effects I None
of I None
chronic I None
selective I None
neuronal I None
lesion I None
of I None
rostral I None
ventrolateral I None
medulla I None
on I None
mean I None
arterial I None
pressure I None
, I None
heart I None
rate I None
, I None
and I None
neurogenic I None
tone I None
in I None
conscious I None
, I None
unrestrained I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
The I None
lesions I None
were I None
placed I None
via I None
bilateral I None
microinjections I None
of I None
30 I None
nmol/200 I None
nl I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartic O Chemical
acid O Chemical
. I None
<eof> I None

<s> O None
The I None
restimulation I None
of I None
this I None
area I None
with I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartic O Chemical
acid O Chemical
15 I None
days I None
postlesion I None
failed I None
to I None
produce I None
a I None
pressor I None
response I None
. I None
<eof> I None

<s> O None
One I None
day I None
postlesion I None
, I None
the I None
resting I None
mean I None
arterial I None
pressure I None
was I None
significantly I None
decreased I None
in I None
lesioned I None
rats I None
when I None
compared I None
with I None
sham I None
rats I None
( I None
100 I None
+ I None
/- I None
7 I None
versus I None
173 I None
+ I None
/- I None
4 I None
mm I None
Hg I None
, I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Fifteen I None
days I None
later I None
, I None
the I None
lesioned I None
group I None
still I None
showed I None
values I None
significantly I None
lower I None
than I None
the I None
sham I None
group I None
( I None
150 I None
+ I None
/- I None
6 I None
versus I None
167 I None
+ I None
/- I None
5 I None
mm I None
Hg I None
, I None
<eof> I None

<s> O None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
No I None
significant I None
heart I None
rate I None
differences I None
were I None
observed I None
between I None
the I None
sham I None
and I None
lesioned I None
groups I None
. I None
<eof> I None

<s> O None
The I None
ganglionic I None
blocker I None
trimethaphan I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
caused I None
similar I None
reductions I None
in I None
mean I None
arterial I None
pressure I None
in I None
both I None
lesioned I None
and I None
sham I None
groups I None
. I None
<eof> I None

<s> O None
The I None
trimethaphan I Chemical
-induced I None
hypotension I Disease
was I None
accompanied I None
by I None
a I None
significant I None
bradycardia I Disease
in I None
lesioned I None
rats I None
( I None
-32 I None
+ I None
<eof> I None

<s> O None
/- I None
13 I None
beats I None
per I None
minute I None
) I None
but I None
a I None
tachycardia I Disease
in I None
sham I None
rats I None
( I None
+ I None
33 I None
+ I None
/- I None
<eof> I None

<s> O None
12 I None
beats I None
per I None
minute I None
) I None
1 I None
day I None
postlesion I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
rostral I None
ventrolateral I None
medulla I None
neurons I None
appear I None
to I None
play I None
a I None
significant I None
role I None
in I None
maintaining I None
hypertension I Disease
in I None
conscious I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
Spinal I None
or I None
suprabulbar I None
structures I None
could I None
be I None
responsible I None
for I None
the I None
gradual I None
recovery I None
of I None
the I None
hypertension I Disease
in I None
the I None
lesioned I None
rats I None
. I None
<eof> I None

<s> O None
Damage I Disease
of O Disease
substantia O Disease
nigra O Disease
pars O Disease
reticulata O Disease
during I None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
status I Disease
epilepticus O Disease
in I None
the I None
rat I None
: I None
immunohistochemical I None
study I None
of I None
neurons I None
, I None
astrocytes I None
and I None
serum I None
- I None
protein I None
extravasation I None
. I None
<eof> I None

<s> O None
The I None
substantia I None
nigra I None
has I None
a I None
gating I None
function I None
controlling I None
the I None
spread I None
of I None
epileptic I Disease
seizure O Disease
activity I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
in I None
models I None
of I None
prolonged I Disease
status O Disease
epilepticus O Disease
<eof> I None

<s> O None
the I None
pars I None
reticulata I None
of I None
substantia I None
nigra I None
( I None
SNR I None
) I None
suffers I None
from I None
a I None
massive I None
lesion I None
which I None
may I None
arise I None
from I None
a I None
massive I None
metabolic I Disease
derangement O Disease
and I None
hyperexcitation I None
developing I None
in I None
the I None
activated I None
SNR I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
status I Disease
epilepticus O Disease
was I None
induced I None
by I None
systemic I None
injection I None
of I None
pilocarpine I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
neuropathology I None
of I None
SNR I None
was I None
investigated I None
using I None
immunohistochemical I None
techniques I None
with I None
the I None
major I None
emphasis I None
on I None
the I None
time I None
- I None
course I None
of I None
changes I None
in I None
neurons I None
and I None
astrocytes I None
. I None
<eof> I None

<s> O None
Animals I None
surviving I None
20 I None
, I None
30 I None
, I None
40 I None
, I None
60 I None
min I None
, I None
2 I None
, I None
3 I None
, I None
6 I None
hours I None
, I None
1 I None
, I None
2 I None
, I None
and I None
3 I None
days I None
after I None
induction I None
of I None
status I Disease
epilepticus O Disease
were I None
perfusion I None
- I None
fixed I None
, I None
and I None
brains I None
processed I None
for I None
immunohistochemical I None
staining I None
of I None
SNR I None
. I None
<eof> I None

<s> O None
Nissl I None
- I None
staining I None
and I None
antibodies I None
against I None
the I None
neuron I None
- I None
specific I None
calcium I Chemical
-binding I None
protein I None
, I None
parvalbumin I None
, I None
served I None
to I None
detect I None
neuronal I Disease
damage O Disease
in I None
SNR I None
. I None
<eof> I None

<s> O None
Antibodies I None
against I None
the I None
astroglia I None
- I None
specific I None
cytoskeletal I None
protein I None
, I None
glial I None
fibrillary I None
acidic I None
protein I None
( I None
GFAP I None
) I None
, I None
and I None
against I None
the I None
glial I None
calcium I Chemical
-binding I None
protein I None
, I None
S-100 I None
protein I None
, I None
were I None
used I None
to I None
assess I None
the I None
status I None
of I None
astrocytes I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
staining I None
for I None
serum I None
- I None
albumin I None
and I None
immunoglobulins I None
in I None
brain I None
tissue I None
was I None
taken I None
as I None
indicator I None
of I None
blood I None
- I None
brain I None
barrier I None
disturbances I None
and I None
vasogenic I Disease
edema O Disease
formation I None
. I None
<eof> I None

<s> O None
Immunohistochemical I None
staining I None
indicated I None
loss I None
of I None
GFAP I None
- I None
staining I None
already I None
at I None
30 I None
min I None
after I None
induction I None
of I None
seizures I Disease
in I None
an I None
oval I None
focus I None
situated I None
in I None
the I None
center I None
of I None
SNR I None
while I None
sparing I None
medial I None
and I None
lateral I None
aspects I None
. I None
<eof> I None

<s> O None
At I None
1 I None
h I None
there I None
was I None
additional I None
vacuolation I None
in I None
S-100 I None
protein I None
staining I None
. I None
<eof> I None

<s> O None
By I None
2 I None
hours I None
, I None
parvalbumin I None
- I None
staining I None
changed I None
in I None
the I None
central I None
SNR I None
indicating I None
neuronal I Disease
damage O Disease
, I None
and I None
Nissl I None
- I None
staining I None
visualized I None
some I None
neuronal I None
distortion I None
. I None
<eof> I None

<s> O None
Staining I None
for I None
serum I None
- I None
proteins I None
occurred I None
in I None
a I None
patchy I None
manner I None
throughout I None
the I None
forebrain I None
during I None
the I None
first I None
hours I None
. I None
<eof> I None

<s> O None
By I None
6 I None
h I None
, I None
vasogenic I Disease
edema O Disease
covered I None
the I None
lesioned I Disease
SNR O Disease
. I None
<eof> I None

<s> O None
By I None
24 I None
h I None
, I None
glial I None
and I None
neuronal I None
markers I None
indicated I None
a I None
massive I None
lesion I None
in I None
the I None
center I None
of I None
SNR I None
. I None
<eof> I None

<s> O None
By I None
48 I None
- I None
72 I None
h I None
, I None
astrocytes I None
surrounding I None
the I None
lesion I None
increased I None
in I None
size I None
, I None
and I None
polymorphic I None
phagocytotic I None
cells I None
invaded I None
the I None
damaged I None
area I None
. I None
<eof> I None

<s> O None
In I None
a I None
further I None
group I None
of I None
animals I None
surviving I None
1 I None
to I None
5 I None
days I None
, I None
conventional I None
paraffin I None
- I None
sections I None
confirmed I None
the I None
neuronal I None
and I None
glial I None
damage I Disease
of O Disease
SNR O Disease
. I None
<eof> I None

<s> O None
Additional I None
pathology I None
of I None
similar I None
quality I None
was I None
found I None
in I None
the I None
globus I None
pallidus I None
. I None
<eof> I None

<s> O None
Since I None
astrocytes I None
were I None
always I None
damaged I None
in I None
parallel I None
with I None
neurons I None
in I None
SNR I None
it I None
is I None
proposed I None
that I None
the I None
anatomical I None
and I None
functional I None
interrelationship I None
between I None
neurons I None
and I None
astrocytes I None
is I None
particularly I None
tight I None
in I None
SNR I None
. I None
<eof> I None

<s> O None
Both I None
cell I None
elements I None
may I None
suffer I None
in I None
common I None
from I None
metabolic I None
disturbance I None
and I None
neurotransmitter I Disease
dysfunction O Disease
as I None
occur I None
during I None
massive I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
Reduced I None
cardiotoxicity I Disease
of I None
<eof> I None

<s> O None
doxorubicin I Chemical
given I None
in I None
the I None
form I None
of I None
N-(2-hydroxypropyl)methacrylamide I Chemical
conjugates I None
: I None
and I None
experimental I None
study I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
A I None
rat I None
model I None
was I None
used I None
to I None
evaluate I None
the I None
general I None
acute I None
toxicity I Disease
and I None
the I None
late I None
cardiotoxicity I Disease
of I None
4 I None
mg I None
/ I None
kg I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
given I None
either I None
as I None
free I None
drug I None
or I None
in I None
the I None
form I None
of I None
three I None
N-(2-hydroxypropyl)methacrylamide I Chemical
<eof> I None

<s> O None
( I None
HPMA I Chemical
) I None
copolymer I None
conjugates I None
. I None
<eof> I None

<s> O None
In I None
these I None
HPMA I Chemical
copolymers I None
, I None
DOX I Chemical
was I None
covalently I None
bound I None
via I None
peptide I None
linkages I None
that I None
were I None
either I None
non I None
- I None
biodegradable I None
( I None
Gly I None
- I None
Gly I None
) I None
or I None
degradable I None
by I None
lysosomal I None
proteinases I None
( I None
Gly I Chemical
- O Chemical
Phe O Chemical
- O Chemical
Leu O Chemical
- O Chemical
Gly O Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
one I None
biodegradable I None
conjugate I None
containing I None
galactosamine I Chemical
was I None
used I None
; I None
this I None
residue I None
was I None
targeted I None
to I None
the I None
liver I None
. I None
<eof> I None

<s> O None
Over I None
the I None
first I None
3 I None
weeks I None
after I None
the I None
i.v I None
. I None
administration I None
of I None
free I None
and I None
polymer I None
- I None
bound I None
DOX I Chemical
, I None
all I None
animals I None
showed I None
a I None
transient I None
reduction I None
in I None
body I None
weight I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
maximal I None
reduction I None
in I None
body I None
weight I None
seen I None
in I None
animals I None
that I None
received I None
polymer I None
- I None
bound I None
DOX I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg I None
/ I None
kg I None
) I None
was I None
significantly I None
lower I None
than I None
that I None
observed I None
in I None
those I None
that I None
received I None
free I None
DOX I Chemical
( I None
4 I None
mg I None
/ I None
kg I None
) I None
or I None
a I None
mixture I None
of I None
the I None
unmodified I None
parent I None
HPMA I Chemical
copolymer I None
and I None
free I None
DOX I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg I None
/ I None
kg I None
; I None
P I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Throughout I None
the I None
study I None
( I None
20 I None
weeks I None
) I None
, I None
deaths I None
related I None
to I None
cardiotoxicity I Disease
were I None
observed I None
only I None
in I None
animals I None
that I None
received I None
either I None
free I None
DOX I Chemical
or I None
the I None
mixture I None
of I None
HPMA I Chemical
copolymer I None
and I None
free I None
DOX I Chemical
; I None
in I None
these I None
cases I None
, I None
histological I None
investigations I None
revealed I None
marked I None
changes I None
in I None
the I None
heart I None
that I None
were I None
consistent I None
with I None
DOX I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Sequential I None
measurements I None
of I None
cardiac I None
output I None
in I None
surviving I None
animals I None
that I None
received I None
either I None
free I None
DOX I Chemical
or I None
the I None
mixture I None
of I None
HPMA I Chemical
copolymer I None
and I None
free I None
<eof> I None

<s> O None
DOX I Chemical
showed I None
a I None
reduction I None
of I None
approximately I None
30 I None
% I None
in I None
function I None
beginning I None
at I None
the I None
4th I None
week I None
after I None
drug I None
administration I None
. I None
<eof> I None

<s> O None
The I None
heart I None
rate I None
in I None
these I None
animals I None
was I None
approximately I None
12 I None
% I None
lower I None
than I None
that I None
measured I None
in I None
age I None
- I None
matched I None
control I None
rats I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Animals I None
that I None
were I None
given I None
the I None
HPMA I Chemical
copolymer I None
conjugates I None
containing I None
DOX I Chemical
exhibited I None
no I None
significant I None
change I None
in I None
cardiac I None
output I None
throughout I None
the I None
study I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
no I None
significant I None
histological I None
change I None
was I None
observed I None
in I None
the I None
heart I None
of I None
animals I None
that I None
received I None
DOX I Chemical
in I None
the I None
form I None
of I None
HPMA I Chemical
copolymer I None
conjugates I None
and I None
were I None
killed I None
at I None
the I None
end I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
However I None
, I None
these I None
animals I None
had I None
shown I None
a I None
significant I None
increase I None
in I None
heart I None
rate I None
beginning I None
at I None
8 I None
weeks I None
after I None
drug I None
administration I None
( I None
P I None
less I None
than I None
0.01).(ABSTRACT I None
TRUNCATED I None
AT I None
400 I None
WORDS I None
) I None
<eof> I None

<s> O None
Topical I None
0.025 I None
% I None
capsaicin I Chemical
in I None
chronic I None
post I Disease
- O Disease
herpetic O Disease
neuralgia O Disease
: I None
efficacy I None
, I None
predictors I None
of I None
response I None
and I None
long I None
- I None
term I None
course I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
evaluate I None
the I None
efficacy I None
, I None
time I None
- I None
course I None
of I None
action I None
and I None
predictors I None
of I None
response I None
to I None
topical I None
capsaicin I Chemical
, I None
39 I None
patients I None
with I None
chronic I None
post I Disease
- O Disease
herpetic O Disease
neuralgia O Disease
<eof> I None

<s> O None
( I None
PHN I Disease
) I None
, I None
median I None
duration I None
24 I None
months I None
, I None
were I None
treated I None
with I None
0.025 I None
% I None
capsaicin I Chemical
cream I None
for I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
During I None
therapy I None
the I None
patients I None
rated I None
their I None
pain I Disease
on I None
a I None
visual I None
analogue I None
scale I None
( I None
VAS I None
) I None
and I None
a I None
verbal I None
outcome I None
scale I None
. I None
<eof> I None

<s> O None
A I None
follow I None
- I None
up I None
investigation I None
was I None
performed I None
10 I None
- I None
12 I None
months I None
after I None
study I None
onset I None
on I None
the I None
patients I None
who I None
had I None
improved I None
. I None
<eof> I None

<s> O None
Nineteen I None
patients I None
( I None
48.7 I None
% I None
) I None
substantially I None
improved I None
after I None
the I None
8-week I None
trial I None
; I None
5 I None
( I None
12.8 I None
% I None
) I None
discontinued I None
therapy I None
due I None
to I None
side I None
- I None
effects I None
such I None
as I None
intolerable I None
capsaicin I Chemical
<eof> I None

<s> O None
-induced I None
burning I None
sensations I None
( I None
4 I None
) I None
or I None
mastitis I Disease
( I None
1 I None
) I None
; I None
15 I None
( I None
38.5 I None
% I None
) I None
reported I None
no I None
benefit I None
. I None
<eof> I None

<s> O None
The I None
decrease I None
in I None
VAS I None
ratings I None
was I None
significant I None
after I None
2 I None
weeks I None
of I None
continuous I None
application I None
. I None
<eof> I None

<s> O None
Of I None
the I None
responders I None
72.2 I None
% I None
were I None
still I None
improved I None
at I None
the I None
follow I None
- I None
up I None
; I None
only I None
one I None
- I None
third I None
of I None
them I None
had I None
continued I None
application I None
irregularly I None
. I None
<eof> I None

<s> O None
Treatment I None
effect I None
was I None
not I None
dependent I None
on I None
patient I None
's I None
age I None
, I None
duration I None
or I None
localization I None
of I None
PHN I Disease
<eof> I None

<s> O None
( I None
trigeminal I None
involvement I None
was I None
excluded I None
) I None
, I None
<eof> I None

<s> O None
sensory I Disease
disturbance O Disease
or I None
pain I Disease
character I None
. I None
<eof> I None

<s> O None
Treatment I None
response I None
was I None
not I None
correlated I None
with I None
the I None
incidence I None
, I None
time I None
- I None
course I None
or I None
severity I None
of I None
capsaicin I Chemical
-induced I None
burning I None
. I None
<eof> I None

<s> O None
If I None
confirmed I None
in I None
controlled I None
trials I None
, I None
the I None
long I None
- I None
term I None
results I None
of I None
this I None
open I None
, I None
non I None
- I None
randomized I None
study I None
might I None
indicate I None
that I None
the I None
analgesic I None
effect I None
of I None
capsaicin I Chemical
in I None
PHN I Disease
is I None
mediated I None
by I None
both I None
interference I None
with I None
neuropeptide I None
metabolism I None
and I None
morphological I None
changes I None
( I None
perhaps I None
degeneration I None
) I None
of I None
nociceptive I None
afferents I None
. I None
<eof> I None

<s> O None
Serotonin I Chemical
reuptake I None
inhibitors I None
, I None
paranoia I Disease
, I None
and I None
the I None
ventral I None
basal I None
ganglia I None
. I None
<eof> I None

<s> O None
Antidepressants I None
have I None
previously I None
been I None
associated I None
with I None
paranoid I Disease
reactions I None
in I None
psychiatric I None
patients I None
. I None
<eof> I None

<s> O None
Five I None
cases I None
of I None
paranoid I Disease
exacerbation I None
with I None
the I None
serotonin I Chemical
reuptake I None
inhibitors I None
fluoxetine I Chemical
and I None
amitriptyline I Chemical
are I None
reported I None
here I None
. I None
<eof> I None

<s> O None
Elements I None
common I None
to I None
these I None
cases I None
included I None
a I None
history I None
of I None
paranoid I Disease
symptomatology I None
and I None
the I None
concomitant I None
occurrence I None
of I None
depressive I None
and I None
psychotic I None
symptoms I None
. I None
<eof> I None

<s> O None
Complicated I None
depressive I Disease
disorders O Disease
( I None
including I None
atypicality I None
of I None
course I None
and I None
symptomatology I None
, I None
chronicity I None
, I None
psychosis I Disease
, I None
bipolarity I None
, I None
and I None
secondary I None
onset I None
in I None
the I None
course I None
of I None
a I None
primary I None
psychosis I Disease
) I None
<eof> I None

<s> O None
may I None
present I None
particular I None
vulnerability I None
to I None
paranoid I Disease
exacerbations I None
associated I None
with I None
serotonin I Chemical
reuptake I None
inhibitors I None
. I None
<eof> I None

<s> O None
Although I None
the I None
pharmacology I None
and I None
neurobiology I None
of I None
paranoia I Disease
remain I None
cryptic I None
, I None
several I None
mechanisms I None
, I None
including I None
5HT3 I None
receptor I None
- I None
mediated I None
dopamine I Chemical
release I None
, I None
beta I None
- I None
noradrenergic I None
receptor I None
downregulation I None
, I None
or I None
GABAB I None
receptor I None
upregulation I None
acting I None
in I None
the I None
vicinity I None
of I None
the I None
ventral I None
basal I None
ganglia I None
( I None
possibly I None
in I None
lateral I None
orbitofrontal I None
or I None
anterior I None
cingulate I None
circuits I None
) I None
, I None
might I None
apply I None
to I None
this I None
phenomenon I None
. I None
<eof> I None

<s> O None
These I None
cases I None
call I None
attention I None
to I None
possible I None
paranoid I Disease
exacerbations I None
with I None
serotonin I Chemical
reuptake I None
blockers I None
in I None
select I None
patients I None
and I None
raise I None
neurobiological I None
considerations I None
regarding I None
paranoia I Disease
. I None
<eof> I None

<s> O None
Five I None
cases I None
of I None
encephalitis I Disease
during I None
treatment I None
of I None
loiasis I Disease
with I None
diethylcarbamazine I Chemical
. I None
<eof> I None

<s> O None
Five I None
cases I None
of I None
encephalitis I Disease
following I None
treatment I None
with I None
diethylcarbamazine I Chemical
<eof> I None

<s> O None
( I None
DEC I Chemical
) I None
were I None
observed I None
in I None
Congolese I None
patients I None
with I None
Loa I None
loa I None
filariasis I Disease
. I None
<eof> I None

<s> O None
Two I None
cases I None
had I None
a I None
fatal I None
outcome I None
and I None
one I None
resulted I None
in I None
severe I None
sequelae I None
. I None
<eof> I None

<s> O None
The I None
notable I None
fact I None
was I None
that I None
this I None
complication I None
occurred I None
in I None
three I None
patients I None
hospitalized I None
before I None
treatment I None
began I None
, I None
with I None
whom I None
particularly I None
strict I None
therapeutic I None
precautions I None
were I None
taken I None
, I None
i.e. I None
, I None
initial I None
dose I None
less I None
than I None
10 I None
mg I None
of I None
DEC I Chemical
, I None
very I None
gradual I None
dose I None
increases I None
, I None
and I None
associated I None
anti I None
- I None
allergic I None
treatment I None
. I None
<eof> I None

<s> O None
This I None
type I None
of I None
drug I None
- I None
induced I None
complication I None
may I None
not I None
be I None
that I None
uncommon I None
in I None
highly I None
endemic I None
regions I None
. I None
<eof> I None

<s> O None
It I None
occurs I None
primarily I None
, I None
but I None
not I None
exclusively I None
, I None
in I None
subjects I None
presenting I None
with I None
a I None
high I None
microfilarial I None
load I None
. I None
<eof> I None

<s> O None
The I None
relationship I None
between I None
the I None
occurrence I None
of I None
encephalitis I Disease
and I None
the I None
decrease I None
in I None
microfilaremia I Disease
is I None
evident I None
. I None
<eof> I None

<s> O None
The I None
pathophysiological I None
mechanisms I None
are I None
discussed I None
in I None
the I None
light I None
of I None
these I None
observations I None
and I None
the I None
few I None
other I None
comments I None
on I None
this I None
subject I None
published I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
Delirium I Disease
in I None
an I None
elderly I None
woman I None
possibly I None
associated I None
with I None
administration I None
of I None
misoprostol I Chemical
. I None
<eof> I None

<s> O None
Misoprostol I Chemical
has I None
been I None
associated I None
with I None
adverse I None
reactions I None
, I None
including I None
gastrointestinal I None
symptoms I None
, I None
gynecologic I None
problems I None
, I None
and I None
headache I Disease
. I None
<eof> I None

<s> O None
Changes I None
in I None
mental I None
status I None
, I None
however I None
, I None
have I None
not I None
been I None
reported I None
. I None
<eof> I None

<s> O None
We I None
present I None
a I None
case I None
in I None
which I None
an I None
89-year I None
- I None
old I None
woman I None
in I None
a I None
long I None
- I None
term I None
care I None
facility I None
became I None
confused I None
after I None
the I None
initiation I None
of I None
misoprostol I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
change I None
in I None
mental I None
status I None
was I None
first I None
reported I None
nine I None
days I None
after I None
the I None
initiation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Her I None
delirium I Disease
significantly I None
improved I None
after I None
misoprostol I Chemical
was I None
discontinued I None
and I None
her I None
mental I None
status I None
returned I None
to I None
normal I None
within I None
a I None
week I None
. I None
<eof> I None

<s> O None
Because I None
no I None
other I None
factors I None
related I None
to I None
this I None
patient I None
changed I None
significantly I None
, I None
the I None
delirium I Disease
<eof> I None

<s> O None
experienced I None
by I None
this I None
patient I None
possibly I None
resulted I None
from I None
misoprostol I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Hepatocellular I None
oxidant I None
stress I None
following I None
intestinal I None
ischemia I Disease
- I None
reperfusion I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Reperfusion I None
of I None
ischemic I Disease
<eof> I None

<s> O None
intestine I None
results I None
in I None
acute I None
liver I Disease
dysfunction O Disease
characterized I None
by I None
hepatocellular I None
enzyme I None
release I None
into I None
plasma I None
, I None
reduction I None
in I None
bile I None
flow I None
rate I None
, I None
and I None
neutrophil I None
sequestration I None
within I None
the I None
liver I None
. I None
<eof> I None

<s> O None
The I None
pathophysiology I None
underlying I None
this I None
acute I None
hepatic I Disease
injury O Disease
is I None
unknown I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
determine I None
whether I None
oxidants I None
are I None
associated I None
with I None
the I None
hepatic I Disease
injury O Disease
and I None
to I None
determine I None
the I None
relative I None
value I None
of I None
several I None
indirect I None
methods I None
of I None
assessing I None
oxidant I None
exposure I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
subjected I None
to I None
a I None
standardized I None
intestinal I None
ischemia I Disease
- I None
reperfusion I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Hepatic I None
tissue I None
was I None
assayed I None
for I None
lipid I None
peroxidation I None
products I None
and I None
oxidized I None
and I None
reduced I None
glutathione I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
change I None
in I None
hepatic I None
tissue I None
total I None
glutathione I Chemical
following I None
intestinal I None
ischemia I Disease
- I None
reperfusion I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Oxidized I Chemical
glutathione O Chemical
<eof> I None

<s> O None
( I None
GSSG I Chemical
) I None
increased I None
significantly I None
following I None
30 I None
and I None
60 I None
min I None
of I None
reperfusion I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
increase I None
in I None
any I None
of I None
the I None
products I None
of I None
lipid I None
peroxidation I None
associated I None
with I None
this I None
injury I None
. I None
<eof> I None

<s> O None
An I None
increase I None
in I None
GSSG I Chemical
within I None
hepatic I None
tissue I None
during I None
intestinal I None
reperfusion I None
suggests I None
exposure I None
of I None
hepatocytes I None
to I None
an I None
oxidant I None
stress I None
. I None
<eof> I None

<s> O None
The I None
lack I None
of I None
a I None
significant I None
increase I None
in I None
products I None
of I None
lipid I None
peroxidation I None
suggests I None
that I None
the I None
oxidant I None
stress I None
is I None
of I None
insufficient I None
magnitude I None
to I None
result I None
in I None
irreversible I None
injury I None
to I None
hepatocyte I None
cell I None
membranes I None
. I None
<eof> I None

<s> O None
These I None
data I None
also I None
suggest I None
that I None
the I None
measurement I None
of I None
tissue I None
GSSG I Chemical
may I None
be I None
a I None
more I None
sensitive I None
indicator I None
of I None
oxidant I None
stress I None
than I None
measurement I None
of I None
products I None
of I None
lipid I None
peroxidation I None
. I None
<eof> I None

<s> O None
Diphenhydramine I Chemical
prevents I None
the I None
haemodynamic I None
changes I None
of I None
cimetidine I Chemical
in I None
ICU I None
patients I None
. I None
<eof> I None

<s> O None
Cimetidine I Chemical
, I None
a I None
histamine I Chemical
2 I None
( I None
H2 I None
) I None
antagonist I None
, I None
produces I None
a I None
decrease I None
in I None
arterial I None
pressure I None
due I None
to I None
vasodilatation I None
, I None
especially I None
in I None
critically I None
ill I None
patients I None
. I None
<eof> I None

<s> O None
This I None
may I None
be I None
because I None
cimetidine I Chemical
acts I None
as I None
a I None
histamine I Chemical
agonist I None
. I None
<eof> I None

<s> O None
We I None
, I None
therefore I None
, I None
investigated I None
the I None
effects I None
of I None
the I None
histamine I Chemical
<eof> I None

<s> O None
1(H1 I None
) I None
receptor I None
antagonist I None
, I None
diphenhydramine I Chemical
, I None
on I None
the I None
haemodynamic I None
changes I None
observed I None
after I None
cimetidine I Chemical
in I None
ICU I None
patients I None
. I None
<eof> I None

<s> O None
Each I None
patient I None
was I None
studied I None
on I None
two I None
separate I None
days I None
. I None
<eof> I None

<s> O None
In I None
a I None
random I None
fashion I None
, I None
they I None
received I None
<eof> I None

<s> O None
cimetidine I Chemical
200 I None
mg I None
iv I None
on I None
one I None
day I None
, I None
and I None
on I None
the I None
other I None
, I None
a I None
pretreatment I None
of I None
diphenhydramine I Chemical
<eof> I None

<s> O None
40 I None
mg I None
iv I None
with I None
cimetidine I Chemical
<eof> I None

<s> O None
200 I None
mg I None
iv I None
. I None
<eof> I None

<s> O None
In I None
the I None
non I None
- I None
pretreatment I None
group I None
, I None
mean I None
arterial I None
pressure I None
( I None
MAP I None
) I None
decreased I None
from I None
107.4 I None
+ I None
/- I None
<eof> I None

<s> O None
8.4 I None
mmHg I None
to I None
86.7 I None
+ I None
/- I None
<eof> I None

<s> O None
11.4 I None
mmHg I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
two I None
minutes I None
after I None
cimetidine I Chemical
. I None
<eof> I None

<s> O None
Also I None
, I None
systemic I None
vascular I None
resistance I None
( I None
SVR I None
) I None
decreased I None
during I None
the I None
eight I None
- I None
minute I None
observation I None
period I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
in I None
the I None
pretreatment I None
group I None
, I None
little I None
haemodynamic I None
change I None
was I None
seen I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
an I None
H1 I None
antagonist I None
may I None
be I None
useful I None
in I None
preventing I None
hypotension I Disease
caused I None
by I None
iv I None
cimetidine I Chemical
, I None
since I None
the I None
vasodilating I None
activity I None
of I None
cimetidine I Chemical
is I None
mediated I None
, I None
in I None
part I None
, I None
through I None
the I None
H1 I None
receptor I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
due I None
to I None
rifampicin I Chemical
. I None
<eof> I None

<s> O None
A I None
23-year I None
- I None
old I None
male I None
patient I None
with I None
bacteriologically I None
proven I None
pulmonary I Disease
tuberculosis O Disease
was I None
treated I None
with I None
the I None
various I None
regimens I None
of I None
antituberculosis I None
drugs I None
for I None
nearly I None
15 I None
months I None
. I None
<eof> I None

<s> O None
Rifampicin I Chemical
was I None
administered I None
thrice I None
as I None
one I None
of I None
the I None
3 I None
- I None
4 I None
drug I None
regimen I None
and I None
each I None
time I None
he I None
developed I None
untoward I None
side I None
effects I None
like I None
nausea I Disease
, I None
vomiting I Disease
and I None
fever I Disease
with I None
chills I None
and I None
rigors I None
. I None
<eof> I None

<s> O None
The I None
last I None
such I None
episode I None
was I None
of I None
acute I None
renal I None
failure I None
at I None
which I None
stage I None
the I None
patient I None
was I None
seen I None
by I None
the I None
authors I None
of I None
this I None
report I None
. I None
<eof> I None

<s> O None
The I None
patient I None
, I None
however I None
, I None
made I None
a I None
full I None
recovery I None
. I None
<eof> I None

<s> O None
Severe I None
polyneuropathy I Disease
and I None
motor I None
loss I None
after I None
intrathecal I None
thiotepa I Chemical
<eof> I None

<s> O None
combination I None
chemotherapy I None
: I None
description I None
of I None
two I None
cases I None
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
severe I None
delayed I None
neurologic I Disease
toxicity O Disease
related I None
to I None
the I None
administration I None
of I None
intrathecal I None
( I None
IT I None
) I None
combination I None
chemotherapy I None
including I None
thiotepa I Chemical
<eof> I None

<s> O None
( I None
TSPA I Chemical
) I None
are I None
presented I None
. I None
<eof> I None

<s> O None
Both I None
cases I None
developed I None
axonal I Disease
neuropathy O Disease
with I None
motor I None
predominance I None
in I None
the I None
lower I None
extremities I None
1 I None
and I None
6 I None
months I None
after I None
IT I None
chemotherapy I None
was I None
administered I None
. I None
<eof> I None

<s> O None
Neurologic I Disease
toxicities O Disease
have I None
been I None
described I None
with I None
IT- I None
methotrexate I Chemical
, I None
IT- I None
cytosine I Chemical
arabinoside O Chemical
and I None
IT- I None
TSPA I Chemical
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
however I None
, I None
axonal I Disease
neuropathy O Disease
<eof> I None

<s> O None
following I None
administration I None
of I None
these I None
three I None
agents I None
has I None
not I None
been I None
previously I None
described I None
. I None
<eof> I None

<s> O None
In I None
spite I None
of I None
the I None
fact I None
that I None
TSPA I Chemical
is I None
a I None
useful I None
IT I None
agent I None
, I None
its I None
combination I None
with I None
MTX I Chemical
, I None
ara I Chemical
- O Chemical
C O Chemical
and I None
radiotherapy I None
could I None
cause I None
severe I None
neurotoxicity I Disease
. I None
<eof> I None

<s> O None
This I None
unexpected I None
complication I None
indicates I None
the I None
need I None
for I None
further I None
toxicology I None
research I None
on I None
IT- I None
TSPA I Chemical
. I None
<eof> I None

<s> O None
Effects I None
of I None
cromakalim I Chemical
and I None
pinacidil I Chemical
on I None
large I None
epicardial I None
and I None
small I None
coronary I None
arteries I None
in I None
conscious I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
i.v I None
. I None
<eof> I None

<s> O None
bolus I None
administration I None
of I None
cromakalim I Chemical
<eof> I None

<s> O None
( I None
1 I None
- I None
10 I None
micrograms I None
/ I None
kg I None
) I None
and I None
pinacidil I Chemical
<eof> I None

<s> O None
( I None
3 I None
- I None
100 I None
micrograms I None
/ I None
kg I None
) I None
on I None
large I None
( I None
circumflex I None
artery I None
) I None
and I None
small I None
coronary I None
arteries I None
and I None
on I None
systemic I None
hemodynamics I None
were I None
investigated I None
in I None
chronically I None
instrumented I None
conscious I None
dogs I None
and I None
compared I None
to I None
those I None
of I None
nitroglycerin I Chemical
( I None
0.03 I None
- I None
10 I None
micrograms I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
Nitroglycerin I Chemical
, I None
up I None
to I None
0.3 I None
micrograms I None
/ I None
kg I None
, I None
selectively I None
increased I None
circumflex I None
artery I None
diameter I None
( I None
CxAD I None
) I None
without I None
simultaneously I None
affecting I None
any I None
other I None
cardiac I None
or I None
systemic I None
hemodynamic I None
parameter I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
cromakalim I Chemical
and I None
pinacidil I Chemical
at I None
all I None
doses I None
and I None
nitroglycerin I Chemical
at I None
doses I None
higher I None
than I None
0.3 I None
micrograms I None
/ I None
kg I None
simultaneously I None
and I None
dose I None
- I None
dependently I None
increased I None
CxAD I None
, I None
coronary I None
blood I None
flow I None
and I None
heart I None
rate I None
and I None
decreased I None
coronary I None
vascular I None
resistance I None
and I None
aortic I None
pressure I None
. I None
<eof> I None

<s> O None
Cromakalim I Chemical
was I None
approximately I None
<eof> I None

<s> O None
8- I None
to I None
9.5-fold I None
more I None
potent I None
than I None
pinacidil I Chemical
in I None
increasing I None
CxAD I None
. I None
<eof> I None

<s> O None
Vasodilation I None
of I None
large I None
and I None
small I None
coronary I None
vessels I None
and I None
hypotension I Disease
induced I None
by I None
cromakalim I Chemical
and I None
pinacidil I Chemical
were I None
not I None
affected I None
by I None
prior I None
combined I None
beta I None
adrenergic I None
and I None
muscarinic I None
receptors I None
blockade I None
but I None
drug I None
- I None
induced I None
tachycardia I Disease
was I None
abolished I None
. I None
<eof> I None

<s> O None
When I None
circumflex I None
artery I None
blood I None
flow I None
was I None
maintained I None
constant I None
, I None
the I None
increases I None
in I None
CxAD I None
induced I None
by I None
cromakalim I Chemical
<eof> I None

<s> O None
( I None
10 I None
micrograms I None
/ I None
kg I None
) I None
, I None
pinacidil I Chemical
<eof> I None

<s> O None
( I None
30 I None
micrograms I None
/ I None
kg I None
) I None
and I None
nitroglycerin I Chemical
<eof> I None

<s> O None
( I None
10 I None
micrograms I None
/ I None
kg I None
) I None
were I None
reduced I None
by I None
68 I None
+ I None
/- I None
7 I None
, I None
54 I None
+ I None
/- I None
<eof> I None

<s> O None
9 I None
and I None
1 I None
+ I None
/- I None
1 I None
% I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
whereas I None
nitroglycerin I Chemical
preferentially I None
and I None
flow I None
- I None
independently I None
dilates I None
large I None
coronary I None
arteries I None
, I None
cromakalim I Chemical
and I None
pinacidil I Chemical
dilate I None
both I None
large I None
and I None
small I None
coronary I None
arteries I None
and I None
this I None
effect I None
is I None
not I None
dependent I None
upon I None
the I None
simultaneous I None
beta I None
adrenoceptors I None
- I None
mediated I None
rise I None
in I None
myocardial I None
metabolic I None
demand I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
two I None
mechanisms I None
at I None
least I None
, I None
direct I None
vasodilation I None
and I None
flow I None
dependency I None
, I None
are I None
involved I None
in I None
the I None
cromakalim I Chemical
- I None
and I None
pinacidil I Chemical
-induced I None
increase I None
in I None
CxAD I None
. I None
<eof> I None

<s> O None
Mefenamic I Chemical
acid O Chemical
-induced I None
neutropenia I Disease
and I None
renal I Disease
failure O Disease
in I None
elderly I None
females I None
with I None
hypothyroidism I Disease
. I None
<eof> I None

<s> O None
We I None
report I None
<eof> I None

<s> O None
mefenamic I Chemical
acid O Chemical
-induced I None
non I None
- I None
oliguric I None
renal I Disease
failure O Disease
and I None
severe I None
neutropenia I Disease
occurring I None
simultaneously I None
in I None
two I None
elderly I None
females I None
. I None
<eof> I None

<s> O None
The I None
neutropenia I Disease
was I None
due I None
to I None
maturation I None
arrest I None
of I None
the I None
myeloid I None
series I None
in I None
one I None
patient I None
. I None
<eof> I None

<s> O None
Both I None
patients I None
were I None
also I None
hypothyroid I Disease
, I None
but I None
it I None
is I None
not I None
clear I None
whether I None
this I None
was I None
a I None
predisposing I None
factor I None
to I None
the I None
development I None
of I None
these I None
adverse I None
reactions I None
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
would I None
seem I None
prudent I None
not I None
to I None
use I None
mefenamic I Chemical
acid O Chemical
in I None
hypothyroid I Disease
patients I None
until I None
the I None
hypothyroidism I Disease
has I None
been I None
corrected I None
. I None
<eof> I None

<s> O None
Etiology I None
of I None
<eof> I None

<s> O None
hypercalcemia I Disease
in I None
hemodialysis I None
patients I None
on I None
calcium I Chemical
carbonate O Chemical
therapy I None
. I None
<eof> I None

<s> O None
Fourteen I None
of I None
39 I None
dialysis I None
patients I None
( I None
36 I None
% I None
) I None
became I None
hypercalcemic I Disease
after I None
switching I None
to I None
calcium I Chemical
carbonate O Chemical
as I None
their I None
principal I None
phosphate I Chemical
binder I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
identify I None
risk I None
factors I None
associated I None
with I None
the I None
development I None
of I None
hypercalcemia I Disease
, I None
indirect I None
parameters I None
of I None
intestinal I None
calcium I Chemical
reabsorption I None
and I None
bone I None
turnover I None
rate I None
in I None
these I None
14 I None
patients I None
were I None
compared I None
with I None
results I None
in I None
14 I None
eucalcemic I None
patients I None
matched I None
for I None
age I None
, I None
sex I None
, I None
length I None
of I None
time I None
on I None
dialysis I None
, I None
and I None
etiology I None
of I None
renal I Disease
disease O Disease
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
experiencing I None
hypercalcemic I Disease
episodes I None
with I None
peak I None
calcium I Chemical
values I None
of I None
2.7 I None
to I None
3.8 I None
mmol I None
/ I None
L I None
( I None
10.7 I None
to I None
15.0 I None
mg I None
/ I None
dL I None
) I None
, I None
patients I None
in I None
the I None
hypercalcemic I Disease
group I None
exhibited I None
a I None
significant I None
increase I None
in I None
the I None
mean I None
calcium I Chemical
concentration I None
obtained I None
during I None
6 I None
months I None
before I None
the I None
switch I None
, I None
compared I None
with I None
the I None
mean I None
value I None
obtained I None
during I None
the I None
7 I None
months I None
of I None
observation I None
after I None
the I None
switch I None
( I None
2.4 I None
+ I None
/- I None
0.03 I None
to I None
2.5 I None
+ I None
/- I None
<eof> I None

<s> O None
0.03 I None
mmol I None
/ I None
L I None
[ I None
9.7 I None
+ I None
/- I None
0.2 I None
to I None
10.2 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
mg I None
/ I None
dL I None
] I None
, I None
P I None
= I None
0.006 I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
eucalcemic I None
patients I None
exhibited I None
no I None
change I None
in I None
mean I None
calcium I Chemical
values I None
over I None
the I None
same I None
time I None
period I None
( I None
2.3 I None
+ I None
/- I None
0.05 I None
to I None
2.3 I None
+ I None
/- I None
<eof> I None

<s> O None
0.05 I None
mmol I None
/ I None
L I None
[ I None
<eof> I None

<s> O None
9.2 I None
+ I None
/- I None
0.2 I None
to I None
9.2 I None
+ I None
/- I None
0.2 I None
mg I None
/ I None
dL I None
] I None
) I None
. I None
<eof> I None

<s> O None
CaCO3 I Chemical
dosage I None
, I None
calculated I None
dietary I None
calcium I Chemical
intake I None
, I None
and I None
circulating I None
levels I None
of I None
vitamin I Chemical
D O Chemical
metabolites I None
were I None
similar I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
Physical I None
activity I None
index I None
and I None
predialysis I None
serum I None
<eof> I None

<s> O None
bicarbonate I Chemical
levels I None
also I None
were I None
similar I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
was I None
a I None
significant I None
difference I None
in I None
parameters I None
reflecting I None
bone I None
turnover I None
rates I None
between I None
groups.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Methyldopa I Chemical
-induced I None
hemolytic I Disease
anemia O Disease
in I None
a I None
15 I None
year I None
old I None
presenting I None
as I None
near- I None
syncope I Disease
. I None
<eof> I None

<s> O None
Methyldopa I Chemical
is I None
an I None
antihypertensive I None
medication I None
which I None
is I None
available I None
generically I None
and I None
under I None
the I None
trade I None
name I None
Aldomet I Chemical
that I None
is I None
widely I None
prescribed I None
in I None
the I None
adult I None
population I None
and I None
infrequently I None
used I None
in I None
children I None
. I None
<eof> I None

<s> O None
Methyldopa I Chemical
causes I None
an I None
autoimmune I Disease
hemolytic O Disease
anemia O Disease
in I None
a I None
small I None
percentage I None
of I None
patients I None
who I None
take I None
the I None
drug I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
methyldopa I Chemical
-induced I None
hemolytic I Disease
anemia O Disease
in I None
a I None
15-year I None
- I None
old I None
boy I None
who I None
presented I None
to I None
the I None
emergency I Disease
department O Disease
with I None
near- I None
syncope I Disease
. I None
<eof> I None

<s> O None
The I None
boy I None
had I None
been I None
treated I None
with I None
intravenous I None
methyldopa I Chemical
during I None
a I None
trauma I Disease
admission I None
seven I None
weeks I None
prior I None
to I None
presentation I None
. I None
<eof> I None

<s> O None
Evaluation I None
revealed I None
a I None
hemoglobin I None
of I None
three I None
grams I None
, I None
3 I None
+ I None
Coombs I None
' I None
test I None
with I None
polyspecific I None
anti I None
- I None
human I None
globulin I None
and I None
monospecific I None
IgG I None
reagents I None
, I None
and I None
a I None
warm I None
reacting I None
autoantibody I None
. I None
<eof> I None

<s> O None
Transfusion I None
and I None
corticosteroid I Chemical
therapy I None
resulted I None
in I None
a I None
complete I None
recovery I None
of I None
the I None
patient I None
. I None
<eof> I None

<s> O None
Emergency I None
physicians I None
treating I None
children I None
must I None
be I None
aware I None
of I None
this I None
syndrome I None
in I None
order I None
to I None
diagnose I None
and I None
treat I None
it I None
correctly I None
. I None
<eof> I None

<s> O None
A I None
brief I None
review I None
of I None
autoimmune I None
and I None
drug I None
- I None
induced I None
hemolytic I Disease
anemias O Disease
is I None
provided I None
. I None
<eof> I None

<s> O None
The I None
long I None
- I None
term I None
safety I None
of I None
danazol I Chemical
in I None
women I None
with I None
hereditary I Disease
angioedema O Disease
. I None
<eof> I None

<s> O None
Although I None
the I None
short I None
- I None
term I None
safety I None
( I None
less I None
than I None
or I None
equal I None
to I None
6 I None
months I None
) I None
of I None
danazol I Chemical
has I None
been I None
established I None
in I None
a I None
variety I None
of I None
settings I None
, I None
no I None
information I None
exists I None
as I None
to I None
its I None
long I None
- I None
term I None
safety I None
. I None
<eof> I None

<s> O None
We I None
therefore I None
investigated I None
the I None
long I None
- I None
term I None
safety I None
of I None
danazol I Chemical
by I None
performing I None
a I None
retrospective I None
chart I None
review I None
of I None
60 I None
female I None
patients I None
with I None
hereditary I Disease
angioedema O Disease
treated I None
with I None
danazol I Chemical
for I None
a I None
continuous I None
period I None
of I None
6 I None
months I None
or I None
longer I None
. I None
<eof> I None

<s> O None
The I None
mean I None
age I None
of I None
the I None
patients I None
was I None
35.2 I None
years I None
and I None
the I None
mean I None
duration I None
of I None
therapy I None
was I None
59.7 I None
months I None
. I None
<eof> I None

<s> O None
Virtually I None
all I None
patients I None
experienced I None
one I None
or I None
more I None
adverse I None
reactions I None
. I None
<eof> I None

<s> O None
Menstrual I Disease
abnormalities O Disease
( I None
79 I None
% I None
) I None
, I None
weight I Disease
gain O Disease
<eof> I None

<s> O None
( I None
60 I None
% I None
) I None
, I None
muscle I Disease
cramps O Disease
/ I None
myalgias I Disease
( I None
40 I None
% I None
) I None
, I None
and I None
transaminase I None
elevations I None
( I None
40 I None
% I None
) I None
were I None
the I None
most I None
common I None
adverse I None
reactions I None
. I None
<eof> I None

<s> O None
The I None
drug I None
was I None
discontinued I None
due I None
to I None
adverse I None
reactions I None
in I None
8 I None
patients I None
. I None
<eof> I None

<s> O None
No I None
patient I None
has I None
died I None
or I None
suffered I None
any I None
apparent I None
long I None
- I None
term I None
sequelae I None
that I None
were I None
directly I None
attributable I None
to I None
the I None
drug I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
, I None
despite I None
a I None
relatively I None
high I None
incidence I None
of I None
adverse I None
reactions I None
, I None
danazol I Chemical
has I None
proven I None
to I None
be I None
remarkably I None
safe I None
over I None
the I None
long I None
- I None
term I None
in I None
this I None
group I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Patient I None
tolerance I None
study I None
of I None
topical I None
chlorhexidine I Chemical
diphosphanilate O Chemical
: I None
a I None
new I None
topical I None
agent I None
for I None
burns I Disease
. I None
<eof> I None

<s> O None
Effective I None
topical I None
antimicrobial I None
agents I None
decrease I None
infection I Disease
and I None
mortality I None
in I None
burn I Disease
patients I None
. I None
<eof> I None

<s> O None
Chlorhexidine I Chemical
phosphanilate O Chemical
<eof> I None

<s> O None
( I None
CHP I Chemical
) I None
, I None
a I None
new I None
broad I None
- I None
spectrum I None
antimicrobial I None
agent I None
, I None
has I None
been I None
evaluated I None
as I None
a I None
topical I None
burn I Disease
wound I None
dressing I None
in I None
cream I None
form I None
, I None
but I None
preliminary I None
clinical I None
trials I None
reported I None
that I None
it I None
was I None
painful I None
upon I None
application I None
. I None
<eof> I None

<s> O None
This I None
study I None
compared I None
various I None
concentrations I None
of I None
CHP I Chemical
to I None
determine I None
if I None
a I None
tolerable I None
concentration I None
could I None
be I None
identified I None
with I None
retention I None
of I None
antimicrobial I None
efficacy I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
nine I None
<eof> I None

<s> O None
burn I Disease
patients I None
, I None
each I None
with I None
two I None
similar I None
burns I Disease
which I None
could I None
be I None
separately I None
treated I None
, I None
were I None
given I None
pairs I None
of I None
treatments I None
at I None
successive I None
12-h I None
intervals I None
over I None
a I None
3-day I None
period I None
. I None
<eof> I None

<s> O None
One I None
burn I Disease
site I None
was I None
treated I None
with I None
each I None
of I None
four I None
different I None
CHP I Chemical
concentrations I None
, I None
from I None
0.25 I None
per I None
cent I None
to I None
2 I None
per I None
cent I None
, I None
their I None
vehicle I None
, I None
and I None
1 I None
per I None
cent I None
silver I Chemical
sulphadiazine O Chemical
<eof> I None

<s> O None
( I None
AgSD I Chemical
) I None
cream I None
, I None
an I None
antimicrobial I None
agent I None
frequently I None
used I None
for I None
topical I None
treatment I None
of I None
burn I Disease
wounds I None
. I None
<eof> I None

<s> O None
The I None
other I None
site I None
was I None
always I None
treated I None
with I None
AgSD I Chemical
cream I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
direct I None
relationship I None
between I None
CHP I Chemical
concentration I None
and I None
patients I None
' I None
ratings I None
of I None
pain I Disease
on I None
an I None
analogue I None
scale I None
. I None
<eof> I None

<s> O None
The I None
0.25 I None
per I None
cent I None
CHP I Chemical
cream I None
was I None
closest I None
to I None
AgSD I Chemical
in I None
pain I Disease
tolerance I None
; I None
however I None
, I None
none I None
of I None
the I None
treatments I None
differed I None
statistically I None
from I None
AgSD I Chemical
or I None
from I None
each I None
other I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
ease I None
of I None
application I None
of I None
CHP I Chemical
creams I None
was I None
less I None
satisfactory I None
than I None
that I None
of I None
AgSD I Chemical
. I None
<eof> I None

<s> O None
It I None
was I None
concluded I None
that I None
formulations I None
at I None
or I None
below I None
0.5 I None
per I None
cent I None
<eof> I None

<s> O None
CHP I Chemical
may I None
prove I None
acceptable I None
for I None
wound I None
care I None
, I None
but I None
the I None
vehicle I None
system I None
needs I None
pharmaceutical I None
improvement I None
to I None
render I None
it I None
more I None
tolerable I None
and I None
easier I None
to I None
use I None
. I None
<eof> I None

<s> O None
Dose I None
- I None
dependent I None
neurotoxicity I Disease
of I None
high I None
- I None
dose I None
busulfan I Chemical
in I None
children I None
: I None
a I None
clinical I None
and I None
pharmacological I None
study I None
. I None
<eof> I None

<s> O None
Busulfan I Chemical
is I None
known I None
to I None
be I None
neurotoxic I Disease
in I None
animals I None
and I None
humans I None
, I None
but I None
its I None
acute I None
neurotoxicity I Disease
remains I None
poorly I None
characterized I None
in I None
children I None
. I None
<eof> I None

<s> O None
We I None
report I None
here I None
a I None
retrospective I None
study I None
of I None
123 I None
children I None
( I None
median I None
age I None
, I None
6.5 I None
years I None
) I None
receiving I None
high I None
- I None
dose I None
busulfan I Chemical
in I None
combined I None
chemotherapy I None
before I None
bone I None
marrow I None
transplantation I None
for I None
malignant I None
solid I None
tumors I Disease
, I None
<eof> I None

<s> O None
brain I Disease
tumors O Disease
excluded I None
. I None
<eof> I None

<s> O None
Busulfan I Chemical
was I None
given I None
p.o I None
. I None
<eof> I None

<s> O None
, I None
every I None
6 I None
hours I None
for I None
16 I None
doses I None
over I None
4 I None
days I None
. I None
<eof> I None

<s> O None
Two I None
total I None
doses I None
were I None
consecutively I None
used I None
: I None
16 I None
mg I None
/ I None
kg I None
, I None
then I None
600 I None
mg I None
/ I None
m2 I None
. I None
<eof> I None

<s> O None
The I None
dose I None
calculation I None
on I None
the I None
basis I None
of I None
body I None
surface I None
area I None
results I None
in I None
higher I None
doses I None
in I None
young I None
children I None
than I None
in I None
older I None
patients I None
( I None
16 I None
to I None
28 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
Ninety I None
- I None
six I None
patients I None
were I None
not I None
given I None
anticonvulsive I None
prophylaxis I None
; I None
7 I None
( I None
7.5 I None
% I None
) I None
developed I None
<eof> I None

<s> O None
seizures I Disease
during I None
the I None
4 I None
days I None
of I None
the I None
busulfan I Chemical
course I None
or I None
within I None
24 I None
h I None
<eof> I None

<s> O None
after I None
the I None
last I None
dosing I None
. I None
<eof> I None

<s> O None
When I None
the I None
total I None
busulfan I Chemical
dose I None
was I None
taken I None
into I None
account I None
, I None
there I None
was I None
a I None
significant I None
difference I None
in I None
terms I None
of I None
neurotoxicity I Disease
incidence I None
among I None
patients I None
under I None
16 I None
mg I None
/ I None
kg I None
( I None
1 I None
of I None
57 I None
, I None
1.7 I None
% I None
) I None
and I None
patients I None
under I None
600 I None
mg I None
/ I None
m2 I None
( I None
6 I None
of I None
39 I None
, I None
15.4 I None
% I None
) I None
<eof> I None

<s> O None
( I None
P I None
less I None
than I None
0.02 I None
) I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
seven I None
patients I None
were I None
given I None
a I None
600-mg I None
/ I None
m2 I None
busulfan I Chemical
total I None
dose I None
with I None
continuous I None
i.v I None
. I None
<eof> I None

<s> O None
infusion I None
of I None
clonazepam I Chemical
; I None
none I None
had I None
any I None
neurological I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
Busulfan I Chemical
levels I None
were I None
measured I None
by I None
a I None
gas I None
chromatographic I None
- I None
mass I None
spectrometry I None
assay I None
in I None
the I None
plasma I None
and I None
cerebrospinal I None
fluid I None
of I None
9 I None
children I None
without I None
central I Disease
nervous O Disease
system O Disease
disease O Disease
<eof> I None

<s> O None
under I None
600 I None
mg I None
/ I None
m2 I None
busulfan I Chemical
with I None
<eof> I None

<s> O None
clonazepam I Chemical
: I None
busulfan I Chemical
cerebrospinal I None
fluid I None
: I None
<eof> I None

<s> O None
plasma I None
ratio I None
was I None
1.39 I None
. I None
<eof> I None

<s> O None
This I None
was I None
significantly I None
different I None
( I None
P I None
less I None
than I None
0.02 I None
) I None
from I None
the I None
cerebrospinal I None
fluid I None
: I None
plasma I None
ratio I None
previously I None
defined I None
in I None
children I None
receiving I None
a I None
16-mg I None
/ I None
kg I None
total I None
dose I None
of I None
busulfan I Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
shows I None
that I None
busulfan I Chemical
<eof> I None

<s> O None
neurotoxicity I Disease
is I None
dose I None
- I None
dependent I None
in I None
children I None
and I None
efficiently I None
prevented I None
by I None
clonazepam I Chemical
. I None
<eof> I None

<s> O None
A I None
busulfan I Chemical
dose I None
calculated I None
on I None
the I None
basis I None
of I None
body I None
surface I None
area I None
, I None
resulting I None
in I None
higher I None
doses I None
in I None
young I None
children I None
, I None
was I None
followed I None
by I None
increased I None
neurotoxicity I Disease
, I None
close I None
to I None
neurotoxicity I Disease
incidence I None
observed I None
in I None
adults I None
. I None
<eof> I None

<s> O None
Since I None
plasma I None
pharmacokinetic I None
studies I None
showed I None
a I None
faster I None
busulfan I Chemical
clearance I None
in I None
children I None
than I None
in I None
adults I None
, I None
this I None
new I None
dose I None
may I None
approximate I None
more I None
closely I None
the I None
adult I None
systemic I None
exposure I None
obtained I None
after I None
the I None
usual I None
16-mg I None
/ I None
kg I None
total I None
dose I None
, I None
with I None
potential I None
inferences I None
in I None
terms I None
of I None
anticancer I None
or I None
myeloablative I None
effects I None
. I None
<eof> I None

<s> O None
The I None
busulfan I Chemical
dose I None
in I None
children I None
and I None
infants I None
undergoing I None
bone I None
marrow I None
transplantation I None
should I None
be I None
reconsidered I None
on I None
the I None
basis I None
of I None
pharmacokinetic I None
studies I None
. I None
<eof> I None

<s> O None
Histamine I Chemical
antagonists I None
and I None
d I Chemical
- O Chemical
tubocurarine O Chemical
-induced I None
<eof> I None

<s> O None
hypotension I Disease
in I None
cardiac I None
surgical I None
patients I None
. I None
<eof> I None

<s> O None
Hemodynamic I None
effects I None
and I None
histamine I Chemical
release I None
by I None
bolus I None
injection I None
of I None
0.35 I None
mg I None
/ I None
kg I None
of I None
d I Chemical
- O Chemical
tubocurarine O Chemical
were I None
studied I None
in I None
24 I None
patients I None
. I None
<eof> I None

<s> O None
H1- I None
and I None
H2- I None
histamine I Chemical
antagonists I None
or I None
placebo I None
were I None
given I None
before I None
dosing I None
with I None
d I Chemical
- O Chemical
tubocurarine O Chemical
in I None
a I None
randomized I None
double I None
- I None
blind I None
fashion I None
to I None
four I None
groups I None
: I None
group I None
1 I None
- I None
-placebo I None
; I None
group I None
2 I None
- I None
- I None
cimetidine I Chemical
, I None
4 I None
mg I None
/ I None
kg I None
, I None
plus I None
placebo I None
; I None
group I None
3 I None
- I None
- I None
chlorpheniramine I Chemical
, I None
0.1 I None
mg I None
/ I None
kg I None
, I None
plus I None
placebo I None
; I None
and I None
group I None
4 I None
- I None
- I None
cimetidine I Chemical
plus I None
chlorpheniramine I Chemical
. I None
<eof> I None

<s> O None
Histamine I Chemical
release I None
occurred I None
in I None
most I None
patients I None
, I None
the I None
highest I None
level I None
2 I None
minutes I None
after I None
d I Chemical
- O Chemical
tubocurarine O Chemical
dosing I None
. I None
<eof> I None

<s> O None
Group I None
1 I None
had I None
a I None
moderate I None
negative I None
correlation I None
between I None
plasma I None
histamine I Chemical
change I None
and I None
systemic I None
vascular I None
resistance I None
( I None
r I None
= I None
0.58 I None
; I None
P I None
less I None
than I None
0.05 I None
) I None
not I None
present I None
in I None
group I None
4 I None
. I None
<eof> I None

<s> O None
Prior I None
dosing I None
with I None
antagonists I None
partially I None
prevented I None
the I None
fall I None
in I None
systemic I None
vascular I None
resistance I None
. I None
<eof> I None

<s> O None
These I None
data I None
demonstrate I None
that I None
the I None
hemodynamic I None
changes I None
associated I None
with I None
d I Chemical
- O Chemical
tubocurarine O Chemical
dosing I None
are I None
only I None
partially I None
explained I None
by I None
histamine I Chemical
release I None
. I None
<eof> I None

<s> O None
Thus I None
prior I None
dosing I None
with I None
H1- I None
<eof> I None

<s> O None
and I None
H2-antagonists I None
provides I None
only I None
partial I None
protection I None
. I None
<eof> I None

<s> O None
Convulsant I None
effect I None
of I None
lindane I Chemical
and I None
regional I None
brain I None
concentration I None
of I None
GABA I Chemical
and I None
dopamine I Chemical
. I None
<eof> I None

<s> O None
Lindane I Chemical
<eof> I None

<s> O None
( I None
gamma I Chemical
- O Chemical
hexachlorocyclohexane O Chemical
) I None
is I None
an I None
organochlorine I None
insecticide I None
with I None
known I None
neurotoxic I Disease
effects I None
. I None
<eof> I None

<s> O None
Its I None
mechanism I None
of I None
action I None
is I None
not I None
well I None
understood I None
although I None
it I None
has I None
been I None
proposed I None
that I None
lindane I Chemical
acts I None
as I None
a I None
non I None
- I None
competitive I None
antagonist I None
at I None
the I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
GABA I Chemical
) I None
-A I None
receptor I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
effect I None
of I None
lindane I Chemical
<eof> I None

<s> O None
( I None
150 I None
mg I None
/ I None
kg I None
) I None
on I None
the I None
GABAergic I None
and I None
dopaminergic I None
systems I None
by I None
measuring I None
the I None
concentration I None
of I None
GABA I Chemical
, I None
<eof> I None

<s> O None
dopamine I Chemical
and I None
its I None
metabolites I None
in I None
7 I None
brain I None
areas I None
at I None
the I None
onset I None
of I None
seizures I Disease
. I None
<eof> I None

<s> O None
All I None
animals I None
suffered I None
tonic I None
convulsions I Disease
at I None
18.3 I None
+ I None
/- I None
<eof> I None

<s> O None
1.4 I None
min I None
after I None
lindane I Chemical
administration I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
GABA I Chemical
was I None
only I None
slightly I None
but I None
significantly I None
decreased I None
in I None
the I None
colliculi I None
without I None
modifications I None
in I None
the I None
other I None
areas I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
dopamine I Chemical
was I None
increased I None
in I None
the I None
mesencephalon I None
and I None
that I None
of I None
its I None
metabolite I None
DOPAC I Chemical
was I None
also I None
increased I None
in I None
the I None
mesencephalon I None
and I None
the I None
striatum I None
. I None
<eof> I None

<s> O None
Unusual I None
complications I None
of I None
antithyroid I None
drug I None
therapy I None
: I None
four I None
case I None
reports I None
and I None
review I None
of I None
literature I None
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
propylthiouracil I Chemical
<eof> I None

<s> O None
-associated I None
acute I None
hepatitis I Disease
, I None
one I None
case I None
of I None
fatal I None
methimazole I Chemical
-associated I None
hepatocellular I Disease
necrosis O Disease
and I None
one I None
case I None
of I None
propylthiouracil I Chemical
-associated I None
lupus I Disease
- O Disease
like O Disease
syndrome O Disease
are I None
described I None
. I None
<eof> I None

<s> O None
The I None
literature I None
related I None
to I None
antithyroid I None
drug I None
side I None
effects I None
and I None
the I None
mechanisms I None
for I None
their I None
occurrence I None
are I None
reviewed I None
and I None
the I None
efficacy I None
and I None
complications I None
of I None
thyroidectomy I None
and I None
radioiodine I None
compared I None
to I None
those I None
of I None
antithyroid I None
drugs I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
in I None
most I None
circumstances I None
131I I None
is I None
the I None
therapy I None
of I None
choice I None
for I None
hyperthyroidism I Disease
. I None
<eof> I None

<s> O None
Anticonvulsant I None
actions I None
of I None
MK-801 I Chemical
on I None
the I None
lithium I Chemical
- I None
pilocarpine I Chemical
model I None
of I None
status I Disease
epilepticus O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
MK-801 I Chemical
, I None
a I None
noncompetitive I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
<eof> I None

<s> O None
( I None
NMDA I Chemical
) I None
receptor I None
antagonist I None
, I None
was I None
tested I None
for I None
anticonvulsant I None
effects I None
in I None
rats I None
using I None
two I None
seizure I Disease
models I None
, I None
coadministration I None
of I None
lithium I Chemical
and I None
pilocarpine I Chemical
and I None
administration I None
of I None
a I None
high I None
dose I None
of I None
pilocarpine I Chemical
alone I None
. I None
<eof> I None

<s> O None
Three I None
major I None
results I None
are I None
reported I None
. I None
<eof> I None

<s> O None
First I None
, I None
pretreatment I None
with I None
MK-801 I Chemical
produced I None
an I None
effective I None
and I None
dose I None
- I None
dependent I None
anticonvulsant I None
action I None
with I None
the I None
lithium I Chemical
- I None
pilocarpine I Chemical
model I None
but I None
not I None
with I None
rats I None
treated I None
with I None
pilocarpine I Chemical
alone I None
, I None
suggesting I None
that I None
different I None
biochemical I None
mechanisms I None
control I None
<eof> I None

<s> O None
seizures I Disease
in I None
these I None
two I None
models I None
. I None
<eof> I None

<s> O None
Second I None
, I None
the I None
anticonvulsant I None
effect I None
of I None
MK-801 I Chemical
in I None
the I None
lithium I Chemical
- I None
pilocarpine I Chemical
model I None
only I None
occurred I None
after I None
initial I None
periods I None
of I None
seizure I Disease
activity I None
. I None
<eof> I None

<s> O None
This I None
observation I None
is I None
suggested I None
to I None
be I None
an I None
in I None
vivo I None
demonstration I None
of I None
the I None
conclusion I None
derived I None
from I None
in I None
vitro I None
experiments I None
that I None
MK-801 I Chemical
binding I None
requires I None
agonist I None
- I None
induced I None
opening I None
of I None
the I None
channel I None
sites I None
of I None
the I None
NMDA I Chemical
receptor I None
. I None
<eof> I None

<s> O None
Third I None
, I None
although I None
it I None
is I None
relatively I None
easy I None
to I None
block I None
seizures I Disease
induced I None
by I None
lithium I Chemical
and I None
pilocarpine I Chemical
by I None
administration I None
of I None
anticonvulsants I None
prior I None
to I None
pilocarpine I Chemical
, I None
it I None
is I None
more I None
difficult I None
to I None
terminate I None
ongoing I None
status I Disease
epilepticus O Disease
and I None
block I None
the I None
lethality I None
of I None
the I None
seizures I Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
<eof> I None

<s> O None
MK-801 I Chemical
30 I None
or I None
60 I None
min I None
after I None
pilocarpine I Chemical
, I None
i.e. I None
, I None
during I None
status I Disease
epilepticus O Disease
, I None
gradually I None
reduced I None
electrical I None
and I None
behavioral I None
seizure I Disease
activity I None
and I None
greatly I None
enhanced I None
the I None
survival I None
rate I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
activation I None
of I None
NMDA I Chemical
receptors I None
plays I None
an I None
important I None
role I None
in I None
status I Disease
epilepticus O Disease
and I None
brain I Disease
damage O Disease
in I None
the I None
lithium I Chemical
- I None
pilocarpine I Chemical
model I None
. I None
<eof> I None

<s> O None
This I None
was I None
further I None
supported I None
by I None
results I None
showing I None
that I None
nonconvulsive I None
doses I None
of I None
NMDA I Chemical
and I None
pilocarpine I Chemical
were I None
synergistic I None
, I None
resulting I None
in I None
status I Disease
epilepticus O Disease
and I None
subsequent I None
mortality I None
. I None
<eof> I None

<s> O None
Nifedipine I Chemical
induced I None
<eof> I None

<s> O None
bradycardia I Disease
in I None
a I None
patient I None
with I None
autonomic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
An I None
80 I None
year I None
old I None
diabetic I Disease
<eof> I None

<s> O None
male I None
with I None
evidence I None
of I None
peripheral I None
and I None
autonomic I None
neuropathy I None
was I None
admitted I None
with I None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
He I None
was I None
found I None
to I None
have I None
atrial I Disease
flutter O Disease
at I None
a I None
ventricular I None
rate I None
of I None
70/min I None
which I None
slowed I None
down I None
to I None
30 I None
- I None
40/min I None
when I None
nifedipine I Chemical
( I None
60 I None
mg I None
) I None
in I None
3 I None
divided I None
doses I None
, I None
during I None
which I None
he I None
was I None
paced I None
at I None
a I None
rate I None
of I None
70/min I None
. I None
<eof> I None

<s> O None
This I None
is I None
inconsistent I None
with I None
the I None
well I None
- I None
established I None
finding I None
that I None
nifedipine I Chemical
induces I None
tachycardia I Disease
in I None
normally I None
innervated I None
hearts I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
hearts I None
deprived I None
of I None
compensatory I None
sympathetic I None
drive I None
, I None
it I None
may I None
lead I None
to I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
haloperidol I Chemical
in I None
cocaine I Chemical
and I None
amphetamine I Chemical
intoxication I None
. I None
<eof> I None

<s> O None
The I None
effectiveness I None
of I None
haloperidol I Chemical
pretreatment I None
in I None
preventing I None
the I None
toxic I None
effects I None
of I None
high I None
doses I None
of I None
amphetamine I Chemical
and I None
cocaine I Chemical
was I None
studied I None
in I None
rats I None
. I None
<eof> I None

<s> O None
In I None
this I None
model I None
, I None
toxic I None
effects I None
were I None
induced I None
by I None
intraperitoneal I None
( I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
injection I None
of I None
amphetamine I Chemical
75 I None
mg I None
/ I None
kg I None
( I None
100 I None
% I None
death I None
rate I None
) I None
or I None
cocaine I Chemical
70 I None
mg I None
/ I None
kg I None
( I None
82 I None
% I None
death I None
rate I None
) I None
. I None
<eof> I None

<s> O None
Haloperidol I Chemical
failed I None
to I None
prevent I None
amphetamine I Chemical
-induced I None
seizures I Disease
, I None
but I None
did I None
lower I None
the I None
mortality I None
rate I None
at I None
most I None
doses I None
tested I None
. I None
<eof> I None

<s> O None
Haloperidol I Chemical
decreased I None
the I None
incidence I None
of I None
cocaine I Chemical
-induced I None
seizures I Disease
at I None
the I None
two I None
highest I None
doses I None
, I None
but I None
the I None
lowering I None
of I None
the I None
mortality I None
rate I None
did I None
not I None
reach I None
statistical I None
significance I None
at I None
any I None
dose I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
a I None
protective I None
role I None
for I None
the I None
central I None
dopamine I Chemical
blocker I None
haloperidol I Chemical
against I None
death I None
from I None
high I None
- I None
dose I None
amphetamine I Chemical
exposure I None
without I None
reducing I None
the I None
incidence I None
of I None
seizures I Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
haloperidol I Chemical
demonstrated I None
an I None
ability I None
to I None
reduce I None
cocaine I Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
without I None
significantly I None
reducing I None
mortality I None
. I None
<eof> I None

<s> O None
Autoradiographic I None
evidence I None
of I None
estrogen I Chemical
binding I None
sites I None
in I None
nuclei I None
of I None
<eof> I None

<s> O None
diethylstilbesterol I Chemical
induced I None
hamster I None
renal I Disease
carcinomas O Disease
. I None
<eof> I None

<s> O None
Estrogen I Chemical
binding I None
sites I None
were I None
demonstrated I None
by I None
autoradiography I None
in I None
one I None
transplantable I None
and I None
five I None
primary I None
diethylstilbesterol I Chemical
induced I None
renal I Disease
carcinomas O Disease
in I None
three I None
hamsters I None
. I None
<eof> I None

<s> O None
Radiolabelling I None
, I None
following I None
the I None
in I None
vivo I None
injection I None
of I None
3H-17 I None
beta I None
estradiol I Chemical
, I None
was I None
increased I None
only I None
over I None
the I None
nuclei I None
of I None
tumor I Disease
cells I None
; I None
stereologic I None
analysis I None
revealed I None
a I None
4.5- I None
to I None
6.7-times I None
higher I None
concentration I None
of I None
reduced I None
silver I Chemical
grains I None
over I None
nuclei I None
than I None
cytoplasm I None
of I None
these I None
cells I None
. I None
<eof> I None

<s> O None
Despite I None
rapid I None
tubular I None
excretion I None
of I None
estradiol I Chemical
which I None
peaked I None
in I None
less I None
than I None
1 I None
h I None
, I None
the I None
normal I None
cells I None
did I None
not I None
appear I None
to I None
bind I None
the I None
ligand I None
. I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
published I None
report I None
documenting I None
the I None
preferential I None
in I None
vivo I None
binding I None
of I None
estrogen I Chemical
to I None
nuclei I None
of I None
cells I None
in I None
estrogen I Chemical
induced I None
hamster I None
renal I Disease
carcinomas O Disease
. I None
<eof> I None

<s> O None
Bradycardia I Disease
due I None
to I None
biperiden I Chemical
. I None
<eof> I None

<s> O None
In I None
a I None
38-year I None
- I None
old I None
male I None
patient I None
suffering I None
from I None
a I None
severe I None
postzosteric I Disease
<eof> I None

<s> O None
trigeminal I Disease
neuralgia O Disease
, I None
intravenous I None
application I None
of I None
10 I None
mg I None
biperiden I Chemical
lactate O Chemical
led I None
to I None
a I None
long I None
- I None
lasting I None
paradoxical I None
reaction I None
characterized I None
by I None
considerable I None
bradycardia I Disease
, I None
dysarthria I Disease
, I None
and I None
dysphagia I Disease
. I None
<eof> I None

<s> O None
The I None
heart I None
rate I None
was I None
back I None
to I None
normal I None
within I None
12 I None
hours I None
upon I None
administration I None
of I None
orciprenaline I Chemical
under I None
cardiac I None
monitoring I None
in I None
an I None
intensive I None
care I None
unit I None
. I None
<eof> I None

<s> O None
Bradycardia I Disease
induced I None
by I None
biperiden I Chemical
is I None
attributed I None
to I None
the I None
speed I None
of I None
injection I None
and I None
to I None
a I None
dose I None
- I None
related I None
dual I None
effect I None
of I None
atropine I Chemical
-like I None
drugs I None
on I None
muscarine I Chemical
receptors I None
. I None
<eof> I None

<s> O None
Deliberate I None
hypotension I Disease
induced I None
by I None
labetalol I Chemical
with I None
halothane I Chemical
, I None
enflurane I Chemical
or I None
isoflurane I Chemical
for I None
middle I None
- I None
ear I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
feasibility I None
of I None
using I None
labetalol I Chemical
, I None
an I None
alpha- I None
and I None
beta I None
- I None
adrenergic I None
blocking I None
agent I None
, I None
as I None
a I None
hypotensive I Disease
agent I None
in I None
combination I None
with I None
inhalation I None
anaesthetics I None
( I None
halothane I Chemical
, I None
enflurane I Chemical
or I None
isoflurane I Chemical
) I None
was I None
studied I None
in I None
23 I None
adult I None
patients I None
undergoing I None
middle I None
- I None
ear I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
mean I None
arterial I None
pressure I None
was I None
decreased I None
from I None
86 I None
+ I None
/- I None
5 I None
( I None
s.e I None
. I None
<eof> I None

<s> O None
mean I None
) I None
<eof> I None

<s> O None
mmHg I None
to I None
52 I None
+ I None
/- I None
<eof> I None

<s> O None
1 I None
mmHg I None
( I None
11.5 I None
+ I None
/- I None
0.7 I None
to I None
6.9 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
kPa I None
) I None
for I None
98 I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
min I None
in I None
the I None
halothane I Chemical
<eof> I None

<s> O None
( I None
H I Chemical
) I None
group I None
, I None
from I None
79 I None
+ I None
/- I None
5 I None
to I None
53 I None
<eof> I None

<s> O None
+ I None
/- I None
1 I None
mmHg I None
( I None
10.5 I None
+ I None
/- I None
0.7 I None
to I None
7.1 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
kPa I None
) I None
for I None
129 I None
+ I None
/- I None
<eof> I None

<s> O None
11 I None
min I None
in I None
the I None
enflurane I Chemical
<eof> I None

<s> O None
( I None
E I Chemical
) I None
group I None
, I None
and I None
from I None
80 I None
+ I None
/- I None
4 I None
to I None
49 I None
+ I None
/- I None
<eof> I None

<s> O None
1 I None
mmHg I None
( I None
10.7 I None
+ I None
/- I None
0.5 I None
to I None
6.5 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
kPa I None
) I None
for I None
135 I None
+ I None
/- I None
<eof> I None

<s> O None
15 I None
min I None
in I None
the I None
isoflurane I Chemical
<eof> I None

<s> O None
( I None
I I Chemical
) I None
group I None
. I None
<eof> I None

<s> O None
The I None
mean I None
H I Chemical
concentration I None
during I None
hypotension I Disease
<eof> I None

<s> O None
in I None
the I None
inspiratory I None
gas I None
was I None
0.7 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
vol% I None
, I None
the I None
mean I None
E I Chemical
concentration I None
1.6 I None
+ I None
/- I None
<eof> I None

<s> O None
0.2 I None
vol% I None
, I None
and I None
the I None
mean I None
I I Chemical
concentration I None
1.0 I None
+ I None
/- I None
<eof> I None

<s> O None
0.1 I None
vol% I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
patients I None
received I None
fentanyl I Chemical
and I None
d I Chemical
- O Chemical
tubocurarine O Chemical
. I None
<eof> I None

<s> O None
The I None
initial I None
dose I None
of I None
labetalol I Chemical
for I None
lowering I None
blood I None
pressure I None
was I None
similar I None
, I None
0.52 I None
- I None
0.59 I None
mg I None
/ I None
kg I None
, I None
in I None
all I None
the I None
groups I None
. I None
<eof> I None

<s> O None
During I None
hypotension I Disease
, I None
the I None
heart I None
rate I None
was I None
stable I None
without I None
tachy- I Disease
or O Disease
bradycardia O Disease
. I None
<eof> I None

<s> O None
The I None
operating I None
conditions I None
regarding I None
bleeding I Disease
were I None
estimated I None
in I None
a I None
double I None
- I None
blind I None
manner I None
, I None
and I None
did I None
not I None
differ I None
significantly I None
between I None
the I None
groups I None
. I None
<eof> I None

<s> O None
During I None
hypotension I Disease
, I None
the I None
serum I None
creatinine I Chemical
concentration I None
rose I None
significantly I None
in I None
all I None
groups I None
from I None
the I None
values I None
before I None
hypotension I Disease
and I None
returned I None
postoperatively I None
to I None
the I None
initial I None
level I None
in I None
the I None
other I None
groups I None
, I None
except I None
the I None
isoflurane I Chemical
group I None
. I None
<eof> I None

<s> O None
After I None
hypotension I Disease
<eof> I None

<s> O None
there I None
was I None
no I None
rebound I None
phenomenon I None
in I None
either I None
blood I None
pressure I None
or I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
labetalol I Chemical
induces I None
easily I None
adjustable I None
hypotension I Disease
without I None
compensatory I None
tachycardia I Disease
and I None
rebound I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Convulsion I Disease
following I None
intravenous I None
fluorescein I Chemical
angiography I None
. I None
<eof> I None

<s> O None
Tonic I Disease
- O Disease
clonic O Disease
seizures O Disease
followed I None
intravenous I None
fluorescein I Chemical
injection I None
for I None
fundus I None
angiography I None
in I None
a I None
47-year I None
- I None
old I None
male I None
. I None
<eof> I None

<s> O None
Despite I None
precautions I None
this I None
adverse I None
reaction I None
recurred I None
on I None
re I None
- I None
exposure I None
to I None
intravenous I None
fluorescein I Chemical
. I None
<eof> I None

<s> O None
Pharmacology I None
of I None
ACC-9653 I Chemical
<eof> I None

<s> O None
( I None
phenytoin I Chemical
prodrug I None
) I None
. I None
<eof> I None

<s> O None
ACC-9653 I Chemical
, I None
the I None
disodium I Chemical
phosphate O Chemical
ester O Chemical
of I None
3-hydroxymethyl-5,5-diphenylhydantoin I Chemical
, I None
is I None
a I None
prodrug I None
of I None
phenytoin I Chemical
with I None
advantageous I None
physicochemical I None
properties I None
. I None
<eof> I None

<s> O None
ACC-9653 I Chemical
is I None
rapidly I None
converted I None
enzymatically I None
to I None
phenytoin I Chemical
in I None
vivo I None
. I None
<eof> I None

<s> O None
ACC-9653 I Chemical
and I None
phenytoin I Chemical
sodium O Chemical
have I None
equivalent I None
anticonvulsant I None
activity I None
against I None
seizures I Disease
induced I None
by I None
maximal I None
electroshock I None
( I None
MES I None
) I None
in I None
mice I None
following I None
i.p I None
. I None
, I None
oral I None
, I None
or I None
i.v I None
. I None
<eof> I None

<s> O None
administration I None
. I None
<eof> I None

<s> O None
The I None
ED50 I None
doses I None
were I None
16 I None
mg I None
/ I None
kg I None
for I None
i.v I None
. I None
<eof> I None

<s> O None
ACC-9653 I Chemical
and I None
8 I None
mg I None
/ I None
kg I None
for I None
i.v I None
. I None
phenytoin I Chemical
sodium O Chemical
. I None
<eof> I None

<s> O None
ACC-9653 I Chemical
and I None
phenytoin I Chemical
sodium O Chemical
have I None
similar I None
antiarrhythmic I None
activity I None
against I None
ouabain I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
ventricular I Disease
tachycardia O Disease
in I None
anesthetized I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
total I None
doses I None
of I None
ACC-9653 I Chemical
or I None
phenytoin I Chemical
sodium O Chemical
necessary I None
to I None
convert I None
the I None
arrhythmia I Disease
to I None
a I None
normal I None
sinus I None
rhythm I None
were I None
24 I None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
and I None
14 I None
+ I None
/- I None
3 I None
mg I None
/ I None
kg I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Only I None
phenytoin I Chemical
sodium O Chemical
displayed I None
in I None
vitro I None
antiarrhythmic I None
activity I None
against I None
<eof> I None

<s> O None
strophanthidin I Chemical
-induced I None
<eof> I None

<s> O None
arrhythmias I Disease
in I None
guinea I None
pig I None
right I None
atria I None
. I None
<eof> I None

<s> O None
In I None
anesthetized I None
dogs I None
, I None
a I None
high I None
dose I None
of I None
ACC-9653 I Chemical
<eof> I None

<s> O None
( I None
31 I None
mg I None
/ I None
kg I None
) I None
was I None
infused I None
over I None
15 I None
, I None
20 I None
, I None
and I None
30 I None
min I None
and I None
the I None
responses I None
were I None
compared I None
to I None
an I None
equimolar I None
dose I None
of I None
phenytoin I Chemical
sodium O Chemical
<eof> I None

<s> O None
( I None
21 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
The I None
ACC-9653 I Chemical
and I None
phenytoin I Chemical
sodium O Chemical
treatments I None
produced I None
similar I None
marked I None
reductions I None
in I None
diastolic I None
blood I None
pressure I None
and I None
contractile I None
force I None
( I None
LVdP I None
/ I None
dt I None
) I None
. I None
<eof> I None

<s> O None
The I None
maximum I None
effects I None
of I None
each I None
treatment I None
occurred I None
at I None
the I None
time I None
of I None
maximum I None
phenytoin I Chemical
sodium O Chemical
levels I None
. I None
<eof> I None

<s> O None
Acute I None
toxicity I Disease
studies I None
of I None
ACC-9653 I Chemical
and I None
phenytoin I Chemical
sodium O Chemical
were I None
carried I None
out I None
in I None
mice I None
, I None
rats I None
, I None
rabbits I None
, I None
and I None
dogs I None
by I None
i.v I None
. I None
, I None
i.m I None
. I None
, I None
and I None
i.p I None
. I None
routes I None
of I None
administration I None
. I None
<eof> I None

<s> O None
The I None
systemic I None
toxic I None
signs I None
of I None
both I None
agents I None
were I None
similar I None
and I None
occurred I None
at I None
approximately I None
equivalent I None
doses I None
. I None
<eof> I None

<s> O None
Importantly I None
, I None
the I None
local I None
irritation I None
of I None
ACC-9653 I Chemical
was I None
markedly I None
less I None
than I None
phenytoin I Chemical
sodium O Chemical
following I None
i.m I None
. I None
<eof> I None

<s> O None
administration.(ABSTRACT I None
TRUNCATED I None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Phenytoin I Chemical
induced I None
fatal I None
hepatic I Disease
injury O Disease
. I None
<eof> I None

<s> O None
A I None
61 I None
year I None
old I None
female I None
developed I None
fatal I None
hepatic I Disease
failure O Disease
after I None
phenytoin I Chemical
administration I None
. I None
<eof> I None

<s> O None
A I None
typical I None
multisystem I None
clinical I None
pattern I None
precedes I None
the I None
manifestations I None
of I None
hepatic I Disease
injury O Disease
. I None
<eof> I None

<s> O None
The I None
hematologic I None
, I None
biochemical I None
and I None
pathologic I None
features I None
indicate I None
a I None
mixed I None
hepatocellular I Disease
damage O Disease
due I None
to I None
drug I Disease
hypersensitivity O Disease
. I None
<eof> I None

<s> O None
In I None
a I None
patient I None
receiving I None
phenytoin I Chemical
who I None
presents I None
a I None
viral I None
- I None
like I None
illness I None
, I None
early I None
recognition I None
and I None
discontinuation I None
of I None
the I None
drug I None
are I None
mandatory I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
lethal I None
pertussis I Chemical
vaccine O Chemical
reaction I None
with I None
histamine I Chemical
H1 I None
antagonists I None
. I None
<eof> I None

<s> O None
We I None
studied I None
mortality I None
after I None
pertussis I Disease
immunization I None
in I None
the I None
mouse I None
. I None
<eof> I None

<s> O None
Without I None
treatment I None
, I None
73 I None
of I None
92 I None
animals I None
( I None
80 I None
% I None
) I None
died I None
after I None
injection I None
of I None
bovine I None
serum I None
albumin I None
( I None
BSA I None
) I None
on I None
day I None
+ I None
7 I None
of I None
pertussis I Disease
immunization I None
. I None
<eof> I None

<s> O None
After I None
pretreatment I None
with I None
3 I None
mg I None
of I None
cyproheptadine I Chemical
, I None
2 I None
mg I None
mianserin I Chemical
, I None
or I None
2 I None
mg I None
<eof> I None

<s> O None
chlorpheniramine I Chemical
, I None
only I None
5 I None
of I None
105 I None
animals I None
( I None
5 I None
% I None
) I None
died I None
after I None
receiving I None
BSA I None
on I None
day I None
+ I None
7 I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
histamine I Chemical
H1 I None
receptors I None
may I None
reduce I None
mortality I None
in I None
pertussis I Disease
immunization I None
- I None
induced I None
encephalopathy I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
Support I None
for I None
adrenaline I Chemical
- I None
hypertension I Disease
<eof> I None

<s> O None
hypothesis I None
: I None
18 I None
hour I None
pressor I None
effect I None
after I None
6 I None
hours I None
adrenaline I Chemical
infusion I None
. I None
<eof> I None

<s> O None
In I None
a I None
double I None
blind I None
, I None
crossover I None
study I None
6 I None
h I None
infusions I None
of I None
adrenaline I Chemical
<eof> I None

<s> O None
( I None
15 I None
ng I None
/ I None
kg I None
/ I None
min I None
; I None
1 I None
ng I None
= I None
5.458 I None
pmol I None
) I None
, I None
noradrenaline I Chemical
<eof> I None

<s> O None
( I None
30 I None
ng I None
/ I None
kg I None
/ I None
min I None
; I None
1 I None
ng I None
= I None
5.911 I None
pmol I None
) I None
, I None
and I None
a I None
5 I None
% I None
dextrose I Chemical
solution I None
( I None
5.4 I None
ml I None
/ I None
h I None
) I None
, I None
were I None
given I None
to I None
ten I None
healthy I None
volunteers I None
in I None
random I None
order I None
2 I None
weeks I None
apart I None
. I None
<eof> I None

<s> O None
By I None
means I None
of I None
intra I None
- I None
arterial I None
ambulatory I None
monitoring I None
the I None
haemodynamic I None
effects I None
were I None
followed I None
for I None
18 I None
h I None
after I None
the I None
infusions I None
were I None
stopped I None
. I None
<eof> I None

<s> O None
Adrenaline I Chemical
, I None
but I None
not I None
noradrenaline I Chemical
, I None
caused I None
a I None
delayed I None
and I None
protracted I None
pressor I None
effect I None
. I None
<eof> I None

<s> O None
Over I None
the I None
total I None
postinfusion I None
period I None
systolic I None
and I None
diastolic I None
arterial I None
pressure I None
were I None
6 I None
( I None
SEM I None
2)% I None
and I None
7 I None
( I None
2)% I None
, I None
respectively I None
, I None
higher I None
than I None
after I None
dextrose I Chemical
infusion I None
( I None
ANOVA I None
, I None
p I None
less I None
than I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
" I None
stress I None
" I None
levels I None
of I None
adrenaline I Chemical
<eof> I None

<s> O None
( I None
230 I None
pg I None
/ I None
ml I None
) I None
for I None
6 I None
h I None
cause I None
<eof> I None

<s> O None
a I None
delayed I None
and I None
protracted I None
pressor I None
effect I None
. I None
<eof> I None

<s> O None
These I None
findings I None
are I None
strong I None
support I None
for I None
the I None
adrenaline I Chemical
- I None
hypertension I Disease
hypothesis I None
in I None
man I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
alkylxanthines I Chemical
on I None
gentamicin I Chemical
-induced I None
<eof> I None

<s> O None
acute I Disease
renal O Disease
failure O Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Adenosine I Chemical
antagonists I None
have I None
been I None
previously I None
shown I None
to I None
be I None
of I None
benefit I None
in I None
some I None
ischaemic I Disease
and I None
nephrotoxic I Disease
models I None
of I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
ARF I Disease
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
effects I None
of I None
three I None
alkylxanthines I Chemical
with I None
different I None
potencies I None
as I None
adenosine I Chemical
antagonists I None
8-phenyltheophylline I Chemical
, I None
theophylline I Chemical
and I None
enprofylline I Chemical
, I None
were I None
examined I None
in I None
rats I None
developing I None
acute I Disease
renal O Disease
failure O Disease
after I None
4 I None
daily I None
injections I None
of I None
gentamicin I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
kg-1 I None
) I None
. I None
<eof> I None

<s> O None
Renal I None
function I None
was I None
assessed I None
by I None
biochemical I None
( I None
plasma I None
urea I Chemical
and I None
creatinine I Chemical
) I None
, I None
functional I None
( I None
urine I None
analysis I None
and I None
[ I None
3H]inulin I None
and I None
[ I None
14C I None
] I None
p I Chemical
- O Chemical
aminohippuric O Chemical
acid O Chemical
clearances I None
) I None
and I None
morphological I None
( I None
degree I None
of I None
necrosis I Disease
) I None
indices I None
. I None
<eof> I None

<s> O None
The I None
various I None
drug I None
treatments I None
produced I None
improvements I None
in I None
some I None
, I None
but I None
not I None
all I None
, I None
measurements I None
of I None
renal I None
function I None
. I None
<eof> I None

<s> O None
However I None
, I None
any I None
improvement I None
produced I None
by I None
drug I None
treatment I None
was I None
largely I None
a I None
result I None
of I None
a I None
beneficial I None
effect I None
exerted I None
by I None
its I None
vehicle I None
( I None
polyethylene I Chemical
glycol O Chemical
and I None
NaOH I Chemical
) I None
. I None
<eof> I None

<s> O None
The I None
lack I None
of I None
any I None
consistent I None
protective I None
effect I None
noted I None
with I None
the I None
alkylxanthines I Chemical
tested I None
in I None
the I None
present I None
study I None
indicates I None
that I None
adenosine I Chemical
plays I None
little I None
, I None
if I None
any I None
, I None
pathophysiological I None
role I None
in I None
gentamicin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
ARF I Disease
. I None
<eof> I None

<s> O None
Adverse I None
ocular I None
reactions I None
possibly I None
associated I None
with I None
isotretinoin I Chemical
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
261 I None
adverse I None
ocular I None
reactions I None
occurred I None
in I None
237 I None
patients I None
who I None
received I None
isotretinoin I Chemical
, I None
a I None
commonly I None
used I None
drug I None
in I None
the I None
treatment I None
of I None
severe I None
cystic I None
acne I Disease
. I None
<eof> I None

<s> O None
Blepharoconjunctivitis I Disease
, I None
subjective I None
complaints I None
of I None
dry I Disease
eyes O Disease
, I None
blurred I Disease
vision O Disease
, I None
contact I None
lens I None
intolerance I None
, I None
and I None
photodermatitis I Disease
are I None
reversible I None
side I None
effects I None
. I None
<eof> I None

<s> O None
More I None
serious I None
ocular I None
adverse I None
reactions I None
include I None
papilledema I Disease
, I None
pseudotumor I Disease
cerebri O Disease
, I None
and I None
white I None
or I None
gray I None
subepithelial I None
corneal I Disease
opacities O Disease
; I None
all I None
of I None
these I None
are I None
reversible I None
if I None
the I None
drug I None
is I None
discontinued I None
. I None
<eof> I None

<s> O None
Reported I None
cases I None
of I None
decreased I None
dark I None
adaptation I None
are I None
under I None
investigation I None
. I None
<eof> I None

<s> O None
Isotretinoin I Chemical
is I None
contraindicated I None
in I None
pregnancy I None
because I None
of I None
the I None
many I None
reported I None
congenital I Disease
abnormalities O Disease
after I None
maternal I None
use I None
( I None
including I None
microphthalmos I Disease
, I None
orbital I None
hypertelorism I Disease
, I None
and I None
optic I Disease
nerve O Disease
hypoplasia O Disease
) I None
. I None
<eof> I None

<s> O None
Procaterol I Chemical
and I None
terbutaline I Chemical
in I None
bronchial I Disease
asthma O Disease
. I None
<eof> I None

<s> O None
A I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
cross I None
- I None
over I None
study I None
. I None
<eof> I None

<s> O None
Procaterol I Chemical
, I None
a I None
new I None
beta-2 I None
adrenoceptor I None
stimulant I None
, I None
was I None
studied I None
in I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
cross I None
- I None
over I None
trial I None
in I None
patients I None
with I None
bronchial I Disease
asthma O Disease
. I None
<eof> I None

<s> O None
Oral I None
procaterol I Chemical
50 I None
micrograms I None
b.d I None
. I None
, I None
<eof> I None

<s> O None
procaterol I Chemical
100 I None
micrograms I None
b.d I None
. I None
, I None
and I None
terbutaline I Chemical
5 I None
mg I None
t.i.d I None
. I None
, I None
were I None
compared I None
when I None
given I None
randomly I None
in I None
1-week I None
treatment I None
periods I None
. I None
<eof> I None

<s> O None
The I None
best I None
clinical I None
effect I None
was I None
found I None
with I None
terbutaline I Chemical
. I None
<eof> I None

<s> O None
Both I None
anti- I None
asthmatic I Disease
and I None
tremorgenic I Disease
effects I None
of I None
procaterol I Chemical
were I None
dose I None
- I None
related I None
. I None
<eof> I None

<s> O None
Procaterol I Chemical
appeared I None
effective I None
in I None
the I None
doses I None
tested I None
, I None
and I None
a I None
twice I None
daily I None
regimen I None
would I None
appear I None
to I None
be I None
suitable I None
with I None
this I None
drug I None
. I None
<eof> I None

<s> O None
Subacute I None
effects I None
of I None
propranolol I Chemical
and I None
B I None
24/76 I None
on I None
isoproterenol I Chemical
-induced I None
rat I None
heart I Disease
hypertrophy O Disease
in I None
correlation I None
with I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
potential I None
beta I None
- I None
receptor I None
blocker I None
, I None
B I None
24/76 I None
i.e. I None
1-(2,4-dichlorophenoxy)-3[2 I None
- I None
3,4-dimethoxyphenyl)ethanolamino]-prop I None
an-2-ol I None
, I None
which I None
is I None
characterized I None
by I None
beta I None
1-adrenoceptor I None
blocking I None
and I None
beta I None
2-adrenoceptor I None
stimulating I None
properties I None
with I None
propranolol I Chemical
. I None
<eof> I None

<s> O None
The I None
studies I None
were I None
performed I None
using I None
an I None
experimental I None
model I None
of I None
isoproterenol I Chemical
-induced I None
heart I Disease
hypertrophy O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
A I None
correlation I None
of I None
the I None
blood I None
pressure I None
was I None
neither I None
found I None
in I None
the I None
development I None
nor I None
in I None
the I None
attempt I None
to I None
suppress I None
the I None
development I None
of I None
heart I Disease
hypertrophy O Disease
with I None
the I None
two I None
beta I None
- I None
receptor I None
blockers I None
. I None
<eof> I None

<s> O None
Both I None
beta I None
- I None
blockers I None
influenced I None
the I None
development I None
of I None
hypertrophy I Disease
to I None
a I None
different I None
, I None
but I None
not I None
reproducible I None
extent I None
. I None
<eof> I None

<s> O None
It I None
was I None
possible I None
to I None
suppress I None
the I None
increased I None
ornithine I Chemical
<eof> I None

<s> O None
decarboxylase I None
activity I None
with I None
both I None
beta I None
- I None
blockers I None
in I None
hypertrophied I Disease
hearts O Disease
, I None
but I None
there I None
was I None
no I None
effect I None
on I None
the I None
heart I None
mass I None
. I None
<eof> I None

<s> O None
Neither I None
propranolol I Chemical
nor I None
B I None
24/76 I None
could I None
stop I None
the I None
changes I None
in I None
the I None
characteristic I None
myosin I None
isoenzyme I None
pattern I None
of I None
the I None
hypertrophied I Disease
rat I None
heart I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
investigations I None
did I None
not I None
provide I None
any I None
evidence I None
that I None
the I None
beta I None
- I None
receptor I None
blockers I None
propranolol I Chemical
and I None
B I None
24/76 I None
have I None
the I None
potency I None
to I None
prevent I None
isoproterenol I Chemical
from I None
producing I None
heart I Disease
hypertrophy O Disease
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
effect I None
of I None
oxitropium I Chemical
bromide O Chemical
and I None
of I None
slow I None
- I None
release I None
theophylline I Chemical
on I None
nocturnal I None
asthma I Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
a I None
new I None
inhaled I None
antimuscarinic I None
drug I None
, I None
oxitropium I Chemical
bromide O Chemical
, I None
and I None
of I None
a I None
slow I None
- I None
release I None
theophylline I Chemical
preparation I None
upon I None
nocturnal I None
asthma I Disease
were I None
compared I None
in I None
a I None
placebo I None
- I None
controlled I None
double I None
- I None
blind I None
study I None
. I None
<eof> I None

<s> O None
Two I None
samples I None
were I None
studied I None
: I None
12 I None
patients I None
received I None
oxitropium I Chemical
at I None
600 I None
micrograms I None
( I None
6 I None
subjects I None
) I None
or I None
at I None
400 I None
micrograms I None
t.i.d I None
. I None
<eof> I None

<s> O None
( I None
6 I None
subjects I None
) I None
whereas I None
11 I None
received I None
theophylline I Chemical
at I None
300 I None
mg I None
b.i.d I None
. I None
<eof> I None

<s> O None
Morning I None
dipping I None
, I None
assessed I None
by I None
the I None
fall I None
in I None
peak I None
flow I None
overnight I None
, I None
was I None
significantly I None
reduced I None
in I None
the I None
periods I None
when I None
either I None
active I None
drug I None
was I None
taken I None
, I None
whereas I None
no I None
difference I None
was I None
noticed I None
during I None
the I None
placebo I None
administration I None
. I None
<eof> I None

<s> O None
No I None
significant I None
difference I None
was I None
noticed I None
between I None
results I None
obtained I None
with I None
either I None
active I None
drug I None
, I None
as I None
well I None
as I None
with I None
either I None
dosage I None
of I None
oxitropium I Chemical
. I None
<eof> I None

<s> O None
No I None
subject I None
reported I None
side I None
effects I None
of I None
oxitropium I Chemical
, I None
as I None
compared I None
to I None
three I None
subjects I None
reporting I None
nausea I Disease
, I None
vomiting I Disease
and I None
tremors I Disease
after I None
theophylline I Chemical
. I None
<eof> I None

<s> O None
Oxitropium I Chemical
proves I None
to I None
be I None
a I None
valuable I None
alternative I None
to I None
theophylline I Chemical
in I None
nocturnal I None
asthma I Disease
, I None
since I None
it I None
is I None
equally I None
potent I None
, I None
safer I None
and I None
does I None
not I None
require I None
the I None
titration I None
of I None
dosage I None
. I None
<eof> I None

<s> O None
Penicillin I Chemical
anaphylaxis I Disease
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
oral I None
penicillin I Chemical
anaphylaxis I Disease
is I None
described I None
, I None
and I None
the I None
terminology I None
, I None
occurrence I None
, I None
clinical I None
manifestations I None
, I None
pathogenesis I None
, I None
prevention I None
, I None
and I None
treatment I None
of I None
anaphylaxis I Disease
are I None
reviewed I None
. I None
<eof> I None

<s> O None
Emergency I None
physicians I None
should I None
be I None
aware I None
of I None
oral I None
penicillin I Chemical
<eof> I None

<s> O None
anaphylaxis I Disease
in I None
order I None
to I None
prevent I None
its I None
occurrence I None
by I None
prescribing I None
the I None
antibiotic I None
judiciously I None
and I None
knowledgeably I None
and I None
to I None
offer I None
optimal I None
medical I None
therapy I None
once I None
this I None
life I None
- I None
threatening I None
reaction I None
has I None
begun I None
. I None
<eof> I None

<s> O None
Reversible I None
valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
dementia I Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
Reversible I None
valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
dementia I Disease
was I None
documented I None
in I None
a I None
21-year I None
- I None
old I None
man I None
with I None
epilepsy I Disease
who I None
had I None
a I None
3-year I None
history I None
of I None
insidious I None
progressive I None
decline I None
in I None
global I None
cognitive I None
abilities I None
documented I None
by I None
serial I None
neuropsychological I None
studies I None
. I None
<eof> I None

<s> O None
Repeat I None
neuropsychological I None
testing I None
7 I None
weeks I None
after I None
discontinuation I None
of I None
the I None
drug I None
revealed I None
dramatic I None
improvement I None
in I None
IQ I None
, I None
memory I None
, I None
naming I None
, I None
and I None
other I None
tasks I None
commensurate I None
with I None
clinical I None
recovery I None
in I None
his I None
intellectual I None
capacity I None
. I None
<eof> I None

<s> O None
Possible I None
pathophysiological I None
mechanisms I None
which I None
may I None
have I None
been I None
operative I None
in I None
this I None
case I None
include I None
: I None
a I None
direct I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
toxic I None
effect I None
of I None
valproic I Chemical
acid O Chemical
; I None
a I None
paradoxical I None
epileptogenic I None
effect I None
secondary I None
to I None
the I None
drug I None
; I None
and I None
an I None
indirect I None
CNS I None
toxic I None
effect I None
mediated I None
through I None
valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperammonemia I Disease
. I None
<eof> I None

<s> O None
Reversal I None
of I None
scopolamine I Chemical
-induced I None
amnesia I Disease
of I None
passive I None
avoidance I None
by I None
pre- I None
and I None
post I None
- I None
training I None
naloxone I Chemical
. I None
<eof> I None

<s> O None
In I None
a I None
series I None
of I None
five I None
experiments I None
, I None
the I None
modulating I None
role I None
of I None
naloxone I Chemical
on I None
a I None
scopolamine I Chemical
-induced I None
<eof> I None

<s> O None
retention I Disease
deficit O Disease
in I None
a I None
passive I None
avoidance I None
paradigm I None
was I None
investigated I None
in I None
mice I None
. I None
<eof> I None

<s> O None
Scopolamine I Chemical
, I None
but I None
not I None
<eof> I None

<s> O None
methyl I Chemical
scopolamine O Chemical
( I None
1 I None
and I None
3 I None
mg I None
/ I None
kg I None
) I None
, I None
induced I None
an I None
amnesia I Disease
as I None
measured I None
by I None
latency I None
and I None
duration I None
parameters I None
. I None
<eof> I None

<s> O None
Naloxone I Chemical
( I None
0.3 I None
, I None
1 I None
, I None
3 I None
, I None
and I None
10 I None
mg I None
/ I None
kg I None
) I None
injected I None
prior I None
to I None
training I None
attenuated I None
the I None
retention I Disease
deficit O Disease
with I None
a I None
peak I None
of I None
activity I None
at I None
3 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
naloxone I Chemical
could I None
be I None
antagonized I None
with I None
morphine I Chemical
<eof> I None

<s> O None
( I None
1 I None
, I None
3 I None
, I None
and I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
demonstrating I None
the I None
opioid I None
specificity I None
of I None
the I None
naloxone I Chemical
effect I None
. I None
<eof> I None

<s> O None
Post I None
- I None
training I None
administration I None
of I None
naloxone I Chemical
<eof> I None

<s> O None
( I None
3 I None
mg I None
/ I None
kg I None
) I None
as I None
a I None
single I None
or I None
as I None
a I None
split I None
dose I None
also I None
attenuated I None
the I None
scopolamine I Chemical
-induced I None
amnesia I Disease
. I None
<eof> I None

<s> O None
Control I None
experiments I None
indicated I None
that I None
neither I None
an I None
increase I None
in I None
pain I Disease
sensitivity I None
( I None
pre I None
- I None
training I None
naloxone I Chemical
) I None
nor I None
an I None
induced I None
aversive I None
state I None
( I None
post I None
- I None
training I None
naloxone I Chemical
) I None
appear I None
to I None
be I None
responsible I None
for I None
the I None
influence I None
of I None
naloxone I Chemical
on I None
the I None
scopolamine I Chemical
-induced I None
retention I Disease
deficit O Disease
. I None
<eof> I None

<s> O None
These I None
results I None
extend I None
previous I None
findings I None
implicating I None
a I None
cholinergic I None
- I None
opioid I None
interaction I None
in I None
memory I None
processes I None
. I None
<eof> I None

<s> O None
A I None
possible I None
mechanism I None
for I None
this I None
interaction I None
involving I None
the I None
septo I None
- I None
hippocampal I None
cholinergic I None
pathway I None
is I None
discussed I None
. I None
<eof> I None

<s> O None
Electron I None
microscopic I None
investigations I None
of I None
the I None
cyclophosphamide I Chemical
-induced I None
<eof> I None

<s> O None
lesions I Disease
of O Disease
the O Disease
urinary O Disease
bladder O Disease
of I None
the I None
rat I None
and I None
their I None
prevention I None
by I None
mesna I Chemical
. I None
<eof> I None

<s> O None
Fully I None
developed I None
<eof> I None

<s> O None
cyclophosphamide I Chemical
-induced I None
<eof> I None

<s> O None
cystitis I Disease
is I None
characterized I None
by I None
nearly I None
complete I None
detachment I None
of I None
the I None
urothelium I None
, I None
severe I None
submucosal I None
<eof> I None

<s> O None
edema I Disease
<eof> I None

<s> O None
owing I None
to I None
damage I None
to I None
the I None
microvascular I None
bed I None
and I None
focal I None
muscle I None
necroses I Disease
. I None
<eof> I None

<s> O None
The I None
initial I None
response I None
to I None
the I None
primary I None
attack I None
by I None
the I None
cyclophosphamide I Chemical
metabolites I None
seems I None
to I None
be I None
fragmentation I None
of I None
the I None
luminal I Chemical
membrane I None
. I None
<eof> I None

<s> O None
This I None
damages I None
the I None
cellular I None
barrier I None
against I None
the I None
hypertonic I None
urine I None
. I None
<eof> I None

<s> O None
Subsequent I None
breaks I None
in I None
the I None
lateral I None
cell I None
membranes I None
of I None
the I None
superficial I None
cells I None
and I None
in I None
all I None
the I None
plasma I None
membranes I None
of I None
the I None
intermediate I None
and I None
basal I None
cells I None
, I None
intercellular I None
and I None
intracellular I None
edema I Disease
and I None
disintegration I None
of I None
the I None
desmosomes I None
and I None
hemidesmosomes I None
lead I None
to I None
progressive I None
degeneration I None
and I None
detachment I None
of I None
the I None
epithelial I None
cells I None
with I None
exposure I None
and I None
splitting I None
of I None
the I None
basal I None
membrane I None
. I None
<eof> I None

<s> O None
The I None
morphological I None
changes I None
of I None
the I None
endothelial I None
cells I None
, I None
which I None
become I None
more I None
pronounced I None
in I None
the I None
later I None
stages I None
of I None
the I None
experiment I None
, I None
the I None
involvement I None
of I None
blood I None
vessels I None
regardless I None
of I None
their I None
diameter I None
and I None
the I None
location I None
- I None
dependent I None
extent I None
of I None
the I None
damage I None
indicate I None
a I None
direct I None
type I None
of I None
damage I None
which I None
is I None
preceded I None
by I None
a I None
mediator I None
- I None
induced I None
increase I None
in I None
permeability I None
, I None
the I None
morphological I None
correlate I None
of I None
which I None
is I None
the I None
formation I None
of I None
gaps I None
in I None
the I None
interendothelial I None
cell I None
connections I None
on I None
the I None
venules I None
. I None
<eof> I None

<s> O None
These I None
changes I None
can I None
be I None
effectively I None
prevented I None
by I None
mesna I Chemical
. I None
<eof> I None

<s> O None
The I None
only I None
sign I None
of I None
a I None
possible I None
involvement I None
is I None
the I None
increase I None
in I None
the I None
number I None
of I None
specific I None
granules I None
with I None
a I None
presumed I None
lysosomal I None
function I None
in I None
the I None
superficial I None
cells I None
. I None
<eof> I None

<s> O None
Increase I None
in I None
intragastric I None
pressure I None
during I None
suxamethonium I Chemical
-induced I None
muscle I Disease
fasciculations O Disease
in I None
children I None
: I None
inhibition I None
by I None
alfentanil I Chemical
. I None
<eof> I None

<s> O None
Changes I None
in I None
intragastric I None
pressure I None
after I None
the I None
administration I None
of I None
suxamethonium I Chemical
<eof> I None

<s> O None
1.5 I None
mg I None
kg-1 I None
i.v I None
. I None
were I None
studied I None
in I None
32 I None
children I None
( I None
mean I None
age I None
6.9 I None
yr I None
) I None
pretreated I None
with I None
either I None
physiological I None
saline I None
or I None
alfentanil I Chemical
50 I None
micrograms I None
kg-1 I None
. I None
<eof> I None

<s> O None
Anaesthesia I None
was I None
induced I None
with I None
thiopentone I Chemical
<eof> I None

<s> O None
5 I None
mg I None
kg-1 I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
and I None
intensity I None
of I None
muscle I Disease
fasciculations O Disease
caused I None
by I None
suxamethonium I Chemical
were I None
significantly I None
greater I None
in I None
the I None
control I None
than I None
in I None
the I None
alfentanil I Chemical
group I None
. I None
<eof> I None

<s> O None
The I None
intragastric I None
pressure I None
during I None
muscle I Disease
fasciculations O Disease
was I None
significantly I None
higher I None
in I None
the I None
control I None
group I None
( I None
16 I None
+ I None
/- I None
<eof> I None

<s> O None
0.7 I None
( I None
SEM I None
) I None
cm I None
H2O I Chemical
) I None
than I None
in I None
the I None
alfentanil I Chemical
group I None
( I None
7.7 I None
+ I None
/- I None
1.5 I None
( I None
SEM I None
) I None
cm I None
H2O I Chemical
) I None
. I None
<eof> I None

<s> O None
The I None
increase I None
in I None
intragastric I None
pressure I None
was I None
directly I None
related I None
to I None
the I None
intensity I None
of I None
muscle I Disease
fasciculations O Disease
<eof> I None

<s> O None
( I None
regression I None
line I None
: I None
y I None
= I None
0.5 I None
+ I None
4.78x I None
with I None
r I None
of I None
0.78 I None
) I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
intragastric I None
pressure I None
increases I None
significantly I None
during I None
muscle I Disease
fasciculations O Disease
caused I None
by I None
suxamethonium I Chemical
in I None
healthy I None
children I None
. I None
<eof> I None

<s> O None
Alfentanil I Chemical
50 I None
micrograms I None
kg-1 I None
effectively I None
inhibits I None
the I None
incidence I None
and I None
intensity I None
of I None
suxamethonium I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
muscle I Disease
fasciculations O Disease
; I None
moreover I None
, I None
intragastric I None
pressure I None
remains I None
at I None
its I None
control I None
value I None
. I None
<eof> I None

<s> O None
Acute I None
insulin I None
treatment I None
normalizes I None
the I None
resistance I None
to I None
the I None
cardiotoxic I Disease
effect I None
of I None
isoproterenol I Chemical
in I None
streptozotocin I Chemical
diabetic I Disease
rats I None
. I None
<eof> I None

<s> O None
A I None
morphometric I None
study I None
of I None
isoproterenol I Chemical
induced I None
myocardial I None
fibrosis I Disease
. I None
<eof> I None

<s> O None
The I None
acute I None
effect I None
of I None
insulin I None
treatment I None
on I None
the I None
earlier I None
reported I None
protective I None
effect I None
of I None
streptozotocin I Chemical
diabetes I Disease
against I None
the I None
cardiotoxic I Disease
effect I None
of I None
high I None
doses I None
of I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
ISO I Chemical
) I None
was I None
investigated I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Thirty I None
to I None
135 I None
min I None
after I None
the I None
injection I None
of I None
crystalline I None
insulin I None
, I None
ISO I Chemical
was I None
given I None
subcutaneously I None
and I None
when I None
ISO I Chemical
induced I None
fibrosis I Disease
in I None
the I None
myocardium I None
was I None
morphometrically I None
analyzed I None
7 I None
days I None
later I None
, I None
a I None
highly I None
significant I None
correlation I None
( I None
r I None
= I None
0.83 I None
, I None
2 I None
p I None
= I None
0.006 I None
) I None
to I None
the I None
slope I None
of I None
the I None
fall I None
in I None
blood I None
<eof> I None

<s> O None
glucose I Chemical
after I None
insulin I None
treatment I None
appeared I None
. I None
<eof> I None

<s> O None
The I None
myocardial I None
content I None
of I None
catecholamines I Chemical
was I None
estimated I None
in I None
these I None
8 I None
day I None
<eof> I None

<s> O None
diabetic I Disease
rats I None
. I None
<eof> I None

<s> O None
The I None
norepinephrine I Chemical
content I None
was I None
significantly I None
increased I None
while I None
epinephrine I Chemical
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
An I None
enhanced I None
sympathetic I None
nervous I None
system I None
activity I None
with I None
a I None
consequent I None
down I None
regulation I None
of I None
the I None
myocardial I None
beta I None
- I None
adrenergic I None
receptors I None
could I None
, I None
therefore I None
, I None
explain I None
this I None
catecholamine I Chemical
resistance I None
. I None
<eof> I None

<s> O None
The I None
rapid I None
reversion I None
after I None
insulin I None
treatment I None
excludes I None
the I None
possibility I None
that I None
streptozotocin I Chemical
in I None
itself I None
causes I None
the I None
ISO I Chemical
resistance I None
and I None
points I None
towards I None
a I None
direct I None
insulin I None
effect I None
on I None
myocardial I None
catecholamine I Chemical
sensitivity I None
in I None
diabetic I Disease
rats I None
. I None
<eof> I None

<s> O None
The I None
phenomenon I None
described I None
might I None
elucidate I None
pathogenetic I None
mechanisms I None
behind I None
toxic I None
myocardial I None
cell I None
degeneration I None
and I None
may I None
possibly I None
have I None
relevance I None
for I None
acute I None
cardiovascular I None
complications I None
in I None
diabetic I Disease
patients I None
. I None
<eof> I None

<s> O None
Differential I None
effects I None
of I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
on I None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
muscarinic I None
cholinergic I None
agonist I None
pilocarpine I Chemical
induces I None
in I None
rats I None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
followed I None
by I None
widespread I None
damage I None
to I None
the I None
forebrain I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
designed I None
to I None
investigate I None
the I None
effect I None
of I None
5 I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
, I None
sodium I Chemical
salicylate O Chemical
, I None
phenylbutazone I Chemical
, I None
indomethacin I Chemical
, I None
ibuprofen I Chemical
and I None
mefenamic I Chemical
acid O Chemical
, I None
on I None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
Pretreatment I None
of I None
rats I None
with I None
sodium I Chemical
salicylate O Chemical
, I None
ED50 I None
103 I None
mg I None
/ I None
kg I None
( I None
60 I None
- I None
174 I None
) I None
, I None
and I None
phenylbutazone I Chemical
, I None
59 I None
mg I None
/ I None
kg I None
( I None
50 I None
- I None
70 I None
) I None
converted I None
the I None
non I None
- I None
convulsant I None
dose I None
of I None
pilocarpine I Chemical
, I None
200 I None
mg I None
/ I None
kg I None
, I None
to I None
a I None
convulsant I None
one I None
. I None
<eof> I None

<s> O None
Indomethacin I Chemical
, I None
1 I None
- I None
10 I None
mg I None
/ I None
kg I None
, I None
and I None
ibuprofen I Chemical
, I None
10 I None
- I None
100 I None
mg I None
/ I None
kg I None
, I None
failed I None
to I None
modulate I None
<eof> I None

<s> O None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
Mefenamic I Chemical
acid O Chemical
, I None
26 I None
( I None
22 I None
- I None
30 I None
) I None
mg I None
/ I None
kg I None
, I None
prevented I None
<eof> I None

<s> O None
seizures I Disease
and I None
protected I None
rats I None
from I None
seizure I Disease
<eof> I None

<s> O None
-related I None
<eof> I None

<s> O None
brain I Disease
damage O Disease
induced I None
by I None
pilocarpine I Chemical
, I None
380 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
differentially I None
modulate I None
the I None
threshold I None
for I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
. I None
<eof> I None

<s> O None
Acute I Disease
neurologic O Disease
dysfunction O Disease
after I None
high I None
- I None
dose I None
etoposide I Chemical
therapy I None
for I None
malignant I Disease
glioma O Disease
. I None
<eof> I None

<s> O None
Etoposide I Chemical
<eof> I None

<s> O None
( I None
VP-16 I Chemical
- O Chemical
213 O Chemical
) I None
has I None
been I None
used I None
in I None
the I None
treatment I None
of I None
many I None
solid I None
tumors I Disease
and I None
hematologic I Disease
malignancies O Disease
. I None
<eof> I None

<s> O None
When I None
used I None
in I None
high I None
doses I None
and I None
in I None
conjunction I None
with I None
autologous I None
bone I None
marrow I None
transplantation I None
, I None
this I None
agent I None
has I None
activity I None
against I None
several I None
treatment I None
- I None
resistant I None
cancers I Disease
including I None
malignant I Disease
glioma O Disease
. I None
<eof> I None

<s> O None
In I None
six I None
of I None
eight I None
patients I None
( I None
75 I None
% I None
) I None
who I None
we I None
treated I None
for I None
recurrent I None
or I None
resistant I None
glioma I Disease
, I None
sudden I None
severe I None
neurologic I Disease
deterioration O Disease
occurred I None
. I None
<eof> I None

<s> O None
This I None
developed I None
a I None
median I None
of I None
9 I None
days I None
after I None
initiation I None
of I None
high I None
- I None
dose I None
etoposide I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Significant I None
clinical I None
manifestations I None
have I None
included I None
confusion I Disease
, I None
papilledema I Disease
, I None
somnolence I Disease
, I None
exacerbation I None
of I None
motor I Disease
deficits O Disease
, I None
and I None
sharp I None
increase I None
in I None
seizure I Disease
activity I None
. I None
<eof> I None

<s> O None
These I None
abnormalities I None
resolved I None
rapidly I None
after I None
initiation I None
of I None
high I None
- I None
dose I None
intravenous I None
dexamethasone I Chemical
therapy I None
. I None
<eof> I None

<s> O None
In I None
all I None
patients I None
, I None
computerized I None
tomographic I None
( I None
CT I None
) I None
brain I None
scans I None
demonstrated I None
stability I None
in I None
tumor I Disease
size I None
and I None
peritumor I None
edema I Disease
when I None
compared I None
with I None
pretransplant I None
scans I None
. I None
<eof> I None

<s> O None
This I None
complication I None
appears I None
to I None
represent I None
a I None
significant I None
new I None
toxicity I Disease
of I None
high I None
- I None
dose I None
etoposide I Chemical
therapy I None
for I None
malignant I Disease
glioma O Disease
. I None
<eof> I None

<s> O None
Progressive I None
bile I Disease
duct O Disease
injury O Disease
after I None
thiabendazole I Chemical
administration I None
. I None
<eof> I None

<s> O None
A I None
27-yr I None
- I None
old I None
man I None
developed I None
jaundice I Disease
<eof> I None

<s> O None
2 I None
wk I None
after I None
exposure I None
to I None
thiabendazole I Chemical
. I None
<eof> I None

<s> O None
Cholestasis I Disease
persisted I None
for I None
3 I None
yr I None
, I None
at I None
which I None
time I None
a I None
liver I None
transplant I None
was I None
performed I None
. I None
<eof> I None

<s> O None
Two I None
liver I None
biopsy I None
specimens I None
and I None
the I None
hepatectomy I None
specimen I None
were I None
remarkable I None
for I None
almost I None
complete I None
disappearance I None
of I None
interlobular I None
bile I None
ducts I None
. I None
<eof> I None

<s> O None
Prominent I None
fibrosis I Disease
and I None
hepatocellular I None
regeneration I None
were I None
also I None
present I None
; I None
however I None
, I None
the I None
lobular I None
architecture I None
was I None
preserved I None
. I None
<eof> I None

<s> O None
This I None
case I None
represents I None
an I None
example I None
of I None
" I None
idiosyncratic I None
" I None
drug I Disease
- O Disease
induced O Disease
liver O Disease
damage O Disease
in I None
which I None
the I None
primary I None
target I None
of I None
injury I None
is I None
the I None
bile I None
duct I None
. I None
<eof> I None

<s> O None
An I None
autoimmune I None
pathogenesis I None
of I None
the I None
bile I Disease
duct O Disease
destruction O Disease
is I None
suggested I None
. I None
<eof> I None

<s> O None
Differential I None
effects I None
of I None
1,4-dihydropyridine I Chemical
<eof> I None

<s> O None
calcium I Chemical
channel O Chemical
blockers O Chemical
: I None
therapeutic I None
implications I None
. I None
<eof> I None

<s> O None
Increasing I None
recognition I None
of I None
the I None
importance I None
of I None
calcium I Chemical
in I None
the I None
pathogenesis I None
of I None
cardiovascular I Disease
disease O Disease
has I None
stimulated I None
research I None
into I None
the I None
use I None
of I None
calcium I Chemical
channel O Chemical
blocking O Chemical
agents O Chemical
for I None
treatment I None
of I None
a I None
variety I None
of I None
cardiovascular I Disease
diseases O Disease
. I None
<eof> I None

<s> O None
The I None
favorable I None
efficacy I None
and I None
tolerability I None
profiles I None
of I None
these I None
agents I None
make I None
them I None
attractive I None
therapeutic I None
modalities I None
. I None
<eof> I None

<s> O None
Clinical I None
applications I None
of I None
calcium I Chemical
channel O Chemical
blockers O Chemical
parallel I None
their I None
tissue I None
selectivity I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
verapamil I Chemical
and I None
diltiazem I Chemical
, I None
which I None
are I None
roughly I None
equipotent I None
in I None
their I None
actions I None
on I None
the I None
heart I None
and I None
vascular I None
smooth I None
muscle I None
, I None
the I None
dihydropyridine I Chemical
calcium I Chemical
channel O Chemical
blockers O Chemical
are I None
a I None
group I None
of I None
potent I None
peripheral I None
vasodilator I None
agents I None
that I None
exert I None
minimal I None
electrophysiologic I None
effects I None
on I None
cardiac I None
nodal I None
or I None
conduction I None
tissue I None
. I None
<eof> I None

<s> O None
As I None
the I None
first I None
dihydropyridine I Chemical
available I None
for I None
use I None
in I None
the I None
United I None
States I None
, I None
nifedipine I Chemical
controls I None
<eof> I None

<s> O None
angina I Disease
and I None
hypertension I Disease
with I None
minimal I None
depression I None
of I None
cardiac I None
function I None
. I None
<eof> I None

<s> O None
Additional I None
members I None
of I None
this I None
group I None
of I None
calcium I Chemical
channel O Chemical
blockers O Chemical
have I None
been I None
studied I None
for I None
a I None
variety I None
of I None
indications I None
for I None
which I None
they I None
may I None
offer I None
advantages I None
over I None
current I None
therapy I None
. I None
<eof> I None

<s> O None
Once I None
or I None
twice I None
daily I None
dosage I None
possible I None
with I None
nitrendipine I Chemical
and I None
nisoldipine I Chemical
offers I None
a I None
convenient I None
administration I None
schedule I None
, I None
which I None
encourages I None
patient I None
compliance I None
in I None
long I None
- I None
term I None
therapy I None
of I None
hypertension I Disease
. I None
<eof> I None

<s> O None
The I None
coronary I None
vasodilating I None
properties I None
of I None
nisoldipine I Chemical
have I None
led I None
to I None
the I None
investigation I None
of I None
this I None
agent I None
for I None
use I None
in I None
angina I Disease
. I None
<eof> I None

<s> O None
Selectivity I None
for I None
the I None
cerebrovascular I None
bed I None
makes I None
nimodipine I Chemical
potentially I None
useful I None
in I None
the I None
treatment I None
of I None
subarachnoid I Disease
hemorrhage O Disease
, I None
migraine I Disease
headache O Disease
, I None
dementia I Disease
, I None
and I None
stroke I Disease
. I None
<eof> I None

<s> O None
In I None
general I None
, I None
the I None
dihydropyridine I Chemical
calcium I Chemical
channel O Chemical
blockers O Chemical
are I None
usually I None
well I None
tolerated I None
, I None
with I None
headache I Disease
, I None
facial I None
flushing I Disease
, I None
palpitations I Disease
, I None
edema I Disease
, I None
nausea I Disease
, I None
anorexia I Disease
, I None
and I None
dizziness I Disease
being I None
the I None
more I None
common I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
The I None
enhancement I None
of I None
aminonucleoside I Chemical
nephrosis I Disease
by I None
the I None
co I None
- I None
administration I None
of I None
protamine I None
. I None
<eof> I None

<s> O None
An I None
experimental I None
model I None
of I None
focal I Disease
segmental O Disease
glomerular O Disease
sclerosis O Disease
<eof> I None

<s> O None
( I None
FSGS I Disease
) I None
was I None
developed I None
in I None
rats I None
by I None
the I None
combined I None
administration I None
of I None
puromycin I Chemical
- O Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
AMNS I Chemical
) I None
and I None
protamine I Chemical
sulfate O Chemical
<eof> I None

<s> O None
( I None
PS I Chemical
) I None
. I None
<eof> I None

<s> O None
Male I None
Sprague I None
- I None
Dawley I None
rats I None
, I None
uninephrectomized I None
three I None
weeks I None
before I None
, I None
received I None
daily I None
injections I None
of I None
subcutaneous I None
AMNS I Chemical
( I None
1 I None
mg/100 I None
g I None
body I None
wt I None
) I None
and I None
intravenous I None
PS I Chemical
<eof> I None

<s> O None
( I None
2 I None
separated I None
doses I None
of I None
2.5 I None
mg/100 I None
g I None
body I None
wt I None
) I None
for I None
four I None
days I None
. I None
<eof> I None

<s> O None
The I None
series I None
of I None
injections I None
were I None
repeated I None
another I None
three I None
times I None
at I None
10 I None
day I None
intervals I None
. I None
<eof> I None

<s> O None
The I None
animals I None
were I None
sacrificed I None
on I None
days I None
24 I None
, I None
52 I None
, I None
and I None
80 I None
. I None
<eof> I None

<s> O None
They I None
developed I None
nephrotic I Disease
syndrome O Disease
and I None
finally I None
renal I Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
time I None
- I None
course I None
curve I None
of I None
creatinine I Chemical
clearance I None
dropped I None
and I None
showed I None
significant I None
difference I None
( I None
P I None
less I None
than I None
0.01 I None
) I None
from I None
that I None
of I None
each I None
control I None
group I None
, I None
such I None
as I None
, I None
AMNS I Chemical
alone I None
, I None
PS I Chemical
alone I None
or I None
saline I None
injected I None
. I None
<eof> I None

<s> O None
Their I None
glomeruli I None
showed I None
changes I None
of I None
progressive I None
FSGS I Disease
. I None
<eof> I None

<s> O None
The I None
ultrastructural I None
studies I None
in I None
the I None
initial I None
stage I None
revealed I None
significant I None
lack I None
of I None
particles I None
of I None
perfused I None
ruthenium I Chemical
red I None
on I None
the I None
lamina I None
rara I None
externa I None
and I None
marked I None
changes I None
in I None
epithelial I None
cell I None
cytoplasm I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
it I None
is I None
suggested I None
that I None
the I None
administration I None
of I None
PS I Chemical
enhances I None
the I None
toxicity I Disease
of I None
AMNS I Chemical
on I None
the I None
glomerulus I None
and I None
readily I None
produces I None
progressive I None
FSGS I Disease
in I None
rats I None
resulting I None
in I None
the I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Theophylline I Chemical
neurotoxicity I Disease
in I None
pregnant I None
rats I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
investigation I None
was I None
to I None
determine I None
whether I None
the I None
neurotoxicity I Disease
of I None
theophylline I Chemical
is I None
altered I None
in I None
advanced I None
pregnancy I None
. I None
<eof> I None

<s> O None
Sprague I None
- I None
Dawley I None
rats I None
that I None
were I None
20 I None
days I None
pregnant I None
and I None
nonpregnant I None
rats I None
of I None
the I None
same I None
age I None
and I None
strain I None
received I None
infusions I None
of I None
aminophylline I Chemical
until I None
onset I None
of I None
maximal I None
seizures I Disease
which I None
occurred I None
after I None
28 I None
and I None
30 I None
minutes I None
respectively I None
. I None
<eof> I None

<s> O None
Theophylline I Chemical
concentrations I None
at I None
this I None
endpoint I None
in I None
serum I None
( I None
total I None
) I None
and I None
CSF I None
were I None
similar I None
but I None
serum I None
( I None
free I None
) I None
and I None
brain I None
concentrations I None
were I None
slightly I None
different I None
in I None
pregnant I None
rats I None
. I None
<eof> I None

<s> O None
Theophylline I Chemical
serum I None
protein I None
binding I None
determined I None
by I None
equilibrium I None
dialysis I None
was I None
lower I None
in I None
pregnant I None
rats I None
. I None
<eof> I None

<s> O None
Fetal I None
serum I None
concentrations I None
at I None
onset I None
of I None
seizures I Disease
in I None
the I None
mother I None
were I None
similar I None
to I None
maternal I None
brain I None
and I None
CSF I None
concentrations I None
and I None
correlated I None
significantly I None
with I None
the I None
former I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
advanced I None
pregnancy I None
has I None
a I None
negligible I None
effect I None
on I None
the I None
neurotoxic I Disease
response I None
to I None
theophylline I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
Hyperkalemia I Disease
induced I None
by I None
indomethacin I Chemical
and I None
naproxen I Chemical
and I None
reversed I None
by I None
fludrocortisone I Chemical
. I None
<eof> I None

<s> O None
We I None
have I None
described I None
a I None
patient I None
with I None
severe I None
rheumatoid I Disease
arthritis O Disease
and I None
a I None
history I None
of I None
mefenamic I Chemical
acid O Chemical
nephropathy I Disease
<eof> I None

<s> O None
in I None
whom I None
hyperkalemia I Disease
and I None
inappropriate I None
hypoaldosteronism I Disease
were I None
caused I None
by I None
both I None
indomethacin I Chemical
and I None
naproxen I Chemical
, I None
without I None
major I None
decline I None
in I None
renal I None
function I None
. I None
<eof> I None

<s> O None
It I None
is I None
likely I None
that I None
preexisting I None
renal I Disease
disease O Disease
predisposed I None
this I None
patient I None
to I None
type I Disease
IV O Disease
renal O Disease
tubular O Disease
acidosis O Disease
with I None
prostaglandin I Chemical
synthetase I None
inhibitors I None
. I None
<eof> I None

<s> O None
Because I None
he I None
was I None
unable I None
to I None
discontinue I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
therapy I None
, I None
fludrocortisone I Chemical
was I None
added I None
, I None
correcting I None
the I None
hyperkalemia I Disease
and I None
allowing I None
indomethacin I Chemical
therapy I None
to I None
be I None
continued I None
safely I None
. I None
<eof> I None

<s> O None
Hypotension I Disease
as I None
a I None
manifestation I None
of I None
cardiotoxicity I Disease
in I None
three I None
patients I None
receiving I None
cisplatin I Chemical
and I None
5-fluorouracil I Chemical
. I None
<eof> I None

<s> O None
Cardiac I None
symptoms I None
, I None
including I None
hypotension I Disease
, I None
developed I None
in I None
three I None
patients I None
with I None
advanced I None
colorectal I Disease
carcinoma O Disease
while I None
being I None
treated I None
with I None
cisplatin I Chemical
<eof> I None

<s> O None
( I None
CDDP I Chemical
) I None
and I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
. I None
<eof> I None

<s> O None
In I None
two I None
patients I None
, I None
hypotension I Disease
was I None
associated I None
with I None
severe I None
left I Disease
ventricular O Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
All I None
three I None
patients I None
required I None
therapy I None
discontinuation I None
. I None
<eof> I None

<s> O None
Cardiac I None
enzymes I None
remained I None
normal I None
despite I None
transient I None
electrocardiographic I None
( I None
EKG I None
) I None
changes I None
. I None
<eof> I None

<s> O None
The I None
presentation I None
and I None
cardiac I None
evaluation I None
( I None
hemodynamic I None
, I None
echocardiographic I None
, I None
and I None
scintigraphic I None
) I None
of I None
these I None
patients I None
suggest I None
new I None
manifestations I None
of I None
5-FU I Chemical
cardiotoxicity I Disease
that I None
may I None
be I None
influenced I None
by I None
CDDP I Chemical
. I None
<eof> I None

<s> O None
The I None
possible I None
pathophysiologic I None
mechanisms I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Fatal I None
aplastic I Disease
anemia O Disease
in I None
a I None
patient I None
treated I None
with I None
carbamazepine I Chemical
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
fatal I None
aplastic I Disease
anemia O Disease
due I None
to I None
carbamazepine I Chemical
treatment I None
in I None
an I None
epileptic I Disease
woman I None
is I None
reported I None
. I None
<eof> I None

<s> O None
Despite I None
concerns I None
of I None
fatal I None
bone I Disease
marrow O Disease
toxicity O Disease
due I None
to I None
carbamazepine I Chemical
, I None
this I None
is I None
only I None
the I None
fourth I None
documented I None
and I None
published I None
report I None
. I None
<eof> I None

<s> O None
Carbamazepine I Chemical
is I None
a I None
safe I None
drug I None
, I None
but I None
physicians I None
and I None
patients I None
should I None
be I None
aware I None
of I None
the I None
exceedingly I None
rare I None
but I None
potentially I None
fatal I None
side I None
effects I None
, I None
better I None
prevented I None
by I None
clinical I None
than I None
by I None
laboratory I None
monitoring I None
. I None
<eof> I None

<s> O None
Participation I None
of I None
a I None
bulbospinal I None
serotonergic I None
pathway I None
in I None
the I None
rat I None
brain I None
in I None
clonidine I Chemical
-induced I None
hypotension I Disease
and I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
microinjection I None
of I None
clonidine I Chemical
<eof> I None

<s> O None
( I None
1 I None
- I None
10 I None
micrograms I None
in I None
1 I None
microliter I None
) I None
into I None
a I None
region I None
adjacent I None
to I None
the I None
ventrolateral I None
surface I None
of I None
the I None
medulla I None
oblongata I None
on I None
cardiovascular I None
function I None
were I None
assessed I None
in I None
urethane I Chemical
-anesthetized I None
rats I None
. I None
<eof> I None

<s> O None
Intramedullary I None
administration I None
of I None
clonidine I Chemical
, I None
but I None
not I None
saline I None
vehicle I None
, I None
caused I None
a I None
dose I None
- I None
dependent I None
decrease I None
in I None
both I None
the I None
mean I None
arterial I None
pressure I None
and I None
the I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
The I None
clonidine I Chemical
-induced I None
hypotension I Disease
was I None
antagonized I None
by I None
prior I None
spinal I None
transection I None
, I None
but I None
not I None
bilateral I None
vagotomy I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
clonidine I Chemical
-induced I None
bradycardia I Disease
was I None
antagonized I None
by I None
prior I None
bilateral I None
vagotomy I None
, I None
but I None
not I None
spinal I None
transection I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
selective I None
destruction I None
of I None
the I None
spinal I None
5-HT I Chemical
nerves I None
, I None
produced I None
by I None
bilateral I None
spinal I None
injection I None
of I None
5,7-dihydroxytryptamine I Chemical
, I None
reduced I None
the I None
magnitude I None
of I None
the I None
vasodepressor I None
or I None
the I None
bradycardiac I Disease
responses I None
to I None
clonidine I Chemical
microinjected I None
into I None
the I None
area I None
near I None
the I None
ventrolateral I None
surface I None
of I None
the I None
medulla I None
oblongata I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
a I None
bulbospinal I None
serotonergic I None
pathway I None
is I None
involved I None
in I None
development I None
of I None
clonidine I Chemical
-induced I None
hypotension I Disease
and I None
bradycardia I Disease
. I None
<eof> I None

<s> O None
The I None
induced I None
hypotension I Disease
is I None
brought I None
about I None
by I None
a I None
decrease I None
in I None
sympathetic I None
efferent I None
activity I None
, I None
whereas I None
the I None
induced I None
bradycardia I Disease
was I None
due I None
to I None
an I None
increase I None
in I None
vagal I None
efferent I None
activity I None
. I None
<eof> I None

<s> O None
Hypertension I Disease
in I None
<eof> I None

<s> O None
neuroblastoma I Disease
induced I None
by I None
imipramine I Chemical
. I None
<eof> I None

<s> O None
Hypertension I Disease
is I None
a I None
well I None
- I None
known I None
finding I None
in I None
some I None
patients I None
with I None
neuroblastoma I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
it I None
has I None
not I None
previously I None
been I None
described I None
in I None
association I None
with I None
the I None
use I None
of I None
Imipramine I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
occurrence I None
of I None
severe I None
hypertension I Disease
( I None
blood I None
pressure I None
190/160 I None
) I None
in I None
a I None
4-year I None
- I None
old I None
girl I None
with I None
neuroblastoma I Disease
who I None
was I None
given I None
Imipramine I Chemical
to I None
control I None
a I None
behavior I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
It I None
was I None
determined I None
later I None
that I None
this I None
patient I None
's I None
tumor I Disease
was I None
recurring I None
at I None
the I None
time I None
of I None
her I None
hypertensive I Disease
episode I None
. I None
<eof> I None

<s> O None
Since I None
she I None
had I None
no I None
blood I None
pressure I None
elevation I None
at I None
initial I None
diagnosis I None
and I None
none I None
following I None
discontinuation I None
of I None
the I None
Imipramine I Chemical
<eof> I None

<s> O None
( I None
when I None
she I None
was I None
in I None
florid I None
relapse I None
) I None
, I None
we I None
believe I None
that I None
this I None
drug I None
rather I None
than I None
her I None
underlying I None
disease I None
alone I None
caused I None
her I None
hypertension I Disease
. I None
<eof> I None

<s> O None
The I None
mechanism I None
for I None
this I None
reaction I None
is I None
believed I None
to I None
be I None
increased I None
levels I None
of I None
vasoactive I None
catecholamines I Chemical
due I None
to I None
interference I None
of I None
their I None
physiologic I None
inactivation I None
by I None
Imipramine I Chemical
. I None
<eof> I None

<s> O None
From I None
this I None
experience I None
, I None
we I None
urge I None
extreme I None
caution I None
in I None
the I None
use I None
of I None
tricyclic I None
antidepressants I None
in I None
children I None
with I None
active I None
neuroblastoma I Disease
. I None
<eof> I None

<s> O None
Rechallenge I None
of I None
patients I None
who I None
developed I None
oral I Disease
candidiasis O Disease
or I None
hoarseness I Disease
with I None
beclomethasone I Chemical
dipropionate O Chemical
. I None
<eof> I None

<s> O None
Of I None
158 I None
asthmatic I Disease
patients I None
who I None
were I None
placed I None
on I None
inhaled I None
<eof> I None

<s> O None
beclomethasone I Chemical
, I None
15 I None
( I None
9.5 I None
% I None
) I None
developed I None
either I None
hoarseness I Disease
<eof> I None

<s> O None
( I None
8) I None
, I None
oral I None
thrush I Disease
( I None
6 I None
) I None
, I None
or I None
both I None
( I None
1 I None
) I None
. I None
<eof> I None

<s> O None
When I None
their I None
adverse I None
reactions I None
subsided I None
, I None
seven I None
of I None
these I None
15 I None
patients I None
were I None
rechallenged I None
with I None
inhaled I None
beclomethasone I Chemical
. I None
<eof> I None

<s> O None
These I None
included I None
five I None
cases I None
who I None
developed I None
hoarseness I Disease
and I None
three I None
who I None
developed I None
Candidiasis I Disease
. I None
<eof> I None

<s> O None
One I None
patient I None
had I None
both I None
. I None
<eof> I None

<s> O None
Oral I None
thrush I Disease
did I None
not I None
recur I None
, I None
but I None
60 I None
% I None
( I None
3/5 I None
) I None
of I None
patients I None
with I None
hoarseness I Disease
had I None
recurrence I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
patients I None
may I None
be I None
restarted I None
on I None
inhaled I None
<eof> I None

<s> O None
beclomethasone I Chemical
when I None
clinically I None
indicated I None
; I None
however I None
, I None
because I None
of I None
the I None
high I None
recurrence I None
rate I None
, I None
patients I None
who I None
develop I None
hoarseness I Disease
should I None
not I None
be I None
re I None
- I None
challenged I None
. I None
<eof> I None

<s> O None
Concomitant I None
use I None
of I None
oral I None
prednisone I Chemical
and I None
topical I None
beclomethasone I Chemical
may I None
increase I None
the I None
risk I None
of I None
developing I None
hoarseness I Disease
or I None
candidiasis I Disease
. I None
<eof> I None

<s> O None
Cyclophosphamide I Chemical
<eof> I None

<s> O None
cardiotoxicity I Disease
: I None
an I None
analysis I None
of I None
dosing I None
as I None
a I None
risk I None
factor I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
undergo I None
bone I None
marrow I None
transplantation I None
are I None
generally I None
immunosuppressed I None
with I None
a I None
dose I None
of I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYA I Chemical
) I None
which I None
is I None
usually I None
calculated I None
based I None
on I None
the I None
patient I None
's I None
weight I None
. I None
<eof> I None

<s> O None
At I None
these I None
high I None
doses I None
of I None
CYA I Chemical
, I None
serious I None
cardiotoxicity I Disease
may I None
occur I None
, I None
but I None
definitive I None
risk I None
factors I None
for I None
the I None
development I None
of I None
such I None
cardiotoxicity I Disease
have I None
not I None
been I None
described I None
. I None
<eof> I None

<s> O None
Since I None
chemotherapeutic I None
agent I None
toxicity I Disease
generally I None
correlates I None
with I None
dose I None
per I None
body I None
surface I None
area I None
, I None
we I None
retrospectively I None
calculated I None
the I None
dose I None
of I None
CYA I Chemical
in I None
patients I None
transplanted I None
at I None
our I None
institution I None
to I None
determine I None
whether I None
the I None
incidence I None
of I None
CYA I Chemical
cardiotoxicity I Disease
correlated I None
with I None
the I None
dose I None
per I None
body I None
surface I None
area I None
. I None
<eof> I None

<s> O None
Eighty I None
patients I None
who I None
were I None
to I None
receive I None
CYA I Chemical
50 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
/ I None
d I None
for I None
four I None
days I None
as I None
preparation I None
for I None
marrow I None
grafting I None
underwent I None
a I None
total I None
of I None
84 I None
transplants I None
for I None
aplastic I Disease
anemia O Disease
, I None
Wiskott I Disease
- O Disease
Aldrich O Disease
syndrome O Disease
, I None
or I None
severe I Disease
combined O Disease
immunodeficiency O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Fourteen I None
of I None
84 I None
( I None
17 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
had I None
symptoms I None
and I None
signs I None
consistent I None
with I None
CYA I Chemical
<eof> I None

<s> O None
cardiotoxicity I Disease
within I None
ten I None
days I None
of I None
receiving I None
1 I None
to I None
4 I None
doses I None
of I None
CYA I Chemical
. I None
<eof> I None

<s> O None
Six I None
of I None
the I None
14 I None
patients I None
died I None
with I None
congestive I Disease
heart O Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
CYA I Chemical
per I None
body I None
surface I None
area I None
was I None
calculated I None
for I None
all I None
patients I None
and I None
the I None
patients I None
were I None
divided I None
into I None
two I None
groups I None
based I None
on I None
daily I None
CYA I Chemical
dose I None
: I None
Group I None
1 I None
, I None
CYA I Chemical
less I None
than I None
or I None
equal I None
to I None
1.55 I None
g I None
/ I None
m2/d I None
; I None
Group I None
2 I None
, I None
CYA I Chemical
greater I None
than I None
1.55 I None
g I None
/ I None
m2/d I None
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
<eof> I None

<s> O None
that I None
was I None
thought I None
to I None
be I None
related I None
to I None
CYA I Chemical
occurred I None
in I None
1/32 I None
( I None
3 I None
% I None
) I None
of I None
patients I None
in I None
Group I None
1 I None
and I None
in I None
13/52 I None
( I None
25 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
in I None
Group I None
2 I None
( I None
P I None
less I None
than I None
0.025 I None
) I None
. I None
<eof> I None

<s> O None
Congestive I Disease
heart O Disease
failure O Disease
caused I None
or I None
contributed I None
to I None
death I None
in I None
0/32 I None
patients I None
in I None
Group I None
1 I None
<eof> I None

<s> O None
v I None
6/52 I None
( I None
12 I None
% I None
) I None
of I None
patients I None
in I None
Group I None
2 I None
( I None
P I None
less I None
than I None
0.25 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
difference I None
in I None
the I None
rate I None
of I None
engraftment I None
of I None
evaluable I None
patients I None
in I None
the I None
two I None
groups I None
( I None
P I None
greater I None
than I None
0.5 I None
) I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
CYA I Chemical
cardiotoxicity I Disease
correlates I None
with I None
CYA I Chemical
dosage I None
as I None
calculated I None
by I None
body I None
surface I None
area I None
, I None
and I None
that I None
patients I None
with I None
aplastic I Disease
anemia O Disease
and I None
immunodeficiencies I Disease
can I None
be I None
effectively I None
prepared I None
for I None
bone I None
marrow I None
grafting I None
at I None
a I None
CYA I Chemical
dose I None
of I None
1.55 I None
g I None
/ I None
m2/d I None
for I None
four I None
days I None
with I None
a I None
lower I None
incidence I None
of I None
cardiotoxicity I Disease
than I None
patients I None
whose I None
CYA I Chemical
dosage I None
is I None
calculated I None
based I None
on I None
weight I None
. I None
<eof> I None

<s> O None
This I None
study I None
reaffirms I None
the I None
principle I None
that I None
drug I None
toxicity I Disease
correlates I None
with I None
dose I None
per I None
body I None
surface I None
area I None
. I None
<eof> I None

<s> O None
Studies I None
of I None
risk I None
factors I None
for I None
aminoglycoside I Chemical
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
epidemiology I None
of I None
aminoglycoside I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
is I None
not I None
fully I None
understood I None
. I None
<eof> I None

<s> O None
Experimental I None
studies I None
in I None
healthy I None
human I None
volunteers I None
indicate I None
aminoglycosides I Chemical
cause I None
proximal I None
tubular I None
damage I None
in I None
most I None
patients I None
, I None
but I None
rarely I None
, I None
if I None
ever I None
, I None
cause I None
glomerular I Disease
or O Disease
tubular O Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Clinical I None
trials I None
of I None
aminoglycosides I Chemical
in I None
seriously I None
ill I None
patients I None
indicate I None
that I None
the I None
relative I None
risk I None
for I None
developing I None
acute I Disease
renal O Disease
failure O Disease
during I None
therapy I None
ranges I None
from I None
8 I None
to I None
10 I None
and I None
that I None
the I None
attributable I None
risk I None
is I None
70 I None
% I None
to I None
80 I None
% I None
. I None
<eof> I None

<s> O None
Further I None
analysis I None
of I None
these I None
data I None
suggests I None
that I None
the I None
duration I None
of I None
therapy I None
, I None
plasma I None
aminoglycoside I Chemical
levels I None
, I None
liver I Disease
disease O Disease
, I None
advanced I None
age I None
, I None
high I None
initial I None
estimated I None
creatinine I Chemical
clearance I None
and I None
, I None
possibly I None
, I None
female I None
gender I None
all I None
increase I None
the I None
risk I None
for I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Other I None
causes I None
of I None
acute I Disease
renal O Disease
failure O Disease
, I None
such I None
as I None
shock I Disease
, I None
appear I None
to I None
have I None
an I None
additive I None
effect I None
. I None
<eof> I None

<s> O None
Predictive I None
models I None
have I None
been I None
developed I None
from I None
these I None
analyses I None
that I None
should I None
be I None
useful I None
for I None
identifying I None
patients I None
at I None
high I None
risk I None
. I None
<eof> I None

<s> O None
These I None
models I None
may I None
also I None
be I None
useful I None
in I None
developing I None
insights I None
into I None
the I None
pathophysiology I None
of I None
aminoglycoside I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Flurothyl I Chemical
seizure I Disease
thresholds I None
in I None
mice I None
treated I None
neonatally I None
with I None
a I None
single I None
injection I None
of I None
monosodium I Chemical
glutamate O Chemical
<eof> I None

<s> O None
( I None
MSG I Chemical
): I None
evaluation I None
of I None
experimental I None
parameters I None
in I None
flurothyl I Chemical
seizure I Disease
testing I None
. I None
<eof> I None

<s> O None
Monosodium I Chemical
glutamate O Chemical
( I None
MSG I Chemical
) I None
administration I None
to I None
neonatal I None
rodents I None
produces I None
convulsions I Disease
and I None
results I None
in I None
numerous I None
biochemical I None
and I None
behavioral I None
deficits I None
. I None
<eof> I None

<s> O None
These I None
studies I None
were I None
undertaken I None
to I None
determine I None
if I None
neonatal I None
administration I None
of I None
MSG I Chemical
produced I None
permanent I None
alterations I None
in I None
seizure I Disease
susceptibility I None
, I None
since I None
previous I None
investigations I None
were I None
inconclusive I None
. I None
<eof> I None

<s> O None
A I None
flurothyl I Chemical
<eof> I None

<s> O None
ether I Chemical
seizure I Disease
<eof> I None

<s> O None
screening I None
technique I None
was I None
used I None
to I None
evaluate I None
seizure I Disease
susceptibility I None
in I None
adult I None
mice I None
that I None
received I None
neonatal I None
injections I None
of I None
MSG I Chemical
<eof> I None

<s> O None
( I None
4 I None
mg I None
/ I None
g I None
and I None
1 I None
mg I None
/ I None
g I None
) I None
. I None
<eof> I None

<s> O None
MSG I Chemical
treatment I None
resulted I None
in I None
significant I None
reductions I None
in I None
whole I None
brain I None
weight I None
but I None
did I None
not I None
alter I None
seizure I Disease
threshold I None
. I None
<eof> I None

<s> O None
A I None
naloxone I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
challenge I None
was I None
also I None
ineffective I None
in I None
altering I None
the I None
seizure I Disease
thresholds I None
of I None
either I None
control I None
of I None
MSG I Chemical
-treated I None
mice I None
. I None
<eof> I None

<s> O None
Flurothyl I Chemical
<eof> I None

<s> O None
ether I Chemical
produced I None
<eof> I None

<s> O None
hypothermia I Disease
which I None
was I None
correlated I None
with I None
the I None
duration I None
of I None
flurothyl I Chemical
exposure I None
; I None
however I None
, I None
the I None
relationship I None
of I None
hypothermia I Disease
to I None
seizure I Disease
induction I None
was I None
unclear I None
. I None
<eof> I None

<s> O None
Flurothyl I Chemical
seizure I Disease
testing I None
proved I None
to I None
be I None
a I None
rapid I None
and I None
reliable I None
technique I None
with I None
which I None
to I None
evaluate I None
seizure I Disease
susceptibility I None
. I None
<eof> I None

<s> O None
Susceptibility I None
to I None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
in I None
rats I None
after I None
microinjection I None
of I None
isoniazid I Chemical
or I None
gamma I Chemical
- O Chemical
vinyl O Chemical
- O Chemical
GABA O Chemical
into I None
the I None
substantia I None
nigra I None
. I None
<eof> I None

<s> O None
Pilocarpine I Chemical
, I None
given I None
intraperitoneally I None
to I None
rats I None
, I None
reproduces I None
the I None
neuropathological I None
sequelae I None
of I None
temporal I Disease
lobe O Disease
epilepsy O Disease
and I None
provides I None
a I None
relevant I None
animal I None
model I None
for I None
studying I None
mechanisms I None
of I None
buildup I None
of I None
convulsive I Disease
activity I None
and I None
pathways I None
operative I None
in I None
the I None
generalization I None
and I None
propagation I None
of I None
seizures I Disease
within I None
the I None
forebrain I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
the I None
effects I None
of I None
manipulating I None
the I None
activity I None
of I None
the I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
GABA I Chemical
) I None
-mediated I None
synaptic I None
inhibition I None
within I None
the I None
substantia I None
nigra I None
on I None
<eof> I None

<s> O None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
in I None
rats I None
, I None
were I None
investigated I None
. I None
<eof> I None

<s> O None
In I None
animals I None
pretreated I None
with I None
microinjections I None
of I None
isoniazid I Chemical
, I None
150 I None
micrograms I None
, I None
an I None
inhibitor I None
of I None
activity I None
of I None
the I None
GABA I Chemical
-synthesizing I None
enzyme I None
, I None
L I Chemical
- O Chemical
glutamic O Chemical
acid O Chemical
decarboxylase I None
, I None
into I None
the I None
substantia I None
nigra I None
pars I None
reticulata I None
( I None
SNR I None
) I None
, I None
bilaterally I None
, I None
non I None
- I None
convulsant I None
doses I None
of I None
pilocarpine I Chemical
, I None
100 I None
and I None
200 I None
mg I None
/ I None
kg I None
, I None
resulted I None
in I None
severe I None
motor I None
limbic I None
seizures I Disease
and I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
Electroencephalographic I None
and I None
behavioral I None
monitoring I None
revealed I None
a I None
profound I None
reduction I None
of I None
the I None
threshold I None
for I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
convulsions I Disease
. I None
<eof> I None

<s> O None
Morphological I None
analysis I None
of I None
frontal I None
forebrain I None
sections I None
with I None
light I None
microscopy I None
revealed I None
seizure I Disease
<eof> I None

<s> O None
-related I None
damage I None
to I None
the I None
hippocampal I None
formation I None
, I None
thalamus I None
, I None
amygdala I None
, I None
olfactory I None
cortex I None
, I None
substantia I None
nigra I None
and I None
neocortex I None
, I None
which I None
is I None
typically I None
observed I None
with I None
pilocarpine I Chemical
in I None
doses I None
exceeding I None
350 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Bilateral I None
intrastriatal I None
injections I None
of I None
isoniazid I Chemical
did I None
not I None
augment I None
<eof> I None

<s> O None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
, I None
200 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Application I None
of I None
an I None
irreversible I None
inhibitor I None
of I None
GABA I Chemical
transaminase I None
, I None
gamma I Chemical
- O Chemical
vinyl O Chemical
- O Chemical
GABA O Chemical
<eof> I None

<s> O None
( I None
D I Chemical
, O Chemical
L-4-amino O Chemical
- O Chemical
hex-5-enoic O Chemical
acid O Chemical
) I None
, I None
5 I None
micrograms I None
, I None
into I None
the I None
SNR I None
, I None
bilaterally I None
, I None
suppressed I None
the I None
appearance I None
of I None
electrographic I None
and I None
behavioral I None
seizures I Disease
produced I None
by I None
pilocarpine I Chemical
, I None
380 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
This I None
treatment I None
was I None
also I None
sufficient I None
to I None
protect I None
animals I None
from I None
the I None
occurrence I None
of I None
brain I Disease
damage O Disease
. I None
<eof> I None

<s> O None
Microinjections I None
of I None
gamma I Chemical
- O Chemical
vinyl O Chemical
- O Chemical
GABA O Chemical
, I None
5 I None
micrograms I None
, I None
into I None
the I None
dorsal I None
striatum I None
, I None
bilaterally I None
, I None
failed I None
to I None
prevent I None
the I None
development I None
of I None
convulsions I Disease
produced I None
by I None
pilocarpine I Chemical
, I None
380 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
The I None
results I None
demonstrate I None
that I None
the I None
threshold I None
for I None
pilocarpine I Chemical
-induced I None
seizures I Disease
in I None
rats I None
is I None
subjected I None
to I None
the I None
regulation I None
of I None
the I None
GABA I Chemical
-mediated I None
synaptic I None
inhibition I None
within I None
the I None
substantia I None
nigra I None
. I None
<eof> I None

<s> O None
Non I None
- I None
invasive I None
detection I None
of I None
coronary I Disease
artery O Disease
disease O Disease
by I None
body I None
surface I None
electrocardiographic I None
mapping I None
after I None
dipyridamole I Chemical
infusion I None
. I None
<eof> I None

<s> O None
Electrocardiographic I None
changes I None
after I None
dipyridamole I Chemical
infusion I None
<eof> I None

<s> O None
( I None
0.568 I None
mg I None
/ I None
kg/4 I None
min I None
) I None
were I None
studied I None
in I None
41 I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
and I None
compared I None
with I None
those I None
after I None
submaximal I None
treadmill I None
exercise I None
by I None
use I None
of I None
the I None
body I None
surface I None
mapping I None
technique I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
divided I None
into I None
three I None
groups I None
; I None
19 I None
patients I None
without I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
non- I None
MI I Disease
group I None
) I None
, I None
14 I None
with I None
anterior I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
ANT I Disease
- O Disease
MI O Disease
) I None
and I None
eight I None
with I None
inferior I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
INF I Disease
- O Disease
MI O Disease
) I None
. I None
<eof> I None

<s> O None
Eighty I None
- I None
seven I None
unipolar I None
electrocardiograms I None
( I None
ECGs I None
) I None
distributed I None
over I None
the I None
entire I None
thoracic I None
surface I None
were I None
simultaneously I None
recorded I None
. I None
<eof> I None

<s> O None
After I None
<eof> I None

<s> O None
dipyridamole I Chemical
, I None
ischemic I Disease
ST I None
- I None
segment I None
depression I Disease
( I None
0.05 I None
mV I None
or I None
more I None
) I None
was I None
observed I None
in I None
84 I None
% I None
of I None
the I None
non- I None
MI I Disease
group I None
, I None
29 I None
% I None
of I None
the I None
ANT I Disease
- O Disease
MI O Disease
group I None
, I None
63 I None
% I None
of I None
the I None
INF I Disease
- O Disease
MI O Disease
group I None
and I None
61 I None
% I None
of I None
the I None
total I None
population I None
. I None
<eof> I None

<s> O None
Exercise I None
- I None
induced I None
ST I None
depression I Disease
was I None
observed I None
in I None
84 I None
% I None
of I None
the I None
non- I None
MI I Disease
group I None
, I None
43 I None
% I None
of I None
the I None
ANT I Disease
- O Disease
MI O Disease
group I None
, I None
38 I None
% I None
of I None
the I None
INF I Disease
- O Disease
MI O Disease
group I None
and I None
61 I None
% I None
of I None
the I None
total I None
. I None
<eof> I None

<s> O None
For I None
individual I None
patients I None
, I None
there I None
were I None
no I None
obvious I None
differences I None
between I None
the I None
body I None
surface I None
distribution I None
of I None
ST I None
depression I Disease
in I None
both I None
tests I None
. I None
<eof> I None

<s> O None
The I None
increase I None
in I None
pressure I None
rate I None
product I None
after I None
dipyridamole I Chemical
was I None
significantly I None
less I None
than I None
that I None
during I None
the I None
treadmill I None
exercise I None
. I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
the I None
dipyridamole I Chemical
-induced I None
myocardial I Disease
ischemia O Disease
is I None
caused I None
by I None
the I None
inhomogenous I None
distribution I None
of I None
myocardial I None
blood I None
flow I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
dipyridamole I Chemical
ECG I None
test I None
is I None
as I None
useful I None
as I None
the I None
exercise I None
ECG I None
test I None
for I None
the I None
assessment I None
of I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Bradycardia I Disease
after I None
high I None
- I None
dose I None
intravenous I None
methylprednisolone I Chemical
therapy I None
. I None
<eof> I None

<s> O None
In I None
5 I None
consecutive I None
patients I None
with I None
rheumatoid I Disease
arthritis O Disease
who I None
received I None
intravenous I None
high I None
- I None
dose I None
methylprednisolone I Chemical
<eof> I None

<s> O None
( I None
MP I Chemical
) I None
therapy I None
( I None
1 I None
g I None
daily I None
for I None
2 I None
or I None
3 I None
consecutive I None
days I None
) I None
, I None
a I None
decline I None
in I None
pulse I None
rate I None
was I None
observed I None
, I None
most I None
pronounced I None
on I None
day I None
4 I None
. I None
<eof> I None

<s> O None
In I None
one I None
of I None
the I None
5 I None
patients I None
the I None
bradycardia I Disease
was I None
associated I None
with I None
complaints I None
of I None
substernal I None
pressure I None
. I None
<eof> I None

<s> O None
Reversal I None
to I None
normal I None
heart I None
rate I None
was I None
found I None
on I None
day I None
7 I None
. I None
<eof> I None

<s> O None
Electrocardiographic I None
registrations I None
showed I None
sinus I Disease
bradycardia O Disease
in I None
all I None
cases I None
. I None
<eof> I None

<s> O None
No I None
significant I None
changes I None
in I None
plasma I None
concentrations I None
of I None
electrolytes I None
were I None
found I None
. I None
<eof> I None

<s> O None
Careful I None
observation I None
of I None
patients I None
receiving I None
high I None
- I None
dose I None
MP I Chemical
is I None
recommended I None
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
MP I Chemical
may I None
be I None
contraindicated I None
in I None
patients I None
with I None
known I None
heart I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
downbeat I Disease
nystagmus O Disease
and I None
oscillopsia I Disease
associated I None
with I None
carbamazepine I Chemical
. I None
<eof> I None

<s> O None
Downbeat I Disease
nystagmus O Disease
is I None
often I None
associated I None
with I None
structural I None
lesions I None
at I None
the I None
craniocervical I None
junction I None
, I None
but I None
has I None
occasionally I None
been I None
reported I None
as I None
a I None
manifestation I None
of I None
metabolic I None
imbalance I None
or I None
drug I None
intoxication I None
. I None
<eof> I None

<s> O None
We I None
recorded I None
the I None
eye I None
movements I None
of I None
two I None
patients I None
with I None
reversible I None
downbeat I Disease
nystagmus O Disease
related I None
to I None
carbamazepine I Chemical
therapy I None
. I None
<eof> I None

<s> O None
The I None
nystagmus I Disease
of I None
both I None
patients I None
resolved I None
after I None
reduction I None
of I None
the I None
serum I None
carbamazepine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Neuroradiologic I None
investigations I None
including I None
magnetic I None
resonance I None
imaging I None
scans I None
in I None
both I None
patients I None
showed I None
no I None
evidence I None
of I None
intracranial I None
abnormality I None
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
downbeat I Disease
nystagmus O Disease
who I None
are I None
taking I None
anticonvulsant I None
medications I None
, I None
consideration I None
should I None
be I None
given I None
to I None
reduction I None
in I None
dose I None
before I None
further I None
investigation I None
is I None
undertaken I None
. I None
<eof> I None

<s> O None
Improvement I None
by I None
denopamine I Chemical
<eof> I None

<s> O None
( I None
TA-064 I Chemical
) I None
of I None
<eof> I None

<s> O None
pentobarbital I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
failure O Disease
in I None
the I None
dog I None
heart I None
- I None
lung I None
preparation I None
. I None
<eof> I None

<s> O None
The I None
efficacy I None
of I None
denopamine I Chemical
, I None
an I None
orally I None
active I None
beta I None
1-adrenoceptor I None
agonist I None
, I None
in I None
improving I None
cardiac I Disease
failure O Disease
was I None
assessed I None
in I None
dog I None
heart I None
- I None
lung I None
preparations I None
. I None
<eof> I None

<s> O None
Cardiac I None
functions I None
depressed I None
by I None
pentobarbital I Chemical
( I None
118 I None
+ I None
<eof> I None

<s> O None
/- I None
<eof> I None

<s> O None
28 I None
mg I None
; I None
mean I None
value I None
+ I None
/- I None
SD I None
) I None
<eof> I None

<s> O None
such I None
that I None
cardiac I None
output I None
and I None
maximum I None
rate I None
of I None
rise I None
of I None
left I None
ventricular I None
pressure I None
( I None
LV I None
dP I None
/ I None
dt I None
max I None
) I None
had I None
been I None
reduced I None
by I None
about I None
35 I None
% I None
and I None
26 I None
% I None
of I None
the I None
respective I None
controls I None
were I None
improved I None
by I None
denopamine I Chemical
<eof> I None

<s> O None
( I None
10 I None
- I None
300 I None
micrograms I None
) I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
With I None
100 I None
micrograms I None
denopamine I Chemical
, I None
almost I None
complete I None
restoration I None
of I None
cardiac I None
performance I None
was I None
attained I None
, I None
associated I None
with I None
a I None
slight I None
increase I None
in I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
No I None
<eof> I None

<s> O None
arrhythmias I Disease
were I None
induced I None
by I None
these I None
doses I None
of I None
denopamine I Chemical
. I None
<eof> I None

<s> O None
The I None
results I None
warrant I None
clinical I None
trials I None
of I None
denopamine I Chemical
in I None
the I None
treatment I None
of I None
cardiac I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Clonazepam I Chemical
monotherapy I None
for I None
epilepsy I Disease
in I None
childhood I None
. I None
<eof> I None

<s> O None
Sixty I None
patients I None
( I None
age I None
- I None
range I None
one I None
month I None
to I None
14 I None
years I None
) I None
with I None
other I None
types I None
of I None
epilepsy I Disease
than I None
<eof> I None

<s> O None
infantile I Disease
spasms O Disease
were I None
treated I None
with I None
clonazepam I Chemical
. I None
<eof> I None

<s> O None
Disappearance I None
of I None
seizures I Disease
and I None
normalization I None
of I None
abnormal I None
EEG I None
with I None
disappearance I None
of I None
seizures I Disease
were I None
recognized I None
in I None
77 I None
% I None
and I None
50 I None
% I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Seizures I Disease
disappeared I None
in I None
71 I None
% I None
of I None
the I None
patients I None
with I None
generalized I None
seizures I Disease
and I None
89 I None
% I None
of I None
partial I None
seizures I Disease
. I None
<eof> I None

<s> O None
Improvement I None
of I None
abnormal I None
EEG I None
was I None
noticed I None
in I None
76 I None
% I None
of I None
diffuse I None
paroxysms I None
and I None
in I None
67 I None
% I None
of I None
focal I None
paroxysms I None
. I None
<eof> I None

<s> O None
In I None
excellent I None
cases I None
, I None
mean I None
effective I None
dosages I None
were I None
0.086 I None
+ I None
/- I None
<eof> I None

<s> O None
0.021 I None
mg I None
/ I None
kg I None
/ I None
day I None
in I None
infants I None
and I None
0.057 I None
+ I None
/- I None
<eof> I None

<s> O None
0.022 I None
mg I None
/ I None
kg I None
/ I None
day I None
in I None
schoolchildren I None
, I None
this I None
difference I None
was I None
statistically I None
significant I None
( I None
p I None
less I None
than I None
0.005 I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
side I None
effects I None
such I None
as I None
drowsiness I Disease
and I None
ataxia I Disease
was I None
only I None
5 I None
% I None
. I None
<eof> I None

<s> O None
Postmarketing I None
study I None
of I None
timolol I Chemical
- I None
hydrochlorothiazide I Chemical
antihypertensive I None
therapy I None
. I None
<eof> I None

<s> O None
A I None
postmarketing I None
surveillance I None
study I None
was I None
conducted I None
to I None
determine I None
the I None
safety I None
and I None
efficacy I None
of I None
a I None
fixed I None
- I None
ratio I None
combination I None
containing I None
10 I None
mg I None
of I None
timolol I Chemical
maleate O Chemical
and I None
25 I None
mg I None
of I None
hydrochlorothiazide I Chemical
, I None
administered I None
twice I None
daily I None
for I None
one I None
month I None
to I None
hypertensive I Disease
patients I None
. I None
<eof> I None

<s> O None
Data I None
on I None
9,037 I None
patients I None
were I None
collected I None
by I None
1,455 I None
participating I None
physicians I None
. I None
<eof> I None

<s> O None
Mean I None
systolic I None
blood I None
pressure I None
decreased I None
25 I None
mmHg I None
and I None
mean I None
diastolic I None
blood I None
pressure I None
declined I None
15 I None
mmHg I None
after I None
one I None
month I None
of I None
timolol I Chemical
- I None
hydrochlorothiazide I Chemical
therapy I None
( I None
P I None
less I None
than I None
0.01 I None
, I None
both I None
comparisons I None
) I None
. I None
<eof> I None

<s> O None
Age I None
, I None
race I None
, I None
and I None
sex I None
appeared I None
to I None
have I None
no I None
influence I None
on I None
the I None
decrease I None
in I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
The I None
antihypertensive I None
effect I None
of I None
the I None
drug I None
was I None
greater I None
in I None
patients I None
with I None
more I None
severe I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Overall I None
, I None
1,453 I None
patients I None
experienced I None
a I None
total I None
of I None
2,658 I None
adverse I None
events I None
, I None
the I None
most I None
common I None
being I None
fatigue I Disease
, I None
dizziness I Disease
, I None
and I None
weakness I Disease
. I None
<eof> I None

<s> O None
Treatment I None
in I None
590 I None
patients I None
was I None
discontinued I None
because I None
of I None
adverse I None
events I None
. I None
<eof> I None

<s> O None
Salicylate I Chemical
<eof> I None

<s> O None
nephropathy I Disease
in I None
the I None
Gunn I None
rat I None
: I None
potential I None
role I None
of I None
prostaglandins I Chemical
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
potential I None
role I None
of I None
prostaglandins I Chemical
in I None
the I None
development I None
of I None
analgesic I None
nephropathy I Disease
in I None
the I None
Gunn I None
strain I None
of I None
rat I None
. I None
<eof> I None

<s> O None
The I None
homozygous I None
Gunn I None
rats I None
have I None
unconjugated I None
hyperbilirubinemia I Disease
due I None
to I None
the I None
absence I None
of I None
glucuronyl I Chemical
transferase I None
, I None
leading I None
to I None
marked I None
bilirubin I Chemical
deposition I None
in I None
renal I None
medulla I None
and I None
papilla I None
. I None
<eof> I None

<s> O None
These I None
rats I None
are I None
also I None
highly I None
susceptible I None
to I None
develop I None
papillary I Disease
necrosis O Disease
with I None
analgesic I None
administration I None
. I None
<eof> I None

<s> O None
We I None
used I None
homozygous I None
( I None
jj I None
) I None
and I None
phenotypically I None
normal I None
heterozygous I None
( I None
jJ I None
) I None
animals I None
. I None
<eof> I None

<s> O None
Four I None
groups I None
of I None
rats I None
( I None
n I None
= I None
7 I None
) I None
were I None
studied I None
: I None
jj I None
and I None
jJ I None
rats I None
treated I None
either I None
with I None
aspirin I Chemical
300 I None
mg I None
/ I None
kg I None
every I None
other I None
day I None
or I None
sham I None
- I None
treated I None
. I None
<eof> I None

<s> O None
After I None
one I None
week I None
, I None
slices I None
of I None
cortex I None
, I None
outer I None
and I None
inner I None
medulla I None
from I None
one I None
kidney I None
were I None
incubated I None
in I None
buffer I None
and I None
prostaglandin I Chemical
synthesis I None
was I None
determined I None
by I None
radioimmunoassay I None
. I None
<eof> I None

<s> O None
The I None
other I None
kidney I None
was I None
examined I None
histologically I None
. I None
<eof> I None

<s> O None
A I None
marked I None
corticomedullary I None
gradient I None
of I None
prostaglandin I Chemical
synthesis I None
was I None
observed I None
in I None
all I None
groups I None
. I None
<eof> I None

<s> O None
PGE2 I Chemical
synthesis I None
was I None
significantly I None
higher I None
in I None
outer I None
medulla I None
, I None
but I None
not I None
cortex I None
or I None
inner I None
medulla I None
, I None
of I None
jj I None
( I None
38 I None
+ I None
/- I None
6 I None
ng I None
/ I None
mg I None
prot I None
) I None
than I None
jJ I None
rats I None
( I None
15 I None
+ I None
/- I None
3 I None
) I None
( I None
p I None
less I None
than I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Aspirin I Chemical
treatment I None
reduced I None
PGE2 I Chemical
synthesis I None
in I None
all I None
regions I None
, I None
but I None
outer I None
medullary I None
PGE2 I Chemical
remained I None
higher I None
in I None
jj I None
( I None
18 I None
+ I None
/- I None
3 I None
) I None
than I None
jJ I None
rats I None
( I None
9 I None
+ I None
/- I None
2 I None
) I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
PGF2 I Chemical
alpha O Chemical
was I None
also I None
significantly I None
higher I None
in I None
the I None
outer I None
medulla I None
of I None
jj I None
rats I None
with I None
and I None
without I None
aspirin I Chemical
administration I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
changes I None
in I None
renal I None
prostaglandin I Chemical
synthesis I None
were I None
accompanied I None
by I None
evidence I None
of I None
renal I Disease
damage O Disease
in I None
aspirin I Chemical
-treated I None
jj I None
but I None
not I None
jJ I None
rats I None
as I None
evidenced I None
by I None
: I None
increased I None
incidence I None
and I None
severity I None
of I None
hematuria I Disease
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.01 I None
) I None
; I None
increased I None
serum I None
creatinine I Chemical
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.05 I None
) I None
; I None
and I None
increase I None
in I None
outer I None
medullary I None
histopathologic I None
lesions I None
( I None
p I None
less I None
than I None
0.005 I None
compared I None
to I None
either I None
sham I None
- I None
treated I None
jj I None
or I None
aspirin I Chemical
-treated I None
jJ I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
enhanced I None
prostaglandin I Chemical
synthesis I None
contributes I None
to I None
maintenance I None
of I None
renal I None
function I None
and I None
morphological I None
integrity I None
, I None
and I None
that I None
inhibition I None
of I None
prostaglandin I Chemical
synthesis I None
may I None
lead I None
to I None
pathological I Disease
renal O Disease
medullary O Disease
lesions O Disease
and I None
deterioration I Disease
of O Disease
renal O Disease
function O Disease
. I None
<eof> I None

<s> O None
Prophylactic I None
lidocaine I Chemical
in I None
the I None
early I None
phase I None
of I None
suspected I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Four I None
hundred I None
two I None
patients I None
with I None
suspected I None
myocardial I Disease
infarction O Disease
seen I None
within I None
6 I None
hours I None
of I None
the I None
onset I None
of I None
symptoms I None
entered I None
a I None
double I None
- I None
blind I None
randomized I None
trial I None
of I None
lidocaine I Chemical
vs I None
placebo I None
. I None
<eof> I None

<s> O None
During I None
the I None
1 I None
hour I None
after I None
administration I None
of I None
the I None
drug I None
the I None
incidence I None
of I None
ventricular I Disease
fibrillation O Disease
or I None
sustained I None
ventricular I Disease
tachycardia O Disease
among I None
the I None
204 I None
patients I None
with I None
acute I None
myocardial I Disease
infarction O Disease
was I None
low I None
, I None
1.5 I None
% I None
. I None
<eof> I None

<s> O None
Lidocaine I Chemical
, I None
given I None
in I None
a I None
300 I None
mg I None
dose I None
intramuscularly I None
followed I None
by I None
100 I None
mg I None
intravenously I None
, I None
did I None
not I None
prevent I None
sustained I None
ventricular I Disease
tachycardia O Disease
, I None
although I None
there I None
was I None
a I None
significant I None
reduction I None
in I None
the I None
number I None
of I None
patients I None
with I None
warning I None
arrhythmias I Disease
between I None
15 I None
and I None
45 I None
minutes I None
after I None
the I None
administration I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
p I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
average I None
plasma I None
lidocaine I Chemical
level I None
10 I None
minutes I None
after I None
administration I None
for I None
patients I None
without I None
a I None
myocardial I Disease
infarction O Disease
was I None
significantly I None
higher I None
than I None
that I None
for I None
patients I None
with I None
an I None
acute I None
infarction I Disease
. I None
<eof> I None

<s> O None
The I None
mean I None
plasma I None
<eof> I None

<s> O None
lidocaine I Chemical
level I None
of I None
patients I None
on I None
beta I None
- I None
blocking I None
agents I None
was I None
no I None
different I None
from I None
that I None
in I None
patients I None
not I None
on I None
beta I None
blocking I None
agents I None
. I None
<eof> I None

<s> O None
During I None
the I None
1-hour I None
study I None
period I None
, I None
the I None
incidence I None
of I None
central I None
nervous I None
system I None
side I None
effects I None
was I None
significantly I None
greater I None
in I None
the I None
lidocaine I Chemical
group I None
, I None
hypotension I Disease
occurred I None
in I None
11 I None
patients I None
, I None
nine I None
of I None
whom I None
had I None
received I None
lidocaine I Chemical
, I None
and I None
four I None
patients I None
died I None
from I None
asystole I Disease
, I None
three I None
of I None
whom I None
had I None
had I None
lidocaine I Chemical
. I None
<eof> I None

<s> O None
We I None
can I None
not I None
advocate I None
the I None
administration I None
of I None
lidocaine I Chemical
prophylactically I None
in I None
the I None
early I None
hours I None
of I None
suspected I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Evidence I None
for I None
a I None
cholinergic I None
role I None
in I None
haloperidol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
. I None
<eof> I None

<s> O None
Experiments I None
in I None
mice I None
tested I None
previous I None
evidence I None
that I None
activation I None
of I None
cholinergic I None
systems I None
promotes I None
catalepsy I Disease
and I None
that I None
cholinergic I None
mechanisms I None
need I None
to I None
be I None
intact I None
for I None
full I None
expression I None
of I None
neuroleptic I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
. I None
<eof> I None

<s> O None
Large I None
doses I None
of I None
the I None
cholinomimetic I None
, I None
pilocarpine I Chemical
, I None
could I None
induce I None
catalepsy I Disease
<eof> I None

<s> O None
when I None
peripheral I None
cholinergic I None
receptors I None
were I None
blocked I None
. I None
<eof> I None

<s> O None
Low I None
doses I None
of I None
pilocarpine I Chemical
caused I None
a I None
pronounced I None
enhancement I None
of I None
the I None
catalepsy I Disease
that I None
was I None
induced I None
by I None
the I None
dopaminergic I None
blocker I None
, I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
A I None
muscarinic I None
receptor I None
blocker I None
, I None
atropine I Chemical
, I None
disrupted I None
haloperidol I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
. I None
<eof> I None

<s> O None
Intracranial I None
injection I None
of I None
an I None
acetylcholine I Chemical
-synthesis I None
inhibitor I None
, I None
hemicholinium I Chemical
, I None
prevented I None
the I None
catalepsy I Disease
that I None
is I None
usually I None
induced I None
by I None
haloperidol I Chemical
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
the I None
hypothesis I None
that I None
the I None
catalepsy I Disease
that I None
is I None
produced I None
by I None
neuroleptics I Chemical
such I None
as I None
haloperidol I Chemical
is I None
actually I None
mediated I None
by I None
intrinsic I None
central I None
cholinergic I None
systems I None
. I None
<eof> I None

<s> O None
Alternatively I None
, I None
activation I None
of I None
central I None
cholinergic I None
systems I None
could I None
promote I None
catalepsy I Disease
by I None
suppression I None
of I None
dopaminergic I None
systems I None
. I None
<eof> I None

<s> O None
Cardiovascular I Disease
dysfunction O Disease
and I None
hypersensitivity I Disease
to I None
sodium I Chemical
pentobarbital O Chemical
induced I None
by I None
chronic I None
barium I Chemical
chloride O Chemical
ingestion I None
. I None
<eof> I None

<s> O None
Barium I Chemical
-supplemented I None
Long I None
- I None
Evans I None
hooded I None
rats I None
were I None
characterized I None
by I None
a I None
persistent I None
hypertension I Disease
<eof> I None

<s> O None
that I None
was I None
evident I None
after I None
1 I None
month I None
of I None
barium I Chemical
<eof> I None

<s> O None
( I None
100 I None
micrograms I None
/ I None
ml I None
mineral I None
fortified I None
water I None
) I None
treatment I None
. I None
<eof> I None

<s> O None
Analysis I None
of I None
in I None
vivo I None
myocardial I None
excitability I None
, I None
contractility I None
, I None
and I None
metabolic I None
characteristics I None
at I None
16 I None
months I None
revealed I None
other I None
significant I None
barium I Chemical
-induced I None
disturbances I Disease
within O Disease
the O Disease
cardiovascular O Disease
system O Disease
. I None
<eof> I None

<s> O None
The I None
most I None
distinctive I None
aspect I None
of I None
the I None
barium I Chemical
effect I None
was I None
a I None
demonstrated I None
hypersensitivity I Disease
of I None
the I None
cardiovascular I None
system I None
to I None
sodium I Chemical
pentobarbital O Chemical
. I None
<eof> I None

<s> O None
Under I None
barbiturate I Chemical
anesthesia I None
, I None
virtually I None
all I None
of I None
the I None
myocardial I None
contractile I None
indices I None
were I None
depressed I None
significantly I None
in I None
barium I Chemical
-exposed I None
rats I None
relative I None
to I None
the I None
corresponding I None
control I None
- I None
fed I None
rats I None
. I None
<eof> I None

<s> O None
The I None
lack I None
of I None
a I None
similar I None
response I None
to I None
ketamine I Chemical
and I None
xylazine I Chemical
anesthesia I None
revealed I None
that I None
the I None
cardiovascular I None
actions I None
of I None
sodium I Chemical
pentobarbital O Chemical
in I None
barium I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
were I None
linked I None
specifically I None
to I None
this I None
anesthetic I None
, I None
and I None
were I None
not I None
representative I None
of I None
a I None
generalized I None
anesthetic I None
response I None
. I None
<eof> I None

<s> O None
Other I None
myocardial I None
pathophysiologic I None
and I None
metabolic I None
changes I None
induced I None
by I None
barium I Chemical
were I None
manifest I None
, I None
irrespective I None
of I None
the I None
anesthetic I None
employed I None
. I None
<eof> I None

<s> O None
The I None
contractile I None
element I None
shortening I None
velocity I None
of I None
the I None
cardiac I None
muscle I None
fibers I None
was I None
significantly I None
slower I None
in I None
both I None
groups I None
of I None
barium I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
relative I None
to I None
the I None
control I None
groups I None
, I None
irrespective I None
of I None
the I None
anesthetic I None
regimen I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
significant I None
disturbances I None
in I None
myocardial I None
energy I None
metabolism I None
were I None
detected I None
in I None
the I None
barium I Chemical
-exposed I None
rats I None
which I None
were I None
consistent I None
with I None
the I None
reduced I None
contractile I None
element I None
shortening I None
velocity I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
excitability I None
of I None
the I None
cardiac I None
conduction I None
system I None
was I None
depressed I None
preferentially I None
in I None
the I None
atrioventricular I None
nodal I None
region I None
of I None
hearts I None
from I None
barium I Chemical
-exposed I None
rats I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
the I None
altered I None
cardiac I None
contractility I None
and I None
excitability I None
characteristics I None
, I None
the I None
myocardial I None
metabolic I Disease
disturbances O Disease
, I None
and I None
the I None
hypersensitivity I Disease
of I None
the I None
cardiovascular I None
system I None
to I None
sodium I Chemical
pentobarbital O Chemical
suggest I None
the I None
existence I None
of I None
a I None
heretofore I None
undescribed I None
cardiomyopathic I Disease
disorder O Disease
induced I None
by I None
chronic I None
barium I Chemical
exposure I None
. I None
<eof> I None

<s> O None
These I None
experimental I None
findings I None
represent I None
the I None
first I None
indication I None
that I None
life I None
- I None
long I None
barium I Chemical
ingestion I None
may I None
have I None
significant I None
adverse I None
effects I None
on I None
the I None
mammalian I None
cardiovascular I None
system I None
. I None
<eof> I None

<s> O None
Propranolol I Chemical
antagonism I None
of I None
phenylpropanolamine I Chemical
<eof> I None

<s> O None
-induced I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Phenylpropanolamine I Chemical
( I None
PPA I Chemical
) I None
overdose I Disease
can I None
cause I None
severe I None
hypertension I Disease
, I None
intracerebral I Disease
hemorrhage O Disease
, I None
and I None
death I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
efficacy I None
and I None
safety I None
of I None
propranolol I Chemical
in I None
the I None
treatment I None
of I None
PPA I Chemical
-induced I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Subjects I None
received I None
propranolol I Chemical
either I None
by I None
mouth I None
for I None
48 I None
hours I None
before I None
PPA I Chemical
or I None
as I None
a I None
rapid I None
intravenous I None
infusion I None
after I None
PPA I Chemical
. I None
<eof> I None

<s> O None
PPA I Chemical
, I None
75 I None
mg I None
alone I None
, I None
increased I None
blood I None
pressure I None
( I None
31 I None
+ I None
/- I None
<eof> I None

<s> O None
14 I None
mm I None
Hg I None
systolic I None
, I None
20 I None
+ I None
/- I None
<eof> I None

<s> O None
5 I None
mm I None
Hg I None
diastolic I None
) I None
, I None
and I None
propranolol I Chemical
pretreatment I None
antagonized I None
this I None
increase I None
( I None
12 I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
mm I None
Hg I None
systolic I None
, I None
<eof> I None

<s> O None
10 I None
+ I None
/- I None
<eof> I None

<s> O None
7 I None
mm I None
Hg I None
diastolic I None
) I None
. I None
<eof> I None

<s> O None
Intravenous I None
propranolol I Chemical
after I None
PPA I Chemical
also I None
decreased I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
Left I None
ventricular I None
function I None
( I None
assessed I None
by I None
echocardiography I None
) I None
showed I None
that I None
PPA I Chemical
increased I None
the I None
stroke I Disease
volume I None
30 I None
% I None
( I None
from I None
62.5 I None
+ I None
/- I None
20.9 I None
to I None
80.8 I None
+ I None
/- I None
22.4 I None
ml I None
) I None
, I None
the I None
ejection I None
fraction I None
9 I None
% I None
( I None
from I None
64 I None
% I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
% I None
to I None
70 I None
% I None
+ I None
/- I None
<eof> I None

<s> O None
7 I None
% I None
) I None
, I None
and I None
cardiac I None
output I None
14 I None
% I None
( I None
from I None
3.6 I None
+ I None
/- I None
0.6 I None
to I None
4.1 I None
+ I None
/- I None
<eof> I None

<s> O None
1.0 I None
L I None
/ I None
min I None
) I None
. I None
<eof> I None

<s> O None
Intravenous I None
propranolol I Chemical
reversed I None
these I None
effects I None
. I None
<eof> I None

<s> O None
Systemic I None
vascular I None
resistance I None
was I None
increased I None
by I None
PPA I Chemical
28 I None
% I None
( I None
from I None
1710 I None
+ I None
/- I None
<eof> I None

<s> O None
200 I None
to I None
2190 I None
+ I None
/- I None
700 I None
dyne I None
X I None
sec I None
/ I None
cm5 I None
) I None
and I None
was I None
further I None
increased I None
by I None
propranolol I Chemical
22 I None
% I None
( I None
to I None
2660 I None
+ I None
/- I None
<eof> I None

<s> O None
1200 I None
dyne I None
X I None
sec I None
/ I None
cm5 I None
) I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
PPA I Chemical
increases I None
blood I None
pressure I None
by I None
increasing I None
systemic I None
vascular I None
resistance I None
and I None
cardiac I None
output I None
, I None
and I None
that I None
propranolol I Chemical
antagonizes I None
this I None
increase I None
by I None
reversing I None
the I None
effect I None
of I None
PPA I Chemical
on I None
cardiac I None
output I None
. I None
<eof> I None

<s> O None
That I None
propranolol I Chemical
antagonizes I None
the I None
pressor I None
effect I None
of I None
PPA I Chemical
is I None
in I None
contrast I None
to I None
the I None
interaction I None
in I None
which I None
propranolol I Chemical
enhances I None
the I None
pressor I None
effect I None
of I None
norepinephrine I Chemical
. I None
<eof> I None

<s> O None
This I None
is I None
probably I None
because I None
PPA I Chemical
has I None
less I None
beta I None
2 I None
activity I None
than I None
does I None
norepinephrine I Chemical
. I None
<eof> I None

<s> O None
Mesangial I None
function I None
and I None
glomerular I Disease
sclerosis O Disease
in I None
rats I None
with I None
aminonucleoside I Chemical
nephrosis I Disease
. I None
<eof> I None

<s> O None
The I None
possible I None
relationship I None
between I None
mesangial I Disease
dysfunction O Disease
and I None
development I None
of I None
glomerular I Disease
sclerosis O Disease
was I None
studied I None
in I None
the I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
model I None
. I None
<eof> I None

<s> O None
Five I None
male I None
Wistar I None
rats I None
received I None
repeated I None
subcutaneous I None
PAN I Chemical
injections I None
; I None
five I None
controls I None
received I None
saline I None
only I None
. I None
<eof> I None

<s> O None
After I None
4 I None
weeks I None
the I None
PAN I Chemical
rats I None
were I None
severely I None
proteinuric I Disease
<eof> I None

<s> O None
( I None
190 I None
+ I None
/- I None
<eof> I None

<s> O None
80 I None
mg/24 I None
hr I None
) I None
, I None
and I None
all I None
rats I None
were I None
given I None
colloidal I None
carbon I Chemical
<eof> I None

<s> O None
( I None
CC I None
) I None
intravenously I None
. I None
<eof> I None

<s> O None
At I None
5 I None
months I None
glomerular I Disease
sclerosis O Disease
was I None
found I None
in I None
7.6 I None
+ I None
/- I None
<eof> I None

<s> O None
3.4 I None
% I None
of I None
the I None
glomeruli I None
of I None
PAN I Chemical
rats I None
; I None
glomeruli I None
of I None
the I None
controls I None
were I None
normal I None
. I None
<eof> I None

<s> O None
Glomeruli I None
of I None
PAN I Chemical
rats I None
contained I None
significantly I None
more I None
CC I None
than I None
glomeruli I None
of I None
controls I None
. I None
<eof> I None

<s> O None
Glomeruli I None
with I None
sclerosis I Disease
<eof> I None

<s> O None
contained I None
significantly I None
more I None
CC I None
than I None
non I None
- I None
sclerotic I None
glomeruli I None
in I None
the I None
same I None
kidneys I None
. I None
<eof> I None

<s> O None
CC I None
was I None
preferentially I None
localized I None
within I None
the I None
sclerotic I None
areas I None
of I None
the I None
affected I None
glomeruli I None
. I None
<eof> I None

<s> O None
Since I None
mesangial I None
CC I None
clearance I None
from I None
the I None
mesangium I None
did I None
not I None
change I None
during I None
chronic I None
PAN I Chemical
treatment I None
, I None
we I None
conclude I None
that I None
this I None
preferential I None
CC I None
localization I None
within I None
the I None
lesions I None
is I None
caused I None
by I None
an I None
increased I None
CC I None
uptake I None
shortly I None
after I None
injection I None
in I None
apparent I None
vulnerable I None
areas I None
where I None
sclerosis I Disease
will I None
develop I None
subsequently I None
. I None
<eof> I None

<s> O None
Cluster I None
analysis I None
showed I None
a I None
random I None
distribution I None
of I None
lesions I None
in I None
the I None
PAN I Chemical
glomeruli I None
in I None
concordance I None
with I None
the I None
random I None
localization I None
of I None
mesangial I None
areas I None
with I None
dysfunction I None
in I None
this I None
model I None
. I None
<eof> I None

<s> O None
Similar I None
to I None
the I None
remnant I None
kidney I None
model I None
in I None
PAN I Chemical
nephrosis I Disease
<eof> I None

<s> O None
the I None
development I None
of I None
glomerular I Disease
sclerosis O Disease
may I None
be I None
related I None
to I None
" I None
mesangial I None
overloading I None
. I None
" I None
<eof> I None

<s> O None
Relationship I None
between I None
nicotine I Chemical
-induced I None
seizures I Disease
and I None
hippocampal I None
nicotinic I None
receptors I None
. I None
<eof> I None

<s> O None
A I None
controversy I None
has I None
existed I None
for I None
several I None
years I None
concerning I None
the I None
physiological I None
relevance I None
of I None
the I None
nicotinic I None
receptor I None
measured I None
by I None
alpha I None
- I None
bungarotoxin I None
binding I None
. I None
<eof> I None

<s> O None
Using I None
mice I None
derived I None
from I None
a I None
classical I None
F2 I None
and I None
backcross I None
genetic I None
design I None
, I None
a I None
relationship I None
between I None
nicotine I Chemical
-induced I None
seizures I Disease
and I None
alpha I None
- I None
bungarotoxin I None
nicotinic I None
receptor I None
concentration I None
was I None
found I None
. I None
<eof> I None

<s> O None
Mice I None
sensitive I None
to I None
the I None
convulsant I None
effects I None
of I None
nicotine I Chemical
had I None
greater I None
alpha I None
- I None
bungarotoxin I None
binding I None
in I None
the I None
hippocampus I None
than I None
seizure I Disease
insensitive I None
mice I None
. I None
<eof> I None

<s> O None
The I None
binding I None
sites I None
from I None
seizure I Disease
<eof> I None

<s> O None
sensitive I None
and I None
resistant I None
mice I None
were I None
equally I None
affected I None
by I None
treatment I None
with I None
dithiothreitol I Chemical
, I None
trypsin I None
or I None
heat I None
. I None
<eof> I None

<s> O None
Thus I None
it I None
appears I None
that I None
the I None
difference I None
between I None
seizure I Disease
sensitive I None
and I None
insensitive I None
animals I None
may I None
be I None
due I None
to I None
a I None
difference I None
in I None
hippocampal I None
nicotinic I None
receptor I None
concentration I None
as I None
measured I None
with I None
alpha I None
- I None
bungarotoxin I None
binding I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
p I Chemical
- O Chemical
aminophenol O Chemical
in I None
acetaminophen I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
: I None
effect I None
of I None
bis(p I Chemical
- O Chemical
nitrophenyl O Chemical
) O Chemical
phosphate O Chemical
on I None
acetaminophen I Chemical
and I None
p I Chemical
- O Chemical
aminophenol O Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
and I None
metabolism I None
in I None
Fischer I None
344 I None
rats I None
. I None
<eof> I None

<s> O None
Acetaminophen I Chemical
<eof> I None

<s> O None
( I None
APAP I Chemical
) I None
produces I None
proximal I None
tubular I Disease
necrosis O Disease
in I None
Fischer I None
344 I None
( I None
F344 I None
) I None
rats I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
p I Chemical
- O Chemical
aminophenol O Chemical
( I None
PAP I Chemical
) I None
, I None
a I None
known I None
potent I None
nephrotoxicant I None
, I None
was I None
identified I None
as I None
a I None
metabolite I None
of I None
APAP I Chemical
in I None
F344 I None
rats I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
determine I None
if I None
PAP I Chemical
formation I None
is I None
a I None
requisite I None
step I None
in I None
APAP I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Therefore I None
, I None
the I None
effect I None
of I None
bis(p I Chemical
- O Chemical
nitrophenyl O Chemical
) O Chemical
phosphate O Chemical
<eof> I None

<s> O None
( I None
BNPP I Chemical
) I None
, I None
an I None
acylamidase I None
inhibitor I None
, I None
on I None
APAP I Chemical
and I None
PAP I Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
and I None
metabolism I None
was I None
determined I None
. I None
<eof> I None

<s> O None
BNPP I Chemical
( I None
1 I None
to I None
8 I None
mM I None
) I None
reduced I None
APAP I Chemical
<eof> I None

<s> O None
deacetylation I None
and I None
covalent I None
binding I None
in I None
F344 I None
renal I None
cortical I None
homogenates I None
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Pretreatment I None
of I None
animals I None
with I None
BNPP I Chemical
prior I None
to I None
APAP I Chemical
or I None
PAP I Chemical
administration I None
resulted I None
in I None
marked I None
reduction I None
of I None
APAP I Chemical
<eof> I None

<s> O None
( I None
900 I None
mg I None
/ I None
kg I None
) I None
<eof> I None

<s> O None
nephrotoxicity I Disease
but I None
not I None
PAP I Chemical
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
This I None
result I None
was I None
not I None
due I None
to I None
altered I None
disposition I None
of I None
either I None
APAP I Chemical
or I None
acetylated I None
metabolites I None
in I None
plasma I None
or I None
renal I None
cortical I None
and I None
hepatic I None
tissue I None
. I None
<eof> I None

<s> O None
Rather I None
, I None
BNPP I Chemical
pretreatment I None
reduced I None
the I None
fraction I None
of I None
APAP I Chemical
excreted I None
as I None
PAP I Chemical
by I None
64 I None
and I None
75 I None
% I None
after I None
<eof> I None

<s> O None
APAP I Chemical
doses I None
of I None
750 I None
and I None
900 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
BNPP I Chemical
did I None
not I None
alter I None
the I None
excretion I None
of I None
APAP I Chemical
or I None
any I None
of I None
its I None
non I None
- I None
deacetylated I None
metabolites I None
nor I None
did I None
BNPP I Chemical
alter I None
excretion I None
of I None
PAP I Chemical
or I None
its I None
metabolites I None
after I None
<eof> I None

<s> O None
PAP I Chemical
doses I None
of I None
150 I None
and I None
300 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
the I None
BNPP I Chemical
-induced I None
reduction I None
in I None
APAP I Chemical
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
appears I None
to I None
be I None
due I None
to I None
inhibition I None
of I None
APAP I Chemical
deacetylation I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
PAP I Chemical
formation I None
, I None
in I None
vivo I None
, I None
accounts I None
, I None
at I None
least I None
in I None
part I None
, I None
for I None
APAP I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
renal I Disease
tubular O Disease
necrosis O Disease
. I None
<eof> I None

<s> O None
Morphine I Chemical
-induced I None
seizures I Disease
in I None
newborn I None
infants I None
. I None
<eof> I None

<s> O None
Two I None
neonates I None
suffered I None
from I None
generalized I None
seizures I Disease
during I None
the I None
course I None
of I None
intravenous I None
morphine I Chemical
sulfate O Chemical
for I None
post I None
- I None
operative I None
analgesia I None
. I None
<eof> I None

<s> O None
They I None
received I None
morphine I Chemical
in I None
doses I None
of I None
32 I None
micrograms I None
/ I None
kg I None
/ I None
hr I None
and I None
40 I None
micrograms I None
<eof> I None

<s> O None
/ I None
kg I None
/ I None
<eof> I None

<s> O None
hr I None
larger I None
than I None
a I None
group I None
of I None
10 I None
neonates I None
who I None
received I None
6 I None
- I None
24 I None
micrograms I None
/ I None
kg I None
/ I None
hr I None
and I None
had I None
no I None
seizures I Disease
. I None
<eof> I None

<s> O None
Plasma I None
concentrations I None
of I None
morphine I Chemical
in I None
these I None
neonates I None
was I None
excessive I None
( I None
60 I None
and I None
90 I None
mg I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
Other I None
known I None
reasons I None
for I None
seizures I Disease
were I None
ruled I None
out I None
and I None
the I None
convulsions I Disease
stopped I None
a I None
few I None
hours I None
after I None
cessation I None
of I None
morphine I Chemical
and I None
did I None
not I None
reoccur I None
in I None
the I None
subsequent I None
8 I None
months I None
. I None
<eof> I None

<s> O None
It I None
is I None
suggested I None
that I None
post I None
- I None
operative I None
intravenous I None
morphine I Chemical
should I None
not I None
exceed I None
20 I None
micrograms I None
/ I None
kg I None
/ I None
ml I None
in I None
neonates I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
vincristine I Chemical
sulfate O Chemical
on I None
Pseudomonas I Disease
infections O Disease
in I None
monkeys I None
. I None
<eof> I None

<s> O None
In I None
rhesus I None
monkeys I None
, I None
intravenous I None
challenge I None
with I None
0.6 I None
x I None
10(10 I None
) I None
to I None
2.2 I None
x I None
10(10)Pseudomonas I None
aeruginosa I None
organisms I None
caused I None
acute I None
illness I None
of I None
4 I None
to I None
5 I None
days I None
' I None
duration I None
with I None
spontaneous I None
recovery I None
in I None
13 I None
of I None
15 I None
monkeys I None
; I None
blood I None
cultures I None
became I None
negative I None
3 I None
to I None
17 I None
days I None
after I None
challenge I None
. I None
<eof> I None

<s> O None
Leukocytosis I Disease
was I None
observed I None
in I None
all I None
monkeys I None
. I None
<eof> I None

<s> O None
Intravenous I None
or I None
intratracheal I None
inoculation I None
of I None
2.0 I None
to I None
2.5 I None
mg I None
of I None
vincristine I Chemical
sulfate O Chemical
was I None
followed I None
by I None
leukopenia I Disease
in I None
4 I None
to I None
5 I None
days I None
. I None
<eof> I None

<s> O None
Intravenous I None
inoculation I None
of I None
4.2 I None
x I None
10(10 I None
) I None
to I None
7.8 I None
x I None
10(10 I None
) I None
pyocin I None
type I None
6 I None
Pseudomonas I None
organisms I None
in I None
monkeys I None
given I None
vincristine I Chemical
sulfate O Chemical
4 I None
days I None
previously I None
resulted I None
in I None
fatal I None
infection I Disease
in I None
11 I None
of I None
14 I None
monkeys I None
, I None
whereas I None
none I None
of I None
four I None
receiving I None
Pseudomonas I None
alone I None
died I None
. I None
<eof> I None

<s> O None
These I None
studies I None
suggest I None
that I None
an I None
antimetabolite I None
- I None
induced I None
leukopenia I Disease
predisposes I None
to I None
severe I None
Pseudomonas I None
sepsis I Disease
and I None
that I None
such I None
monkeys I None
may I None
serve I None
as I None
a I None
biological I None
model I None
for I None
study I None
of I None
comparative I None
efficacy I None
of I None
antimicrobial I None
agents I None
. I None
<eof> I None

<s> O None
Central I None
excitatory I None
actions I None
of I None
flurazepam I Chemical
. I None
<eof> I None

<s> O None
Toxic I None
actions I None
of I None
flurazepam I Chemical
<eof> I None

<s> O None
( I None
FZP I Chemical
) I None
were I None
studied I None
in I None
cats I None
, I None
mice I None
and I None
rats I None
. I None
<eof> I None

<s> O None
High I None
doses I None
caused I None
an I None
apparent I None
central I None
excitation I None
, I None
most I None
clearly I None
seen I None
as I None
clonic I None
convulsions I Disease
, I None
superimposed I None
on I None
general I None
depression I Disease
. I None
<eof> I None

<s> O None
Following I None
a I None
lethal I None
dose I None
, I None
death I None
was I None
always I None
associated I None
with I None
convulsions I Disease
. I None
<eof> I None

<s> O None
Comparing I None
the I None
relative I None
sensitivity I None
to I None
central I None
depression I Disease
and I None
excitation I None
revealed I None
that I None
rats I None
were I None
least I None
likely I None
to I None
have I None
convulsions I Disease
at I None
doses I None
that I None
did I None
not I None
first I None
cause I None
loss I Disease
of O Disease
consciousness O Disease
, I None
while I None
cats I None
most I None
clearly I None
showed I None
marked I None
central I None
excitatory I None
actions I None
. I None
<eof> I None

<s> O None
Signs I None
of I None
FZP I Chemical
toxocity I Disease
in I None
cats I None
included I None
excessive I None
salivation I Disease
, I None
extreme I None
apprehensive I None
behavior I None
, I None
retching I None
, I None
muscle I Disease
tremors O Disease
and I None
convulsions I Disease
. I None
<eof> I None

<s> O None
An I None
interaction I None
between I None
FZP I Chemical
and I None
pentylenetetrazol I Chemical
<eof> I None

<s> O None
( I None
PTZ I Chemical
) I None
was I None
shown I None
by I None
pretreating I None
mice I None
with I None
FZP I Chemical
before I None
PTZ I Chemical
challenge I None
. I None
<eof> I None

<s> O None
As I None
a I None
function I None
of I None
dose I None
, I None
FZP I Chemical
first I None
protected I None
against I None
convulsions I Disease
and I None
death I None
. I None
<eof> I None

<s> O None
At I None
higher I None
doses I None
, I None
however I None
, I None
convulsions I Disease
again I None
emerged I None
. I None
<eof> I None

<s> O None
These I None
doses I None
of I None
FZP I Chemical
were I None
lower I None
than I None
those I None
that I None
would I None
alone I None
cause I None
convulsions I Disease
. I None
<eof> I None

<s> O None
These I None
results I None
may I None
be I None
relevant I None
to I None
the I None
use I None
of I None
FZP I Chemical
in I None
clinical I None
situations I None
in I None
which I None
there I None
is I None
increased I None
neural I None
excitability I None
, I None
such I None
as I None
epilepsy I Disease
or I None
sedative I None
- I None
hypnotic I None
drug I None
withdrawal I None
. I None
<eof> I None

<s> O None
Evidence I None
for I None
cardiac I None
beta I None
2-adrenoceptors I None
in I None
man I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
effects I None
of I None
single I None
doses I None
of I None
50 I None
mg I None
atenolol I Chemical
<eof> I None

<s> O None
( I None
cardioselective I None
) I None
, I None
40 I None
mg I None
propranolol I Chemical
( I None
nonselective I None
) I None
, I None
and I None
placebo I None
on I None
both I None
exercise- I None
and I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
tachycardia I Disease
in I None
two I None
experiments I None
involving I None
nine I None
normal I None
subjects I None
. I None
<eof> I None

<s> O None
Maximal I None
exercise I None
heart I None
rate I None
was I None
reduced I None
from I None
187 I None
+ I None
/- I None
<eof> I None

<s> O None
4(SEM I None
<eof> I None

<s> O None
) I None
after I None
placebo I None
to I None
146 I None
+ I None
/- I None
<eof> I None

<s> O None
7 I None
bpm I None
after I None
atenolol I Chemical
and I None
138 I None
<eof> I None

<s> O None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
bpm I None
after I None
propranolol I Chemical
, I None
but I None
there I None
were I None
no I None
differences I None
between I None
the I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
effects I None
on I None
isoproterenol I Chemical
<eof> I None

<s> O None
tachycardia I Disease
were I None
determined I None
before I None
and I None
after I None
atropine I Chemical
<eof> I None

<s> O None
( I None
0.04 I None
mg I None
/ I None
kg I None
IV I None
) I None
. I None
<eof> I None

<s> O None
Isoproterenol I Chemical
sensitivity I None
was I None
determined I None
as I None
the I None
intravenous I None
dose I None
that I None
increased I None
heart I None
rate I None
by I None
25 I None
bpm I None
( I None
CD25 I None
) I None
and I None
this I None
was I None
increased I None
from I None
1.8 I None
+ I None
/- I None
0.3 I None
micrograms I None
after I None
placebo I None
to I None
38.9 I None
+ I None
/- I None
<eof> I None

<s> O None
8.3 I None
micrograms I None
after I None
propranolol I Chemical
and I None
8.3 I None
+ I None
/- I None
<eof> I None

<s> O None
1.7 I None
micrograms I None
after I None
atenolol I Chemical
. I None
<eof> I None

<s> O None
The I None
difference I None
in I None
the I None
effects I None
of I None
the I None
two I None
was I None
significant I None
. I None
<eof> I None

<s> O None
After I None
atropine I Chemical
the I None
CD25 I None
was I None
unchanged I None
after I None
placebo I None
( I None
2.3 I None
+ I None
/- I None
<eof> I None

<s> O None
0.3 I None
micrograms I None
) I None
and I None
atenolol I Chemical
( I None
7.7 I None
+ I None
/- I None
<eof> I None

<s> O None
1.3 I None
micrograms I None
) I None
; I None
it I None
was I None
reduced I None
after I None
propranolol I Chemical
( I None
24.8 I None
+ I None
/- I None
<eof> I None

<s> O None
5.0 I None
micrograms I None
) I None
, I None
but I None
remained I None
different I None
from I None
atenolol I Chemical
. I None
<eof> I None

<s> O None
This I None
change I None
with I None
propranolol I Chemical
sensitivity I None
was I None
calculated I None
as I None
the I None
apparent I None
Ka I None
, I None
this I None
was I None
unchanged I None
by I None
atropine I Chemical
( I None
11.7 I None
+ I None
<eof> I None

<s> O None
/- I None
2.1 I None
and I None
10.1 I None
+ I None
/- I None
<eof> I None

<s> O None
2.5 I None
ml I None
/ I None
ng I None
) I None
. I None
<eof> I None

<s> O None
These I None
data I None
are I None
consistent I None
with I None
the I None
hypothesis I None
that I None
exercise I None
- I None
induced I None
tachycardia I Disease
results I None
largely I None
from I None
beta I None
1-receptor I None
activation I None
that I None
is I None
blocked I None
by I None
both I None
cardioselective I None
and I None
nonselective I None
drugs I None
, I None
whereas I None
isoproterenol I Chemical
activates I None
both I None
beta I None
1- I None
and I None
beta I None
<eof> I None

<s> O None
2-receptors I None
<eof> I None

<s> O None
so I None
that I None
after I None
cardioselective I None
blockade I None
there I None
remains I None
a I None
beta I None
2-component I None
that I None
can I None
be I None
blocked I None
with I None
a I None
nonselective I None
drug I None
. I None
<eof> I None

<s> O None
While I None
there I None
appear I None
to I None
be I None
beta I None
2-receptors I None
in I None
the I None
human I None
heart I None
, I None
their I None
physiologic I None
or I None
pathologic I None
roles I None
remain I None
to I None
be I None
defined I None
. I None
<eof> I None

<s> O None
Hormones I None
and I None
risk I None
of I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
This I None
paper I None
reports I None
the I None
results I None
of I None
a I None
study I None
of I None
50 I None
menopausal I None
women I None
receiving I None
hormonal I None
replacement I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
majority I None
( I None
29 I None
) I None
had I None
surgical I None
menopause I None
; I None
their I None
mean I None
age I None
was I None
45.7 I None
years I None
. I None
<eof> I None

<s> O None
It I None
was I None
hypothesized I None
that I None
progestins I Chemical
could I None
equilibrate I None
the I None
effects I None
of I None
the I None
estrogenic I None
stimulation I None
on I None
the I None
mammary I None
and I None
endometrial I None
target I None
tissues I None
of I None
women I None
on I None
hormonal I None
replacement I None
therapy I None
. I None
<eof> I None

<s> O None
The I None
treatment I None
schedule I None
consisted I None
of I None
conjugated I Chemical
estrogens O Chemical
<eof> I None

<s> O None
( I None
Premarin I Chemical
) I None
1.25 I None
mg I None
/ I None
day I None
for I None
21 I None
days I None
and I None
<eof> I None

<s> O None
Medroxyprogesterone I Chemical
acetate O Chemical
10 I None
mg I None
/ I None
day I None
for I None
10 I None
days I None
in I None
each I None
month I None
. I None
<eof> I None

<s> O None
The I None
mean I None
treatment I None
period I None
was I None
18 I None
months I None
. I None
<eof> I None

<s> O None
During I None
the I None
follow I None
- I None
up I None
period I None
, I None
attention I None
was I None
paid I None
to I None
breast I None
modifications I None
as I None
evidenced I None
by I None
symptomatology I None
, I None
physical I None
examination I None
, I None
and I None
plate I None
thermography I None
. I None
<eof> I None

<s> O None
Mastodynia I Disease
was I None
reported I None
by I None
21 I None
patients I None
, I None
and I None
physical I None
examination I None
revealed I None
a I None
light I None
increase I None
in I None
breast I None
firmness I None
in I None
12 I None
women I None
and I None
a I None
moderate I None
increase I None
in I None
breast I None
nodularity I None
in I None
2 I None
women I None
. I None
<eof> I None

<s> O None
Themography I None
confirmed I None
the I None
existence I None
of I None
an I None
excessive I None
breast I None
stimulation I None
in I None
1 I None
women I None
who I None
complained I None
of I None
moderate I None
mastodynia I Disease
and I None
in I None
5 I None
of I None
the I None
7 I None
women I None
who I None
complained I None
of I None
severe I None
mastodynia I Disease
. I None
<eof> I None

<s> O None
Normalization I None
was I None
obtained I None
by I None
halving I None
the I None
estrogen I Chemical
dose I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
hormonal I None
replacement I None
therapy I None
can I None
be I None
safely I None
prescribed I None
if I None
the I None
following I None
criteria I None
are I None
satisfied I None
: I None
1 I None
) I None
preliminary I None
evaluation I None
of I None
patients I None
from I None
a I None
clinical I None
, I None
metabolic I None
, I None
cytologic I None
, I None
and I None
mammographic I None
perspective I None
; I None
2 I None
) I None
cyclic I None
treatment I None
schedule I None
, I None
with I None
a I None
progestative I None
phase I None
of I None
10 I None
days I None
; I None
and I None
3 I None
) I None
periodic I None
complete I None
follow I None
- I None
up I None
, I None
with I None
accurate I None
thermographic I None
evaluation I None
of I None
the I None
breast I None
target I None
tissues I None
. I None
<eof> I None

<s> O None
Early I None
infections I Disease
in I None
kidney I None
, I None
heart I None
, I None
and I None
liver I None
transplant I None
recipients I None
on I None
cyclosporine I Chemical
. I None
<eof> I None

<s> O None
Eighty I None
- I None
one I None
renal I None
, I None
seventeen I None
heart I None
, I None
and I None
twenty I None
- I None
four I None
liver I None
transplant I None
patients I None
were I None
followed I None
for I None
infection I Disease
. I None
<eof> I None

<s> O None
Seventeen I None
renal I None
patients I None
received I None
azathioprine I Chemical
<eof> I None

<s> O None
( I None
Aza I Chemical
) I None
and I None
prednisone I Chemical
as I None
part I None
of I None
a I None
randomized I None
trial I None
of I None
immunosuppression I None
with I None
21 I None
cyclosporine I Chemical
<eof> I None

<s> O None
-and- I None
prednisone I Chemical
-treated I None
renal I None
transplant I None
patients I None
. I None
<eof> I None

<s> O None
All I None
others I None
received I None
cyclosporine I Chemical
and I None
prednisone I Chemical
. I None
<eof> I None

<s> O None
The I None
randomized I None
Aza I Chemical
patients I None
had I None
more I None
overall I None
infections I Disease
<eof> I None

<s> O None
( I None
P I None
less I None
than I None
0.05 I None
) I None
and I None
more I None
nonviral I None
infections I Disease
<eof> I None

<s> O None
( I None
P I None
less I None
than I None
0.02 I None
) I None
than I None
the I None
randomized I None
cyclosporine I Chemical
patients I None
. I None
<eof> I None

<s> O None
Heart I None
and I None
liver I None
patients I None
had I None
more I None
infections I Disease
than I None
cyclosporine I Chemical
renal I None
patients I None
but I None
fewer I None
infections I Disease
than I None
the I None
Aza I Chemical
renal I None
patients I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
infectious I None
deaths I None
in I None
renal I None
transplant I None
patients I None
on I None
cyclosporine I Chemical
or I None
Aza I Chemical
, I None
but I None
infection I Disease
played I None
a I None
major I None
role I None
in I None
3 I None
out I None
of I None
6 I None
cardiac I None
transplant I None
deaths I None
and I None
in I None
8 I None
out I None
of I None
9 I None
liver I None
transplant I None
deaths I None
. I None
<eof> I None

<s> O None
Renal I None
patients I None
on I None
cyclosporine I Chemical
had I None
the I None
fewest I None
bacteremias I Disease
. I None
<eof> I None

<s> O None
Analysis I None
of I None
site I None
of I None
infection I Disease
showed I None
a I None
preponderance I None
of I None
abdominal I Disease
infections O Disease
in I None
liver I None
patients I None
, I None
intrathoracic I None
infections I Disease
in I None
heart I None
patients I None
, I None
and I None
urinary I Disease
tract O Disease
infections O Disease
in I None
renal I None
patients I None
. I None
<eof> I None

<s> O None
Pulmonary I None
infections I Disease
were I None
less I None
common I None
in I None
<eof> I None

<s> O None
cyclosporine I Chemical
-treated I None
renal I None
patients I None
than I None
in I None
Aza I Chemical
-treated I None
patients I None
( I None
P I None
less I None
than I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Aza I Chemical
patients I None
had I None
significantly I None
more I None
staphylococcal I Disease
infections O Disease
than I None
all I None
other I None
transplant I None
groups I None
( I None
P I None
less I None
than I None
0.005 I None
) I None
, I None
and I None
systemic I None
fungal I Disease
infections O Disease
occurred I None
only I None
in I None
the I None
liver I None
transplant I None
group I None
. I None
<eof> I None

<s> O None
Cytomegalovirus I None
( I None
CMV I None
) I None
shedding I None
or I None
serological I None
rises I None
in I None
antibody I None
titer I None
, I None
or I None
both I None
occurred I None
in I None
78 I None
% I None
of I None
cyclosporine I Chemical
patients I None
and I None
76 I None
% I None
of I None
Aza I Chemical
patients I None
. I None
<eof> I None

<s> O None
Of I None
the I None
cyclosporine I Chemical
patients I None
, I None
15 I None
% I None
had I None
symptoms I None
related I None
to I None
CMV I Disease
infection O Disease
. I None
<eof> I None

<s> O None
Serological I None
evidence I None
for I None
Epstein I Disease
Barr O Disease
Virus O Disease
infection O Disease
was I None
found I None
in I None
20 I None
% I None
of I None
65 I None
cyclosporine I Chemical
patients I None
studied I None
. I None
<eof> I None

<s> O None
Three I None
had I None
associated I None
symptoms I None
, I None
and I None
one I None
developed I None
a I None
lymphoma I Disease
. I None
<eof> I None

<s> O None
Structure I None
- I None
activity I None
and I None
dose I None
- I None
effect I None
relationships I None
of I None
the I None
antagonism I None
of I None
picrotoxin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
seizures I Disease
by I None
cholecystokinin I Chemical
, I None
fragments I None
and I None
analogues I None
of I None
cholecystokinin I Chemical
in I None
mice I None
. I None
<eof> I None

<s> O None
Intraperitoneal I None
administration I None
of I None
cholecystokinin I Chemical
octapeptide O Chemical
sulphate I None
ester I None
( I None
CCK-8 I Chemical
-SE I None
) I None
and I None
nonsulphated I None
cholecystokinin I Chemical
octapeptide O Chemical
<eof> I None

<s> O None
( I None
CCK-8 I Chemical
-NS I None
) I None
enhanced I None
the I None
latency I None
of I None
seizures I Disease
induced I None
by I None
picrotoxin I Chemical
in I None
mice I None
. I None
<eof> I None

<s> O None
Experiments I None
with I None
N- I None
and I None
C I None
- I None
terminal I None
fragments I None
revealed I None
that I None
the I None
C I None
- I None
terminal I None
tetrapeptide I None
( I None
CCK-5 I None
- I None
8 I None
) I None
was I None
the I None
active I None
centre I None
of I None
the I None
CCK I None
octapeptide I None
molecule I None
. I None
<eof> I None

<s> O None
The I None
analogues I None
<eof> I None

<s> O None
CCK-8 I Chemical
-SE I None
and I None
<eof> I None

<s> O None
CCK-8 I Chemical
<eof> I None

<s> O None
-NS I None
<eof> I None

<s> O None
( I None
dose I None
range I None
0.2 I None
- I None
6.4 I None
mumol I None
/ I None
kg I None
) I None
and I None
caerulein I Chemical
dose I None
range I None
0.1 I None
- I None
0.8 I None
mumol I None
/ I None
kg I None
) I None
showed I None
bell I None
- I None
shaped I None
dose I None
- I None
effect I None
curves I None
, I None
with I None
the I None
greatest I None
maximum I None
inhibition I None
for I None
<eof> I None

<s> O None
CCK-8 I Chemical
-NS I None
. I None
<eof> I None

<s> O None
The I None
peptide I None
CCK-5 I None
- I None
8 I None
had I None
weak I None
anticonvulsant I None
activity I None
in I None
comparison I None
to I None
the I None
octapeptides I None
, I None
3.2 I None
mumol I None
/ I None
kg I None
and I None
larger I None
doses I None
of I None
the I None
reference I None
drug I None
, I None
diazepam I Chemical
, I None
totally I None
prevented I None
<eof> I None

<s> O None
picrotoxin I Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
and I None
mortality I None
. I None
<eof> I None

<s> O None
The I None
maximum I None
effect I None
of I None
the I None
peptides I None
tested I None
was I None
less I None
than I None
that I None
of I None
diazepam I Chemical
. I None
<eof> I None

<s> O None
Experiments I None
with I None
analogues I None
and I None
derivatives I None
of I None
CCK-5 I None
- I None
8 I None
demonstrated I None
that I None
the I None
effectiveness I None
of I None
the I None
beta I None
- I None
alanyl I None
derivatives I None
of I None
CCK-5 I None
- I None
8 I None
were I None
enhanced I None
and I None
that I None
they I None
were I None
equipotent I None
with I None
<eof> I None

<s> O None
CCK-8 I Chemical
<eof> I None

<s> O None
-SE I None
. I None
<eof> I None

<s> O None
Of I None
the I None
CCK-2 I None
- I None
8 I None
analogues I None
, I None
Ser(SO3H)7-Ac I None
- I None
CCK-2 I None
- I None
8-SE I None
and I None
<eof> I None

<s> O None
Thr(SO3H)7-Ac I None
- I None
CCK-2 I None
- I None
8-SE I None
and I None
Hyp(SO3H)-Ac I None
- I None
CCK-2 I None
- I None
8-SE I None
were I None
slightly I None
more I None
active I None
than I None
CCK-8 I Chemical
<eof> I None

<s> O None
-SE I None
. I None
<eof> I None

<s> O None
Vasopressin I Chemical
as I None
a I None
possible I None
contributor I None
to I None
hypertension I Disease
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
vasopressin I Chemical
as I None
a I None
pressor I None
agent I None
to I None
the I None
hypertensive I Disease
process I None
was I None
examined I None
. I None
<eof> I None

<s> O None
Vasopressin I Chemical
plays I None
a I None
major I None
role I None
in I None
the I None
pathogenesis I None
of I None
DOCA I Chemical
-salt I None
<eof> I None

<s> O None
hypertension I Disease
, I None
since I None
the I None
elevation I None
of I None
blood I None
pressure I None
was I None
not I None
substantial I None
in I None
the I None
rats I None
with I None
lithium I Chemical
-treated I None
diabetes I Disease
insipidus O Disease
after I None
DOCA I Chemical
-salt I None
treatment I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
DDAVP I Chemical
which I None
has I None
antidiuretic I None
action I None
but I None
minimal I None
vasopressor I None
effect I None
failed I None
to I None
increase I None
blood I None
pressure I None
to I None
the I None
levels I None
observed I None
after I None
administration I None
of I None
AVP I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
pressor I None
action I None
of I None
vasopressin I Chemical
appears I None
to I None
be I None
important I None
in I None
the I None
development I None
of I None
this I None
model I None
of I None
hypertension I Disease
, I None
since I None
the I None
enhanced I None
pressor I None
responsiveness I None
to I None
the I None
hormone I None
was I None
observed I None
in I None
the I None
initial I None
stage I None
of I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Increased I None
secretion I None
of I None
vasopressin I Chemical
from I None
neurohypophysis I None
also I None
promotes I None
the I None
function I None
of I None
the I None
hormone I None
as I None
a I None
pathogenetic I None
factor I None
in I None
hypertension I Disease
. I None
<eof> I None

<s> O None
An I None
unproportional I None
release I None
of I None
vasopressin I Chemical
compared I None
to I None
plasma I None
osmolality I None
may I None
be I None
induced I None
by I None
the I None
absence I None
of I None
an I None
adjusting I None
control I None
of I None
angiotensin I Chemical
II I None
forming I None
and I None
receptor I None
binding I None
capacity I None
for I None
sodium I Chemical
balance I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
role I None
of I None
vasopressin I Chemical
remains I None
to I None
be I None
determined I None
in I None
human I None
essential I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Toxic I Disease
hepatitis O Disease
induced I None
by I None
disulfiram I Chemical
in I None
a I None
non I None
- I None
alcoholic I None
. I None
<eof> I None

<s> O None
A I None
reversible I None
toxic I Disease
liver O Disease
damage O Disease
was I None
observed I None
in I None
a I None
non I None
- I None
alcoholic I None
woman I None
treated I None
with I None
disulfiram I Chemical
. I None
<eof> I None

<s> O None
The I None
causative I None
relationship I None
was I None
proven I None
by I None
challenge I None
. I None
<eof> I None

<s> O None
Atrial I Disease
thrombosis O Disease
involving I None
the I None
heart I None
of I None
F-344 I None
rats I None
ingesting I None
quinacrine I Chemical
hydrochloride O Chemical
. I None
<eof> I None

<s> O None
Quinacrine I Chemical
hydrochloride O Chemical
is I None
toxic I None
for I None
the I None
heart I None
of I None
F-344 I None
rats I None
. I None
<eof> I None

<s> O None
Rats I None
treated I None
with I None
500 I None
ppm I None
quinacrine I Chemical
hydrochloride O Chemical
in I None
the I None
diet I None
all I None
developed I None
a I None
high I None
incidence I None
of I None
left I None
atrial I Disease
thrombosis O Disease
. I None
<eof> I None

<s> O None
The I None
lesion I None
was I None
associated I None
with I None
cardiac I Disease
hypertrophy O Disease
and I None
dilatation I None
and I None
focal I None
myocardial I Disease
degeneration O Disease
. I None
<eof> I None

<s> O None
Rats I None
died I None
from I None
cardiac I Disease
hypertrophy O Disease
with I None
severe I None
acute I None
and I None
chronic I None
congestion I None
of I None
the I None
lungs I None
, I None
liver I None
, I None
and I None
other I None
organs I None
. I None
<eof> I None

<s> O None
Seventy I None
percent I None
of I None
rats I None
given I None
250 I None
ppm I None
quinacrine I Chemical
hydrochloride O Chemical
and I None
1,000 I None
ppm I None
sodium I Chemical
nitrite O Chemical
simultaneously I None
in I None
the I None
diet I None
had I None
<eof> I None

<s> O None
thrombosis I Disease
of I None
the I None
atria I None
of I None
the I None
heart I None
, I None
while I None
untreated I None
control I None
rats I None
in I None
this I None
laboratory I None
did I None
not I None
have I None
atrial I Disease
thrombosis O Disease
. I None
<eof> I None

<s> O None
Sodium I Chemical
nitrite O Chemical
in I None
combination I None
with I None
quinacrine I Chemical
hydrochloride O Chemical
appeared I None
to I None
have I None
no I None
additional I None
effect I None
. I None
<eof> I None

<s> O None
Alternating I Disease
sinus O Disease
rhythm O Disease
and I None
intermittent I None
sinoatrial I Disease
block O Disease
induced I None
by I None
propranolol I Chemical
. I None
<eof> I None

<s> O None
Alternating I Disease
sinus O Disease
rhythm O Disease
and I None
intermittent I None
sinoatrial I Disease
( O Disease
S O Disease
- O Disease
A O Disease
) O Disease
block O Disease
was I None
observed I None
in I None
a I None
57-year I None
- I None
old I None
woman I None
, I None
under I None
treatment I None
for I None
angina I Disease
with I None
80 I None
mg I None
propranolol I Chemical
daily I None
. I None
<eof> I None

<s> O None
The I None
electrocardiogram I None
showed I None
alternation I None
of I None
long I None
and I None
short I None
P I None
- I None
P I None
intervals I None
and I None
occasional I None
pauses I None
. I None
<eof> I None

<s> O None
These I None
pauses I None
were I None
always I None
preceded I None
by I None
the I None
short I None
P I None
- I None
P I None
intervals I None
and I None
were I None
usually I None
followed I None
by I None
one I None
or I None
two I None
P I None
- I None
P I None
intervals I None
of I None
0.92 I None
- I None
0.95 I None
s I None
representing I None
the I None
basic I None
sinus I None
cycle I None
. I None
<eof> I None

<s> O None
Following I None
these I None
basic I None
sinus I None
cycles I None
, I None
alternating I Disease
rhythm O Disease
started I None
with I None
the I None
longer I None
P I None
- I None
P I None
interval I None
. I None
<eof> I None

<s> O None
The I None
long I None
P I None
- I None
P I None
intervals I None
ranged I None
between I None
1.04 I None
- I None
1.12 I None
s I None
and I None
the I None
short I None
P I None
- I None
P I None
intervals I None
between I None
0.80 I None
- I None
0.84 I None
s I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
duration I None
of I None
the I None
pauses I None
were I None
equal I None
or I None
almost I None
equal I None
to I None
one I None
short I None
plus I None
one I None
long I None
P I None
- I None
P I None
interval I None
or I None
to I None
twice I None
the I None
basic I None
sinus I None
cycle I None
. I None
<eof> I None

<s> O None
In I None
one I None
recording I None
a I None
short I None
period I None
of I None
regular I None
sinus I None
rhythm I None
with I None
intermittent I None
2/1 I None
S I Disease
- O Disease
A O Disease
block O Disease
was I None
observed I None
. I None
<eof> I None

<s> O None
This I None
short I None
period I None
of I None
sinus I None
rhythm I None
was I None
interrupted I None
by I None
sudden I None
prolongation I None
of I None
the I None
P I None
- I None
P I None
interval I None
starting I None
the I None
alternative I None
rhythm I None
. I None
<eof> I None

<s> O None
There I None
were I None
small I None
changes I None
in I None
the I None
shape I None
of I None
the I None
P I None
waves I None
and I None
P I None
- I None
R I None
intervals I None
. I None
<eof> I None

<s> O None
S I None
- I None
<eof> I None

<s> O None
A I None
conduction I None
through I None
two I None
pathways I None
, I None
the I None
first I None
with I None
2/1 I None
block I None
the I None
second I None
having I None
0.12 I None
- I None
0.14 I None
s I None
longer I None
conduction I None
time I None
and I None
with I None
occasional I None
2/1 I None
block I None
was I None
proposed I None
for I None
the I None
explanation I None
of I None
the I None
alternating I None
P I None
- I None
P I None
interval I None
and I None
other I None
electrocardiographic I None
features I None
seen I None
. I None
<eof> I None

<s> O None
Atropine I Chemical
1 I None
mg I None
given I None
intravenously I None
resulted I None
in I None
shortening I None
of I None
all I None
P I None
- I None
P I None
intervals I None
without I None
changing I None
the I None
rhythm I None
. I None
<eof> I None

<s> O None
The I None
abnormal I None
rhythm I None
disappeared I None
with I None
the I None
withdrawal I None
of I None
propranolol I Chemical
and I None
when I None
the I None
drug I None
was I None
restarted I None
a I None
2/1 I None
S I Disease
- O Disease
A O Disease
block O Disease
was I None
seen I None
. I None
<eof> I None

<s> O None
This I None
was I None
accepted I None
as I None
evidence I None
for I None
propranolol I Chemical
being I None
the I None
cause I None
of I None
this I None
conduction I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Antitumor I None
effect I None
, I None
cardiotoxicity I Disease
, I None
and I None
nephrotoxicity I Disease
of I None
doxorubicin I Chemical
in I None
the I None
IgM I None
solid I None
immunocytoma I Disease
-bearing I None
LOU I None
/ I None
M I None
/ I None
WSL I None
rat I None
. I None
<eof> I None

<s> O None
Antitumor I None
activity I None
, I None
cardiotoxicity I Disease
, I None
and I None
nephrotoxicity I Disease
induced I None
by I None
doxorubicin I Chemical
were I None
studied I None
in I None
LOU I None
/ I None
M I None
/ I None
WSL I None
inbred I None
rats I None
each I None
bearing I None
a I None
transplantable I None
solid I None
IgM I None
immunocytoma I Disease
. I None
<eof> I None

<s> O None
Animals I None
with I None
a I None
tumor I Disease
<eof> I None

<s> O None
( I None
diameter I None
, I None
15.8 I None
+ I None
/- I None
<eof> I None

<s> O None
3.3 I None
mm I None
) I None
were I None
treated I None
with I None
iv I None
injections I None
of I None
doxorubicin I Chemical
on I None
5 I None
consecutive I None
days I None
, I None
followed I None
by I None
1 I None
weekly I None
injection I None
for I None
7 I None
weeks I None
( I None
dose I None
range I None
, I None
0.015 I None
- I None
4.0 I None
mg I None
/ I None
kg I None
body I None
wt I None
) I None
. I None
<eof> I None

<s> O None
Tumor I Disease
regression I None
was I None
observed I None
with I None
0.5 I None
mg I None
doxorubicin I Chemical
/kg I None
. I None
<eof> I None

<s> O None
Complete I None
disappearance I None
of I None
the I None
tumor I Disease
was I None
induced I None
with I None
1.0 I None
mg I None
doxorubicin I Chemical
/kg I None
. I None
<eof> I None

<s> O None
Histologic I None
evidence I None
of I None
cardiotoxicity I Disease
scored I None
as I None
grade I None
III I None
was I None
only I None
observed I None
at I None
a I None
dose I None
of I None
1.0 I None
mg I None
doxorubicin I Chemical
/kg I None
. I None
<eof> I None

<s> O None
Light I None
microscopic I None
evidence I None
of I None
renal I Disease
damage O Disease
was I None
seen I None
above I None
a I None
dose I None
of I None
0.5 I None
mg I None
doxorubicin I Chemical
/kg I None
, I None
which I None
resulted I None
in I None
albuminuria I Disease
and I None
very I None
low I None
serum I None
albumin I None
levels I None
. I None
<eof> I None

<s> O None
In I None
the I None
group I None
that I None
received I None
1.0 I None
mg I None
doxorubicin I Chemical
/kg I None
, I None
the I None
serum I None
albumin I None
level I None
decreased I None
from I None
33.6 I None
+ I None
/- I None
4.1 I None
to I None
1.5 I None
+ I None
/- I None
<eof> I None

<s> O None
0.5 I None
g I None
/ I None
liter I None
. I None
<eof> I None

<s> O None
Ascites I Disease
and I None
hydrothorax I Disease
were I None
observed I None
simultaneously I None
. I None
<eof> I None

<s> O None
The I None
same I None
experiments I None
were I None
performed I None
with I None
non- I None
tumor I Disease
-bearing I None
rats I None
, I None
in I None
which I None
no I None
major I None
differences I None
were I None
observed I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
antitumor I None
activity I None
, I None
cardiotoxicity I Disease
, I None
and I None
nephrotoxicity I Disease
were I None
studied I None
simultaneously I None
in I None
the I None
same I None
LOU I None
/ I None
M I None
/ I None
WSL I None
rat I None
. I None
<eof> I None

<s> O None
Albuminuria I Disease
due I None
to I None
renal I Disease
damage O Disease
led I None
to I None
extremely I None
low I None
serum I None
albumin I None
levels I None
, I None
so I None
ascites I Disease
and I None
hydrothorax I Disease
were I None
not I None
necessarily I None
a I None
consequence I None
of I None
the I None
observed I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
Intraoperative I None
bradycardia I Disease
and I None
hypotension I Disease
associated I None
with I None
timolol I Chemical
and I None
pilocarpine I Chemical
eye I None
drops I None
. I None
<eof> I None

<s> O None
A I None
69-yr I None
- I None
old I None
man I None
, I None
who I None
was I None
concurrently I None
being I None
treated I None
with I None
pilocarpine I Chemical
nitrate O Chemical
and I None
timolol I Chemical
maleate O Chemical
eye I None
drops I None
, I None
developed I None
a I None
bradycardia I Disease
and I None
became I None
hypotensive I Disease
during I None
halothane I Chemical
anaesthesia I None
. I None
<eof> I None

<s> O None
Both I None
timolol I Chemical
and I None
pilocarpine I Chemical
were I None
subsequently I None
identified I None
in I None
a I None
24-h I None
collection I None
of I None
urine I None
. I None
<eof> I None

<s> O None
Timolol I Chemical
( I None
but I None
not I None
pilocarpine I Chemical
) I None
was I None
detected I None
in I None
a I None
sample I None
of I None
plasma I None
removed I None
during I None
surgery I None
; I None
the I None
plasma I None
concentration I None
of I None
timolol I Chemical
<eof> I None

<s> O None
( I None
2.6 I None
ng I None
ml-1 I None
) I None
was I None
consistent I None
with I None
partial I None
beta I None
- I None
adrenoceptor I None
blockade I None
. I None
<eof> I None

<s> O None
It I None
is I None
postulated I None
that I None
this I None
action I None
may I None
have I None
been I None
enhanced I None
during I None
halothane I Chemical
anaesthesia I None
with I None
resultant I None
bradycardia I Disease
and I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Pilocarpine I Chemical
may I None
have I None
had I None
a I None
contributory I None
effect I None
. I None
<eof> I None

<s> O None
Succinylcholine I Chemical
<eof> I None

<s> O None
apnoea I Disease
: I None
attempted I None
reversal I None
with I None
anticholinesterases I None
. I None
<eof> I None

<s> O None
Anticholinesterases I None
were I None
administered I None
in I None
an I None
attempt I None
to I None
antagonize I None
prolonged I None
neuromuscular I Disease
blockade O Disease
following I None
the I None
administration I None
of I None
succinylcholine I Chemical
in I None
a I None
patient I None
later I None
found I None
to I None
be I None
homozygous I None
for I None
atypical I None
plasma I None
cholinesterase I None
. I None
<eof> I None

<s> O None
Edrophonium I Chemical
10 I None
mg I None
, I None
given I None
74 I None
min I None
after I None
succinylcholine I Chemical
, I None
when I None
train I None
- I None
of I None
- I None
four I None
stimulation I None
was I None
characteristic I None
of I None
phase I None
II I None
block I None
, I None
produced I None
partial I None
antagonism I None
which I None
was I None
not I None
sustained I None
. I None
<eof> I None

<s> O None
Repeated I None
doses I None
of I None
edrophonium I Chemical
to I None
70 I None
mg I None
and I None
neostigmine I Chemical
to I None
2.5 I None
mg I None
did I None
not I None
antagonize I None
or I None
augment I None
the I None
block I None
. I None
<eof> I None

<s> O None
Spontaneous I None
respiration I None
recommenced I None
200 I None
min I None
after I None
succinylcholine I Chemical
administration I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
anticholinesterases I None
are I None
only I None
partially I None
effective I None
in I None
restoring I None
neuromuscular I None
function I None
in I None
succinylcholine I Chemical
<eof> I None

<s> O None
apnoea I Disease
despite I None
muscle I None
twitch I None
activity I None
typical I None
of I None
phase I None
II I None
block I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
doxorubicin I Chemical
on I None
<eof> I None

<s> O None
[ I Chemical
omega O Chemical
- O Chemical
I-131]heptadecanoic O Chemical
acid O Chemical
myocardial I None
scintigraphy I None
and I None
echocardiography I None
in I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
serial I None
treatment I None
with I None
doxorubicin I Chemical
on I None
dynamic I None
myocardial I None
scintigraphy I None
with I None
[ I Chemical
omega O Chemical
- O Chemical
I-131]heptadecanoic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
I-131 I Chemical
HA O Chemical
) I None
, I None
and I None
on I None
global I None
left I None
- I None
ventricular I None
function I None
determined I None
echocardiographically I None
, I None
were I None
studied I None
in I None
a I None
group I None
of I None
nine I None
mongrel I None
dogs I None
. I None
<eof> I None

<s> O None
Total I None
extractable I None
myocardial I None
lipid I None
was I None
compared I None
postmortem I None
between I None
a I None
group I None
of I None
control I None
dogs I None
and I None
doxorubicin I Chemical
<eof> I None

<s> O None
-treated I None
dogs I None
. I None
<eof> I None

<s> O None
A I None
significant I None
and I None
then I None
progressive I None
fall I None
in I None
global I None
LV I None
function I None
was I None
observed I None
at I None
a I None
cumulative I None
doxorubicin I Chemical
dose I None
of I None
4 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
A I None
significant I None
increase I None
in I None
the I None
myocardial I None
t1/2 I None
of I None
the I None
I-131 I Chemical
HA O Chemical
was I None
observed I None
only I None
at I None
a I None
higher I None
cumulative I None
dose I None
, I None
10 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
No I None
significant I None
alteration I None
in I None
total I None
extractable I None
myocardial I None
lipids I None
was I None
observed I None
between I None
control I None
dogs I None
and I None
those I None
treated I None
with I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Our I None
findings I None
suggest I None
that I None
the I None
changes I None
leading I None
to I None
an I None
alteration I None
of I None
myocardial I None
dynamic I None
imaging I None
with I None
I-131 I Chemical
HA O Chemical
are I None
not I None
the I None
initiating I None
factor I None
in I None
doxorubicin I Chemical
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
Hemodynamics I None
and I None
myocardial I None
metabolism I None
under I None
deliberate I None
hypotension I Disease
. I None
<eof> I None

<s> O None
An I None
experimental I None
study I None
in I None
dogs I None
. I None
<eof> I None

<s> O None
Coronary I None
blood I None
flow I None
, I None
cardiac I None
work I None
and I None
metabolism I None
were I None
studied I None
in I None
dogs I None
under I None
sodium I Chemical
nitroprusside O Chemical
<eof> I None

<s> O None
( I None
SNP I Chemical
) I None
and I None
trimetaphan I Chemical
<eof> I None

<s> O None
( I None
TMP I Chemical
) I None
deliberate I None
hypotension I Disease
( I None
20 I None
% I None
and I None
40 I None
% I None
mean I None
pressure I None
decrease I None
from I None
baseline I None
) I None
. I None
<eof> I None

<s> O None
Regarding I None
the I None
effects I None
of I None
drug I None
- I None
induced I None
hypotension I Disease
on I None
coronary I None
blood I None
flow I None
, I None
aortic I None
and I None
coronary I None
sinus I None
metabolic I None
data I None
( I None
pH I None
, I None
pO2 I None
, I None
pCO2 I None
) I None
we I None
could I None
confirm I None
that I None
nitroprusside I Chemical
<eof> I None

<s> O None
hypotension I Disease
could I None
be I None
safely I None
used I None
to I None
30 I None
% I None
mean I None
blood I None
pressure I None
decrease I None
from I None
control I None
, I None
trimetaphan I Chemical
hypotension I Disease
to I None
20 I None
% I None
mean I None
blood I None
pressure I None
decrease I None
. I None
<eof> I None

<s> O None
Cardiac I None
work I None
was I None
significantly I None
reduced I None
during I None
SNP I Chemical
hypotension I Disease
. I None
<eof> I None

<s> O None
Myocardial I None
O2 I Chemical
<eof> I None

<s> O None
consumption I None
and I None
O2 I Chemical
availability I None
were I None
directly I None
dependent I None
on I None
the I None
coronary I None
perfusion I None
. I None
<eof> I None

<s> O None
Careful I None
invasive I None
monitoring I None
of I None
the I None
blood I None
pressure I None
, I None
blood I None
gases I None
and I None
of I None
the I None
ECG I None
ST I None
- I None
T I None
segment I None
is I None
mandatory I None
. I None
<eof> I None

<s> O None
Evidence I None
for I None
a I None
selective I None
brain I None
noradrenergic I None
involvement I None
in I None
the I None
locomotor I None
stimulant I None
effects I None
of I None
amphetamine I Chemical
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Male I None
rats I None
received I None
the I None
noradrenaline I Chemical
neurotoxin I None
DSP4 I Chemical
( I None
50 I None
mg I None
/ I None
kg I None
) I None
7 I None
days I None
prior I None
to I None
injection I None
of I None
D I Chemical
- O Chemical
amphetamine O Chemical
<eof> I None

<s> O None
( I None
10 I None
or I None
40 I None
mumol I None
/ I None
kg I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
The I None
hyperactivity I Disease
induced I None
by I None
D I Chemical
- O Chemical
amphetamine O Chemical
<eof> I None

<s> O None
( I None
10 I None
mumol I None
/ I None
kg I None
) I None
was I None
significantly I None
reduced I None
by I None
DSP4 I Chemical
pretreatment I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
increased I None
rearings I None
and I None
the I None
amphetamine I Chemical
-induced I None
stereotypies I Disease
were I None
not I None
blocked I None
by I None
pretreatment I None
with I None
DSP4 I Chemical
. I None
<eof> I None

<s> O None
The I None
reduction I None
of I None
amphetamine I Chemical
hyperactivity I Disease
induced I None
by I None
DSP4 I Chemical
was I None
blocked I None
by I None
pretreatment I None
with I None
the I None
noradrenaline I Chemical
-uptake I None
blocking I None
agent I None
, I None
desipramine I Chemical
, I None
which I None
prevents I None
the I None
neurotoxic I Disease
action I None
of I None
DSP4 I Chemical
. I None
<eof> I None

<s> O None
The I None
present I None
results I None
suggest I None
a I None
selective I None
involvement I None
of I None
central I None
noradrenergic I None
neurones I None
in I None
the I None
locomotor I None
stimulant I None
effect I None
of I None
amphetamine I Chemical
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Accelerated I Disease
junctional O Disease
rhythms O Disease
during I None
oral I None
verapamil I Chemical
therapy I None
. I None
<eof> I None

<s> O None
This I None
study I None
examined I None
the I None
frequency I None
of I None
atrioventricular I None
( I None
AV I None
) I None
dissociation I None
and I None
accelerated I Disease
junctional O Disease
rhythms O Disease
in I None
59 I None
patients I None
receiving I None
oral I None
verapamil I Chemical
. I None
<eof> I None

<s> O None
Accelerated I Disease
junctional O Disease
rhythms O Disease
and I None
AV I None
dissociation I None
were I None
frequent I None
in I None
patients I None
with I None
supraventricular I Disease
tachyarrhythmias O Disease
, I None
particularly I None
AV I None
nodal I None
reentry I None
. I None
<eof> I None

<s> O None
Verapamil I Chemical
administration I None
to I None
these I None
patients I None
led I None
to I None
an I None
asymptomatic I None
increase I None
in I None
activity I None
of I None
these I None
junctional I None
pacemakers I None
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
various I None
chest I Disease
pain O Disease
syndromes I None
, I None
verapamil I Chemical
neither I None
increased I None
the I None
frequency I None
of I None
junctional I None
rhythms I None
nor I None
suppressed I None
their I None
role I None
as I None
escape I None
rhythms I None
under I None
physiologically I None
appropriate I None
circumstances I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
ovarian I Disease
cancer O Disease
with I None
a I None
combination I None
of I None
cis I Chemical
- O Chemical
platinum O Chemical
, I None
adriamycin I Chemical
, I None
cyclophosphamide I Chemical
and I None
hexamethylmelamine I Chemical
. I None
<eof> I None

<s> O None
During I None
the I None
last I None
2 I None
1/2 I None
years I None
, I None
38 I None
patients I None
with I None
ovarian I Disease
cancer O Disease
were I None
treated I None
with I None
a I None
combination I None
of I None
cisplatinum I Chemical
<eof> I None

<s> O None
( I None
CPDD I Chemical
) I None
, I None
50 I None
mg I None
/ I None
m2 I None
, I None
adriamycin I Chemical
, I None
30 I None
mg I None
/ I None
m2 I None
, I None
cyclophosphamide I Chemical
, I None
300 I None
mg I None
/ I None
m2 I None
, I None
on I None
day I None
1 I None
; I None
and I None
hexamethylmelamine I Chemical
( I None
HMM I Chemical
) I None
, I None
6 I None
mg I None
/ I None
kg I None
daily I None
, I None
for I None
14 I None
days I None
. I None
<eof> I None

<s> O None
Each I None
course I None
was I None
repeated I None
monthly I None
. I None
<eof> I None

<s> O None
2 I None
patients I None
had I None
stage I None
II I None
, I None
14 I None
stage I None
III I None
and I None
22 I None
stage I None
IV I None
disease I None
. I None
<eof> I None

<s> O None
14 I None
of I None
the I None
38 I None
patients I None
were I None
previously I None
treated I None
with I None
chemotherapy I None
, I None
1 I None
with I None
radiation I None
, I None
6 I None
with I None
both I None
chemotherapy I None
and I None
radiation I None
, I None
and I None
17 I None
did I None
not I None
have I None
any I None
treatment I None
before I None
CPDD I Chemical
combination I None
. I None
<eof> I None

<s> O None
31 I None
of I None
the I None
38 I None
cases I None
( I None
81.5 I None
% I None
) I None
demonstrated I None
objective I None
responses I None
lasting I None
for I None
2 I None
months I None
or I None
more I None
. I None
<eof> I None

<s> O None
These I None
responses I None
were I None
partial I None
in I None
19 I None
and I None
complete I None
in I None
12 I None
cases I None
. I None
<eof> I None

<s> O None
Hematologic I Disease
toxicity O Disease
was I None
moderate I None
and I None
with I None
reversible I None
anemia I Disease
developing I None
in I None
71 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Gastrointestinal I None
side I None
effects I None
from I None
CPDD I Chemical
were I None
universal I None
. I None
<eof> I None

<s> O None
HMM I Chemical
gastrointestinal I Disease
toxicity O Disease
<eof> I None

<s> O None
necessitated I None
discontinuation I None
of I None
the I None
drug I None
in I None
5 I None
patients I None
. I None
<eof> I None

<s> O None
Severe I None
nephrotoxicity I Disease
was I None
observed I None
in I None
2 I None
patients I None
but I None
was I None
reversible I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
drug I None
- I None
related I None
deaths I None
. I None
<eof> I None

<s> O None
Nontraumatic I None
dissecting I Disease
aneurysm O Disease
of I None
the I None
basilar I None
artery I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
nontraumatic I None
dissecting I Disease
aneurysm O Disease
of I None
the I None
basilar I None
artery I None
in I None
association I None
with I None
hypertension I Disease
, I None
smoke I None
, I None
and I None
oral I Chemical
contraceptives O Chemical
is I None
reported I None
in I None
a I None
young I None
female I None
patient I None
with I None
a I None
locked I Disease
- O Disease
in O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Propylthiouracil I Chemical
-induced I None
hepatic I Disease
damage O Disease
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
propylthiouracil I Chemical
-induced I None
liver I Disease
damage O Disease
have I None
been I None
observed I None
. I None
<eof> I None

<s> O None
The I None
first I None
case I None
is I None
of I None
an I None
acute I None
type I None
of I None
damage I None
, I None
proven I None
by I None
rechallenge I None
; I None
the I None
second I None
presents I None
a I None
clinical I None
and I None
histologic I None
picture I None
resembling I None
chronic I Disease
active O Disease
hepatitis O Disease
, I None
with I None
spontaneous I None
remission I None
. I None
<eof> I None

<s> O None
Studies I None
on I None
the I None
bradycardia I Disease
induced I None
by I None
bepridil I Chemical
. I None
<eof> I None

<s> O None
Bepridil I Chemical
, I None
a I None
novel I None
active I None
compound I None
for I None
prophylactic I None
treatment I None
of I None
anginal I Disease
attacks O Disease
, I None
induced I None
persistent I None
bradycardia I Disease
and I None
a I None
non I None
- I None
specific I None
anti- I None
tachycardial I Disease
effect I None
, I None
the I None
mechanisms I None
of I None
which I None
were I None
investigated I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
perfusion I None
of I None
bepridil I Chemical
in I None
the I None
life I None
- I None
support I None
medium I None
for I None
isolated I None
sino I None
- I None
atrial I None
tissue I None
from I None
rabbit I None
heart I None
, I None
caused I None
a I None
reduction I None
in I None
action I None
potential I None
( I None
AP I None
) I None
spike I None
frequency I None
( I None
recorded I None
by I None
KCl I Chemical
microelectrodes I None
) I None
starting I None
at I None
doses I None
of I None
5 I None
X I None
10(-6 I None
) I None
<eof> I None

<s> O None
M. I None
<eof> I None

<s> O None
This I None
effect I None
was I None
dose I None
- I None
dependent I None
up I None
to I None
concentrations I None
of I None
5 I None
X I None
10(-5 I None
<eof> I None

<s> O None
) I None
M I None
, I None
whereupon I None
blockade I None
of I None
sinus I None
activity I None
set I None
in I None
. I None
<eof> I None

<s> O None
Bepridil I Chemical
at I None
a I None
dose I None
of I None
5 I None
X I None
10(-6 I None
) I None
<eof> I None

<s> O None
M I None
, I None
induced I None
a I None
concomitant I None
reduction I None
in I None
AP I None
amplitude I None
( I None
falling I None
from I None
71 I None
+ I None
/- I None
<eof> I None

<s> O None
8 I None
mV I None
to I None
47 I None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
mV I None
) I None
, I None
maximum I None
systolic I None
depolarization I None
velocity I None
( I None
phase I None
0 I None
) I None
which I None
fell I None
from I None
1.85 I None
+ I None
/- I None
0.35 I None
V I None
<eof> I None

<s> O None
/ I None
s I None
to I None
0.84 I None
+ I None
/- I None
<eof> I None

<s> O None
0.28 I None
V I None
/ I None
s I None
, I None
together I None
with I None
maximum I None
diastolic I None
depolarization I None
velocity I None
( I None
phase I None
4 I None
) I None
which I None
fell I None
from I None
38 I None
+ I None
/- I None
<eof> I None

<s> O None
3 I None
mV I None
/ I None
s I None
to I None
24 I None
+ I None
/- I None
<eof> I None

<s> O None
5 I None
mV I None
/ I None
s I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
injection I None
of I None
bepridil I Chemical
at I None
a I None
dose I None
of I None
5 I None
mg I None
/ I None
kg I None
( I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
into I None
6 I None
anaesthetized I None
dogs I None
which I None
had I None
undergone I None
ablation I None
of I None
all I None
the I None
extrinsic I None
cardiac I None
afferent I None
nerve I None
supply I None
, I None
together I None
with I None
a I None
bilateral I None
medullo I None
- I None
adrenalectomy I None
, I None
caused I None
a I None
marked I None
reduction I None
in I None
heart I None
rate I None
which I None
fell I None
from I None
98.7 I None
+ I None
/- I None
<eof> I None

<s> O None
4.2 I None
beats I None
/ I None
min I None
to I None
76 I None
+ I None
/- I None
<eof> I None

<s> O None
5.3 I None
beats I None
/ I None
min I None
sustained I None
for I None
more I None
than I None
45 I None
min I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
bepridil I Chemical
reduces I None
heart I None
rate I None
by I None
acting I None
directly I None
on I None
the I None
sinus I None
node I None
. I None
<eof> I None

<s> O None
This I None
effect I None
, I None
which I None
results I None
in I None
a I None
flattening I None
of I None
the I None
phase I None
0 I None
and I None
phase I None
4 I None
slope I None
, I None
together I None
with I None
a I None
longer I None
AP I None
duration I None
, I None
may I None
be I None
due I None
to I None
an I None
increase I None
in I None
the I None
time I None
constants I None
of I None
slow I None
inward I None
ionic I None
currents I None
( I None
already I None
demonstrated I None
elsewhere I None
) I None
, I None
but I None
also I None
to I None
an I None
increased I None
time I None
constant I None
for I None
deactivation I None
of I None
the I None
outward I None
potassium I Chemical
current I None
( I None
Ip I None
) I None
. I None
<eof> I None

<s> O None
Hepatitis I Disease
and I None
renal I Disease
tubular O Disease
acidosis O Disease
after I None
anesthesia I None
with I None
methoxyflurane I Chemical
. I None
<eof> I None

<s> O None
A I None
69-year I None
- I None
old I None
man I None
operated I None
for I None
acute I Disease
cholecystitis O Disease
under I None
methoxyflurane I Chemical
<eof> I None

<s> O None
anesthesia I None
developed I None
postoperatively I None
a I None
hepatic I Disease
insufficiency O Disease
syndrome O Disease
and I None
renal I Disease
tubular O Disease
acidosis O Disease
. I None
<eof> I None

<s> O None
Massive I None
bleeding I Disease
appeared I None
during I None
surgery I None
which I None
lasted I None
for I None
six I None
hours I None
. I None
<eof> I None

<s> O None
Postoperative I None
evolution I None
under I None
supportive I None
therapy I None
was I None
favourable I None
. I None
<eof> I None

<s> O None
Complete I None
recovery I None
was I None
confirmed I None
by I None
repeated I None
controls I None
performed I None
over I None
a I None
period I None
of I None
one I None
year I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
Pituitary I None
response I None
to I None
luteinizing I None
hormone I None
- I None
releasing I None
hormone I None
during I None
<eof> I None

<s> O None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
a I None
6-hour I None
infusion I None
with I None
haloperidol I Chemical
on I None
serum I None
prolactin I None
and I None
luteinizing I None
hormone I None
( I None
LH I None
) I None
levels I None
was I None
studied I None
in I None
a I None
group I None
of I None
male I None
subjects I None
. I None
<eof> I None

<s> O None
Five I None
hours I None
after I None
starting I None
the I None
infusions I None
, I None
a I None
study I None
of I None
the I None
pituitary I None
responses I None
to I None
LH I None
- I None
releasing I None
hormone I None
( I None
LH I None
- I None
RH I None
) I None
was I None
carried I None
out I None
. I None
<eof> I None

<s> O None
Control I None
patients I None
received I None
infusions I None
of I None
0.9 I None
% I None
NaCl I Chemical
solution I None
. I None
<eof> I None

<s> O None
During I None
the I None
course I None
of I None
haloperidol I Chemical
infusions I None
, I None
significant I None
hyperprolactinemia I Disease
was I None
found I None
, I None
together I None
with I None
an I None
abolished I None
pituitary I None
response I None
to I None
LH I None
- I None
RH I None
, I None
as I None
compared I None
with I None
responses I None
of I None
control I None
subjects I None
. I None
<eof> I None

<s> O None
Antirifampicin I None
antibodies I None
in I None
acute I None
rifampicin I Chemical
-associated I None
renal I Disease
failure O Disease
. I None
<eof> I None

<s> O None
5 I None
patients I None
with I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
3 I None
with I None
thrombopenia I Disease
and I None
hemolysis I Disease
) I None
induced I None
by I None
the I None
reintroduction I None
of I None
rifampicin I Chemical
are I None
described I None
. I None
<eof> I None

<s> O None
No I None
correlation I None
was I None
found I None
between I None
the I None
severity I None
of I None
clinical I None
manifestations I None
and I None
the I None
total I None
dose I None
taken I None
by I None
the I None
patients I None
. I None
<eof> I None

<s> O None
In I None
all I None
but I None
1 I None
patient I None
, I None
antirifampicin I None
antibodies I None
were I None
detected I None
. I None
<eof> I None

<s> O None
Antibodies I None
suggested I None
to I None
be I None
of I None
the I None
IgM I None
class I None
were I None
detected I None
in I None
all I None
3 I None
patients I None
with I None
hematological I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
The I None
pattern I None
of I None
non I None
- I None
specific I None
acute I Disease
tubular O Disease
necrosis O Disease
found I None
in I None
the I None
2 I None
biopsied I None
patients I None
, I None
indistinguishable I None
from I None
that I None
of I None
ischemic I None
origin I None
, I None
raised I None
the I None
possibility I None
of I None
a I None
vascular I None
- I None
mediated I None
damage I None
. I None
<eof> I None

<s> O None
In I None
3 I None
patients I None
, I None
the I None
possibility I None
of I None
a I None
triggering I None
immunoallergic I None
mechanism I None
is I None
discussed I None
. I None
<eof> I None

<s> O None
Cardiovascular I None
effects I None
of I None
hypotension I Disease
induced I None
by I None
adenosine I Chemical
triphosphate O Chemical
and I None
sodium I Chemical
nitroprusside O Chemical
on I None
dogs I None
with I None
denervated I None
hearts I None
. I None
<eof> I None

<s> O None
Adenosine I Chemical
triphosphate O Chemical
( I None
ATP I Chemical
) I None
and I None
sodium I Chemical
nitroprusside O Chemical
<eof> I None

<s> O None
( I None
SNP I Chemical
) I None
are I None
administered I None
to I None
patients I None
to I None
induce I None
and I None
control I None
hypotension I Disease
during I None
anesthesia I None
. I None
<eof> I None

<s> O None
SNP I Chemical
is I None
authorized I None
for I None
clinical I None
use I None
in I None
USA I None
and I None
UK I None
, I None
and I None
ATP I Chemical
is I None
clinically I None
used I None
in I None
other I None
countries I None
such I None
as I None
Japan I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
how I None
these I None
two I None
drugs I None
act I None
on I None
the I None
cardiovascular I None
systems I None
of I None
20 I None
dogs I None
whose I None
hearts I None
had I None
been I None
denervated I None
by I None
a I None
procedure I None
we I None
had I None
devised I None
. I None
<eof> I None

<s> O None
ATP I Chemical
( I None
10 I None
dogs I None
) I None
or I None
SNP I Chemical
( I None
10 I None
dogs I None
) I None
was I None
administered I None
to I None
reduce I None
mean I None
arterial I None
pressure I None
by I None
30 I None
% I None
to I None
70 I None
% I None
of I None
control I None
. I None
<eof> I None

<s> O None
Before I None
, I None
during I None
and I None
after I None
induced I None
hypotension I Disease
, I None
we I None
measured I None
major I None
cardiovascular I None
parameters I None
. I None
<eof> I None

<s> O None
Hypotension I Disease
induced I None
by I None
ATP I Chemical
was I None
accompanied I None
by I None
significant I None
decreases I None
in I None
mean I None
pulmonary I None
arterial I None
pressure I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
central I None
venous I None
pressure I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
left I None
ventricular I None
end I None
- I None
diastolic I None
pressure I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
total I None
peripheral I None
resistance I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
rate I None
pressure I None
product I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
total I None
body I None
oxygen I Chemical
consumption I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
, I None
and I None
heart I None
rate I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
; I None
all I None
these I None
variables I None
returned I None
normal I None
within I None
30 I None
min I None
after I None
ATP I Chemical
was I None
stopped I None
. I None
<eof> I None

<s> O None
Cardiac I None
output I None
did I None
not I None
change I None
. I None
<eof> I None

<s> O None
During I None
hypotension I Disease
produced I None
by I None
SNP I Chemical
similar I None
decreases I None
were I None
observed I None
in I None
mean I None
pulmonary I None
arterial I None
pressure I None
( I None
p I None
less I None
than I None
0.01 I None
) I None
, I None
central I None
venous I None
pressure I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
left I None
ventricular I None
end I None
- I None
diastolic I None
pressure I None
( I None
p I None
less I None
than I None
0.01 I None
) I None
, I None
total I None
peripheral I None
resistance I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
rate I None
pressure I None
product I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
, I None
and I None
oxygen I Chemical
content I None
difference I None
between I None
arterial I None
and I None
mixed I None
venous I None
blood I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
, I None
while I None
heart I None
rate I None
( I None
p I None
less I None
than I None
0.001 I None
) I None
and I None
cardiac I None
output I None
( I None
p I None
less I None
than I None
0.05 I None
) I None
were I None
increased I None
. I None
<eof> I None

<s> O None
Recoveries I None
of I None
heart I None
rate I None
and I None
left I None
ventricular I None
end I None
- I None
diastolic I None
pressure I None
were I None
not I None
shown I None
within I None
60 I None
min I None
after I None
SNP I Chemical
had I None
been I None
stopped I None
. I None
<eof> I None

<s> O None
Both I None
ATP I Chemical
and I None
SNP I Chemical
should I None
act I None
on I None
the I None
pacemaker I None
tissue I None
of I None
the I None
heart I None
. I None
<eof> I None

<s> O None
Comparative I None
study I None
: I None
Endografine I Chemical
<eof> I None

<s> O None
( I None
diatrizoate I Chemical
) I None
, I None
Vasurix I Chemical
polyvidone O Chemical
<eof> I None

<s> O None
( I None
acetrizoate I Chemical
) I None
, I None
Dimer I Chemical
- O Chemical
X O Chemical
<eof> I None

<s> O None
( I None
iocarmate I Chemical
) I None
and I None
Hexabrix I Chemical
<eof> I None

<s> O None
( I None
ioxaglate I Chemical
) I None
in I None
hysterosalpingography I None
. I None
<eof> I None

<s> O None
Side I None
effects I None
of I None
hysterosalpingography I None
with I None
Dimer I Chemical
- O Chemical
X O Chemical
, I None
Hexabrix I Chemical
, I None
Vasurix I Chemical
polyvidone O Chemical
and I None
Endografine I Chemical
in I None
142 I None
consecutive I None
patients I None
, I None
receiving I None
one I None
of I None
the I None
four I None
tested I None
media I None
were I None
evaluated I None
from I None
replies I None
to I None
postal I None
questionnaires I None
. I None
<eof> I None

<s> O None
The I None
Dimer I Chemical
- O Chemical
X O Chemical
group I None
had I None
a I None
higher I None
incidence I None
of I None
nausea I Disease
and I None
dizziness I Disease
. I None
<eof> I None

<s> O None
The I None
Endografine I Chemical
group I None
had I None
a I None
higher I None
incidence I None
of I None
abdominal I Disease
pain O Disease
. I None
<eof> I None

<s> O None
These I None
differences I None
occur I None
especially I None
in I None
the I None
age I None
groups I None
under I None
30 I None
years I None
. I None
<eof> I None

<s> O None
Hexabrix I Chemical
and I None
Vasurix I Chemical
polyvidone O Chemical
are I None
considered I None
the I None
best I None
contrast I Chemical
media O Chemical
for I None
hysterosalpingography I None
and I None
perhaps I None
because I None
of I None
its I None
low I None
toxicity I Disease
Hexabrix I Chemical
should I None
be I None
preferred I None
. I None
<eof> I None

<s> O None
Post- I None
suxamethonium I Chemical
pains I Disease
in I None
Nigerian I None
surgical I None
patients I None
. I None
<eof> I None

<s> O None
Contrary I None
to I None
an I None
earlier I None
report I None
by I None
Coxon I None
, I None
scoline I Chemical
<eof> I None

<s> O None
pain I Disease
occurs I None
in I None
African I None
negroes I None
. I None
<eof> I None

<s> O None
Its I None
incidence I None
was I None
determined I None
in I None
a I None
prospective I None
study I None
involving I None
a I None
total I None
of I None
100 I None
Nigerian I None
patients I None
( I None
50 I None
out I None
- I None
patients I None
and I None
50 I None
in I None
- I None
patients I None
) I None
. I None
<eof> I None

<s> O None
About I None
62 I None
% I None
of I None
the I None
out I None
- I None
patients I None
developed I None
scoline I Chemical
<eof> I None

<s> O None
pain I Disease
as I None
compared I None
with I None
about I None
26 I None
% I None
among I None
the I None
in I None
- I None
patients I None
. I None
<eof> I None

<s> O None
The I None
abolition I None
of I None
muscle I None
fasciculations I Disease
( I None
by I None
0.075mg I None
/ I None
kg I None
dose I None
of I None
Fazadinium I Chemical
) I None
did I None
not I None
influence I None
the I None
occurrence I None
of I None
scoline I Chemical
pain I Disease
. I None
<eof> I None

<s> O None
Neither I None
the I None
type I None
of I None
induction I None
agent I None
( I None
Althesin I Chemical
or I None
Thiopentone I Chemical
) I None
nor I None
the I None
salt I None
preparation I None
of I None
suxamethonium I Chemical
used I None
( I None
chloride I Chemical
or I None
bromide I Chemical
) I None
, I None
affected I None
the I None
incidence I None
of I None
scoline I Chemical
pain I Disease
. I None
<eof> I None

<s> O None
Medial I None
changes I None
in I None
arterial I None
spasm I Disease
induced I None
by I None
L I Chemical
- O Chemical
norepinephrine O Chemical
. I None
<eof> I None

<s> O None
In I None
normal I None
rats I None
, I None
the I None
media I None
of I None
small I None
arteries I None
( I None
0.4 I None
- I None
-0.2 I None
mm I None
in I None
diameter I None
) I None
previously I None
was I None
shown I None
to I None
contain I None
intracellular I None
vacuoles I None
, I None
identified I None
ultrastructurally I None
as I None
herniations I None
of I None
one I None
smooth I None
muscle I None
cell I None
into I None
another I None
. I None
<eof> I None

<s> O None
The I None
hypothesis I None
that I None
intense I None
vasoconstriction I None
would I None
increase I None
the I None
number I None
of I None
such I None
vacuoles I None
has I None
been I None
tested I None
. I None
<eof> I None

<s> O None
In I None
the I None
media I None
of I None
the I None
saphenous I None
artery I None
and I None
its I None
distal I None
branch I None
, I None
vasoconstriction I None
induced I None
by I None
L I Chemical
- O Chemical
norepinephrine O Chemical
produced I None
many I None
cell I None
- I None
to I None
- I None
cell I None
hernias I Disease
within I None
15 I None
minutes I None
. I None
<eof> I None

<s> O None
At I None
1 I None
day I None
their I None
number I None
was I None
reduced I None
to I None
about I None
1/10 I None
of I None
the I None
original I None
number I None
. I None
<eof> I None

<s> O None
By I None
7 I None
days I None
the I None
vessel I None
was I None
almost I None
restored I None
to I None
normal I None
. I None
<eof> I None

<s> O None
Triple I None
stimulation I None
over I None
1 I None
day I None
induced I None
more I None
severe I None
changes I None
in I None
the I None
media I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
smooth I None
muscle I None
cells I None
are I None
susceptible I None
to I None
damage I None
in I None
the I None
course I None
of I None
their I None
specific I None
function I None
. I None
<eof> I None

<s> O None
The I None
experimental I None
data I None
are I None
discussed I None
in I None
relation I None
to I None
medial I None
changes I None
observed I None
in I None
other I None
instances I None
of I None
arterial I None
spasm I Disease
. I None
<eof> I None

<s> O None
Endothelial I None
changes I None
that I None
developed I None
in I None
the I None
same I None
experimental I None
model I None
were I None
described I None
in I None
a I None
previous I None
paper I None
. I None
<eof> I None

<s> O None
Abnormalities I None
of I None
the I None
pupil I None
and I None
visual I None
- I None
evoked I None
potential I None
in I None
quinine I Chemical
amblyopia I Disease
. I None
<eof> I None

<s> O None
Total I None
blindness I Disease
with I None
a I None
transient I None
tonic I Disease
pupillary O Disease
response I None
, I None
denervation I None
supersensitivity I None
, I None
and I None
abnormal I None
visual I None
- I None
evoked I None
potentials I None
developed I None
in I None
a I None
54-year I None
- I None
old I None
man I None
after I None
the I None
use I None
of I None
quinine I Chemical
sulfate O Chemical
for I None
leg I Disease
cramps O Disease
. I None
<eof> I None

<s> O None
He I None
later I None
recovered I None
normal I None
visual I None
acuity I None
. I None
<eof> I None

<s> O None
A I None
transient I None
tonic I Disease
pupillary O Disease
response I None
, I None
denervation I None
supersensitivity I None
, I None
and I None
abnormal I None
visual I None
- I None
evoked I None
potentials I None
in I None
quinine I Chemical
toxicity I Disease
, I None
to I None
our I None
knowledge I None
, I None
have I None
not I None
been I None
previously I None
reported I None
. I None
<eof> I None

<s> O None
Suxamethonium I Chemical
-induced I None
jaw I Disease
stiffness O Disease
and I None
myalgia I Disease
associated I None
with I None
atypical I None
cholinesterase I None
: I None
case I None
report I None
. I None
<eof> I None

<s> O None
An I None
11-year I None
- I None
old I None
boy I None
was I None
given I None
halothane I Chemical
, I None
nitrous I Chemical
oxide O Chemical
and I None
oxygen I Chemical
, I None
pancuronium I Chemical
0.4 I None
mg I None
and I None
<eof> I None

<s> O None
suxamethonium I Chemical
100 I None
mg I None
for I None
induction I None
of I None
anaesthesia I None
. I None
<eof> I None

<s> O None
In I None
response I None
to I None
this I None
a I None
marked I None
jaw I Disease
stiffness O Disease
occurred I None
which I None
lasted I None
for I None
two I None
minutes I None
and I None
the I None
anaesthesia I None
were I None
terminated I None
. I None
<eof> I None

<s> O None
Four I None
hours I None
of I None
apnoea I Disease
ensued I None
and I None
he I None
suffered I None
generalized I None
severe I None
myalgia I Disease
lasting I None
for I None
one I None
week I None
. I None
<eof> I None

<s> O None
He I None
was I None
found I None
to I None
have I None
atypical I None
plasma I None
cholinesterase I None
with I None
a I None
dibucaine I Chemical
number I None
of I None
12 I None
, I None
indicating I None
homozygocity I None
. I None
<eof> I None

<s> O None
This I None
was I None
verified I None
by I None
study I None
of I None
the I None
family I None
. I None
<eof> I None

<s> O None
The I None
case I None
shows I None
that I None
prolonged I Disease
jaw O Disease
rigidity O Disease
and I None
myalgia I Disease
may I None
occur I None
after I None
suxamethonium I Chemical
in I None
patients I None
with I None
atypical I None
cholinesterase I None
despite I None
pretreatment I None
with I None
pancuronium I Chemical
. I None
<eof> I None

<s> O None
Indomethacin I Chemical
-induced I None
hyperkalemia I Disease
in I None
three I None
patients I None
with I None
gouty I Disease
arthritis O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
three I None
patients I None
in I None
whom I None
severe I None
, I None
life I None
- I None
threatening I None
hyperkalemia I Disease
and I None
renal I Disease
insufficiency O Disease
developed I None
after I None
treatment I None
of I None
acute I None
gouty I Disease
arthritis O Disease
with I None
indomethacin I Chemical
. I None
<eof> I None

<s> O None
This I None
complication I None
may I None
result I None
from I None
an I None
inhibition I None
of I None
prostaglandin I Chemical
synthesis I None
and I None
consequent I None
hyporeninemic I Disease
hypoaidosteronism O Disease
. I None
<eof> I None

<s> O None
Careful I None
attention I None
to I None
renal I None
function I None
and I None
potassium I Chemical
balance I None
in I None
patients I None
receiving I None
indomethacin I Chemical
or I None
other I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
agents I None
, I None
particularly I None
in I None
those I None
patients I None
with I None
diabetes I Disease
mellitus O Disease
or I None
preexisting I None
renal I Disease
disease O Disease
, I None
will I None
help I None
prevent I None
this I None
potentially I None
serious I None
complication I None
. I None
<eof> I None

<s> O None
Etomidate I Chemical
: I None
a I None
foreshortened I None
clinical I None
trial I None
. I None
<eof> I None

<s> O None
A I None
clinical I None
evaluation I None
of I None
etomidate I Chemical
for I None
outpatient I None
cystoscopy I None
was I None
embarked I None
upon I None
. I None
<eof> I None

<s> O None
Unpremedicated I None
patients I None
were I None
given I None
fentanyl I Chemical
1 I None
microgram I None
/ I None
kg I None
followed I None
by I None
etomidate I Chemical
0.3 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
Anaesthesia I None
was I None
maintained I None
with I None
intermittent I None
etomidate I Chemical
in I None
2 I None
- I None
4 I None
mg I None
doses I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
interviewed I None
personally I None
later I None
the I None
same I None
day I None
, I None
and I None
by I None
questionnaire I None
three I None
to I None
four I None
weeks I None
later I None
. I None
<eof> I None

<s> O None
The I None
trial I None
was I None
discontinued I None
after I None
20 I None
cases I None
because I None
of I None
an I None
unacceptable I None
incidence I None
of I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Venous I None
pain I Disease
occurred I None
in I None
68 I None
% I None
of I None
patients I None
and I None
50 I None
% I None
had I None
redness I None
, I None
pain I Disease
or I None
swelling I Disease
related I None
to I None
the I None
injection I None
site I None
, I None
in I None
some I None
cases I None
lasting I None
up I None
to I None
three I None
weeks I None
after I None
anaesthesia I None
. I None
<eof> I None

<s> O None
Skeletal I None
movements I None
occurred I None
in I None
50 I None
% I None
of I None
patients I None
; I None
30 I None
% I None
experienced I None
<eof> I None

<s> O None
respiratory I Disease
upset O Disease
, I None
one I None
sufficiently I None
severe I None
to I None
necessitate I None
abandoning I None
the I None
technique I None
. I None
<eof> I None

<s> O None
Nausea I Disease
and I None
vomiting I Disease
occurred I None
in I None
40 I None
% I None
and I None
25 I None
% I None
had I None
disturbing I None
emergence I None
psychoses I Disease
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
are I None
improved I None
by I None
fluoxetine I Chemical
. I None
<eof> I None

<s> O None
We I None
evaluated I None
the I None
severity I None
of I None
motor I Disease
disability O Disease
and I None
dyskinesias I Disease
in I None
seven I None
levodopa I Chemical
-responsive I None
patients I None
with I None
Parkinson I Disease
's O Disease
disease O Disease
after I None
an I None
acute I None
challenge I None
with I None
the I None
mixed I None
dopamine I Chemical
agonist I None
, I None
apomorphine I Chemical
, I None
before I None
and I None
after I None
the I None
administration I None
of I None
fluoxetine I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
twice I None
per I None
day I None
) I None
for I None
11 I None
+ I None
/- I None
<eof> I None

<s> O None
1 I None
days I None
. I None
<eof> I None

<s> O None
After I None
fluoxetine I Chemical
treatment I None
, I None
there I None
was I None
a I None
significant I None
47 I None
% I None
improvement I None
( I None
p I None
< I None
0.05 I None
) I None
of I None
<eof> I None

<s> O None
apomorphine I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
without I None
modification I None
of I None
parkinsonian I Disease
motor I Disease
disability O Disease
. I None
<eof> I None

<s> O None
The I None
dyskinesias I Disease
were I None
reduced I None
predominantly I None
in I None
the I None
lower I None
limbs I None
during I None
the I None
onset I None
and I None
disappearance I None
of I None
dystonic I None
dyskinesias I None
( I None
onset- I None
and I None
end I None
- I None
of I None
- I None
dose I None
dyskinesias I Disease
) I None
and I None
in I None
the I None
upper I None
limbs I None
during I None
choreic I None
mid I None
- I None
dose I None
dyskinesias I None
. I None
<eof> I None

<s> O None
The I None
results I None
suggest I None
that I None
increased I None
brain I None
serotoninergic I None
transmission I None
with I None
fluoxetine I Chemical
may I None
reduce I None
levodopa I Chemical
- I None
or I None
dopamine I Chemical
agonist I None
- I None
induced I None
dyskinesias I Disease
without I None
aggravating I None
parkinsonian I Disease
motor I Disease
disability O Disease
. I None
<eof> I None

<s> O None
A I None
large I None
population I None
- I None
based I None
follow I None
- I None
up I None
study I None
of I None
trimethoprim I Chemical
- O Chemical
sulfamethoxazole O Chemical
, I None
trimethoprim I Chemical
, I None
and I None
cephalexin I Chemical
for I None
uncommon I None
serious I None
drug I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
We I None
conducted I None
a I None
population I None
- I None
based I None
45-day I None
follow I None
- I None
up I None
study I None
of I None
232,390 I None
people I None
who I None
were I None
prescribed I None
trimethoprim I Chemical
- O Chemical
sulfamethoxazole O Chemical
<eof> I None

<s> O None
( I None
TMP I Chemical
- O Chemical
SMZ O Chemical
) I None
, I None
266,951 I None
prescribed I None
trimethoprim I Chemical
alone I None
, I None
and I None
196,397 I None
prescribed I None
cephalexin I Chemical
, I None
to I None
estimate I None
the I None
risk I None
of I None
serious I None
liver I None
, I None
blood I None
, I None
skin I None
, I None
and I None
renal I None
disorders I None
resulting I None
in I None
referral I None
or I None
hospitalization I None
associated I None
with I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
results I None
were I None
based I None
on I None
information I None
recorded I None
on I None
office I None
computers I None
by I None
selected I None
general I None
practitioners I None
in I None
the I None
United I None
Kingdom I None
, I None
together I None
with I None
a I None
review I None
of I None
clinical I None
records I None
. I None
<eof> I None

<s> O None
The I None
risk I None
of I None
clinically I None
important I None
idiopathic I None
liver I Disease
disease O Disease
was I None
similar I None
for I None
persons I None
prescribed I None
TMP I Chemical
- O Chemical
SMZ O Chemical
<eof> I None

<s> O None
( I None
5.2/100,000 I None
) I None
and I None
those I None
prescribed I None
trimethoprim I Chemical
alone I None
( I None
3.8/100,000 I None
) I None
. I None
<eof> I None

<s> O None
The I None
risk I None
for I None
those I None
prescribed I None
cephalexin I Chemical
was I None
somewhat I None
lower I None
( I None
2.0/100,000 I None
) I None
. I None
<eof> I None

<s> O None
Only I None
five I None
patients I None
experienced I None
blood I None
disorders I None
, I None
one I None
of I None
whom I None
was I None
exposed I None
to I None
TMP I Chemical
- O Chemical
SMZ O Chemical
; I None
of I None
seven I None
with I None
erythema I Disease
multiforme O Disease
and I None
Stevens I Disease
- O Disease
Johnson O Disease
syndrome O Disease
, I None
four I None
were I None
exposed I None
to I None
TMP I Chemical
- O Chemical
SMZ O Chemical
. I None
<eof> I None

<s> O None
The I None
one I None
case I None
of I None
toxic I Disease
epidermal O Disease
necrolysis O Disease
occurred I None
in I None
a I None
patient I None
who I None
took I None
cephalexin I Chemical
. I None
<eof> I None

<s> O None
Finally I None
, I None
only I None
five I None
cases I None
of I None
acute I None
parenchymal I None
renal I Disease
disease O Disease
occurred I None
, I None
none I None
likely I None
to I None
be I None
caused I None
by I None
a I None
study I None
drug I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
the I None
risk I None
of I None
the I None
serious I None
diseases I None
studied I None
is I None
small I None
for I None
the I None
three I None
agents I None
, I None
and I None
compares I None
reasonably I None
with I None
the I None
risk I None
for I None
many I None
other I None
antibiotics I None
. I None
<eof> I None

<s> O None
Clinical I None
safety I None
of I None
lidocaine I Chemical
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
STUDY I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
safety I None
of I None
lidocaine I Chemical
in I None
the I None
setting I None
of I None
cocaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
A I None
retrospective I None
, I None
multicenter I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
nine I None
university I None
, I None
university I None
- I None
affiliated I None
, I None
or I None
community I None
hospitals I None
during I None
a I None
6-year I None
period I None
( I None
total I None
of I None
117 I None
cumulative I None
hospital I None
- I None
years I None
) I None
. I None
<eof> I None

<s> O None
PARTICIPANTS I None
: I None
<eof> I None

<s> O None
Patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
MI I Disease
who I None
received I None
lidocaine I Chemical
in I None
the I None
emergency I None
department I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
29 I None
patients I None
who I None
received I None
lidocaine I Chemical
in I None
the I None
setting I None
of I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
MI I Disease
, I None
no I None
patient I None
died I None
; I None
exhibited I None
bradydysrhythmias I Disease
, I None
ventricular I Disease
tachycardia O Disease
, I None
or I None
ventricular I Disease
fibrillation O Disease
; I None
or I None
experienced I None
seizures I Disease
after I None
administration I None
of I None
lidocaine I Chemical
<eof> I None

<s> O None
( I None
95 I None
% I None
confidence I None
interval I None
, I None
0 I None
% I None
to I None
11 I None
% I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Despite I None
theoretical I None
concerns I None
that I None
lidocaine I Chemical
may I None
enhance I None
cocaine I Chemical
toxicity I Disease
, I None
the I None
use I None
of I None
lidocaine I Chemical
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
MI I Disease
was I None
not I None
associated I None
with I None
significant I None
cardiovascular I None
or I None
central I None
nervous I None
system I None
toxicity I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
3-hour I None
infusion I None
given I None
alone I None
and I None
combined I None
with I None
carboplatin I Chemical
: I None
preliminary I None
results I None
of I None
dose I None
- I None
escalation I None
trials I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
<eof> I None

<s> O None
( I None
Taxol I Chemical
; I None
Bristol I None
- I None
Myers I None
Squibb I None
Company I None
, I None
Princeton I None
, I None
NJ I None
) I None
by I None
3-hour I None
infusion I None
was I None
combined I None
with I None
carboplatin I Chemical
in I None
a I None
phase I None
I I None
/ I None
II I None
study I None
directed I None
to I None
patients I None
with I None
non I Disease
- O Disease
small O Disease
cell O Disease
lung O Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Carboplatin I Chemical
was I None
given I None
at I None
a I None
fixed I None
target I None
area I None
under I None
the I None
concentration I None
- I None
time I None
curve I None
of I None
6.0 I None
by I None
the I None
Calvert I None
formula I None
, I None
whereas I None
paclitaxel I Chemical
was I None
escalated I None
in I None
patient I None
cohorts I None
from I None
150 I None
mg I None
/ I None
m2 I None
( I None
dose I None
level I None
I I None
) I None
to I None
175 I None
, I None
200 I None
, I None
225 I None
, I None
and I None
250 I None
mg I None
/ I None
m2 I None
. I None
<eof> I None

<s> O None
The I None
225 I None
mg I None
/ I None
m2 I None
level I None
was I None
expanded I None
for I None
the I None
phase I None
II I None
study I None
since I None
the I None
highest I None
level I None
achieved I None
( I None
250 I None
mg I None
/ I None
m2 I None
) I None
required I None
modification I None
because I None
of I None
nonhematologic I None
toxicities I Disease
<eof> I None

<s> O None
( I None
arthralgia I Disease
and I None
sensory I Disease
neuropathy O Disease
) I None
. I None
<eof> I None

<s> O None
Therapeutic I None
effects I None
were I None
noted I None
at I None
all I None
dose I None
levels I None
, I None
with I None
objective I None
responses I None
in I None
17 I None
( I None
two I None
complete I None
and I None
15 I None
partial I None
regressions I None
) I None
of I None
41 I None
previously I None
untreated I None
patients I None
. I None
<eof> I None

<s> O None
Toxicities I Disease
were I None
compared I None
with I None
a I None
cohort I None
of I None
patients I None
in I None
a I None
phase I None
I I None
trial I None
of I None
paclitaxel I Chemical
alone I None
at I None
identical I None
dose I None
levels I None
. I None
<eof> I None

<s> O None
Carboplatin I Chemical
did I None
not I None
appear I None
to I None
add I None
to I None
the I None
hematologic I Disease
toxicities O Disease
observed I None
, I None
and I None
the I None
paclitaxel I Chemical
/ I None
carboplatin I Chemical
combination I None
could I None
be I None
dosed I None
every I None
3 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
dose I None
- I None
dependent I None
effect I None
of I None
misoprostol I Chemical
on I None
indomethacin I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
dysfunction O Disease
in I None
well I None
compensated I None
cirrhosis I Disease
. I None
<eof> I None

<s> O None
Misoprostol I Chemical
( I None
200 I None
micrograms I None
) I None
has I None
been I None
shown I None
to I None
acutely I None
counteract I None
the I None
indomethacin I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
dysfunction O Disease
in I None
well I None
compensated I None
cirrhotic I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
determine I None
if I None
the I None
prophylactic I None
value I None
of I None
misoprostol I Chemical
was I None
dose I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
Parameters I None
of I None
renal I None
hemodynamics I None
and I None
tubular I None
sodium I Chemical
and I None
water I None
handling I None
were I None
assessed I None
by I None
clearance I None
techniques I None
in I None
26 I None
well I None
compensated I None
<eof> I None

<s> O None
cirrhotic I Disease
patients I None
before I None
and I None
after I None
an I None
oral I None
combination I None
of I None
50 I None
mg I None
of I None
indomethacin I Chemical
and I None
various I None
doses I None
of I None
misoprostol I Chemical
. I None
<eof> I None

<s> O None
The I None
200-micrograms I None
dose I None
was I None
able I None
to I None
totally I None
abolish I None
the I None
deleterious I None
renal I None
effects I None
of I None
indomethacin I Chemical
, I None
whereas I None
the I None
800-micrograms I None
dose I None
resulted I None
in I None
significant I None
worsening I None
of I None
renal I None
hemodynamics I None
and I None
sodium I Chemical
retention I None
. I None
<eof> I None

<s> O None
These I None
changes I None
were I None
maximal I None
in I None
the I None
hour I None
immediately I None
after I None
medications I None
and I None
slowly I None
returned I None
toward I None
base I None
- I None
line I None
levels I None
thereafter I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
the I None
renal I None
protective I None
effects I None
of I None
misoprostol I Chemical
is I None
dose I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
However I None
, I None
until I None
this I None
apparent I None
ability I None
of I None
200 I None
micrograms I None
of I None
misoprostol I Chemical
to I None
prevent I None
the I None
adverse I None
effects I None
of I None
indomethacin I Chemical
on I None
renal I None
function I None
is I None
confirmed I None
with I None
chronic I None
frequent I None
dosing I None
, I None
it I None
would I None
be I None
prudent I None
to I None
avoid I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
therapy I None
in I None
patients I None
with I None
cirrhosis I Disease
. I None
<eof> I None

<s> O None
Increased I None
frequency I None
and I None
severity I None
of I None
angio I Disease
- O Disease
oedema O Disease
related I None
to I None
long I None
- I None
term I None
therapy I None
with I None
angiotensin I Chemical
- O Chemical
converting O Chemical
enzyme O Chemical
inhibitor O Chemical
in I None
two I None
patients I None
. I None
<eof> I None

<s> O None
Adverse I None
reactions I None
to I None
drugs I None
are I None
well I None
recognized I None
as I None
a I None
cause I None
of I None
acute I None
or I None
chronic I None
urticaria I Disease
, I None
and I None
angio I Disease
- O Disease
oedema O Disease
. I None
<eof> I None

<s> O None
Angiotensin I Chemical
- O Chemical
converting O Chemical
enzyme O Chemical
( O Chemical
ACE O Chemical
) O Chemical
inhibitors O Chemical
, I None
used I None
to I None
treat I None
hypertension I Disease
and I None
congestive I Disease
heart O Disease
failure O Disease
, I None
were I None
introduced I None
in I None
Europe I None
in I None
the I None
middle I None
of I None
the I None
eighties I None
, I None
and I None
the I None
use I None
of I None
these I None
drugs I None
has I None
increased I None
progressively I None
. I None
<eof> I None

<s> O None
Soon I None
after I None
the I None
introduction I None
of I None
ACE I Chemical
inhibitors O Chemical
, I None
acute I None
bouts I None
of I None
angio I Disease
- O Disease
oedema O Disease
were I None
reported I None
in I None
association I None
with I None
the I None
use I None
of I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
We I None
wish I None
to I None
draw I None
attention I None
to I None
the I None
possibility I None
of I None
adverse I None
reactions I None
to I None
ACE I Chemical
inhibitors O Chemical
after I None
long I None
- I None
term I None
use I None
and I None
in I None
patients I None
with I None
pre I None
- I None
existing I None
angio I Disease
- O Disease
oedema O Disease
. I None
<eof> I None

<s> O None
Myoclonus I Disease
associated I None
with I None
lorazepam I Chemical
therapy I None
in I None
very I None
- I None
low I None
- I None
birth I None
- I None
weight I None
infants I None
. I None
<eof> I None

<s> O None
Lorazepam I Chemical
is I None
being I None
used I None
with I None
increasing I None
frequency I None
as I None
a I None
sedative I None
in I None
the I None
newborn I None
and I None
the I None
young I None
infant I None
. I None
<eof> I None

<s> O None
Concern I None
has I None
been I None
raised I None
with I None
regard I None
to I None
the I None
safety I None
of I None
lorazepam I Chemical
in I None
this I None
age I None
group I None
, I None
especially I None
in I None
very I None
- I None
low I None
- I None
birth I None
- I None
weight I None
( I None
VLBW I None
; I None
< I None
1,500 I None
g I None
) I None
infants I None
. I None
<eof> I None

<s> O None
Three I None
young I None
infants I None
, I None
all I None
of I None
birth I None
weight I None
< I None
1,500 I None
g I None
, I None
experienced I None
<eof> I None

<s> O None
myoclonus I Disease
following I None
the I None
intravenous I None
administration I None
of I None
lorazepam I Chemical
. I None
<eof> I None

<s> O None
The I None
potential I None
<eof> I None

<s> O None
neurotoxic I Disease
effects I None
of I None
the I None
drug I None
( I None
and I None
its I None
vehicle I None
) I None
in I None
this I None
population I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Injectable I None
<eof> I None

<s> O None
lorazepam I Chemical
should I None
be I None
used I None
with I None
caution I None
in I None
VLBW I None
infants I None
. I None
<eof> I None

<s> O None
Transvenous I None
right I None
ventricular I None
pacing I None
during I None
cardiopulmonary I None
resuscitation I None
of I None
pediatric I None
patients I None
with I None
acute I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
the I None
cardiopulmonary I None
resuscitation I None
efforts I None
on I None
five I None
patients I None
who I None
presented I None
in I None
acute I None
circulatory I Disease
failure O Disease
from I None
myocardial I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Three I None
patients I None
had I None
acute I None
viral I None
myocarditis I Disease
, I None
one I None
had I None
a I None
carbamazepine I Chemical
-induced I None
acute I None
eosinophilic I None
myocarditis I None
, I None
and I None
one I None
had I None
cardiac I None
hemosiderosis I None
resulting I None
in I None
acute I None
cardiogenic I Disease
shock O Disease
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
continuously I None
monitored I None
with I None
central I None
venous I None
and I None
arterial I None
catheters I None
in I None
addition I None
to I None
routine I None
noninvasive I None
monitoring I None
. I None
<eof> I None

<s> O None
An I None
introducer I None
sheath I None
, I None
a I None
pacemaker I None
, I None
and I None
sterile I None
pacing I None
wires I None
were I None
made I None
readily I None
available I None
for I None
the I None
patients I None
, I None
should I None
the I None
need I None
arise I None
to I None
terminate I None
resistant I None
cardiac I None
dysrhythmias I Disease
. I None
<eof> I None

<s> O None
All I None
patients I None
developed I None
cardiocirculatory I None
arrest I None
associated I None
with I None
extreme I None
hypotension I Disease
and I None
dysrhythmias I Disease
within I None
the I None
first I None
48 I None
hours I None
of I None
their I None
admission I None
to I None
the I None
pediatric I None
intensive I None
care I None
unit I None
( I None
PICU I None
) I None
. I None
<eof> I None

<s> O None
Right I None
ventricular I None
pacemaker I None
wires I None
were I None
inserted I None
in I None
all I None
of I None
them I None
during I None
cardiopulmonary I None
resuscitation I None
( I None
CPR I None
) I None
. I None
<eof> I None

<s> O None
In I None
four I None
patients I None
, I None
cardiac I None
pacing I None
was I None
used I None
, I None
resulting I None
in I None
a I None
temporary I None
captured I None
rhythm I None
and I None
restoration I None
of I None
their I None
cardiac I None
output I None
. I None
<eof> I None

<s> O None
These I None
patients I None
had I None
a I None
second I None
event I None
of I None
cardiac I Disease
arrest O Disease
, I None
resulting I None
in I None
death I None
, I None
within I None
10 I None
to I None
60 I None
minutes I None
. I None
<eof> I None

<s> O None
In I None
one I None
patient I None
, I None
cardiac I None
pacing I None
was I None
not I None
used I None
, I None
because I None
he I None
converted I None
to I None
normal I None
sinus I None
rhythm I None
by I None
electrical I None
defibrillation I None
within I None
three I None
minutes I None
of I None
initiating I None
CPR I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
cardiac I None
pacing I None
during I None
resuscitative I None
efforts I None
in I None
pediatric I None
patients I None
suffering I None
from I None
acute I None
myocardial I Disease
dysfunction O Disease
may I None
not I None
have I None
long I None
- I None
term I None
value I None
in I None
and I None
of I None
itself I None
; I None
however I None
, I None
if I None
temporary I None
hemodynamic I None
stability I None
is I None
achieved I None
by I None
this I None
procedure I None
, I None
it I None
may I None
provide I None
additional I None
time I None
needed I None
to I None
institute I None
other I None
therapeutic I None
modalities I None
. I None
<eof> I None

<s> O None
Efficacy I None
and I None
safety I None
of I None
granisetron I Chemical
, I None
a I None
selective I None
5-hydroxytryptamine I Chemical
-3 I None
receptor I None
antagonist I None
, I None
in I None
the I None
prevention I None
of I None
nausea I Disease
and I None
vomiting I Disease
induced I None
by I None
high I None
- I None
dose I None
cisplatin I Chemical
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
assess I None
the I None
antiemetic I None
effects I None
and I None
safety I None
profile I None
of I None
four I None
different I None
doses I None
of I None
granisetron I Chemical
<eof> I None

<s> O None
( I None
Kytril I Chemical
; I None
SmithKline I None
Beecham I None
Pharmaceuticals I None
, I None
Philadelphia I None
, I None
PA I None
) I None
when I None
administered I None
as I None
a I None
single I None
intravenous I None
( I None
IV I None
) I None
dose I None
for I None
prophylaxis I None
of I None
cisplatin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nausea I Disease
and I None
vomiting I Disease
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
One I None
hundred I None
eighty I None
- I None
four I None
chemotherapy I None
- I None
naive I None
patients I None
receiving I None
high I None
- I None
dose I None
cisplatin I Chemical
( I None
81 I None
to I None
120 I None
mg I None
/ I None
m2 I None
) I None
were I None
randomized I None
to I None
receive I None
one I None
of I None
four I None
granisetron I Chemical
doses I None
( I None
5 I None
, I None
10 I None
, I None
20 I None
, I None
or I None
40 I None
micrograms I None
/ I None
kg I None
) I None
administered I None
before I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
observed I None
on I None
an I None
inpatient I None
basis I None
for I None
18 I None
to I None
24 I None
hours I None
, I None
and I None
vital I None
signs I None
, I None
nausea I Disease
, I None
vomiting I Disease
, I None
retching I None
, I None
and I None
appetite I None
were I None
assessed I None
. I None
<eof> I None

<s> O None
Safety I None
analyses I None
included I None
incidence I None
of I None
adverse I None
experiences I None
and I None
laboratory I None
parameter I None
changes I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
After I None
granisetron I Chemical
doses I None
of I None
5 I None
, I None
10 I None
, I None
20 I None
, I None
and I None
40 I None
micrograms I None
/ I None
kg I None
, I None
a I None
major I None
response I None
( I None
< I None
or I None
= I None
two I None
vomiting I Disease
or I None
retching I None
episodes I None
, I None
and I None
no I None
antiemetic I None
rescue I None
) I None
was I None
recorded I None
in I None
23 I None
% I None
, I None
57 I None
% I None
, I None
58 I None
% I None
, I None
and I None
60 I None
% I None
of I None
patients I None
, I None
respectively I None
, I None
and I None
a I None
complete I None
response I None
( I None
no I None
vomiting I Disease
or I None
retching I None
, I None
and I None
no I None
antiemetic I None
rescue I None
) I None
in I None
18 I None
% I None
, I None
41 I None
% I None
, I None
40 I None
% I None
, I None
and I None
47 I None
% I None
of I None
patients I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
statistically I None
longer I None
time I None
to I None
first I None
episode I None
of I None
nausea I Disease
( I None
P I None
= I None
.0015 I None
) I None
and I None
vomiting I Disease
<eof> I None

<s> O None
( I None
P I None
= I None
.0001 I None
) I None
, I None
and I None
fewer I None
patients I None
were I None
administered I None
additional I None
antiemetic I None
medication I None
in I None
the I None
10-micrograms I None
/ I None
kg I None
dosing I None
groups I None
than I None
in I None
the I None
5-micrograms I None
/ I None
kg I None
dosing I None
group I None
. I None
<eof> I None

<s> O None
As I None
granisetron I Chemical
dose I None
increased I None
, I None
appetite I None
return I None
increased I None
( I None
P I None
= I None
.040 I None
) I None
. I None
<eof> I None

<s> O None
Headache I Disease
was I None
the I None
most I None
frequently I None
reported I None
adverse I None
event I None
( I None
20 I None
% I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
A I None
single I None
10- I None
, I None
20- I None
, I None
or I None
40-micrograms I None
/ I None
kg I None
dose I None
of I None
<eof> I None

<s> O None
granisetron I Chemical
was I None
effective I None
in I None
controlling I None
vomiting I Disease
in I None
57 I None
% I None
to I None
60 I None
% I None
of I None
patients I None
who I None
received I None
cisplatin I Chemical
at I None
doses I None
greater I None
than I None
81 I None
mg I None
/ I None
m2 I None
and I None
totally I None
prevented I None
vomiting I Disease
in I None
40 I None
% I None
to I None
47 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
statistically I None
significant I None
differences I None
in I None
efficacy I None
between I None
the I None
10-micrograms I None
/ I None
kg I None
dose I None
and I None
the I None
20- I None
and I None
40-micrograms I None
/ I None
kg I None
doses I None
. I None
<eof> I None

<s> O None
Granisetron I Chemical
was I None
well I None
tolerated I None
at I None
all I None
doses I None
. I None
<eof> I None

<s> O None
Adverse I None
interaction I None
between I None
clonidine I Chemical
and I None
verapamil I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
two I None
cases I None
of I None
a I None
possible I None
adverse I None
interaction I None
between I None
clonidine I Chemical
and I None
verapamil I Chemical
resulting I None
in I None
atrioventricular I Disease
( O Disease
AV O Disease
) O Disease
block O Disease
in I None
both I None
patients I None
and I None
severe I None
hypotension I Disease
in I None
one I None
patient I None
. I None
<eof> I None

<s> O None
CASE I None
SUMMARIES I None
: I None
<eof> I None

<s> O None
A I None
54-year I None
- I None
old I None
woman I None
with I None
hyperaldosteronism I Disease
was I None
treated I None
with I None
verapamil I Chemical
<eof> I None

<s> O None
480 I None
mg I None
/ I None
d I None
and I None
spironolactone I Chemical
100 I None
mg I None
/ I None
d I None
. I None
<eof> I None

<s> O None
After I None
the I None
addition I None
of I None
a I None
minimal I None
dose I None
of I None
clonidine I Chemical
( I None
0.15 I None
mg I None
bid I None
) I None
, I None
she I None
developed I None
complete I None
AV I Disease
block O Disease
and I None
severe I None
hypotension I Disease
, I None
which I None
resolved I None
upon I None
cessation I None
of I None
all I None
medications I None
. I None
<eof> I None

<s> O None
A I None
65-year I None
- I None
old I None
woman I None
was I None
treated I None
with I None
extended I None
- I None
release I None
verapamil I Chemical
240 I None
mg I None
/ I None
d I None
. I None
<eof> I None

<s> O None
After I None
the I None
addition I None
of I None
clonidine I Chemical
0.15 I None
mg I None
bid I None
she I None
developed I None
complete I None
AV I Disease
block O Disease
, I None
which I None
resolved I None
after I None
all I None
therapy I None
was I None
stopped I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
An I None
adverse I None
interaction I None
between I None
clonidine I Chemical
and I None
verapamil I Chemical
has I None
not I None
been I None
reported I None
previously I None
. I None
<eof> I None

<s> O None
We I None
describe I None
two I None
such I None
cases I None
and I None
discuss I None
the I None
various I None
mechanisms I None
that I None
might I None
cause I None
such I None
an I None
interaction I None
. I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
acquainted I None
with I None
this I None
possibly I None
fatal I None
interaction I None
between I None
two I None
commonly I None
used I None
antihypertensive I None
drugs I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Caution I None
is I None
recommended I None
in I None
combining I None
clonidine I Chemical
and I None
verapamil I Chemical
therapy I None
, I None
even I None
in I None
patients I None
who I None
do I None
not I None
have I None
sinus I None
or I None
AV I None
node I None
dysfunction I None
. I None
<eof> I None

<s> O None
The I None
two I None
drugs I None
may I None
act I None
synergistically I None
on I None
both I None
the I None
AV I None
node I None
and I None
the I None
peripheral I None
circulation I None
. I None
<eof> I None

<s> O None
Pharmacological I None
studies I None
on I None
a I None
new I None
dihydrothienopyridine I Chemical
calcium O Chemical
antagonist I None
, I None
S-312-d I Chemical
. I None
<eof> I None

<s> O None
5th I None
communication I None
: I None
anticonvulsant I None
effects I None
in I None
mice I None
. I None
<eof> I None

<s> O None
S-312 I Chemical
, I None
S-312-d I Chemical
, I None
but I None
not I None
S-312-l I Chemical
, I None
L I None
- I None
type I None
calcium I Chemical
channel I None
antagonists I None
, I None
showed I None
anticonvulsant I None
effects I None
on I None
the I None
audiogenic I Disease
tonic O Disease
convulsions O Disease
in I None
DBA/2 I None
mice I None
; I None
and I None
their I None
ED50 I None
values I None
were I None
18.4 I None
( I None
12.8 I None
- I None
27.1 I None
) I None
<eof> I None

<s> O None
mg I None
/ I None
kg I None
, I None
p.o I None
. I None
<eof> I None

<s> O None
and I None
15.0 I None
( I None
10.2 I None
- I None
23.7 I None
) I None
<eof> I None

<s> O None
mg I None
/ I None
kg I None
, I None
p.o I None
. I None
, I None
respectively I None
, I None
while I None
that I None
of I None
<eof> I None

<s> O None
flunarizine I Chemical
was I None
34.0 I None
( I None
26.0 I None
- I None
44.8 I None
) I None
mg I None
/ I None
kg I None
, I None
p.o I None
. I None
<eof> I None

<s> O None
Although I None
moderate I None
anticonvulsant I None
effects I None
of I None
S-312-d I Chemical
in I None
higher I None
doses I None
were I None
observed I None
against I None
the I None
clonic I None
convulsions I Disease
induced I None
by I None
pentylenetetrazole I Chemical
<eof> I None

<s> O None
( I None
85 I None
mg I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
or I None
bemegride I Chemical
( I None
40 I None
mg I None
/ I None
kg I None
, I None
s.c I None
. I None
) I None
, I None
no I None
effects I None
were I None
observed I None
in I None
convulsions I Disease
induced I None
by I None
N I Chemical
- O Chemical
methyl O Chemical
- O Chemical
D O Chemical
- O Chemical
aspartate O Chemical
, I None
picrotoxin I Chemical
, I None
or I None
electroshock I None
in I None
Slc I None
: I None
ddY I None
mice I None
. I None
<eof> I None

<s> O None
S-312-d I Chemical
may I None
be I None
useful I None
in I None
the I None
therapy I None
of I None
certain I None
types I None
of I None
human I None
epilepsy I Disease
. I None
<eof> I None

<s> O None
Transmural I None
myocardial I Disease
infarction O Disease
with I None
sumatriptan I Chemical
. I None
<eof> I None

<s> O None
For I None
sumatriptan I Chemical
, I None
tightness I None
in I None
the I None
chest I None
caused I None
by I None
an I None
unknown I None
mechanism I None
has I None
been I None
reported I None
in I None
3 I None
- I None
5 I None
% I None
of I None
users I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
47-year I None
- I None
old I None
woman I None
with I None
an I None
acute I None
myocardial I Disease
infarction O Disease
after I None
administration I None
of I None
sumatriptan I Chemical
<eof> I None

<s> O None
6 I None
mg I None
subcutaneously I None
for I None
cluster I Disease
headache O Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
no I None
history I None
of I None
underlying I None
ischaemic I Disease
heart O Disease
disease O Disease
or I None
Prinzmetal I Disease
's O Disease
angina O Disease
. I None
<eof> I None

<s> O None
She I None
recovered I None
without I None
complications I None
. I None
<eof> I None

<s> O None
Flumazenil I Chemical
induces I None
<eof> I None

<s> O None
seizures I Disease
and I None
death I None
in I None
mixed I None
cocaine I Chemical
- I None
diazepam I Chemical
intoxications I None
. I None
<eof> I None

<s> O None
STUDY I None
HYPOTHESIS I None
: I None
Administration I None
of I None
the I None
benzodiazepine I Chemical
antagonist I None
flumazenil I Chemical
may I None
unmask I None
seizures I Disease
in I None
mixed I None
cocaine I Chemical
- I None
benzodiazepine I Chemical
intoxication I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Male I None
Sprague I None
- I None
Dawley I None
rats I None
received I None
100 I None
mg I None
/ I None
kg I None
cocaine I Chemical
IP I None
alone I None
, I None
5 I None
mg I None
/ I None
kg I None
diazepam I Chemical
alone I None
, I None
or I None
a I None
combination I None
of I None
diazepam I Chemical
and I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
Three I None
minutes I None
later I None
, I None
groups I None
were I None
challenged I None
with I None
vehicle I None
or I None
flumazenil I Chemical
5 I None
or I None
10 I None
mg I None
/ I None
kg I None
IP I None
. I None
<eof> I None

<s> O None
Animal I None
behavior I None
, I None
seizures I Disease
( I None
time I None
to I None
and I None
incidence I None
) I None
, I None
death I None
( I None
time I None
to I None
and I None
incidence I None
) I None
, I None
and I None
cortical I None
EEG I None
tracings I None
were I None
recorded I None
. I None
<eof> I None

<s> O None
INTERVENTIONS I None
: I None
<eof> I None

<s> O None
Administration I None
of I None
flumazenil I Chemical
to I None
animals I None
after I None
they I None
had I None
received I None
a I None
combination I None
dose I None
of I None
cocaine I Chemical
and I None
diazepam I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
group I None
1 I None
, I None
animals I None
received I None
cocaine I Chemical
followed I None
by I None
vehicle I None
. I None
<eof> I None

<s> O None
This I None
resulted I None
in I None
100 I None
% I None
developing I None
seizures I Disease
and I None
death I None
. I None
<eof> I None

<s> O None
Group I None
2 I None
received I None
diazepam I Chemical
alone I None
followed I None
by I None
vehicle I None
. I None
<eof> I None

<s> O None
Animals I None
became I None
somnolent I None
and I None
none I None
died I None
. I None
<eof> I None

<s> O None
Group I None
3 I None
received I None
<eof> I None

<s> O None
diazepam I Chemical
followed I None
by I None
5 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
flumazenil I Chemical
. I None
<eof> I None

<s> O None
Animals I None
became I None
somnolent I None
after I None
diazepam I Chemical
and I None
then I None
active I None
after I None
flumazenil I Chemical
administration I None
. I None
<eof> I None

<s> O None
In I None
group I None
4 I None
, I None
a I None
combination I None
of I None
cocaine I Chemical
and I None
diazepam I Chemical
was I None
administered I None
simultaneously I None
. I None
<eof> I None

<s> O None
This I None
resulted I None
in I None
no I None
overt I None
or I None
EEG I None
- I None
detectable I None
<eof> I None

<s> O None
seizures I Disease
and I None
a I None
50 I None
% I None
incidence I None
of I None
death I None
. I None
<eof> I None

<s> O None
Group I None
5 I None
received I None
a I None
similar I None
combination I None
of I None
cocaine I Chemical
and I None
diazepam I Chemical
, I None
followed I None
later I None
by I None
5 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
flumazenil I Chemical
. I None
<eof> I None

<s> O None
This I None
resulted I None
in I None
an I None
increased I None
incidence I None
of I None
seizures I Disease
, I None
90 I None
% I None
( I None
P I None
< I None
.01 I None
) I None
, I None
and I None
death I None
, I None
100 I None
% I None
( I None
P I None
< I None
or I None
= I None
.01 I None
) I None
, I None
compared I None
with I None
group I None
4 I None
. I None
<eof> I None

<s> O None
Group I None
6 I None
received I None
cocaine I Chemical
and I None
diazepam I Chemical
followed I None
by I None
10 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
flumazenil I Chemical
. I None
<eof> I None

<s> O None
This I None
also I None
resulted I None
in I None
an I None
increased I None
incidence I None
of I None
seizures I Disease
, I None
90 I None
% I None
( I None
P I None
< I None
or I None
= I None
.01 I None
) I None
, I None
and I None
death I None
, I None
90 I None
% I None
( I None
P I None
< I None
or I None
= I None
.05 I None
) I None
, I None
compared I None
with I None
group I None
4 I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Flumazenil I Chemical
can I None
unmask I None
seizures I Disease
and I None
increase I None
the I None
incidence I None
of I None
death I None
in I None
a I None
model I None
of I None
combined I None
cocaine I Chemical
- I None
diazepam I Chemical
intoxications I None
. I None
<eof> I None

<s> O None
Mechanisms I None
for I None
protective I None
effects I None
of I None
free I None
radical I None
scavengers I None
on I None
gentamicin I Chemical
-mediated I None
nephropathy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Studies I None
were I None
performed I None
to I None
examine I None
the I None
mechanisms I None
for I None
the I None
protective I None
effects I None
of I None
free I None
radical I None
scavengers I None
on I None
gentamicin I Chemical
<eof> I None

<s> O None
( I None
GM I Chemical
) I None
-mediated I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
GM I Chemical
at I None
40 I None
mg I None
/ I None
kg I None
sc I None
for I None
13 I None
days I None
to I None
rats I None
induced I None
a I None
significant I None
reduction I None
in I None
renal I None
blood I None
flow I None
( I None
RBF I None
) I None
and I None
inulin I None
clearance I None
( I None
CIn I None
) I None
as I None
well I None
as I None
marked I None
tubular I Disease
damage O Disease
. I None
<eof> I None

<s> O None
A I None
significant I None
reduction I None
in I None
urinary I None
guanosine I Chemical
3',5'-cyclic O Chemical
monophosphate O Chemical
<eof> I None

<s> O None
( I None
cGMP I Chemical
) I None
excretion I None
and I None
a I None
significant I None
increase I None
in I None
renal I None
cortical I None
renin I None
and I None
endothelin-1 I None
contents I None
were I None
also I None
observed I None
in I None
GM I Chemical
-mediated I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
Superoxide I Chemical
dismutase I None
( I None
SOD I None
) I None
or I None
dimethylthiourea I Chemical
<eof> I None

<s> O None
( I None
DMTU I Chemical
) I None
significantly I None
lessened I None
the I None
GM I Chemical
-induced I None
decrement I None
in I None
CIn I None
. I None
<eof> I None

<s> O None
The I None
SOD I None
- I None
induced I None
increase I None
in I None
glomerular I None
filtration I None
rate I None
was I None
associated I None
with I None
a I None
marked I None
improvement I None
in I None
RBF I None
, I None
an I None
increase I None
in I None
urinary I None
cGMP I Chemical
excretion I None
, I None
and I None
a I None
decrease I None
in I None
renal I None
renin I None
and I None
endothelin-1 I None
content I None
. I None
<eof> I None

<s> O None
SOD I None
did I None
not I None
attenuate I None
the I None
tubular I Disease
damage O Disease
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
DMTU I Chemical
significantly I None
reduced I None
the I None
tubular I Disease
damage O Disease
and I None
lipid I None
peroxidation I None
, I None
but I None
it I None
did I None
not I None
affect I None
renal I None
hemodynamics I None
and I None
vasoactive I None
substances I None
. I None
<eof> I None

<s> O None
Neither I None
SOD I None
nor I None
DMTU I Chemical
affected I None
the I None
renal I None
cortical I None
GM I Chemical
content I None
in I None
GM I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
1 I None
) I None
both I None
SOD I None
and I None
DMTU I Chemical
have I None
protective I None
effects I None
on I None
GM I Chemical
<eof> I None

<s> O None
-mediated I None
<eof> I None

<s> O None
nephropathy I Disease
, I None
2 I None
) I None
the I None
mechanisms I None
for I None
the I None
protective I None
effects I None
differ I None
for I None
SOD I None
and I None
DMTU I Chemical
, I None
and I None
3 I None
) I None
superoxide I Chemical
anions I None
play I None
a I None
critical I None
role I None
in I None
GM I Chemical
<eof> I None

<s> O None
-induced I None
renal I None
vasoconstriction I None
. I None
<eof> I None

<s> O None
Assessment I None
of I None
cardiomyocyte I None
DNA I None
synthesis I None
during I None
hypertrophy I Disease
in I None
adult I None
mice I None
. I None
<eof> I None

<s> O None
The I None
ability I None
of I None
cardiomyocytes I None
to I None
synthesize I None
DNA I None
in I None
response I None
to I None
experimentally I None
induced I None
cardiac I Disease
hypertrophy O Disease
was I None
assessed I None
in I None
adult I None
mice I None
. I None
<eof> I None

<s> O None
Isoproterenol I Chemical
delivered I None
by I None
osmotic I None
minipump I None
implantation I None
in I None
adult I None
C3Heb I None
/ I None
FeJ I None
mice I None
resulted I None
in I None
a I None
46 I None
% I None
increase I None
in I None
heart I None
weight I None
and I None
a I None
19.3 I None
% I None
increase I None
in I None
cardiomyocyte I None
area I None
. I None
<eof> I None

<s> O None
No I None
DNA I None
synthesis I None
, I None
as I None
assessed I None
by I None
autoradiographic I None
analysis I None
of I None
isolated I None
cardiomyocytes I None
, I None
was I None
observed I None
in I None
control I None
or I None
hypertrophic I Disease
hearts O Disease
. I None
<eof> I None

<s> O None
A I None
survey I None
of I None
15 I None
independent I None
inbred I None
strains I None
of I None
mice I None
revealed I None
that I None
ventricular I None
cardiomyocyte I None
nuclear I None
number I None
ranged I None
from I None
3 I None
to I None
13 I None
% I None
mononucleate I None
, I None
suggesting I None
that I None
cardiomyocyte I None
terminal I None
differentiation I None
is I None
influenced I None
directly I None
or I None
indirectly I None
by I None
genetic I None
background I None
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
the I None
capacity I None
for I None
reactive I None
DNA I None
synthesis I None
was I None
also I None
subject I None
to I None
genetic I None
regulation I None
, I None
cardiac I Disease
hypertrophy O Disease
was I None
induced I None
in I None
the I None
strains I None
of I None
mice I None
comprising I None
the I None
extremes I None
of I None
the I None
nuclear I None
number I None
survey I None
. I None
<eof> I None

<s> O None
These I None
data I None
indicate I None
that I None
adult I None
mouse I None
atrial I None
and I None
ventricular I None
cardiomyocytes I None
do I None
not I None
synthesize I None
DNA I None
in I None
response I None
to I None
isoproterenol I Chemical
-induced I None
cardiac I Disease
hypertrophy O Disease
. I None
<eof> I None

<s> O None
Central I None
cardiovascular I None
effects I None
of I None
AVP I Chemical
and I None
ANP I None
in I None
normotensive I None
and I None
spontaneously I None
hypertensive I Disease
rats I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
compare I None
influence I None
of I None
central I None
arginine I Chemical
vasopressin O Chemical
( I None
AVP I Chemical
) I None
and I None
of I None
atrial I None
natriuretic I None
peptide I None
( I None
ANP I None
) I None
on I None
control I None
of I None
arterial I None
blood I None
pressure I None
( I None
MAP I None
) I None
and I None
heart I None
rate I None
( I None
HR I None
) I None
in I None
normotensive I None
( I None
WKY I None
) I None
and I None
spontaneously I None
hypertensive I Disease
( I None
SHR I None
) I None
rats I None
. I None
<eof> I None

<s> O None
Three I None
series I None
of I None
experiments I None
were I None
performed I None
on I None
30 I None
WKY I None
and I None
30 I None
SHR I None
, I None
chronically I None
instrumented I None
with I None
guide I None
tubes I None
in I None
the I None
lateral I None
ventricle I None
( I None
LV I None
) I None
and I None
arterial I None
and I None
venous I None
catheters I None
. I None
<eof> I None

<s> O None
MAP I None
and I None
HR I None
were I None
monitored I None
before I None
and I None
after I None
i.v I None
. I None
<eof> I None

<s> O None
injections I None
of I None
either I None
vehicle I None
or I None
1 I None
, I None
10 I None
and I None
50 I None
ng I None
of I None
AVP I Chemical
and I None
25 I None
, I None
125 I None
and I None
500 I None
ng I None
of I None
ANP I None
. I None
<eof> I None

<s> O None
Sensitivity I None
of I None
cardiac I None
component I None
of I None
baroreflex I None
( I None
CCB I None
) I None
, I None
expressed I None
as I None
a I None
slope I None
of I None
the I None
regression I None
line I None
was I None
determined I None
from I None
relationships I None
between I None
systolic I None
arterial I None
pressure I None
( I None
SAP I None
) I None
and I None
HR I None
period I None
( I None
HRp I None
) I None
during I None
phenylephrine I Chemical
<eof> I None

<s> O None
( I None
Phe I Chemical
) I None
-induced I None
<eof> I None

<s> O None
hypertension I Disease
and I None
sodium I Chemical
nitroprusside O Chemical
<eof> I None

<s> O None
( I None
SN I Chemical
) I None
-induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
CCB I None
was I None
measured I None
before I None
and I None
after I None
administration I None
of I None
either I None
vehicle I None
, I None
AVP I Chemical
, I None
ANP I None
, I None
or I None
both I None
peptides I None
together I None
. I None
<eof> I None

<s> O None
Increases I None
of I None
MAP I None
occurred I None
after I None
LV I None
administration I None
of I None
1 I None
, I None
10 I None
and I None
50 I None
ng I None
of I None
AVP I Chemical
in I None
WKY I None
and I None
of I None
10 I None
and I None
50 I None
ng I None
in I None
SHR I None
. I None
<eof> I None

<s> O None
ANP I None
did I None
not I None
cause I None
significant I None
changes I None
in I None
MAP I None
in I None
both I None
strains I None
as I None
compared I None
to I None
vehicle I None
, I None
but I None
it I None
abolished I None
AVP I Chemical
-induced I None
MAP I None
increase I None
in I None
WKY I None
and I None
SHR I None
. I None
<eof> I None

<s> O None
CCB I None
was I None
reduced I None
in I None
WKY I None
and I None
SHR I None
after I None
LV I None
administration I None
of I None
AVP I Chemical
during I None
SN I Chemical
-induced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
In I None
SHR I None
but I None
not I None
in I None
WKY I None
administration I None
of I None
ANP I None
, I None
AVP I Chemical
and I None
ANP I None
+ I None
AVP I Chemical
decreased I None
CCB I None
during I None
Phe I Chemical
-induced I None
MAP I None
elevation I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
centrally I None
applied I None
AVP I Chemical
and I None
ANP I None
exert I None
differential I None
effects I None
on I None
blood I None
pressure I None
and I None
baroreflex I None
control I None
of I None
heart I None
rate I None
in I None
WKY I None
and I None
SHR I None
and I None
suggest I None
interaction I None
of I None
these I None
two I None
peptides I None
in I None
blood I None
pressure I None
regulation I None
at I None
the I None
level I None
of I None
central I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
Cutaneous I None
exposure I None
to I None
warfarin I Chemical
<eof> I None

<s> O None
-like I None
anticoagulant I None
causing I None
an I None
intracerebral I Disease
hemorrhage O Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
intercerebral I None
hematoma I Disease
due I None
to I None
warfarin I Chemical
-induced I None
coagulopathy I Disease
is I None
presented I None
. I None
<eof> I None

<s> O None
The I None
39-year I None
- I None
old I None
woman I None
had I None
spread I None
a I None
warfarin I Chemical
-type I None
<eof> I None

<s> O None
rat I None
poison I None
around I None
her I None
house I None
weekly I None
using I None
her I None
bare I None
hands I None
, I None
with I None
no I None
washing I None
post I None
application I None
. I None
<eof> I None

<s> O None
Percutaneous I None
absorption I None
of I None
warfarin I Chemical
causing I None
coagulopathy I Disease
, I None
reported I None
three I None
times I None
in I None
the I None
past I None
, I None
is I None
a I None
significant I None
risk I None
if I None
protective I None
measures I None
, I None
such I None
as I None
gloves I None
, I None
are I None
not I None
used I None
. I None
<eof> I None

<s> O None
An I None
adverse I None
drug I None
interaction I None
with I None
piroxicam I Chemical
, I None
which I None
she I None
took I None
occasionally I None
, I None
may I None
have I None
exacerbated I None
the I None
coagulopathy I Disease
. I None
<eof> I None

<s> O None
Pediatric I None
heart I None
transplantation I None
without I None
chronic I None
maintenance I None
steroids I Chemical
. I None
<eof> I None

<s> O None
From I None
1986 I None
to I None
February I None
1993 I None
, I None
40 I None
children I None
aged I None
2 I None
months I None
to I None
18 I None
years I None
( I None
average I None
age I None
10.4 I None
+ I None
/- I None
<eof> I None

<s> O None
5.8 I None
years I None
) I None
underwent I None
heart I None
transplantation I None
. I None
<eof> I None

<s> O None
Indications I None
for I None
transplantation I None
were I None
idiopathic I Disease
cardiomyopathy O Disease
( I None
52 I None
% I None
) I None
, I None
congenital I Disease
heart O Disease
disease O Disease
<eof> I None

<s> O None
( I None
35 I None
% I None
) I None
with I None
and I None
without I None
prior I None
repair I None
( I None
71 I None
% I None
and I None
29 I None
% I None
, I None
respectively I None
) I None
, I None
hypertrophic I Disease
cardiomyopathy O Disease
( I None
5 I None
% I None
) I None
, I None
valvular I Disease
heart O Disease
disease O Disease
<eof> I None

<s> O None
( I None
3 I None
% I None
) I None
, I None
and I None
doxorubicin I Chemical
cardiomyopathy I Disease
<eof> I None

<s> O None
( I None
5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
managed I None
with I None
cyclosporine I Chemical
and I None
azathioprine I Chemical
. I None
<eof> I None

<s> O None
No I None
prophylaxis I None
with I None
antilymphocyte I None
globulin I None
was I None
used I None
. I None
<eof> I None

<s> O None
Steroids I Chemical
were I None
given I None
to I None
39 I None
% I None
of I None
patients I None
for I None
refractory I None
rejection I None
, I None
but I None
weaning I None
was I None
always I None
attempted I None
and I None
generally I None
successful I None
( I None
64 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
( I None
14 I None
% I None
) I None
received I None
maintenance I None
steroids I Chemical
. I None
<eof> I None

<s> O None
Four I None
patients I None
died I None
in I None
the I None
perioperative I None
period I None
and I None
one I None
died I None
4 I None
months I None
later I None
. I None
<eof> I None

<s> O None
There I None
have I None
been I None
no I None
deaths I None
related I None
to I None
rejection I None
or I None
infection I Disease
. I None
<eof> I None

<s> O None
Average I None
follow I None
- I None
up I None
was I None
36 I None
+ I None
/- I None
<eof> I None

<s> O None
19 I None
months I None
( I None
range I None
1 I None
to I None
65 I None
months I None
) I None
. I None
<eof> I None

<s> O None
Cumulative I None
survival I None
is I None
88 I None
% I None
at I None
5 I None
years I None
. I None
<eof> I None

<s> O None
In I None
patients I None
less I None
than I None
7 I None
years I None
of I None
age I None
, I None
rejection I None
was I None
monitored I None
noninvasively I None
. I None
<eof> I None

<s> O None
In I None
the I None
first I None
postoperative I None
month I None
, I None
89 I None
% I None
of I None
patients I None
were I None
treated I None
for I None
rejection I None
. I None
<eof> I None

<s> O None
Freedom I None
from I None
serious I None
infections I Disease
was I None
83 I None
% I None
at I None
1 I None
month I None
and I None
65 I None
% I None
at I None
1 I None
year I None
. I None
<eof> I None

<s> O None
Cytomegalovirus I Disease
infections O Disease
were I None
treated I None
successfully I None
with I None
ganciclovir I Chemical
in I None
11 I None
patients I None
. I None
<eof> I None

<s> O None
No I None
impairment I None
of I None
growth I None
was I None
observed I None
in I None
children I None
who I None
underwent I None
transplantation I None
compared I None
with I None
a I None
control I None
population I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
one I None
patients I None
( I None
60 I None
% I None
) I None
have I None
undergone I None
annual I None
catheterizations I None
and I None
no I None
sign I None
of I None
graft I None
atherosclerosis I Disease
has I None
been I None
observed I None
. I None
<eof> I None

<s> O None
Seizures I Disease
occurred I None
in I None
five I None
patients I None
( I None
14 I None
% I None
) I None
and I None
hypertension I Disease
was I None
treated I None
in I None
10 I None
patients I None
( I None
28 I None
% I None
) I None
. I None
<eof> I None

<s> O None
No I None
patient I None
was I None
disabled I None
and I None
no I None
lymphoproliferative I Disease
disorder O Disease
was I None
observed.(ABSTRACT I None
TRUNCATED I None
<eof> I None

<s> O None
AT I None
250 I None
WORDS I None
) I None
<eof> I None

<s> O None
Delirium I Disease
during I None
fluoxetine I Chemical
treatment I None
. I None
<eof> I None

<s> O None
A I None
case I None
report I None
. I None
<eof> I None

<s> O None
The I None
correlation I None
between I None
high I None
serum I None
tricyclic I None
antidepressant I None
concentrations I None
and I None
central I None
nervous I None
system I None
side I None
effects I None
has I None
been I None
well I None
established I None
. I None
<eof> I None

<s> O None
Only I None
a I None
few I None
reports I None
exist I None
, I None
however I None
, I None
on I None
the I None
relationship I None
between I None
the I None
serum I None
concentrations I None
of I None
selective I None
serotonin I Chemical
reuptake I None
inhibitors I None
( I None
SSRIs I None
) I None
and I None
their I None
toxic I None
effects I None
. I None
<eof> I None

<s> O None
In I None
some I None
cases I None
, I None
a I None
high I None
serum I None
concentration I None
of I None
citalopram I Chemical
<eof> I None

<s> O None
( I None
> I None
600 I None
nmol I None
/ I None
L I None
) I None
in I None
elderly I None
patients I None
has I None
been I None
associated I None
with I None
increased I None
somnolence I Disease
and I None
movement I Disease
difficulties O Disease
. I None
<eof> I None

<s> O None
Widespread I None
cognitive I Disease
disorders O Disease
, I None
such I None
as I None
delirium I Disease
, I None
have I None
not I None
been I None
previously I None
linked I None
with I None
high I None
blood I None
levels I None
of I None
SSRIs I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
, I None
we I None
describe I None
a I None
patient I None
with I None
acute I None
hyperkinetic I Disease
delirium I Disease
connected I None
with I None
a I None
high I None
serum I None
total I None
fluoxetine I Chemical
<eof> I None

<s> O None
( I None
fluoxetine I Chemical
plus I None
desmethylfluoxetine I Chemical
) I None
concentration I None
. I None
<eof> I None

<s> O None
Pulmonary I Disease
edema O Disease
and I None
shock I Disease
after I None
high I None
- I None
dose I None
aracytine I Chemical
- O Chemical
C O Chemical
for I None
lymphoma I Disease
; I None
possible I None
role I None
of I None
TNF I None
- I None
alpha I None
and I None
PAF I None
. I None
<eof> I None

<s> O None
Four I None
out I None
of I None
23 I None
consecutive I None
patients I None
treated I None
with I None
high I None
- I None
dose I None
Ara I Chemical
- O Chemical
C O Chemical
for I None
lymphomas I Disease
in I None
our I None
institution I None
developed I None
a I None
strikingly I None
similar I None
syndrome I None
during I None
the I None
perfusion I None
. I None
<eof> I None

<s> O None
It I None
was I None
characterized I None
by I None
the I None
onset I None
of I None
fever I Disease
, I None
diarrhea I Disease
, I None
shock I Disease
, I None
pulmonary I Disease
edema O Disease
, I None
acute I Disease
renal O Disease
failure O Disease
, I None
metabolic I Disease
acidosis O Disease
, I None
weight I Disease
gain O Disease
and I None
leukocytosis I Disease
. I None
<eof> I None

<s> O None
Thorough I None
bacteriological I None
screening I None
failed I None
to I None
provide I None
evidence I None
of I None
infection I Disease
. I None
<eof> I None

<s> O None
Sequential I None
biological I None
assays I None
of I None
IL-1 I None
, I None
IL-2 I None
, I None
TNF I None
and I None
PAF I None
were I None
performed I None
during I None
Ara I Chemical
- O Chemical
C O Chemical
infusion I None
to I None
ten I None
patients I None
, I None
including I None
the I None
four I None
who I None
developed I None
the I None
syndrome I None
. I None
<eof> I None

<s> O None
TNF I None
and I None
PAF I None
activity I None
was I None
found I None
in I None
the I None
serum I None
of I None
respectively I None
two I None
and I None
four I None
of I None
the I None
cases I None
, I None
but I None
not I None
in I None
the I None
six I None
controls I None
. I None
<eof> I None

<s> O None
As I None
TNF I None
and I None
PAF I None
are I None
thought I None
to I None
be I None
involved I None
in I None
the I None
development I None
of I None
septic I None
shock I Disease
and I None
adult I Disease
respiratory O Disease
distress O Disease
syndrome O Disease
, I None
we I None
hypothesize I None
that I None
high I None
- I None
dose I None
Ara I Chemical
- O Chemical
C O Chemical
may I None
be I None
associated I None
with I None
cytokine I None
release I None
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
clentiazem I Chemical
against I None
epinephrine I Chemical
-induced I None
cardiac I Disease
injury O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
clentiazem I Chemical
, I None
a I None
1,5-benzothiazepine I Chemical
calcium I Chemical
antagonist I None
, I None
on I None
epinephrine I Chemical
-induced I None
cardiomyopathy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
With I None
2-week I None
chronic I None
epinephrine I Chemical
infusion I None
, I None
16 I None
of I None
30 I None
rats I None
died I None
within I None
4 I None
days I None
, I None
and I None
severe I None
ischemic I Disease
lesions O Disease
and I None
fibrosis I Disease
of I None
the I None
left I None
ventricles I None
were I None
observed I None
. I None
<eof> I None

<s> O None
In I None
epinephrine I Chemical
-treated I None
rats I None
, I None
left I None
atrial I None
and I None
left I None
ventricular I None
papillary I None
muscle I None
contractile I None
responses I None
to I None
isoproterenol I Chemical
were I None
reduced I None
, I None
but I None
responses I None
to I None
calcium I Chemical
were I None
normal I None
or I None
enhanced I None
compared I None
to I None
controls I None
. I None
<eof> I None

<s> O None
Left I None
ventricular I None
alpha I None
and I None
beta I None
adrenoceptor I None
densities I None
were I None
also I None
reduced I None
compared I None
to I None
controls I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
clentiazem I Chemical
prevented I None
<eof> I None

<s> O None
epinephrine I Chemical
-induced I None
death I None
( I None
P I None
< I None
.05 I None
) I None
, I None
and I None
attenuated I None
the I None
ventricular I None
ischemic I Disease
lesions O Disease
and I None
fibrosis I Disease
, I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Left I None
atrial I None
and I None
left I None
ventricular I None
papillary I None
muscle I None
contractile I None
responses I None
to I None
isoproterenol I Chemical
were I None
reduced I None
compared I None
to I None
controls I None
in I None
groups I None
treated I None
with I None
clentiazem I Chemical
alone I None
, I None
but I None
combined I None
with I None
epinephrine I Chemical
, I None
<eof> I None

<s> O None
clentiazem I Chemical
restored I None
left I None
atrial I None
responses I None
and I None
enhanced I None
left I None
ventricular I None
papillary I None
responses I None
to I None
isoproterenol I Chemical
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
clentiazem I Chemical
did I None
not I None
prevent I None
epinephrine I Chemical
-induced I None
down I None
- I None
regulation I None
of I None
alpha I None
and I None
beta I None
adrenoceptors I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
clentiazem I Chemical
, I None
infused I None
alone I None
, I None
resulted I None
in I None
decreased I None
adrenergic I None
receptor I None
densities I None
in I None
the I None
left I None
ventricle I None
. I None
<eof> I None

<s> O None
Clentiazem I Chemical
also I None
did I None
not I None
prevent I None
the I None
enhanced I None
responses I None
to I None
calcium I Chemical
seen I None
in I None
the I None
epinephrine I Chemical
-treated I None
animals I None
, I None
although I None
the I None
high I None
dose I None
of I None
clentiazem I Chemical
partially I None
attenuated I None
the I None
maximal I None
response I None
to I None
calcium I Chemical
compared I None
to I None
<eof> I None

<s> O None
epinephrine I Chemical
-treated I None
animals I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
clentiazem I Chemical
attenuated I None
<eof> I None

<s> O None
epinephrine I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
injury O Disease
, I None
possibly I None
through I None
its I None
effect I None
on I None
the I None
adrenergic I None
pathway I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
induced I None
<eof> I None

<s> O None
myocardial I Disease
ischemia O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
myocardial I Disease
ischemia O Disease
induced I None
by I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
The I None
ischemia I Disease
probably I None
induced I None
by I None
coronary I Disease
artery O Disease
spasm O Disease
was I None
reversed I None
by I None
nitroglycerin I Chemical
and I None
calcium I Chemical
blocking I None
agents I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
monitored I None
by I None
ECG I None
in I None
freely I None
moving I None
mice I None
. I None
<eof> I None

<s> O None
A I None
new I None
model I None
to I None
test I None
potential I None
protectors I None
. I None
<eof> I None

<s> O None
In I None
laboratory I None
animals I None
, I None
histology I None
is I None
most I None
commonly I None
used I None
to I None
study I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
for I None
monitoring I None
during I None
treatment I None
, I None
large I None
numbers I None
of I None
animals I None
are I None
needed I None
. I None
<eof> I None

<s> O None
Recently I None
we I None
developed I None
a I None
new I None
method I None
to I None
measure I None
ECG I None
values I None
in I None
freely I None
moving I None
mice I None
by I None
telemetry I None
. I None
<eof> I None

<s> O None
With I None
this I None
model I None
we I None
investigated I None
the I None
effect I None
of I None
chronic I None
doxorubicin I Chemical
administration I None
on I None
the I None
ECG I None
of I None
freely I None
moving I None
BALB I None
/ I None
<eof> I None

<s> O None
c I None
mice I None
and I None
the I None
efficacy I None
of I None
ICRF-187 I Chemical
as I None
a I None
protective I None
agent I None
. I None
<eof> I None

<s> O None
The I None
ST I None
interval I None
significantly I None
widened I None
from I None
15.0 I None
+ I None
/- I None
1.5 I None
to I None
56.8 I None
+ I None
/- I None
<eof> I None

<s> O None
11.8 I None
ms I None
in I None
week I None
10 I None
( I None
7 I None
weekly I None
doses I None
of I None
4 I None
mg I None
/ I None
kg I None
doxorubicin I Chemical
given I None
i.v I None
. I None
plus I None
3 I None
weeks I None
of I None
observation I None
) I None
. I None
<eof> I None

<s> O None
The I None
ECG I None
of I None
the I None
control I None
animals I None
did I None
not I None
change I None
during I None
the I None
entire I None
study I None
. I None
<eof> I None

<s> O None
After I None
sacrifice I None
the I None
hearts I None
of I None
<eof> I None

<s> O None
doxorubicin I Chemical
-treated I None
animals I None
were I None
enlarged I None
and I None
the I None
atria I None
were I None
hypertrophic I Disease
. I None
<eof> I None

<s> O None
As I None
this I None
schedule I None
exerted I None
more I None
toxicity I Disease
than I None
needed I None
to I None
investigate I None
protective I None
agents I None
, I None
the I None
protection I None
of I None
ICRF-187 I Chemical
was I None
determined I None
using I None
a I None
dose I None
schedule I None
with I None
lower I None
general I None
toxicity I Disease
<eof> I None

<s> O None
( I None
6 I None
weekly I None
doses I None
of I None
4 I None
mg I None
/ I None
kg I None
doxorubicin I Chemical
given I None
i.v I None
. I None
<eof> I None

<s> O None
plus I None
2 I None
weeks I None
of I None
observation I None
) I None
. I None
<eof> I None

<s> O None
On I None
this I None
schedule I None
, I None
the I None
animals I None
' I None
hearts I None
appeared I None
normal I None
after I None
sacrifice I None
and I None
ICRF-187 I Chemical
( I None
50 I None
mg I None
/ I None
kg I None
given I None
i.p I None
. I None
<eof> I None

<s> O None
1 I None
h I None
before I None
doxorubicin I Chemical
) I None
provided I None
almost I None
full I None
protection I None
. I None
<eof> I None

<s> O None
These I None
data I None
were I None
confirmed I None
by I None
histology I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
this I None
new I None
model I None
is I None
very I None
sensitive I None
and I None
enables I None
monitoring I None
of I None
the I None
development I None
of I None
cardiotoxicity I Disease
with I None
time I None
. I None
<eof> I None

<s> O None
These I None
findings I None
result I None
in I None
a I None
model I None
that I None
allows I None
the I None
testing I None
of I None
protectors I None
against I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
as I None
demonstrated I None
by I None
the I None
protection I None
provided I None
by I None
ICRF-187 I Chemical
. I None
<eof> I None

<s> O None
Epinephrine I Chemical
dysrhythmogenicity I None
is I None
not I None
enhanced I None
by I None
subtoxic I None
bupivacaine I Chemical
in I None
dogs I None
. I None
<eof> I None

<s> O None
Since I None
bupivacaine I Chemical
and I None
epinephrine I Chemical
may I None
both I None
precipitate I None
dysrhythmias I Disease
, I None
circulating I None
bupivacaine I Chemical
during I None
regional I None
anesthesia I None
could I None
potentiate I None
dysrhythmogenic I None
effects I None
of I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
We I None
therefore I None
examined I None
whether I None
bupivacaine I Chemical
alters I None
the I None
dysrhythmogenicity I None
of I None
subsequent I None
administration I None
of I None
epinephrine I Chemical
in I None
conscious I None
, I None
healthy I None
dogs I None
and I None
in I None
anesthetized I None
dogs I None
with I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
Forty I None
- I None
one I None
conscious I None
dogs I None
received I None
10 I None
micrograms.kg-1.min-1 I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
Seventeen I None
animals I None
responded I None
with I None
ventricular I Disease
tachycardia O Disease
<eof> I None

<s> O None
( I None
VT I Disease
) I None
within I None
3 I None
min I None
. I None
<eof> I None

<s> O None
After I None
3 I None
h I None
, I None
these I None
responders I None
randomly I None
received I None
1 I None
or I None
2 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
bupivacaine I Chemical
or I None
saline I None
over I None
5 I None
min I None
, I None
followed I None
by I None
10 I None
micrograms.kg-1.min-1 I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
bupivacaine I Chemical
groups I None
, I None
epinephrine I Chemical
caused I None
fewer I None
prodysrhythmic I None
effects I None
than I None
without I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
VT I Disease
appeared I None
in I None
fewer I None
dogs I None
and I None
at I None
a I None
later I None
time I None
, I None
and I None
there I None
were I None
more I None
sinoatrial I None
beats I None
and I None
less I None
ectopies I None
. I None
<eof> I None

<s> O None
Epinephrine I Chemical
shortened I None
QT I None
less I None
after I None
bupivacaine I Chemical
than I None
in I None
control I None
animals I None
. I None
<eof> I None

<s> O None
One I None
day I None
after I None
experimental I None
myocardial I Disease
infarction O Disease
, I None
six I None
additional I None
halothane I Chemical
-anesthetized I None
dogs I None
received I None
4 I None
micrograms.kg-1.min-1 I None
epinephrine I Chemical
until I None
VT I Disease
appeared I None
. I None
<eof> I None

<s> O None
After I None
45 I None
min I None
, I None
1 I None
mg I None
/ I None
kg I None
bupivacaine I Chemical
was I None
injected I None
over I None
5 I None
min I None
, I None
again I None
followed I None
by I None
4 I None
micrograms.kg-1.min-1 I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
In I None
these I None
dogs I None
, I None
the I None
prodysrhythmic I None
response I None
to I None
epinephrine I Chemical
was I None
also I None
mitigated I None
by I None
preceding I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
Bupivacaine I Chemical
antagonizes I None
epinephrine I Chemical
dysrhythmogenicity I None
in I None
conscious I None
dogs I None
susceptible I None
to I None
VT I Disease
and I None
in I None
anesthetized I None
dogs I None
with I None
spontaneous I None
postinfarct I None
<eof> I None

<s> O None
dysrhythmias I Disease
. I None
<eof> I None

<s> O None
There I None
is I None
no I None
evidence I None
that I None
systemic I None
subtoxic I None
bupivacaine I Chemical
administration I None
enhances I None
the I None
dysrhythmogenicity I None
of I None
subsequent I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
Milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
induced I None
by I None
1,25(OH)2D I Chemical
in I None
a I None
patient I None
with I None
hypoparathyroidism I Disease
. I None
<eof> I None

<s> O None
Milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
was I None
first I None
described I None
70 I None
years I None
ago I None
in I None
the I None
context I None
of I None
the I None
treatment I None
of I None
peptic I Disease
ulcer O Disease
disease O Disease
with I None
large I None
amounts I None
of I None
calcium I Chemical
and I None
alkali I Chemical
. I None
<eof> I None

<s> O None
Although I None
with I None
current I None
ulcer I Disease
therapy I None
( I None
H-2 I None
blockers I None
, I None
omeprazole I Chemical
, I None
and I None
sucralfate I Chemical
) I None
, I None
the I None
frequency I None
of I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
has I None
decreased I None
significantly I None
, I None
the I None
classic I None
triad I None
of I None
hypercalcemia I Disease
, I None
alkalosis I Disease
, I None
and I None
renal I Disease
impairment O Disease
remains I None
the I None
hallmark I None
of I None
the I None
syndrome I None
. I None
<eof> I None

<s> O None
Milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
can I None
present I None
serious I None
and I None
occasionally I None
life I None
- I None
threatening I None
illness I None
unless I None
diagnosed I None
and I None
treated I None
appropriately I None
. I None
<eof> I None

<s> O None
This I None
article I None
presents I None
a I None
patient I None
with I None
hypoparathyroidism I Disease
who I None
was I None
treated I None
with I None
calcium I Chemical
carbonate O Chemical
and I None
calcitriol I Chemical
resulting I None
in I None
two I None
admissions I None
to I None
the I None
hospital I None
for I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
successfully I None
treated I None
with I None
intravenous I None
pamidronate I Chemical
on I None
his I None
first I None
admission I None
and I None
with I None
hydrocortisone I Chemical
on I None
the I None
second I None
. I None
<eof> I None

<s> O None
This I None
illustrates I None
intravenous I None
pamidronate I Chemical
as I None
a I None
valuable I None
therapeutic I None
tool I None
when I None
milk I Disease
- O Disease
alkali O Disease
syndrome O Disease
presents I None
as I None
hypercalcemic I Disease
emergency O Disease
. I None
<eof> I None

<s> O None
Encephalopathy I Disease
during I None
amitriptyline I Chemical
therapy I None
: I None
are I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
and I None
serotonin I Disease
syndrome O Disease
spectrum I None
disorders I None
? I None
<eof> I None

<s> O None
This I None
report I None
describes I None
a I None
case I None
of I None
encephalopathy I Disease
developed I None
in I None
the I None
course I None
of I None
amitriptyline I Chemical
therapy I None
, I None
during I None
a I None
remission I None
of I None
unipolar I Disease
depression O Disease
. I None
<eof> I None

<s> O None
This I None
patient I None
could I None
have I None
been I None
diagnosed I None
as I None
having I None
either I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NMS I Disease
) I None
or I None
serotonin I Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
SS I Disease
) I None
. I None
<eof> I None

<s> O None
The I None
major I None
determinant I None
of I None
the I None
symptoms I None
may I None
have I None
been I None
dopamine I Chemical
/ I None
serotonin I Chemical
imbalance I None
in I None
the I None
central I None
nervous I None
system I None
. I None
<eof> I None

<s> O None
The I None
NMS I Disease
-like I None
<eof> I None

<s> O None
encephalopathy I Disease
that I None
develops I None
in I None
association I None
with I None
the I None
use I None
of I None
antidepressants I None
indicates I None
that I None
NMS I Disease
and I None
SS I Disease
are I None
spectrum I None
disorders I None
induced I None
by I None
drugs I None
with I None
both I None
antidopaminergic I None
and I None
serotonergic I None
effects I None
. I None
<eof> I None

<s> O None
Genetic I None
separation I None
of I None
tumor I Disease
growth I None
and I None
hemorrhagic I Disease
phenotypes I None
in I None
an I None
estrogen I Chemical
-induced I None
tumor I Disease
. I None
<eof> I None

<s> O None
Chronic I None
administration I None
of I None
estrogen I Chemical
to I None
the I None
Fischer I None
344 I None
( I None
F344 I None
) I None
rat I None
induces I None
growth I None
of I None
large I None
, I None
hemorrhagic I Disease
pituitary I Disease
tumors O Disease
. I None
<eof> I None

<s> O None
Ten I None
weeks I None
of I None
diethylstilbestrol I Chemical
<eof> I None

<s> O None
( I None
DES I Chemical
) I None
treatment I None
caused I None
female I None
F344 I None
rat I None
pituitaries I None
to I None
grow I None
to I None
an I None
average I None
of I None
109.2 I None
+ I None
/- I None
<eof> I None

<s> O None
6.3 I None
mg I None
( I None
mean I None
+ I None
/- I None
SE I None
) I None
<eof> I None

<s> O None
versus I None
11.3 I None
+ I None
/- I None
<eof> I None

<s> O None
1.4 I None
mg I None
for I None
untreated I None
rats I None
, I None
and I None
to I None
become I None
highly I None
hemorrhagic I Disease
. I None
<eof> I None

<s> O None
The I None
same I None
DES I Chemical
treatment I None
produced I None
no I None
significant I None
growth I None
( I None
8.9 I None
+ I None
/- I None
0.5 I None
mg I None
for I None
treated I None
females I None
versus I None
8.7 I None
+ I None
/- I None
1.1 I None
for I None
untreated I None
females I None
) I None
or I None
morphological I None
changes I None
in I None
Brown I None
Norway I None
( I None
BN I None
) I None
rat I None
pituitaries I None
. I None
<eof> I None

<s> O None
An I None
F1 I None
hybrid I None
of I None
F344 I None
and I None
BN I None
exhibited I None
significant I None
pituitary I None
growth I None
after I None
10 I None
weeks I None
of I None
DES I Chemical
treatment I None
with I None
an I None
average I None
mass I None
of I None
26.3 I None
+ I None
/- I None
<eof> I None

<s> O None
0.7 I None
mg I None
compared I None
with I None
8.6 I None
+ I None
/- I None
0.9 I None
mg I None
for I None
untreated I None
rats I None
. I None
<eof> I None

<s> O None
Surprisingly I None
, I None
the I None
F1 I None
hybrid I None
<eof> I None

<s> O None
tumors I Disease
were I None
not I None
hemorrhagic I Disease
and I None
had I None
hemoglobin I None
content I None
and I None
outward I None
appearance I None
identical I None
to I None
that I None
of I None
BN I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
both I None
growth I None
and I None
morphological I None
changes I None
is I None
due I None
to I None
multiple I None
genes I None
. I None
<eof> I None

<s> O None
However I None
, I None
while I None
DES I Chemical
-induced I None
pituitary I None
growth I None
exhibited I None
quantitative I None
, I None
additive I None
inheritance I None
, I None
the I None
hemorrhagic I Disease
phenotype I None
exhibited I None
recessive I None
, I None
epistatic I None
inheritance I None
. I None
<eof> I None

<s> O None
Only I None
5 I None
of I None
the I None
160 I None
F2 I None
pituitaries I None
exhibited I None
the I None
hemorrhagic I Disease
phenotype I None
; I None
36 I None
of I None
the I None
160 I None
F2 I None
pituitaries I None
were I None
in I None
the I None
F344 I None
range I None
of I None
mass I None
, I None
but I None
31 I None
of I None
these I None
were I None
not I None
hemorrhagic I Disease
, I None
indicating I None
that I None
the I None
hemorrhagic I Disease
phenotype I None
is I None
not I None
merely I None
a I None
consequence I None
of I None
extensive I None
growth I None
. I None
<eof> I None

<s> O None
The I None
hemorrhagic I Disease
F2 I None
pituitaries I None
were I None
all I None
among I None
the I None
most I None
massive I None
, I None
indicating I None
that I None
some I None
of I None
the I None
genes I None
regulate I None
both I None
phenotypes I None
. I None
<eof> I None

<s> O None
Increased I None
expression I None
of I None
neuronal I None
nitric I Chemical
oxide O Chemical
synthase I None
in I None
bladder I None
afferent I None
pathways I None
following I None
chronic I None
bladder I Disease
irritation O Disease
. I None
<eof> I None

<s> O None
Immunocytochemical I None
techniques I None
were I None
used I None
to I None
examine I None
alterations I None
in I None
the I None
expression I None
of I None
neuronal I None
nitric I Chemical
oxide O Chemical
synthase I None
( I None
NOS I None
) I None
in I None
bladder I None
pathways I None
following I None
acute I None
and I None
chronic I None
irritation I Disease
of O Disease
the O Disease
urinary O Disease
tract O Disease
of I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Chemical I None
cystitis I Disease
was I None
induced I None
by I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYP I Chemical
) I None
which I None
is I None
metabolized I None
to I None
acrolein I Chemical
, I None
an I None
irritant I None
eliminated I None
in I None
the I None
urine I None
. I None
<eof> I None

<s> O None
Injection I None
of I None
CYP I Chemical
<eof> I None

<s> O None
( I None
n I None
= I None
10 I None
, I None
75 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
2 I None
hours I None
prior I None
to I None
perfusion I None
( I None
acute I None
treatment I None
) I None
of I None
the I None
animals I None
increased I None
Fos I None
- I None
immunoreactivity I None
( I None
IR I None
) I None
in I None
neurons I None
in I None
the I None
dorsal I None
commissure I None
, I None
dorsal I None
horn I None
, I None
and I None
autonomic I None
regions I None
of I None
spinal I None
segments I None
( I None
L1-L2 I None
and I None
L6-S1 I None
) I None
which I None
receive I None
afferent I None
inputs I None
from I None
the I None
bladder I None
, I None
urethra I None
, I None
and I None
ureter I None
. I None
<eof> I None

<s> O None
Fos I None
- I None
IR I None
in I None
the I None
spinal I None
cord I None
was I None
not I None
changed I None
in I None
rats I None
receiving I None
chronic I None
CYP I Chemical
treatment I None
( I None
n I None
= I None
15 I None
, I None
75 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
, I None
every I None
3rd I None
day I None
for I None
2 I None
weeks I None
) I None
. I None
<eof> I None

<s> O None
In I None
control I None
animals I None
and I None
in I None
animals I None
treated I None
acutely I None
with I None
CYP I Chemical
, I None
only I None
small I None
numbers I None
of I None
NOS I None
- I None
IR I None
cells I None
( I None
0.5 I None
- I None
0.7 I None
cell I None
profiles I None
/ I None
sections I None
) I None
were I None
detected I None
in I None
the I None
L6-S1 I None
dorsal I None
root I None
ganglia I None
( I None
DRG I None
) I None
. I None
<eof> I None

<s> O None
Chronic I None
CYP I Chemical
administration I None
significantly I None
( I None
P I None
< I None
or I None
= I None
.002 I None
) I None
increased I None
bladder I None
weight I None
by I None
60 I None
% I None
and I None
increased I None
( I None
<eof> I None

<s> O None
7- I None
to I None
11-fold I None
) I None
the I None
numbers I None
of I None
NOS I None
- I None
immunoreactive I None
( I None
IR I None
) I None
afferent I None
neurons I None
in I None
the I None
L6-S1 I None
DRG I None
. I None
<eof> I None

<s> O None
A I None
small I None
increase I None
( I None
1.5-fold I None
) I None
also I None
occurred I None
in I None
the I None
L1 I None
DRG I None
, I None
but I None
no I None
change I None
was I None
detected I None
in I None
the I None
L2 I None
and I None
L5 I None
DRG I None
. I None
<eof> I None

<s> O None
Bladder I None
afferent I None
cells I None
in I None
the I None
L6-S1 I None
DRG I None
labeled I None
by I None
Fluorogold I None
( I None
40 I None
microliters I None
) I None
injected I None
into I None
the I None
bladder I None
wall I None
did I None
not I None
exhibit I None
NOS I None
- I None
IR I None
in I None
control I None
animals I None
; I None
however I None
, I None
following I None
chronic I None
CYP I Chemical
administration I None
, I None
a I None
significant I None
percentage I None
of I None
bladder I None
afferent I None
neurons I None
were I None
NOS I None
- I None
IR I None
: I None
L6 I None
( I None
19.8 I None
+ I None
/- I None
4.6 I None
% I None
) I None
and I None
S1 I None
( I None
25.3 I None
+ I None
/- I None
<eof> I None

<s> O None
2.9 I None
% I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
neuronal I None
gene I None
expression I None
in I None
visceral I None
sensory I None
pathways I None
can I None
be I None
upregulated I None
by I None
chemical I None
irritation I None
of I None
afferent I None
receptors I None
in I None
the I None
urinary I None
tract I None
and/or I None
that I None
pathological I None
changes I None
in I None
the I None
urinary I None
tract I None
can I None
initiate I None
chemical I None
signals I None
that I None
alter I None
the I None
chemical I None
properties I None
of I None
visceral I None
afferent I None
neurons I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
a I None
new I None
calcium I Chemical
antagonist I None
, I None
CD-832 I Chemical
, I None
on I None
isoproterenol I Chemical
-induced I None
myocardial I Disease
ischemia O Disease
in I None
dogs I None
with I None
partial I None
coronary I Disease
stenosis O Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
CD-832 I Chemical
on I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
ISO I Chemical
) I None
-induced I None
<eof> I None

<s> O None
myocardial I Disease
ischemia O Disease
were I None
studied I None
in I None
dogs I None
with I None
partial I None
coronary I Disease
stenosis O Disease
of I None
the I None
left I None
circumflex I None
coronary I None
artery I None
and I None
findings I None
were I None
compared I None
with I None
those I None
for I None
nifedipine I Chemical
or I None
diltiazem I Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
coronary I Disease
artery O Disease
stenosis O Disease
, I None
3-min I None
periods I None
of I None
intracoronary I None
ISO I Chemical
infusion I None
( I None
10 I None
ng I None
/ I None
kg I None
/ I None
min I None
) I None
increased I None
heart I None
rate I None
and I None
maximal I None
rate I None
of I None
left I None
ventricular I None
pressure I None
rise I None
, I None
which I None
resulted I None
in I None
a I None
decrease I None
in I None
percentage I None
segmental I None
shortening I None
and I None
ST I None
- I None
segment I None
elevation I None
of I None
the I None
epicardial I None
electrocardiogram I None
. I None
<eof> I None

<s> O None
After I None
the I None
control I None
ISO I Chemical
infusion I None
with I None
stenosis I Disease
was I None
performed I None
, I None
equihypotensive I None
doses I None
of I None
CD-832 I Chemical
<eof> I None

<s> O None
( I None
3 I None
and I None
10 I None
micrograms I None
/ I None
kg I None
/ I None
min I None
, I None
n I None
= I None
7 I None
) I None
, I None
nifedipine I Chemical
<eof> I None

<s> O None
( I None
1 I None
and I None
3 I None
micrograms I None
/ I None
kg I None
/ I None
min I None
, I None
n I None
= I None
9 I None
) I None
or I None
diltiazem I Chemical
( I None
10 I None
and I None
30 I None
micrograms I None
/ I None
kg I None
/ I None
min I None
, I None
n I None
= I None
7 I None
) I None
were I None
infused I None
5 I None
min I None
before I None
and I None
during I None
the I None
second I None
and I None
third I None
ISO I Chemical
infusion I None
. I None
<eof> I None

<s> O None
Both I None
CD-832 I Chemical
and I None
diltiazem I Chemical
, I None
but I None
not I None
nifedipine I Chemical
, I None
significantly I None
reduced I None
the I None
increase I None
in I None
heart I None
rate I None
induced I None
by I None
ISO I Chemical
infusion I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
nifedipine I Chemical
, I None
CD-832 I Chemical
( I None
10 I None
micrograms I None
/ I None
kg I None
/ I None
min I None
) I None
prevented I None
the I None
decrease I None
in I None
percentage I None
segmental I None
shortening I None
from I None
32 I None
+ I None
/- I None
<eof> I None

<s> O None
12 I None
% I None
to I None
115 I None
+ I None
/- I None
<eof> I None

<s> O None
26 I None
% I None
of I None
the I None
control I None
value I None
( I None
P I None
< I None
.01 I None
) I None
and I None
ST I None
- I None
segment I None
elevation I None
from I None
5.6 I None
+ I None
/- I None
<eof> I None

<s> O None
1.0 I None
mV I None
to I None
1.6 I None
+ I None
/- I None
<eof> I None

<s> O None
1.3 I None
mV I None
( I None
P I None
< I None
.01 I None
) I None
at I None
3 I None
min I None
after I None
ISO I Chemical
infusion I None
with I None
stenosis I Disease
. I None
<eof> I None

<s> O None
Diltiazem I Chemical
( I None
30 I None
micrograms I None
/ I None
kg I None
/ I None
min I None
) I None
also I None
prevented I None
the I None
decrease I None
in I None
percentage I None
segmental I None
shortening I None
from I None
34 I None
+ I None
/- I None
<eof> I None

<s> O None
14 I None
% I None
to I None
63 I None
+ I None
/- I None
<eof> I None

<s> O None
18 I None
% I None
of I None
the I None
control I None
value I None
( I None
P I None
< I None
.05 I None
) I None
and I None
ST I None
- I None
segment I None
elevation I None
from I None
4.7 I None
+ I None
/- I None
<eof> I None

<s> O None
0.7 I None
mV I None
to I None
2.1 I None
+ I None
/- I None
<eof> I None

<s> O None
0.7 I None
mV I None
( I None
P I None
< I None
.01 I None
) I None
at I None
3 I None
min I None
after I None
ISO I Chemical
infusion I None
with I None
stenosis I Disease
. I None
<eof> I None

<s> O None
These I None
data I None
show I None
that I None
CD-832 I Chemical
improves I None
myocardial I Disease
ischemia O Disease
during I None
ISO I Chemical
infusion I None
with I None
stenosis I Disease
and I None
suggest I None
that I None
the I None
negative I None
chronotropic I None
property I None
of I None
CD-832 I Chemical
plays I None
a I None
major I None
role I None
in I None
the I None
beneficial I None
effects I None
of I None
CD-832 I Chemical
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
recombinant I None
human I None
insulin I None
- I None
like I None
growth I None
factor I None
- I None
I I None
on I None
chronic I None
puromycin I Chemical
aminonucleoside O Chemical
nephropathy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
We I None
recently I None
demonstrated I None
that I None
recombinant I None
hGH I None
exacerbates I None
renal I None
functional I None
and I None
structural I None
injury I None
in I None
chronic I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
<eof> I None

<s> O None
nephropathy I Disease
, I None
an I None
experimental I None
model I None
of I None
glomerular I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
examined I None
whether I None
recombinant I None
human I None
( I None
rh I None
) I None
IGF I None
- I None
I I None
is I None
a I None
safer I None
alternative I None
for I None
the I None
treatment I None
of I None
growth I Disease
failure O Disease
in I None
rats I None
with I None
chronic I None
PAN I Chemical
nephropathy I Disease
. I None
<eof> I None

<s> O None
The I None
glomerulopathy I Disease
was I None
induced I None
by I None
seven I None
serial I None
injections I None
of I None
PAN I Chemical
over I None
12 I None
wk I None
. I None
<eof> I None

<s> O None
Experimental I None
animals I None
( I None
n I None
= I None
6 I None
) I None
received I None
rhIGF I None
- I None
I I None
, I None
400 I None
micrograms I None
/ I None
d I None
, I None
whereas I None
control I None
rats I None
( I None
n I None
= I None
6 I None
) I None
received I None
the I None
vehicle I None
. I None
<eof> I None

<s> O None
rhIGF I None
- I None
I I None
improved I None
weight I None
gain I None
by I None
14 I None
% I None
( I None
p I None
< I None
0.05 I None
) I None
, I None
without I None
altering I None
hematocrit I None
or I None
blood I None
pressure I None
in I None
rats I None
with I None
renal I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Urinary I None
protein I None
excretion I None
was I None
unaltered I None
by I None
rhIGF I None
- I None
I I None
treatment I None
in I None
rats I None
with I None
chronic I None
PAN I Chemical
nephropathy I Disease
. I None
<eof> I None

<s> O None
After I None
12 I None
wk I None
, I None
the I None
inulin I None
clearance I None
was I None
higher I None
in I None
rhIGF I None
- I None
I I None
- I None
treated I None
rats I None
, I None
0.48 I None
+ I None
/- I None
0.08 I None
versus I None
0.24 I None
+ I None
/- I None
0.06 I None
mL I None
/ I None
min/100 I None
g I None
of I None
body I None
weight I None
in I None
untreated I None
PAN I Chemical
nephropathy I Disease
animals I None
, I None
p I None
< I None
0.05 I None
. I None
<eof> I None

<s> O None
The I None
improvement I None
in I None
GFR I None
was I None
not I None
associated I None
with I None
enhanced I None
glomerular I Disease
hypertrophy O Disease
or I None
increased I None
segmental I None
glomerulosclerosis I Disease
, I None
tubulointerstitial I Disease
injury O Disease
, I None
or I None
renal I None
cortical I None
malondialdehyde I Chemical
content I None
. I None
<eof> I None

<s> O None
In I None
rats I None
with I None
PAN I Chemical
<eof> I None

<s> O None
nephropathy I Disease
, I None
administration I None
of I None
rhIGF I None
- I None
I I None
increased I None
IGF I None
- I None
I I None
and I None
GH I None
receptor I None
gene I None
expression I None
, I None
without I None
altering I None
the I None
steady I None
state I None
level I None
of I None
IGF I None
- I None
I I None
receptor I None
mRNA I None
. I None
<eof> I None

<s> O None
In I None
normal I None
rats I None
with I None
intact I None
kidneys I None
, I None
rhIGF I None
- I None
I I None
administration I None
( I None
n I None
= I None
4 I None
) I None
did I None
not I None
alter I None
weight I None
gain I None
, I None
blood I None
pressure I None
, I None
proteinuria I Disease
, I None
GFR I None
, I None
glomerular I None
planar I None
area I None
, I None
renal I None
cortical I None
malondialdehyde I Chemical
content I None
, I None
or I None
glomerular I None
or I None
tubulointerstitial I Disease
damage O Disease
, I None
compared I None
with I None
untreated I None
animals I None
( I None
n I None
= I None
4 I None
) I None
. I None
<eof> I None

<s> O None
rhIGF I None
- I None
<eof> I None

<s> O None
I I None
treatment I None
reduced I None
the I None
steady I None
state I None
renal I None
IGF I None
- I None
I I None
mRNA I None
level I None
but I None
did I None
not I None
modify I None
gene I None
expression I None
of I None
the I None
IGF I None
- I None
I I None
or I None
GH I None
receptors I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
: I None
1 I None
) I None
administration I None
of I None
rhIGF I None
- I None
I I None
improves I None
growth I None
and I None
GFR I None
in I None
rats I None
with I None
chronic I None
PAN I Chemical
<eof> I None

<s> O None
nephropathy I Disease
and I None
2 I None
) I None
unlike I None
rhGH I None
, I None
long I None
- I None
term I None
use I None
of I None
rhIGF I None
<eof> I None

<s> O None
- I None
I I None
does I None
not I None
worsen I None
renal I None
functional I None
and I None
structural I None
injury I None
in I None
this I None
disease I None
model I None
. I None
<eof> I None

<s> O None
Nefiracetam I Chemical
( I None
DM-9384 I Chemical
) I None
reverses I None
<eof> I None

<s> O None
apomorphine I Chemical
-induced I None
<eof> I None

<s> O None
amnesia I Disease
of I None
a I None
passive I None
avoidance I None
response I None
: I None
delayed I None
emergence I None
of I None
the I None
memory I None
retention I None
effects I None
. I None
<eof> I None

<s> O None
Nefiracetam I Chemical
is I None
a I None
novel I None
pyrrolidone I Chemical
derivative I None
which I None
attenuates I None
scopolamine I Chemical
-induced I None
learning I Disease
and O Disease
post O Disease
- O Disease
training O Disease
consolidation O Disease
deficits O Disease
. I None
<eof> I None

<s> O None
Given I None
that I None
apomorphine I Chemical
inhibits I None
passive I None
avoidance I None
retention I None
when I None
given I None
during I None
training I None
or I None
in I None
a I None
defined I None
10 I None
- I None
12h I None
post I None
- I None
training I None
period I None
, I None
we I None
evaluated I None
the I None
ability I None
of I None
nefiracetam I Chemical
to I None
attenuate I None
amnesia I Disease
induced I None
by I None
dopaminergic I None
agonism I None
. I None
<eof> I None

<s> O None
A I None
step I None
- I None
down I None
passive I None
avoidance I None
paradigm I None
was I None
employed I None
and I None
nefiracetam I Chemical
<eof> I None

<s> O None
( I None
3 I None
mg I None
/ I None
kg I None
) I None
and I None
apomorphine I Chemical
<eof> I None

<s> O None
( I None
0.5 I None
mg I None
/ I None
kg I None
) I None
were I None
given I None
alone I None
or I None
in I None
combination I None
during I None
training I None
and I None
at I None
the I None
10 I None
- I None
12h I None
post I None
- I None
training I None
period I None
of I None
consolidation I None
. I None
<eof> I None

<s> O None
Co I None
- I None
administration I None
of I None
nefiracetam I Chemical
and I None
apomorphine I Chemical
during I None
training I None
or I None
10h I None
thereafter I None
produced I None
no I None
significant I None
anti I None
- I None
amnesic I None
effect I None
. I None
<eof> I None

<s> O None
However I None
, I None
administration I None
of I None
nefiracetam I Chemical
during I None
training I None
completely I None
reversed I None
the I None
amnesia I Disease
induced I None
by I None
apomorphine I Chemical
at I None
the I None
10h I None
post I None
- I None
training I None
time I None
and I None
the I None
converse I None
was I None
also I None
true I None
. I None
<eof> I None

<s> O None
These I None
effects I None
were I None
not I None
mediated I None
by I None
a I None
dopaminergic I None
mechanism I None
as I None
nefiracetam I Chemical
, I None
at I None
millimolar I None
concentrations I None
, I None
failed I None
to I None
displace I None
either I None
[ I None
3H I None
] I None
SCH I Chemical
23390 O Chemical
or I None
[ I None
3H I None
] I None
spiperone I Chemical
binding I None
from I None
D1 I None
or I None
D2 I None
<eof> I None

<s> O None
dopamine I Chemical
receptor I None
subtypes I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
It I None
is I None
suggested I None
that I None
nefiracetam I Chemical
augments I None
molecular I None
processes I None
in I None
the I None
early I None
stages I None
of I None
events I None
which I None
ultimately I None
lead I None
to I None
consolidation I None
of I None
memory I None
. I None
<eof> I None

<s> O None
Human I None
corticotropin I Chemical
<eof> I None

<s> O None
-releasing I None
hormone I None
and I None
thyrotropin I Chemical
-releasing I None
hormone I None
modulate I None
the I None
hypercapnic I Disease
ventilatory I None
response I None
in I None
humans I None
. I None
<eof> I None

<s> O None
Human I None
corticotropin I Chemical
<eof> I None

<s> O None
-releasing I None
hormone I None
( I None
hCRH I None
) I None
and I None
thyrotropin I Chemical
-releasing I None
hormone I None
( I None
TRH I None
) I None
are I None
known I None
to I None
stimulate I None
ventilation I None
after I None
i.v I None
. I None
<eof> I None

<s> O None
administration I None
in I None
humans I None
. I None
<eof> I None

<s> O None
In I None
a I None
placebo I None
- I None
controlled I None
, I None
single I None
- I None
blind I None
study I None
we I None
aimed I None
to I None
clarify I None
if I None
both I None
peptides I None
act I None
by I None
altering I None
central I None
chemosensitivity I None
. I None
<eof> I None

<s> O None
Two I None
subsequent I None
CO2 I Chemical
<eof> I None

<s> O None
-rebreathing I None
tests I None
were I None
performed I None
in I None
healthy I None
young I None
volunteers I None
. I None
<eof> I None

<s> O None
During I None
the I None
first I None
test I None
0.9 I None
% I None
NaCl I Chemical
was I None
given I None
i.v I None
. I None
; I None
during I None
the I None
second I None
test I None
200 I None
micrograms I None
of I None
hCRH I None
( I None
n I None
= I None
12 I None
) I None
or I None
400 I None
micrograms I None
of I None
TRH I None
( I None
n I None
= I None
6 I None
) I None
was I None
administered I None
i.v I None
. I None
<eof> I None

<s> O None
Nine I None
subjects I None
received I None
0.9 I None
% I None
NaCl I Chemical
i.v I None
. I None
<eof> I None

<s> O None
during I None
both I None
rebreathing I None
manoeuvres I None
. I None
<eof> I None

<s> O None
The I None
CO2 I Chemical
-response I None
curves I None
for I None
the I None
two I None
tests I None
were I None
compared I None
within I None
the I None
same I None
subject I None
. I None
<eof> I None

<s> O None
In I None
the I None
hCRH I None
group I None
a I None
marked I None
parallel I None
shift I None
of I None
the I None
CO2 I Chemical
-response I None
curve I None
to I None
the I None
left I None
was I None
observed I None
after I None
hCRH I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
The I None
same I None
effect I None
occurred I None
following I None
TRH I None
but I None
was I None
less I None
striking I None
( I None
P I None
= I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
hCRH I None
and I None
TRH I None
caused I None
a I None
reduction I None
in I None
the I None
CO2 I Chemical
threshold I None
. I None
<eof> I None

<s> O None
The I None
CO2 I Chemical
-response I None
curves I None
in I None
the I None
control I None
group I None
were I None
nearly I None
identical I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
an I None
additive I None
effect I None
of I None
both I None
releasing I None
hormones I None
on I None
the I None
hypercapnic I Disease
ventilatory I None
response I None
in I None
humans I None
, I None
presumably I None
independent I None
of I None
central I None
chemosensitivity I None
. I None
<eof> I None

<s> O None
Lamivudine I Chemical
is I None
effective I None
in I None
suppressing I None
hepatitis I Disease
B O Disease
virus I None
DNA I None
in I None
Chinese I None
<eof> I None

<s> O None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
carriers I None
: I None
a I None
placebo I None
- I None
controlled I None
trial I None
. I None
<eof> I None

<s> O None
Lamivudine I Chemical
is I None
a I None
novel I None
2',3'-dideoxy I Chemical
cytosine O Chemical
analogue I None
that I None
has I None
potent I None
inhibitory I None
effects I None
on I None
hepatitis I Disease
B O Disease
virus I None
replication I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
We I None
performed I None
a I None
single I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
study I None
to I None
assess I None
its I None
effectiveness I None
and I None
safety I None
in I None
Chinese I None
hepatitis I Chemical
B O Chemical
surface O Chemical
antigen O Chemical
<eof> I None

<s> O None
( I None
HBsAg I Chemical
) I None
carriers I None
. I None
<eof> I None

<s> O None
Forty I None
- I None
two I None
<eof> I None

<s> O None
Chinese I None
HBsAg I Chemical
carriers I None
were I None
randomized I None
to I None
receive I None
placebo I None
( I None
6 I None
patients I None
) I None
or I None
lamivudine I Chemical
orally I None
in I None
dosages I None
of I None
25 I None
mg I None
, I None
100 I None
mg I None
, I None
or I None
300 I None
mg I None
daily I None
( I None
12 I None
patients I None
for I None
each I None
dosage I None
) I None
. I None
<eof> I None

<s> O None
The I None
drug I None
was I None
given I None
for I None
4 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
patients I None
were I None
closely I None
monitored I None
clinically I None
, I None
biochemically I None
, I None
and I None
serologically I None
up I None
to I None
4 I None
weeks I None
after I None
drug I None
treatment I None
. I None
<eof> I None

<s> O None
All I None
36 I None
patients I None
receiving I None
lamivudine I Chemical
had I None
a I None
decrease I None
in I None
hepatitis I Disease
B O Disease
virus I None
( I None
HBV I None
) I None
DNA I None
values I None
of I None
> I None
90 I None
% I None
( I None
P I None
< I None
.001 I None
compared I None
with I None
placebo I None
) I None
. I None
<eof> I None

<s> O None
Although I None
25 I None
mg I None
of I None
lamivudine I Chemical
was I None
slightly I None
less I None
effective I None
than I None
100 I None
mg I None
( I None
P I None
= I None
.011 I None
) I None
and I None
300 I None
mg I None
( I None
P I None
= I None
.005 I None
) I None
, I None
it I None
still I None
induced I None
94 I None
% I None
suppression I None
of I None
HBV I None
DNA I None
after I None
the I None
fourth I None
week I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
HBV I None
DNA I None
values I None
returned I None
to I None
pretreatment I None
levels I None
within I None
4 I None
weeks I None
of I None
cessation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
change I None
in I None
the I None
hepatitis I Disease
B O Disease
<eof> I None

<s> O None
e I None
antigen I None
status I None
or I None
in I None
aminotransferase I None
levels I None
. I None
<eof> I None

<s> O None
No I None
serious I None
adverse I None
events I None
were I None
observed I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
a I None
4-week I None
course I None
of I None
lamivudine I Chemical
was I None
safe I None
and I None
effective I None
in I None
suppression I None
of I None
HBV I None
DNA I None
in I None
Chinese I None
HBsAg I Chemical
carriers I None
. I None
<eof> I None

<s> O None
The I None
suppression I None
was I None
> I None
90 I None
% I None
but I None
reversible I None
. I None
<eof> I None

<s> O None
Studies I None
with I None
long I None
- I None
term I None
lamivudine I Chemical
administration I None
should I None
be I None
performed I None
to I None
determine I None
if I None
prolonged I None
suppression I None
of I None
HBV I None
DNA I None
can I None
be I None
achieved I None
. I None
<eof> I None

<s> O None
Population I None
- I None
based I None
study I None
of I None
risk I None
of I None
venous I Disease
thromboembolism O Disease
associated I None
with I None
various I None
oral I Chemical
contraceptives O Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Four I None
studies I None
published I None
since I None
December I None
, I None
1995 I None
, I None
reported I None
that I None
the I None
incidence I None
of I None
venous I Disease
thromboembolism O Disease
<eof> I None

<s> O None
( I None
VTE I Disease
) I None
was I None
higher I None
in I None
women I None
who I None
used I None
oral I Chemical
contraceptives O Chemical
<eof> I None

<s> O None
( I None
OCs I Chemical
) I None
containing I None
the I None
third I None
- I None
generation I None
progestagens I Chemical
gestodene I Chemical
or I None
desogestrel I Chemical
than I None
in I None
users I None
of I None
OCs I Chemical
containing I None
second I None
- I None
generation I None
progestagens I Chemical
. I None
<eof> I None

<s> O None
However I None
, I None
confounding I None
and I None
bias I None
in I None
the I None
design I None
of I None
these I None
studies I None
may I None
have I None
affected I None
the I None
findings I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
our I None
study I None
was I None
to I None
re I None
- I None
examine I None
the I None
association I None
between I None
risk I None
of I None
VTE I Disease
and I None
OC I Chemical
use I None
with I None
a I None
different I None
study I None
design I None
and I None
analysis I None
to I None
avoid I None
some I None
of I None
the I None
bias I None
and I None
confounding I None
of I None
the I None
earlier I None
studies I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
used I None
computer I None
records I None
of I None
patients I None
from I None
143 I None
general I None
practices I None
in I None
the I None
UK I None
. I None
<eof> I None

<s> O None
The I None
study I None
was I None
based I None
on I None
the I None
medical I None
records I None
of I None
about I None
540,000 I None
women I None
born I None
between I None
1941 I None
and I None
1981 I None
. I None
<eof> I None

<s> O None
All I None
women I None
who I None
had I None
a I None
recorded I None
diagnosis I None
of I None
deep I Disease
- O Disease
vein O Disease
thrombosis O Disease
, I None
venous I Disease
thrombosis O Disease
not I None
otherwise I None
specified I None
, I None
or I None
pulmonary I None
embolus I None
during I None
the I None
study I None
period I None
, I None
and I None
who I None
had I None
been I None
treated I None
with I None
an I None
anticoagulant I None
were I None
identified I None
as I None
potential I None
cases I None
of I None
VTE I Disease
. I None
<eof> I None

<s> O None
We I None
did I None
a I None
cohort I None
analysis I None
to I None
estimate I None
and I None
compare I None
incidence I None
of I None
VTE I Disease
in I None
users I None
of I None
the I None
main I None
OC I Chemical
preparations I None
, I None
and I None
a I None
nested I None
case I None
- I None
control I None
study I None
to I None
calculate I None
the I None
odds I None
ratios I None
of I None
VTE I Disease
associated I None
with I None
use I None
of I None
different I None
types I None
of I None
OC I Chemical
, I None
after I None
adjustment I None
for I None
potential I None
confounding I None
factors I None
. I None
<eof> I None

<s> O None
In I None
the I None
case I None
- I None
control I None
study I None
, I None
we I None
matched I None
cases I None
to I None
controls I None
by I None
exact I None
year I None
of I None
birth I None
, I None
practice I None
, I None
and I None
current I None
use I None
of I None
OCs I Chemical
. I None
<eof> I None

<s> O None
We I None
used I None
a I None
multiple I None
logistic I None
regression I None
model I None
that I None
included I None
body I None
- I None
mass I None
index I None
, I None
number I None
of I None
cycles I None
, I None
change I None
in I None
type I None
of I None
OC I Chemical
prescribed I None
within I None
3 I None
months I None
of I None
the I None
event I None
, I None
previous I None
pregnancy I None
, I None
and I None
concurrent I None
disease I None
. I None
<eof> I None

<s> O None
FINDINGS I None
: I None
85 I None
women I None
met I None
the I None
inclusion I None
criteria I None
for I None
VTE I Disease
, I None
two I None
of I None
whom I None
were I None
users I None
of I None
progestagen I Chemical
-only I None
OCs I Chemical
. I None
<eof> I None

<s> O None
Of I None
the I None
83 I None
cases I None
of I None
VTE I Disease
associated I None
with I None
use I None
of I None
combined I None
OCs I Chemical
, I None
43 I None
were I None
recorded I None
as I None
deep I Disease
- O Disease
vein O Disease
thrombosis O Disease
, I None
35 I None
as I None
pulmonary I None
thrombosis I Disease
, I None
and I None
five I None
as I None
venous I Disease
thrombosis O Disease
not I None
otherwise I None
specified I None
. I None
<eof> I None

<s> O None
The I None
crude I None
rate I None
of I None
VTE I Disease
per I None
10,000 I None
woman I None
- I None
years I None
was I None
4.10 I None
in I None
current I None
users I None
of I None
any I None
OC I Chemical
, I None
3.10 I None
in I None
users I None
of I None
second I None
- I None
generation I None
OCs I Chemical
, I None
and I None
4.96 I None
in I None
users I None
of I None
third I None
- I None
generation I None
preparations I None
. I None
<eof> I None

<s> O None
After I None
adjustment I None
for I None
age I None
, I None
the I None
rate I None
ratio I None
of I None
VTE I Disease
in I None
users I None
of I None
third I None
- I None
generation I None
relative I None
to I None
second I None
- I None
generation I None
OCs I Chemical
was I None
1.68 I None
( I None
95 I None
% I None
CI I None
1.04 I None
- I None
2.75 I None
) I None
. I None
<eof> I None

<s> O None
Logistic I None
regression I None
showed I None
no I None
significant I None
difference I None
in I None
the I None
risk I None
of I None
VTE I Disease
between I None
users I None
of I None
third I None
- I None
generation I None
and I None
second I None
- I None
generation I None
OCs I Chemical
. I None
<eof> I None

<s> O None
Among I None
users I None
of I None
third I None
- I None
generation I None
progestagens I Chemical
, I None
the I None
risk I None
of I None
VTE I Disease
was I None
higher I None
in I None
users I None
of I None
desogestrel I Chemical
with I None
20 I None
g I None
ethinyloestradiol I Chemical
than I None
in I None
users I None
of I None
gestodene I Chemical
or I None
desogestrel I Chemical
with I None
30 I None
g I None
ethinyloestradiol I Chemical
. I None
<eof> I None

<s> O None
With I None
all I None
second I None
- I None
generation I None
OCs I Chemical
as I None
the I None
reference I None
, I None
the I None
odds I None
ratios I None
for I None
VTE I Disease
were I None
3.49 I None
( I None
1.21 I None
- I None
10.12 I None
) I None
for I None
desogestrel I Chemical
plus I None
<eof> I None

<s> O None
20 I None
g I None
ethinyloestradiol I Chemical
and I None
1.18 I None
<eof> I None

<s> O None
( I None
0.66 I None
- I None
2.17 I None
) I None
for I None
the I None
other I None
third I None
- I None
generation I None
progestagens I Chemical
. I None
<eof> I None

<s> O None
INTERPRETATION I None
: I None
<eof> I None

<s> O None
The I None
previously I None
reported I None
increase I None
in I None
odds I None
ratio I None
associated I None
with I None
third I None
- I None
generation I None
OCs I Chemical
when I None
compared I None
with I None
second I None
- I None
generation I None
products I None
is I None
likely I None
to I None
have I None
been I None
the I None
result I None
of I None
residual I None
confounding I None
by I None
age I None
. I None
<eof> I None

<s> O None
The I None
increased I None
odds I None
ratio I None
associated I None
with I None
products I None
containing I None
20 I None
micrograms I None
ethinyloestradiol I Chemical
and I None
desogestrel I Chemical
compared I None
with I None
the I None
30 I None
micrograms I None
product I None
is I None
biologically I None
implausible I None
, I None
and I None
is I None
likely I None
to I None
be I None
the I None
result I None
of I None
preferential I None
prescribing I None
and I None
, I None
thus I None
, I None
confounding I None
. I None
<eof> I None

<s> O None
MK-801 I Chemical
augments I None
<eof> I None

<s> O None
pilocarpine I Chemical
-induced I None
electrographic I None
<eof> I None

<s> O None
seizure I Disease
but I None
protects I None
against I None
brain I Disease
damage O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
authors I None
examined I None
the I None
anticonvulsant I None
effects I None
of I None
MK-801 I Chemical
on I None
the I None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
seizure I Disease
model I None
. I None
<eof> I None

<s> O None
Intraperitoneal I None
injection I None
of I None
pilocarpine I Chemical
<eof> I None

<s> O None
( I None
400 I None
mg I None
/ I None
kg I None
) I None
induced I None
tonic I Disease
and O Disease
clonic O Disease
seizure O Disease
. I None
<eof> I None

<s> O None
Scopolamine I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
) I None
and I None
pentobarbital I Chemical
( I None
5 I None
mg I None
/ I None
kg I None
) I None
prevented I None
development I None
of I None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
behavioral I None
seizure I Disease
but I None
MK-801 I Chemical
( I None
0.5 I None
mg I None
/ I None
kg I None
) I None
did I None
not I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
An I None
electrical I None
seizure I Disease
measured I None
with I None
hippocampal I None
EEG I None
appeared I None
in I None
the I None
pilocarpine I Chemical
-treated I None
group I None
. I None
<eof> I None

<s> O None
Scopolamine I Chemical
and I None
pentobarbital I Chemical
blocked I None
the I None
pilocarpine I Chemical
-induced I None
electrographic I None
seizure I Disease
, I None
MK-801 I Chemical
<eof> I None

<s> O None
treatment I None
augmented I None
the I None
electrographic I None
seizure I Disease
induced I None
by I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
Brain I Disease
damage O Disease
was I None
assessed I None
by I None
examining I None
the I None
hippocampus I None
microscopically I None
. I None
<eof> I None

<s> O None
Pilocarpine I Chemical
produced I None
<eof> I None

<s> O None
neuronal I Disease
death O Disease
in I None
the I None
hippocampus I None
, I None
which I None
showed I None
pyknotic I None
changes I None
. I None
<eof> I None

<s> O None
Pentobarbital I Chemical
, I None
scopolamine I Chemical
and I None
MK-801 I Chemical
protected I None
the I None
brain I Disease
damage O Disease
by I None
pilocarpine I Chemical
, I None
though I None
in I None
the I None
MK-801 I Chemical
-treated I None
group I None
, I None
the I None
pyramidal I None
cells I None
of I None
hippocampus I None
appeared I None
darker I None
than I None
normal I None
. I None
<eof> I None

<s> O None
In I None
all I None
treatments I None
, I None
granule I None
cells I None
of I None
the I None
dentate I None
gyrus I None
were I None
not I None
affected I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
status I Disease
epilepticus O Disease
induced I None
by I None
pilocarpine I Chemical
is I None
initiated I None
by I None
cholinergic I None
overstimulation I None
and I None
propagated I None
by I None
glutamatergic I None
transmission I None
, I None
the I None
elevation I None
of I None
which I None
may I None
cause I None
brain I Disease
damage O Disease
through I None
an I None
excitatory I None
NMDA I Chemical
receptor I None
- I None
mediated I None
mechanism I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
, I None
5-fluorouracil I Chemical
, I None
and I None
folinic I Chemical
acid O Chemical
in I None
metastatic I None
breast I Disease
cancer O Disease
: I None
BRE-26 I None
, I None
a I None
phase I None
II I None
trial I None
. I None
<eof> I None

<s> O None
5-Fluorouracil I Chemical
plus I None
folinic I Chemical
acid O Chemical
and I None
paclitaxel I Chemical
<eof> I None

<s> O None
( I None
Taxol I Chemical
; I None
Bristol I None
- I None
Myers I None
Squibb I None
Company I None
, I None
Princeton I None
, I None
NJ I None
) I None
are I None
effective I None
salvage I None
therapies I None
for I None
metastatic I None
breast I Disease
cancer O Disease
patients I None
. I None
<eof> I None

<s> O None
Paclitaxel I Chemical
and I None
5-fluorouracil I Chemical
have I None
additive I None
cytotoxicity I Disease
in I None
MCF-7 I None
cell I None
lines I None
. I None
<eof> I None

<s> O None
We I None
performed I None
a I None
phase I None
II I None
trial I None
of I None
paclitaxel I Chemical
<eof> I None

<s> O None
175 I None
mg I None
/ I None
m2 I None
over I None
3 I None
hours I None
on I None
day I None
I I None
followed I None
by I None
<eof> I None

<s> O None
folinic I Chemical
acid O Chemical
300 I None
mg I None
over I None
1 I None
hour I None
before I None
<eof> I None

<s> O None
5-fluorouracil I Chemical
350 I None
mg I None
/ I None
m2 I None
on I None
days I None
1 I None
to I None
3 I None
every I None
28 I None
days I None
( I None
TFL I None
) I None
in I None
women I None
with I None
metastatic I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Analysis I None
is I None
reported I None
on I None
37 I None
patients I None
with I None
a I None
minimum I None
of I None
6 I None
months I None
follow I None
- I None
up I None
who I None
received I None
a I None
total I None
of I None
192 I None
cycles I None
of I None
TFL I None
: I None
nine I None
cycles I None
( I None
5 I None
% I None
) I None
were I None
associated I None
with I None
grade I None
3/4 I None
neutropenia I Disease
requiring I None
hospitalization I None
; I None
seven I None
( I None
4 I None
% I None
) I None
cycles I None
in I None
two I None
patients I None
required I None
granulocyte I Chemical
colony O Chemical
- O Chemical
stimulating O Chemical
factor O Chemical
due I None
to I None
neutropenia I Disease
; I None
no I None
patient I None
required I None
platelet I None
transfusions I None
. I None
<eof> I None

<s> O None
Grade I None
3/4 I None
nonhematologic I None
<eof> I None

<s> O None
toxicities I Disease
were I None
uncommon I None
. I None
<eof> I None

<s> O None
Among I None
the I None
34 I None
patients I None
evaluable I None
for I None
response I None
, I None
there I None
were I None
three I None
complete I None
responses I None
( I None
9 I None
% I None
) I None
and I None
18 I None
partial I None
responses I None
( I None
53 I None
% I None
) I None
for I None
an I None
overall I None
response I None
rate I None
of I None
62 I None
% I None
. I None
<eof> I None

<s> O None
Of I None
the I None
19 I None
evaluable I None
patients I None
with I None
prior I None
doxorubicin I Chemical
exposure I None
, I None
11 I None
( I None
58 I None
% I None
) I None
responded I None
compared I None
with I None
nine I None
of I None
15 I None
( I None
60 I None
% I None
) I None
without I None
prior I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Plasma I None
paclitaxel I Chemical
<eof> I None

<s> O None
concentrations I None
were I None
measured I None
at I None
the I None
completion I None
of I None
paclitaxel I Chemical
infusion I None
and I None
at I None
24 I None
hours I None
in I None
19 I None
patients I None
. I None
<eof> I None

<s> O None
TFL I None
is I None
an I None
active I None
, I None
well I None
- I None
tolerated I None
regimen I None
in I None
metastatic I None
breast I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Efficacy I None
and I None
proarrhythmia I Disease
with I None
the I None
use I None
of I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
for I None
sustained I None
ventricular I Disease
tachyarrhythmias O Disease
. I None
<eof> I None

<s> O None
This I None
study I None
prospectively I None
evaluated I None
the I None
clinical I None
efficacy I None
, I None
the I None
incidence I None
of I None
torsades I Disease
de O Disease
pointes O Disease
, I None
and I None
the I None
presumable I None
risk I None
factors I None
for I None
torsades I Disease
de O Disease
pointes O Disease
in I None
patients I None
treated I None
with I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
for I None
sustained I None
ventricular I Disease
tachyarrhythmias O Disease
. I None
<eof> I None

<s> O None
Eighty I None
- I None
one I None
consecutive I None
patients I None
( I None
54 I None
with I None
coronary I Disease
artery O Disease
disease O Disease
, I None
and I None
20 I None
with I None
dilated I Disease
cardiomyopathy O Disease
) I None
with I None
inducible I None
sustained I None
ventricular I Disease
tachycardia O Disease
or I None
ventricular I Disease
fibrillation O Disease
received I None
oral I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
to I None
prevent I None
induction I None
of I None
the I None
ventricular I Disease
tachyarrhythmia O Disease
. I None
<eof> I None

<s> O None
During I None
oral I None
loading I None
with I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
, I None
continuous I None
electrocardiographic I None
( I None
ECG I None
) I None
monitoring I None
was I None
performed I None
. I None
<eof> I None

<s> O None
Those I None
patients I None
in I None
whom I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
prevented I None
induction I None
of I None
ventricular I Disease
tachycardia O Disease
or I None
ventricular I Disease
fibrillation O Disease
were I None
discharged I None
with I None
the I None
drug I None
and I None
followed I None
up I None
on I None
an I None
outpatient I None
basis I None
for I None
21 I None
+ I None
/- I None
<eof> I None

<s> O None
18 I None
months I None
. I None
<eof> I None

<s> O None
Induction I None
of I None
the I None
ventricular I Disease
tachyarrhythmia O Disease
was I None
prevented I None
by I None
oral I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
in I None
35 I None
( I None
43 I None
% I None
) I None
patients I None
; I None
the I None
ventricular I Disease
tachyarrhythmia O Disease
remained I None
inducible I None
in I None
40 I None
( I None
49 I None
% I None
) I None
patients I None
; I None
and I None
two I None
( I None
2.5 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
did I None
not I None
tolerate I None
even I None
40 I None
mg I None
of I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
once I None
daily I None
. I None
<eof> I None

<s> O None
Four I None
( I None
5 I None
% I None
) I None
patients I None
had I None
from I None
<eof> I None

<s> O None
torsades I Disease
de O Disease
pointes O Disease
during I None
the I None
initial I None
oral I None
treatment I None
with I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
. I None
<eof> I None

<s> O None
Neither I None
ECG I None
[ I None
sinus I None
- I None
cycle I None
length I None
( I None
SCL I None
) I None
, I None
QT I None
or I None
QTc I None
interval I None
, I None
or I None
U I None
wave I None
] I None
nor I None
clinical I None
parameters I None
identified I None
patients I None
at I None
risk I None
for I None
torsades I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
oral I None
dose I None
of I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
was I None
significantly I None
lower I None
in I None
patients I None
with I None
torsades I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
200 I None
+ I None
/- I None
46 I None
vs. I None
328 I None
+ I None
/- I None
<eof> I None

<s> O None
53 I None
mg I None
/ I None
day I None
; I None
p I None
= I None
0.0017 I None
) I None
. I None
<eof> I None

<s> O None
Risk I None
factors I None
associated I None
with I None
the I None
development I None
of I None
torsades I Disease
de O Disease
pointes O Disease
were I None
the I None
appearance I None
of I None
an I None
U I None
wave I None
( I None
p I None
= I None
0.049 I None
) I None
, I None
female I None
gender I None
( I None
p I None
= I None
0.015 I None
) I None
, I None
and I None
significant I None
dose I None
- I None
corrected I None
changes I None
of I None
SCL I None
, I None
QT I None
interval I None
, I None
and I None
QTc I None
interval I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
During I None
follow I None
- I None
up I None
, I None
seven I None
( I None
20 I None
% I None
) I None
patients I None
had I None
a I None
nonfatal I None
ventricular I Disease
tachycardia O Disease
recurrence I None
, I None
and I None
two I None
( I None
6 I None
% I None
) I None
patients I None
died I None
suddenly I None
. I None
<eof> I None

<s> O None
One I None
female I None
patient I None
with I None
stable I None
cardiac I Disease
disease O Disease
had I None
recurrent I None
<eof> I None

<s> O None
torsades I Disease
de O Disease
pointes O Disease
after I None
2 I None
years I None
of I None
successful I None
treatment I None
with I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
. I None
<eof> I None

<s> O None
Torsades I Disease
de O Disease
pointes O Disease
occurred I None
early I None
during I None
treatment I None
even I None
with I None
low I None
doses I None
of I None
oral I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
. I None
<eof> I None

<s> O None
Pronounced I None
changes I None
in I None
the I None
surface I None
ECG I None
( I None
cycle I None
length I None
, I None
QT I None
, I None
and I None
QTc I None
) I None
in I None
relation I None
to I None
the I None
dose I None
of I None
oral I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
might I None
identify I None
a I None
subgroup I None
of I None
patients I None
with I None
an I None
increased I None
risk I None
for I None
torsades I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
Other I None
ECG I None
parameters I None
before I None
the I None
application I None
of I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
did I None
not I None
identify I None
patients I None
at I None
increased I None
risk I None
for I None
torsades I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
Recurrence I None
rates I None
of I None
ventricular I Disease
tachyarrhythmias O Disease
are I None
high I None
despite I None
complete I None
suppression I None
of I None
the I None
arrhythmia I Disease
during I None
programmed I None
stimulation I None
. I None
<eof> I None

<s> O None
Therefore I None
programmed I None
electrical I None
stimulation I None
in I None
the I None
case I None
of I None
d I Chemical
, O Chemical
l O Chemical
- O Chemical
sotalol O Chemical
seems I None
to I None
be I None
of I None
limited I None
prognostic I None
value I None
. I None
<eof> I None

<s> O None
Chronic I None
hyperprolactinemia I Disease
and I None
changes I None
in I None
dopamine I Chemical
neurons I None
. I None
<eof> I None

<s> O None
The I None
tuberoinfundibular I None
dopaminergic I None
( I None
TIDA I None
) I None
system I None
is I None
known I None
to I None
inhibit I None
prolactin I None
( I None
PRL I None
) I None
secretion I None
. I None
<eof> I None

<s> O None
In I None
young I None
animals I None
this I None
system I None
responds I None
to I None
acute I None
elevations I None
in I None
serum I None
PRL I None
by I None
increasing I None
its I None
activity I None
. I None
<eof> I None

<s> O None
However I None
, I None
this I None
responsiveness I None
is I None
lost I None
in I None
aging I None
rats I None
with I None
chronically I None
high I None
serum I None
PRL I None
levels I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
induce I None
hyperprolactinemia I Disease
in I None
rats I None
for I None
extended I None
periods I None
of I None
time I None
and I None
examine I None
its I None
effects I None
on I None
dopaminergic I None
systems I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Hyperprolactinemia I Disease
was I None
induced I None
by I None
treatment I None
with I None
haloperidol I Chemical
, I None
a I None
dopamine I Chemical
receptor I None
antagonist I None
, I None
and I None
Palkovits I None
' I None
microdissection I None
technique I None
in I None
combination I None
with I None
high I None
- I None
performance I None
liquid I None
chromatography I None
was I None
used I None
to I None
measure I None
neurotransmitter I None
concentrations I None
in I None
several I None
areas I None
of I None
the I None
brain I None
. I None
<eof> I None

<s> O None
After I None
6 I None
months I None
of I None
hyperprolactinemia I Disease
, I None
dopamine I Chemical
( I None
DA I Chemical
) I None
concentrations I None
in I None
the I None
median I None
eminence I None
( I None
ME I None
) I None
increased I None
by I None
84 I None
% I None
over I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
Nine I None
months I None
of I None
hyperprolactinemia I Disease
produced I None
a I None
50 I None
% I None
increase I None
in I None
DA I Chemical
concentrations I None
in I None
the I None
ME I None
over I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
However I None
, I None
DA I Chemical
response I None
was I None
lost I None
if I None
a I None
9-month I None
long I None
haloperidol I Chemical
-induced I None
hyperprolactinemia I Disease
was I None
followed I None
by I None
a I None
1 I None
1/2 I None
month I None
- I None
long I None
extremely I None
high I None
increase I None
in I None
serum I None
PRL I None
levels I None
produced I None
by I None
implantation I None
of I None
MMQ I None
cells I None
under I None
the I None
kidney I None
capsule I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
change I None
in I None
the I None
levels I None
of I None
DA I Chemical
, I None
norepinephrine I Chemical
<eof> I None

<s> O None
( I None
NE I Chemical
) I None
, I None
serotonin I Chemical
<eof> I None

<s> O None
( I None
5-HT I Chemical
) I None
, I None
or I None
their I None
metabolites I None
in I None
the I None
arcuate I None
nucleus I None
( I None
AN I None
) I None
, I None
medial I None
preoptic I None
area I None
( I None
MPA I None
) I None
, I None
caudate I None
putamen I None
( I None
CP I None
) I None
, I None
substantia I None
nigra I None
( I None
SN I None
) I None
, I None
and I None
zona I None
incerta I None
( I None
ZI I None
) I None
, I None
except I None
for I None
a I None
decrease I None
in I None
5-hydroxyindoleacetic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
5-HIAA I Chemical
) I None
in I None
the I None
AN I None
after I None
6-months I None
of I None
hyperprolactinemia I Disease
and I None
an I None
increase I None
in I None
DA I Chemical
concentrations I None
in I None
the I None
AN I None
after I None
9-months I None
of I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
hyperprolactinemia I Disease
specifically I None
affects I None
TIDA I None
neurons I None
and I None
these I None
effects I None
vary I None
, I None
depending I None
on I None
the I None
duration I None
and I None
intensity I None
of I None
hyperprolactinemia I Disease
. I None
<eof> I None

<s> O None
The I None
age I None
- I None
related I None
decrease I None
in I None
hypothalamic I None
dopamine I Chemical
function I None
may I None
be I None
associated I None
with I None
increases I None
in I None
PRL I None
secretion I None
. I None
<eof> I None

<s> O None
Treatment I None
- I None
related I None
disseminated I None
necrotizing I None
leukoencephalopathy I Disease
with I None
characteristic I None
contrast I None
enhancement I None
of I None
the I None
white I None
matter I None
. I None
<eof> I None

<s> O None
This I None
report I None
describes I None
unique I None
contrast I None
enhancement I None
of I None
the I None
white I None
matter I None
on I None
T1-weighted I None
magnetic I None
resonance I None
images I None
of I None
two I None
patients I None
with I None
disseminated I None
necrotizing I None
leukoencephalopathy I Disease
, I None
which I None
developed I None
from I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
treated I None
with I None
high I None
- I None
dose I None
methotrexate I Chemical
. I None
<eof> I None

<s> O None
In I None
both I None
patients I None
, I None
the I None
enhancement I None
was I None
more I None
pronounced I None
near I None
the I None
base I None
of I None
the I None
brain I None
than I None
at I None
the I None
vertex I None
. I None
<eof> I None

<s> O None
Necropsy I None
of I None
the I None
first I None
case I None
revealed I None
loss I Disease
of O Disease
myelination O Disease
and I None
necrosis I Disease
of I None
the I None
white I None
matter I None
. I None
<eof> I None

<s> O None
Possible I None
mechanisms I None
causing I None
such I None
a I None
leukoencephalopathy I Disease
are I None
discussed I None
. I None
<eof> I None

<s> O None
Thrombotic I Disease
complications I None
in I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
during I None
all I Chemical
- O Chemical
trans O Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
acute I Disease
renal O Disease
failure O Disease
, I None
due I None
to I None
occlusion I Disease
of O Disease
renal O Disease
vessels O Disease
in I None
a I None
patient I None
with I None
acute I Disease
promyelocytic O Disease
leukemia O Disease
<eof> I None

<s> O None
( I None
APL I Disease
) I None
treated I None
with I None
all I Chemical
- O Chemical
trans O Chemical
- O Chemical
retinoic O Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
ATRA I Chemical
) I None
and I None
tranexamic I Chemical
acid O Chemical
has I None
been I None
described I None
recently I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
acute I Disease
renal O Disease
failure O Disease
in I None
an I None
APL I Disease
patient I None
treated I None
with I None
ATRA I Chemical
alone I None
. I None
<eof> I None

<s> O None
This I None
case I None
further I None
supports I None
the I None
concern I None
about I None
thromboembolic I Disease
complications I None
associated I None
with I None
ATRA I Chemical
therapy I None
in I None
APL I Disease
patients I None
. I None
<eof> I None

<s> O None
The I None
patients I None
, I None
a I None
43-year I None
- I None
old I None
man I None
, I None
presented I None
all I None
the I None
signs I None
and I None
symptoms I None
of I None
APL I Disease
and I None
was I None
included I None
in I None
a I None
treatment I None
protocol I None
with I None
ATRA I Chemical
. I None
<eof> I None

<s> O None
After I None
10 I None
days I None
of I None
treatment I None
, I None
he I None
developed I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
that I None
was I None
completely I None
reversible I None
after I None
complete I None
remission I None
of I None
<eof> I None

<s> O None
APL I Disease
was I None
achieved I None
and I None
therapy I None
discontinued I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
ATRA I Chemical
is I None
a I None
valid I None
therapeutic I None
choice I None
for I None
patients I None
with I None
APL I Disease
, I None
although I None
the I None
procoagulant I None
tendency I None
is I None
not I None
completely I None
corrected I None
. I None
<eof> I None

<s> O None
Thrombotic I Disease
events I None
, I None
however I None
, I None
could I None
be I None
avoided I None
by I None
using I None
low I None
- I None
dose I None
heparin I Chemical
. I None
<eof> I None

<s> O None
Pupillary I None
changes I None
associated I None
with I None
the I None
development I None
of I None
stimulant I None
- I None
induced I None
mania I Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
A I None
30-year I None
- I None
old I None
cocaine I Chemical
-dependent I None
man I None
who I None
was I None
a I None
subject I None
in I None
a I None
study I None
evaluating I None
the I None
anticraving I None
efficacy I None
of I None
the I None
stimulant I None
medication I None
diethylpropion I Chemical
<eof> I None

<s> O None
( I None
DEP I Chemical
) I None
became I None
manic I Disease
during I None
his I None
second I None
week I None
on I None
the I None
study I None
drug I None
. I None
<eof> I None

<s> O None
Pupillometric I None
changes I None
while I None
on I None
DEP I Chemical
, I None
especially I None
changes I None
in I None
the I None
total I None
power I None
of I None
pupillary I Disease
oscillation O Disease
, I None
were I None
dramatically I None
different I None
than I None
those I None
observed I None
in I None
the I None
eight I None
other I None
study I None
subjects I None
who I None
did I None
not I None
become I None
manic I Disease
. I None
<eof> I None

<s> O None
The I None
large I None
changes I None
in I None
total I None
power I None
of I None
pupillary I Disease
oscillation O Disease
occurred I None
a I None
few I None
days I None
before I None
the I None
patient I None
became I None
fully I None
manic I Disease
. I None
<eof> I None

<s> O None
Such I None
medication I None
- I None
associated I None
changes I None
in I None
the I None
total I None
power I None
of I None
pupillary I Disease
oscillation O Disease
might I None
be I None
of I None
utility I None
in I None
identifying I None
persons I None
at I None
risk I None
for I None
manic I Disease
<eof> I None

<s> O None
-like I None
adverse I None
effects I None
during I None
the I None
medical I None
use I None
of I None
psychomotor I None
stimulants I None
or I None
sympathomimetic I None
agents I None
. I None
<eof> I None

<s> O None
The I None
negative I None
mucosal I None
potential I None
: I None
separating I None
central I None
and I None
peripheral I None
effects I None
of I None
NSAIDs I None
in I None
man I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
We I None
wanted I None
to I None
test I None
whether I None
assessment I None
of I None
both I None
a I None
central I None
pain I Disease
-related I None
signal I None
( I None
chemo I None
- I None
somatosensory I None
evoked I None
potential I None
, I None
CSSEP I None
) I None
and I None
a I None
concomitantly I None
recorded I None
peripheral I None
signal I None
( I None
negative I None
mucosal I None
potential I None
, I None
NMP I None
) I None
allows I None
for I None
separation I None
of I None
central I None
and I None
peripheral I None
effects I None
of I None
NSAIDs I None
. I None
<eof> I None

<s> O None
For I None
this I None
purpose I None
, I None
experimental I None
conditions I None
were I None
created I None
in I None
which I None
NSAIDs I None
had I None
previously I None
been I None
observed I None
to I None
produce I None
effects I None
on I None
phasic I None
and I None
tonic I None
pain I Disease
by I None
either I None
central I None
or I None
peripheral I None
mechanisms I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
According I None
to I None
a I None
double I None
- I None
blind I None
, I None
randomised I None
, I None
controlled I None
, I None
threefold I None
cross I None
- I None
over I None
design I None
, I None
18 I None
healthy I None
subjects I None
( I None
11 I None
males I None
, I None
7 I None
females I None
; I None
mean I None
age I None
26 I None
years I None
) I None
received I None
either I None
placebo I None
, I None
400 I None
mg I None
ibuprofen I Chemical
, I None
or I None
800 I None
mg I None
ibuprofen I Chemical
. I None
<eof> I None

<s> O None
Phasic I None
pain I Disease
was I None
applied I None
by I None
means I None
of I None
short I None
pulses I None
of I None
CO2 I Chemical
to I None
the I None
nasal I None
mucosa I None
( I None
stimulus I None
duration I None
500 I None
ms I None
, I None
interval I None
approximately I None
60 I None
s I None
) I None
, I None
and I None
tonic I None
pain I Disease
was I None
induced I None
in I None
the I None
nasal I None
cavity I None
by I None
means I None
of I None
dry I None
air I None
of I None
controlled I None
temperature I None
, I None
humidity I None
and I None
flow I None
rate I None
( I None
22 I None
degrees I None
C I None
, I None
0 I None
% I None
relative I None
humidity I None
, I None
145 I None
ml.s-1 I None
) I None
. I None
<eof> I None

<s> O None
Both I None
CSSEPs I None
as I None
central I None
and I None
NMPs I None
as I None
peripheral I None
correlates I None
of I None
pain I Disease
were I None
obtained I None
in I None
response I None
to I None
the I None
CO2 I Chemical
stimuli I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
the I None
subjects I None
rated I None
the I None
intensity I None
of I None
both I None
phasic I None
and I None
tonic I None
pain I Disease
by I None
means I None
of I None
visual I None
analogue I None
scales I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
As I None
described I None
earlier I None
, I None
administration I None
of I None
ibuprofen I Chemical
was I None
followed I None
by I None
a I None
decrease I None
in I None
tonic I None
pain I Disease
but I None
- I None
relative I None
to I None
placebo I None
- I None
an I None
increase I None
in I None
correlates I None
of I None
phasic I None
pain I Disease
, I None
indicating I None
a I None
specific I None
effect I None
of I None
ibuprofen I Chemical
on I None
the I None
interaction I None
between I None
the I None
pain I Disease
stimuli I None
under I None
these I None
special I None
experimental I None
conditions I None
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
similar I None
behaviour I None
of I None
CSSEP I None
and I None
NMP I None
, I None
it I None
was I None
concluded I None
that I None
the I None
pharmacological I None
process I None
underlying I None
this I None
phenomenon I None
was I None
localised I None
in I None
the I None
periphery I None
. I None
<eof> I None

<s> O None
By I None
means I None
of I None
the I None
simultaneous I None
recording I None
of I None
interrelated I None
peripheral I None
and I None
central I None
electrophysiologic I None
correlates I None
of I None
nociception I None
, I None
it I None
was I None
possible I None
to I None
separate I None
central I None
and I None
peripheral I None
effects I None
of I None
an I None
NSAID I None
. I None
<eof> I None

<s> O None
The I None
major I None
advantage I None
of I None
this I None
pain I Disease
model I None
is I None
the I None
possibility I None
of I None
obtaining I None
peripheral I None
pain I Disease
-related I None
activity I None
directly I None
using I None
a I None
non I None
- I None
invasive I None
technique I None
in I None
humans I None
. I None
<eof> I None

<s> O None
Acute I None
severe I None
depression I Disease
following I None
peri I None
- I None
operative I None
ondansetron I Chemical
. I None
<eof> I None

<s> O None
A I None
41-year I None
- I None
old I None
woman I None
with I None
a I None
strong I None
history I None
of I None
postoperative I Disease
nausea O Disease
and O Disease
vomiting O Disease
presented I None
for I None
abdominal I None
hysterectomy I None
3 I None
months I None
after I None
a I None
previous I None
anaesthetic I None
where I None
ondansetron I Chemical
<eof> I None

<s> O None
prophylaxis I None
had I None
been I None
used I None
. I None
<eof> I None

<s> O None
She I None
had I None
developed I None
a I None
severe I None
acute I None
major I Disease
depression O Disease
disorder O Disease
almost I None
immediately I None
thereafter I None
, I None
possibly I None
related I None
to I None
the I None
use I None
of I None
a I None
serotonin I Chemical
antagonist I None
. I None
<eof> I None

<s> O None
Nine I None
years I None
before I None
she I None
had I None
experienced I None
a I None
self I None
- I None
limited I None
puerperal I None
depressive I Disease
episode O Disease
. I None
<eof> I None

<s> O None
Anaesthesia I None
with I None
a I None
propofol I Chemical
infusion I None
and I None
avoidance I None
of I None
serotonin I Chemical
antagonists I None
provided I None
a I None
nausea I Disease
-free I None
postoperative I None
course I None
without I None
exacerbation I None
of I None
the I None
depression I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Hypertensive I Disease
response I None
during I None
dobutamine I Chemical
stress I None
echocardiography I None
. I None
<eof> I None

<s> O None
Among I None
3,129 I None
dobutamine I Chemical
stress I None
echocardiographic I None
studies I None
, I None
a I None
hypertensive I Disease
response I None
, I None
defined I None
as I None
systolic I None
blood I None
pressure I None
( I None
BP I None
) I None
> I None
or I None
= I None
220 I None
mm I None
Hg I None
and/or I None
diastolic I None
BP I None
> I None
or I None
= I None
110 I None
mm I None
Hg I None
, I None
occurred I None
in I None
30 I None
patients I None
( I None
1 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
this I None
response I None
more I None
often I None
had I None
a I None
history I None
of I None
hypertension I Disease
and I None
had I None
higher I None
resting I None
systolic I None
and I None
diastolic I None
BP I None
before I None
dobutamine I Chemical
infusion I None
. I None
<eof> I None

<s> O None
Continuously I None
nebulized I None
albuterol I Chemical
in I None
severe I None
exacerbations I None
of I None
asthma I Disease
in I None
adults I None
: I None
a I None
case I None
- I None
controlled I None
study I None
. I None
<eof> I None

<s> O None
A I None
retrospective I None
, I None
case I None
- I None
controlled I None
analysis I None
comparing I None
patients I None
admitted I None
to I None
a I None
medical I None
intensive I None
care I None
unit I None
with I None
severe I None
exacerbations I None
of I None
asthma I Disease
who I None
received I None
continuously I None
nebulized I None
albuterol I Chemical
( I None
CNA I None
) I None
versus I None
intermittent I None
albuterol I Chemical
<eof> I None

<s> O None
( I None
INA I None
) I None
treatments I None
is I None
reported I None
. I None
<eof> I None

<s> O None
Forty I None
matched I None
pairs I None
of I None
patients I None
with I None
asthma I Disease
are I None
compared I None
. I None
<eof> I None

<s> O None
CNA I None
was I None
administered I None
for I None
a I None
mean I None
of I None
11 I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
hr I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
cardiac I Disease
dysrhythmias O Disease
was I None
similar I None
between I None
groups I None
. I None
<eof> I None

<s> O None
Symptomatic I None
<eof> I None

<s> O None
hypokalemia I Disease
did I None
not I None
occur I None
. I None
<eof> I None

<s> O None
CNA I None
patients I None
had I None
higher I None
heart I None
rates I None
during I None
treatment I None
, I None
which I None
may I None
reflect I None
severity I None
of I None
illness I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
intubation I None
was I None
similar I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
CNA I None
and I None
INA I None
demonstrated I None
similar I None
profiles I None
with I None
regard I None
to I None
safety I None
, I None
morbidity I None
, I None
and I None
mortality I None
. I None
<eof> I None

<s> O None
Hyperosmolar I Disease
nonketotic O Disease
coma O Disease
precipitated I None
by I None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
. I None
<eof> I None

<s> O None
A I None
45-year I None
- I None
old I None
man I None
, I None
with I None
a I None
10-year I None
history I None
of I None
manic I Disease
depression O Disease
treated I None
with I None
lithium I Chemical
, I None
was I None
admitted I None
with I None
hyperosmolar I Disease
, O Disease
nonketotic O Disease
coma O Disease
. I None
<eof> I None

<s> O None
He I None
gave I None
a I None
five I None
- I None
year I None
history I None
of I None
polyuria I Disease
and I None
polydipsia I Disease
, I None
during I None
which I None
time I None
urinalysis I None
had I None
been I None
negative I None
for I None
glucose I Chemical
. I None
<eof> I None

<s> O None
After I None
recovery I None
from I None
hyperglycaemia I Disease
, I None
he I None
remained I None
<eof> I None

<s> O None
polyuric I Disease
despite I None
normal I None
blood I None
glucose I Chemical
concentrations I None
; I None
<eof> I None

<s> O None
water I None
deprivation I None
testing I None
indicated I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
, I None
likely I None
to I None
be I None
<eof> I None

<s> O None
lithium I Chemical
<eof> I None

<s> O None
-induced I None
. I None
<eof> I None

<s> O None
We I None
hypothesize I None
that I None
when I None
this I None
man I None
developed I None
type I Disease
2 O Disease
diabetes O Disease
, I None
chronic I None
polyuria I Disease
due I None
to I None
nephrogenic I Disease
diabetes O Disease
insipidus O Disease
was I None
sufficient I None
to I None
precipitate I None
hyperosmolar I None
dehydration I Disease
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
intracoronary I None
infusion I None
of I None
cocaine I Chemical
on I None
left I None
ventricular I None
systolic I None
and I None
diastolic I None
function I None
in I None
humans I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
In I None
dogs I None
, I None
a I None
large I None
amount I None
of I None
intravenous I None
cocaine I Chemical
causes I None
a I None
profound I None
deterioration I Disease
of O Disease
left O Disease
ventricular O Disease
( O Disease
LV O Disease
) O Disease
systolic O Disease
function O Disease
and I None
an I None
increase I None
in I None
LV I None
end I None
- I None
diastolic I None
pressure I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
done I None
to I None
assess I None
the I None
influence I None
of I None
a I None
high I None
intracoronary I None
cocaine I Chemical
concentration I None
on I None
LV I None
systolic I None
and I None
diastolic I None
function I None
in I None
humans I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
<eof> I None

<s> O None
In I None
20 I None
patients I None
( I None
14 I None
men I None
and I None
6 I None
women I None
aged I None
39 I None
to I None
72 I None
years I None
) I None
referred I None
for I None
cardiac I None
catheterization I None
for I None
the I None
evaluation I None
of I None
chest I Disease
pain O Disease
, I None
we I None
measured I None
heart I None
rate I None
, I None
systemic I None
arterial I None
pressure I None
, I None
LV I None
pressure I None
and I None
its I None
first I None
derivative I None
( I None
dP I None
/ I None
dt I None
) I None
, I None
and I None
LV I None
volumes I None
and I None
ejection I None
fraction I None
before I None
and I None
during I None
the I None
final I None
2 I None
to I None
3 I None
minutes I None
of I None
a I None
15-minute I None
intracoronary I None
infusion I None
of I None
saline I None
( I None
n=10 I None
, I None
control I None
subjects I None
) I None
or I None
cocaine I Chemical
hydrochloride O Chemical
1 I None
mg I None
/ I None
min I None
( I None
n=10 I None
) I None
. I None
<eof> I None

<s> O None
No I None
variable I None
changed I None
with I None
saline I None
. I None
<eof> I None

<s> O None
With I None
cocaine I Chemical
, I None
the I None
drug I None
concentration I None
in I None
blood I None
obtained I None
from I None
the I None
coronary I None
sinus I None
was I None
3.0+/-0.4 I None
( I None
mean+/-SD I None
) I None
mg I None
/ I None
L I None
, I None
similar I None
in I None
magnitude I None
to I None
the I None
blood I None
cocaine I Chemical
concentration I None
reported I None
in I None
abusers I None
dying I None
of I None
cocaine I Chemical
intoxication I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
induced I None
no I None
significant I None
change I None
in I None
heart I None
rate I None
, I None
LV I None
dP I None
/ I None
dt I None
( I None
positive I None
or I None
negative I None
) I None
, I None
or I None
LV I None
end I None
- I None
diastolic I None
volume I None
, I None
but I None
it I None
caused I None
an I None
increase I None
in I None
systolic I None
and I None
mean I None
arterial I None
pressures I None
, I None
LV I None
end I None
- I None
diastolic I None
pressure I None
, I None
and I None
LV I None
end I None
- I None
systolic I None
volume I None
, I None
as I None
well I None
as I None
a I None
decrease I None
in I None
LV I None
ejection I None
fraction I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
humans I None
, I None
the I None
intracoronary I None
infusion I None
of I None
cocaine I Chemical
sufficient I None
in I None
amount I None
to I None
achieve I None
a I None
high I None
drug I None
concentration I None
in I None
coronary I None
sinus I None
blood I None
causes I None
a I None
deterioration I Disease
of O Disease
LV O Disease
systolic O Disease
and O Disease
diastolic O Disease
performance O Disease
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
thrombocytopenia I Disease
, I None
paradoxical I None
thromboembolism I Disease
, I None
and I None
other I None
side I None
effects I None
of I None
heparin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Although I None
several I None
new I None
anticoagulant I None
drugs I None
are I None
in I None
development I None
, I None
heparin I Chemical
remains I None
the I None
drug I None
of I None
choice I None
for I None
most I None
anticoagulation I None
needs I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
effects I None
of I None
heparin I Chemical
are I None
meritorious I None
, I None
but I None
side I None
effects I None
do I None
exist I None
. I None
<eof> I None

<s> O None
Important I None
untoward I None
effects I None
of I None
heparin I Chemical
therapy I None
including I None
heparin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
, I None
heparin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
osteoporosis I Disease
, I None
eosinophilia I Disease
, I None
skin I Disease
reactions O Disease
, I None
allergic I Disease
reactions O Disease
other I None
than I None
thrombocytopenia I Disease
and I None
alopecia I Disease
will I None
be I None
discussed I None
in I None
this I None
article I None
. I None
<eof> I None

<s> O None
Nonopaque I None
crystal I None
deposition I None
causing I None
ureteric I Disease
obstruction O Disease
in I None
patients I None
with I None
HIV I None
undergoing I None
indinavir I Chemical
therapy I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
We I None
describe I None
the I None
unique I None
CT I None
features I None
of I None
ureteric I Disease
calculi O Disease
in I None
six I None
HIV I Disease
- O Disease
infected O Disease
patients I None
receiving I None
indinavir I Chemical
, I None
the I None
most I None
commonly I None
used I None
HIV I None
protease I None
inhibitor I None
, I None
which I None
is I None
associated I None
with I None
an I None
increased I None
incidence I None
of I None
urolithiasis I Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Ureteric I Disease
obstruction O Disease
caused I None
by I None
precipitated I None
indinavir I Chemical
crystals I None
may I None
be I None
difficult I None
to I None
diagnose I None
with I None
unenhanced I None
CT I None
. I None
<eof> I None

<s> O None
The I None
calculi I None
are I None
not I None
opaque I None
, I None
and I None
secondary I None
signs I None
of I None
obstruction I None
may I None
be I None
absent I None
or I None
minimal I None
and I None
should I None
be I None
sought I None
carefully I None
. I None
<eof> I None

<s> O None
Images I None
may I None
need I None
to I None
be I None
obtained I None
using I None
i.v I None
. I None
<eof> I None

<s> O None
contrast I None
material I None
to I None
enable I None
diagnosis I None
of I None
ureteric I None
stones I None
or I None
obstruction I None
in I None
patients I None
with I None
HIV I Disease
infection O Disease
who I None
receive I None
indinavir I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Ischemic I Disease
colitis O Disease
and I None
sumatriptan I Chemical
use I None
. I None
<eof> I None

<s> O None
Sumatriptan I Chemical
succinate O Chemical
, I None
a I None
serotonin I Chemical
-1 I None
( I None
5-hydroxytryptamine I Chemical
-1 I None
) I None
receptor I None
agonist I None
, I None
is I None
an I None
antimigraine I None
drug I None
that I None
is I None
reported I None
to I None
act I None
by I None
selectively I None
constricting I None
intracranial I None
arteries I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
vasopressor I None
responses I None
that I None
are I None
distinct I None
from I None
the I None
cranial I None
circulation I None
have I None
been I None
demonstrated I None
to I None
occur I None
in I None
the I None
systemic I None
, I None
pulmonary I None
, I None
and I None
coronary I None
circulations I None
. I None
<eof> I None

<s> O None
Cases I None
have I None
been I None
published I None
of I None
coronary I Disease
vasospasm O Disease
, I None
myocardial I Disease
ischemia O Disease
, I None
and I None
myocardial I Disease
infarction O Disease
occurring I None
after I None
sumatriptan I Chemical
use I None
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
the I None
development I None
of I None
8 I None
serious I None
cases I None
of I None
ischemic I Disease
colitis O Disease
in I None
patients I None
with I None
migraine I Disease
treated I None
with I None
sumatriptan I Chemical
. I None
<eof> I None

<s> O None
Pallidotomy I None
with I None
the I None
gamma I None
knife I None
: I None
a I None
positive I None
experience I None
. I None
<eof> I None

<s> O None
51 I None
patients I None
with I None
medically I None
refractory I None
Parkinson I Disease
's O Disease
disease O Disease
underwent I None
stereotactic I None
posteromedial I None
pallidotomy I None
between I None
August I None
1993 I None
and I None
February I None
1997 I None
for I None
treatment I None
of I None
bradykinesia I Disease
, I None
rigidity I Disease
, I None
and I None
L I Chemical
- O Chemical
DOPA O Chemical
-induced I None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
In I None
29 I None
patients I None
, I None
the I None
pallidotomies I None
were I None
performed I None
with I None
the I None
Leksell I None
Gamma I None
Knife I None
and I None
in I None
22 I None
they I None
were I None
performed I None
with I None
the I None
standard I None
radiofrequency I None
( I None
RF I None
) I None
method I None
. I None
<eof> I None

<s> O None
Clinical I None
assessment I None
as I None
well I None
as I None
blinded I None
ratings I None
of I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
Rating I None
Scale I None
( I None
UPDRS I None
) I None
scores I None
were I None
carried I None
out I None
pre- I None
and I None
postoperatively I None
. I None
<eof> I None

<s> O None
Mean I None
follow I None
- I None
up I None
time I None
is I None
20.6 I None
months I None
( I None
range I None
6 I None
- I None
48 I None
) I None
and I None
all I None
except I None
4 I None
patients I None
have I None
been I None
followed I None
more I None
than I None
one I None
year I None
. I None
<eof> I None

<s> O None
85 I None
percent I None
of I None
patients I None
with I None
dyskinesias I Disease
were I None
relieved I None
of I None
symptoms I None
, I None
regardless I None
of I None
whether I None
the I None
pallidotomies I None
were I None
performed I None
with I None
the I None
Gamma I None
Knife I None
or I None
radiofrequency I None
methods I None
. I None
<eof> I None

<s> O None
About I None
2/3 I None
of I None
the I None
patients I None
in I None
both I None
Gamma I None
Knife I None
and I None
radiofrequency I None
groups I None
showed I None
improvements I None
in I None
bradykinesia I Disease
and I None
rigidity I Disease
, I None
although I None
when I None
considered I None
as I None
a I None
group I None
neither I None
the I None
Gamma I None
Knife I None
nor I None
the I None
radiofrequency I None
group I None
showed I None
statistically I None
significant I None
improvements I None
in I None
UPDRS I None
scores I None
. I None
<eof> I None

<s> O None
One I None
patient I None
in I None
the I None
Gamma I None
Knife I None
group I None
( I None
3.4 I None
% I None
) I None
developed I None
a I None
homonymous I Disease
hemianopsia O Disease
9 I None
months I None
following I None
treatment I None
and I None
5 I None
patients I None
( I None
27.7 I None
% I None
) I None
in I None
the I None
radiofrequency I None
group I None
became I None
transiently I None
confused I None
postoperatively I None
. I None
<eof> I None

<s> O None
No I None
other I None
complications I None
were I None
seen I None
. I None
<eof> I None

<s> O None
Gamma I None
Knife I None
pallidotomy I None
is I None
as I None
effective I None
as I None
radiofrequency I None
pallidotomy I None
in I None
controlling I None
certain I None
of I None
the I None
symptoms I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
It I None
may I None
be I None
the I None
only I None
practical I None
technique I None
available I None
in I None
certain I None
patients I None
, I None
such I None
as I None
those I None
who I None
take I None
anticoagulants I None
, I None
have I None
bleeding I Disease
diatheses I None
or I None
serious I None
systemic I None
medical I None
illnesses I None
. I None
<eof> I None

<s> O None
It I None
is I None
a I None
viable I None
option I None
for I None
other I None
patients I None
as I None
well I None
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
and I None
methylphenidate I Chemical
. I None
<eof> I None

<s> O None
A I None
1-year I None
- I None
old I None
female I None
presented I None
with I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
probably I None
caused I None
by I None
methylphenidate I Chemical
. I None
<eof> I None

<s> O None
She I None
had I None
defects I None
in I None
the I None
supratentorial I None
brain I None
including I None
the I None
basal I None
ganglia I None
and I None
the I None
striatum I None
( I None
multicystic I Disease
encephalomalacia O Disease
) I None
due I None
to I None
severe I None
perinatal I None
hypoxic I Disease
- O Disease
ischemic O Disease
encephalopathy O Disease
, I None
which I None
was I None
considered I None
to I None
be I None
a I None
possible I None
predisposing I None
factor I None
causing I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
A I None
dopaminergic I None
blockade I None
mechanism I None
generally I None
is I None
accepted I None
as I None
the I None
pathogenesis I None
of I None
this I None
syndrome I None
. I None
<eof> I None

<s> O None
However I None
, I None
methylphenidate I Chemical
is I None
a I None
dopamine I Chemical
agonist I None
via I None
the I None
inhibition I None
of I None
uptake I None
of I None
dopamine I Chemical
, I None
and I None
therefore I None
dopaminergic I None
systems I None
in I None
the I None
brainstem I None
( I None
mainly I None
the I None
midbrain I None
) I None
and I None
the I None
spinal I None
cord I None
were I None
unlikely I None
to I None
participate I None
in I None
the I None
onset I None
of I None
this I None
syndrome I None
. I None
<eof> I None

<s> O None
A I None
relative I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
-ergic I None
deficiency I None
might I None
occur I None
because I None
diazepam I Chemical
, I None
a I None
gamma I Chemical
- O Chemical
aminobutyric O Chemical
acid O Chemical
-mimetic I None
agent I None
, I None
was I None
strikingly I None
effective I None
. I None
<eof> I None

<s> O None
This I None
is I None
the I None
first I None
reported I None
patient I None
with I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
probably I None
caused I None
by I None
methylphenidate I Chemical
. I None
<eof> I None

<s> O None
Differential I None
effects I None
of I None
17alpha I Chemical
- O Chemical
ethinylestradiol O Chemical
on I None
the I None
neutral I None
and I None
acidic I None
pathways I None
of I None
bile I Chemical
salt O Chemical
synthesis I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
17alpha I Chemical
- O Chemical
ethinylestradiol O Chemical
<eof> I None

<s> O None
( I None
EE I Chemical
) I None
on I None
the I None
neutral I None
and I None
acidic I None
biosynthetic I None
pathways I None
of I None
bile I Chemical
salt O Chemical
<eof> I None

<s> O None
( I None
BS I Chemical
) I None
synthesis I None
were I None
evaluated I None
in I None
rats I None
with I None
an I None
intact I None
enterohepatic I None
circulation I None
and I None
in I None
rats I None
with I None
long I None
- I None
term I None
bile I None
diversion I None
to I None
induce I None
BS I Chemical
synthesis I None
. I None
<eof> I None

<s> O None
For I None
this I None
purpose I None
, I None
bile I Chemical
salt O Chemical
pool I None
composition I None
, I None
synthesis I None
of I None
individual I None
BS I Chemical
in I None
vivo I None
, I None
hepatic I None
activities I None
, I None
and I None
expression I None
levels I None
of I None
cholesterol I Chemical
<eof> I None

<s> O None
7alpha I None
- I None
hydroxylase I None
( I None
CYP7A I None
) I None
, I None
and I None
sterol I Chemical
27-hydroxylase I None
( I None
CYP27 I None
) I None
, I None
as I None
well I None
as I None
of I None
other I None
enzymes I None
involved I None
in I None
BS I Chemical
synthesis I None
, I None
were I None
analyzed I None
in I None
rats I None
treated I None
with I None
EE I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
, I None
3 I None
days I None
) I None
or I None
its I None
vehicle I None
. I None
<eof> I None

<s> O None
BS I Chemical
pool I None
size I None
was I None
decreased I None
by I None
27 I None
% I None
but I None
total I None
BS I Chemical
synthesis I None
was I None
not I None
affected I None
by I None
EE I Chemical
in I None
intact I None
rats I None
. I None
<eof> I None

<s> O None
Synthesis I None
of I None
cholate I Chemical
was I None
reduced I None
by I None
68 I None
% I None
in I None
EE I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
, I None
while I None
that I None
of I None
chenodeoxycholate I Chemical
was I None
increased I None
by I None
60 I None
% I None
. I None
<eof> I None

<s> O None
The I None
recently I None
identified I None
Delta22-isomer I None
of I None
beta I None
- I None
muricholate I None
contributed I None
for I None
5.4 I None
% I None
and I None
18.3 I None
% I None
( I None
P I None
< I None
0.01 I None
) I None
to I None
the I None
pool I None
in I None
control I None
and I None
EE I Chemical
-treated I None
rats I None
, I None
respectively I None
, I None
but I None
could I None
not I None
be I None
detected I None
in I None
bile I None
after I None
exhaustion I None
of I None
the I None
pool I None
. I None
<eof> I None

<s> O None
A I None
clear I None
reduction I None
of I None
BS I Chemical
synthesis I None
was I None
found I None
in I None
bile I None
- I None
diverted I None
rats I None
treated I None
with I None
EE I Chemical
, I None
yet I None
biliary I None
BS I Chemical
composition I None
was I None
only I None
minimally I None
affected I None
. I None
<eof> I None

<s> O None
Activity I None
of I None
CYP7A I None
was I None
decreased I None
by I None
EE I Chemical
in I None
both I None
intact I None
and I None
bile I None
- I None
diverted I None
rats I None
, I None
whereas I None
the I None
activity I None
of I None
the I None
CYP27 I None
was I None
not I None
affected I None
. I None
<eof> I None

<s> O None
Hepatic I None
mRNA I None
levels I None
of I None
CYP7A I None
were I None
significantly I None
reduced I None
by I None
EE I Chemical
in I None
bile I None
- I None
diverted I None
rats I None
only I None
; I None
CYP27 I None
mRNA I None
levels I None
were I None
not I None
affected I None
by I None
EE I Chemical
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
mRNA I None
levels I None
of I None
sterol I Chemical
<eof> I None

<s> O None
12alpha I None
- I None
hydroxylase I None
and I None
lithocholate I None
<eof> I None

<s> O None
6beta I None
- I None
hydroxylase I None
were I None
increased I None
by I None
bile I None
diversion I None
and I None
suppressed I None
by I None
EE I Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
shows I None
that I None
17alpha I Chemical
- O Chemical
ethinylestradiol O Chemical
<eof> I None

<s> O None
( I None
EE I Chemical
) I None
-induced I None
<eof> I None

<s> O None
intrahepatic I Disease
cholestasis O Disease
in I None
rats I None
is I None
associated I None
with I None
selective I None
inhibition I None
of I None
the I None
neutral I None
pathway I None
of I None
bile I Chemical
salt O Chemical
<eof> I None

<s> O None
( I None
BS I Chemical
) I None
synthesis I None
. I None
<eof> I None

<s> O None
Simultaneous I None
impairment I None
of I None
other I None
enzymes I None
in I None
the I None
BS I Chemical
biosynthetic I None
pathways I None
may I None
contribute I None
to I None
overall I None
effects I None
of I None
EE I Chemical
on I None
BS I Chemical
synthesis I None
. I None
<eof> I None

<s> O None
Glibenclamide I Chemical
-sensitive I None
hypotension I Disease
produced I None
by I None
helodermin I Chemical
assessed I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
helodermin I Chemical
, I None
a I None
basic I None
35- I None
amino I Chemical
acid O Chemical
peptide I None
isolated I None
from I None
the I None
venom I None
of I None
a I None
lizard I None
salivary I None
gland I None
, I None
on I None
arterial I None
blood I None
pressure I None
and I None
heart I None
rate I None
were I None
examined I None
in I None
the I None
rat I None
, I None
focusing I None
on I None
the I None
possibility I None
that I None
activation I None
of I None
ATP I Chemical
sensitive I None
K I Chemical
+ I None
<eof> I None

<s> O None
( I None
K I Chemical
( I None
ATP I Chemical
) I None
) I None
channels I None
is I None
involved I None
in I None
the I None
responses I None
. I None
<eof> I None

<s> O None
The I None
results I None
were I None
also I None
compared I None
with I None
those I None
of I None
vasoactive I None
intestinal I None
polypeptide I None
( I None
VIP I None
) I None
. I None
<eof> I None

<s> O None
Helodermin I Chemical
produced I None
<eof> I None

<s> O None
hypotension I Disease
in I None
a I None
dose I None
- I None
dependent I None
manner I None
with I None
approximately I None
similar I None
potency I None
and I None
duration I None
to I None
VIP I None
. I None
<eof> I None

<s> O None
Hypotension I Disease
induced I None
by I None
both I None
peptides I None
was I None
significantly I None
attenuated I None
by I None
glibenclamide I Chemical
, I None
which I None
abolished I None
a I None
levcromakalim I Chemical
-produced I None
decrease I None
in I None
arterial I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
Oxyhemoglobin I None
did I None
not I None
affect I None
helodermin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hypotension I Disease
, I None
<eof> I None

<s> O None
whereas I None
it I None
shortened I None
the I None
duration I None
of I None
acetylcholine I Chemical
<eof> I None

<s> O None
( I None
ACh I Chemical
) I None
-produced I None
<eof> I None

<s> O None
hypotension I Disease
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
helodermin I Chemical
-produced I None
<eof> I None

<s> O None
hypotension I Disease
is I None
partly I None
attributable I None
to I None
the I None
activation I None
of I None
glibenclamide I Chemical
-sensitive I None
<eof> I None

<s> O None
K I Chemical
+ I None
channels I None
<eof> I None

<s> O None
( I None
K I Chemical
( I None
ATP I Chemical
) I None
channels I None
) I None
, I None
which I None
presumably I None
exist I None
on I None
arterial I None
smooth I None
muscle I None
cells I None
. I None
<eof> I None

<s> O None
EDRF I None
<eof> I None

<s> O None
( I None
endothelium I None
- I None
derived I None
relaxing I None
factor)/ I None
nitric I Chemical
oxide O Chemical
does I None
not I None
seem I None
to I None
play I None
an I None
important I None
role I None
in I None
the I None
peptide I None
- I None
produced I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
efficacy I None
and I None
adverse I None
event I None
of I None
nifedipine I Chemical
sustained I None
- I None
release I None
tablets I None
for I None
cyclosporin I Chemical
A O Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hypertension I Disease
in I None
patients I None
with I None
psoriasis I Disease
. I None
<eof> I None

<s> O None
Thirteen I None
<eof> I None

<s> O None
psoriatic I Disease
patients I None
with I None
hypertension I Disease
during I None
the I None
course I None
of I None
cyclosporin I Chemical
A O Chemical
therapy I None
were I None
treated I None
for I None
25 I None
months I None
with I None
a I None
calcium I Chemical
channel I None
blocker I None
, I None
sustained I None
- I None
release I None
nifedipine I Chemical
, I None
to I None
study I None
the I None
clinical I None
antihypertensive I None
effects I None
and I None
adverse I None
events I None
during I None
treatment I None
with I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
Seven I None
of I None
the I None
13 I None
patients I None
had I None
exhibited I None
a I None
subclinical I None
hypertensive I Disease
state I None
before I None
cyclosporin I Chemical
A O Chemical
therapy I None
. I None
<eof> I None

<s> O None
Both I None
systolic I None
and I None
diastolic I None
blood I None
pressures I None
of I None
these I None
13 I None
patients I None
were I None
decreased I None
significantly I None
after I None
4 I None
weeks I None
of I None
nifedipine I Chemical
therapy I None
, I None
and I None
blood I None
pressure I None
was I None
maintained I None
within I None
the I None
normal I None
range I None
thereafter I None
for I None
25 I None
months I None
. I None
<eof> I None

<s> O None
The I None
adverse I None
events I None
during I None
combined I None
therapy I None
with I None
cyclosporin I Chemical
A O Chemical
and I None
nifedipine I Chemical
included I None
an I None
increase I None
in I None
blood I Chemical
urea O Chemical
nitrogen O Chemical
levels I None
in I None
9 I None
of I None
the I None
13 I None
patients I None
and I None
development I None
of I None
gingival I Disease
hyperplasia O Disease
in I None
2 I None
of I None
the I None
13 I None
patients I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
indicate I None
that I None
sustained I None
- I None
release I None
nifedipine I Chemical
is I None
useful I None
for I None
hypertensive I Disease
psoriatic I Disease
patients I None
under I None
long I None
- I None
term I None
treatment I None
with I None
cyclosporin I Chemical
A O Chemical
, I None
but I None
that I None
these I None
patients I None
should I None
be I None
monitored I None
for I None
gingival I Disease
hyperplasia O Disease
. I None
<eof> I None

<s> O None
Torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
ventricular I Disease
tachycardia O Disease
during I None
low I None
dose I None
intermittent I None
dobutamine I Chemical
treatment I None
in I None
a I None
patient I None
with I None
dilated I Disease
cardiomyopathy O Disease
and I None
congestive I Disease
heart O Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
authors I None
describe I None
the I None
case I None
of I None
a I None
56-year I None
- I None
old I None
woman I None
with I None
chronic I None
, I None
severe I None
heart I Disease
failure O Disease
secondary I None
to I None
dilated I Disease
cardiomyopathy O Disease
and I None
absence I None
of I None
significant I None
ventricular I Disease
arrhythmias O Disease
who I None
developed I None
QT I Disease
prolongation O Disease
and I None
torsade I Disease
de O Disease
pointes O Disease
ventricular I Disease
tachycardia O Disease
during I None
one I None
cycle I None
of I None
intermittent I None
low I None
dose I None
( I None
2.5 I None
mcg I None
/ I None
kg I None
per I None
min I None
) I None
dobutamine I Chemical
. I None
<eof> I None

<s> O None
This I None
report I None
of I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
ventricular I Disease
tachycardia O Disease
during I None
intermittent I None
dobutamine I Chemical
supports I None
the I None
hypothesis I None
that I None
unpredictable I None
fatal I None
arrhythmias I Disease
may I None
occur I None
even I None
with I None
low I None
doses I None
and I None
in I None
patients I None
with I None
no I None
history I None
of I None
significant I None
rhythm I None
disturbances I None
. I None
<eof> I None

<s> O None
The I None
mechanisms I None
of I None
proarrhythmic I None
effects I None
of I None
Dubutamine I Chemical
are I None
discussed I None
. I None
<eof> I None

<s> O None
Positive I None
skin I None
tests I None
in I None
late I None
reactions I None
to I None
radiographic I None
contrast I Chemical
media O Chemical
. I None
<eof> I None

<s> O None
In I None
the I None
last I None
few I None
years I None
delayed I None
reactions I None
several I None
hours I None
after I None
the I None
injection I None
of I None
radiographic I None
and I None
contrast I Chemical
materials O Chemical
<eof> I None

<s> O None
( I None
PRC I Chemical
) I None
have I None
been I None
described I None
with I None
increasing I None
frequency I None
. I None
<eof> I None

<s> O None
The I None
authors I None
report I None
two I None
observations I None
on I None
patients I None
with I None
delayed I None
reactions I None
in I None
whom I None
intradermoreactions I None
( I None
IDR I None
) I None
and I None
patch I None
tests I None
to I None
a I None
series I None
of I None
ionic I None
and I None
non I None
ionic I None
PRC I Chemical
were I None
studied I None
. I None
<eof> I None

<s> O None
After I None
angiography I None
by I None
the I None
venous I None
route I None
in I None
patient I None
n I None
degree I None
1 I None
a I None
biphasic I None
reaction I None
with I None
an I None
immediate I None
reaction I None
( I None
dyspnea I Disease
, I None
loss I Disease
of O Disease
consciousness O Disease
) I None
and I None
delayed I None
macro I Disease
- O Disease
papular O Disease
rash O Disease
appeared I None
, I None
whilst I None
patient I None
n I None
degree I None
2 I None
developed I None
a I None
generalised I None
sensation I None
of I None
heat I None
, I None
persistent I None
pain I Disease
at I None
the I None
site I None
of I None
injection I None
immediately I None
and I None
a I None
generalised I None
macro I None
- I None
papular I None
reaction I None
after I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
The I None
skin I None
tests I None
revealed I None
positive I None
delayed I None
reactions I None
of I None
24 I None
hours I None
and I None
48 I None
hours I None
by I None
IDR I None
and I None
patch I None
tests I None
to I None
only I None
some I None
PRC I Chemical
with I None
common I None
chains I None
in I None
their I None
structures I None
. I None
<eof> I None

<s> O None
The I None
positive I None
skin I None
tests I None
are I None
in I None
favour I None
of I None
immunological I None
reactions I None
and I None
may I None
help I None
in I None
diagnosis I None
of I None
allergy I Disease
in I None
the I None
patients I None
. I None
<eof> I None

<s> O None
Risk I None
of I None
transient I None
hyperammonemic I None
encephalopathy I None
in I None
cancer I Disease
patients I None
who I None
received I None
continuous I None
infusion I None
of I None
5-fluorouracil I Chemical
with I None
the I None
complication I None
of I None
dehydration I Disease
and I None
infection I Disease
. I None
<eof> I None

<s> O None
From I None
1986 I None
to I None
1998 I None
, I None
29 I None
cancer I Disease
patients I None
who I None
had I None
32 I None
episodes I None
of I None
transient I None
hyperammonemic I None
encephalopathy I None
related I None
to I None
continuous I None
infusion I None
of I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
were I None
identified I None
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
patients I None
had I None
decompensated I None
liver I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Onset I None
of I None
hyperammonemic I None
encephalopathy I None
varied I None
from I None
0.5 I None
to I None
5 I None
days I None
( I None
mean I None
: I None
2.6 I None
+ I None
/- I None
<eof> I None

<s> O None
1.3 I None
days I None
) I None
after I None
the I None
initiation I None
of I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Plasma I None
ammonium I Chemical
level I None
ranged I None
from I None
248 I None
to I None
2387 I None
microg% I None
( I None
mean I None
<eof> I None

<s> O None
: I None
626 I None
+ I None
/- I None
<eof> I None

<s> O None
431 I None
microg% I None
) I None
. I None
<eof> I None

<s> O None
Among I None
the I None
32 I None
episodes I None
, I None
26 I None
( I None
81 I None
% I None
) I None
had I None
various I None
degrees I None
of I None
azotemia I Disease
, I None
18 I None
( I None
56 I None
% I None
) I None
occurred I None
during I None
bacterial I Disease
infections O Disease
and I None
14 I None
( I None
44 I None
% I None
) I None
without I None
<eof> I None

<s> O None
infection I Disease
occurred I None
during I None
periods I None
of I None
dehydration I Disease
. I None
<eof> I None

<s> O None
Higher I None
plasma I None
<eof> I None

<s> O None
ammonium I Chemical
levels I None
and I None
more I None
rapid I None
onset I None
of I None
hyperammonemia I Disease
were I None
seen I None
in I None
18 I None
patients I None
with I None
bacterial I Disease
infections O Disease
( I None
p=0.003 I None
and I None
0.0006 I None
, I None
respectively I None
) I None
and I None
in I None
nine I None
patients I None
receiving I None
high I None
daily I None
doses I None
( I None
2600 I None
or I None
1800 I None
<eof> I None

<s> O None
mg I None
/ I None
m2 I None
) I None
of I None
5-FU I Chemical
<eof> I None

<s> O None
( I None
p=0.0001 I None
and I None
< I None
0.0001 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
In I None
25 I None
out I None
of I None
32 I None
episodes I None
( I None
78 I None
% I None
) I None
, I None
plasma I None
ammonium I Chemical
levels I None
and I None
mental I None
status I None
returned I None
to I None
normal I None
within I None
2 I None
days I None
after I None
adequate I None
management I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
hyperammonemic I None
encephalopathy I None
can I None
occur I None
in I None
patients I None
receiving I None
continuous I None
infusion I None
of I None
5-FU I Chemical
. I None
<eof> I None

<s> O None
Azotemia I Disease
, I None
body I None
fluid I None
insufficiency I None
and I None
bacterial I Disease
infections O Disease
were I None
frequently I None
found I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
It I None
is I None
therefore I None
important I None
to I None
recognize I None
this I None
condition I None
in I None
patients I None
receiving I None
continuous I None
infusion I None
of I None
5-FU I Chemical
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
quinine I Chemical
and I None
4-aminopyridine I Chemical
on I None
conditioned I None
place I None
preference I None
and I None
changes I None
in I None
motor I None
activity I None
induced I None
by I None
morphine I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
two I None
unselective I None
potassium I Chemical
<eof> I None

<s> O None
( I None
K I Chemical
( I None
+ I None
) I None
- I None
) I None
channel I None
blockers I None
, I None
quinine I Chemical
( I None
12.5 I None
, I None
25 I None
and I None
50 I None
mg I None
/ I None
kg I None
) I None
and I None
4-aminopyridine I Chemical
( I None
1 I None
and I None
2 I None
mg I None
/ I None
kg I None
) I None
, I None
on I None
conditioned I None
place I None
preference I None
and I None
biphasic I None
changes I None
in I None
motor I None
activity I None
induced I None
by I None
morphine I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
) I None
were I None
tested I None
in I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
Quinine I Chemical
is I None
known I None
to I None
block I None
voltage- I None
, I None
calcium I Chemical
- I None
and I None
ATP I Chemical
-sensitive I None
K I Chemical
( I None
+ I None
) I None
-channels I None
while I None
4-aminopyridine I Chemical
is I None
known I None
to I None
block I None
voltage I None
- I None
sensitive I None
K I Chemical
( I None
+ I None
<eof> I None

<s> O None
) I None
-channels I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
In I None
the I None
counterbalanced I None
method I None
, I None
quinine I Chemical
attenuated I None
morphine I Chemical
-induced I None
place I None
preference I None
, I None
whereas I None
4-aminopyridine I Chemical
was I None
ineffective I None
. I None
<eof> I None

<s> O None
In I None
the I None
motor I None
activity I None
test I None
measured I None
with I None
an I None
Animex I None
- I None
activity I None
meter I None
neither I None
of I None
the I None
K I Chemical
( I None
+ I None
) I None
-channel I None
<eof> I None

<s> O None
blockers I None
affected I None
<eof> I None

<s> O None
morphine I Chemical
-induced I None
<eof> I None

<s> O None
hypoactivity I Disease
, I None
but I None
both I None
K I Chemical
( I None
+ I None
) I None
<eof> I None

<s> O None
-channel I None
blockers I None
prevented I None
morphine I Chemical
-induced I None
secondary I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
the I None
involvement I None
of I None
quinine I Chemical
-sensitive I None
but I None
not I None
4-aminopyridine I Chemical
-sensitive I None
K I Chemical
( I None
+ I None
) I None
-channels I None
in I None
morphine I Chemical
reward I None
. I None
<eof> I None

<s> O None
It I None
is I None
also I None
suggested I None
that I None
the I None
blockade I None
of I None
K I Chemical
( I None
+ I None
) I None
-channels I None
sensitive I None
to I None
these I None
blockers I None
is I None
not I None
sufficient I None
to I None
prevent I None
morphine I Chemical
-induced I None
<eof> I None

<s> O None
hypoactivity I Disease
whereas I None
<eof> I None

<s> O None
morphine I Chemical
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
seems I None
to I None
be I None
connected I None
to I None
both I None
quinine I Chemical
- I None
and I None
4-aminopyridine I Chemical
-sensitive I None
K I Chemical
( I None
+ I None
) I None
-channels I None
. I None
<eof> I None

<s> O None
Nociceptin I Chemical
/ I None
orphanin I Chemical
FQ O Chemical
and I None
nocistatin I Chemical
on I None
learning I None
and I None
memory I None
impairment I None
induced I None
by I None
scopolamine I Chemical
in I None
mice I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
Nociceptin I Chemical
, I None
also I None
known I None
as I None
orphanin I Chemical
FQ O Chemical
, I None
is I None
an I None
endogenous I None
ligand I None
for I None
the I None
orphan I None
opioid I None
receptor I None
- I None
like I None
receptor I None
1 I None
( I None
ORL1 I None
) I None
and I None
involves I None
in I None
various I None
functions I None
in I None
the I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
nocistatin I Chemical
is I None
recently I None
isolated I None
from I None
the I None
same I None
precursor I None
as I None
nociceptin I Chemical
and I None
blocks I None
nociceptin I Chemical
-induced I None
allodynia I Disease
and I None
hyperalgesia I Disease
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
Although I None
ORL1 I None
receptors I None
which I None
display I None
a I None
high I None
degree I None
of I None
sequence I None
homology I None
with I None
classical I None
opioid I None
receptors I None
are I None
abundant I None
in I None
the I None
hippocampus I None
, I None
little I None
is I None
known I None
regarding I None
their I None
role I None
in I None
learning I None
and I None
memory I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
designed I None
to I None
investigate I None
whether I None
nociceptin I Chemical
/ I None
orphanin I Chemical
FQ O Chemical
and I None
nocistatin I Chemical
could I None
modulate I None
impairment I None
of I None
learning I None
and I None
memory I None
induced I None
by I None
scopolamine I Chemical
, I None
a I None
muscarinic I None
cholinergic I None
receptor I None
antagonist I None
, I None
using I None
spontaneous I None
alternation I None
of I None
Y I None
- I None
maze I None
and I None
step I None
- I None
down I None
type I None
passive I None
avoidance I None
tasks I None
in I None
mice I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
While I None
nocistatin I Chemical
( I None
0.5 I None
- I None
5.0 I None
nmol I None
mouse-1 I None
, I None
i.c.v I None
. I None
) I None
administered I None
30 I None
min I None
before I None
spontaneous I None
alternation I None
performance I None
or I None
the I None
training I None
session I None
of I None
the I None
passive I None
avoidance I None
task I None
, I None
had I None
no I None
effect I None
on I None
spontaneous I None
alternation I None
or I None
passive I None
avoidance I None
behaviours I None
, I None
a I None
lower I None
per I None
cent I None
alternation I None
and I None
shorter I None
median I None
step I None
- I None
down I None
latency I None
in I None
the I None
retention I None
test I None
were I None
obtained I None
in I None
nociceptin I Chemical
( I None
1.5 I None
and/or I None
5.0 I None
nmol I None
mouse-1 I None
, I None
i.c.v.)-treated I None
normal I None
mice I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
nocistatin I Chemical
( I None
1.5 I None
and/or I None
5.0 I None
nmol I None
mouse-1 I None
, I None
i.c.v I None
. I None
) I None
<eof> I None

<s> O None
30 I None
min I None
before I None
spontaneous I None
alternation I None
performance I None
or I None
the I None
training I None
session I None
of I None
the I None
passive I None
avoidance I None
task I None
, I None
attenuated I None
the I None
scopolamine I Chemical
-induced I None
impairment I None
of I None
spontaneous I None
alternation I None
and I None
passive I None
avoidance I None
behaviours I None
. I None
<eof> I None

<s> O None
6 I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicated I None
that I None
nocistatin I Chemical
, I None
a I None
new I None
biologically I None
active I None
peptide I None
, I None
ameliorates I None
impairments I None
of I None
spontaneous I None
alternation I None
and I None
passive I None
avoidance I None
induced I None
by I None
scopolamine I Chemical
, I None
and I None
suggested I None
that I None
these I None
peptides I None
play I None
opposite I None
roles I None
in I None
learning I None
and I None
memory I None
. I None
<eof> I None

<s> O None
Meloxicam I Chemical
-induced I None
liver I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
female I None
patient I None
with I None
rheumatoid I Disease
arthritis O Disease
who I None
developed I None
acute I None
cytolytic I None
hepatitis I Disease
due I None
to I None
meloxicam I Chemical
. I None
<eof> I None

<s> O None
Recently I None
introduced I None
in I None
Belgium I None
, I None
meloxicam I Chemical
is I None
the I None
first I None
nonsteroidal I None
antiinflammatory I None
drug I None
with I None
selective I None
action I None
on I None
the I None
inducible I None
form I None
of I None
cyclooxygenase I None
2 I None
. I None
<eof> I None

<s> O None
The I None
acute I None
cytolytic I None
hepatitis I Disease
occurred I None
rapidly I None
after I None
meloxicam I Chemical
administration I None
and I None
was I None
associated I None
with I None
the I None
development I None
of I None
antinuclear I None
antibodies I None
suggesting I None
a I None
hypersensitivity I Disease
mechanism I None
. I None
<eof> I None

<s> O None
This I None
first I None
case I None
of I None
meloxicam I Chemical
related I None
<eof> I None

<s> O None
liver I Disease
toxicity O Disease
demonstrates I None
the I None
potential I None
of I None
this I None
drug I None
to I None
induce I None
hepatic I Disease
damage O Disease
. I None
<eof> I None

<s> O None
Induction I None
of I None
apoptosis I None
by I None
remoxipride I Chemical
metabolites I None
in I None
HL60 I None
and I None
CD34+/CD19- I None
human I None
bone I None
marrow I None
progenitor I None
cells I None
: I None
potential I None
relevance I None
to I None
remoxipride I Chemical
-induced I None
aplastic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
The I None
antipsychotic I None
agent I None
, I None
remoxipride I Chemical
[ I None
( I Chemical
S)-(-)-3-bromo O Chemical
- O Chemical
N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz O Chemical
amide O Chemical
] I None
has I None
been I None
associated I None
with I None
acquired I None
aplastic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
We I None
have I None
examined I None
the I None
ability I None
of I None
remoxipride I Chemical
, I None
three I None
pyrrolidine I Chemical
ring I None
metabolites I None
and I None
five I None
aromatic I None
ring I None
metabolites I None
of I None
the I None
parent I None
compound I None
to I None
induce I None
apoptosis I None
in I None
HL60 I None
cells I None
and I None
human I None
bone I None
marrow I None
progenitor I None
( I None
HBMP I None
) I None
cells I None
. I None
<eof> I None

<s> O None
Cells I None
were I None
treated I None
for I None
0 I None
- I None
24 I None
h I None
with I None
each I None
compound I None
( I None
0 I None
- I None
200 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Apoptosis I None
was I None
assessed I None
by I None
fluorescence I None
microscopy I None
in I None
Hoechst I Chemical
33342 O Chemical
- I None
and I None
propidium I Chemical
iodide O Chemical
stained I None
cell I None
samples I None
. I None
<eof> I None

<s> O None
Results I None
were I None
confirmed I None
by I None
determination I None
of I None
internucleosomal I None
DNA I None
fragmentation I None
using I None
gel I None
electrophoresis I None
for I None
HL60 I None
cell I None
samples I None
and I None
terminal I None
deoxynucleotidyl I None
transferase I None
assay I None
in I None
HBMP I None
cells I None
. I None
<eof> I None

<s> O None
The I None
catechol I Chemical
and I None
hydroquinone I Chemical
metabolites I None
, I None
NCQ436 I Chemical
and I None
NCQ344 I Chemical
, I None
induced I None
apoptosis I None
in I None
HL60 I None
and I None
HBMP I None
cells I None
in I None
a I None
time- I None
and I None
concentration I None
dependent I None
manner I None
, I None
while I None
the I None
phenols I Chemical
, I None
NCR181 I None
, I None
FLA873 I None
, I None
and I None
FLA797 I Chemical
, I None
and I None
the I None
derivatives I None
formed I None
by I None
oxidation I None
of I None
the I None
pyrrolidine I Chemical
ring I None
, I None
FLA838 I None
, I None
NCM001 I None
, I None
and I None
NCL118 I None
, I None
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
No I None
necrosis I Disease
was I None
observed I None
in I None
cells I None
treated I None
with I None
NCQ436 I Chemical
but I None
NCQ344 I Chemical
had I None
a I None
biphasic I None
effect I None
in I None
both I None
cell I None
types I None
, I None
inducing I None
apoptosis I None
at I None
lower I None
concentrations I None
and I None
necrosis I Disease
at I None
higher I None
concentrations I None
. I None
<eof> I None

<s> O None
These I None
data I None
show I None
that I None
the I None
catechol I Chemical
and I None
hydroquinone I Chemical
metabolites I None
of I None
remoxipride I Chemical
have I None
direct I None
toxic I None
effects I None
in I None
HL60 I None
and I None
HBMP I None
cells I None
, I None
leading I None
to I None
apoptosis I None
, I None
while I None
the I None
phenol I Chemical
metabolites I None
were I None
inactive I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
benzene I Chemical
-derived I None
<eof> I None

<s> O None
catechol I Chemical
and I None
hydroquinone I Chemical
, I None
but I None
not I None
phenol I Chemical
, I None
induce I None
apoptosis I None
in I None
HBMP I None
cells I None
[ I None
Moran I None
et I None
al I None
. I None
, I None
Mol I None
. I None
<eof> I None

<s> O None
Pharmacol I None
. I None
, I None
50 I None
( I None
1996 I None
) I None
<eof> I None

<s> O None
610 I None
- I None
615 I None
] I None
. I None
<eof> I None

<s> O None
We I None
propose I None
that I None
remoxipride I Chemical
and I None
benzene I Chemical
may I None
induce I None
aplastic I Disease
anemia O Disease
via I None
production I None
of I None
similar I None
reactive I None
metabolites I None
and I None
that I None
the I None
ability I None
of I None
NCQ436 I Chemical
and I None
NCQ344 I Chemical
to I None
induce I None
apoptosis I None
in I None
HBMP I None
cells I None
may I None
contribute I None
to I None
the I None
mechanism I None
underlying I None
acquired I None
aplastic I Disease
anemia O Disease
<eof> I None

<s> O None
that I None
has I None
been I None
associated I None
with I None
remoxipride I Chemical
. I None
<eof> I None

<s> O None
Synthesis I None
and I None
preliminary I None
pharmacological I None
investigations I None
of I None
1-(1,2-dihydro-2-acenaphthylenyl)piperazine I Chemical
derivatives I None
as I None
potential I None
atypical I None
antipsychotic I None
agents I None
in I None
mice I None
. I None
<eof> I None

<s> O None
In I None
research I None
towards I None
the I None
development I None
of I None
new I None
atypical I None
antipsychotic I None
agents I None
, I None
one I None
strategy I None
is I None
that I None
the I None
dopaminergic I None
system I None
can I None
be I None
modulated I None
through I None
manipulation I None
of I None
the I None
serotonergic I None
system I None
. I None
<eof> I None

<s> O None
The I None
synthesis I None
and I None
preliminary I None
pharmacological I None
evaluation I None
of I None
a I None
series I None
of I None
potential I None
atypical I None
antipsychotic I None
agents I None
based I None
on I None
the I None
structure I None
of I None
1-(1,2-dihydro-2-acenaphthylenyl)piperazine I Chemical
<eof> I None

<s> O None
( I None
7 I None
) I None
is I None
described I None
. I None
<eof> I None

<s> O None
Compound I None
7e I None
, I None
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy I Chemical
dro-1H- O Chemical
indol-2-one O Chemical
, I None
from I None
this I None
series I None
showed I None
significant I None
affinities I None
at I None
the I None
5-HT1A I None
and I None
5-HT2A I None
receptors I None
and I None
moderate I None
affinity I None
at I None
the I None
D2 I None
receptor I None
. I None
<eof> I None

<s> O None
7e I None
exhibits I None
a I None
high I None
reversal I None
of I None
catalepsy I Disease
induced I None
by I None
haloperidol I Chemical
indicating I None
its I None
atypical I None
antipsychotic I None
nature I None
. I None
<eof> I None

<s> O None
Sub I None
- I None
chronic I None
inhibition I None
of I None
nitric I Chemical
- O Chemical
oxide O Chemical
synthesis I None
modifies I None
<eof> I None

<s> O None
haloperidol I Chemical
-induced I None
catalepsy I Disease
and I None
the I None
number I None
of I None
NADPH I Chemical
<eof> I None

<s> O None
-diaphorase I None
neurons I None
in I None
mice I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
NG I Chemical
- O Chemical
nitro O Chemical
- O Chemical
L O Chemical
- O Chemical
arginine O Chemical
<eof> I None

<s> O None
( I None
L I Chemical
- O Chemical
NOARG O Chemical
) I None
, I None
an I None
inhibitor I None
of I None
nitric I Chemical
- O Chemical
oxide O Chemical
synthase I None
( I None
NOS I None
) I None
, I None
induces I None
catalepsy I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
This I None
effect I None
undergoes I None
rapid I None
tolerance I None
, I None
showing I None
a I None
significant I None
decrease I None
after I None
2 I None
days I None
of I None
sub I None
- I None
chronic I None
L I Chemical
- O Chemical
NOARG O Chemical
treatment I None
. I None
<eof> I None

<s> O None
Nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
has I None
been I None
shown I None
to I None
influence I None
dopaminergic I None
neurotransmission I None
in I None
the I None
striatum I None
. I None
<eof> I None

<s> O None
Neuroleptic I None
drugs I None
such I None
as I None
haloperidol I Chemical
, I None
which I None
block I None
dopamine I Chemical
receptors I None
, I None
also I None
cause I None
catalepsy I Disease
in I None
rodents I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
investigate I None
the I None
effects I None
of I None
subchronic I None
L I Chemical
- O Chemical
NOARG O Chemical
treatment I None
in I None
haloperidol I Chemical
-induced I None
catalepsy I Disease
and I None
the I None
number I None
of I None
NOS I None
neurons I None
in I None
areas I None
related I None
to I None
motor I None
control I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
albino I None
Swiss I None
mice I None
were I None
treated I None
sub I None
- I None
chronically I None
( I None
twice I None
a I None
day I None
for I None
4 I None
days I None
) I None
with I None
L I Chemical
- O Chemical
NOARG O Chemical
<eof> I None

<s> O None
( I None
40 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
or I None
haloperidol I Chemical
( I None
1 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
Catalepsy I Disease
was I None
evaluated I None
at I None
the I None
beginning I None
and I None
the I None
end I None
of I None
the I None
treatments I None
. I None
<eof> I None

<s> O None
Reduced I None
<eof> I None

<s> O None
nicotinamide I Chemical
adenine O Chemical
dinucleotide O Chemical
phosphate O Chemical
<eof> I None

<s> O None
-diaphorase I None
<eof> I None

<s> O None
( I None
NADPH I Chemical
-d I None
) I None
histochemistry I None
was I None
also I None
employed I None
to I None
visualize I None
NOS I None
as I None
an I None
index I None
of I None
enzyme I None
expression I None
in I None
mice I None
brain I None
regions I None
related I None
to I None
motor I None
control I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
L I Chemical
- O Chemical
NOARG O Chemical
sub I None
- I None
chronic I None
administration I None
produced I None
tolerance I None
of I None
L I Chemical
- O Chemical
NOARG O Chemical
and I None
of I None
<eof> I None

<s> O None
haloperidol I Chemical
-induced I None
<eof> I None

<s> O None
catalepsy I Disease
. I None
<eof> I None

<s> O None
It I None
also I None
induced I None
an I None
increase I None
in I None
the I None
number I None
of I None
NADPH I Chemical
-d I None
- I None
positive I None
cells I None
in I None
the I None
dorsal I None
part I None
of I None
the I None
caudate I None
and I None
accumbens I None
nuclei I None
compared I None
with I None
haloperidol I Chemical
and I None
in I None
the I None
pedunculopontine I None
tegmental I None
nucleus I None
compared I None
with I None
saline I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
there I None
was I None
a I None
decrease I None
in I None
NADPH I Chemical
-d I None
<eof> I None

<s> O None
neuron I None
number I None
in I None
the I None
substantia I None
nigra I None
, I None
pars I None
compacta I None
in I None
both I None
haloperidol I Chemical
-treated I None
and I None
L I Chemical
- O Chemical
NOARG O Chemical
-treated I None
animals I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
results I None
give I None
further I None
support I None
to I None
the I None
hypothesis I None
that I None
NO I Chemical
plays I None
a I None
role I None
in I None
motor I None
behavior I None
control I None
and I None
suggest I None
that I None
it I None
may I None
take I None
part I None
in I None
the I None
synaptic I None
changes I None
produced I None
by I None
antipsychotic I None
treatment I None
. I None
<eof> I None

<s> O None
Prolonged I None
<eof> I None

<s> O None
left I Disease
ventricular O Disease
dysfunction O Disease
occurs I None
in I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
after I None
both I None
dobutamine I Chemical
and I None
exercise I None
induced I None
myocardial I Disease
ischaemia O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
pharmacological I None
stress I None
leads I None
to I None
prolonged I None
but I None
reversible I None
left I Disease
ventricular O Disease
dysfunction O Disease
in I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
, I None
similar I None
to I None
that I None
seen I None
after I None
exercise I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
A I None
randomised I None
crossover I None
study I None
of I None
recovery I None
time I None
of I None
systolic I None
and I None
diastolic I None
left I None
ventricular I None
function I None
after I None
exercise I None
and I None
dobutamine I Chemical
induced I None
<eof> I None

<s> O None
ischaemia I Disease
. I None
<eof> I None

<s> O None
SUBJECTS I None
: I None
10 I None
patients I None
with I None
stable I Disease
angina O Disease
, I None
angiographically I None
proven I None
coronary I Disease
artery O Disease
disease O Disease
, I None
and I None
normal I None
left I None
ventricular I None
function I None
. I None
<eof> I None

<s> O None
INTERVENTIONS I None
: I None
<eof> I None

<s> O None
Treadmill I None
exercise I None
and I None
dobutamine I Chemical
stress I None
were I None
performed I None
on I None
different I None
days I None
. I None
<eof> I None

<s> O None
Quantitative I None
assessment I None
of I None
systolic I None
and I None
diastolic I None
left I None
ventricular I None
function I None
was I None
performed I None
using I None
transthoracic I None
echocardiography I None
at I None
baseline I None
and I None
at I None
regular I None
intervals I None
after I None
each I None
test I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Both I None
forms I None
of I None
stress I None
led I None
to I None
prolonged I None
but I None
reversible I None
systolic I None
and I None
diastolic I None
dysfunction I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
difference I None
in I None
the I None
maximum I None
double I None
product I None
( I None
p I None
= I None
0.53 I None
) I None
or I None
ST I None
depression I Disease
<eof> I None

<s> O None
( I None
p I None
= I None
0.63 I None
) I None
with I None
either I None
form I None
of I None
stress I None
. I None
<eof> I None

<s> O None
After I None
exercise I None
, I None
ejection I None
fraction I None
was I None
reduced I None
at I None
15 I None
and I None
30 I None
minutes I None
compared I None
with I None
baseline I None
( I None
mean I None
( I None
SEM I None
) I None
, I None
-5.6 I None
<eof> I None

<s> O None
( I None
1.5)% I None
, I None
p I None
< I None
0.05 I None
; I None
and I None
-6.1 I None
( I None
2.2)% I None
, I None
<eof> I None

<s> O None
p I None
< I None
0 I None
. I None
01 I None
) I None
, I None
and I None
at I None
30 I None
and I None
45 I None
minutes I None
after I None
dobutamine I Chemical
<eof> I None

<s> O None
( I None
-10.8 I None
( I None
1.8)% I None
and I None
-5 I None
. I None
5 I None
( I None
1.8)% I None
, I None
both I None
p I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Regional I None
analysis I None
showed I None
a I None
reduction I None
in I None
the I None
worst I None
affected I None
segment I None
15 I None
and I None
30 I None
minutes I None
after I None
exercise I None
( I None
-27.9 I None
( I None
7.2)% I None
and I None
-28.6 I None
( I None
5.7)% I None
, I None
both I None
p I None
< I None
0.01 I None
) I None
, I None
and I None
at I None
30 I None
minutes I None
after I None
dobutamine I Chemical
<eof> I None

<s> O None
( I None
-32 I None
( I None
5.3)% I None
, I None
<eof> I None

<s> O None
p I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
The I None
isovolumic I None
relaxation I None
period I None
was I None
prolonged I None
45 I None
minutes I None
after I None
each I None
form I None
of I None
stress I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
, I None
dobutamine I Chemical
induced I None
ischaemia I Disease
results I None
in I None
prolonged I None
reversible I None
left I Disease
ventricular O Disease
dysfunction O Disease
, I None
presumed I None
to I None
be I None
myocardial I Disease
stunning O Disease
, I None
similar I None
to I None
that I None
seen I None
after I None
exercise I None
. I None
<eof> I None

<s> O None
Dobutamine I Chemical
induced I None
<eof> I None

<s> O None
ischaemia I Disease
could I None
therefore I None
be I None
used I None
to I None
study I None
the I None
pathophysiology I None
of I None
this I None
phenomenon I None
further I None
in I None
patients I None
with I None
coronary I Disease
artery O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Anorexigens I None
and I None
pulmonary I Disease
hypertension O Disease
in I None
the I None
United I None
States I None
: I None
results I None
from I None
the I None
surveillance I None
of I None
North I None
American I None
pulmonary I Disease
hypertension O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
use I None
of I None
appetite I None
suppressants I None
in I None
Europe I None
has I None
been I None
associated I None
with I None
the I None
development I None
of I None
primary I Disease
pulmonary O Disease
hypertension O Disease
<eof> I None

<s> O None
( I None
PPH I Disease
) I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
fenfluramine I Chemical
appetite I None
suppressants I None
became I None
widely I None
used I None
in I None
the I None
United I None
States I None
but I None
were I None
withdrawn I None
in I None
September I None
1997 I None
because I None
of I None
concerns I None
over I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
<eof> I None

<s> O None
: I None
We I None
conducted I None
a I None
prospective I None
surveillance I None
study I None
on I None
patients I None
diagnosed I None
with I None
pulmonary I Disease
hypertension O Disease
at I None
12 I None
large I None
referral I None
centers I None
in I None
North I None
America I None
. I None
<eof> I None

<s> O None
Data I None
collected I None
on I None
patients I None
seen I None
from I None
September I None
1 I None
, I None
1996 I None
, I None
to I None
December I None
31 I None
, I None
1997 I None
, I None
included I None
the I None
cause I None
of I None
the I None
pulmonary I Disease
hypertension O Disease
and I None
its I None
severity I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
no I None
identifiable I None
cause I None
of I None
pulmonary I Disease
hypertension O Disease
were I None
classed I None
as I None
PPH I Disease
. I None
<eof> I None

<s> O None
A I None
history I None
of I None
drug I None
exposure I None
also I None
was I None
taken I None
with I None
special I None
attention I None
on I None
the I None
use I None
of I None
antidepressants I None
, I None
anorexigens I None
, I None
and I None
amphetamines I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Five I None
hundred I None
seventy I None
- I None
nine I None
patients I None
were I None
studied I None
, I None
205 I None
with I None
PPH I Disease
and I None
374 I None
with I None
pulmonary I Disease
hypertension O Disease
from I None
other I None
causes I None
( I None
secondary I None
pulmonary I Disease
hypertension O Disease
[ I None
SPH I None
] I None
) I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
anorexigens I None
was I None
common I None
in I None
both I None
groups I None
. I None
<eof> I None

<s> O None
However I None
, I None
of I None
the I None
medications I None
surveyed I None
, I None
only I None
the I None
fenfluramines I Chemical
had I None
a I None
significant I None
preferential I None
association I None
with I None
PPH I Disease
as I None
compared I None
with I None
SPH I None
( I None
adjusted I None
odds I None
ratio I None
for I None
use I None
> I None
6 I None
months I None
, I None
7.5 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
1.7 I None
to I None
32.4 I None
) I None
. I None
<eof> I None

<s> O None
The I None
association I None
was I None
stronger I None
with I None
longer I None
duration I None
of I None
use I None
when I None
compared I None
to I None
shorter I None
duration I None
of I None
use I None
and I None
was I None
more I None
pronounced I None
in I None
recent I None
users I None
than I None
in I None
remote I None
users I None
. I None
<eof> I None

<s> O None
An I None
unexpectedly I None
high I None
( I None
11.4 I None
% I None
) I None
number I None
of I None
patients I None
with I None
SPH I None
had I None
used I None
anorexigens I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
magnitude I None
of I None
the I None
association I None
with I None
PPH I Disease
, I None
the I None
increase I None
of I None
association I None
with I None
increasing I None
duration I None
of I None
use I None
, I None
and I None
the I None
specificity I None
for I None
fenfluramines I Chemical
are I None
consistent I None
with I None
previous I None
studies I None
indicating I None
that I None
fenfluramines I Chemical
are I None
causally I None
related I None
to I None
PPH I Disease
. I None
<eof> I None

<s> O None
The I None
high I None
prevalence I None
of I None
anorexigen I None
use I None
in I None
patients I None
with I None
SPH I None
also I None
raises I None
the I None
possibility I None
that I None
these I None
drugs I None
precipitate I None
pulmonary I Disease
hypertension O Disease
in I None
patients I None
with I None
underlying I None
conditions I None
associated I None
with I None
SPH I None
. I None
<eof> I None

<s> O None
Clinical I None
aspects I None
of I None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
and I None
thrombosis I Disease
and I None
other I None
side I None
effects I None
of I None
heparin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Heparin I Chemical
, I None
first I None
used I None
to I None
prevent I None
the I None
clotting I None
of I None
blood I None
in I None
vitro I None
, I None
has I None
been I None
clinically I None
used I None
to I None
treat I None
thrombosis I Disease
for I None
more I None
than I None
50 I None
years I None
. I None
<eof> I None

<s> O None
Although I None
several I None
new I None
anticoagulant I None
drugs I None
are I None
in I None
development I None
, I None
heparin I Chemical
remains I None
the I None
anticoagulant I None
of I None
choice I None
to I None
treat I None
acute I None
thrombotic I Disease
episodes I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
effects I None
of I None
heparin I Chemical
are I None
meritorious I None
, I None
but I None
side I None
effects I None
do I None
exist I None
. I None
<eof> I None

<s> O None
Bleeding I Disease
is I None
the I None
primary I None
untoward I None
effect I None
of I None
heparin I Chemical
. I None
<eof> I None

<s> O None
Major I None
bleeding I Disease
is I None
of I None
primary I None
concern I None
in I None
patients I None
receiving I None
heparin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
However I None
, I None
additional I None
important I None
untoward I None
effects I None
of I None
heparin I Chemical
therapy I None
include I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
, I None
heparin I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
osteoporosis I Disease
, I None
eosinophilia I Disease
, I None
skin I Disease
reactions O Disease
, I None
allergic I Disease
reactions O Disease
other I None
than I None
thrombocytopenia I Disease
, I None
alopecia I Disease
, I None
transaminasemia I None
, I None
hyperkalemia I Disease
, I None
hypoaldosteronism I Disease
, I None
and I None
priapism I Disease
. I None
<eof> I None

<s> O None
These I None
side I None
effects I None
are I None
relatively I None
rare I None
in I None
a I None
given I None
individual I None
, I None
but I None
given I None
the I None
extremely I None
widespread I None
use I None
of I None
heparin I Chemical
, I None
some I None
are I None
quite I None
common I None
, I None
particularly I None
HITT I Disease
and I None
osteoporosis I Disease
. I None
<eof> I None

<s> O None
Although I None
reasonable I None
incidences I None
of I None
many I None
of I None
these I None
side I None
effects I None
can I None
be I None
" I None
softly I None
" I None
deduced I None
from I None
current I None
reports I None
dealing I None
with I None
unfractionated I None
heparin I Chemical
, I None
at I None
present I None
the I None
incidences I None
of I None
these I None
side I None
effects I None
with I None
newer I None
low I None
molecular I None
weight I None
heparins I Chemical
appear I None
to I None
be I None
much I None
less I None
common I None
. I None
<eof> I None

<s> O None
However I None
, I None
only I None
longer I None
experience I None
will I None
more I None
clearly I None
define I None
the I None
incidence I None
of I None
each I None
side I None
effect I None
with I None
low I None
molecular I None
weight I None
preparations I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
bilateral I None
optic I Disease
neuropathy O Disease
in I None
a I None
patient I None
on I None
tacrolimus I Chemical
<eof> I None

<s> O None
( I None
FK506 I Chemical
) I None
therapy I None
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
bilateral I None
optic I Disease
neuropathy O Disease
in I None
a I None
patient I None
receiving I None
tacrolimus I Chemical
<eof> I None

<s> O None
( I None
FK I Chemical
506 O Chemical
, I None
Prograf I None
; I None
Fujisawa I None
USA I None
, I None
Inc I None
, I None
Deerfield I None
, I None
Illinois I None
) I None
for I None
immunosuppression I None
after I None
orthotropic I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Case I None
report I None
. I None
<eof> I None

<s> O None
In I None
a I None
58-year I None
- I None
old I None
man I None
receiving I None
tacrolimus I Chemical
after I None
orthotropic I None
liver I None
transplantation I None
, I None
serial I None
neuro I None
- I None
ophthalmologic I None
examinations I None
and I None
laboratory I None
studies I None
were I None
performed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
patient I None
had I None
episodic I None
deterioration I None
of I None
vision I None
in I None
both I None
eyes I None
, I None
with I None
clinical I None
features I None
resembling I None
ischemic I Disease
optic O Disease
neuropathies O Disease
. I None
<eof> I None

<s> O None
Deterioration I Disease
of O Disease
vision O Disease
occurred I None
despite I None
discontinuation I None
of I None
the I None
tacrolimus I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Tacrolimus I Chemical
and I None
other I None
immunosuppressive I None
agents I None
may I None
be I None
associated I None
with I None
optic I Disease
nerve O Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Hypercalcemia I Disease
, I None
arrhythmia I Disease
, I None
and I None
mood I None
stabilizers I None
. I None
<eof> I None

<s> O None
Recent I None
findings I None
in I None
a I None
bipolar I Disease
patient I None
receiving I None
maintenance I None
lithium I Chemical
therapy I None
who I None
developed I None
hypercalcemia I Disease
and I None
severe I None
bradyarrhythmia I Disease
prompted I None
the I None
authors I None
to I None
conduct I None
a I None
retrospective I None
study I None
of I None
bipolar I Disease
patients I None
with I None
lithium I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hypercalcemia I Disease
. I None
<eof> I None

<s> O None
A I None
printout I None
of I None
all I None
cases I None
of I None
hypercalcemia I Disease
that I None
presented I None
during I None
a I None
1-year I None
period I None
was I None
generated I None
. I None
<eof> I None

<s> O None
After I None
eliminating I None
spurious I None
hypercalcemias I Disease
or I None
those I None
associated I None
with I None
intravenous I None
fluids I None
, I None
the I None
authors I None
identified I None
18 I None
non- I None
lithium I Chemical
-treated I None
patients I None
with I None
hypercalcemias I Disease
related I None
to I None
malignancies I Disease
and I None
other I None
medical I None
conditions I None
( I None
group I None
A I None
) I None
and I None
12 I None
patients I None
with I None
lithium I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hypercalcemia I Disease
( I None
group I None
B I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
in I None
group I None
B I None
were I None
not I None
comparable I None
to I None
those I None
in I None
group I None
A I None
, I None
as I None
the I None
latter I None
were I None
medically I None
compromised I None
and I None
were I None
receiving I None
multiple I None
pharmacotherapies I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
two I None
control I None
groups I None
were I None
generated I None
: I None
group I None
C1 I None
, I None
which I None
included I None
age- I None
and I None
sex I None
- I None
comparable I None
lithium I Chemical
-treated I None
bipolar I Disease
normocalcemic I None
patients I None
, I None
and I None
group I None
C2 I None
, I None
which I None
included I None
bipolar I Disease
normocalcemic I None
patients I None
treated I None
with I None
anticonvulsant I None
mood I None
stabilizers I None
. I None
<eof> I None

<s> O None
The I None
electrocardiographic I None
( I None
ECG I None
) I None
findings I None
for I None
patients I None
in I None
group I None
B I None
were I None
compared I None
with I None
those I None
of I None
patients I None
in I None
groups I None
C1 I None
and I None
C2 I None
. I None
<eof> I None

<s> O None
It I None
was I None
found I None
that I None
these I None
groups I None
did I None
not I None
differ I None
in I None
their I None
overall I None
frequency I None
of I None
ECG I None
abnormalities I None
; I None
however I None
, I None
there I None
were I None
significant I None
differences I None
in I None
the I None
frequency I None
of I None
conduction I None
defects I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
hypercalcemia I Disease
resulting I None
from I None
medical I None
diseases I None
and I None
bipolar I Disease
patients I None
with I None
lithium I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
hypercalcemia I Disease
had I None
significantly I None
higher I None
frequencies I None
of I None
conduction I None
defects I None
. I None
<eof> I None

<s> O None
Patients I None
in I None
group I None
A I None
had I None
significant I None
mortality I None
at I None
2-year I None
follow I None
- I None
up I None
( I None
28 I None
% I None
) I None
, I None
in I None
contrast I None
to I None
zero I None
mortality I None
in I None
the I None
other I None
three I None
groups I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
implications I None
of I None
these I None
findings I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Attenuation I None
of I None
nephrotoxicity I Disease
by I None
a I None
novel I None
lipid I None
nanosphere I None
( I None
NS-718 I None
) I None
incorporating I None
amphotericin I Chemical
B O Chemical
. I None
<eof> I None

<s> O None
NS-718 I None
, I None
a I None
lipid I None
nanosphere I None
incorporating I None
amphotericin I Chemical
B O Chemical
, I None
is I None
effective I None
against I None
pathogenic I None
fungi I None
and I None
has I None
low I None
toxicity I Disease
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
toxicity I Disease
of I None
NS-718 I None
with I None
that I None
of I None
Fungizone I Chemical
<eof> I None

<s> O None
( I None
amphotericin I Chemical
B O Chemical
- O Chemical
sodium O Chemical
deoxycholate O Chemical
; I None
D I Chemical
- O Chemical
AmB O Chemical
) I None
in I None
vitro I None
using I None
renal I None
cell I None
cultures I None
and I None
in I None
vivo I None
by I None
biochemical I None
analysis I None
, I None
histopathological I None
study I None
of I None
the I None
kidney I None
and I None
pharmacokinetic I None
study I None
of I None
amphotericin I Chemical
B O Chemical
following I None
intravenous I None
infusion I None
of I None
the I None
formulation I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Incubation I None
with I None
NS-718 I None
resulted I None
in I None
significantly I None
less I None
damage I None
of I None
cultured I None
human I None
renal I None
proximal I None
tubular I None
epithelial I None
cells I None
compared I None
with I None
D I Chemical
- O Chemical
AmB O Chemical
. I None
<eof> I None

<s> O None
Serum I None
blood I None
urea I Chemical
and I None
creatinine I Chemical
concentrations I None
increased I None
significantly I None
in I None
rats I None
given I None
an I None
iv I None
infusion I None
of I None
D I Chemical
- O Chemical
AmB O Chemical
3 I None
mg I None
/ I None
kg I None
but I None
not I None
in I None
those I None
given I None
the I None
same I None
dose I None
of I None
NS-718 I None
. I None
<eof> I None

<s> O None
Histopathological I None
examination I None
of I None
the I None
kidney I None
showed I None
tubular I Disease
necrosis O Disease
in I None
D I Chemical
- O Chemical
AmB O Chemical
-treated I None
rats I None
but I None
no I None
change I None
in I None
NS-718-treated I None
rats I None
. I None
<eof> I None

<s> O None
Amphotericin I Chemical
B O Chemical
concentrations I None
in I None
the I None
kidney I None
in I None
NS-718-treated I None
rats I None
were I None
higher I None
than I None
those I None
in I None
D I Chemical
- O Chemical
AmB O Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Our I None
in I None
vitro I None
and I None
in I None
vivo I None
results I None
suggest I None
that I None
incorporation I None
of I None
amphotericin I Chemical
B O Chemical
into I None
lipid I None
nanospheres I None
of I None
NS-718 I None
attenuates I None
the I None
nephrotoxicity I Disease
of I None
amphotericin I Chemical
B O Chemical
. I None
<eof> I None

<s> O None
Patterns I None
of I None
sulfadiazine I Chemical
acute I Disease
nephrotoxicity O Disease
. I None
<eof> I None

<s> O None
Sulfadiazine I Chemical
<eof> I None

<s> O None
acute I Disease
nephrotoxicity O Disease
is I None
reviving I None
specially I None
because I None
of I None
its I None
use I None
in I None
toxoplasmosis I Disease
in I None
HIV I None
- I None
positive I None
patients I None
. I None
<eof> I None

<s> O None
We I None
report I None
4 I None
cases I None
, I None
one I None
of I None
them I None
in I None
a I None
previously I None
healthy I None
person I None
. I None
<eof> I None

<s> O None
Under I None
treatment I None
with I None
sulfadiazine I Chemical
<eof> I None

<s> O None
they I None
developed I None
oliguria I Disease
, I None
abdominal I Disease
pain O Disease
, I None
renal I Disease
failure O Disease
and I None
showed I None
multiple I None
radiolucent I None
renal I Disease
calculi O Disease
in I None
echography I None
. I None
<eof> I None

<s> O None
All I None
patients I None
recovered I None
their I None
previous I None
normal I None
renal I None
function I None
after I None
adequate I None
hydration I None
and I None
alcalinization I None
. I None
<eof> I None

<s> O None
A I None
nephrostomy I None
tube I None
had I None
to I None
be I None
placed I None
in I None
one I None
of I None
the I None
patients I None
for I None
ureteral I Disease
lithiasis O Disease
in I None
a I None
single I None
functional I None
kidney I None
. I None
<eof> I None

<s> O None
None I None
of I None
them I None
needed I None
dialysis I None
or I None
a I None
renal I None
biopsy I None
because I None
of I None
a I None
typical I None
benign I None
course I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
sulfadiazine I Chemical
requires I None
exquisite I None
control I None
of I None
renal I None
function I None
, I None
an I None
increase I None
in I None
water I None
ingestion I None
and I None
possibly I None
the I None
alcalinization I None
of I None
the I None
urine I None
. I None
<eof> I None

<s> O None
We I None
communicate I None
a I None
case I None
in I None
a I None
previously I None
healthy I None
person I None
, I None
a I None
fact I None
not I None
found I None
in I None
the I None
recent I None
literature I None
. I None
<eof> I None

<s> O None
Probably I None
many I None
more I None
cases I None
are I None
not I None
detected I None
. I None
<eof> I None

<s> O None
We I None
think I None
that I None
a I None
prospective I None
study I None
would I None
be I None
useful I None
. I None
<eof> I None

<s> O None
Downbeat I Disease
nystagmus O Disease
associated I None
with I None
intravenous I None
patient I None
- I None
controlled I None
administration I None
of I None
morphine I Chemical
. I None
<eof> I None

<s> O None
IMPLICATIONS I None
: I None
<eof> I None

<s> O None
This I None
case I None
documents I None
a I None
patient I None
who I None
developed I None
dizziness I Disease
with I None
downbeating I Disease
nystagmus O Disease
while I None
receiving I None
a I None
relatively I None
large I None
dose I None
of I None
IV I None
patient I None
- I None
controlled I None
analgesia I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Although I None
there I None
have I None
been I None
case I None
reports I None
of I None
epidural I None
morphine I Chemical
with I None
these I None
symptoms I None
and I None
signs I None
, I None
this I None
has I None
not I None
been I None
previously I None
documented I None
with I None
IV I None
or I None
patient I None
- I None
controlled I None
analgesia I None
morphine I Chemical
. I None
<eof> I None

<s> O None
Hemodynamic I None
and I None
antiadrenergic I None
effects I None
of I None
dronedarone I Chemical
and I None
amiodarone I Chemical
in I None
animals I None
with I None
a I None
healed I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
The I None
hemodynamic I None
and I None
antiadrenergic I None
effects I None
of I None
dronedarone I Chemical
, I None
a I None
noniodinated I None
compound I None
structurally I None
related I None
to I None
amiodarone I Chemical
, I None
were I None
compared I None
with I None
those I None
of I None
amiodarone I Chemical
after I None
prolonged I None
oral I None
administration I None
, I None
both I None
at I None
rest I None
and I None
during I None
sympathetic I None
stimulation I None
in I None
conscious I None
dogs I None
with I None
a I None
healed I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
All I None
dogs I None
( I None
n I None
= I None
6 I None
) I None
randomly I None
received I None
orally I None
dronedarone I Chemical
<eof> I None

<s> O None
( I None
10 I None
and I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
amiodarone I Chemical
<eof> I None

<s> O None
( I None
10 I None
and I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
and I None
placebo I None
twice I None
daily I None
for I None
7 I None
days I None
, I None
with I None
a I None
3-week I None
washout I None
between I None
consecutive I None
treatments I None
. I None
<eof> I None

<s> O None
Heart I None
rate I None
( I None
HR I None
) I None
, I None
mean I None
arterial I None
pressure I None
( I None
MBP I None
) I None
, I None
positive I None
rate I None
of I None
increase I None
of I None
left I None
ventricular I None
pressure I None
( I None
+ I None
LVdP I None
/ I None
dt I None
) I None
, I None
echocardiographically I None
assessed I None
left I None
ventricular I None
ejection I None
fraction I None
( I None
LVEF I None
) I None
, I None
and I None
fractional I None
shortening I None
( I None
FS I None
) I None
, I None
as I None
well I None
as I None
chronotropic I None
response I None
to I None
isoproterenol I Chemical
and I None
exercise I None
- I None
induced I None
sympathetic I None
stimulation I None
were I None
evaluated I None
under I None
baseline I None
and I None
posttreatment I None
conditions I None
. I None
<eof> I None

<s> O None
Resting I None
values I None
of I None
LVEF I None
, I None
FS I None
, I None
+ I None
LVdP I None
/ I None
dt I None
, I None
and I None
MBP I None
remained I None
unchanged I None
whatever I None
the I None
drug I None
and I None
the I None
dosing I None
regimen I None
, I None
whereas I None
resting I None
HR I None
was I None
significantly I None
and I None
dose I None
- I None
dependently I None
lowered I None
after I None
dronedarone I Chemical
and I None
to I None
a I None
lesser I None
extent I None
after I None
amiodarone I Chemical
. I None
<eof> I None

<s> O None
Both I None
dronedarone I Chemical
and I None
amiodarone I Chemical
significantly I None
reduced I None
the I None
exercise I None
- I None
induced I None
tachycardia I Disease
and I None
, I None
at I None
the I None
highest I None
dose I None
, I None
decreased I None
the I None
isoproterenol I Chemical
-induced I None
tachycardia I Disease
. I None
<eof> I None

<s> O None
Thus I None
, I None
dronedarone I Chemical
and I None
amiodarone I Chemical
displayed I None
a I None
similar I None
level I None
of I None
antiadrenergic I None
effect I None
and I None
did I None
not I None
impair I None
the I None
resting I None
left I None
ventricular I None
function I None
. I None
<eof> I None

<s> O None
Consequently I None
, I None
dronedarone I Chemical
might I None
be I None
particularly I None
suitable I None
for I None
the I None
treatment I None
and I None
prevention I None
of I None
various I None
clinical I None
arrhythmias I Disease
, I None
without I None
compromising I None
the I None
left I None
ventricular I None
function I None
. I None
<eof> I None

<s> O None
Phase I None
2 I None
trial I None
of I None
liposomal I None
doxorubicin I Chemical
( I None
40 I None
mg I None
/ I None
m(2 I None
) I None
) I None
in I None
platinum I Chemical
/ I None
paclitaxel I Chemical
<eof> I None

<s> O None
-refractory I None
<eof> I None

<s> O None
ovarian I None
and I None
fallopian I None
tube I None
cancers I None
and I None
primary I None
carcinoma I Disease
of O Disease
the O Disease
peritoneum O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Several I None
studies I None
have I None
demonstrated I None
liposomal I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
Doxil I Chemical
) I None
to I None
be I None
an I None
active I None
antineoplastic I None
agent I None
in I None
platinum I Chemical
<eof> I None

<s> O None
-resistant I None
<eof> I None

<s> O None
ovarian I Disease
cancer O Disease
, I None
with I None
dose I None
limiting I None
toxicity I Disease
of I None
the I None
standard I None
dosing I None
regimen I None
<eof> I None

<s> O None
( I None
50 I None
mg I None
/ I None
m(2 I None
) I None
<eof> I None

<s> O None
q I None
4 I None
weeks I None
) I None
being I None
severe I None
erythrodysesthesia I Disease
<eof> I None

<s> O None
( I None
" I None
hand I Disease
- O Disease
foot O Disease
syndrome O Disease
") I None
and I None
stomatitis I Disease
. I None
<eof> I None

<s> O None
We I None
wished I None
to I None
develop I None
a I None
more I None
tolerable I None
liposomal I None
doxorubicin I Chemical
<eof> I None

<s> O None
treatment I None
regimen I None
and I None
document I None
its I None
level I None
of I None
activity I None
in I None
a I None
well I None
- I None
defined I None
patient I None
population I None
with I None
platinum I Chemical
<eof> I None

<s> O None
/ I None
paclitaxel I Chemical
-refractory I None
disease I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
MATERIALS I None
: I None
<eof> I None

<s> O None
Patients I None
with I None
ovarian I None
or I None
fallopian I None
tube I None
cancers I None
or I None
primary I None
peritoneal I Disease
carcinoma O Disease
with I None
platinum I Chemical
<eof> I None

<s> O None
/ I None
paclitaxel I Chemical
-refractory I None
disease I None
( I None
stable I None
or I None
progressive I None
disease I None
following I None
treatment I None
with I None
these I None
agents I None
or I None
previous I None
objective I None
response I None
<3 I None
months I None
in I None
duration I None
) I None
were I None
treated I None
with I None
liposomal I None
doxorubicin I Chemical
at I None
a I None
dose I None
of I None
40 I None
mg I None
/ I None
m(2 I None
) I None
<eof> I None

<s> O None
q I None
4 I None
weeks I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
49 I None
patients I None
( I None
median I None
age I None
: I None
60 I None
; I None
range I None
41 I None
- I None
81 I None
) I None
entered I None
this I None
phase I None
2 I None
trial I None
. I None
<eof> I None

<s> O None
The I None
median I None
number I None
of I None
prior I None
regimens I None
was I None
2 I None
( I None
range I None
: I None
1 I None
- I None
6 I None
) I None
. I None
<eof> I None

<s> O None
Six I None
( I None
12 I None
% I None
) I None
and I None
4 I None
( I None
8 I None
% I None
) I None
patients I None
experienced I None
grade I None
2 I None
hand I Disease
- O Disease
foot O Disease
syndrome O Disease
and I None
stomatitis I Disease
, I None
respectively I None
( I None
no I None
episodes I None
of I None
grade I None
3 I None
) I None
. I None
<eof> I None

<s> O None
One I None
patient I None
developed I None
grade I None
3 I None
diarrhea I Disease
requiring I None
hospitalization I None
for I None
hydration I None
. I None
<eof> I None

<s> O None
Six I None
( I None
12 I None
% I None
) I None
individuals I None
required I None
dose I None
reductions I None
. I None
<eof> I None

<s> O None
The I None
median I None
number I None
of I None
courses I None
of I None
liposomal I None
doxorubicin I Chemical
administered I None
on I None
this I None
protocol I None
was I None
2 I None
( I None
range I None
: I None
1 I None
- I None
12 I None
) I None
. I None
<eof> I None

<s> O None
Four I None
of I None
44 I None
patients I None
( I None
9 I None
% I None
) I None
evaluable I None
for I None
response I None
exhibited I None
objective I None
and I None
subjective I None
evidence I None
of I None
an I None
antineoplastic I None
effect I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
This I None
modified I None
liposomal I None
doxorubicin I Chemical
<eof> I None

<s> O None
regimen I None
results I None
in I None
less I None
toxicity I Disease
<eof> I None

<s> O None
( I None
stomatitis I Disease
, I None
hand I Disease
- O Disease
foot O Disease
syndrome O Disease
) I None
than I None
the I None
standard I None
FDA I None
- I None
approved I None
dose I None
schedule I None
. I None
<eof> I None

<s> O None
Definite I None
, I None
although I None
limited I None
, I None
antineoplastic I None
activity I None
is I None
observed I None
in I None
patients I None
with I None
well I None
- I None
defined I None
platinum I Chemical
- I None
and I None
paclitaxel I Chemical
-refractory I None
ovarian I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
Efficacy I None
of I None
olanzapine I Chemical
in I None
acute I None
bipolar I Disease
mania O Disease
: I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
study I None
. I None
<eof> I None

<s> O None
The I None
Olanzipine I Chemical
HGGW I None
Study I None
Group I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
We I None
compared I None
the I None
efficacy I None
and I None
safety I None
of I None
olanzapine I Chemical
vs I None
placebo I None
for I None
the I None
treatment I None
of I None
acute I None
bipolar I Disease
mania O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Four I None
- I None
week I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
parallel I None
study I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
115 I None
patients I None
with I None
a I None
DSM I None
- I None
IV I None
diagnosis I None
of I None
bipolar I Disease
disorder O Disease
, I None
manic I Disease
or I None
mixed I None
, I None
were I None
randomized I None
to I None
olanzapine I Chemical
, I None
5 I None
to I None
20 I None
mg I None
/ I None
d I None
( I None
n I None
= I None
55 I None
) I None
, I None
or I None
placebo I None
( I None
n I None
= I None
60 I None
) I None
. I None
<eof> I None

<s> O None
The I None
primary I None
efficacy I None
measure I None
was I None
the I None
Young- I None
Mania I Disease
Rating I None
Scale I None
( I None
Y I None
- I None
MRS I None
) I None
total I None
score I None
. I None
<eof> I None

<s> O None
Response I None
and I None
euthymia I None
were I None
defined I None
, I None
a I None
priori I None
, I None
as I None
at I None
least I None
a I None
50 I None
% I None
improvement I None
from I None
baseline I None
to I None
end I None
point I None
and I None
as I None
a I None
score I None
of I None
no I None
less I None
than I None
12 I None
at I None
end I None
point I None
in I None
the I None
Y I None
- I None
MRS I None
total I None
score I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Safety I None
was I None
assessed I None
using I None
adverse I None
events I None
, I None
Extrapyramidal I Disease
Symptom O Disease
<eof> I None

<s> O None
( I None
EPS I Disease
) I None
rating I None
scales I None
, I None
laboratory I None
values I None
, I None
electrocardiograms I None
, I None
vital I None
signs I None
, I None
and I None
weight I None
change I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Olanzapine I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
demonstrated I None
a I None
statistically I None
significant I None
greater I None
mean I None
( I None
+ I None
/- I None
SD I None
) I None
improvement I None
in I None
Y I None
- I None
MRS I None
total I None
score I None
than I None
placebo I None
- I None
treated I None
patients I None
( I None
-14.8 I None
+ I None
/- I None
12.5 I None
and I None
-8.1 I None
<eof> I None

<s> O None
+ I None
/- I None
12.7 I None
, I None
respectively I None
; I None
P<.001 I None
) I None
, I None
which I None
was I None
evident I None
at I None
the I None
first I None
postbaseline I None
observation I None
1 I None
week I None
after I None
randomization I None
and I None
was I None
maintained I None
throughout I None
the I None
study I None
( I None
last I None
observation I None
carried I None
forward I None
) I None
. I None
<eof> I None

<s> O None
Olanzapine I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
demonstrated I None
a I None
higher I None
rate I None
of I None
response I None
( I None
65 I None
% I None
vs I None
43 I None
% I None
, I None
respectively I None
; I None
P I None
= I None
.02 I None
) I None
and I None
euthymia I None
( I None
61 I None
% I None
vs I None
36 I None
% I None
, I None
respectively I None
; I None
P I None
= I None
. I None
<eof> I None

<s> O None
01 I None
) I None
than I None
placebo I None
- I None
treated I None
patients I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
statistically I None
significant I None
differences I None
in I None
EPSs I Disease
between I None
groups I None
. I None
<eof> I None

<s> O None
However I None
, I None
olanzapine I Chemical
-treated I None
patients I None
had I None
a I None
statistically I None
significant I None
greater I None
mean I None
( I None
+ I None
/- I None
SD I None
) I None
<eof> I None

<s> O None
weight I Disease
gain O Disease
than I None
placebo I None
- I None
treated I None
patients I None
( I None
2.1 I None
+ I None
/- I None
2.8 I None
vs I None
0.45 I None
+ I None
/- I None
<eof> I None

<s> O None
2.3 I None
kg I None
, I None
respectively I None
) I None
and I None
also I None
experienced I None
more I None
treatment I None
- I None
emergent I None
somnolence I Disease
<eof> I None

<s> O None
( I None
21 I None
patients I None
[ I None
38.2 I None
% I None
] I None
vs I None
5 I None
[ I None
8.3 I None
% I None
] I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Olanzapine I Chemical
demonstrated I None
greater I None
efficacy I None
than I None
placebo I None
in I None
the I None
treatment I None
of I None
acute I None
bipolar I Disease
mania O Disease
and I None
was I None
generally I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
pupil I Disease
dilation O Disease
with I None
tropicamide I Chemical
on I None
vision I None
and I None
driving I None
simulator I None
performance I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
assess I None
the I None
effect I None
of I None
pupil I Disease
dilation O Disease
on I None
vision I None
and I None
driving I None
ability I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
series I None
of I None
tests I None
on I None
various I None
parameters I None
of I None
visual I None
function I None
and I None
driving I None
simulator I None
performance I None
were I None
performed I None
on I None
12 I None
healthy I None
drivers I None
, I None
before I None
and I None
after I None
pupil I Disease
dilation O Disease
using I None
guttae I None
<eof> I None

<s> O None
tropicamide I Chemical
1 I None
% I None
. I None
<eof> I None

<s> O None
A I None
driving I None
simulator I None
( I None
Transport I None
Research I None
Laboratory I None
) I None
was I None
used I None
to I None
measure I None
reaction I None
time I None
( I None
RT I None
) I None
, I None
speed I None
maintenance I None
and I None
steering I None
accuracy I None
. I None
<eof> I None

<s> O None
Tests I None
of I None
basic I None
visual I None
function I None
included I None
high- I None
and I None
low I None
- I None
contrast I None
visual I None
acuity I None
( I None
HCVA I None
and I None
LCVA I None
) I None
<eof> I None

<s> O None
, I None
Pelli I None
- I None
Robson I None
contrast I None
threshold I None
( I None
CT I None
) I None
and I None
Goldmann I None
perimetry I None
( I None
FIELDS I None
) I None
. I None
<eof> I None

<s> O None
Useful I None
Field I None
of I None
View I None
( I None
UFOV I None
-- I None
a I None
test I None
of I None
visual I None
attention I None
) I None
was I None
also I None
undertaken I None
. I None
<eof> I None

<s> O None
The I None
mean I None
differences I None
in I None
the I None
pre- I None
and I None
post I None
- I None
dilatation I None
measurements I None
were I None
tested I None
for I None
statistical I None
significance I None
at I None
the I None
95 I None
% I None
level I None
using I None
one I None
- I None
tail I None
paired I None
t I None
- I None
tests I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Pupillary I Disease
dilation O Disease
resulted I None
in I None
a I None
statistically I None
significant I None
deterioration I None
in I None
CT I None
and I None
HCVA I None
only I None
. I None
<eof> I None

<s> O None
Five I None
of I None
12 I None
drivers I None
also I None
exhibited I None
deterioration I None
in I None
LCVA I None
, I None
CT I None
and I None
RT I None
. I None
<eof> I None

<s> O None
Little I None
evidence I None
emerged I None
for I None
deterioration I None
in I None
FIELDS I None
and I None
UFOV I None
. I None
<eof> I None

<s> O None
Also I None
, I None
7 I None
of I None
12 I None
drivers I None
appeared I None
to I None
adjust I None
their I None
driving I None
behaviour I None
by I None
reducing I None
their I None
speed I None
on I None
the I None
driving I None
simulator I None
, I None
leading I None
to I None
improved I None
steering I None
accuracy I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Pupillary I Disease
dilation O Disease
may I None
lead I None
to I None
a I None
decrease I None
in I None
vision I None
and I None
daylight I None
driving I None
performance I None
in I None
young I None
people I None
. I None
<eof> I None

<s> O None
A I None
larger I None
study I None
, I None
including I None
a I None
broader I None
spectrum I None
of I None
subjects I None
, I None
is I None
warranted I None
before I None
guidelines I None
can I None
be I None
recommended I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
isotretinoin I Disease
embryopathy O Disease
with I None
bilateral I None
anotia I Disease
and I None
Taussig I Disease
- O Disease
Bing O Disease
malformation O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
newborn I None
infant I None
with I None
multiple I None
congenital I None
anomalies I None
( I None
anotia I Disease
and I None
Taussig I Disease
- O Disease
Bing O Disease
malformation O Disease
) I None
due I None
to I None
exposure I None
to I None
isotretinoin I Chemical
within I None
the I None
first I None
trimester I None
. I None
<eof> I None

<s> O None
In I None
this I None
paper I None
we I None
aim I None
to I None
draw I None
to I None
the I None
fact I None
that I None
caution I None
is I None
needed I None
when I None
prescribing I None
<eof> I None

<s> O None
vitamin I Chemical
A O Chemical
-containing I None
drugs I None
to I None
women I None
of I None
childbearing I None
years I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
methoxamine I Chemical
on I None
maximum I None
urethral I None
pressure I None
in I None
women I None
with I None
genuine I None
stress I Disease
incontinence O Disease
: I None
a I None
placebo I None
- I None
controlled I None
, I None
double I None
- I None
blind I None
crossover I None
study I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
evaluate I None
the I None
potential I None
role I None
for I None
a I None
selective I None
alpha1-adrenoceptor I None
agonist I None
in I None
the I None
treatment I None
of I None
urinary I Disease
stress O Disease
incontinence O Disease
. I None
<eof> I None

<s> O None
A I None
randomised I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
, I None
crossover I None
study I None
design I None
was I None
employed I None
. I None
<eof> I None

<s> O None
Half I None
log I None
incremental I None
doses I None
of I None
intravenous I None
methoxamine I Chemical
or I None
placebo I None
( I None
saline I None
) I None
were I None
administered I None
to I None
a I None
group I None
of I None
women I None
with I None
genuine I None
stress I Disease
incontinence O Disease
while I None
measuring I None
maximum I None
urethral I None
pressure I None
( I None
MUP I None
) I None
, I None
blood I None
pressure I None
, I None
heart I None
rate I None
, I None
and I None
symptomatic I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Methoxamine I Chemical
evoked I None
non I None
- I None
significant I None
increases I None
in I None
MUP I None
and I None
diastolic I None
blood I None
pressure I None
but I None
caused I None
a I Disease
significant O Disease
rise O Disease
in O Disease
systolic O Disease
blood O Disease
pressure O Disease
and I None
significant I None
fall I None
in I None
heart I None
rate I None
at I None
maximum I None
dosage I None
. I None
<eof> I None

<s> O None
Systemic I None
side I None
effects I None
including I None
piloerection I None
, I None
headache I Disease
, I None
and I None
cold I None
extremities I None
were I None
experienced I None
in I None
all I None
subjects I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
the I None
clinical I None
usefulness I None
of I None
direct I None
, I None
peripherally I None
acting I None
sub I None
- I None
type I None
- I None
selective I None
alpha1-adrenoceptor I None
agonists I None
in I None
the I None
medical I None
treatment I None
of I None
stress I Disease
incontinence O Disease
may I None
be I None
limited I None
by I None
associated I None
piloerection I None
and I None
cardiovascular I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Toleration I None
of I None
high I None
doses I None
of I None
angiotensin I Chemical
- O Chemical
converting O Chemical
enzyme O Chemical
inhibitors O Chemical
in I None
patients I None
with I None
chronic I None
heart I Disease
failure O Disease
: I None
results I None
from I None
the I None
ATLAS I None
trial I None
. I None
<eof> I None

<s> O None
The I None
Assessment I None
of I None
Treatment I None
with I None
Lisinopril I Chemical
and I None
Survival I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Treatment I None
with I None
angiotensin I Chemical
- O Chemical
converting O Chemical
enzyme O Chemical
( O Chemical
ACE O Chemical
) O Chemical
inhibitors O Chemical
<eof> I None

<s> O None
reduces I None
mortality I None
and I None
morbidity I None
in I None
patients I None
with I None
chronic I None
heart I Disease
failure O Disease
<eof> I None

<s> O None
( I None
CHF I Disease
) I None
, I None
but I None
most I None
affected I None
patients I None
are I None
not I None
receiving I None
these I None
agents I None
or I None
are I None
being I None
treated I None
with I None
doses I None
lower I None
than I None
those I None
found I None
to I None
be I None
efficacious I None
in I None
trials I None
, I None
primarily I None
because I None
of I None
concerns I None
about I None
the I None
safety I None
and I None
tolerability I None
of I None
these I None
agents I None
, I None
especially I None
at I None
the I None
recommended I None
doses I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
examines I None
the I None
safety I None
and I None
tolerability I None
of I None
high- I None
compared I None
with I None
low I None
- I None
dose I None
lisinopril I Chemical
in I None
CHF I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
Assessment I None
of I None
Lisinopril I Chemical
and I None
Survival I None
study I None
was I None
a I None
multicenter I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
trial I None
in I None
which I None
patients I None
with I None
or I None
without I None
previous I None
ACE I Chemical
inhibitor O Chemical
treatment I None
were I None
stabilized I None
receiving I None
medium I None
- I None
dose I None
lisinopril I Chemical
( I None
12.5 I None
or I None
15.0 I None
mg I None
once I None
daily I None
[ I None
OD I None
] I None
) I None
for I None
2 I None
to I None
4 I None
weeks I None
and I None
then I None
randomized I None
to I None
high- I None
( I None
35.0 I None
or I None
32.5 I None
mg I None
OD I None
) I None
or I None
low I None
- I None
dose I None
( I None
5.0 I None
or I None
2.5 I None
mg I None
OD I None
) I None
groups I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
New I None
York I None
Heart I None
Association I None
classes I None
II I None
to I None
IV I None
CHF I Disease
and I None
left I None
ventricular I None
ejection I None
fractions I None
of I None
no I None
greater I None
than I None
0.30 I None
( I None
n I None
= I None
3164 I None
) I None
were I None
randomized I None
and I None
followed I None
up I None
for I None
a I None
median I None
of I None
46 I None
months I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
occurrence I None
of I None
adverse I None
events I None
and I None
the I None
need I None
for I None
discontinuation I None
and I None
dose I None
reduction I None
during I None
treatment I None
, I None
with I None
a I None
focus I None
on I None
hypotension I Disease
and I None
renal I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
405 I None
patients I None
not I None
previously I None
receiving I None
an I None
ACE I Chemical
inhibitor O Chemical
, I None
doses I None
in I None
only I None
4.2 I None
% I None
could I None
not I None
be I None
titrated I None
to I None
the I None
medium I None
doses I None
required I None
for I None
randomization I None
because I None
of I None
symptoms I None
possibly I None
related I None
to I None
hypotension I Disease
( I None
2.0 I None
% I None
) I None
or I None
because I None
of I None
renal I Disease
dysfunction O Disease
or I None
hyperkalemia I Disease
( I None
2.3 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Doses I None
in I None
more I None
than I None
90 I None
% I None
of I None
randomized I None
patients I None
in I None
the I None
high- I None
and I None
low I None
- I None
dose I None
groups I None
were I None
titrated I None
to I None
their I None
assigned I None
target I None
, I None
and I None
the I None
mean I None
doses I None
of I None
blinded I None
medication I None
in I None
both I None
groups I None
remained I None
similar I None
throughout I None
the I None
study I None
. I None
<eof> I None

<s> O None
Withdrawals I None
occurred I None
in I None
27.1 I None
% I None
of I None
the I None
high- I None
and I None
30.7 I None
% I None
of I None
the I None
low I None
- I None
dose I None
groups I None
. I None
<eof> I None

<s> O None
Subgroups I None
presumed I None
to I None
be I None
at I None
higher I None
risk I None
for I None
ACE I Chemical
inhibitor O Chemical
intolerance I None
( I None
blood I None
pressure I None
, I None
< I None
120 I None
mm I None
Hg I None
; I None
creatinine I Chemical
, I None
> I None
or I None
= I None
132.6 I None
micromol I None
/ I None
L I None
[ I None
> I None
or I None
= I None
1.5 I None
mg I None
/ I None
dL I None
] I None
; I None
age I None
, I None
> I None
or I None
= I None
70 I None
years I None
; I None
and I None
patients I None
with I None
diabetes I Disease
) I None
generally I None
tolerated I None
the I None
high I None
- I None
dose I None
strategy I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
findings I None
demonstrate I None
that I None
ACE I Chemical
inhibitor O Chemical
therapy I None
in I None
most I None
patients I None
with I None
CHF I Disease
can I None
be I None
successfully I None
titrated I None
to I None
and I None
maintained I None
at I None
high I None
doses I None
, I None
and I None
that I None
more I None
aggressive I None
use I None
of I None
these I None
agents I None
is I None
warranted I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
, I None
ethanol I Chemical
, I None
and I None
cocaethylene I Chemical
<eof> I None

<s> O None
cardiotoxity I Disease
in I None
an I None
animal I None
model I None
of I None
cocaine I None
and I None
ethanol I None
abuse I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
Simultaneous I None
abuse I None
of I None
cocaine I None
and I None
ethanol I None
affects I None
12 I None
million I None
Americans I None
annually I None
. I None
<eof> I None

<s> O None
In I None
combination I None
, I None
these I None
substances I None
are I None
substantially I None
more I None
toxic I None
than I None
either I None
drug I None
alone I None
. I None
<eof> I None

<s> O None
Their I None
combined I None
cardiac I Disease
toxicity O Disease
may I None
be I None
due I None
to I None
independent I None
effects I None
of I None
each I None
drug I None
; I None
however I None
, I None
they I None
may I None
also I None
be I None
due I None
to I None
cocaethylene I Chemical
<eof> I None

<s> O None
( I None
CE I Chemical
) I None
, I None
a I None
cocaine I Chemical
metabolite I None
formed I None
only I None
in I None
the I None
presence I None
of I None
ethanol I Chemical
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
delineate I None
the I None
role I None
of I None
CE I Chemical
in I None
the I None
combined I None
cardiotoxicity I Disease
of I None
cocaine I Chemical
and I None
ethanol I Chemical
in I None
a I None
model I None
simulating I None
their I None
abuse I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
three I None
dogs I None
were I None
randomized I None
to I None
receive I None
either I None
1 I None
) I None
three I None
intravenous I None
( I None
IV I None
) I None
boluses I None
of I None
cocaine I Chemical
7.5 I None
mg I None
/ I None
kg I None
with I None
ethanol I Chemical
<eof> I None

<s> O None
( I None
1 I None
g I None
/ I None
kg I None
) I None
as I None
an I None
IV I None
infusion I None
( I None
C+E I None
, I None
n I None
= I None
8) I None
, I None
2 I None
) I None
three I None
cocaine I Chemical
boluses I None
only I None
( I None
C I None
, I None
n I None
= I None
6 I None
) I None
, I None
3 I None
) I None
ethanol I Chemical
infusion I None
only I None
( I None
E I None
, I None
n I None
= I None
5 I None
) I None
, I None
or I None
4 I None
) I None
placebo I None
boluses I None
and I None
infusion I None
( I None
n I None
= I None
4 I None
) I None
. I None
<eof> I None

<s> O None
Hemodynamic I None
measurements I None
, I None
electrocardiograms I None
, I None
and I None
serum I None
drug I None
concentrations I None
were I None
obtained I None
at I None
baseline I None
, I None
and I None
then I None
at I None
fixed I None
time I None
intervals I None
after I None
each I None
drug I None
was I None
administered I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Two I None
of I None
eight I None
dogs I None
in I None
the I None
C+E I None
group I None
experienced I None
cardiovascular I Disease
collapse O Disease
. I None
<eof> I None

<s> O None
The I None
most I None
dramatic I None
hemodynamic I None
changes I None
occurred I None
after I None
each I None
cocaine I Chemical
bolus I None
in I None
the I None
C+E I None
and I None
C I None
only I None
groups I None
; I None
however I None
, I None
persistent I None
hemodynamic I None
changes I None
occurred I None
in I None
the I None
C+E I None
group I None
. I None
<eof> I None

<s> O None
Peak I None
CE I Chemical
levels I None
were I None
associated I None
with I None
a I None
45 I None
% I None
( I None
SD I None
+ I None
/- I None
<eof> I None

<s> O None
22 I None
% I None
, I None
95 I None
% I None
CI I None
<eof> I None

<s> O None
= I None
22 I None
% I None
to I None
69 I None
% I None
) I None
<eof> I None

<s> O None
decrease I Disease
in O Disease
cardiac O Disease
output O Disease
( I None
p I None
< I None
0.05 I None
) I None
, I None
a I None
56 I None
% I None
( I None
SD I None
+ I None
/- I None
<eof> I None

<s> O None
23 I None
% I None
, I None
95 I None
% I None
CI I None
<eof> I None

<s> O None
= I None
32 I None
% I None
to I None
80 I None
% I None
) I None
decrease I None
in I None
dP I None
/ I None
dt(max I None
) I None
( I None
p I None
< I None
.006 I None
) I None
, I None
and I None
a I None
23 I None
% I None
( I None
SD I None
+ I None
/- I None
<eof> I None

<s> O None
15 I None
% I None
, I None
95 I None
% I None
CI I None
<eof> I None

<s> O None
= I None
7 I None
% I None
to I None
49 I None
% I None
) I None
decrease I None
in I None
SVO(2 I None
) I None
<eof> I None

<s> O None
( I None
p I None
< I None
0.025 I None
) I None
. I None
<eof> I None

<s> O None
Ventricular I Disease
arrhythmias O Disease
were I None
primarily I None
observed I None
in I None
the I None
C+E I None
group I None
, I None
in I None
which I None
four I None
of I None
eight I None
dogs I None
experienced I None
ventricular I Disease
tachycardia O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Cocaine I Chemical
and I None
ethanol I Chemical
in I None
combination I None
were I None
more I None
toxic I None
than I None
either I None
substance I None
alone I None
. I None
<eof> I None

<s> O None
Co I None
- I None
administration I None
resulted I None
in I None
prolonged I None
cardiac I Disease
toxicity O Disease
and I None
was I None
dysrhythmogenic I None
. I None
<eof> I None

<s> O None
Peak I None
serum I None
cocaethylene I Chemical
<eof> I None

<s> O None
concentrations I None
were I None
associated I None
with I None
prolonged I None
myocardial I Disease
depression O Disease
. I None
<eof> I None

<s> O None
Worsening I None
of I None
Parkinsonism I Disease
after I None
the I None
use I None
of I None
veralipride I Chemical
for I None
treatment I None
of I None
menopause I None
: I None
case I None
report I None
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
female I None
patient I None
with I None
stable I None
Parkinson I Disease
's O Disease
disease O Disease
who I None
has I None
shown I None
a I None
marked I None
worsening I None
of I None
her I None
motor I None
functions I None
following I None
therapy I None
of I None
menopause I None
related I None
symptoms I None
with I None
veralipride I Chemical
, I None
as I None
well I None
as I None
the I None
improvement I None
of I None
her I None
symptoms I None
back I None
to I None
baseline I None
after I None
discontinuation I None
of I None
the I None
drug I None
. I None
<eof> I None

<s> O None
We I None
emphasize I None
the I None
anti I None
- I None
dopaminergic I None
effect I None
of I None
veralipride I Chemical
. I None
<eof> I None

<s> O None
Viracept I Chemical
and I None
irregular I Disease
heartbeat O Disease
warning I None
. I None
<eof> I None

<s> O None
A I None
group I None
of I None
doctors I None
in I None
Boston I None
warn I None
that I None
the I None
protease I None
inhibitor I None
Viracept I Chemical
may I None
cause I None
an I None
irregular I Disease
heart O Disease
beat O Disease
, I None
known I None
as I None
bradycardia I Disease
, I None
in I None
people I None
with I None
HIV I None
. I None
<eof> I None

<s> O None
Bradycardia I Disease
occurred I None
in I None
a I None
45-year I None
- I None
old I None
male I None
patient I None
who I None
was I None
Viracept I Chemical
in I None
combination I None
with I None
other I None
anti I None
- I None
HIV I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
symptoms I None
ceased I None
after I None
switching I None
to I None
another I None
drug I None
combination I None
. I None
<eof> I None

<s> O None
Frequency I None
of I None
appearance I None
of I None
myeloperoxidase I None
- I None
antineutrophil I None
cytoplasmic I None
antibody I None
( I None
MPO I None
- I None
ANCA I None
) I None
in I None
Graves I Disease
' O Disease
disease O Disease
patients I None
treated I None
with I None
propylthiouracil I Chemical
and I None
the I None
relationship I None
between I None
MPO I None
- I None
ANCA I None
and I None
clinical I None
manifestations I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Myeloperoxidase I None
antineutrophil I None
cytoplasmic I None
antibody I None
( I None
MPO I None
- I None
ANCA)-positive I None
vasculitis I Disease
has I None
been I None
reported I None
in I None
patients I None
with I None
Graves I Disease
' O Disease
disease O Disease
who I None
were I None
treated I None
with I None
propylthiouracil I Chemical
<eof> I None

<s> O None
( I None
PTU I Chemical
) I None
. I None
<eof> I None

<s> O None
The I None
appearance I None
of I None
MPO I None
- I None
ANCA I None
in I None
these I None
cases I None
was I None
suspected I None
of I None
being I None
related I None
to I None
PTU I Chemical
because I None
the I None
titres I None
of I None
MPO I None
- I None
ANCA I None
decreased I None
when I None
PTU I Chemical
was I None
stopped I None
. I None
<eof> I None

<s> O None
Nevertheless I None
, I None
there I None
have I None
been I None
no I None
studies I None
on I None
the I None
temporal I None
relationship I None
between I None
the I None
appearance I None
of I None
MPO I None
- I None
ANCA I None
and I None
vasculitis I Disease
during I None
PTU I Chemical
therapy I None
, I None
or I None
on I None
the I None
incidence I None
of I None
MPO I None
- I None
ANCA I None
in I None
untreated I None
Graves I Disease
' O Disease
disease O Disease
patients I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
sought I None
to I None
address I None
these I None
parameters I None
in I None
patients I None
with I None
Graves I Disease
' O Disease
disease O Disease
. I None
<eof> I None

<s> O None
PATIENTS I None
: I None
<eof> I None

<s> O None
We I None
investigated I None
102 I None
untreated I None
patients I None
with I None
hyperthyroidism I Disease
due I None
to I None
Graves I Disease
' O Disease
disease O Disease
for I None
the I None
presence I None
of I None
MPO I None
- I None
ANCA I None
, I None
and I None
for I None
the I None
development I None
vasculitis I Disease
after I None
starting I None
PTU I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
nine I None
of I None
them I None
were I None
later I None
excluded I None
because I None
of I None
adverse I None
effects I None
of I None
PTU I Chemical
or I None
because I None
the I None
observation I None
period I None
was I None
less I None
than I None
3 I None
months I None
. I None
<eof> I None

<s> O None
The I None
remaining I None
73 I None
patients I None
( I None
55 I None
women I None
and I None
18 I None
men I None
) I None
, I None
all I None
of I None
whom I None
were I None
examined I None
for I None
more I None
than I None
3 I None
months I None
, I None
were I None
adopted I None
as I None
the I None
subjects I None
of I None
the I None
investigation I None
. I None
<eof> I None

<s> O None
The I None
median I None
observation I None
period I None
was I None
23.6 I None
months I None
( I None
range I None
: I None
3 I None
- I None
37 I None
months I None
) I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
MPO I None
- I None
ANCA I None
was I None
measured I None
at I None
intervals I None
of I None
2 I None
- I None
6 I None
months I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Before I None
treatment I None
, I None
the I None
MPO I None
- I None
ANCA I None
titres I None
of I None
all I None
102 I None
untreated I None
<eof> I None

<s> O None
Graves I Disease
' O Disease
disease O Disease
patients I None
were I None
within I None
the I None
reference I None
range I None
( I None
below I None
10 I None
U I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
Three I None
( I None
4.1 I None
% I None
) I None
of I None
the I None
73 I None
patients I None
were I None
positive I None
for I None
MPO I None
- I None
ANCA I None
at I None
13 I None
, I None
16 I None
and I None
17 I None
months I None
, I None
respectively I None
, I None
after I None
the I None
start I None
of I None
PTU I Chemical
therapy I None
. I None
<eof> I None

<s> O None
In I None
two I None
of I None
them I None
, I None
the I None
MPO I None
- I None
ANCA I None
titres I None
transiently I None
increased I None
to I None
12.8 I None
and I None
15.0 I None
U I None
/ I None
ml I None
, I None
respectively I None
, I None
despite I None
continued I None
PTU I Chemical
therapy I None
, I None
but I None
no I None
vasculitic I Disease
disorders O Disease
developed I None
. I None
<eof> I None

<s> O None
In I None
the I None
third I None
patient I None
, I None
the I None
MPO I None
- I None
ANCA I None
titre I None
increased I None
to I None
204 I None
U I None
/ I None
ml I None
and I None
she I None
developed I None
a I None
higher I None
fever I Disease
, I None
oral I Disease
ulcers O Disease
and I None
polyarthralgia I Disease
, I None
but I None
the I None
symptoms I None
resolved I None
2 I None
weeks I None
after I None
stopping I None
PTU I Chemical
therapy I None
, I None
and I None
the I None
MPO I None
- I None
ANCA I None
titre I None
decreased I None
to I None
20.7 I None
U I None
/ I None
ml I None
by I None
4 I None
months I None
after I None
discontinuing I None
PTU I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
PTU I Chemical
therapy I None
may I None
be I None
related I None
to I None
the I None
appearance I None
of I None
MPO I None
- I None
ANCA I None
, I None
but I None
MPO I None
- I None
ANCA I None
does I None
not I None
appear I None
to I None
be I None
closely I None
related I None
to I None
vasculitis I Disease
. I None
<eof> I None

<s> O None
Prevalence I None
of I None
heart I Disease
disease O Disease
in I None
asymptomatic I None
chronic I None
cocaine I Chemical
users I None
. I None
<eof> I None

<s> O None
To I None
determine I None
the I None
prevalence I None
of I None
heart I Disease
disease O Disease
in I None
outpatient I None
young I None
asymptomatic I None
chronic I None
cocaine I Chemical
users I None
, I None
35 I None
cocaine I Chemical
users I None
and I None
32 I None
age I None
- I None
matched I None
controls I None
underwent I None
resting I None
and I None
exercise I None
electrocardiography I None
( I None
ECG I None
) I None
and I None
Doppler I None
echocardiography I None
. I None
<eof> I None

<s> O None
Findings I None
consistent I None
with I None
coronary I Disease
artery O Disease
disease O Disease
were I None
detected I None
in I None
12 I None
( I None
34 I None
% I None
) I None
patients I None
and I None
3 I None
( I None
9 I None
% I None
) I None
controls I None
( I None
p I None
= I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Decreased I None
left I None
ventricular I None
systolic I None
function I None
was I None
demonstrated I None
in I None
5 I None
( I None
14 I None
% I None
) I None
patients I None
, I None
but I None
in I None
none I None
of I None
the I None
controls I None
( I None
p I None
= I None
0.055 I None
) I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
resting I None
and I None
peak I None
exercise I None
<eof> I None

<s> O None
abnormal I Disease
left O Disease
ventricular O Disease
filling O Disease
was I None
detected I None
in I None
38 I None
and I None
35 I None
% I None
of I None
patients I None
as I None
compared I None
to I None
19 I None
and I None
9 I None
% I None
of I None
controls I None
, I None
respectively I None
( I None
p I None
= I None
0.11 I None
and I None
0.02 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
coronary I None
artery I None
or I None
myocardial I None
disease I None
is I None
common I None
( I None
38 I None
% I None
) I None
in I None
young I None
asymptomatic I None
chronic I None
cocaine I Chemical
users I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
screening I None
ECG I None
and I None
echocardiography I None
may I None
be I None
warranted I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
Cardioprotective I None
effects I None
of I None
Picrorrhiza I None
kurroa I None
against I None
isoproterenol I Chemical
-induced I None
myocardial I None
stress I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
cardioprotective I None
effect I None
of I None
the I None
ethanol I Chemical
extract I None
of I None
Picrorrhiza I None
kurroa I None
rhizomes I None
and I None
roots I None
( I None
PK I None
) I None
on I None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
in I None
rats I None
with I None
respect I None
to I None
lipid I None
metabolism I None
in I None
serum I None
and I None
heart I None
tissue I None
has I None
been I None
investigated I None
. I None
<eof> I None

<s> O None
Oral I None
pre I None
- I None
treatment I None
with I None
PK I None
( I None
80 I None
mg I None
kg(-1 I None
) I None
day(-1 I None
) I None
for I None
15 I None
days I None
) I None
significantly I None
prevented I None
the I None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
myocardial I Disease
infarction O Disease
and I None
maintained I None
the I None
rats I None
at I None
near I None
normal I None
status I None
. I None
<eof> I None

<s> O None
Phase I None
2 I None
early I None
afterdepolarization I None
as I None
a I None
trigger I None
of I None
polymorphic I None
ventricular I Disease
tachycardia O Disease
in I None
acquired I None
long I Disease
- O Disease
QT O Disease
syndrome O Disease
: I None
direct I None
evidence I None
from I None
intracellular I None
recordings I None
in I None
the I None
intact I None
left I None
ventricular I None
wall I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
This I None
study I None
examined I None
the I None
role I None
of I None
phase I None
2 I None
early I None
afterdepolarization I None
( I None
EAD I None
) I None
in I None
producing I None
a I None
trigger I None
to I None
initiate I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
TdP I Disease
) I None
with I None
<eof> I None

<s> O None
QT I Disease
prolongation O Disease
induced I None
by I None
dl- I None
sotalol I Chemical
and I None
azimilide I Chemical
. I None
<eof> I None

<s> O None
The I None
contribution I None
of I None
transmural I None
dispersion I None
of I None
repolarization I None
( I None
TDR I None
) I None
to I None
transmural I None
propagation I None
of I None
EAD I None
and I None
the I None
maintenance I None
of I None
TdP I Disease
was I None
also I None
evaluated I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
<eof> I None

<s> O None
Transmembrane I None
action I None
potentials I None
from I None
epicardium I None
, I None
midmyocardium I None
, I None
and I None
endocardium I None
were I None
recorded I None
simultaneously I None
, I None
together I None
with I None
a I None
transmural I None
ECG I None
, I None
in I None
arterially I None
perfused I None
canine I None
and I None
rabbit I None
left I None
ventricular I None
preparations I None
. I None
<eof> I None

<s> O None
dl- I None
<eof> I None

<s> O None
Sotalol I Chemical
preferentially I None
prolonged I None
action I None
potential I None
duration I None
( I None
APD I None
) I None
in I None
M I None
cells I None
dose I None
- I None
dependently I None
( I None
1 I None
to I None
100 I None
micromol I None
/ I None
L I None
) I None
, I None
leading I None
to I None
QT I Disease
prolongation O Disease
and I None
an I None
increase I None
in I None
TDR I None
. I None
<eof> I None

<s> O None
Azimilide I Chemical
, I None
however I None
, I None
significantly I None
prolonged I None
APD I None
and I None
QT I None
interval I None
at I None
concentrations I None
from I None
0.1 I None
to I None
10 I None
micromol I None
/ I None
<eof> I None

<s> O None
L I None
but I None
shortened I None
them I None
at I None
30 I None
micromol I None
/ I None
<eof> I None

<s> O None
L. I None
Unlike I None
dl- I None
sotalol I Chemical
, I None
<eof> I None

<s> O None
azimilide I Chemical
<eof> I None

<s> O None
( I None
> I None
3 I None
micromol I None
/ I None
L I None
) I None
increased I None
epicardial I None
APD I None
markedly I None
, I None
causing I None
a I None
diminished I None
TDR I None
. I None
<eof> I None

<s> O None
Although I None
both I None
dl- I None
sotalol I Chemical
and I None
azimilide I Chemical
rarely I None
induced I None
EADs I None
in I None
canine I None
left I None
ventricles I None
, I None
they I None
produced I None
frequent I None
EADs I None
in I None
rabbits I None
, I None
in I None
which I None
more I None
pronounced I None
QT I Disease
prolongation O Disease
was I None
seen I None
. I None
<eof> I None

<s> O None
An I None
increase I None
in I None
TDR I None
by I None
dl- I None
sotalol I Chemical
facilitated I None
transmural I None
propagation I None
of I None
EADs I None
that I None
initiated I None
multiple I None
episodes I None
of I None
spontaneous I None
TdP I Disease
in I None
3 I None
of I None
6 I None
rabbit I None
left I None
ventricles I None
. I None
<eof> I None

<s> O None
Of I None
note I None
, I None
although I None
azimilide I Chemical
( I None
3 I None
to I None
10 I None
micromol I None
/ I None
L I None
) I None
increased I None
APD I None
more I None
than I None
dl- I None
sotalol I Chemical
, I None
its I None
EADs I None
often I None
failed I None
to I None
propagate I None
transmurally I None
, I None
probably I None
because I None
of I None
a I None
diminished I None
TDR I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
This I None
study I None
provides I None
the I None
first I None
direct I None
evidence I None
from I None
intracellular I None
action I None
potential I None
recordings I None
that I None
phase I None
2 I None
EAD I None
can I None
be I None
generated I None
from I None
intact I None
ventricular I None
wall I None
and I None
produce I None
a I None
trigger I None
to I None
initiate I None
the I None
onset I None
of I None
TdP I Disease
under I None
QT I Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
Prenatal I None
cocaine I Chemical
exposure I None
and I None
cranial I None
sonographic I None
findings I None
in I None
preterm I Disease
infants O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Prenatal I None
cocaine I Chemical
exposure I None
has I None
been I None
linked I None
with I None
subependymal I None
hemorrhage I Disease
and I None
the I None
formation I None
of I None
cysts I Disease
<eof> I None

<s> O None
that I None
are I None
detectable I None
on I None
cranial I None
sonography I None
in I None
neonates I None
born I None
at I None
term I None
. I None
<eof> I None

<s> O None
We I None
sought I None
to I None
determine I None
if I None
prenatal I None
cocaine I Chemical
<eof> I None

<s> O None
exposure I None
increases I None
the I None
incidence I None
of I None
subependymal I None
cysts I None
in I None
preterm I Disease
infants O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
retrospectively I None
reviewed I None
the I None
medical I None
records I None
and I None
cranial I None
sonograms I None
obtained I None
during I None
a I None
1-year I None
period I None
on I None
122 I None
premature I Disease
( O Disease
< O Disease
36 O Disease
weeks O Disease
of O Disease
gestation O Disease
) O Disease
infants O Disease
. I None
<eof> I None

<s> O None
Infants I None
were I None
categorized I None
into I None
1 I None
of I None
2 I None
groups I None
: I None
those I None
exposed I None
to I None
cocaine I Chemical
and I None
those I None
not I None
exposed I None
to I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
Infants I None
were I None
assigned I None
to I None
the I None
cocaine I Chemical
-exposed I None
group I None
if I None
there I None
was I None
a I None
maternal I None
history I None
of I None
cocaine I Disease
abuse O Disease
during I None
pregnancy I None
or I None
if I None
maternal I None
or I None
neonatal I None
urine I None
toxicology I None
results I None
were I None
positive I None
at I None
the I None
time I None
of I None
delivery I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Five I None
of I None
the I None
122 I None
infants I None
were I None
excluded I None
from I None
the I None
study I None
because I None
of I None
insufficient I None
medical I None
and I None
drug I None
histories I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
subependymal I None
cysts I None
in I None
the I None
117 I None
remaining I None
infants I None
was I None
14 I None
% I None
( I None
16 I None
of I None
117 I None
) I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
subependymal I None
cysts I None
in I None
infants I None
exposed I None
to I None
cocaine I Chemical
<eof> I None

<s> O None
prenatally I None
was I None
44 I None
% I None
( I None
8 I None
of I None
18 I None
) I None
compared I None
with I None
8 I None
% I None
( I None
8 I None
of I None
99 I None
) I None
in I None
the I None
unexposed I None
group I None
( I None
p I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
We I None
found I None
an I None
increased I None
incidence I None
of I None
subependymal I None
cyst I None
formation I None
in I None
preterm I Disease
infants O Disease
who I None
were I None
exposed I None
to I None
cocaine I Chemical
<eof> I None

<s> O None
prenatally I None
. I None
<eof> I None

<s> O None
This I None
result I None
is I None
consistent I None
with I None
results I None
of I None
similar I None
studies I None
in I None
term I None
infants I None
. I None
<eof> I None

<s> O None
Thalidomide I Chemical
<eof> I None

<s> O None
neuropathy I Disease
in I None
patients I None
treated I None
for I None
metastatic I None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
We I None
prospectively I None
evaluated I None
<eof> I None

<s> O None
thalidomide I Chemical
-induced I None
neuropathy I Disease
using I None
electrodiagnostic I None
studies I None
. I None
<eof> I None

<s> O None
Sixty I None
- I None
seven I None
men I None
with I None
metastatic I None
androgen I Chemical
-independent I None
<eof> I None

<s> O None
prostate I Disease
cancer O Disease
in I None
an I None
open I None
- I None
label I None
trial I None
of I None
oral I None
thalidomide I Chemical
underwent I None
neurologic I None
examinations I None
and I None
nerve I None
conduction I None
studies I None
( I None
NCS I None
) I None
prior I None
to I None
and I None
at I None
3-month I None
intervals I None
during I None
treatment I None
. I None
<eof> I None

<s> O None
NCS I None
included I None
recording I None
of I None
sensory I None
nerve I None
action I None
potentials I None
( I None
SNAPs I None
) I None
from I None
median I None
, I None
radial I None
, I None
ulnar I None
, I None
and I None
sural I None
nerves I None
. I None
<eof> I None

<s> O None
SNAP I None
amplitudes I None
for I None
each I None
nerve I None
were I None
expressed I None
as I None
the I None
percentage I None
of I None
its I None
baseline I None
, I None
and I None
the I None
mean I None
of I None
the I None
four I None
was I None
termed I None
the I None
SNAP I None
index I None
. I None
<eof> I None

<s> O None
A I None
40 I None
% I None
decline I None
in I None
the I None
SNAP I None
index I None
was I None
considered I None
clinically I None
significant I None
. I None
<eof> I None

<s> O None
Thalidomide I Chemical
was I None
discontinued I None
in I None
55 I None
patients I None
for I None
lack I None
of I None
therapeutic I None
response I None
. I None
<eof> I None

<s> O None
Of I None
67 I None
patients I None
initially I None
enrolled I None
, I None
24 I None
remained I None
on I None
thalidomide I Chemical
for I None
3 I None
months I None
, I None
8 I None
remained I None
at I None
6 I None
months I None
, I None
and I None
3 I None
remained I None
at I None
9 I None
months I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
developed I None
neuropathy I Disease
. I None
<eof> I None

<s> O None
Clinical I None
symptoms I None
and I None
a I None
decline I None
in I None
the I None
SNAP I None
index I None
occurred I None
concurrently I None
. I None
<eof> I None

<s> O None
Older I None
age I None
and I None
cumulative I None
dose I None
were I None
possible I None
contributing I None
factors I None
. I None
<eof> I None

<s> O None
Neuropathy I Disease
may I None
thus I None
be I None
a I None
common I None
complication I None
of I None
thalidomide I Chemical
in I None
older I None
patients I None
. I None
<eof> I None

<s> O None
The I None
SNAP I None
index I None
can I None
be I None
used I None
to I None
monitor I None
peripheral I Disease
neuropathy O Disease
, I None
but I None
not I None
for I None
early I None
detection I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
copper I Chemical
/ I None
zinc I Chemical
- I None
superoxide I Chemical
dismutase I None
protects I None
from I None
kanamycin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hearing I Disease
loss O Disease
. I None
<eof> I None

<s> O None
The I None
participation I None
of I None
reactive I None
oxygen I Chemical
species I None
in I None
aminoglycoside I Chemical
-induced I None
<eof> I None

<s> O None
ototoxicity I Disease
has I None
been I None
deduced I None
from I None
observations I None
that I None
aminoglycoside I Chemical
- I None
iron I Chemical
complexes I None
catalyze I None
the I None
formation I None
of I None
superoxide I Chemical
radicals I None
in I None
vitro I None
and I None
that I None
antioxidants I None
attenuate I None
<eof> I None

<s> O None
ototoxicity I Disease
in I None
vivo I None
. I None
<eof> I None

<s> O None
We I None
therefore I None
hypothesized I None
that I None
overexpression I None
of I None
Cu I Chemical
/ I None
Zn I Chemical
- I None
superoxide I Chemical
dismutase I None
( I None
h I None
- I None
SOD1 I None
) I None
should I None
protect I None
transgenic I None
mice I None
from I None
ototoxicity I Disease
. I None
<eof> I None

<s> O None
Immunocytochemistry I None
confirmed I None
expression I None
of I None
h I None
- I None
SOD1 I None
in I None
inner I None
ear I None
tissues I None
of I None
transgenic I None
C57BL/6-TgN[SOD1]3Cje I None
mice I None
. I None
<eof> I None

<s> O None
Transgenic I None
and I None
nontransgenic I None
littermates I None
received I None
kanamycin I Chemical
<eof> I None

<s> O None
( I None
400 I None
mg I None
/ I None
kg I None
body I None
weight I None
/ I None
day I None
) I None
for I None
10 I None
days I None
beginning I None
on I None
day I None
10 I None
after I None
birth I None
. I None
<eof> I None

<s> O None
Auditory I None
thresholds I None
were I None
tested I None
by I None
evoked I None
auditory I None
brain I None
stem I None
responses I None
at I None
1 I None
month I None
after I None
birth I None
. I None
<eof> I None

<s> O None
In I None
nontransgenic I None
animals I None
, I None
the I None
threshold I None
in I None
the I None
kanamycin I Chemical
-treated I None
group I None
was I None
45 I None
- I None
50 I None
dB I None
higher I None
than I None
in I None
saline I None
- I None
injected I None
controls I None
. I None
<eof> I None

<s> O None
In I None
the I None
transgenic I None
group I None
, I None
kanamycin I Chemical
increased I None
the I None
threshold I None
by I None
only I None
15 I None
dB I None
over I None
the I None
respective I None
controls I None
. I None
<eof> I None

<s> O None
The I None
effects I None
were I None
similar I None
at I None
12 I None
and I None
24 I None
kHz I None
. I None
<eof> I None

<s> O None
The I None
protection I None
by I None
overexpression I None
of I None
superoxide I Chemical
dismutase I None
supports I None
the I None
hypothesis I None
that I None
oxidant I None
stress I None
plays I None
a I None
significant I None
role I None
in I None
aminoglycoside I Chemical
<eof> I None

<s> O None
-induced I None
ototoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
results I None
also I None
suggest I None
transgenic I None
animals I None
as I None
suitable I None
models I None
to I None
investigate I None
the I None
underlying I None
mechanisms I None
and I None
possible I None
strategies I None
for I None
prevention I None
. I None
<eof> I None

<s> O None
Prednisone I Chemical
induces I None
<eof> I None

<s> O None
anxiety I Disease
and I None
glial I None
cerebral I None
changes I None
in I None
rats I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
assess I None
whether I None
prednisone I Chemical
<eof> I None

<s> O None
( I None
PDN I Chemical
) I None
produces I None
anxiety I Disease
and/or I None
cerebral I None
glial I None
changes I None
in I None
rats I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
studied I None
and I None
3 I None
groups I None
were I None
formed I None
( I None
8 I None
rats I None
per I None
group I None
) I None
. I None
<eof> I None

<s> O None
The I None
moderate I None
- I None
dose I None
group I None
received I None
5 I None
mg I None
/ I None
kg I None
/ I None
day I None
PDN I Chemical
released I None
from I None
a I None
subcutaneous I None
implant I None
. I None
<eof> I None

<s> O None
In I None
the I None
high I None
- I None
dose I None
group I None
, I None
implants I None
containing I None
PDN I Chemical
equivalent I None
to I None
60 I None
mg I None
/ I None
kg I None
/ I None
day I None
were I None
applied I None
. I None
<eof> I None

<s> O None
In I None
the I None
control I None
group I None
implants I None
contained I None
no I None
PDN I Chemical
. I None
<eof> I None

<s> O None
Anxiety I Disease
was I None
assessed I None
using I None
an I None
open I None
field I None
and I None
elevated I None
plus I None
- I None
maze I None
devices I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
cells I None
and I None
cytoplasmic I None
transformation I None
of I None
astrocytes I None
and I None
microglia I None
cells I None
were I None
assessed I None
by I None
immunohistochemical I None
analyses I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Anxiety I Disease
was I None
documented I None
in I None
both I None
groups I None
of I None
<eof> I None

<s> O None
PDN I Chemical
treated I None
rats I None
compared I None
with I None
controls I None
. I None
<eof> I None

<s> O None
The I None
magnitude I None
of I None
transformation I None
of I None
the I None
microglia I None
assessed I None
by I None
the I None
number I None
of I None
intersections I None
was I None
significantly I None
higher I None
in I None
the I None
PDN I Chemical
groups I None
than I None
in I None
controls I None
in I None
the I None
prefrontal I None
cortex I None
( I None
moderate I None
- I None
dose I None
, I None
24.1 I None
; I None
high I None
- I None
dose I None
, I None
23.6 I None
; I None
controls I None
18.7 I None
; I None
p I None
< I None
0.01 I None
) I None
and I None
striatum I None
( I None
moderate I None
- I None
dose I None
25.6 I None
; I None
high I None
- I None
dose I None
26.3 I None
; I None
controls I None
18.9 I None
; I None
p I None
< I None
0.01 I None
) I None
, I None
but I None
not I None
in I None
hippocampus I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
stained I None
microglia I None
cells I None
was I None
significantly I None
higher I None
in I None
the I None
PDN I Chemical
treated I None
groups I None
in I None
the I None
prefrontal I None
cortex I None
than I None
in I None
controls I None
( I None
moderate I None
- I None
dose I None
, I None
29.1 I None
; I None
high I None
- I None
dose I None
, I None
28.4 I None
; I None
control I None
, I None
17.7 I None
cells I None
per I None
field I None
; I None
p I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Stained I None
microglia I None
cells I None
were I None
significantly I None
more I None
numerous I None
striatum I None
and I None
hippocampus I None
in I None
the I None
high I None
- I None
dose I None
group I None
compared I None
to I None
controls I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Subacute I None
exposure I None
to I None
PDN I Chemical
induced I None
<eof> I None

<s> O None
anxiety I Disease
and I None
reactivity I None
of I None
microglia I None
. I None
<eof> I None

<s> O None
The I None
relevance I None
of I None
these I None
features I None
for I None
patients I None
using I None
PDN I Chemical
remains I None
to I None
be I None
elucidated I None
. I None
<eof> I None

<s> O None
Phase I None
II I None
study I None
of I None
carboplatin I Chemical
and I None
liposomal I None
doxorubicin I Chemical
in I None
patients I None
with I None
recurrent I None
squamous I None
cell I None
carcinoma I None
of I None
the I None
cervix I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
activity I None
of I None
the I None
combination I None
of I None
carboplatin I Chemical
and I None
liposomal I None
doxorubicin I Chemical
was I None
tested I None
in I None
a I None
Phase I None
II I None
study I None
of I None
patients I None
with I None
recurrent I None
cervical I Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
combination I None
of I None
carboplatin I Chemical
<eof> I None

<s> O None
( I None
area I None
under I None
the I None
concentration I None
curve I None
[ I None
AUC I None
] I None
, I None
5 I None
) I None
and I None
liposomal I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
Doxil I Chemical
; I None
starting I None
dose I None
, I None
40 I None
mg I None
/ I None
m(2 I None
) I None
) I None
was I None
administered I None
intravenously I None
every I None
28 I None
days I None
to I None
37 I None
patients I None
with I None
recurrent I None
squamous I None
cell I None
cervical I None
carcinoma I None
to I None
determine I None
antitumor I None
activity I None
and I None
toxicity I Disease
profile I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
nine I None
patients I None
were I None
assessable I None
for I None
response I None
, I None
and I None
35 I None
patients I None
were I None
assessable I None
for I None
toxicity I Disease
. I None
<eof> I None

<s> O None
The I None
overall I None
response I None
rate I None
was I None
38 I None
% I None
, I None
the I None
median I None
time I None
to I None
response I None
was I None
10 I None
weeks I None
, I None
the I None
median I None
duration I None
of I None
response I None
was I None
26 I None
weeks I None
, I None
and I None
the I None
median I None
survival I None
was I None
37 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
main I None
toxic I None
effect I None
was I None
myelosuppression I Disease
, I None
with I None
Grade I None
3 I None
and I None
4 I None
neutropenia I Disease
in I None
16 I None
patients I None
, I None
anemia I Disease
in I None
12 I None
patients I None
, I None
thrombocytopenia I Disease
in I None
11 I None
patients I None
, I None
and I None
neutropenic I None
fever I None
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
Four I None
patients I None
had I None
five I None
infusion I None
- I None
related I None
reactions I None
during I None
the I None
infusion I None
of I None
liposomal I None
doxorubicin I Chemical
, I None
leading I None
to I None
treatment I None
discontinuation I None
in I None
three I None
patients I None
. I None
<eof> I None

<s> O None
Grade I None
> I None
or I None
= I None
2 I None
nonhematologic I None
toxicity I Disease
included I None
nausea I Disease
<eof> I None

<s> O None
in I None
17 I None
patients I None
, I None
<eof> I None

<s> O None
emesis I Disease
in I None
14 I None
patients I None
, I None
fatigue I Disease
in I None
9 I None
patients I None
, I None
mucositis I Disease
and/or I None
stomatitis I Disease
in I None
8 I None
patients I None
, I None
constipation I Disease
in I None
6 I None
patients I None
, I None
weight I Disease
loss O Disease
in I None
5 I None
patients I None
, I None
hand I Disease
- O Disease
foot O Disease
syndrome O Disease
in I None
2 I None
patients I None
, I None
and I None
skin I Disease
reactions O Disease
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
combination I None
of I None
carboplatin I Chemical
and I None
liposomal I None
doxorubicin I Chemical
has I None
modest I None
activity I None
in I None
patients I None
with I None
recurrent I None
cervical I Disease
carcinoma O Disease
. I None
<eof> I None

<s> O None
Antimicrobial I None
- I None
induced I None
mania I Disease
( I None
antibiomania I Disease
): I None
a I None
review I None
of I None
spontaneous I None
reports I None
. I None
<eof> I None

<s> O None
The I None
authors I None
reviewed I None
reported I None
cases I None
of I None
antibiotic I None
- I None
induced I None
manic I Disease
episodes I None
by I None
means I None
of I None
a I None
MEDLINE I None
and I None
PsychLit I None
search I None
for I None
reports I None
of I None
antibiotic I None
- I None
induced I None
mania I Disease
. I None
<eof> I None

<s> O None
Unpublished I None
reports I None
were I None
requested I None
from I None
the I None
World I None
Health I None
Organization I None
( I None
WHO I None
) I None
and I None
the I None
Food I None
and I None
Drug I None
Administration I None
( I None
FDA I None
) I None
. I None
<eof> I None

<s> O None
Twenty I None
- I None
one I None
reports I None
of I None
antimicrobial I None
- I None
induced I None
mania I Disease
were I None
found I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
There I None
were I None
6 I None
cases I None
implicating I None
clarithromycin I Chemical
, I None
13 I None
implicating I None
isoniazid I Chemical
, I None
and I None
1 I None
case I None
each I None
implicating I None
erythromycin I Chemical
and I None
amoxicillin I Chemical
. I None
<eof> I None

<s> O None
The I None
WHO I None
reported I None
82 I None
cases I None
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
clarithromycin I Chemical
was I None
implicated I None
in I None
23 I None
( I None
27.6 I None
% I None
) I None
cases I None
, I None
ciprofloxacin I Chemical
in I None
12 I None
( I None
14.4 I None
% I None
) I None
cases I None
, I None
and I None
ofloxacin I Chemical
in I None
10 I None
( I None
12 I None
% I None
) I None
cases I None
. I None
<eof> I None

<s> O None
Cotrimoxazole I Chemical
, I None
metronidazole I Chemical
, I None
and I None
erythromycin I Chemical
were I None
involved I None
in I None
15 I None
reported I None
<eof> I None

<s> O None
manic I Disease
episodes I None
. I None
<eof> I None

<s> O None
Cases I None
reported I None
by I None
the I None
FDA I None
showed I None
clarithromycin I Chemical
and I None
ciprofloxacin I Chemical
to I None
be I None
the I None
most I None
frequently I None
associated I None
with I None
the I None
development I None
of I None
mania I Disease
. I None
<eof> I None

<s> O None
Statistical I None
analysis I None
of I None
the I None
data I None
would I None
not I None
have I None
demonstrated I None
a I None
significant I None
statistical I None
correlative I None
risk I None
and I None
was I None
therefore I None
not I None
undertaken I None
. I None
<eof> I None

<s> O None
Patients I None
have I None
an I None
increased I None
risk I None
of I None
developing I None
mania I Disease
while I None
being I None
treated I None
with I None
antimicrobials I None
. I None
<eof> I None

<s> O None
Although I None
this I None
is I None
not I None
a I None
statistically I None
significant I None
risk I None
, I None
physicians I None
must I None
be I None
aware I None
of I None
the I None
effect I None
and I None
reversibility I None
. I None
<eof> I None

<s> O None
Further I None
research I None
clearly I None
is I None
required I None
to I None
determine I None
the I None
incidence I None
of I None
antimicrobial I None
- I None
induced I None
mania I Disease
, I None
the I None
relative I None
risk I None
factors I None
of I None
developing I None
an I None
antimicrobial I None
- I None
induced I None
manic I Disease
episode I None
among I None
various I None
demographic I None
populations I None
, I None
and I None
the I None
incidence I None
of I None
patients I None
who I None
continue I None
to I None
have I None
persistent I None
affective I None
disorders I None
once I None
the I None
initial I None
episode I None
, I None
which I None
occurs I None
while I None
the I None
patient I None
is I None
taking I None
antibiotics I None
, I None
subsides I None
. I None
<eof> I None

<s> O None
The I None
authors I None
elected I None
to I None
name I None
this I None
syndrome I None
" I None
antibiomania I Disease
. I None
" I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
ocular I Disease
dyskinesias O Disease
in I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Levodopa I Chemical
-induced I None
<eof> I None

<s> O None
ocular I Disease
dyskinesias O Disease
are I None
very I None
uncommon I None
. I None
<eof> I None

<s> O None
Usually I None
they I None
occur I None
simultaneously I None
with I None
limb I None
peak I None
- I None
dose I None
choreatic I Disease
dyskinesias O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
a I None
patient I None
with I None
leftward I None
and I None
upward I None
deviations I None
of I None
gaze I None
during I None
the I None
peak I None
effect I None
of I None
levodopa I Chemical
, I None
and I None
hypothesize I None
that I None
a I None
severe I None
dopaminergic I None
denervation I None
in I None
the I None
caudate I None
nucleus I None
is I None
needed I None
for I None
the I None
appearance I None
of I None
these I None
levodopa I Chemical
-induce I None
ocular I Disease
dyskinesias O Disease
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
glyceryl I Chemical
trinitrate O Chemical
with I None
diclofenac I Chemical
for I None
the I None
treatment I None
of I None
primary I None
dysmenorrhea I Disease
: I None
an I None
open I None
, I None
randomized I None
, I None
cross I None
- I None
over I None
trial I None
. I None
<eof> I None

<s> O None
Primary I None
dysmenorrhea I Disease
is I None
a I None
syndrome I None
characterized I None
by I None
painful I None
uterine I None
contractility I None
caused I None
by I None
a I None
hypersecretion I None
of I None
endometrial I None
prostaglandins I Chemical
; I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
are I None
the I None
first I None
choice I None
for I None
its I None
treatment I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
vivo I None
and I None
in I None
vitro I None
studies I None
have I None
demonstrated I None
that I None
myometrial I None
cells I None
are I None
also I None
targets I None
of I None
the I None
relaxant I None
effects I None
of I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
determine I None
the I None
efficacy I None
of I None
glyceryl I Chemical
trinitrate O Chemical
<eof> I None

<s> O None
( I None
GTN I Chemical
) I None
, I None
an I None
NO I Chemical
donor I None
, I None
in I None
the I None
resolution I None
of I None
primary I None
dysmenorrhea I Disease
in I None
comparison I None
with I None
diclofenac I Chemical
<eof> I None

<s> O None
( I None
DCF I Chemical
) I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
24 I None
patients I None
with I None
the I None
diagnosis I None
of I None
severe I None
primary I None
dysmenorrhea I Disease
were I None
studied I None
during I None
two I None
consecutive I None
menstrual I None
cycles I None
. I None
<eof> I None

<s> O None
In I None
an I None
open I None
, I None
cross I None
- I None
over I None
, I None
controlled I None
design I None
, I None
patients I None
were I None
randomized I None
to I None
receive I None
either I None
DCF I Chemical
per I None
os I None
or I None
GTN I Chemical
patches I None
the I None
first I None
days I None
of I None
menses I None
, I None
when I None
menstrual I None
cramps I None
became I None
unendurable I None
. I None
<eof> I None

<s> O None
In I None
the I None
subsequent I None
cycle I None
the I None
other I None
treatment I None
was I None
used I None
. I None
<eof> I None

<s> O None
Patients I None
received I None
up I None
to I None
3 I None
doses I None
/ I None
day I None
of I None
50 I None
mg I None
DCF I Chemical
or I None
2.5 I None
mg/24 I None
<eof> I None

<s> O None
h I None
transdermal I None
GTN I Chemical
for I None
the I None
first I None
3 I None
days I None
of I None
the I None
cycle I None
, I None
according I None
to I None
their I None
needs I None
. I None
<eof> I None

<s> O None
The I None
participants I None
recorded I None
menstrual I None
symptoms I None
and I None
possible I None
side I None
- I None
effects I None
at I None
different I None
times I None
( I None
0 I None
, I None
30 I None
, I None
60 I None
, I None
120 I None
minutes I None
) I None
after I None
the I None
first I None
dose I None
of I None
medication I None
on I None
the I None
first I None
day I None
of I None
the I None
cycle I None
, I None
with I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
difference I None
in I None
pain I Disease
<eof> I None

<s> O None
intensity I None
score I None
( I None
DPI I None
) I None
was I None
the I None
main I None
outcome I None
variable I None
. I None
<eof> I None

<s> O None
Both I None
treatments I None
significantly I None
reduced I None
DPI I None
by I None
the I None
30th I None
minute I None
( I None
GTN I Chemical
, I None
-12.8 I None
<eof> I None

<s> O None
+ I None
/- I None
17.9 I None
; I None
DCF I Chemical
, I None
-18.9 I None
+ I None
/- I None
16.6 I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
DCF I Chemical
continued I None
to I None
be I None
effective I None
in I None
reducing I None
pelvic I Disease
pain O Disease
for I None
two I None
hours I None
, I None
whereas I None
GTN I Chemical
scores I None
remained I None
more I None
or I None
less I None
stable I None
after I None
30 I None
min I None
and I None
significantly I None
higher I None
than I None
those I None
for I None
DFC I None
( I None
after I None
one I None
hour I None
: I None
GTN I Chemical
, I None
-12.8 I None
+ I None
/- I None
17.9 I None
; I None
DFC I None
, I None
-18.9 I None
+ I None
<eof> I None

<s> O None
/- I None
16.6 I None
and I None
after I None
two I None
hours I None
: I None
GTN I Chemical
, I None
-23.7 I None
+ I None
/- I None
20.5 I None
; I None
DFC I None
, I None
-59.7 I None
+ I None
/- I None
17.9 I None
, I None
p I None
= I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
Low I Disease
back O Disease
pain O Disease
was I None
also I None
relieved I None
by I None
both I None
drugs I None
. I None
<eof> I None

<s> O None
Headache I Disease
was I None
significantly I None
increased I None
by I None
GTN I Chemical
but I None
not I None
by I None
DCF I Chemical
. I None
<eof> I None

<s> O None
Eight I None
patients I None
stopped I None
using I None
GTN I Chemical
because I None
headache I Disease
--attributed I None
to I None
its I None
use I None
-- I None
became I None
intolerable I None
. I None
<eof> I None

<s> O None
These I None
findings I None
indicate I None
that I None
GTN I Chemical
has I None
a I None
reduced I None
efficacy I None
and I None
tolerability I None
by I None
comparison I None
with I None
DCF I Chemical
in I None
the I None
treatment I None
of I None
primary I None
dysmenorrhea I Disease
. I None
<eof> I None

<s> O None
Temocapril I Chemical
, I None
a I None
long I None
- I None
acting I None
non I None
- I None
SH I None
group I None
angiotensin I Chemical
<eof> I None

<s> O None
converting I None
enzyme I None
inhibitor I None
, I None
modulates I None
glomerular I Disease
injury O Disease
in I None
chronic I None
puromycin I Chemical
aminonucleoside O Chemical
nephrosis I Disease
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
determine I None
whether I None
chronic I None
administration I None
of I None
temocapril I Chemical
, I None
a I None
long I None
- I None
acting I None
non I None
- I None
SH I None
group I None
angiotensin I Chemical
<eof> I None

<s> O None
converting I None
enzyme I None
( I None
ACE I None
) I None
inhibitor I None
, I None
reduced I None
<eof> I None

<s> O None
proteinuria I Disease
, I None
inhibited I None
glomerular I None
hypertrophy I Disease
and I None
prevented I None
<eof> I None

<s> O None
glomerulosclerosis I Disease
in I None
chronic I None
puromycin I Chemical
aminonucleoside O Chemical
<eof> I None

<s> O None
( I None
PAN I Chemical
) I None
- I None
induced I None
nephrotic I Disease
rats I None
. I None
<eof> I None

<s> O None
Nephrosis I Disease
was I None
induced I None
by I None
injection I None
of I None
PAN I Chemical
<eof> I None

<s> O None
( I None
15mg/100 I None
g I None
body I None
weight I None
) I None
in I None
male I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
rats I None
. I None
<eof> I None

<s> O None
Four I None
groups I None
were I None
used I None
, I None
i I None
) I None
the I None
PAN I Chemical
group I None
( I None
14 I None
) I None
, I None
ii I None
) I None
PAN I Chemical
/ I None
temocapril I Chemical
( I None
13 I None
) I None
, I None
iii I None
) I None
temocapril I Chemical
<eof> I None

<s> O None
( I None
14 I None
) I None
and I None
iv I None
) I None
untreated I None
controls I None
( I None
15 I None
) I None
. I None
<eof> I None

<s> O None
Temocapril I Chemical
<eof> I None

<s> O None
( I None
8 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
was I None
administered I None
to I None
the I None
rats I None
which I None
were I None
killed I None
at I None
weeks I None
4 I None
, I None
14 I None
or I None
20 I None
. I None
<eof> I None

<s> O None
At I None
each I None
time I None
point I None
, I None
systolic I None
blood I None
pressure I None
( I None
BP I None
) I None
, I None
urinary I None
protein I None
excretion I None
and I None
renal I None
histopathological I None
findings I None
were I None
evaluated I None
, I None
and I None
morphometric I None
image I None
analysis I None
was I None
done I None
. I None
<eof> I None

<s> O None
Systolic I None
BP I None
in I None
the I None
PAN I Chemical
group I None
was I None
significantly I None
high I None
at I None
4 I None
, I None
14 I None
and I None
20 I None
weeks I None
, I None
but I None
was I None
normal I None
in I None
the I None
PAN I Chemical
/ I None
temocapril I Chemical
group I None
. I None
<eof> I None

<s> O None
Urinary I None
protein I None
excretion I None
in I None
the I None
PAN I Chemical
group I None
increased I None
significantly I None
, I None
peaking I None
at I None
8 I None
days I None
, I None
then I None
decreased I None
at I None
4 I None
weeks I None
, I None
but I None
rose I None
again I None
significantly I None
at I None
14 I None
and I None
20 I None
weeks I None
. I None
<eof> I None

<s> O None
Temocapril I Chemical
did I None
not I None
attenuate I None
<eof> I None

<s> O None
proteinuria I Disease
at I None
8 I None
days I None
, I None
but I None
it I None
did I None
markedly I None
lower I None
it I None
from I None
weeks I None
4 I None
to I None
20 I None
. I None
<eof> I None

<s> O None
The I None
glomerulosclerosis I Disease
index I None
( I None
GSI I None
) I None
was I None
6.21 I None
% I None
at I None
4 I None
weeks I None
and I None
respectively I None
25.35 I None
% I None
and I None
30.49 I None
% I None
at I None
14 I None
and I None
20 I None
weeks I None
in I None
the I None
PAN I Chemical
group I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
correlation I None
between I None
urinary I None
protein I None
excretion I None
and I None
GSI I None
<eof> I None

<s> O None
( I None
r I None
= I None
0.808 I None
, I None
p I None
< I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
The I None
ratio I None
of I None
glomerular I None
tuft I None
area I None
to I None
the I None
area I None
of I None
Bowman I None
's I None
capsules I None
( I None
GT I None
/ I None
BC I None
) I None
in I None
the I None
PAN I Chemical
group I None
was I None
significantly I None
increased I None
, I None
but I None
it I None
was I None
significantly I None
lower I None
in I None
the I None
PAN I Chemical
/ I None
temocapril I Chemical
group I None
. I None
<eof> I None

<s> O None
It I None
appears I None
that I None
temocapril I Chemical
was I None
effective I None
in I None
retarding I None
renal I None
progression I None
and I None
protected I None
renal I None
function I None
in I None
PAN I Chemical
neprotic I Disease
rats I None
. I None
<eof> I None

<s> O None
Pulmonary I Disease
hypertension O Disease
after I None
ibuprofen I Chemical
prophylaxis I None
in I None
very I None
preterm I None
infants I None
. I None
<eof> I None

<s> O None
We I None
report I None
three I None
cases I None
of I None
severe I None
hypoxaemia I Disease
after I None
ibuprofen I Chemical
administration I None
during I None
a I None
randomised I None
controlled I None
trial I None
of I None
prophylactic I None
treatment I None
of I None
patent I Disease
ductus O Disease
arteriosus O Disease
with I None
ibuprofen I Chemical
in I None
premature I None
infants I None
born I None
at I None
less I None
than I None
28 I None
weeks I None
of I None
gestation I None
. I None
<eof> I None

<s> O None
Echocardiography I None
showed I None
severely I None
decreased I None
pulmonary I None
blood I None
flow I None
. I None
<eof> I None

<s> O None
Hypoxaemia I Disease
resolved I None
quickly I None
on I None
inhaled I None
nitric I Chemical
oxide O Chemical
therapy I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
investigators I None
involved I None
in I None
similar I None
trials I None
pay I None
close I None
attention I None
to I None
pulmonary I None
pressure I None
if I None
hypoxaemia I Disease
occurs I None
after I None
prophylactic I None
administration I None
of I None
ibuprofen I Chemical
. I None
<eof> I None

<s> O None
Hyponatremia I Disease
and I None
syndrome I Disease
of O Disease
inappropriate O Disease
anti O Disease
- O Disease
diuretic O Disease
hormone O Disease
reported I None
with I None
the I None
use I None
of I None
Vincristine I Chemical
: I None
an I None
over I None
- I None
representation I None
of I None
Asians I None
? I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
This I None
retrospective I None
study I None
used I None
a I None
pharmaceutical I None
company I None
's I None
global I None
safety I None
database I None
to I None
determine I None
the I None
reporting I None
rate I None
of I None
hyponatremia I Disease
and/or I None
syndrome I Disease
of O Disease
inappropriate O Disease
secretion O Disease
of O Disease
anti O Disease
- O Disease
diuretic O Disease
hormone O Disease
<eof> I None

<s> O None
( I None
SIADH I Disease
) I None
among I None
<eof> I None

<s> O None
vincristine I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
and I None
to I None
explore I None
the I None
possibility I None
of I None
at I None
- I None
risk I None
population I None
subgroups I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
We I None
searched I None
the I None
Eli I None
Lilly I None
and I None
Company I None
's I None
computerized I None
adverse I None
event I None
database I None
for I None
all I None
reported I None
cases I None
of I None
hyponatremia I Disease
and/or I None
SIADH I Disease
as I None
of I None
1 I None
November I None
1999 I None
that I None
had I None
been I None
reported I None
during I None
the I None
use I None
of I None
vincristine I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
76 I None
cases I None
of I None
hyponatremia I Disease
and/or I None
SIADH I Disease
associated I None
with I None
vincristine I Chemical
use I None
were I None
identified I None
. I None
<eof> I None

<s> O None
The I None
overall I None
reporting I None
rate I None
was I None
estimated I None
to I None
be I None
1.3/100,000 I None
treated I None
patients I None
. I None
<eof> I None

<s> O None
The I None
average I None
age I None
of I None
patients I None
was I None
35.6 I None
+ I None
/- I None
<eof> I None

<s> O None
28.3 I None
years I None
, I None
and I None
62 I None
% I None
were I None
males I None
. I None
<eof> I None

<s> O None
Approximately I None
75 I None
% I None
of I None
the I None
patients I None
were I None
receiving I None
treatment I None
for I None
leukemia I Disease
or I None
lymphoma I Disease
. I None
<eof> I None

<s> O None
Among I None
the I None
39 I None
reports I None
that I None
included I None
information I None
on I None
race I None
, I None
the I None
racial I None
distribution I None
was I None
: I None
1 I None
Black I None
, I None
3 I None
Caucasian I None
, I None
and I None
35 I None
Asian I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
Asian I None
patients I None
may I None
be I None
at I None
increased I None
risk I None
of I None
hyponatremia I Disease
and/or I None
SIADH I Disease
associated I None
with I None
vincristine I Chemical
use I None
. I None
<eof> I None

<s> O None
Although I None
the I None
overall I None
reported I None
rate I None
of I None
SIADH I Disease
associated I None
with I None
vincristine I Chemical
is I None
very I None
low I None
, I None
physicians I None
caring I None
for I None
Asian I None
oncology I None
patients I None
should I None
be I None
aware I None
of I None
this I None
potential I None
serious I None
but I None
reversible I None
adverse I None
event I None
. I None
<eof> I None

<s> O None
Delayed I None
toxicity I Disease
of I None
cyclophosphamide I Chemical
on I None
the I None
bladder I None
of I None
DBA/2 I None
and I None
C57BL/6 I None
female I None
mouse I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
describes I None
the I None
delayed I None
development I None
of I None
a I None
severe I None
bladder I None
pathology I None
in I None
a I None
susceptible I None
strain I None
of I None
mice I None
( I None
DBA/2 I None
) I None
but I None
not I None
in I None
a I None
resistant I None
strain I None
( I None
C57BL/6 I None
) I None
when I None
both I None
were I None
treated I None
with I None
a I None
single I None
300 I None
mg I None
/ I None
kg I None
dose I None
of I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CY I Chemical
) I None
. I None
<eof> I None

<s> O None
Inbred I None
DBA/2 I None
and I None
C57BL/6 I None
female I None
mice I None
were I None
injected I None
with I None
CY I Chemical
, I None
and I None
the I None
effect I None
of I None
the I None
drug I None
on I None
the I None
bladder I None
was I None
assessed I None
during I None
100 I None
days I None
by I None
light I None
microscopy I None
using I None
different I None
staining I None
procedures I None
, I None
and I None
after I None
30 I None
days I None
by I None
conventional I None
electron I None
microscopy I None
. I None
<eof> I None

<s> O None
Early I None
CY I Chemical
<eof> I None

<s> O None
toxicity I Disease
caused I None
a I None
typical I None
haemorrhagic I Disease
cystitis I Disease
in I None
both I None
strains I None
that I None
was I None
completely I None
repaired I None
in I None
about I None
7 I None
- I None
10 I None
days I None
. I None
<eof> I None

<s> O None
After I None
30 I None
days I None
of I None
CY I Chemical
injection I None
ulcerous I None
and I None
non I None
- I None
ulcerous I None
forms I None
of I None
chronic I None
cystitis I Disease
appeared I None
in I None
86 I None
% I None
of I None
DBA/2 I None
mice I None
but I None
only I None
in I None
4 I None
% I None
of I None
C57BL/6 I None
mice I None
. I None
<eof> I None

<s> O None
Delayed I None
cystitis I Disease
was I None
characterized I None
by I None
infiltration I None
and I None
transepithelial I None
passage I None
into I None
the I None
lumen I None
of I None
inflammatory I None
cells I None
and I None
by I None
frequent I None
exfoliation I None
of I None
the I None
urothelium I None
. I None
<eof> I None

<s> O None
Mast I None
cells I None
appeared I None
in I None
the I None
connective I None
and I None
muscular I None
layers I None
of I None
the I None
bladder I None
at I None
a I None
much I None
higher I None
number I None
in I None
DBA/2 I None
mice I None
than I None
in I None
C57BL/6 I None
mice I None
or I None
untreated I None
controls I None
. I None
<eof> I None

<s> O None
Electron I None
microscopy I None
disclosed I None
the I None
absence I None
of I None
the I None
typical I None
discoidal I None
vesicles I None
normally I None
present I None
in I None
the I None
cytoplasm I None
of I None
surface I None
cells I None
. I None
<eof> I None

<s> O None
Instead I None
, I None
numerous I None
abnormal I None
vesicles I None
containing I None
one I None
or I None
several I None
dark I None
granules I None
were I None
observed I None
in I None
the I None
cytoplasm I None
of I None
cells I None
from I None
all I None
the I None
epithelial I None
layers I None
. I None
<eof> I None

<s> O None
Delayed I None
<eof> I None

<s> O None
cystitis I Disease
still I None
persisted I None
in I None
DBA/2 I None
mice I None
100 I None
days I None
after I None
treatment I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
delayed I None
toxicity I Disease
of I None
CY I Chemical
in I None
female I None
DBA/2 I None
mice I None
causes I None
a I None
bladder I None
pathology I None
that I None
is I None
not I None
observed I None
in I None
C57BL/6 I None
mice I None
. I None
<eof> I None

<s> O None
This I None
pathology I None
resembles I None
interstitial I Disease
cystitis O Disease
in I None
humans I None
and I None
could I None
perhaps I None
be I None
used I None
as I None
an I None
animal I None
model I None
for I None
studies I None
on I None
the I None
disease I None
. I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
5-fluorouracil I Chemical
/ I None
folinic I Chemical
acid O Chemical
in I None
combination I None
with I None
three I None
- I None
weekly I None
mitomycin I Chemical
C O Chemical
in I None
the I None
treatment I None
of I None
advanced I None
gastric I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
A I None
phase I None
II I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
24-hour I None
continuous I None
infusion I None
of I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
and I None
folinic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
FA I Chemical
) I None
as I None
part I None
of I None
several I None
new I None
multidrug I None
chemotherapy I None
regimens I None
in I None
advanced I None
gastric I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
AGC I Disease
) I None
has I None
shown I None
to I None
be I None
effective I None
, I None
with I None
low I None
toxicity I Disease
. I None
<eof> I None

<s> O None
In I None
a I None
previous I None
phase I None
II I None
study I None
with I None
3-weekly I None
bolus I None
5-FU I Chemical
, I None
FA I Chemical
and I None
mitomycin I Chemical
C O Chemical
<eof> I None

<s> O None
( I None
MMC I Chemical
) I None
<eof> I None

<s> O None
we I None
found I None
a I None
low I None
toxicity I Disease
rate I None
and I None
response I None
rates I None
comparable I None
to I None
those I None
of I None
regimens I None
such I None
as I None
ELF I None
, I None
FAM I None
or I None
FAMTX I None
, I None
and I None
a I None
promising I None
median I None
overall I None
survival I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
improve I None
this I None
MMC I Chemical
-dependent I None
schedule I None
we I None
initiated I None
a I None
phase I None
II I None
study I None
with I None
high I None
- I None
dose I None
5-FU I Chemical
/ I None
FA I Chemical
and I None
3-weekly I None
bolus I None
MMC I Chemical
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
From I None
February I None
, I None
1998 I None
to I None
September I None
, I None
2000 I None
we I None
recruited I None
33 I None
patients I None
with I None
AGC I Disease
to I None
receive I None
weekly I None
24-hour I None
5-FU I Chemical
2,600 I None
mg I None
/ I None
m(2 I None
) I None
preceded I None
by I None
2-hour I None
FA I Chemical
500 I None
mg I None
/ I None
m(2 I None
) I None
for I None
6 I None
weeks I None
, I None
followed I None
by I None
a I None
2-week I None
rest I None
period I None
. I None
<eof> I None

<s> O None
Bolus I None
MMC I Chemical
10 I None
mg I None
/ I None
m(2 I None
) I None
was I None
added I None
in I None
3-weekly I None
intervals I None
. I None
<eof> I None

<s> O None
Treatment I None
given I None
on I None
an I None
outpatient I None
basis I None
, I None
using I None
portable I None
pump I None
systems I None
, I None
was I None
repeated I None
on I None
day I None
57 I None
. I None
<eof> I None

<s> O None
Patients I None
' I None
characteristics I None
were I None
: I None
male I None
/ I None
female I None
ratio I None
20/13 I None
; I None
median I None
age I None
57 I None
( I None
27 I None
- I None
75 I None
) I None
years I None
; I None
median I None
WHO I None
status I None
1 I None
( I None
0 I None
- I None
2 I None
) I None
. I None
<eof> I None

<s> O None
18 I None
patients I None
had I None
a I None
primary I None
AGC I Disease
, I None
and I None
15 I None
showed I None
a I None
relapsed I None
AGC I Disease
. I None
<eof> I None

<s> O None
Median I None
follow I None
- I None
up I None
was I None
11.8 I None
months I None
( I None
<eof> I None

<s> O None
range I None
of I None
those I None
surviving I None
: I None
2.7 I None
- I None
11.8 I None
months I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
32 I None
patients I None
were I None
evaluable I None
for I None
response I None
- I None
complete I None
remission I None
9.1 I None
% I None
( I None
n I None
= I None
3 I None
) I None
, I None
partial I None
remission I None
45.5 I None
% I None
( I None
n I None
= I None
15 I None
) I None
, I None
no I None
change I None
27.3 I None
% I None
( I None
n I None
= I None
9 I None
) I None
, I None
progressive I None
disease I None
15.1 I None
% I None
( I None
n I None
= I None
5 I None
) I None
. I None
<eof> I None

<s> O None
Median I None
overall I None
survival I None
time I None
was I None
10.2 I None
months I None
[ I None
95 I None
% I None
confidence I None
interval I None
( I None
CI I None
) I None
: I None
8.7 I None
- I None
11.6 I None
] I None
, I None
and I None
median I None
progression I None
- I None
free I None
survival I None
time I None
was I None
7.6 I None
months I None
( I None
95 I None
% I None
CI I None
: I None
4.4 I None
- I None
10.9 I None
) I None
. I None
<eof> I None

<s> O None
The I None
worst I None
toxicities I Disease
( I None
% I None
) I None
observed I None
were I None
( I None
CTC I None
- I None
NCI I None
1/2/3 I None
) I None
: I None
<eof> I None

<s> O None
leukopenia I Disease
45.5/18.2/6.1 I None
, I None
thrombocytopenia I Disease
33.3/9.1/6.1 I None
, I None
vomitus I Disease
24.2/9.1/0 I None
, I None
diarrhea I Disease
36.4/6.1/3.0 I None
, I None
stomatitis I Disease
18.2/9.1/0 I None
, I None
hand I Disease
- O Disease
foot O Disease
syndrome O Disease
12.1/0/0 I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
developed I None
hemolytic I Disease
- O Disease
uremic O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
HUS I Disease
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
5-FU I Chemical
/ I None
FA I Chemical
/ I None
MMC I Chemical
is I None
an I None
effective I None
and I None
well I None
- I None
tolerated I None
outpatient I None
regimen I None
for I None
AGC I Disease
<eof> I None

<s> O None
( I None
objective I None
response I None
rate I None
54.6 I None
% I None
) I None
. I None
<eof> I None

<s> O None
It I None
may I None
serve I None
as I None
an I None
alternative I None
to I None
cisplatin I Chemical
<eof> I None

<s> O None
-containing I None
regimens I None
; I None
however I None
, I None
it I None
has I None
to I None
be I None
considered I None
that I None
possibly I None
HUS I Disease
may I None
occur I None
. I None
<eof> I None

<s> O None
Persistent I None
sterile I None
leukocyturia I Disease
is I None
associated I None
with I None
impaired I Disease
renal O Disease
function O Disease
in I None
human I Disease
immunodeficiency O Disease
virus O Disease
type O Disease
1-infected O Disease
children I None
treated I None
with I None
indinavir I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Prolonged I None
administration I None
of I None
indinavir I Chemical
is I None
associated I None
with I None
the I None
occurrence I None
of I None
a I None
variety I None
of I None
renal I None
complications I None
in I None
adults I None
. I None
<eof> I None

<s> O None
These I None
well I None
- I None
documented I None
side I None
effects I None
have I None
restricted I None
the I None
use I None
of I None
this I None
potent I None
protease I None
inhibitor I None
in I None
children I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
A I None
prospective I None
study I None
to I None
monitor I None
indinavir I Chemical
-related I None
nephrotoxicity I Disease
in I None
a I None
cohort I None
of I None
30 I None
human I Disease
immunodeficiency O Disease
virus O Disease
type O Disease
1-infected O Disease
children I None
treated I None
with I None
indinavir I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Urinary I None
pH I None
, I None
albumin I None
, I None
creatinine I Chemical
, I None
the I None
presence I None
of I None
erythrocytes I None
, I None
leukocytes I None
, I None
bacteria I None
and I None
crystals I None
, I None
and I None
culture I None
were I None
analyzed I None
every I None
3 I None
months I None
for I None
96 I None
weeks I None
. I None
<eof> I None

<s> O None
Serum I None
creatinine I Chemical
levels I None
were I None
routinely I None
determined I None
at I None
the I None
same I None
time I None
points I None
. I None
<eof> I None

<s> O None
Steady I None
- I None
state I None
pharmacokinetics I None
of I None
indinavir I Chemical
were I None
done I None
at I None
week I None
4 I None
after I None
the I None
initiation I None
of I None
indinavir I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
cumulative I None
incidence I None
of I None
persistent I None
sterile I None
leukocyturia I Disease
( I None
> I None
or I None
= I None
75 I None
cells/ I None
micro I None
L I None
in I None
at I None
least I None
2 I None
consecutive I None
visits I None
) I None
after I None
96 I None
weeks I None
was I None
53 I None
% I None
. I None
<eof> I None

<s> O None
Persistent I None
sterile I None
leukocyturia I Disease
was I None
frequently I None
associated I None
with I None
a I None
mild I None
increase I None
in I None
the I None
urine I None
albumin/ I None
creatinine I Chemical
ratio I None
and I None
by I None
microscopic I None
hematuria I Disease
. I None
<eof> I None

<s> O None
The I None
cumulative I None
incidence I None
of I None
serum I None
creatinine I Chemical
levels I None
> I None
50 I None
% I None
above I None
normal I None
was I None
33 I None
% I None
after I None
96 I None
weeks I None
. I None
<eof> I None

<s> O None
Children I None
with I None
persistent I None
sterile I None
leukocyturia I Disease
more I None
frequently I None
had I None
serum I None
creatinine I Chemical
levels I None
of I None
50 I None
% I None
above I None
normal I None
than I None
those I None
children I None
without I None
persistent I None
sterile I None
leukocyturia I Disease
. I None
<eof> I None

<s> O None
In I None
children I None
younger I None
than I None
5.6 I None
years I None
, I None
persistent I None
sterile I None
leukocyturia I Disease
was I None
significantly I None
more I None
frequent I None
than I None
in I None
older I None
children I None
. I None
<eof> I None

<s> O None
A I None
higher I None
cumulative I None
incidence I None
of I None
persistent I None
leukocyturia I Disease
was I None
found I None
in I None
children I None
with I None
an I None
area I None
under I None
the I None
curve I None
> I None
<eof> I None

<s> O None
19 I None
mg I None
/ I None
L I None
x I None
h I None
or I None
a I None
peak I None
serum I None
level I None
of I None
indinavir I Chemical
> I None
<eof> I None

<s> O None
12 I None
mg I None
/ I None
L. I None
<eof> I None

<s> O None
In I None
4 I None
children I None
, I None
indinavir I Chemical
was I None
discontinued I None
because I None
of I None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
Subsequently I None
, I None
the I None
serum I None
creatinine I Chemical
levels I None
decreased I None
, I None
the I None
urine I None
albumin/ I None
creatinine I Chemical
ratios I None
returned I None
to I None
zero I None
, I None
and I None
the I None
leukocyturia I Disease
disappeared I None
within I None
3 I None
months I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Children I None
treated I None
with I None
indinavir I Chemical
have I None
a I None
high I None
cumulative I None
incidence I None
of I None
persistent I None
sterile I None
leukocyturia I Disease
. I None
<eof> I None

<s> O None
Children I None
with I None
persistent I None
sterile I None
leukocyturia I Disease
more I None
frequently I None
had I None
an I None
increase I None
in I None
serum I None
creatinine I Chemical
levels I None
of I None
> I None
50 I None
% I None
above I None
normal I None
. I None
<eof> I None

<s> O None
Younger I None
children I None
have I None
an I None
additional I None
risk I None
for I None
renal I None
complications I None
. I None
<eof> I None

<s> O None
The I None
impairment I Disease
of O Disease
the O Disease
renal O Disease
function O Disease
in I None
these I None
children I None
occurred I None
in I None
the I None
absence I None
of I None
clinical I None
symptoms I None
of I None
nephrolithiasis I Disease
. I None
<eof> I None

<s> O None
Indinavir I Chemical
-associated I None
<eof> I None

<s> O None
nephrotoxicity I Disease
must I None
be I None
monitored I None
closely I None
, I None
especially I None
in I None
children I None
with I None
risk I None
factors I None
such I None
as I None
persistent I None
sterile I None
leukocyturia I Disease
, I None
age I None
< I None
5.6 I None
years I None
, I None
an I None
area I None
under I None
the I None
curve I None
of I None
indinavir I Chemical
<eof> I None

<s> O None
> I None
<eof> I None

<s> O None
19 I None
mg I None
/ I None
L I None
x I None
<eof> I None

<s> O None
h I None
, I None
and I None
a I None
C(max I None
) I None
> I None
12 I None
mg I None
/ I None
L. I None
<eof> I None

<s> O None
Utility I None
of I None
troponin I None
I I None
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
Baseline I None
electrocardiogram I None
abnormalities I None
and I None
market I None
elevations I None
not I None
associated I None
with I None
myocardial I Disease
necrosis O Disease
make I None
accurate I None
diagnosis I None
of I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
difficult I None
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
Troponin I None
sampling I None
may I None
offer I None
greater I None
diagnostic I None
utility I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
assess I None
outcomes I None
based I None
on I None
troponin I None
positivity I None
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
chest I Disease
pain O Disease
admitted I None
for I None
exclusion I None
of I None
MI I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Outcomes I None
were I None
examined I None
in I None
patients I None
admitted I None
for I None
possible I None
MI I Disease
after I None
cocaine I Chemical
use I None
. I None
<eof> I None

<s> O None
All I None
patients I None
underwent I None
a I None
rapid I None
rule I None
- I None
in I None
protocol I None
that I None
included I None
serial I None
sampling I None
of I None
creatine I Chemical
kinase I None
( I None
CK I None
) I None
, I None
CK I None
- I None
MB I None
, I None
and I None
cardiac I None
troponin I None
I I None
( I None
cTnI I None
) I None
over I None
eight I None
hours I None
. I None
<eof> I None

<s> O None
Outcomes I None
included I None
CK I None
- I None
MB I None
MI I Disease
( I None
CK I None
- I None
MB I None
> I None
or= I None
8 I None
ng I None
/ I None
mL I None
with I None
a I None
relative I None
index I None
[ I None
( I None
CK I None
- I None
MB I None
x I None
100)/total I None
CK I None
] I None
> I None
or= I None
4 I None
, I None
cardiac I Disease
death O Disease
, I None
and I None
significant I None
coronary I Disease
disease O Disease
<eof> I None

<s> O None
( I None
> I None
or=50 I None
% I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
the I None
246 I None
admitted I None
patients I None
, I None
34 I None
( I None
14 I None
% I None
) I None
met I None
CK I None
- I None
MB I None
criteria I None
for I None
MI I Disease
and I None
38 I None
( I None
16 I None
% I None
) I None
had I None
cTnI I None
elevations I None
. I None
<eof> I None

<s> O None
Angiography I None
was I None
performed I None
in I None
29 I None
of I None
38 I None
patients I None
who I None
were I None
cTnI I None
- I None
positive I None
, I None
with I None
significant I None
disease I None
present I None
in I None
25 I None
( I None
86 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Three I None
of I None
the I None
four I None
patients I None
without I None
significant I None
disease I None
who I None
had I None
cTnI I None
elevations I None
met I None
CK I None
- I None
MB I None
criteria I None
for I None
MI I Disease
, I None
and I None
the I None
other I None
had I None
a I None
peak I None
CK I None
- I None
MB I None
level I None
of I None
13 I None
ng I None
/ I None
mL. I None
Sensitivities I None
, I None
specificities I None
, I None
and I None
positive I None
and I None
negative I None
likelihood I None
ratios I None
for I None
predicting I None
cardiac I Disease
death O Disease
or I None
significant I None
disease I None
were I None
high I None
for I None
both I None
CK I None
- I None
MB I None
MI I Disease
and I None
cTnI I None
and I None
were I None
not I None
significantly I None
different I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Most I None
patients I None
with I None
cTnI I None
elevations I None
meet I None
CK I None
- I None
MB I None
criteria I None
for I None
MI I Disease
, I None
as I None
well I None
as I None
have I None
a I None
high I None
incidence I None
of I None
underlying I None
significant I None
disease I None
. I None
<eof> I None

<s> O None
Troponin I None
appears I None
to I None
have I None
an I None
equivalent I None
diagnostic I None
accuracy I None
compared I None
with I None
CK I None
- I None
MB I None
for I None
diagnosing I None
necrosis I Disease
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
and I None
suspected I None
MI I Disease
. I None
<eof> I None

<s> O None
Acute I None
interstitial I Disease
nephritis O Disease
due I None
to I None
nicergoline I Chemical
<eof> I None

<s> O None
( I None
Sermion I Chemical
) I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
acute I None
interstitial I Disease
nephritis O Disease
<eof> I None

<s> O None
( I None
AIN I Disease
) I None
due I None
to I None
nicergoline I Chemical
<eof> I None

<s> O None
( I None
Sermion I Chemical
) I None
. I None
<eof> I None

<s> O None
A I None
50-year I None
- I None
old I None
patient I None
admitted I None
to I None
our I None
hospital I None
for I None
fever I Disease
and I None
acute I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Before I None
admission I None
, I None
he I None
had I None
been I None
taking I None
nicergoline I Chemical
and I None
bendazac I Chemical
lysine O Chemical
due I None
to I None
retinal I Disease
vein O Disease
occlusion O Disease
at I None
ophthalmologic I None
department I None
. I None
<eof> I None

<s> O None
Thereafter I None
, I None
he I None
experienced I None
intermittent I None
fever I Disease
and I None
skin I Disease
rash O Disease
. I None
<eof> I None

<s> O None
On I None
admission I None
, I None
clinical I None
symptoms I None
( I None
i.e. I None
arthralgia I Disease
and I None
fever I Disease
) I None
and I None
laboratory I None
findings I None
( I None
i.e. I None
eosinophilia I Disease
and I None
renal I Disease
failure O Disease
) I None
suggested I None
AIN I Disease
, I None
and I None
which I None
was I None
confirmed I None
by I None
pathologic I None
findings I None
on I None
renal I None
biopsy I None
. I None
<eof> I None

<s> O None
A I None
lymphocyte I None
transformation I None
test I None
demonstrated I None
a I None
positive I None
result I None
against I None
nicergoline I Chemical
. I None
<eof> I None

<s> O None
Treatment I None
was I None
consisted I None
of I None
withdrawal I None
of I None
nicergoline I Chemical
and I None
intravenous I None
methylprednisolone I Chemical
, I None
and I None
his I None
renal I None
function I None
was I None
completely I None
recovered I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
first I None
report I None
of I None
nicergoline I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
AIN I Disease
. I None
<eof> I None

<s> O None
Neuroleptic I Disease
malignant O Disease
syndrome O Disease
complicated I None
by I None
massive I None
intestinal I None
bleeding I Disease
in I None
a I None
patient I None
with I None
chronic I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
A I None
patient I None
with I None
chronic I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
CRF I Disease
) I None
developed I None
neuroleptic I Disease
malignant O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
NMS I Disease
) I None
after I None
administration I None
of I None
risperidone I Chemical
and I None
levomepromazine I Chemical
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
the I None
typical I None
symptoms I None
of I None
NMS I Disease
, I None
massive I None
intestinal I None
bleeding I Disease
was I None
observed I None
during I None
the I None
episode I None
. I None
<eof> I None

<s> O None
This I None
report I None
suggests I None
that I None
NMS I Disease
in I None
a I None
patient I None
with I None
CRF I Disease
may I None
be I None
complicated I None
by I None
intestinal I None
bleeding I Disease
and I None
needs I None
special I None
caution I None
for I None
this I None
complication I None
. I None
<eof> I None

<s> O None
Blood I None
brain I None
barrier I None
in I None
right- I None
and I None
left I None
- I None
pawed I None
female I None
rats I None
assessed I None
by I None
a I None
new I None
staining I None
method I None
. I None
<eof> I None

<s> O None
The I None
asymmetrical I None
breakdown I None
of I None
the I None
blood I None
- I None
brain I None
barrier I None
( I None
BBB I None
) I None
was I None
studied I None
in I None
female I None
rats I None
. I None
<eof> I None

<s> O None
Paw I None
preference I None
was I None
assessed I None
by I None
a I None
food I None
reaching I None
test I None
. I None
<eof> I None

<s> O None
Adrenaline I Chemical
-induced I None
<eof> I None

<s> O None
hypertension I Disease
was I None
used I None
to I None
destroy I None
the I None
BBB I None
, I None
which I None
was I None
evaluated I None
using I None
triphenyltetrazolium I Chemical
<eof> I None

<s> O None
( I None
TTC I Chemical
) I None
staining I None
of I None
the I None
brain I None
slices I None
just I None
after I None
giving I None
adrenaline I Chemical
for I None
30 I None
s. I None
<eof> I None

<s> O None
In I None
normal I None
rats I None
, I None
the I None
whole I None
brain I None
sections I None
exhibited I None
complete I None
staining I None
with I None
TTC I Chemical
. I None
<eof> I None

<s> O None
After I None
adrenaline I Chemical
infusion I None
for I None
30 I None
s I None
, I None
there I None
were I None
large I None
unstained I None
areas I None
in I None
the I None
left I None
brain I None
in I None
right I None
- I None
pawed I None
animals I None
, I None
and I None
vice I None
versa I None
in I None
left I None
- I None
pawed I None
animals I None
. I None
<eof> I None

<s> O None
Similar I None
results I None
were I None
obtained I None
in I None
seizure I Disease
-induced I None
breakdown I None
of I None
BBB I None
. I None
<eof> I None

<s> O None
These I None
results I None
were I None
explained I None
by I None
an I None
asymmetric I None
cerebral I None
blood I None
flow I None
depending I None
upon I None
the I None
paw I None
preference I None
in I None
rats I None
. I None
<eof> I None

<s> O None
It I None
was I None
suggested I None
that I None
this I None
new I None
method I None
and I None
the I None
results I None
are I None
consistent I None
with I None
contralateral I None
motor I None
control I None
that I None
may I None
be I None
important I None
in I None
determining I None
the I None
dominant I None
cerebral I None
hemisphere I None
in I None
animals I None
. I None
<eof> I None

<s> O None
Carvedilol I Chemical
protects I None
against I None
doxorubicin I Chemical
-induced I None
mitochondrial I None
cardiomyopathy I Disease
. I None
<eof> I None

<s> O None
Several I None
cytopathic I None
mechanisms I None
have I None
been I None
suggested I None
to I None
mediate I None
the I None
dose I None
- I None
limiting I None
cumulative I None
and I None
irreversible I None
cardiomyopathy I Disease
caused I None
by I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Recent I None
evidence I None
indicates I None
that I None
oxidative I None
stress I None
and I None
mitochondrial I Disease
dysfunction O Disease
are I None
key I None
factors I None
in I None
the I None
pathogenic I None
process I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
investigation I None
was I None
to I None
test I None
the I None
hypothesis I None
that I None
carvedilol I Chemical
, I None
a I None
nonselective I None
beta I None
- I None
adrenergic I None
receptor I None
antagonist I None
with I None
potent I None
antioxidant I None
properties I None
, I None
protects I None
against I None
the I None
cardiac I None
and I None
hepatic I None
mitochondrial I None
bioenergetic I None
dysfunction I None
associated I None
with I None
subchronic I None
doxorubicin I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Heart I None
and I None
liver I None
mitochondria I None
were I None
isolated I None
from I None
rats I None
treated I None
for I None
7 I None
weeks I None
with I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
sc I None
/ I None
week I None
) I None
, I None
carvedilol I Chemical
<eof> I None

<s> O None
( I None
1 I None
mg I None
/ I None
kg I None
ip I None
/ I None
week I None
) I None
, I None
or I None
the I None
combination I None
of I None
the I None
two I None
drugs I None
. I None
<eof> I None

<s> O None
Heart I None
mitochondria I None
isolated I None
from I None
doxorubicin I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
exhibited I None
depressed I None
rates I None
for I None
state I None
3 I None
respiration I None
( I None
336 I None
+ I None
/- I None
<eof> I None

<s> O None
26 I None
versus I None
425 I None
+ I None
/- I None
<eof> I None

<s> O None
53 I None
natom I None
O I None
/ I None
min I None
/ I None
mg I None
protein I None
) I None
and I None
a I None
lower I None
respiratory I None
control I None
ratio I None
( I None
RCR I None
) I None
( I None
4.3 I None
+ I None
/- I None
0.6 I None
versus I None
5.8 I None
+ I None
/- I None
0.4 I None
) I None
compared I None
with I None
cardiac I None
mitochondria I None
isolated I None
from I None
saline I None
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
Mitochondrial I None
calcium I Chemical
-loading I None
capacity I None
and I None
the I None
activity I None
of I None
NADH I None
- I None
dehydrogenase I None
were I None
also I None
suppressed I None
in I None
cardiac I None
mitochondria I None
from I None
doxorubicin I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Doxorubicin I Chemical
treatment I None
also I None
caused I None
a I None
decrease I None
in I None
RCR I None
for I None
liver I None
mitochondria I None
( I None
3.9 I None
+ I None
/- I None
0.9 I None
versus I None
5.6 I None
+ I None
/- I None
0.7 I None
for I None
control I None
rats I None
) I None
and I None
inhibition I None
of I None
hepatic I None
cytochrome I None
oxidase I None
activity I None
. I None
<eof> I None

<s> O None
Coadministration I None
of I None
carvedilol I Chemical
decreased I None
the I None
extent I None
of I None
cellular I None
vacuolization I None
in I None
cardiac I None
myocytes I None
and I None
prevented I None
the I None
inhibitory I None
effect I None
of I None
doxorubicin I Chemical
on I None
mitochondrial I None
respiration I None
in I None
both I None
heart I None
and I None
liver I None
. I None
<eof> I None

<s> O None
Carvedilol I Chemical
also I None
prevented I None
the I None
decrease I None
in I None
mitochondrial I None
Ca I Chemical
( I None
2 I None
+ I None
) I None
loading I None
capacity I None
and I None
the I None
inhibition I None
of I None
the I None
respiratory I None
complexes I None
of I None
heart I None
mitochondria I None
caused I None
by I None
doxorubicin I Chemical
. I None
<eof> I None

<s> O None
Carvedilol I Chemical
by I None
itself I None
did I None
not I None
affect I None
any I None
of I None
the I None
parameters I None
measured I None
for I None
heart I None
or I None
liver I None
mitochondria I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
this I None
protection I None
by I None
carvedilol I Chemical
against I None
both I None
the I None
structural I None
and I None
functional I None
cardiac I None
tissue I None
damage I None
may I None
afford I None
significant I None
clinical I None
advantage I None
in I None
minimizing I None
the I None
dose I None
- I None
limiting I None
mitochondrial I Disease
dysfunction O Disease
and I None
cardiomyopathy I Disease
that I None
accompanies I None
long I None
- I None
term I None
doxorubicin I Chemical
therapy I None
in I None
cancer I Disease
patients I None
. I None
<eof> I None

<s> O None
Cocaine I Chemical
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
is I None
more I None
influenced I None
by I None
adenosine I Chemical
receptor I None
agonists I None
than I None
amphetamine I Chemical
-induced I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
The I None
influence I None
of I None
adenosine I Chemical
receptor I None
agonists I None
and I None
antagonists I None
on I None
cocaine I Chemical
-and I None
<eof> I None

<s> O None
amphetamine I Chemical
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
was I None
examined I None
in I None
mice I None
. I None
<eof> I None

<s> O None
All I None
adenosine I Chemical
receptor I None
agonists I None
significantly I None
decreased I Disease
the O Disease
locomotor O Disease
activity O Disease
in I None
mice I None
, I None
and I None
the I None
effects I None
were I None
dose I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
It I None
seems I None
that I None
adenosine I Chemical
A1 I None
and I None
A2 I None
receptors I None
might I None
be I None
involved I None
in I None
this I None
reaction I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
all I None
adenosine I Chemical
receptor I None
agonists I None
: I None
2-p-(2-carboxyethyl)phenethylamino-5'-N I Chemical
- O Chemical
ethylcarboxamidoadenosine O Chemical
( I None
CGS I Chemical
21680 O Chemical
) I None
, I None
A2A I None
receptor I None
agonist I None
, I None
N6-cyclopentyladenosine I Chemical
<eof> I None

<s> O None
( I None
CPA I Chemical
) I None
, I None
A1 I None
receptor I None
agonist I None
, I None
and I None
5'-N I Chemical
- O Chemical
ethylcarboxamidoadenosine O Chemical
( I None
NECA I Chemical
) I None
, I None
A2/A1 I None
receptor I None
agonist I None
significantly I None
and I None
dose I None
- I None
dependently I None
decreased I None
cocaine I Chemical
<eof> I None

<s> O None
-induced I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
CPA I Chemical
reduced I None
cocaine I Chemical
action I None
at I None
the I None
doses I None
which I None
, I None
given I None
alone I None
, I None
did I None
not I None
influence I None
motility I None
, I None
while I None
CGS I Chemical
21680 O Chemical
and I None
NECA I Chemical
decreased I None
the I None
action I None
of I None
cocaine I Chemical
at I None
the I None
doses I None
which I None
, I None
given I None
alone I None
, I None
decreased I None
locomotor I None
activity I None
in I None
animals I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
the I None
involvement I None
of I None
both I None
adenosine I Chemical
receptors I None
in I None
the I None
action I None
of I None
cocaine I Chemical
although I None
agonists I None
of I None
A1 I None
receptors I None
seem I None
to I None
have I None
stronger I None
influence I None
on I None
it I None
. I None
<eof> I None

<s> O None
The I None
selective I None
blockade I None
of I None
A2 I None
adenosine I Chemical
receptor I None
by I None
DMPX I Chemical
<eof> I None

<s> O None
( I None
3,7-dimethyl-1-propargylxanthine I Chemical
) I None
significantly I None
enhanced I None
<eof> I None

<s> O None
cocaine I Chemical
-induced I None
locomotor I None
activity I None
of I None
animals I None
. I None
<eof> I None

<s> O None
Caffeine I Chemical
had I None
similar I None
action I None
but I None
the I None
effect I None
was I None
not I None
significant I None
. I None
<eof> I None

<s> O None
CPT I Chemical
<eof> I None

<s> O None
( I None
8-cyclopentyltheophylline I Chemical
) I None
--A1 I None
<eof> I None

<s> O None
receptor I None
antagonist I None
, I None
did I None
not I None
show I None
any I None
influence I None
in I None
this I None
test I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
all I None
adenosine I Chemical
receptor I None
agonists I None
decreased I None
amphetamine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
hyperactivity I Disease
, I None
but I None
at I None
the I None
higher I None
doses I None
than I None
those I None
which I None
were I None
active I None
in I None
cocaine I Chemical
-induced I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
The I None
selective I None
blockade I None
of I None
A2 I None
adenosine I Chemical
receptors I None
( I None
DMPX I Chemical
) I None
and I None
non I None
- I None
selective I None
blockade I None
of I None
adenosine I Chemical
receptors I None
( I None
caffeine I Chemical
) I None
significantly I None
increased I None
the I None
action I None
of I None
amphetamine I Chemical
in I None
the I None
locomotor I None
activity I None
test I None
. I None
<eof> I None

<s> O None
Our I None
results I None
have I None
shown I None
that I None
all I None
adenosine I Chemical
receptor I None
agonists I None
( I None
A1 I None
and I None
A2 I None
) I None
reduce I None
cocaine I Chemical
- I None
and I None
amphetamine I Chemical
-induced I None
locomotor I None
activity I None
and I None
indicate I None
that I None
cocaine I Chemical
-induced I None
hyperactivity I Disease
is I None
more I None
influenced I None
by I None
adenosine I Chemical
receptor I None
agonists I None
( I None
particularly I None
A1 I None
receptors I None
) I None
than I None
amphetamine I Chemical
-induced I None
hyperactivity I Disease
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
and I None
the I None
risk I None
of I None
bradyarrhythmia I Disease
requiring I None
permanent I None
pacemaker I None
in I None
elderly I None
patients I None
with I None
atrial I Disease
fibrillation O Disease
and I None
prior I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
determine I None
whether I None
the I None
use I None
of I None
amiodarone I Chemical
in I None
patients I None
with I None
atrial I Disease
fibrillation O Disease
<eof> I None

<s> O None
( I None
AF I Disease
) I None
increases I None
the I None
risk I None
of I None
bradyarrhythmia I Disease
requiring I None
a I None
permanent I None
pacemaker I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Reports I None
of I None
severe I None
bradyarrhythmia I Disease
during I None
amiodarone I Chemical
therapy I None
are I None
infrequent I None
and I None
limited I None
to I None
studies I None
assessing I None
the I None
therapy I None
's I None
use I None
in I None
the I None
management I None
of I None
patients I None
with I None
ventricular I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
study I None
cohort I None
of I None
8,770 I None
patients I None
age I None
> I None
or I None
= I None
65 I None
years I None
with I None
a I None
new I None
diagnosis I None
of I None
AF I Disease
was I None
identified I None
from I None
a I None
provincewide I None
database I None
of I None
Quebec I None
residents I None
with I None
a I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
MI I Disease
) I None
between I None
1991 I None
and I None
1999 I None
. I None
<eof> I None

<s> O None
Using I None
a I None
nested I None
case I None
- I None
control I None
design I None
, I None
477 I None
cases I None
of I None
bradyarrhythmia I Disease
requiring I None
a I None
permanent I None
pacemaker I None
were I None
matched I None
( I None
1:4 I None
) I None
to I None
1,908 I None
controls I None
. I None
<eof> I None

<s> O None
Multivariable I None
logistic I None
regression I None
was I None
used I None
to I None
estimate I None
the I None
odds I None
ratio I None
( I None
OR I None
) I None
of I None
pacemaker I None
insertion I None
associated I None
with I None
amiodarone I Chemical
use I None
, I None
controlling I None
for I None
baseline I None
risk I None
factors I None
and I None
exposure I None
to I None
sotalol I Chemical
, I None
Class I None
I I None
antiarrhythmic I None
agents I None
, I None
beta I None
- I None
blockers I None
, I None
calcium I Chemical
channel I None
blockers I None
, I None
and I None
digoxin I Chemical
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
amiodarone I Chemical
use I None
was I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
pacemaker I None
insertion I None
( I None
OR I None
: I None
2.14 I None
, I None
95 I None
% I None
confidence I None
interval I None
[ I None
CI I None
] I None
: I None
1.30 I None
to I None
3.54 I None
) I None
. I None
<eof> I None

<s> O None
This I None
effect I None
was I None
modified I None
by I None
gender I None
, I None
with I None
a I None
greater I None
risk I None
in I None
women I None
versus I None
men I None
( I None
OR I None
: I None
3.86 I None
, I None
95 I None
% I None
CI I None
: I None
1.70 I None
to I None
8.75 I None
vs. I None
OR I None
: I None
1.52 I None
, I None
95 I None
% I None
CI I None
: I None
0.80 I None
to I None
2.89 I None
) I None
. I None
<eof> I None

<s> O None
Digoxin I Chemical
was I None
the I None
only I None
other I None
medication I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
pacemaker I None
insertion I None
( I None
<eof> I None

<s> O None
OR I None
: I None
1.78 I None
, I None
95 I None
% I None
CI I None
: I None
1.37 I None
to I None
2.31 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
This I None
study I None
suggests I None
that I None
the I None
use I None
of I None
amiodarone I Chemical
in I None
elderly I None
patients I None
with I None
AF I Disease
and I None
a I None
previous I None
MI I Disease
increases I None
the I None
risk I None
of I None
bradyarrhythmia I Disease
requiring I None
a I None
permanent I None
pacemaker I None
. I None
<eof> I None

<s> O None
The I None
finding I None
of I None
an I None
augmented I None
risk I None
of I None
pacemaker I None
insertion I None
in I None
elderly I None
women I None
receiving I None
amiodarone I Chemical
requires I None
further I None
investigation I None
. I None
<eof> I None

<s> O None
Indomethacin I Chemical
-induced I None
morphologic I None
changes I None
in I None
the I None
rat I None
urinary I None
bladder I None
epithelium I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
morphologic I None
changes I None
in I None
rat I None
urothelium I None
induced I None
by I None
indomethacin I Chemical
. I None
<eof> I None

<s> O None
Nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
- I None
induced I None
<eof> I None

<s> O None
cystitis I Disease
is I None
a I None
poorly I None
recognized I None
and I None
under I None
- I None
reported I None
condition I None
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
tiaprofenic I Chemical
acid O Chemical
, I None
indomethacin I Chemical
has I None
been I None
reported I None
to I None
be I None
associated I None
with I None
this I None
condition I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Three I None
groups I None
were I None
established I None
: I None
a I None
control I None
group I None
( I None
n I None
= I None
10 I None
) I None
, I None
a I None
high I None
- I None
dose I None
group I None
( I None
n I None
= I None
10 I None
) I None
, I None
treated I None
with I None
one I None
intraperitoneal I None
injection I None
of I None
indomethacin I Chemical
20 I None
mg I None
/ I None
kg I None
, I None
and I None
a I None
therapeutic I None
dose I None
group I None
( I None
n I None
= I None
10 I None
) I None
in I None
which I None
oral I None
indomethacin I Chemical
was I None
administered I None
3.25 I None
mg I None
/ I None
kg I None
body I None
weight I None
daily I None
for I None
3 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
animals I None
were I None
then I None
killed I None
and I None
the I None
bladders I None
removed I None
for I None
light I None
and I None
electron I None
microscopic I None
studies I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
light I None
microscopic I None
findings I None
showed I None
some I None
focal I None
epithelial I None
degeneration I None
that I None
was I None
more I None
prominent I None
in I None
the I None
high I None
- I None
dose I None
group I None
. I None
<eof> I None

<s> O None
When I None
compared I None
with I None
the I None
control I None
group I None
, I None
both I None
indomethacin I Chemical
groups I None
revealed I None
statistically I None
increased I None
numbers I None
of I None
mast I None
cells I None
in I None
the I None
mucosa I None
( I None
P I None
< I None
0.0001 I None
) I None
and I None
penetration I None
of I None
lanthanum I Chemical
nitrate O Chemical
through I None
intercellular I None
areas I None
of I None
the I None
epithelium I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
difference I None
in I None
mast I None
cell I None
counts I None
between I None
the I None
high I None
and I None
therapeutic I None
dose I None
groups I None
was I None
also I None
statistically I None
significant I None
( I None
P I None
< I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Indomethacin I Chemical
resulted I None
in I None
histopathologic I None
findings I None
typical I None
of I None
interstitial I Disease
cystitis O Disease
, I None
such I None
as I None
leaky I None
bladder I None
epithelium I None
and I None
mucosal I None
mastocytosis I Disease
. I None
<eof> I None

<s> O None
The I None
true I None
incidence I None
of I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
- I None
induced I None
cystitis I Disease
in I None
humans I None
must I None
be I None
clarified I None
by I None
prospective I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
An I None
open I None
- I None
label I None
phase I None
II I None
study I None
of I None
low I None
- I None
dose I None
thalidomide I Chemical
in I None
androgen I Chemical
-independent I None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
The I None
antiangiogenic I None
effects I None
of I None
thalidomide I Chemical
have I None
been I None
assessed I None
in I None
clinical I None
trials I None
in I None
patients I None
with I None
various I None
solid I None
and I None
haematological I Disease
malignancies O Disease
. I None
<eof> I None

<s> O None
Thalidomide I Chemical
blocks I None
the I None
activity I None
of I None
angiogenic I None
agents I None
including I None
bFGF I None
, I None
VEGF I None
and I None
IL-6 I None
. I None
<eof> I None

<s> O None
We I None
undertook I None
an I None
open I None
- I None
label I None
study I None
using I None
thalidomide I Chemical
100 I None
mg I None
once I None
daily I None
for I None
up I None
to I None
6 I None
months I None
in I None
20 I None
men I None
with I None
<eof> I None

<s> O None
androgen I Chemical
-independent I None
<eof> I None

<s> O None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
The I None
mean I None
time I None
of I None
study I None
was I None
109 I None
days I None
( I None
median I None
107 I None
, I None
range I None
4 I None
- I None
184 I None
days I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
underwent I None
regular I None
measurement I None
of I None
prostate I None
- I None
specific I None
antigen I None
( I None
PSA I None
) I None
, I None
urea I Chemical
and I None
electrolytes I None
, I None
serum I None
bFGF I None
and I None
VEGF I None
. I None
<eof> I None

<s> O None
Three I None
men I None
( I None
15 I None
% I None
) I None
showed I None
a I None
decline I None
in I None
serum I None
PSA I None
of I None
at I None
least I None
50 I None
% I None
, I None
sustained I None
throughout I None
treatment I None
. I None
<eof> I None

<s> O None
Of I None
16 I None
men I None
treated I None
for I None
at I None
least I None
2 I None
months I None
, I None
six I None
( I None
37.5 I None
% I None
) I None
showed I None
a I None
fall I None
in I None
absolute I None
PSA I None
by I None
a I None
median I None
of I None
48 I None
% I None
. I None
<eof> I None

<s> O None
Increasing I None
levels I None
of I None
serum I None
bFGF I None
and I None
VEGF I None
were I None
associated I None
with I None
progressive I None
disease I None
; I None
five I None
of I None
six I None
men I None
who I None
demonstrated I None
a I None
fall I None
in I None
PSA I None
also I None
showed I None
a I None
decline I None
in I None
bFGF I None
and I None
VEGF I None
levels I None
, I None
and I None
three I None
of I None
four I None
men I None
with I None
a I None
rising I None
PSA I None
showed I None
an I None
increase I None
in I None
both I None
growth I None
factors I None
. I None
<eof> I None

<s> O None
Adverse I None
effects I None
included I None
constipation I Disease
, I None
morning I None
drowsiness I Disease
, I None
dizziness I Disease
and I None
rash I Disease
, I None
and I None
resulted I None
in I None
withdrawal I None
from I None
the I None
study I None
by I None
three I None
men I None
. I None
<eof> I None

<s> O None
Evidence I None
of I None
peripheral I Disease
sensory O Disease
neuropathy O Disease
was I None
found I None
in I None
nine I None
of I None
13 I None
men I None
before I None
treatment I None
. I None
<eof> I None

<s> O None
In I None
the I None
seven I None
men I None
who I None
completed I None
six I None
months I None
on I None
thalidomide I Chemical
, I None
subclinical I None
evidence I None
of I None
peripheral I Disease
neuropathy O Disease
was I None
found I None
in I None
four I None
before I None
treatment I None
, I None
but I None
in I None
all I None
seven I None
at I None
repeat I None
testing I None
. I None
<eof> I None

<s> O None
The I None
findings I None
indicate I None
that I None
thalidomide I Chemical
may I None
be I None
an I None
option I None
for I None
patients I None
who I None
have I None
failed I None
other I None
forms I None
of I None
therapy I None
, I None
provided I None
close I None
follow I None
- I None
up I None
is I None
maintained I None
for I None
development I None
of I None
peripheral I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
Central I Disease
nervous O Disease
system O Disease
toxicity O Disease
following I None
the I None
administration I None
of I None
levobupivacaine I Chemical
for I None
lumbar I None
plexus I None
block I None
: I None
<eof> I None

<s> O None
A I None
report I None
of I None
two I None
cases I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
AND I None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
Central I None
nervous I None
system I None
and I None
cardiac I None
toxicity I None
following I None
the I None
administration I None
of I None
local I None
anesthetics I None
is I None
a I None
recognized I None
complication I None
of I None
regional I None
anesthesia I None
. I None
<eof> I None

<s> O None
Levobupivacaine I Chemical
, I None
the I None
pure I None
S(- I None
) I None
<eof> I None

<s> O None
enantiomer I None
of I None
bupivacaine I Chemical
, I None
was I None
developed I None
to I None
improve I None
the I None
cardiac I None
safety I None
profile I None
of I None
bupivacaine I Chemical
. I None
<eof> I None

<s> O None
We I None
describe I None
2 I None
cases I None
of I None
grand I Disease
mal O Disease
seizures O Disease
following I None
accidental I None
intravascular I None
injection I None
of I None
levobupivacaine I Chemical
. I None
<eof> I None

<s> O None
CASE I None
REPORT I None
: I None
<eof> I None

<s> O None
Two I None
patients I None
presenting I None
for I None
elective I None
orthopedic I None
surgery I None
of I None
the I None
lower I None
limb I None
underwent I None
blockade I None
of I None
the I None
lumbar I None
plexus I None
via I None
the I None
posterior I None
approach I None
. I None
<eof> I None

<s> O None
Immediately I None
after I None
the I None
administration I None
of I None
levobupivacaine I Chemical
0.5 I None
% I None
with I None
epinephrine I Chemical
2.5 I None
microgram I None
/ I None
mL I None
, I None
the I None
patients I None
developed I None
<eof> I None

<s> O None
grand I Disease
mal O Disease
seizures O Disease
, I None
despite I None
negative I None
aspiration I None
for I None
blood I None
and I None
no I None
clinical I None
signs I None
of I None
intravenous I None
epinephrine I Chemical
administration I None
. I None
<eof> I None

<s> O None
The I None
seizures I Disease
were I None
successfully I None
treated I None
with I None
sodium I Chemical
thiopental O Chemical
in I None
addition I None
to I None
succinylcholine I Chemical
in I None
1 I None
patient I None
. I None
<eof> I None

<s> O None
Neither I None
patient I None
developed I None
signs I None
of I None
cardiovascular I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
Both I None
patients I None
were I None
treated I None
preoperatively I None
with I None
beta I None
- I None
adrenergic I None
antagonist I None
medications I None
, I None
which I None
may I None
have I None
masked I None
the I None
cardiovascular I None
signs I None
of I None
the I None
unintentional I None
intravascular I None
administration I None
of I None
levobupivacaine I Chemical
with I None
epinephrine I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Although I None
levobupivacaine I Chemical
may I None
have I None
a I None
safer I None
cardiac I Disease
toxicity O Disease
profile I None
than I None
racemic I None
bupivacaine I Chemical
, I None
if I None
adequate I None
amounts I None
of I None
levobupivacaine I Chemical
reach I None
the I None
circulation I None
, I None
it I None
will I None
result I None
in I None
convulsions I Disease
. I None
<eof> I None

<s> O None
Plasma I None
concentrations I None
sufficient I None
to I None
result I None
in I None
central I Disease
nervous O Disease
system O Disease
toxicity O Disease
did I None
not I None
produce I None
manifestations I None
of I None
cardiac I Disease
toxicity O Disease
in I None
these I None
2 I None
patients I None
. I None
<eof> I None

<s> O None
Anaesthetic I None
complications I None
associated I None
with I None
myotonia I Disease
congenita O Disease
: I None
case I None
study I None
and I None
comparison I None
with I None
other I None
myotonic I Disease
disorders O Disease
. I None
<eof> I None

<s> O None
Myotonia I Disease
congenita O Disease
<eof> I None

<s> O None
( I None
MC I Disease
) I None
is I None
caused I None
by I None
a I None
defect I None
in I None
the I None
skeletal I None
muscle I None
chloride I Chemical
channel I None
function I None
, I None
which I None
may I None
cause I None
sustained I Disease
membrane O Disease
depolarisation O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
previously I None
healthy I None
32-year I None
- I None
old I None
woman I None
who I None
developed I None
a I None
life I None
- I None
threatening I None
muscle I Disease
spasm O Disease
and I None
secondary I None
ventilation I None
difficulties I None
following I None
a I None
preoperative I None
injection I None
of I None
suxamethonium I Chemical
. I None
<eof> I None

<s> O None
The I None
muscle I Disease
spasms O Disease
disappeared I None
spontaneously I None
and I None
the I None
surgery I None
proceeded I None
without I None
further I None
problems I None
. I None
<eof> I None

<s> O None
When I None
subsequently I None
questioned I None
, I None
she I None
reported I None
minor I None
symptoms I None
suggesting I None
a I None
myotonic I Disease
condition O Disease
. I None
<eof> I None

<s> O None
Myotonia I Disease
was I None
found I None
on I None
clinical I None
examination I None
and I None
EMG I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
MC I Disease
was I None
confirmed I None
genetically I None
. I None
<eof> I None

<s> O None
Neither I None
the I None
patient I None
nor I None
the I None
anaesthetist I None
were I None
aware I None
of I None
the I None
diagnosis I None
before I None
this I None
potentially I None
lethal I None
complication I None
occurred I None
. I None
<eof> I None

<s> O None
We I None
give I None
a I None
brief I None
overview I None
of I None
ion I Disease
channel O Disease
disorders O Disease
including I None
malignant I Disease
hyperthermia O Disease
and I None
their I None
anaesthetic I None
considerations I None
. I None
<eof> I None

<s> O None
Respiratory I None
pattern I None
in I None
a I None
rat I None
model I None
of I None
epilepsy I Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Apnea I Disease
is I None
known I None
to I None
occur I None
during I None
seizures I Disease
, I None
but I None
systematic I None
studies I None
of I None
ictal I None
respiratory I None
changes I None
in I None
adults I None
are I None
few I None
. I None
<eof> I None

<s> O None
Data I None
regarding I None
respiratory I None
pattern I None
defects I None
during I None
interictal I None
periods I None
also I None
are I None
scarce I None
. I None
<eof> I None

<s> O None
Here I None
we I None
sought I None
to I None
generate I None
information I None
with I None
regard I None
to I None
the I None
interictal I None
period I None
in I None
animals I None
with I None
<eof> I None

<s> O None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
epilepsy I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Twelve I None
rats I None
( I None
six I None
chronically I None
epileptic I Disease
animals I None
and I None
six I None
controls I None
) I None
were I None
anesthetized I None
, I None
given I None
tracheotomies I None
, I None
and I None
subjected I None
to I None
hyperventilation I Disease
or I None
hypoventilation I None
conditions I None
. I None
<eof> I None

<s> O None
Breathing I None
movements I None
caused I None
changes I None
in I None
thoracic I None
volume I None
and I None
forced I None
air I None
to I None
flow I None
tidally I None
through I None
a I None
pneumotachograph I None
. I None
<eof> I None

<s> O None
This I None
flow I None
was I None
measured I None
by I None
using I None
a I None
differential I None
pressure I None
transducer I None
, I None
passed I None
through I None
a I None
polygraph I None
, I None
and I None
from I None
this I None
to I None
a I None
computer I None
with I None
custom I None
software I None
that I None
derived I None
ventilation I None
( I None
VE I None
) I None
, I None
tidal I None
volume I None
( I None
VT I None
) I None
, I None
inspiratory I None
time I None
( I None
TI I None
) I None
, I None
expiratory I None
time I None
( I None
TE I None
) I None
, I None
breathing I None
frequency I None
( I None
f I None
) I None
, I None
and I None
mean I None
inspiratory I None
flow I None
( I None
VT I None
/ I None
TI I None
) I None
on I None
a I None
breath I None
- I None
by I None
- I None
breath I None
basis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
hyperventilation I Disease
maneuver I None
caused I None
a I None
decrease I None
in I None
spontaneous I None
ventilation I None
in I None
pilocarpine I Chemical
-treated I None
and I None
control I None
rats I None
. I None
<eof> I None

<s> O None
Although I None
VE I None
had I None
a I None
similar I None
decrease I None
in I None
both I None
groups I None
, I None
in I None
the I None
epileptic I Disease
group I None
, I None
the I None
decrease I None
in I None
VE I None
was I None
due I None
to I None
a I None
significant I None
( I None
p I None
< I None
0.05 I None
) I None
increase I None
in I None
TE I None
peak I None
in I None
relation I None
to I None
that I None
of I None
the I None
control I None
animals I None
. I None
<eof> I None

<s> O None
The I None
hypoventilation I None
maneuver I None
led I None
to I None
an I None
increase I None
in I None
the I None
arterial I None
Paco2 I None
, I None
followed I None
by I None
an I None
increase I None
in I None
VE I None
. I None
<eof> I None

<s> O None
In I None
the I None
epileptic I Disease
group I None
, I None
the I None
increase I None
in I None
VE I None
was I None
mediated I None
by I None
a I None
significant I None
( I None
p I None
< I None
0.05 I None
) I None
decrease I None
in I None
TE I None
peak I None
compared I None
with I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
Systemic I None
application I None
of I None
KCN I None
, I None
to I None
evaluate I None
the I None
effects I None
of I None
peripheral I None
chemoreception I None
activation I None
on I None
ventilation I None
, I None
led I None
to I None
a I None
similar I None
increase I None
in I None
VE I None
for I None
both I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
pilocarpine I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
have I None
an I None
altered I None
ability I None
to I None
react I None
to I None
( I None
or I None
compensate I None
for I None
) I None
blood I None
gas I None
changes I None
with I None
changes I None
in I None
ventilation I None
and I None
suggest I None
that I None
it I None
is I None
centrally I None
determined I None
. I None
<eof> I None

<s> O None
We I None
speculate I None
on I None
the I None
possible I None
relation I None
of I None
the I None
current I None
findings I None
on I None
treating I None
different I None
epilepsy I Disease
-associated I None
conditions I None
. I None
<eof> I None

<s> O None
Increased I None
serum I None
soluble I None
Fas I None
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
due I None
to I None
paracetamol I Chemical
overdose I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
/ I None
AIMS I None
: I None
<eof> I None

<s> O None
Experimental I None
studies I None
have I None
suggested I None
that I None
apoptosis I None
via I None
the I None
Fas I None
/ I None
Fas I None
Ligand I None
signaling I None
system I None
may I None
play I None
an I None
important I None
role I None
in I None
the I None
development I None
of I None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
investigate I None
the I None
soluble I None
form I None
of I None
Fas I None
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
METHODOLOGY I None
: I None
<eof> I None

<s> O None
Serum I None
levels I None
of I None
sFas I None
( I None
soluble I None
Fas I None
) I None
were I None
measured I None
by I None
ELISA I None
in I None
24 I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
and I None
10 I None
normal I None
control I None
subjects I None
. I None
<eof> I None

<s> O None
Serum I None
levels I None
of I None
tumor I Disease
necrosis I Disease
factor I None
- I None
alpha I None
and I None
interferon I None
- I None
gamma I None
were I None
also I None
determined I None
by I None
ELISA I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Serum I None
sFas I None
was I None
significantly I None
increased I None
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
<eof> I None

<s> O None
( I None
median I None
, I None
26.8 I None
U I None
/ I None
mL I None
; I None
range I None
, I None
6.9 I None
- I None
52.7 I None
U I None
/ I None
mL I None
) I None
compared I None
to I None
the I None
normal I None
controls I None
( I None
median I None
, I None
8.6 I None
U I None
/ I None
mL I None
; I None
range I None
, I None
6.5 I None
- I None
12.0 I None
U I None
/ I None
mL I None
, I None
P I None
< I None
0.0001 I None
) I None
. I None
<eof> I None

<s> O None
Levels I None
were I None
significantly I None
greater I None
in I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
due I None
to I None
paracetamol I Chemical
overdose I Disease
<eof> I None

<s> O None
( I None
median I None
, I None
28.7 I None
U I None
/ I None
mL I None
; I None
range I None
, I None
12.8 I None
- I None
52.7 I None
U I None
/ I None
mL I None
, I None
n I None
= I None
17 I None
) I None
than I None
those I None
due I None
to I None
non I None
- I None
A I None
to I None
E I None
hepatitis I Disease
<eof> I None

<s> O None
( I None
median I None
, I None
12.5 I None
U I None
/ I None
mL I None
; I None
range I None
, I None
6.9 I None
- I None
46.0 I None
U I None
/ I None
mL I None
, I None
n I None
= I None
7 I None
, I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
relationship I None
of I None
sFas I None
to I None
eventual I None
outcome I None
in I None
the I None
patients I None
. I None
<eof> I None

<s> O None
A I None
significant I None
correlation I None
was I None
observed I None
between I None
serum I None
sFas I None
levels I None
and I None
aspartate I Chemical
aminotransferase I None
( I None
r I None
= I None
0.613 I None
, I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
increased I None
concentration I None
of I None
sFas I None
in I None
serum I None
of I None
patients I None
with I None
acute I Disease
liver O Disease
failure O Disease
may I None
reflect I None
activation I None
of I None
Fas I None
- I None
mediated I None
apoptosis I None
in I None
the I None
liver I None
and I None
this I None
together I None
with I None
increased I None
tumor I Disease
necrosis I Disease
factor I None
<eof> I None

<s> O None
- I None
alpha I None
may I None
be I None
an I None
important I None
factor I None
in I None
liver I None
cell I None
loss I None
. I None
<eof> I None

<s> O None
Bilateral I None
subthalamic I None
nucleus I None
stimulation I None
for I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
High I None
frequency I None
stimulation I None
of I None
the I None
subthalamic I None
nucleus I None
( I None
STN I None
) I None
is I None
known I None
to I None
ameliorate I None
the I None
signs I None
and I None
symptoms I None
of I None
advanced I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
AIM I None
: I None
We I None
studied I None
the I None
effect I None
of I None
high I None
frequency I None
STN I None
stimulation I None
in I None
23 I None
patients I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Twenty I None
- I None
three I None
patients I None
suffering I None
from I None
severe I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
Stages I None
III I None
- I None
V I None
on I None
Hoehn I None
and I None
Yahr I None
scale I None
) I None
and I None
, I None
particularly I None
bradykinesia I Disease
, I None
rigidity I Disease
, I None
and I None
levodopa I Chemical
-induced I None
dyskinesias I Disease
underwent I None
bilateral I None
implantation I None
of I None
electrodes I None
in I None
the I None
STN I None
. I None
<eof> I None

<s> O None
Preoperative I None
and I None
postoperative I None
assessments I None
of I None
these I None
patients I None
at I None
1 I None
, I None
3 I None
, I None
6 I None
and I None
12 I None
months I None
follow I None
- I None
up I None
, I None
in I None
" I None
on I None
" I None
and I None
" I None
off I None
" I None
drug I None
conditions I None
, I None
was I None
carried I None
out I None
using I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
Rating I None
Scale I None
, I None
Hoehn I None
and I None
Yahr I None
staging I None
, I None
England I None
activities I None
of I None
daily I None
living I None
score I None
and I None
video I None
recordings I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
After I None
one I None
year I None
of I None
electrical I None
stimulation I None
of I None
the I None
STN I None
, I None
the I None
patients I None
' I None
scores I None
for I None
activities I None
of I None
daily I None
living I None
and I None
motor I None
examination I None
scores I None
( I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
Rating I None
Scale I None
parts I None
II I None
and I None
III I None
) I None
off I None
medication I None
improved I None
by I None
62 I None
% I None
and I None
61 I None
% I None
respectively I None
( I None
p<0.0005 I None
) I None
. I None
<eof> I None

<s> O None
The I None
subscores I None
for I None
the I None
akinesia I Disease
, I None
rigidity I Disease
, I None
tremor I Disease
and I None
gait I None
also I None
improved I None
. I None
<eof> I None

<s> O None
( I None
p<0.0005 I None
) I None
. I None
<eof> I None

<s> O None
The I None
average I None
levodopa I Chemical
dose I None
decreased I None
from I None
813 I None
mg I None
to I None
359 I None
mg I None
. I None
<eof> I None

<s> O None
The I None
cognitive I None
functions I None
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
Two I None
patients I None
developed I None
device I None
- I None
related I None
complications I None
and I None
two I None
patients I None
experienced I None
abnormal I None
weight I None
gain I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Bilateral I None
subthalamic I None
nucleus I None
stimulation I None
is I None
an I None
effective I None
treatment I None
for I None
advanced I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
It I None
reduces I None
the I None
severity I None
of I None
" I None
off I None
" I None
phase I None
symptoms I None
, I None
improves I None
the I None
axial I None
symptoms I None
and I None
reduces I None
levodopa I Chemical
requirements I None
. I None
<eof> I None

<s> O None
The I None
reduction I None
in I None
the I None
levodopa I Chemical
dose I None
is I None
useful I None
in I None
controlling I None
drug I Disease
- O Disease
induced O Disease
dyskinesias O Disease
. I None
<eof> I None

<s> O None
Ocular I None
motility I None
changes I None
after I None
subtenon I None
carboplatin I Chemical
chemotherapy I None
for I None
retinoblastoma I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Focal I None
subtenon I None
carboplatin I Chemical
injections I None
have I None
recently I None
been I None
used I None
as I None
a I None
presumably I None
toxicity I Disease
-free I None
adjunct I None
to I None
systemic I None
chemotherapy I None
for I None
intraocular I None
retinoblastoma I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
our I None
clinical I None
experience I None
with I None
abnormal I Disease
ocular O Disease
motility O Disease
in I None
patients I None
treated I None
with I None
subtenon I None
carboplatin I Chemical
chemotherapy I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
noted I None
abnormal I Disease
ocular O Disease
motility O Disease
in I None
10 I None
consecutive I None
patients I None
with I None
retinoblastoma I Disease
who I None
had I None
received I None
subtenon I None
carboplatin I Chemical
. I None
<eof> I None

<s> O None
During I None
ocular I None
manipulation I None
under I None
general I None
anesthesia I None
, I None
we I None
assessed I None
their I None
eyes I None
by I None
forced I None
duction I None
testing I None
, I None
comparing I None
ocular I None
motility I None
after I None
tumor I Disease
control I None
with I None
ocular I None
motility I None
at I None
diagnosis I None
. I None
<eof> I None

<s> O None
Eyes I None
subsequently I None
enucleated I None
because I None
of I None
treatment I None
failure I None
( I None
n I None
= I None
4 I None
) I None
were I None
examined I None
histologically I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Limitation I None
of I None
ocular I None
motility I None
was I None
detected I None
in I None
all I None
12 I None
eyes I None
of I None
10 I None
patients I None
treated I None
for I None
intraocular I None
retinoblastoma I Disease
with I None
1 I None
to I None
6 I None
injections I None
of I None
subtenon I None
carboplatin I Chemical
as I None
part I None
of I None
multimodality I None
therapy I None
. I None
<eof> I None

<s> O None
Histopathological I None
examination I None
revealed I None
many I None
lipophages I None
in I None
the I None
periorbital I None
fat I None
surrounding I None
the I None
optic I None
nerve I None
in I None
1 I None
eye I None
, I None
indicative I None
of I None
phagocytosis I None
of I None
previously I None
existing I None
fat I None
cells I None
and I None
suggesting I None
prior I None
fat I None
necrosis I Disease
. I None
<eof> I None

<s> O None
The I None
enucleations I None
were I None
technically I None
difficult I None
and I None
hazardous I None
for I None
globe I None
rupture I Disease
because I None
of I None
extensive I None
orbital I None
soft I None
tissue I None
adhesions I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Subtenon I None
carboplatin I Chemical
chemotherapy I None
is I None
associated I None
with I None
significant I None
fibrosis I Disease
of I None
orbital I None
soft I None
tissues I None
, I None
leading I None
to I None
mechanical I None
restriction I None
of I None
eye I None
movements I None
and I None
making I None
subsequent I None
enucleation I None
difficult I None
. I None
<eof> I None

<s> O None
Subtenon I None
carboplatin I Chemical
is I None
not I None
free I None
of I None
toxicity I Disease
, I None
and I None
its I None
use I None
is I None
best I None
restricted I None
to I None
specific I None
indications I None
. I None
<eof> I None

<s> O None
Ethambutol I Chemical
and I None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
To I None
demonstrate I None
the I None
association I None
between I None
ethambutol I Chemical
and I None
optic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Thirteen I None
patients I None
who I None
developed I None
optic I Disease
neuropathy O Disease
after I None
being I None
treated I None
with I None
ethambutol I Chemical
for I None
tuberculosis I None
of I None
the I None
lung I None
or I None
lymph I None
node I None
at I None
Siriraj I None
Hospital I None
between I None
1997 I None
and I None
2001 I None
were I None
retrospectively I None
reviewed I None
. I None
<eof> I None

<s> O None
The I None
clinical I None
characteristics I None
and I None
initial I None
and I None
final I None
visual I None
acuity I None
were I None
analyzed I None
to I None
determine I None
visual I None
outcome I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
patients I None
had I None
optic I Disease
neuropathy O Disease
<eof> I None

<s> O None
between I None
1 I None
to I None
6 I None
months I None
( I None
mean I None
= I None
2.9 I None
months I None
) I None
after I None
starting I None
ethambutol I Chemical
therapy I None
at I None
a I None
dosage I None
ranging I None
from I None
13 I None
to I None
20 I None
mg I None
/ I None
kg I None
/ I None
day I None
<eof> I None

<s> O None
( I None
mean I None
= I None
17 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
. I None
<eof> I None

<s> O None
Seven I None
( I None
54 I None
% I None
) I None
of I None
the I None
13 I None
patients I None
experienced I None
visual I None
recovery I None
after I None
stopping I None
the I None
drug I None
. I None
<eof> I None

<s> O None
Of I None
6 I None
patients I None
with I None
irreversible I None
visual I Disease
impairment O Disease
, I None
4 I None
patients I None
had I None
diabetes I Disease
mellitus O Disease
, I None
glaucoma I Disease
and I None
a I None
history I None
of I None
heavy I None
smoking I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Early I None
recognition I None
of I None
optic I Disease
neuropathy O Disease
should I None
be I None
considered I None
in I None
patients I None
with I None
ethambutol I Chemical
therapy I None
. I None
<eof> I None

<s> O None
A I None
low I None
dose I None
and I None
prompt I None
discontinuation I None
of I None
the I None
drug I None
is I None
recommended I None
particularly I None
in I None
individuals I None
with I None
diabetes I Disease
mellitus O Disease
, I None
glaucoma I Disease
or I None
who I None
are I None
heavy I None
smokers I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
compensatory I None
gustatory I Disease
hyperhidrosis O Disease
with I None
topical I None
glycopyrrolate I Chemical
. I None
<eof> I None

<s> O None
Gustatory I Disease
hyperhidrosis O Disease
is I None
facial I None
sweating I Disease
usually I None
associated I None
with I None
the I None
eating I None
of I None
hot I None
spicy I None
food I None
or I None
even I None
smelling I None
this I None
food I None
. I None
<eof> I None

<s> O None
Current I None
options I None
of I None
treatment I None
include I None
oral I None
anticholinergic I None
drugs I None
, I None
the I None
topical I None
application I None
of I None
anticholinergics I None
or I None
aluminum I Chemical
chloride O Chemical
, I None
and I None
the I None
injection I None
of I None
botulinum I None
toxin I None
. I None
<eof> I None

<s> O None
Thirteen I None
patients I None
have I None
been I None
treated I None
to I None
date I None
with I None
1.5 I None
% I None
or I None
2 I None
% I None
topical I None
glycopyrrolate I Chemical
. I None
<eof> I None

<s> O None
All I None
patients I None
had I None
gustatory I Disease
hyperhidrosis O Disease
, I None
which I None
interfered I None
with I None
their I None
social I None
activities I None
, I None
after I None
transthroacic I None
endoscopic I None
sympathectomy I None
, I None
and I None
which I None
was I None
associated I None
with I None
compensatory I None
focal I None
hyperhidrosis I Disease
. I None
<eof> I None

<s> O None
After I None
applying I None
topical I None
glycopyrrolate I Chemical
, I None
the I None
subjective I None
effect I None
was I None
excellent I None
<eof> I None

<s> O None
( I None
no I None
sweating I Disease
after I None
eating I None
hot I None
spicy I None
food I None
) I None
in I None
10 I None
patients I None
( I None
77 I None
% I None
) I None
, I None
and I None
fair I None
( I None
clearly I None
reduced I None
sweating I Disease
) I None
in I None
3 I None
patients I None
( I None
23 I None
% I None
) I None
. I None
<eof> I None

<s> O None
All I None
had I None
reported I None
incidents I None
of I None
being I None
very I None
embarrassed I None
whilst I None
eating I None
hot I None
spicy I None
foods I None
. I None
<eof> I None

<s> O None
Adverse I None
effects I None
included I None
a I None
mildly I None
dry I Disease
mouth O Disease
and I None
a I None
sore I Disease
throat O Disease
in I None
2 I None
patients I None
( I None
2 I None
% I None
glycopyrrolate I Chemical
) I None
, I None
a I None
light I None
headache I Disease
in I None
1 I None
patient I None
( I None
1.5 I None
% I None
glycopyrrolate I Chemical
) I None
. I None
<eof> I None

<s> O None
The I None
topical I None
application I None
of I None
a I None
glycopyrrolate I Chemical
pad I None
appeared I None
to I None
be I None
safe I None
, I None
efficacious I None
, I None
well I None
tolerated I None
, I None
and I None
a I None
convenient I None
method I None
of I None
treatment I None
for I None
moderate I None
to I None
severe I None
symptoms I None
of I None
gustatory I Disease
hyperhidrosis O Disease
in I None
post I None
transthoracic I None
endoscopic I None
sympathectomy I None
or I None
sympathicotomy I None
patients I None
, I None
with I None
few I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Pharmacological I None
characteristics I None
and I None
side I None
effects I None
of I None
a I None
new I None
galenic I None
formulation I None
of I None
propofol I Chemical
without I None
soyabean I None
oil I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
pharmacokinetics I None
, I None
pharmacodynamics I None
and I None
safety I None
profile I None
of I None
a I None
new I None
galenic I None
formulation I None
of I None
propofol I Chemical
<eof> I None

<s> O None
( I None
AM149 I None
1 I None
% I None
) I None
, I None
which I None
does I None
not I None
contain I None
soyabean I None
oil I None
, I None
with I None
a I None
standard I None
formulation I None
of I None
propofol I Chemical
<eof> I None

<s> O None
( I None
Disoprivan I Chemical
1 I None
% I None
) I None
. I None
<eof> I None

<s> O None
In I None
a I None
randomised I None
, I None
double I None
- I None
blind I None
, I None
cross I None
- I None
over I None
study I None
, I None
30 I None
healthy I None
volunteers I None
received I None
a I None
single I None
intravenous I None
bolus I None
injection I None
of I None
2.5 I None
mg.kg-1 I None
propofol I Chemical
. I None
<eof> I None

<s> O None
Plasma I None
propofol I Chemical
levels I None
were I None
measured I None
for I None
48 I None
h I None
following I None
drug I None
administration I None
and I None
evaluated I None
according I None
to I None
a I None
three I None
- I None
compartment I None
model I None
. I None
<eof> I None

<s> O None
The I None
pharmacodynamic I None
parameters I None
assessed I None
included I None
induction I None
and I None
emergence I None
times I None
, I None
respiratory I None
and I None
cardiovascular I None
effects I None
, I None
and I None
pain I Disease
on I None
injection I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
monitored I None
for I None
side I None
effects I None
over I None
48 I None
h. I None
Owing I None
to I None
a I None
high I None
incidence I None
of I None
thrombophlebitis I Disease
, I None
the I None
study I None
was I None
terminated I None
prematurely I None
and I None
only I None
the I None
data I None
of I None
the I None
two I None
parallel I None
treatment I None
groups I None
( I None
15 I None
patients I None
in I None
each I None
group I None
) I None
were I None
analysed I None
. I None
<eof> I None

<s> O None
Plasma I None
concentrations I None
did I None
not I None
differ I None
significantly I None
between I None
the I None
two I None
formulations I None
. I None
<eof> I None

<s> O None
Anaesthesia I None
induction I None
and I None
emergence I None
times I None
, I None
respiratory I None
and I None
cardiovascular I None
variables I None
showed I None
no I None
significant I None
differences I None
between I None
the I None
two I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Pain I Disease
on I None
injection I None
( I None
80 I None
vs. I None
20 I None
% I None
, I None
p I None
< I None
0.01 I None
) I None
and I None
thrombophlebitis I Disease
<eof> I None

<s> O None
( I None
93.3 I None
vs. I None
6.6 I None
% I None
, I None
p I None
< I None
0.001 I None
) I None
occurred I None
more I None
frequently I None
with I None
AM149 I None
than I None
with I None
Disoprivan I Chemical
. I None
<eof> I None

<s> O None
Although I None
both I None
formulations I None
had I None
similar I None
pharmacokinetic I None
and I None
pharmacodynamic I None
profiles I None
the I None
new I None
formulation I None
is I None
not I None
suitable I None
for I None
clinical I None
use I None
due I None
to I None
the I None
high I None
incidence I None
of I None
thrombophlebitis I Disease
produced I None
. I None
<eof> I None

<s> O None
Vinorelbine I Chemical
-related I None
cardiac I None
events I None
: I None
a I None
meta I None
- I None
analysis I None
of I None
randomized I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
Several I None
cases I None
of I None
cardiac I None
adverse I None
reactions I None
related I None
to I None
vinorelbine I Chemical
<eof> I None

<s> O None
( I None
VNR I Chemical
) I None
have I None
been I None
reported I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
quantify I None
the I None
incidence I None
of I None
these I None
cardiac I None
events I None
, I None
we I None
performed I None
a I None
meta I None
- I None
analysis I None
of I None
clinical I None
trials I None
comparing I None
VNR I Chemical
with I None
other I None
chemotherapeutic I None
agents I None
in I None
the I None
treatment I None
of I None
various I None
malignancies I Disease
. I None
<eof> I None

<s> O None
Randomized I None
clinical I None
trials I None
comparing I None
VNR I Chemical
with I None
other I None
drugs I None
in I None
the I None
treatment I None
of I None
cancer I Disease
were I None
searched I None
in I None
Medline I None
, I None
Embase I None
, I None
Evidence I None
- I None
based I None
Medicine I None
Reviews I None
databases I None
and I None
the I None
Cochrane I None
library I None
from I None
1987 I None
to I None
2002 I None
. I None
<eof> I None

<s> O None
Outcomes I None
of I None
interest I None
were I None
severe I None
cardiac I None
events I None
, I None
toxic I None
deaths I None
and I None
cardiac I None
event I None
- I None
related I None
deaths I None
reported I None
in I None
each I None
publication I None
. I None
<eof> I None

<s> O None
We I None
found I None
19 I None
trials I None
, I None
involving I None
2441 I None
patients I None
treated I None
by I None
VNR I Chemical
and I None
2050 I None
control I None
patients I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
cardiac I None
events I None
with I None
VNR I Chemical
was I None
1.19 I None
% I None
[ I None
95 I None
% I None
confidence I None
interval I None
( I None
CI I None
) I None
( I None
0.75 I None
; I None
1.67 I None
) I None
] I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
difference I None
in I None
the I None
risk I None
of I None
cardiac I None
events I None
between I None
VNR I Chemical
and I None
other I None
drugs I None
<eof> I None

<s> O None
[ I None
odds I None
ratio I None
: I None
0.92 I None
, I None
95 I None
% I None
CI I None
( I None
0.54 I None
; I None
1.55 I None
) I None
] I None
. I None
<eof> I None

<s> O None
The I None
risk I None
of I None
VNR I Chemical
cardiac I None
events I None
was I None
similar I None
to I None
vindesine I Chemical
<eof> I None

<s> O None
( I None
VDS I Chemical
) I None
and I None
other I None
cardiotoxic I Disease
drugs I None
[ I None
fluorouracil I Chemical
, I None
anthracyclines I Chemical
, I None
gemcitabine I Chemical
<eof> I None

<s> O None
( I None
GEM I Chemical
) I None
<eof> I None

<s> O None
em I None
leader I None
] I None
. I None
<eof> I None

<s> O None
Even I None
if I None
it I None
did I None
not I None
reach I None
statistical I None
significance I None
because I None
of I None
a I None
few I None
number I None
of I None
cases I None
, I None
the I None
risk I None
was I None
lower I None
in I None
trials I None
excluding I None
patients I None
with I None
cardiac I None
history I None
, I None
and I None
seemed I None
to I None
be I None
higher I None
in I None
trials I None
including I None
patients I None
with I None
pre I None
- I None
existing I None
cardiac I Disease
diseases O Disease
. I None
<eof> I None

<s> O None
Vinorelbine I Chemical
-related I None
cardiac I None
events I None
concern I None
about I None
1 I None
% I None
of I None
treated I None
patients I None
in I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
risk I None
associated I None
with I None
VNR I Chemical
seems I None
to I None
be I None
similar I None
to I None
that I None
of I None
other I None
chemotherapeutic I None
agents I None
in I None
the I None
same I None
indications I None
. I None
<eof> I None

<s> O None
MRI I None
findings I None
of I None
hypoxic I None
cortical I None
laminar I None
necrosis I Disease
in I None
a I None
child I None
with I None
hemolytic I Disease
anemia O Disease
crisis I None
. I None
<eof> I None

<s> O None
We I None
present I None
magnetic I None
resonance I None
imaging I None
findings I None
of I None
a I None
5-year I None
- I None
old I None
girl I None
who I None
had I None
a I None
rapidly I None
installing I None
hemolytic I Disease
anemia O Disease
crisis I None
induced I None
by I None
trimethoprim I Chemical
- O Chemical
sulfomethoxazole O Chemical
, I None
resulting I None
in I None
cerebral I Disease
anoxia O Disease
leading I None
to I None
permanent I None
damage I None
. I None
<eof> I None

<s> O None
Magnetic I None
Resonance I None
imaging I None
revealed I None
cortical I None
laminar I None
necrosis I Disease
in I None
arterial I None
border I None
zones I None
in I None
both I None
cerebral I None
hemispheres I None
, I None
ischemic I None
changes I None
in I None
subcortical I None
white I None
matter I None
of I None
left I None
cerebral I None
hemisphere I None
, I None
and I None
in I None
the I None
left I None
putamen I None
. I None
<eof> I None

<s> O None
Although I None
cortical I None
laminar I None
<eof> I None

<s> O None
necrosis I Disease
is I None
a I None
classic I None
entity I None
in I None
adulthood I None
related I None
to I None
conditions I None
of I None
energy I None
depletions I None
, I None
there I None
are I None
few I None
reports I None
available I None
in I None
children I None
. I None
<eof> I None

<s> O None
A I None
wide I None
review I None
of I None
the I None
literature I None
is I None
also I None
presented I None
. I None
<eof> I None

<s> O None
The I None
natural I None
history I None
of I None
Vigabatrin I Chemical
associated I None
<eof> I None

<s> O None
visual I Disease
field O Disease
defects O Disease
in I None
patients I None
electing I None
to I None
continue I None
their I None
medication I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
natural I None
history I None
of I None
visual I Disease
field O Disease
defects O Disease
in I None
a I None
group I None
of I None
patients I None
known I None
to I None
have I None
<eof> I None

<s> O None
Vigabatrin I Chemical
<eof> I None

<s> O None
-associated I None
changes I None
who I None
elected I None
to I None
continue I None
the I None
medication I None
because I None
of I None
good I None
seizure I Disease
control I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
All I None
patients I None
taking I None
Vigabatrin I Chemical
alone I None
or I None
in I None
combination I None
with I None
other I None
antiepileptic I None
drugs I None
for I None
at I None
least I None
5 I None
years I None
( I None
range I None
5 I None
- I None
12 I None
years I None
) I None
were I None
entered I None
into I None
a I None
visual I None
surveillance I None
programme I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
followed I None
up I None
at I None
6-monthly I None
intervals I None
for I None
not I None
less I None
than I None
18 I None
months I None
( I None
range I None
18 I None
- I None
43 I None
months I None
) I None
. I None
<eof> I None

<s> O None
In I None
all I None
, I None
16 I None
patients I None
with I None
unequivocal I None
defects I None
continued I None
the I None
medication I None
. I None
<eof> I None

<s> O None
Following I None
already I None
published I None
methodology I None
( I None
Eye I None
2002 I None
; I None
16;567 I None
- I None
571 I None
) I None
monocular I None
mean I None
radial I None
degrees I None
( I None
MRDs I None
) I None
to I None
the I None
I/4e I None
isopter I None
on I None
Goldmann I None
perimetry I None
was I None
calculated I None
for I None
the I None
right I None
eye I None
at I None
the I None
time I None
of I None
discovery I None
of I None
a I None
visual I Disease
field O Disease
defect O Disease
and I None
again I None
after I None
not I None
less I None
than I None
18 I None
months I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Mean I None
right I None
eye I None
MRD I None
at I None
presentation I None
was I None
36.98 I None
degrees I None
( I None
range I None
22.25 I None
- I None
51.0 I None
) I None
, I None
compared I None
to I None
38.40 I None
degrees I None
( I None
range I None
22.5 I None
- I None
49.75 I None
) I None
after I None
follow I None
- I None
up I None
; I None
P=0.338 I None
unpaired I None
t I None
- I None
test I None
. I None
<eof> I None

<s> O None
Only I None
one I None
patient I None
demonstrated I None
a I None
deterioration I Disease
in O Disease
visual O Disease
field O Disease
during I None
the I None
study I None
period I None
and I None
discontinued I None
treatment I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Established I None
<eof> I None

<s> O None
visual I Disease
field O Disease
defects O Disease
presumed I None
to I None
be I None
due I None
to I None
Vigabatrin I Chemical
<eof> I None

<s> O None
therapy I None
did I None
not I None
usually I None
progress I None
in I None
spite I None
of I None
continuing I None
use I None
of I None
the I None
medication I None
. I None
<eof> I None

<s> O None
These I None
data I None
give I None
support I None
to I None
the I None
hypothesis I None
that I None
the I None
pathogenesis I None
of I None
Vigabatrin I Chemical
-associated I None
visual I Disease
field O Disease
defects O Disease
may I None
be I None
an I None
idiosyncratic I None
adverse I None
drug I None
reaction I None
rather I None
than I None
dose I None
- I None
dependent I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Induction I None
of I None
rosaceiform I None
dermatitis I Disease
during I None
treatment I None
of I None
facial I Disease
inflammatory O Disease
dermatoses O Disease
with I None
tacrolimus I Chemical
ointment I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Tacrolimus I Chemical
ointment I None
is I None
increasingly I None
used I None
for I None
anti I None
- I None
inflammatory I None
treatment I None
of I None
sensitive I None
areas I None
such I None
as I None
the I None
face I None
, I None
and I None
recent I None
observations I None
indicate I None
that I None
the I None
treatment I None
is I None
effective I None
in I None
steroid I Chemical
-aggravated I None
<eof> I None

<s> O None
rosacea I Disease
and I None
perioral I Disease
dermatitis O Disease
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
rosaceiform I None
dermatitis I Disease
as I None
a I None
complication I None
of I None
treatment I None
with I None
tacrolimus I Chemical
ointment I None
. I None
<eof> I None

<s> O None
OBSERVATIONS I None
: I None
<eof> I None

<s> O None
Six I None
adult I None
patients I None
with I None
inflammatory I Disease
facial O Disease
dermatoses O Disease
were I None
treated I None
with I None
tacrolimus I Chemical
ointment I None
because I None
of I None
the I None
ineffectiveness I None
of I None
standard I None
treatments I None
. I None
<eof> I None

<s> O None
Within I None
2 I None
to I None
3 I None
weeks I None
of I None
initially I None
effective I None
and I None
well I None
- I None
tolerated I None
treatment I None
, I None
3 I None
patients I None
with I None
a I None
history I None
of I None
rosacea I Disease
and I None
1 I None
with I None
a I None
history I None
of I None
acne I Disease
experienced I None
sudden I None
worsening I None
with I None
pustular I None
rosaceiform I None
lesions I None
. I None
<eof> I None

<s> O None
Biopsy I None
revealed I None
an I None
abundance I None
of I None
Demodex I None
mites I None
in I None
2 I None
of I None
these I None
patients I None
. I None
<eof> I None

<s> O None
In I None
1 I None
patient I None
with I None
eyelid I None
eczema I Disease
, I None
rosaceiform I None
periocular I Disease
dermatitis O Disease
gradually I None
appeared I None
after I None
3 I None
weeks I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
In I None
1 I None
patient I None
with I None
atopic I Disease
dermatitis O Disease
, I None
telangiectatic I None
and I None
papular I Disease
rosacea O Disease
insidiously I None
appeared I None
after I None
5 I None
months I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Our I None
observations I None
suggest I None
that I None
the I None
spectrum I None
of I None
rosaceiform I None
dermatitis I Disease
as I None
a I None
complication I None
of I None
treatment I None
with I None
tacrolimus I Chemical
ointment I None
is I None
heterogeneous I None
. I None
<eof> I None

<s> O None
A I None
variety I None
of I None
factors I None
, I None
such I None
as I None
vasoactive I None
properties I None
of I None
tacrolimus I Chemical
, I None
proliferation I None
of I None
Demodex I None
due I None
to I None
local I None
immunosuppression I None
, I None
and I None
the I None
occlusive I None
properties I None
of I None
the I None
ointment I None
, I None
may I None
be I None
involved I None
in I None
the I None
observed I None
phenomena I None
. I None
<eof> I None

<s> O None
Future I None
studies I None
are I None
needed I None
to I None
identify I None
individual I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Structural I None
abnormalities I None
in I None
the I None
brains I None
of I None
human I None
subjects I None
who I None
use I None
methamphetamine I Chemical
. I None
<eof> I None

<s> O None
We I None
visualize I None
, I None
for I None
the I None
first I None
time I None
, I None
the I None
profile I None
of I None
structural I Disease
deficits O Disease
in O Disease
the O Disease
human O Disease
brain O Disease
associated I None
with I None
chronic I None
methamphetamine I Chemical
<eof> I None

<s> O None
( I None
MA I Chemical
) I None
abuse I None
. I None
<eof> I None

<s> O None
Studies I None
of I None
human I None
subjects I None
who I None
have I None
used I None
MA I Chemical
chronically I None
have I None
revealed I None
deficits I None
in I None
dopaminergic I None
and I None
serotonergic I None
systems I None
and I None
cerebral I None
metabolic I Disease
abnormalities O Disease
. I None
<eof> I None

<s> O None
Using I None
magnetic I None
resonance I None
imaging I None
( I None
MRI I None
) I None
and I None
new I None
computational I None
brain I None
- I None
mapping I None
techniques I None
, I None
we I None
determined I None
the I None
pattern I None
of I None
structural I None
brain I None
alterations I None
associated I None
with I None
chronic I None
MA I Chemical
abuse I None
in I None
human I None
subjects I None
and I None
related I None
these I None
deficits I None
to I None
cognitive I Disease
impairment O Disease
. I None
<eof> I None

<s> O None
We I None
used I None
high I None
- I None
resolution I None
MRI I None
and I None
surface I None
- I None
based I None
computational I None
image I None
analyses I None
to I None
map I None
regional I None
abnormalities I Disease
in O Disease
the O Disease
cortex O Disease
, O Disease
hippocampus O Disease
, O Disease
white O Disease
matter O Disease
, O Disease
and O Disease
ventricles O Disease
in I None
22 I None
human I None
subjects I None
who I None
used I None
MA I Chemical
and I None
21 I None
age I None
- I None
matched I None
, I None
healthy I None
controls I None
. I None
<eof> I None

<s> O None
Cortical I None
maps I None
revealed I None
severe I None
gray I None
- I None
matter I None
deficits I None
in I None
the I None
cingulate I None
, I None
limbic I None
, I None
and I None
paralimbic I None
cortices I None
of I None
MA I Chemical
abusers I None
( I None
averaging I None
11.3 I None
% I None
below I None
control I None
; I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
On I None
average I None
, I None
MA I Chemical
abusers I None
had I None
7.8 I None
% I None
smaller I None
hippocampal I None
volumes I None
than I None
control I None
subjects I None
( I None
p I None
< I None
0.01 I None
; I None
left I None
, I None
p I None
= I None
0.01 I None
; I None
right I None
, I None
p I None
< I None
0.05 I None
) I None
and I None
significant I None
white I None
- I None
matter I None
hypertrophy I Disease
( I None
7.0 I None
% I None
; I None
p I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Hippocampal I None
deficits I None
were I None
mapped I None
and I None
correlated I None
with I None
memory I None
performance I None
on I None
a I None
word I None
- I None
recall I None
test I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
MRI I None
- I None
based I None
maps I None
suggest I None
that I None
chronic I None
methamphetamine I Chemical
abuse I None
causes I None
a I None
selective I None
pattern I None
of I None
cerebral I None
deterioration I None
that I None
contributes I None
to I None
impaired I Disease
memory O Disease
performance O Disease
. I None
<eof> I None

<s> O None
MA I Chemical
may I None
selectively I None
damage I None
the I None
medial I None
temporal I None
lobe I None
and I None
, I None
consistent I None
with I None
metabolic I None
studies I None
, I None
the I None
cingulate I None
- I None
limbic I None
cortex I None
, I None
inducing I None
neuroadaptation I None
, I None
neuropil I None
reduction I None
, I None
or I None
cell I None
death I None
. I None
<eof> I None

<s> O None
Prominent I None
white I None
- I None
matter I None
hypertrophy I Disease
may I None
result I None
from I None
altered I None
myelination I None
and I None
adaptive I None
glial I None
changes I None
, I None
including I None
gliosis I Disease
secondary I None
to I None
neuronal I Disease
damage O Disease
. I None
<eof> I None

<s> O None
These I None
brain I None
substrates I None
may I None
help I None
account I None
for I None
the I None
symptoms I None
of I None
MA I Chemical
abuse I None
, I None
providing I None
therapeutic I None
targets I None
for I None
drug I None
- I None
induced I None
brain I Disease
injury O Disease
. I None
<eof> I None

<s> O None
Disruption I None
of I None
hepatic I None
lipid I None
homeostasis I None
in I None
mice I None
after I None
amiodarone I Chemical
treatment I None
is I None
associated I None
with I None
peroxisome I None
proliferator I None
- I None
activated I None
receptor I None
- I None
alpha I None
target I None
gene I None
activation I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
, I None
an I None
efficacious I None
and I None
widely I None
used I None
antiarrhythmic I None
agent I None
, I None
has I None
been I None
reported I None
to I None
cause I None
hepatotoxicity I Disease
in I None
some I None
patients I None
. I None
<eof> I None

<s> O None
To I None
gain I None
insight I None
into I None
the I None
mechanism I None
of I None
this I None
unwanted I None
effect I None
, I None
mice I None
were I None
administered I None
various I None
doses I None
of I None
amiodarone I Chemical
and I None
examined I None
for I None
changes I None
in I None
hepatic I None
histology I None
and I None
gene I None
regulation I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
induced I None
<eof> I None

<s> O None
hepatomegaly I Disease
, I None
hepatocyte I None
microvesicular I None
lipid I None
accumulation I None
, I None
and I None
a I None
significant I None
decrease I None
in I None
serum I None
triglycerides I Chemical
and I None
glucose I Chemical
. I None
<eof> I None

<s> O None
Northern I None
blot I None
analysis I None
of I None
hepatic I None
RNA I None
revealed I None
a I None
dose I None
- I None
dependent I None
increase I None
in I None
the I None
expression I None
of I None
a I None
number I None
of I None
genes I None
critical I None
for I None
fatty I Chemical
acid O Chemical
oxidation I None
, I None
lipoprotein I None
assembly I None
, I None
and I None
lipid I None
transport I None
. I None
<eof> I None

<s> O None
Many I None
of I None
these I None
genes I None
are I None
regulated I None
by I None
the I None
peroxisome I None
proliferator I None
- I None
activated I None
receptor I None
- I None
alpha I None
( I None
PPARalpha I None
) I None
, I None
a I None
ligand I None
- I None
activated I None
nuclear I None
hormone I None
receptor I None
transcription I None
factor I None
. I None
<eof> I None

<s> O None
The I None
absence I None
of I None
induction I None
of I None
these I None
genes I None
as I None
well I None
as I None
hepatomegaly I Disease
in I None
PPARalpha I None
knockout I None
<eof> I None

<s> O None
[ I None
PPARalpha-/- I None
] I None
mice I None
indicated I None
that I None
the I None
effects I None
of I None
amiodarone I Chemical
were I None
dependent I None
upon I None
the I None
presence I None
of I None
a I None
functional I None
PPARalpha I None
gene I None
. I None
<eof> I None

<s> O None
Compared I None
to I None
wild I None
- I None
type I None
mice I None
, I None
treatment I None
of I None
PPARalpha-/- I None
mice I None
with I None
amiodarone I Chemical
resulted I None
in I None
an I None
increased I None
rate I None
and I None
extent I None
of I None
total I None
body I None
weight I Disease
loss O Disease
. I None
<eof> I None

<s> O None
The I None
inability I None
of I None
amiodarone I Chemical
to I None
directly I None
activate I None
either I None
human I None
or I None
mouse I None
PPARalpha I None
transiently I None
expressed I None
in I None
human I None
HepG2 I None
<eof> I None

<s> O None
hepatoma I Disease
cells I None
indicates I None
that I None
the I None
effects I None
of I None
amiodarone I Chemical
on I None
the I None
function I None
of I None
this I None
receptor I None
were I None
indirect I None
. I None
<eof> I None

<s> O None
Based I None
upon I None
these I None
results I None
, I None
we I None
conclude I None
that I None
amiodarone I Chemical
disrupts I None
hepatic I None
lipid I None
homeostasis I None
and I None
that I None
the I None
increased I None
expression I None
of I None
PPARalpha I None
target I None
genes I None
is I None
secondary I None
to I None
this I None
toxic I None
effect I None
. I None
<eof> I None

<s> O None
These I None
results I None
provide I None
important I None
new I None
mechanistic I None
information I None
regarding I None
the I None
hepatotoxic I Disease
effects I None
of I None
amiodarone I Chemical
and I None
indicate I None
that I None
PPARalpha I None
protects I None
against I None
amiodarone I Chemical
-induced I None
hepatotoxicity I Disease
. I None
<eof> I None

<s> O None
Safety I None
and I None
compliance I None
with I None
once I None
- I None
daily I None
niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
as I None
initial I None
therapy I None
in I None
the I None
Impact I None
of I None
Medical I None
Subspecialty I None
on I None
Patient I None
Compliance I None
to I None
Treatment I None
( I None
IMPACT I None
) I None
study I None
. I None
<eof> I None

<s> O None
Niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
is I None
a I None
new I None
combination I None
product I None
approved I None
for I None
treatment I None
of I None
primary I None
hypercholesterolemia I Disease
and I None
mixed I None
dyslipidemia I Disease
. I None
<eof> I None

<s> O None
This I None
open I None
- I None
labeled I None
, I None
multicenter I None
study I None
evaluated I None
the I None
safety I None
of I None
bedtime I None
<eof> I None

<s> O None
niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
when I None
dosed I None
as I None
initial I None
therapy I None
and I None
patient I None
compliance I None
to I None
treatment I None
in I None
various I None
clinical I None
practice I None
settings I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
4,499 I None
patients I None
with I None
dyslipidemia I Disease
requiring I None
drug I None
intervention I None
was I None
enrolled I None
at I None
1,081 I None
sites I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
treated I None
with I None
1 I None
tablet I None
( I None
500 I None
mg I None
of I None
niacin I Chemical
extended I None
- I None
release/20 I None
mg I None
of I None
lovastatin I Chemical
) I None
once I None
nightly I None
for I None
4 I None
weeks I None
and I None
then I None
2 I None
tablets I None
for I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
Patients I None
also I None
received I None
dietary I None
counseling I None
, I None
educational I None
materials I None
, I None
and I None
reminders I None
to I None
call I None
a I None
toll I None
- I None
free I None
number I None
that I None
provided I None
further I None
education I None
about I None
dyslipidemia I Disease
and I None
niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
. I None
<eof> I None

<s> O None
Primary I None
end I None
points I None
were I None
study I None
compliance I None
, I None
increases I None
in I None
liver I None
transaminases I None
to I None
> I None
3 I None
times I None
the I None
upper I None
limit I None
of I None
normal I None
, I None
and I None
clinical I None
myopathy I Disease
. I None
<eof> I None

<s> O None
Final I None
study I None
status I None
was I None
available I None
for I None
4,217 I None
patients I None
( I None
94 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Compliance I None
to I None
niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
was I None
77 I None
% I None
, I None
with I None
3,245 I None
patients I None
completing I None
the I None
study I None
. I None
<eof> I None

<s> O None
Patients I None
in I None
the I None
southeast I None
and I None
those I None
enrolled I None
by I None
endocrinologists I None
had I None
the I None
lowest I None
compliance I None
and I None
highest I None
adverse I None
event I None
rates I None
. I None
<eof> I None

<s> O None
Flushing I Disease
was I None
the I None
most I None
common I None
adverse I None
event I None
, I None
reported I None
by I None
18 I None
% I None
of I None
patients I None
and I None
leading I None
to I None
discontinuation I None
by I None
6 I None
% I None
. I None
<eof> I None

<s> O None
Incidence I None
of I None
increased I None
aspartate I Chemical
aminotransferase I None
and/or I None
alanine I Chemical
aminotransferase I None
> I None
3 I None
times I None
the I None
upper I None
limit I None
of I None
normal I None
was I None
< I None
0.3 I None
% I None
. I None
<eof> I None

<s> O None
An I None
increase I None
of I None
<eof> I None

<s> O None
creatine I Chemical
phosphokinase I None
to I None
> I None
5 I None
times I None
the I None
upper I None
limit I None
of I None
normal I None
occurred I None
in I None
0.24 I None
% I None
of I None
patients I None
, I None
and I None
no I None
cases I None
of I None
drug I None
- I None
induced I None
myopathy I Disease
were I None
observed I None
. I None
<eof> I None

<s> O None
Niacin I Chemical
extended O Chemical
- O Chemical
release O Chemical
/ O Chemical
lovastatin O Chemical
<eof> I None

<s> O None
1,000/40 I None
mg I None
, I None
dosed I None
as I None
initial I None
therapy I None
, I None
was I None
associated I None
with I None
good I None
compliance I None
and I None
safety I None
and I None
had I None
very I None
low I None
incidences I None
of I None
increased I None
liver I None
and I None
muscle I None
enzymes I None
. I None
<eof> I None

<s> O None
Protective I None
effect I None
of I None
Terminalia I Chemical
chebula O Chemical
against I None
experimental I None
myocardial I Disease
injury O Disease
induced I None
by I None
isoproterenol I Chemical
. I None
<eof> I None

<s> O None
Cardioprotective I None
effect I None
of I None
ethanolic I Chemical
extract O Chemical
of O Chemical
Terminalia O Chemical
chebula O Chemical
fruits O Chemical
<eof> I None

<s> O None
( I None
500 I None
mg I None
/ I None
kg I None
body I None
wt I None
) I None
was I None
examined I None
in I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
/ I None
kg I None
body I None
wt I None
) I None
<eof> I None

<s> O None
induced I None
myocardial I Disease
damage O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
In I None
isoproterenol I Chemical
administered I None
rats I None
, I None
the I None
level I None
of I None
lipid I None
peroxides I Chemical
increased I None
significantly I None
in I None
the I None
serum I None
and I None
heart I None
. I None
<eof> I None

<s> O None
A I None
significant I None
decrease I None
was I None
observed I None
in I None
the I None
activity I None
of I None
the I None
myocardial I None
marker I None
enzymes I None
with I None
a I None
concomitant I None
increase I None
in I None
their I None
activity I None
in I None
serum I None
. I None
<eof> I None

<s> O None
Histopathological I None
examination I None
was I None
carried I None
out I None
to I None
confirm I None
the I None
myocardial I None
necrosis I Disease
. I None
<eof> I None

<s> O None
T. I Chemical
chebula O Chemical
extract O Chemical
pretreatment I None
was I None
found I None
to I None
ameliorate I None
the I None
effect I None
of I None
isoproterenol I Chemical
on I None
lipid I None
peroxide I Chemical
formation I None
and I None
retained I None
the I None
activities I None
of I None
the I None
diagnostic I None
marker I None
enzymes I None
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
postoperative I None
anxiety I Disease
due I None
to I None
low I None
dose I None
droperidol I Chemical
used I None
with I None
patient I None
- I None
controlled I None
analgesia I None
. I None
<eof> I None

<s> O None
A I None
multiparous I None
woman I None
in I None
good I None
psychological I None
health I None
underwent I None
urgent I None
caesarean I None
section I None
in I None
labour I None
. I None
<eof> I None

<s> O None
Postoperatively I None
, I None
she I None
was I None
given I None
a I None
patient I None
- I None
controlled I None
analgesia I None
device I None
delivering I None
boluses I None
of I None
diamorphine I Chemical
0.5 I None
mg I None
and I None
droperidol I Chemical
0.025 I None
mg I None
. I None
<eof> I None

<s> O None
Whilst I None
using I None
the I None
device I None
she I None
gradually I None
became I None
anxious I None
, I None
the I None
feeling I None
worsening I None
after I None
each I None
bolus I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
of I None
droperidol I Chemical
-induced I None
<eof> I None

<s> O None
psychological I Disease
disturbance O Disease
was I None
not I None
made I None
straight I None
away I None
although I None
on I None
subsequent I None
close I None
questioning I None
the I None
patient I None
gave I None
a I None
very I None
clear I None
history I None
. I None
<eof> I None

<s> O None
After I None
she I None
had I None
received I None
a I None
total I None
of I None
only I None
0.9 I None
mg I None
droperidol I Chemical
, I None
a I None
syringe I None
containing I None
diamorphine I Chemical
only I None
was I None
substituted I None
and I None
her I None
unease I None
resolved I None
completely I None
. I None
<eof> I None

<s> O None
We I None
feel I None
that I None
, I None
although I None
the I None
dramatic I None
extrapyramidal I None
side I None
effects I None
of I None
dopaminergic I None
antiemetics I None
are I None
well I None
known I None
, I None
more I None
subtle I None
manifestations I None
may I None
easily I None
be I None
overlooked I None
. I None
<eof> I None

<s> O None
Accurate I None
patient I None
history I None
contributes I None
to I None
differentiating I None
diabetes I Disease
insipidus O Disease
: I None
a I None
case I None
study I None
. I None
<eof> I None

<s> O None
This I None
case I None
study I None
highlights I None
the I None
important I None
contribution I None
of I None
nursing I None
in I None
obtaining I None
an I None
accurate I None
health I None
history I None
. I None
<eof> I None

<s> O None
The I None
case I None
discussed I None
herein I None
initially I None
appeared I None
to I None
be I None
neurogenic I Disease
diabetes O Disease
insipidus O Disease
<eof> I None

<s> O None
( I None
DI I Disease
) I None
secondary I None
to I None
a I None
traumatic I Disease
brain O Disease
injury O Disease
. I None
<eof> I None

<s> O None
The I None
nursing I None
staff I None
, I None
by I None
reviewing I None
the I None
patient I None
's I None
health I None
history I None
with I None
his I None
family I None
, I None
discovered I None
a I None
history I None
of I None
polydipsia I Disease
and I None
long I None
- I None
standing I None
lithium I Chemical
use I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
is I None
implicated I None
in I None
drug I None
- I None
induced I None
nephrogenic I Disease
DI O Disease
, I None
and I None
because I None
the I None
patient I None
had I None
not I None
received I None
lithium I Chemical
since I None
being I None
admitted I None
to I None
the I None
hospital I None
, I None
his I None
treatment I None
changed I None
to I None
focus I None
on I None
nephrogenic I Disease
DI O Disease
. I None
<eof> I None

<s> O None
By I None
combining I None
information I None
from I None
the I None
patient I None
history I None
, I None
the I None
physical I None
examination I None
, I None
and I None
radiologic I None
and I None
laboratory I None
studies I None
, I None
the I None
critical I None
care I None
team I None
demonstrated I None
that I None
the I None
patient I None
had I None
been I None
self I None
- I None
treating I None
his I None
lithium I Chemical
-induced I None
nephrogenic I Disease
DI O Disease
and I None
developed I None
neurogenic I Disease
DI O Disease
secondary I None
to I None
brain I Disease
trauma O Disease
. I None
<eof> I None

<s> O None
Thus I None
successful I None
treatment I None
required I None
that I None
nephrogenic I None
and I None
neurogenic I Disease
DI O Disease
be I None
treated I None
concomitantly I None
. I None
<eof> I None

<s> O None
Factors I None
contributing I None
to I None
ribavirin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
anemia I Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
AND I None
AIM I None
: I None
<eof> I None

<s> O None
Interferon I Chemical
and I None
ribavirin I Chemical
combination I None
therapy I None
for I None
chronic I Disease
hepatitis O Disease
C O Disease
produces I None
hemolytic I Disease
anemia O Disease
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
conducted I None
to I None
identify I None
the I None
factors I None
contributing I None
to I None
ribavirin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
anemia I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Eighty I None
- I None
eight I None
patients I None
with I None
chronic I Disease
hepatitis O Disease
C O Disease
who I None
received I None
interferon I Chemical
- O Chemical
alpha-2b O Chemical
at I None
a I None
dose I None
of I None
6 I None
MU I None
administered I None
intramuscularly I None
for I None
24 I None
weeks I None
in I None
combination I None
with I None
ribavirin I Chemical
administered I None
orally I None
at I None
a I None
dose I None
of I None
600 I None
mg I None
or I None
800 I None
mg I None
participated I None
in I None
the I None
study I None
. I None
<eof> I None

<s> O None
A I None
hemoglobin I None
concentration I None
of I None
< I None
10 I None
g I None
/ I None
dL I None
was I None
defined I None
as I None
ribavirin I Chemical
-induced I None
anemia I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Ribavirin I Chemical
-induced I None
<eof> I None

<s> O None
anemia I Disease
occurred I None
in I None
18 I None
( I None
20.5 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
during I None
treatment I None
. I None
<eof> I None

<s> O None
A I None
2 I None
g I None
/ I None
dL I None
decrease I None
in I None
hemoglobin I None
concentrations I None
in I None
patients I None
with I None
anemia I Disease
was I None
observed I None
at I None
week I None
2 I None
after I None
the I None
start I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
hemoglobin I None
concentration I None
in I None
patients I None
with I None
> I None
or I None
= I None
2 I None
g I None
/ I None
dL I None
decrease I None
at I None
week I None
2 I None
was I None
observed I None
to I None
be I None
significantly I None
lower I None
even I None
after I None
week I None
2 I None
than I None
in I None
patients I None
with I None
< I None
2 I None
g I None
/ I None
dL I None
decrease I None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
A I None
significant I None
relationship I None
was I None
observed I None
between I None
the I None
rate I None
of I None
reduction I None
of I None
hemoglobin I None
concentrations I None
at I None
week I None
2 I None
and I None
the I None
severity I None
of I None
anemia I Disease
<eof> I None

<s> O None
( I None
P I None
< I None
0.01 I None
) I None
. I None
<eof> I None

<s> O None
Such I None
factors I None
as I None
sex I None
( I None
female I None
) I None
, I None
age I None
( I None
> I None
or I None
= I None
60 I None
years I None
old I None
) I None
, I None
and I None
the I None
ribavirin I Chemical
dose I None
by I None
body I None
weight I None
( I None
12 I None
mg I None
/ I None
kg I None
or I None
more I None
) I None
were I None
significant I None
by I None
univariate I None
analysis I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Careful I None
administration I None
is I None
necessary I None
in I None
patients I None
<eof> I None

<s> O None
> I None
<eof> I None

<s> O None
or I None
= I None
60 I None
years I None
old I None
, I None
in I None
female I None
patients I None
, I None
and I None
in I None
patients I None
receiving I None
a I None
ribavirin I Chemical
dose I None
of I None
12 I None
mg I None
/ I None
kg I None
or I None
more I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
experience I None
a I None
fall I None
in I None
hemoglobin I None
concentrations I None
of I None
2 I None
g I None
/ I None
dL I None
or I None
more I None
at I None
week I None
2 I None
after I None
the I None
start I None
of I None
treatment I None
should I None
be I None
monitored I None
with I None
particular I None
care I None
. I None
<eof> I None

<s> O None
Oxidative I None
damage I None
precedes I None
nitrative I None
damage I None
in I None
adriamycin I Chemical
-induced I None
cardiac I None
mitochondrial I Disease
injury O Disease
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
determine I None
if I None
elevated I None
reactive I None
oxygen I Chemical
<eof> I None

<s> O None
( I None
ROS)/ I None
nitrogen I Chemical
species I None
( I None
RNS I None
) I None
reported I None
to I None
be I None
present I None
in I None
adriamycin I Chemical
<eof> I None

<s> O None
( I None
ADR I Chemical
) I None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
actually I None
resulted I None
in I None
cardiomyocyte I None
oxidative I None
/ I None
nitrative I None
damage I None
, I None
and I None
to I None
quantitatively I None
determine I None
the I None
time I None
course I None
and I None
subcellular I None
localization I None
of I None
these I None
postulated I None
damage I None
products I None
using I None
an I None
in I None
vivo I None
approach I None
. I None
<eof> I None

<s> O None
B6C3 I None
mice I None
were I None
treated I None
with I None
a I None
single I None
dose I None
of I None
20 I None
mg I None
/ I None
kg I None
ADR I Chemical
. I None
<eof> I None

<s> O None
Ultrastructural I None
damage I None
and I None
levels I None
of I None
4-hydroxy-2-nonenal I Chemical
<eof> I None

<s> O None
( I None
4HNE I Chemical
) I None
<eof> I None

<s> O None
-protein I None
adducts I None
and I None
3-nitrotyrosine I Chemical
( I None
3NT I Chemical
) I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
Quantitative I None
ultrastructural I None
damage I None
using I None
computerized I None
image I None
techniques I None
showed I None
cardiomyocyte I None
injury I None
as I None
early I None
as I None
3 I None
hours I None
, I None
with I None
mitochondria I None
being I None
the I None
most I None
extensively I None
and I None
progressively I None
injured I None
subcellular I None
organelle I None
. I None
<eof> I None

<s> O None
Analysis I None
of I None
4HNE I Chemical
protein I None
adducts I None
by I None
immunogold I None
electron I None
microscopy I None
showed I None
appearance I None
of I None
4HNE I Chemical
protein I None
adducts I None
in I None
mitochondria I None
as I None
early I None
as I None
3 I None
hours I None
, I None
with I None
a I None
peak I None
at I None
6 I None
hours I None
and I None
subsequent I None
decline I None
at I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
3NT I Chemical
levels I None
were I None
significantly I None
increased I None
in I None
all I None
subcellular I None
compartments I None
at I None
6 I None
hours I None
and I None
subsequently I None
declined I None
at I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
Our I None
data I None
showed I None
ADR I Chemical
induced I None
<eof> I None

<s> O None
4HNE I Chemical
<eof> I None

<s> O None
-protein I None
<eof> I None

<s> O None
adducts I None
in I None
mitochondria I None
at I None
the I None
same I None
time I None
point I None
as I None
when I None
mitochondrial I Disease
injury O Disease
initially I None
appeared I None
. I None
<eof> I None

<s> O None
These I None
results I None
document I None
for I None
the I None
first I None
time I None
in I None
vivo I None
that I None
mitochondrial I Disease
oxidative O Disease
damage O Disease
precedes I None
nitrative I None
damage I None
. I None
<eof> I None

<s> O None
The I None
progressive I None
nature I None
of I None
mitochondrial I Disease
injury O Disease
suggests I None
that I None
mitochondria I None
, I None
not I None
other I None
subcellular I None
organelles I None
, I None
are I None
the I None
major I None
site I None
of I None
intracellular I None
injury I None
. I None
<eof> I None

<s> O None
Sotalol I Chemical
-induced I None
coronary I Disease
spasm O Disease
in I None
a I None
patient I None
with I None
dilated I Disease
cardiomyopathy O Disease
associated I None
with I None
sustained I None
ventricular I Disease
tachycardia O Disease
. I None
<eof> I None

<s> O None
A I None
54-year I None
- I None
old I None
man I None
with I None
severe I None
left I None
ventricular I Disease
dysfunction O Disease
due I None
to I None
dilated I Disease
cardiomyopathy O Disease
was I None
referred I None
to I None
our I None
hospital I None
for I None
symptomatic I None
incessant I None
sustained I None
ventricular I Disease
tachycardia O Disease
<eof> I None

<s> O None
( I None
VT I Disease
) I None
. I None
<eof> I None

<s> O None
After I None
the I None
administration I None
of I None
nifekalant I Chemical
hydrochloride O Chemical
, I None
sustained I None
VT I Disease
was I None
terminated I None
. I None
<eof> I None

<s> O None
An I None
alternate I None
class I None
III I None
agent I None
, I None
sotalol I Chemical
, I None
was I None
also I None
effective I None
for I None
the I None
prevention I None
of I None
VT I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
one I None
month I None
after I None
switching I None
over I None
nifekalant I Chemical
to I None
sotalol I Chemical
, I None
a I None
short I None
duration I None
of I None
ST I None
elevation I None
was I None
documented I None
in I None
ECG I None
monitoring I None
at I None
almost I None
the I None
same I None
time I None
for I None
three I None
consecutive I None
days I None
. I None
<eof> I None

<s> O None
ST I None
elevation I None
with I None
chest I None
discomfort I None
disappeared I None
since I None
he I None
began I None
taking I None
long I None
- I None
acting I None
diltiazem I Chemical
. I None
<eof> I None

<s> O None
Coronary I Disease
vasospasm O Disease
may I None
be I None
induced I None
by I None
the I None
non I None
- I None
selective I None
beta I None
- I None
blocking I None
properties I None
of I None
sotalol I Chemical
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
antidepressant I None
trazodone I Chemical
, I None
a I None
5-HT I Chemical
2A/2C I None
receptor I None
antagonist I None
, I None
on I None
dopamine I Chemical
<eof> I None

<s> O None
-dependent I None
behaviors I None
in I None
rats I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
5-Hydroxytryptamine I Chemical
, I None
via I None
stimulation I None
of I None
5-HT I Chemical
<eof> I None

<s> O None
2C I None
receptors I None
, I None
exerts I None
a I None
tonic I None
inhibitory I None
influence I None
on I None
dopaminergic I None
neurotransmission I None
, I None
whereas I None
activation I None
of I None
5-HT I Chemical
2A I None
receptors I None
enhances I None
stimulated I None
DAergic I None
neurotransmission I None
. I None
<eof> I None

<s> O None
The I None
antidepressant I None
trazodone I Chemical
is I None
a I None
5-HT I Chemical
2A/2C I None
receptor I None
antagonist I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
effect I None
of I None
trazodone I Chemical
treatment I None
on I None
behaviors I None
dependent I None
on I None
the I None
functional I None
status I None
of I None
the I None
nigrostriatal I None
DAergic I None
system I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
effect I None
of I None
pretreatment I None
with I None
trazodone I Chemical
on I None
dexamphetamine I Chemical
- I None
and I None
apomorphine I Chemical
-induced I None
oral I Disease
stereotypies O Disease
, I None
on I None
catalepsy I Disease
induced I None
by I None
haloperidol I Chemical
and I None
apomorphine I Chemical
( I None
0.05 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
, I None
on I None
ergometrine I Chemical
<eof> I None

<s> O None
-induced I None
wet I None
dog I None
shake I None
( I None
WDS I None
) I None
behavior I None
and I None
<eof> I None

<s> O None
fluoxetine I Chemical
-induced I None
penile I None
erections I None
was I None
studied I None
in I None
rats I None
. I None
<eof> I None

<s> O None
We I None
also I None
investigated I None
whether I None
trazodone I Chemical
induces I None
catalepsy I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Trazodone I Chemical
at I None
2.5 I None
- I None
20 I None
mg I None
/ I None
kg I None
i.p I None
. I None
<eof> I None

<s> O None
did I None
not I None
induce I None
catalepsy I Disease
, I None
and I None
did I None
not I None
antagonize I None
apomorphine I Chemical
( I None
1.5 I None
and I None
3 I None
mg I None
/ I None
kg I None
) I None
stereotypy I None
and I None
apomorphine I Chemical
( I None
0.05 I None
mg I None
/ I None
kg)-induced I None
catalepsy I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
pretreatment I None
with I None
5 I None
, I None
10 I None
and I None
20 I None
mg I None
/ I None
kg I None
i.p I None
. I None
<eof> I None

<s> O None
trazodone I Chemical
enhanced I None
dexamphetamine I Chemical
stereotypy I None
, I None
and I None
antagonized I None
haloperidol I Chemical
catalepsy I Disease
, I None
ergometrine I Chemical
-induced I None
WDS I None
behavior I None
and I None
<eof> I None

<s> O None
fluoxetine I Chemical
-induced I None
penile I None
erections I None
. I None
<eof> I None

<s> O None
Trazodone I Chemical
at I None
30 I None
, I None
40 I None
and I None
50 I None
mg I None
/ I None
kg I None
i.p I None
. I None
induced I None
<eof> I None

<s> O None
catalepsy I Disease
and I None
antagonized I None
apomorphine I Chemical
and I None
dexamphetamine I Chemical
stereotypies I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Our I None
results I None
indicate I None
that I None
trazodone I Chemical
at I None
2.5 I None
- I None
20 I None
mg I None
/ I None
kg I None
does I None
not I None
block I None
pre- I None
and I None
postsynaptic I None
striatal I None
D2 I None
DA I None
receptors I None
, I None
while I None
at I None
30 I None
, I None
40 I None
and I None
50 I None
mg I None
/ I None
kg I None
<eof> I None

<s> O None
it I None
blocks I None
postsynaptic I None
striatal I None
D2 I None
DA I None
receptors I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
at I None
5 I None
, I None
10 I None
and I None
20 I None
mg I None
/ I None
kg I None
, I None
trazodone I Chemical
blocks I None
5-HT I Chemical
2A I None
and I None
5-HT I Chemical
2C I None
receptors I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
trazodone I Chemical
( I None
5 I None
, I None
10 I None
and I None
20 I None
mg I None
/ I None
kg I None
) I None
, I None
by I None
blocking I None
the I None
5-HT I Chemical
<eof> I None

<s> O None
2C I None
receptors I None
, I None
releases I None
the I None
nigrostriatal I None
DAergic I None
neurons I None
from I None
tonic I None
inhibition I None
caused I None
by I None
5-HT I Chemical
, I None
and I None
thereby I None
potentiates I None
dexamphetamine I Chemical
stereotypy I None
and I None
antagonizes I None
haloperidol I Chemical
catalepsy I Disease
. I None
<eof> I None

<s> O None
Swallowing I Disease
abnormalities O Disease
and I None
dyskinesia I Disease
in I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Gastrointestinal I Disease
abnormalities O Disease
in I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
have I None
been I None
known I None
for I None
almost I None
two I None
centuries I None
, I None
but I None
many I None
aspects I None
concerning I None
their I None
pathophysiology I None
have I None
not I None
been I None
completely I None
clarified I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
characterize I None
the I None
oropharyngeal I None
dynamics I None
in I None
PD I Disease
patients I None
with I None
and I None
without I None
<eof> I None

<s> O None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
dyskinesia I Disease
. I None
<eof> I None

<s> O None
Fifteen I None
dyskinetic I Disease
, I None
12 I None
nondyskinetic I None
patients I None
, I None
and I None
a I None
control I None
group I None
were I None
included I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
asked I None
about I None
dysphagia I Disease
and I None
evaluated I None
with I None
the I None
Unified I None
Parkinson I Disease
's O Disease
Disease O Disease
Rating I None
Scale I None
Parts I None
II I None
and I None
III I None
and I None
the I None
Hoehn I None
and I None
Yahr I None
scale I None
. I None
<eof> I None

<s> O None
Deglutition I None
was I None
assessed I None
using I None
modified I None
barium I Chemical
swallow I None
with I None
videofluoroscopy I None
. I None
<eof> I None

<s> O None
Nondyskinetic I None
patients I None
, I None
but I None
not I None
the I None
dyskinetic I Disease
ones I None
, I None
showed I None
less I None
oropharyngeal I None
swallowing I None
efficiency I None
( I None
OPSE I None
) I None
for I None
liquid I None
food I None
than I None
controls I None
( I None
Dunnett I None
, I None
P I None
= I None
0.02 I None
) I None
. I None
<eof> I None

<s> O None
Dyskinetic I Disease
patients I None
tended I None
to I None
have I None
a I None
greater I None
OPSE I None
than I None
nondyskinetic I None
( I None
Dunnett I None
, I None
P I None
= I None
0.06 I None
) I None
. I None
<eof> I None

<s> O None
Patients I None
who I None
were I None
using I None
a I None
higher I None
dose I None
of I None
levodopa I Chemical
had I None
a I None
greater I None
OPSE I None
and I None
a I None
trend I None
toward I None
a I None
smaller I None
oral I None
transit I None
time I None
( I None
Pearson I None
's I None
correlation I None
, I None
P I None
= I None
0.01 I None
and I None
0.08 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Neither I None
the I None
report I None
of I None
dysphagia I Disease
nor I None
any I None
of I None
the I None
PD I Disease
severity I None
parameters I None
correlated I None
to I None
the I None
videofluoroscopic I None
variables I None
. I None
<eof> I None

<s> O None
In I None
the I None
current I None
study I None
, I None
dyskinetic I Disease
patients I None
performed I None
better I None
in I None
swallowing I None
function I None
, I None
which I None
could I None
be I None
explained I None
on I None
the I None
basis I None
of I None
a I None
greater I None
levodopa I Chemical
dose I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
a I None
role I None
for I None
levodopa I Chemical
in I None
the I None
oral I None
phase I None
of I None
deglutition I None
and I None
confirm I None
that I None
dysphagia I Disease
is I None
not I None
a I None
good I None
predictor I None
of I None
deglutition I None
alterations I None
in I None
PD I Disease
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
nuclear I None
factor I None
- I None
kappaB I None
activation I None
attenuates I None
tubulointerstitial I Disease
nephritis O Disease
induced I None
by I None
gentamicin I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Animals I None
treated I None
with I None
gentamicin I Chemical
can I None
show I None
residual I None
areas I None
of I None
interstitial I None
fibrosis I Disease
in I None
the I None
renal I None
cortex I None
. I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
the I None
expression I None
of I None
nuclear I None
factor I None
- I None
kappaB I None
( I None
NF I None
- I None
kappaB I None
) I None
, I None
mitogen I None
- I None
activated I None
protein I None
( I None
MAP I None
) I None
kinases I None
and I None
macrophages I None
in I None
the I None
renal I None
cortex I None
and I None
structural I None
and I None
functional I None
renal I None
changes I None
of I None
rats I None
treated I None
with I None
gentamicin I Chemical
or I None
gentamicin I Chemical
+ I None
pyrrolidine I Chemical
dithiocarbamate O Chemical
<eof> I None

<s> O None
( I None
PDTC I Chemical
) I None
, I None
an I None
NF I None
- I None
kappaB I None
inhibitor I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
38 I None
female I None
Wistar I None
rats I None
were I None
injected I None
with I None
gentamicin I Chemical
, I None
40 I None
mg I None
/ I None
kg I None
, I None
twice I None
a I None
day I None
for I None
9 I None
days I None
, I None
38 I None
with I None
gentamicin I Chemical
+ I None
PDTC I Chemical
, I None
and I None
28 I None
with I None
0.15 I None
M I None
NaCl I Chemical
solution I None
. I None
<eof> I None

<s> O None
The I None
animals I None
were I None
killed I None
5 I None
and I None
30 I None
days I None
after I None
these I None
injections I None
and I None
the I None
kidneys I None
were I None
removed I None
for I None
histological I None
and I None
immunohistochemical I None
studies I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
the I None
immunohistochemical I None
studies I None
were I None
scored I None
according I None
to I None
the I None
extent I None
of I None
staining I None
. I None
<eof> I None

<s> O None
The I None
fractional I None
interstitial I None
area I None
was I None
determined I None
by I None
morphometry I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Gentamicin I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
presented I None
a I None
transitory I None
increase I None
in I None
plasma I None
creatinine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Increased I None
ED-1 I None
, I None
MAP I None
kinases I None
and I None
NF I None
- I None
kappaB I None
staining I None
were I None
also I None
observed I None
in I None
the I None
renal I None
cortex I None
from I None
all I None
gentamicin I Chemical
-treated I None
rats I None
compared I None
to I None
control I None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
The I None
animals I None
killed I None
on I None
day I None
30 I None
also I None
presented I None
fibrosis I Disease
in I None
the I None
renal I None
cortex I None
despite I None
the I None
recovery I None
of I None
renal I None
function I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
PDTC I Chemical
reduced I None
the I None
functional I None
and I None
structural I None
changes I None
induced I None
by I None
gentamicin I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
data I None
show I None
that I None
inhibition I None
of I None
NF I None
- I None
kappaB I None
activation I None
attenuates I None
tubulointerstitial I Disease
nephritis O Disease
induced I None
by I None
gentamicin I Chemical
. I None
<eof> I None

<s> O None
Glucose I Chemical
metabolism I None
in I None
patients I None
with I None
schizophrenia I Disease
treated I None
with I None
atypical I None
antipsychotic I None
agents I None
: I None
a I None
frequently I None
sampled I None
intravenous I None
glucose I Chemical
tolerance I None
test I None
and I None
minimal I None
model I None
analysis I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
While I None
the I None
incidence I None
of I None
new I None
- I None
onset I None
diabetes I Disease
mellitus O Disease
may I None
be I None
increasing I None
in I None
patients I None
with I None
schizophrenia I Disease
treated I None
with I None
certain I None
atypical I None
antipsychotic I None
agents I None
, I None
it I None
remains I None
unclear I None
whether I None
atypical I None
agents I None
are I None
directly I None
affecting I None
glucose I Chemical
metabolism I None
or I None
simply I None
increasing I None
known I None
risk I None
factors I None
for I None
diabetes I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
study I None
the I None
2 I None
drugs I None
most I None
clearly I None
implicated I None
( I None
clozapine I Chemical
and I None
olanzapine I Chemical
) I None
and I None
risperidone I Chemical
using I None
a I None
frequently I None
sampled I None
intravenous I None
glucose I Chemical
tolerance I None
test I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
A I None
cross I None
- I None
sectional I None
design I None
in I None
stable I None
, I None
treated I None
patients I None
with I None
schizophrenia I Disease
evaluated I None
using I None
a I None
frequently I None
sampled I None
intravenous I None
glucose I Chemical
tolerance I None
test I None
and I None
the I None
Bergman I None
minimal I None
model I None
analysis I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
Subjects I None
were I None
recruited I None
from I None
an I None
urban I None
community I None
mental I None
health I None
clinic I None
and I None
were I None
studied I None
at I None
a I None
general I None
clinical I None
research I None
center I None
. I None
<eof> I None

<s> O None
Patients I None
<eof> I None

<s> O None
Fifty I None
subjects I None
signed I None
informed I None
consent I None
and I None
41 I None
underwent I None
the I None
frequently I None
sampled I None
intravenous I None
glucose I Chemical
tolerance I None
test I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
six I None
nonobese I None
subjects I None
with I None
schizophrenia I Disease
or I None
schizoaffective I Disease
disorder O Disease
, I None
matched I None
by I None
body I None
mass I None
index I None
and I None
treated I None
with I None
either I None
clozapine I Chemical
, I None
olanzapine I Chemical
, I None
or I None
risperidone I Chemical
, I None
were I None
included I None
in I None
the I None
analysis I None
. I None
<eof> I None

<s> O None
MAIN I None
OUTCOME I None
MEASURES I None
: I None
Fasting I None
plasma I None
<eof> I None

<s> O None
glucose I Chemical
and I None
fasting I None
serum I None
insulin I None
levels I None
, I None
insulin I Disease
sensitivity O Disease
index I None
, I None
homeostasis I None
model I None
assessment I None
of I None
insulin I Disease
resistance O Disease
, I None
and I None
glucose I Chemical
effectiveness I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
mean I None
+ I None
/- I None
SD I None
duration I None
of I None
treatment I None
with I None
the I None
identified I None
atypical I None
antipsychotic I None
agent I None
was I None
68.3 I None
+ I None
/- I None
<eof> I None

<s> O None
28.9 I None
months I None
( I None
clozapine I Chemical
) I None
, I None
29.5 I None
+ I None
/- I None
<eof> I None

<s> O None
17.5 I None
months I None
( I None
olanzapine I Chemical
) I None
, I None
and I None
40.9 I None
+ I None
/- I None
33.7 I None
( I None
risperidone I Chemical
) I None
. I None
<eof> I None

<s> O None
Fasting I None
serum I None
insulin I None
concentrations I None
differed I None
among I None
groups I None
( I None
F(33 I None
) I None
= I None
3.35 I None
; I None
P I None
= I None
.047 I None
) I None
<eof> I None

<s> O None
( I None
clozapine I Chemical
> I None
olanzapine I Chemical
> I None
risperidone I Chemical
) I None
with I None
significant I None
differences I None
between I None
clozapine I Chemical
and I None
risperidone I Chemical
( I None
t(33 I None
) I None
<eof> I None

<s> O None
= I None
2.32 I None
; I None
P I None
= I None
.03 I None
) I None
and I None
olanzapine I Chemical
and I None
risperidone I Chemical
( I None
t(33 I None
) I None
<eof> I None

<s> O None
= I None
2.15 I None
; I None
P I None
= I None
.04 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
difference I None
in I None
insulin I Disease
sensitivity O Disease
index I None
among I None
groups I None
( I None
F(33 I None
) I None
= I None
10.66 I None
; I None
P<.001 I None
) I None
( I None
clozapine I Chemical
< I None
olanzapine I Chemical
< I None
risperidone I Chemical
) I None
, I None
with I None
subjects I None
who I None
received I None
clozapine I Chemical
and I None
olanzapine I Chemical
exhibiting I None
significant I None
insulin I Disease
resistance O Disease
compared I None
with I None
subjects I None
who I None
were I None
treated I None
with I None
risperidone I Chemical
<eof> I None

<s> O None
( I None
clozapine I Chemical
vs I None
risperidone I Chemical
, I None
t(33 I None
) I None
<eof> I None

<s> O None
= I None
-4.29 I None
<eof> I None

<s> O None
; I None
P<.001 I None
; I None
olanzapine I Chemical
vs I None
risperidone I Chemical
, I None
t(33 I None
) I None
<eof> I None

<s> O None
= I None
<eof> I None

<s> O None
-3.62 I None
; I None
P I None
= I None
.001 I None
[ I None
P<.001 I None
] I None
) I None
. I None
<eof> I None

<s> O None
The I None
homeostasis I None
model I None
assessment I None
of I None
insulin I Disease
resistance O Disease
also I None
differed I None
significantly I None
among I None
groups I None
( I None
F(33 I None
) I None
= I None
4.92 I None
; I None
P I None
= I None
.01 I None
) I None
<eof> I None

<s> O None
( I None
clozapine I Chemical
> I None
olanzapine I Chemical
> I None
risperidone I Chemical
) I None
<eof> I None

<s> O None
( I None
clozapine I Chemical
vs I None
risperidone I Chemical
, I None
t(33 I None
) I None
= I None
2.94 I None
; I None
P I None
= I None
.006 I None
; I None
olanzapine I Chemical
vs I None
risperidone I Chemical
, I None
t(33 I None
) I None
<eof> I None

<s> O None
= I None
2.42 I None
; I None
P I None
= I None
.02 I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
difference I None
among I None
groups I None
in I None
glucose I Chemical
effectiveness I None
( I None
F(30 I None
) I None
<eof> I None

<s> O None
= I None
4.18 I None
; I None
P I None
= I None
.02 I None
) I None
<eof> I None

<s> O None
( I None
clozapine I Chemical
< I None
olanzapine I Chemical
< I None
risperidone I Chemical
) I None
with I None
significant I None
differences I None
between I None
clozapine I Chemical
and I None
risperidone I Chemical
( I None
t(30 I None
) I None
<eof> I None

<s> O None
= I None
-2.59 I None
; I None
P I None
= I None
.02 I None
) I None
and I None
olanzapine I Chemical
and I None
risperidone I Chemical
( I None
t(30 I None
) I None
= I None
-2.34 I None
, I None
P I None
= I None
.03 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Both I None
nonobese I None
<eof> I None

<s> O None
clozapine I Chemical
- I None
and I None
olanzapine I Chemical
<eof> I None

<s> O None
-treated I None
groups I None
displayed I None
significant I None
insulin I Disease
resistance O Disease
and I None
impairment I None
of I None
glucose I Chemical
effectiveness I None
compared I None
with I None
risperidone I Chemical
-treated I None
subjects I None
. I None
<eof> I None

<s> O None
Patients I None
taking I None
clozapine I Chemical
and I None
olanzapine I Chemical
must I None
be I None
examined I None
for I None
insulin I Disease
resistance O Disease
and I None
its I None
consequences I None
. I None
<eof> I None

<s> O None
Focal I None
cerebral I Disease
ischemia O Disease
in I None
rats I None
: I None
effect I None
of I None
<eof> I None

<s> O None
phenylephrine I Chemical
-induced I None
<eof> I None

<s> O None
hypertension I Disease
during I None
reperfusion I None
. I None
<eof> I None

<s> O None
After I None
180 I None
min I None
of I None
temporary I None
middle I Disease
cerebral O Disease
artery O Disease
occlusion O Disease
in I None
spontaneously I None
hypertensive I Disease
rats I None
, I None
the I None
effect I None
of I None
phenylephrine I Chemical
-induced I None
hypertension I Disease
on I None
<eof> I None

<s> O None
ischemic I Disease
brain O Disease
injury O Disease
and I None
blood I None
- I None
brain I None
barrier I None
permeability I None
was I None
determined I None
. I None
<eof> I None

<s> O None
Blood I None
pressure I None
was I None
manipulated I None
by I None
one I None
of I None
the I None
following I None
schedules I None
during I None
120 I None
min I None
of I None
reperfusion I None
: I None
Control I None
, I None
normotensive I None
reperfusion I None
; I None
90/ I None
hypertension I Disease
( I None
90/ I None
HTN I Disease
) I None
, I None
blood I None
pressure I None
was I None
increased I None
by I None
35 I None
mm I None
Hg I None
during I None
the I None
initial I None
90 I None
min I None
of I None
reperfusion I None
only I None
; I None
<eof> I None

<s> O None
15/ I None
hypertension I Disease
( I None
15/ I None
HTN I Disease
) I None
, I None
normotensive I None
reperfusion I None
for I None
30 I None
min I None
followed I None
by I None
15 I None
min I None
of I None
hypertension I Disease
and I None
75 I None
min I None
of I None
normotension I None
. I None
<eof> I None

<s> O None
Part I None
A I None
, I None
for I None
eight I None
rats I None
in I None
each I None
group I None
brain I Disease
injury O Disease
was I None
evaluated I None
by I None
staining I None
tissue I None
using I None
2,3,5-triphenyltetrazolium I Chemical
chloride O Chemical
and I None
edema I Disease
was I None
evaluated I None
by I None
microgravimetry I None
. I None
<eof> I None

<s> O None
Part I None
B I None
, I None
for I None
eight I None
different I None
rats I None
in I None
each I None
group I None
blood I None
- I None
brain I None
barrier I None
permeability I None
was I None
evaluated I None
by I None
measuring I None
the I None
amount I None
and I None
extent I None
of I None
extravasation I None
of I None
Evans I None
Blue I None
dye I None
. I None
<eof> I None

<s> O None
Brain I Disease
injury O Disease
( I None
percentage I None
of I None
the I None
ischemic I Disease
hemisphere O Disease
) I None
was I None
less I None
in I None
the I None
15/ I None
HTN I Disease
group I None
( I None
16 I None
+ I None
/- I None
6 I None
, I None
mean I None
+ I None
/- I None
<eof> I None

<s> O None
SD I None
) I None
versus I None
the I None
90/ I None
HTN I Disease
group I None
( I None
30 I None
+ I None
<eof> I None

<s> O None
/- I None
6 I None
) I None
, I None
which I None
was I None
in I None
turn I None
less I None
than I None
the I None
control I None
group I None
( I None
42 I None
+ I None
/- I None
5 I None
) I None
. I None
<eof> I None

<s> O None
Specific I None
gravity I None
was I None
greater I None
in I None
the I None
15/ I None
HTN I Disease
group I None
( I None
1.043 I None
+ I None
/- I None
0.002 I None
) I None
versus I None
the I None
90/ I None
HTN I Disease
( I None
1.036 I None
+ I None
/- I None
0.003 I None
) I None
and I None
control I None
( I None
1.037 I None
+ I None
/- I None
0.003 I None
) I None
groups I None
. I None
<eof> I None

<s> O None
Evans I Chemical
Blue O Chemical
( I None
mug I None
g-1 I None
of I None
brain I None
tissue I None
) I None
was I None
greater I None
in I None
the I None
90/ I None
HTN I Disease
group I None
( I None
24.4 I None
+ I None
/- I None
6.0 I None
) I None
versus I None
the I None
control I None
group I None
( I None
12.3 I None
+ I None
/- I None
<eof> I None

<s> O None
4.1 I None
) I None
, I None
which I None
was I None
in I None
turn I None
greater I None
than I None
the I None
15/ I None
HTN I Disease
group I None
( I None
7.3 I None
+ I None
/- I None
3.2 I None
) I None
. I None
<eof> I None

<s> O None
This I None
study I None
supports I None
a I None
hypothesis I None
that I None
during I None
reperfusion I None
, I None
a I None
short I None
interval I None
of I None
hypertension I Disease
decreases I None
brain I Disease
injury O Disease
and I None
edema I Disease
; I None
and I None
that I None
sustained I None
hypertension I Disease
increases I None
the I None
risk I None
of I None
vasogenic I Disease
edema O Disease
. I None
<eof> I None

<s> O None
People I None
aged I None
over I None
75 I None
in I None
atrial I Disease
fibrillation O Disease
on I None
warfarin I Chemical
: I None
the I None
rate I None
of I None
major I None
hemorrhage I Disease
and I None
stroke I Disease
in I None
more I None
than I None
500 I None
patient I None
- I None
years I None
of I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
incidence I None
of I None
major I None
hemorrhage I Disease
and I None
stroke I Disease
in I None
people I None
aged I None
76 I None
and I None
older I None
with I None
atrial I Disease
fibrillation O Disease
on I None
adjusted I None
- I None
dose I None
warfarin I Chemical
who I None
had I None
been I None
recently I None
been I None
admitted I None
to I None
hospital I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
A I None
retrospective I None
observational I None
cohort I None
study I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
<eof> I None

<s> O None
A I None
major I None
healthcare I None
network I None
involving I None
four I None
tertiary I None
hospitals I None
. I None
<eof> I None

<s> O None
PARTICIPANTS I None
: I None
<eof> I None

<s> O None
Two I None
hundred I None
thirty I None
- I None
five I None
patients I None
aged I None
76 I None
and I None
older I None
admitted I None
to I None
a I None
major I None
healthcare I None
network I None
between I None
July I None
1 I None
, I None
2001 I None
, I None
and I None
June I None
30 I None
, I None
2002 I None
, I None
with I None
<eof> I None

<s> O None
atrial I Disease
fibrillation O Disease
on I None
warfarin I Chemical
were I None
enrolled I None
. I None
<eof> I None

<s> O None
MEASUREMENTS I None
: I None
Information I None
regarding I None
major I None
bleeding I Disease
episodes I None
, I None
strokes I Disease
, I None
and I None
warfarin I Chemical
use I None
was I None
obtained I None
from I None
patients I None
, I None
relatives I None
, I None
primary I None
physicians I None
, I None
and I None
medical I None
records I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Two I None
hundred I None
twenty I None
- I None
eight I None
patients I None
( I None
42 I None
% I None
men I None
) I None
with I None
a I None
mean I None
age I None
of I None
81.1 I None
( I None
range I None
76 I None
- I None
94 I None
) I None
were I None
included I None
in I None
the I None
analysis I None
. I None
<eof> I None

<s> O None
Total I None
follow I None
- I None
up I None
on I None
warfarin I Chemical
was I None
530 I None
years I None
( I None
mean I None
28 I None
months I None
) I None
. I None
<eof> I None

<s> O None
There I None
were I None
53 I None
major I None
hemorrhages I Disease
, I None
for I None
an I None
annual I None
rate I None
of I None
10.0 I None
% I None
, I None
including I None
24 I None
( I None
45.3 I None
% I None
) I None
life I None
- I None
threatening I None
and I None
five I None
( I None
9.4 I None
% I None
) I None
fatal I None
bleeds I None
. I None
<eof> I None

<s> O None
The I None
annual I None
stroke I Disease
rate I None
after I None
initiation I None
of I None
warfarin I Chemical
was I None
2.6 I None
% I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
rate I None
of I None
major I None
hemorrhage I Disease
was I None
high I None
in I None
this I None
old I None
, I None
frail I None
group I None
, I None
but I None
excluding I None
fatalities I None
, I None
resulted I None
in I None
no I None
long I None
- I None
term I None
sequelae I None
, I None
and I None
the I None
stroke I Disease
rate I None
on I None
warfarin I Chemical
was I None
low I None
, I None
demonstrating I None
how I None
effective I None
warfarin I Chemical
<eof> I None

<s> O None
treatment I None
is I None
. I None
<eof> I None

<s> O None
Safety I None
of I None
celecoxib I Chemical
in I None
patients I None
with I None
adverse I None
skin I Disease
reactions O Disease
to I None
acetaminophen I Chemical
<eof> I None

<s> O None
( I None
paracetamol I Chemical
) I None
and I None
nimesulide I Chemical
associated I None
or I None
not I None
with I None
common I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Acetaminophen I Chemical
<eof> I None

<s> O None
( I None
paracetamol I Chemical
-- I None
P I Chemical
) I None
and I None
Nimesulide I Chemical
<eof> I None

<s> O None
( I None
N I Chemical
) I None
are I None
widely I None
used I None
analgesic I None
- I None
antipyretic I None
/ I None
anti I None
- I None
inflammatory I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
adverse I None
hypersensitivity I Disease
reactions I None
to I None
these I None
agents I None
is I None
generally I None
low I None
. I None
<eof> I None

<s> O None
On I None
the I None
contrary I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
are I None
commonly I None
involved I None
in I None
such I None
reactions I None
. I None
<eof> I None

<s> O None
Celecoxib I Chemical
<eof> I None

<s> O None
( I None
CE I Chemical
) I None
is I None
a I None
novel I None
drug I None
, I None
with I None
high I None
selectivity I None
and I None
affinity I None
for I None
COX-2 I None
enzyme I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
We I None
evaluated I None
the I None
tolerability I None
of I None
CE I Chemical
in I None
a I None
group I None
of I None
patients I None
with I None
documented I None
history I None
of I None
adverse I None
cutaneous I Disease
reactions O Disease
to I None
P I Chemical
and I None
N I Chemical
associated I None
or I None
not I None
to I None
classic I None
NSAIDs I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
studied I None
9 I None
patients I None
with I None
hypersensitivity I Disease
to I None
P I Chemical
and I None
N I Chemical
with I None
or I None
without I None
associated I None
reactions I None
to I None
classic I None
NSAIDs I None
. I None
<eof> I None

<s> O None
The I None
diagnosis I None
of I None
P I Chemical
and I None
N I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
skin I Disease
reactions O Disease
was I None
based I None
in I None
vivo I None
challenge I None
. I None
<eof> I None

<s> O None
The I None
placebo I None
was I None
blindly I None
administered I None
at I None
the I None
beginning I None
of I None
each I None
challenge I None
. I None
<eof> I None

<s> O None
After I None
three I None
days I None
, I None
a I None
cumulative I None
dosage I None
of I None
200 I None
mg I None
of I None
CE I Chemical
in I None
refracted I None
doses I None
were I None
given I None
. I None
<eof> I None

<s> O None
After I None
2 I None
- I None
3 I None
days I None
, I None
a I None
single I None
dose I None
of I None
200 I None
mg I None
was I None
administered I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
observed I None
for I None
6 I None
hours I None
after I None
each I None
challenge I None
, I None
and I None
controlled I None
again I None
after I None
24 I None
hours I None
to I None
exclude I None
delayed I None
reactions I None
. I None
<eof> I None

<s> O None
The I None
challenge I None
was I None
considered I None
positive I None
if I None
one I None
or I None
more I None
of I None
the I None
following I None
appeared I None
: I None
erythema I Disease
, I None
rush I None
or I None
urticaria I Disease
- I None
angioedema I Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
No I None
reaction I None
was I None
observed I None
with I None
placebo I None
and I None
eight I None
patients I None
( I None
88.8 I None
% I None
) I None
tolerated I None
<eof> I None

<s> O None
CE I Chemical
. I None
<eof> I None

<s> O None
Only I None
one I None
patient I None
developed I None
a I None
moderate I None
angioedema I Disease
of I None
the I None
lips I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Only I None
one I None
hypersensitivity I Disease
reaction I None
to I None
CE I Chemical
was I None
documented I None
among I None
9 I None
P I Chemical
and I None
N I Chemical
-highly I None
NSAIDs I None
intolerant I None
patients I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
we I None
conclude I None
that I None
CE I Chemical
is I None
a I None
reasonably I None
safe I None
alternative I None
to I None
be I None
used I None
in I None
subjects I None
who I None
do I None
not I None
tolerate I None
P I Chemical
and I None
N I Chemical
. I None
<eof> I None

<s> O None
Case I None
- I None
control I None
study I None
of I None
regular I None
analgesic I None
and I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
use I None
and I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Studies I None
on I None
the I None
association I None
between I None
the I None
long I None
- I None
term I None
use I None
of I None
aspirin I Chemical
and I None
other I None
analgesic I None
and I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
and I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
( I None
ESRD I Disease
) I None
have I None
given I None
conflicting I None
results I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
examine I None
this I None
association I None
, I None
a I None
case I None
- I None
control I None
study I None
with I None
incident I None
cases I None
of I None
ESRD I Disease
was I None
carried I None
out I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
cases I None
were I None
all I None
patients I None
entering I None
the I None
local I None
dialysis I None
program I None
because I None
of I None
ESRD I Disease
in I None
the I None
study I None
area I None
between I None
June I None
1 I None
, I None
1995 I None
and I None
November I None
30 I None
, I None
1997 I None
. I None
<eof> I None

<s> O None
They I None
were I None
classified I None
according I None
to I None
the I None
underlying I None
disease I None
, I None
which I None
had I None
presumably I None
led I None
them I None
to I None
ESRD I Disease
. I None
<eof> I None

<s> O None
Controls I None
were I None
patients I None
admitted I None
to I None
the I None
same I None
hospitals I None
from I None
where I None
the I None
cases I None
arose I None
, I None
also I None
matched I None
by I None
age I None
and I None
sex I None
. I None
<eof> I None

<s> O None
Odds I None
ratios I None
were I None
calculated I None
using I None
a I None
conditional I None
logistic I None
model I None
, I None
including I None
potential I None
confounding I None
factors I None
, I None
both I None
for I None
the I None
whole I None
study I None
population I None
and I None
for I None
the I None
various I None
underlying I None
diseases I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Five I None
hundred I None
and I None
eighty I None
- I None
three I None
cases I None
and I None
1190 I None
controls I None
were I None
included I None
in I None
the I None
analysis I None
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
use I None
of I None
any I None
analgesic I None
was I None
associated I None
with I None
an I None
overall I None
odds I None
ratio I None
of I None
1.22 I None
( I None
95 I None
% I None
CI I None
, I None
0.89 I None
- I None
1.66 I None
) I None
. I None
<eof> I None

<s> O None
For I None
specific I None
groups I None
of I None
drugs I None
, I None
the I None
risks I None
were I None
1.56 I None
( I None
1.05 I None
- I None
2.30 I None
) I None
for I None
aspirin I Chemical
, I None
1.03 I None
( I None
0.60 I None
- I None
1.76 I None
) I None
for I None
pyrazolones I Chemical
, I None
0.80 I None
( I None
0.39 I None
- I None
1.63 I None
) I None
for I None
paracetamol I Chemical
, I None
and I None
0.94 I None
( I None
0.57 I None
- I None
1.56 I None
) I None
for I None
nonaspirin I None
NSAIDs I None
. I None
<eof> I None

<s> O None
The I None
risk I None
of I None
ESRD I Disease
associated I None
with I None
aspirin I Chemical
was I None
related I None
to I None
the I None
cumulated I None
dose I None
and I None
duration I None
of I None
use I None
, I None
and I None
it I None
was I None
particularly I None
high I None
among I None
the I None
subset I None
of I None
patients I None
with I None
vascular I None
nephropathy I Disease
as I None
underlying I None
disease I None
[ I None
2.35 I None
( I None
1.17 I None
- I None
4.72 I None
) I None
] I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
data I None
indicate I None
that I None
long I None
- I None
term I None
use I None
of I None
nonaspirin I None
analgesic I None
drugs I None
and I None
NSAIDs I None
is I None
not I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
ESRD I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
chronic I None
use I None
of I None
aspirin I Chemical
may I None
increase I None
the I None
risk I None
of I None
ESRD I Disease
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
amisulpride I Chemical
<eof> I None

<s> O None
overdose I Disease
: I None
a I None
cause I None
for I None
prolonged I Disease
QT O Disease
syndrome O Disease
. I None
<eof> I None

<s> O None
Two I None
cases I None
of I None
deliberate I None
self- I None
poisoning I Disease
with I None
5 I None
g I None
and I None
3.6 I None
g I None
of I None
amisulpride I Chemical
, I None
respectively I None
, I None
are I None
reported I None
. I None
<eof> I None

<s> O None
In I None
both I None
cases I None
, I None
QT I Disease
prolongation O Disease
and I None
hypocalcaemia I Disease
were I None
noted I None
. I None
<eof> I None

<s> O None
The I None
QT I Disease
prolongation O Disease
appeared I None
to I None
respond I None
to I None
administration I None
of I None
i.v I None
. I None
<eof> I None

<s> O None
calcium I Chemical
gluconate O Chemical
. I None
<eof> I None

<s> O None
Growth I None
- I None
associated I None
protein I None
43 I None
expression I None
in I None
hippocampal I None
molecular I None
layer I None
of I None
chronic I None
epileptic I Disease
rats I None
treated I None
with I None
cycloheximide I Chemical
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
GAP43 I None
has I None
been I None
thought I None
to I None
be I None
linked I None
with I None
mossy I None
fiber I None
sprouting I None
( I None
MFS I None
) I None
in I None
various I None
experimental I None
models I None
of I None
epilepsy I Disease
. I None
<eof> I None

<s> O None
To I None
investigate I None
how I None
GAP43 I None
expression I None
( I None
GAP43-ir I None
) I None
correlates I None
with I None
MFS I None
, I None
we I None
assessed I None
the I None
intensity I None
( I None
densitometry I None
) I None
and I None
extension I None
( I None
width I None
) I None
of I None
GAP43-ir I None
in I None
the I None
inner I None
molecular I None
layer I None
of I None
the I None
dentate I None
gyrus I None
( I None
IML I None
) I None
of I None
rats I None
subject I None
to I None
status I Disease
epilepticus O Disease
induced I None
by I None
pilocarpine I Chemical
<eof> I None

<s> O None
( I None
Pilo I Chemical
) I None
, I None
previously I None
injected I None
or I None
not I None
with I None
cycloheximide I Chemical
<eof> I None

<s> O None
( I None
CHX I Chemical
) I None
, I None
which I None
has I None
been I None
shown I None
to I None
inhibit I None
MFS I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
CHX I Chemical
was I None
injected I None
before I None
the I None
Pilo I Chemical
injection I None
in I None
adult I None
Wistar I None
rats I None
. I None
<eof> I None

<s> O None
The I None
Pilo I Chemical
group I None
was I None
injected I None
with I None
the I None
same I None
drugs I None
, I None
except I None
for I None
CHX I Chemical
. I None
<eof> I None

<s> O None
Animals I None
were I None
killed I None
between I None
30 I None
and I None
60 I None
days I None
later I None
, I None
and I None
brain I None
sections I None
were I None
processed I None
for I None
GAP43 I None
immunohistochemistry I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Densitometry I None
showed I None
no I None
significant I None
difference I None
regarding I None
GAP43-ir I None
in I None
the I None
IML I None
between I None
Pilo I Chemical
, I None
CHX I Chemical
+ I None
Pilo I Chemical
, I None
and I None
control I None
groups I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
results I None
of I None
the I None
width I None
of I None
the I None
GAP43-ir I None
band I None
in I None
the I None
IML I None
showed I None
that I None
CHX I Chemical
+ I None
Pilo I Chemical
and I None
control I None
animals I None
had I None
a I None
significantly I None
larger I None
band I None
( I None
p I None
= I None
0.03 I None
) I None
as I None
compared I None
with I None
that I None
in I None
the I None
Pilo I Chemical
group I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Our I None
current I None
finding I None
that I None
animals I None
in I None
the I None
CHX I Chemical
+ I None
Pilo I Chemical
group I None
have I None
a I None
GAP43-ir I None
band I None
in I None
the I None
IML I None
, I None
similar I None
to I None
that I None
of I None
controls I None
, I None
reinforces I None
prior I None
data I None
on I None
the I None
blockade I None
of I None
MFS I None
in I None
these I None
animals I None
. I None
<eof> I None

<s> O None
The I None
change I None
in I None
GAP43-ir I None
present I None
in I None
Pilo I Chemical
<eof> I None

<s> O None
-treated I None
animals I None
was I None
a I None
thinning I None
of I None
the I None
band I None
to I None
a I None
very I None
narrow I None
layer I None
just I None
above I None
the I None
granule I None
cell I None
layer I None
that I None
is I None
likely I None
to I None
be I None
associated I None
with I None
the I None
loss I None
of I None
hilar I None
cell I None
projections I None
that I None
express I None
GAP-43 I None
. I None
<eof> I None

<s> O None
Nicotine I Chemical
antagonizes I None
<eof> I None

<s> O None
caffeine I Chemical
- I None
but I None
not I None
<eof> I None

<s> O None
pentylenetetrazole I Chemical
-induced I None
anxiogenic I None
effect I None
in I None
mice I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
<eof> I None

<s> O None
Nicotine I Chemical
and I None
caffeine I Chemical
are I None
widely I None
consumed I None
licit I None
psychoactive I None
drugs I None
worldwide I None
. I None
<eof> I None

<s> O None
Epidemiological I None
studies I None
showed I None
that I None
they I None
were I None
generally I None
used I None
concurrently I None
. I None
<eof> I None

<s> O None
Although I None
some I None
studies I None
in I None
experimental I None
animals I None
indicate I None
clear I None
pharmacological I None
interactions I None
between I None
them I None
, I None
no I None
studies I None
have I None
shown I None
a I None
specific I None
interaction I None
on I None
anxiety I Disease
responses I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
present I None
study I None
investigates I None
the I None
effects I None
of I None
nicotine I Chemical
on I None
anxiety I Disease
induced I None
by I None
caffeine I Chemical
and I None
another I None
anxiogenic I None
drug I None
, I None
pentylenetetrazole I Chemical
, I None
in I None
mice I None
. I None
<eof> I None

<s> O None
The I None
elevated I None
plus I None
- I None
maze I None
( I None
EPM I None
) I None
test I None
was I None
used I None
to I None
evaluate I None
the I None
effects I None
of I None
drugs I None
on I None
anxiety I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Adult I None
male I None
Swiss I None
Webster I None
mice I None
( I None
25 I None
- I None
32 I None
g I None
) I None
were I None
given I None
nicotine I Chemical
( I None
0.05 I None
- I None
0.25 I None
mg I None
/ I None
kg I None
s.c I None
. I None
) I None
or I None
saline I None
10 I None
min I None
before I None
caffeine I Chemical
<eof> I None

<s> O None
( I None
70 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
or I None
pentylenetetrazole I Chemical
( I None
15 I None
and I None
30 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
injections I None
. I None
<eof> I None

<s> O None
After I None
15 I None
min I None
, I None
mice I None
were I None
evaluated I None
for I None
their I None
open- I None
and I None
closed I None
- I None
arm I None
time I None
and I None
entries I None
on I None
the I None
EPM I None
for I None
a I None
10-min I None
session I None
. I None
<eof> I None

<s> O None
Locomotor I None
activity I None
was I None
recorded I None
for I None
individual I None
groups I None
by I None
using I None
the I None
same I None
treatment I None
protocol I None
with I None
the I None
EPM I None
test I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Nicotine I Chemical
( I None
0.05 I None
- I None
0.25 I None
mg I None
/ I None
kg I None
) I None
itself I None
did I None
not I None
produce I None
any I None
significant I None
effect I None
in I None
the I None
EPM I None
test I None
, I None
whereas I None
caffeine I Chemical
<eof> I None

<s> O None
( I None
70 I None
mg I None
/ I None
kg I None
) I None
and I None
pentylenetetrazole I Chemical
( I None
30 I None
mg I None
/ I None
kg I None
) I None
produced I None
an I None
anxiogenic I None
effect I None
, I None
apparent I None
with I None
decreases I None
in I None
open I None
- I None
arm I None
time I None
and I None
entry I None
. I None
<eof> I None

<s> O None
Nicotine I Chemical
( I None
0.25 I None
mg I None
/ I None
kg I None
) I None
pretreatment I None
blocked I None
the I None
caffeine I Chemical
- I None
but I None
not I None
pentylenetetrazole I Chemical
-induced I None
anxiety I Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
each I None
drug I None
and I None
their I None
combinations I None
did I None
not I None
produce I None
any I None
effect I None
on I None
locomotor I None
activity I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
the I None
antagonistic I None
effect I None
of I None
nicotine I Chemical
on I None
caffeine I Chemical
-induced I None
<eof> I None

<s> O None
anxiety I Disease
is I None
specific I None
to I None
caffeine I Chemical
, I None
instead I None
of I None
a I None
non I None
- I None
specific I None
anxiolytic I None
effect I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
it I None
may I None
extend I None
the I None
current I None
findings I None
on I None
the I None
interaction I None
between I None
nicotine I Chemical
and I None
caffeine I Chemical
. I None
<eof> I None

<s> O None
Long I None
term I None
hormone I None
therapy I None
for I None
perimenopausal I None
and I None
postmenopausal I None
women I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Hormone I None
therapy I None
( I None
HT I None
) I None
is I None
widely I None
used I None
for I None
controlling I None
menopausal I Disease
symptoms O Disease
. I None
<eof> I None

<s> O None
It I None
has I None
also I None
been I None
used I None
for I None
the I None
management I None
and I None
prevention I None
of I None
cardiovascular I Disease
disease O Disease
, I None
osteoporosis I Disease
and I None
dementia I Disease
in I None
older I None
women I None
but I None
the I None
evidence I None
supporting I None
its I None
use I None
for I None
these I None
indications I None
is I None
largely I None
observational I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
To I None
assess I None
the I None
effect I None
of I None
long I None
- I None
term I None
HT I None
on I None
mortality I None
, I None
heart I Disease
disease O Disease
, I None
venous I Disease
thromboembolism O Disease
, I None
stroke I Disease
, I None
transient I Disease
ischaemic O Disease
attacks O Disease
, I None
breast I Disease
cancer O Disease
, I None
colorectal I Disease
cancer O Disease
, I None
ovarian I Disease
cancer O Disease
, I None
endometrial I Disease
cancer O Disease
, I None
gallbladder I Disease
disease O Disease
, I None
cognitive I None
function I None
, I None
dementia I Disease
, I None
fractures I Disease
and I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
SEARCH I None
STRATEGY I None
: I None
<eof> I None

<s> O None
We I None
searched I None
the I None
following I None
databases I None
up I None
to I None
November I None
2004 I None
: I None
the I None
Cochrane I None
Menstrual I None
Disorders I None
and I None
Subfertility I None
Group I None
Trials I None
Register I None
, I None
Cochrane I None
Central I None
Register I None
of I None
Controlled I None
Trials I None
( I None
CENTRAL I None
) I None
, I None
MEDLINE I None
, I None
EMBASE I None
, I None
Biological I None
Abstracts I None
. I None
<eof> I None

<s> O None
Relevant I None
non I None
- I None
indexed I None
journals I None
and I None
conference I None
abstracts I None
were I None
also I None
searched I None
. I None
<eof> I None

<s> O None
SELECTION I None
CRITERIA I None
: I None
<eof> I None

<s> O None
Randomised I None
double I None
- I None
blind I None
trials I None
of I None
HT I None
( I None
oestrogens I Chemical
with I None
or I None
without I None
progestogens I Chemical
) I None
versus I None
placebo I None
, I None
taken I None
for I None
at I None
least I None
one I None
year I None
by I None
perimenopausal I None
or I None
postmenopausal I None
women I None
. I None
<eof> I None

<s> O None
DATA I None
COLLECTION I None
AND I None
ANALYSIS I None
: I None
<eof> I None

<s> O None
Fifteen I None
RCTs I None
were I None
included I None
. I None
<eof> I None

<s> O None
Trials I None
were I None
assessed I None
for I None
quality I None
and I None
two I None
review I None
authors I None
extracted I None
data I None
independently I None
. I None
<eof> I None

<s> O None
They I None
calculated I None
risk I None
ratios I None
for I None
dichotomous I None
outcomes I None
and I None
weighted I None
mean I None
differences I None
for I None
continuous I None
outcomes I None
. I None
<eof> I None

<s> O None
Clinical I None
heterogeneity I None
precluded I None
meta I None
- I None
analysis I None
for I None
most I None
outcomes I None
. I None
<eof> I None

<s> O None
MAIN I None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
the I None
statistically I None
significant I None
results I None
were I None
derived I None
from I None
the I None
two I None
biggest I None
trials I None
. I None
<eof> I None

<s> O None
In I None
relatively I None
healthy I None
women I None
, I None
combined I None
continuous I None
HT I None
significantly I None
increased I None
the I None
risk I None
of I None
venous I Disease
thromboembolism O Disease
or I None
coronary I None
event I None
( I None
after I None
one I None
year I None
's I None
use I None
) I None
, I None
stroke I Disease
<eof> I None

<s> O None
( I None
after I None
3 I None
years I None
) I None
, I None
breast I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
after I None
5 I None
years I None
) I None
and I None
gallbladder I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
<eof> I None

<s> O None
oestrogen I Chemical
<eof> I None

<s> O None
-only I None
<eof> I None

<s> O None
HT I None
also I None
significantly I None
increased I None
the I None
risk I None
of I None
stroke I Disease
and I None
gallbladder I Disease
disease O Disease
. I None
<eof> I None

<s> O None
Overall I None
, I None
the I None
only I None
statistically I None
significant I None
benefits I None
of I None
HT I None
were I None
a I None
decreased I None
incidence I None
of I None
fractures I Disease
and I None
colon I Disease
cancer O Disease
with I None
long I None
- I None
term I None
use I None
. I None
<eof> I None

<s> O None
Among I None
relatively I None
healthy I None
women I None
over I None
65 I None
years I None
taking I None
continuous I None
combined I None
HT I None
, I None
there I None
was I None
a I None
statistically I None
significant I None
increase I None
in I None
the I None
incidence I None
of I None
dementia I Disease
. I None
<eof> I None

<s> O None
Among I None
women I None
with I None
cardiovascular I Disease
disease O Disease
, I None
long I None
- I None
term I None
use I None
of I None
combined I None
continuous I None
HT I None
significantly I None
increased I None
the I None
risk I None
of I None
venous I Disease
thromboembolism O Disease
. I None
<eof> I None

<s> O None
No I None
trials I None
focussed I None
specifically I None
on I None
younger I None
women I None
. I None
<eof> I None

<s> O None
However I None
, I None
one I None
trial I None
analysed I None
subgroups I None
of I None
2839 I None
relatively I None
healthy I None
50 I None
to I None
59 I None
year I None
- I None
old I None
women I None
taking I None
combined I None
continuous I None
HT I None
and I None
1637 I None
taking I None
oestrogen I Chemical
<eof> I None

<s> O None
-only I None
<eof> I None

<s> O None
HT I None
, I None
versus I None
similar I None
- I None
sized I None
placebo I None
groups I None
. I None
<eof> I None

<s> O None
The I None
only I None
significantly I None
increased I None
risk I None
reported I None
was I None
for I None
venous I Disease
thromboembolism O Disease
in I None
women I None
taking I None
combined I None
continuous I None
HT I None
; I None
their I None
absolute I None
risk I None
remained I None
very I None
low I None
. I None
<eof> I None

<s> O None
AUTHORS I None
' I None
CONCLUSIONS I None
: I None
HT I None
is I None
not I None
indicated I None
for I None
the I None
routine I None
management I None
of I None
chronic I Disease
disease O Disease
. I None
<eof> I None

<s> O None
We I None
need I None
more I None
evidence I None
on I None
the I None
safety I None
of I None
HT I None
for I None
menopausal I None
symptom I None
control I None
, I None
though I None
short I None
- I None
term I None
use I None
appears I None
to I None
be I None
relatively I None
safe I None
for I None
healthy I None
younger I None
women I None
. I None
<eof> I None

<s> O None
Drug I Disease
- O Disease
induced O Disease
liver O Disease
injury O Disease
: I None
an I None
analysis I None
of I None
461 I None
incidences I None
submitted I None
to I None
the I None
Spanish I None
registry I None
over I None
a I None
10-year I None
period I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
& I None
AIMS I None
: I None
<eof> I None

<s> O None
Progress I None
in I None
the I None
understanding I None
of I None
susceptibility I None
factors I None
to I None
drug I Disease
- O Disease
induced O Disease
liver O Disease
injury O Disease
<eof> I None

<s> O None
( I None
DILI I Disease
) I None
and I None
outcome I None
predictability I None
are I None
hampered I None
by I None
the I None
lack I None
of I None
systematic I None
programs I None
to I None
detect I None
bona I None
fide I None
cases I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
cooperative I None
network I None
was I None
created I None
in I None
1994 I None
in I None
Spain I None
to I None
identify I None
all I None
suspicions I None
of I None
DILI I Disease
following I None
a I None
prospective I None
structured I None
report I None
form I None
. I None
<eof> I None

<s> O None
The I None
liver I Disease
damage O Disease
was I None
characterized I None
according I None
to I None
hepatocellular I None
, I None
cholestatic I Disease
, I None
and I None
mixed I None
laboratory I None
criteria I None
and I None
to I None
histologic I None
criteria I None
when I None
available I None
. I None
<eof> I None

<s> O None
Further I None
evaluation I None
of I None
causality I None
assessment I None
was I None
centrally I None
performed I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Since I None
April I None
1994 I None
to I None
August I None
2004 I None
, I None
461 I None
out I None
of I None
570 I None
submitted I None
cases I None
, I None
involving I None
505 I None
drugs I None
, I None
were I None
deemed I None
to I None
be I None
related I None
to I None
DILI I Disease
. I None
<eof> I None

<s> O None
The I None
antiinfective I None
group I None
of I None
drugs I None
was I None
the I None
more I None
frequently I None
incriminated I None
, I None
amoxicillin I Chemical
- O Chemical
clavulanate O Chemical
accounting I None
for I None
the I None
12.8 I None
% I None
of I None
the I None
whole I None
series I None
. I None
<eof> I None

<s> O None
The I None
hepatocellular I None
pattern I None
of I None
damage I None
was I None
the I None
most I None
common I None
( I None
58 I None
% I None
) I None
, I None
was I None
inversely I None
correlated I None
with I None
age I None
( I None
P I None
< I None
.0001 I None
) I None
, I None
and I None
had I None
the I None
worst I None
outcome I None
( I None
Cox I None
regression I None
, I None
P I None
< I None
.034 I None
) I None
. I None
<eof> I None

<s> O None
Indeed I None
, I None
the I None
incidence I None
of I None
liver I None
transplantation I None
and I None
death I None
in I None
this I None
group I None
was I None
11.7 I None
% I None
if I None
patients I None
had I None
jaundice I Disease
at I None
presentation I None
, I None
whereas I None
the I None
corresponding I None
figure I None
was I None
3.8 I None
% I None
in I None
nonjaundiced I None
patients I None
( I None
P I None
< I None
.04 I None
) I None
. I None
<eof> I None

<s> O None
Factors I None
associated I None
with I None
the I None
development I None
of I None
fulminant I Disease
hepatic O Disease
failure O Disease
were I None
female I None
sex I None
( I None
OR I None
= I None
25 I None
; I None
95 I None
% I None
CI I None
: I None
4.1 I None
- I None
151 I None
; I None
P I None
< I None
.0001 I None
) I None
, I None
hepatocellular I None
damage I None
( I None
OR I None
= I None
7.9 I None
; I None
95 I None
% I None
CI I None
: I None
1.6 I None
- I None
37 I None
; I None
P I None
< I None
.009 I None
) I None
, I None
and I None
higher I None
baseline I None
plasma I None
<eof> I None

<s> O None
bilirubin I Chemical
value I None
( I None
OR I None
= I None
1.15 I None
; I None
95 I None
% I None
CI I None
: I None
1.09 I None
- I None
1.22 I None
; I None
<eof> I None

<s> O None
P I None
< I None
.0001 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Patients I None
with I None
drug I None
- I None
induced I None
hepatocellular I None
jaundice I Disease
have I None
11.7 I None
% I None
chance I None
of I None
progressing I None
to I None
death I None
or I None
transplantation I None
. I None
<eof> I None

<s> O None
Amoxicillin I Chemical
- O Chemical
clavulanate O Chemical
stands I None
out I None
as I None
the I None
most I None
common I None
drug I None
related I None
to I None
DILI I Disease
. I None
<eof> I None

<s> O None
Morphological I None
evaluation I None
of I None
the I None
effect I None
of I None
d I Chemical
- O Chemical
ribose O Chemical
on I None
adriamycin I Chemical
-evoked I None
<eof> I None

<s> O None
cardiotoxicity I Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
influence I None
of I None
d I Chemical
- O Chemical
ribose O Chemical
on I None
<eof> I None

<s> O None
adriamycin I Chemical
-induced I None
<eof> I None

<s> O None
myocardiopathy I Disease
in I None
rats I None
was I None
studied I None
. I None
<eof> I None

<s> O None
Adriamycin I Chemical
in I None
the I None
cumulative I None
dose I None
of I None
25 I None
mg I None
/ I None
kg I None
evoked I None
fully I None
developed I None
cardiac I Disease
toxicity O Disease
. I None
<eof> I None

<s> O None
D I Chemical
- O Chemical
ribose O Chemical
in I None
the I None
multiple I None
doses I None
of I None
200 I None
mg I None
/ I None
kg I None
did I None
not I None
influence I None
<eof> I None

<s> O None
ADR I Chemical
<eof> I None

<s> O None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
In I None
vivo I None
evidences I None
suggesting I None
the I None
role I None
of I None
oxidative I None
stress I None
in I None
pathogenesis I None
of I None
vancomycin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
: I None
protection I None
by I None
erdosteine I Chemical
. I None
<eof> I None

<s> O None
The I None
aims I None
of I None
this I None
study I None
were I None
to I None
examine I None
vancomycin I Chemical
<eof> I None

<s> O None
( I None
VCM I Chemical
) I None
<eof> I None

<s> O None
-induced I None
oxidative I None
stress I None
that I None
promotes I None
production I None
of I None
reactive I None
oxygen I Chemical
species I None
( I None
ROS I None
) I None
and I None
to I None
investigate I None
the I None
role I None
of I None
erdosteine I Chemical
, I None
an I None
expectorant I None
agent I None
, I None
which I None
has I None
also I None
antioxidant I None
properties I None
, I None
on I None
kidney I None
tissue I None
against I None
the I None
possible I None
VCM I Chemical
-induced I None
<eof> I None

<s> O None
renal I Disease
impairment O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
divided I None
into I None
three I None
groups I None
: I None
sham I None
, I None
VCM I Chemical
and I None
VCM I Chemical
plus I None
erdosteine I Chemical
. I None
<eof> I None

<s> O None
VCM I Chemical
was I None
administrated I None
intraperitoneally I None
( I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
with I None
200mgkg(-1 I None
) I None
twice I None
daily I None
for I None
7 I None
days I None
. I None
<eof> I None

<s> O None
Erdosteine I Chemical
was I None
administered I None
orally I None
. I None
<eof> I None

<s> O None
VCM I Chemical
administration I None
to I None
control I None
rats I None
significantly I None
increased I None
renal I None
malondialdehyde I Chemical
<eof> I None

<s> O None
( I None
MDA I Chemical
) I None
and I None
urinary I None
N I None
- I None
acetyl I None
- I None
beta I None
- I None
d I None
- I None
glucosaminidase I None
( I None
NAG I None
, I None
a I None
marker I None
of I None
renal I Disease
tubular O Disease
injury O Disease
) I None
excretion I None
but I None
decreased I None
<eof> I None

<s> O None
superoxide I Chemical
dismutase I None
( I None
SOD I None
) I None
and I None
catalase I None
( I None
CAT I None
) I None
activities I None
. I None
<eof> I None

<s> O None
Erdosteine I Chemical
administration I None
with I None
VCM I Chemical
injections I None
caused I None
significantly I None
decreased I None
renal I None
MDA I Chemical
and I None
urinary I None
NAG I None
excretion I None
, I None
and I None
increased I None
SOD I None
activity I None
, I None
but I None
not I None
CAT I None
activity I None
in I None
renal I None
tissue I None
when I None
compared I None
with I None
VCM I Chemical
alone I None
. I None
<eof> I None

<s> O None
Erdosteine I Chemical
showed I None
histopathological I None
protection I None
against I None
VCM I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
. I None
<eof> I None

<s> O None
There I None
were I None
a I None
significant I None
dilatation I None
of I None
tubular I None
lumens I None
, I None
extensive I None
epithelial I None
cell I None
vacuolization I None
, I None
atrophy I Disease
, I None
desquamation I Disease
, I None
and I None
necrosis I Disease
in I None
VCM I Chemical
-treated I None
rats I None
more I None
than I None
those I None
of I None
the I None
control I None
and I None
the I None
erdosteine I Chemical
groups I None
. I None
<eof> I None

<s> O None
Erdosteine I Chemical
caused I None
a I None
marked I None
reduction I None
in I None
the I None
extent I None
of I None
tubular I None
damage I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
oxidative I None
tubular I None
damage I None
plays I None
an I None
important I None
role I None
in I None
the I None
VCM I Chemical
-induced I None
<eof> I None

<s> O None
nephrotoxicity I Disease
and I None
the I None
modulation I None
of I None
oxidative I None
stress I None
with I None
erdosteine I Chemical
reduces I None
the I None
VCM I Chemical
-induced I None
<eof> I None

<s> O None
kidney I Disease
damage O Disease
both I None
at I None
the I None
biochemical I None
and I None
histological I None
levels I None
. I None
<eof> I None

<s> O None
Does I None
domperidone I Chemical
potentiate I None
mirtazapine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
restless I Disease
legs O Disease
syndrome O Disease
? I None
<eof> I None

<s> O None
There I None
is I None
now I None
evidence I None
to I None
suggest I None
a I None
central I None
role I None
for I None
the I None
dopaminergic I None
system I None
in I None
restless I Disease
legs O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
RLS I Disease
) I None
. I None
<eof> I None

<s> O None
For I None
example I None
, I None
the I None
symptoms I None
of I None
RLS I Disease
can I None
be I None
dramatically I None
improved I None
by I None
levodopa I Chemical
and I None
dopamine I Chemical
agonists I None
, I None
whereas I None
central I None
dopamine I Chemical
D2 I None
receptor I None
antagonists I None
can I None
induce I None
or I None
aggravate I None
RLS I Disease
symptoms I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
there I None
is I None
no I None
previous I None
report I None
regarding I None
whether I None
domperidone I Chemical
, I None
a I None
peripheral I None
dopamine I Chemical
D2 I None
receptor I None
antagonist I None
, I None
can I None
also I None
induce I None
or I None
aggravate I None
symptoms I None
of I None
RLS I Disease
. I None
<eof> I None

<s> O None
Mirtazapine I Chemical
, I None
the I None
first I None
noradrenergic I None
and I None
specific I None
serotonergic I None
antidepressant I None
( I None
NaSSA I None
) I None
, I None
has I None
been I None
associated I None
with I None
RLS I Disease
in I None
several I None
recent I None
publications I None
. I None
<eof> I None

<s> O None
The I None
authors I None
report I None
here I None
a I None
depressed I None
patient I None
comorbid I None
with I None
postprandial I Disease
dyspepsia O Disease
who I None
developed I None
RLS I Disease
after I None
mirtazapine I Chemical
had I None
been I None
added I None
to I None
his I None
domperidone I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Our I None
patient I None
started I None
to I None
have I None
symptoms I None
of I None
RLS I Disease
only I None
after I None
he I None
had I None
been I None
treated I None
with I None
mirtazapine I Chemical
, I None
and I None
his I None
RLS I Disease
symptoms I None
resolved I None
completely I None
upon I None
discontinuation I None
of I None
his I None
mirtazapine I Chemical
. I None
<eof> I None

<s> O None
Such I None
a I None
temporal I None
relationship I None
between I None
the I None
use I None
of I None
mirtazapine I Chemical
and I None
the I None
symptoms I None
of I None
RLS I Disease
in I None
our I None
patient I None
did I None
not I None
support I None
a I None
potentiating I None
effect I None
of I None
domperione I Chemical
on I None
mirtazapine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
RLS I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
physicians I None
should I None
be I None
aware I None
of I None
the I None
possibility I None
that I None
mirtazapine I Chemical
can I None
be I None
associated I None
with I None
RLS I Disease
in I None
some I None
individuals I None
, I None
especially I None
those I None
receiving I None
concomitant I None
dopamine I Chemical
D2 I None
receptor I None
antagonists I None
. I None
<eof> I None

<s> O None
Antiandrogenic I None
therapy I None
can I None
cause I None
coronary I Disease
arterial O Disease
disease O Disease
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
study I None
the I None
change I None
of I None
lipid I None
metabolism I None
by I None
antiandrogen I None
therapy I None
in I None
patients I None
with I None
prostate I Disease
cancer O Disease
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHODS I None
<eof> I None

<s> O None
: I None
We I None
studied I None
with I None
a I None
2.5 I None
years I None
follow I None
- I None
up I None
the I None
changes I None
in I None
plasma I None
cholesterols I Chemical
<eof> I None

<s> O None
( I None
C I Chemical
) I None
, I None
triglycerides I Chemical
<eof> I None

<s> O None
( I None
TG I Chemical
) I None
, I None
lipoproteins I None
( I None
LP I None
) I None
, I None
and I None
apolipoproteins I None
( I None
Apo I None
<eof> I None

<s> O None
) I None
B-100 I None
, I None
A I None
- I None
I I None
, I None
and I None
A I None
- I None
II I None
<eof> I None

<s> O None
pro I None
fi I None
les I None
in I None
24 I None
patients I None
of I None
mean I None
age I None
60 I None
years I None
with I None
low I None
risk I None
prostate I Disease
cancer O Disease
<eof> I None

<s> O None
( I None
stage I None
: I None
T1cN0M0 I None
, I None
Gleason I None
score I None
: I None
2 I None
- I None
5 I None
) I None
during I None
treatment I None
with I None
cyproterone I Chemical
acetate O Chemical
<eof> I None

<s> O None
( I None
CPA I Chemical
) I None
without I None
surgical I None
management I None
or I None
radiation I None
therapy I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Significant I None
decreases I None
of I None
HDL I None
- I None
C I None
, I None
Apo I None
A I None
- I None
I I None
and I None
Apo I None
A I None
- I None
II I None
and I None
an I None
increase I None
of I None
triglyceride I Chemical
levels I None
in I None
VLDL I None
were I None
induced I None
by I None
CPA I Chemical
. I None
<eof> I None

<s> O None
After I None
a I None
period I None
of I None
2.5 I None
years I None
on I None
CPA I Chemical
treatment I None
, I None
four I None
patients I None
out I None
of I None
twenty I None
- I None
four I None
were I None
found I None
to I None
be I None
affected I None
by I None
coronary I Disease
heart O Disease
disease O Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Ischaemic I None
coronary I Disease
arteriosclerosis O Disease
with I None
an I None
incidence I None
rate I None
of I None
16.6 I None
% I None
as I None
caused I None
by I None
prolonged I None
CPA I Chemical
therapy I None
is I None
mediated I None
through I None
changes I None
in I None
HDL I None
cholesterol I Chemical
, I None
Apo I None
A I None
- I None
I I None
and I None
Apo I None
A I None
- I None
II I None
pro I None
fi I None
les I None
, I None
other I None
than I None
the I None
well I None
- I None
known I None
hyperglyceridemic I Disease
effect O Disease
caused I None
by I None
estrogen I Chemical
. I None
<eof> I None

<s> O None
5-Fluorouracil I Chemical
<eof> I None

<s> O None
cardiotoxicity I Disease
induced I None
by I None
alpha I Chemical
- O Chemical
fluoro O Chemical
- O Chemical
beta O Chemical
- O Chemical
alanine O Chemical
. I None
<eof> I None

<s> O None
Cardiotoxicity I Disease
is I None
a I None
rare I None
complication I None
occurring I None
during I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
treatment I None
for I None
malignancies I Disease
. I None
<eof> I None

<s> O None
We I None
herein I None
report I None
the I None
case I None
of I None
a I None
70-year I None
- I None
old I None
man I None
with I None
5-FU I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
, I None
in I None
whom I None
a I None
high I None
serum I None
level I None
of I None
alpha I Chemical
- O Chemical
fluoro O Chemical
- O Chemical
beta O Chemical
- O Chemical
alanine O Chemical
<eof> I None

<s> O None
( I None
FBAL I Chemical
) I None
was I None
observed I None
. I None
<eof> I None

<s> O None
The I None
patient I None
, I None
who I None
had I None
unresectable I None
colon I Disease
cancer O Disease
metastases I None
to I None
the I None
liver I None
and I None
lung I None
, I None
was I None
referred I None
to I None
us I None
for I None
chemotherapy I None
from I None
an I None
affiliated I None
hospital I None
; I None
he I None
had I None
no I None
cardiac I None
history I None
. I None
<eof> I None

<s> O None
After I None
admission I None
, I None
the I None
patient I None
received I None
a I None
continuous I None
intravenous I None
infusion I None
of I None
5-FU I Chemical
<eof> I None

<s> O None
( I None
1000 I None
mg I None
/ I None
day I None
) I None
, I None
during I None
which I None
precordial I Disease
pain O Disease
with I None
right I Disease
bundle O Disease
branch O Disease
block O Disease
occurred I None
concomitantly I None
with I None
a I None
high I None
serum I None
FBAL I Chemical
concentration I None
of I None
1955 I None
ng I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Both I None
the I None
precordial I Disease
pain O Disease
and I None
the I None
electrocardiographic I None
changes I None
disappeared I None
spontaneously I None
after I None
the I None
discontinuation I None
of I None
5-FU I Chemical
. I None
<eof> I None

<s> O None
As I None
the I None
precordial I Disease
pain O Disease
in I None
this I None
patient I None
was I None
considered I None
to I None
have I None
been I None
due I None
to I None
5-FU I Chemical
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
, I None
the I None
administration I None
of I None
5-FU I Chemical
was I None
abandoned I None
. I None
<eof> I None

<s> O None
Instead I None
, I None
oral I None
administration I None
of I None
S-1 I None
( I None
a I None
derivative I None
of I None
5-FU I Chemical
) I None
, I None
at I None
200 I None
mg I None
/ I None
day I None
twice I None
a I None
week I None
, I None
was I None
instituted I None
, I None
because I None
S-1 I None
has I None
a I None
strong I None
inhibitory I None
effect I None
on I None
dihydropyrimidine I Chemical
dehydrogenase I None
, I None
which I None
catalyzes I None
the I None
degradative I None
of I None
5-FU I Chemical
into I None
FBAL I Chemical
. I None
<eof> I None

<s> O None
The I None
serum I None
FBAL I Chemical
concentration I None
subsequently I None
decreased I None
to I None
352 I None
ng I None
/ I None
ml I None
, I None
the I None
same I None
as I None
the I None
value I None
measured I None
on I None
the I None
first I None
day I None
of I None
S-1 I None
administration I None
. I None
<eof> I None

<s> O None
Thereafter I None
, I None
no I None
cardiac I Disease
symptoms O Disease
were I None
observed I None
. I None
<eof> I None

<s> O None
The I None
patient I None
achieved I None
a I None
partial I None
response I None
6 I None
months I None
after I None
the I None
initiation I None
of I None
the I None
S-1 I None
treatment I None
. I None
<eof> I None

<s> O None
The I None
experience I None
of I None
this I None
case I None
, I None
together I None
with I None
a I None
review I None
of I None
the I None
literature I None
, I None
suggests I None
that I None
FBAL I Chemical
is I None
related I None
to I None
5-FU I Chemical
-induced I None
cardiotoxicity I Disease
. I None
S-1 I None
may I None
be I None
administered I None
safely I None
to I None
patients I None
with I None
5-FU I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
. I None
<eof> I None

<s> O None
The I None
influence I None
of I None
the I None
time I None
interval I None
between I None
monoHER I Chemical
and I None
doxorubicin I Chemical
administration I None
on I None
the I None
protection I None
against I None
doxorubicin I Chemical
-induced I None
cardiotoxicity I Disease
in I None
mice I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
Despite I None
its I None
well I None
- I None
known I None
cardiotoxicity I Disease
, I None
the I None
anthracyclin I None
doxorubicin I Chemical
<eof> I None

<s> O None
( I None
DOX I Chemical
) I None
continues I None
to I None
be I None
an I None
effective I None
and I None
widely I None
used I None
chemotherapeutic I None
agent I None
. I None
<eof> I None

<s> O None
DOX I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
damage O Disease
presumably I None
results I None
from I None
the I None
formation I None
of I None
free I None
radicals I None
by I None
DOX I Chemical
. I None
<eof> I None

<s> O None
Reactive I None
oxygen I Chemical
species I None
particularly I None
affect I None
the I None
cardiac I None
myocytes I None
because I None
these I None
cells I None
seem I None
to I None
have I None
a I None
relatively I None
poor I None
antioxidant I None
defense I None
system I None
. I None
<eof> I None

<s> O None
The I None
semisynthetic I None
flavonoid I Chemical
monohydroxyethylrutoside I Chemical
<eof> I None

<s> O None
( I None
monoHER I Chemical
) I None
showed I None
cardioprotection I None
against I None
DOX I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiotoxicity I Disease
through I None
its I None
radical I None
scavenging I None
and I None
iron I Chemical
chelating I None
properties I None
. I None
<eof> I None

<s> O None
Because I None
of I None
the I None
relatively I None
short I None
final I None
half I None
- I None
life I None
of I None
monoHER I Chemical
( I None
about I None
30 I None
min I None
) I None
, I None
it I None
is I None
expected I None
that I None
the I None
time I None
interval I None
between I None
monoHER I Chemical
and I None
DOX I Chemical
might I None
be I None
of I None
influence I None
on I None
the I None
cardioprotective I None
effect I None
of I None
monoHER I Chemical
. I None
<eof> I None

<s> O None
Therefore I None
, I None
the I None
aim I None
of I None
the I None
present I None
study I None
was I None
to I None
investigate I None
this I None
possible I None
effect I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Six I None
groups I None
of I None
6 I None
BALB I None
/ I None
c I None
mice I None
were I None
treated I None
with I None
saline I None
, I None
DOX I Chemical
alone I None
or I None
DOX I Chemical
( I None
4 I None
mg I None
/ I None
kg I None
i.v I None
. I None
) I None
preceded I None
by I None
monoHER I Chemical
<eof> I None

<s> O None
( I None
500 I None
mg I None
/ I None
kg I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
with I None
an I None
interval I None
of I None
10 I None
, I None
30 I None
, I None
60 I None
or I None
120 I None
min I None
. I None
<eof> I None

<s> O None
After I None
a I None
6-week I None
treatment I None
period I None
and I None
additional I None
observation I None
for I None
2 I None
weeks I None
, I None
the I None
mice I None
were I None
sacrificed I None
. I None
<eof> I None

<s> O None
Their I None
cardiac I None
tissues I None
were I None
processed I None
for I None
light I None
microscopy I None
, I None
after I None
which I None
cardiomyocyte I Disease
damage O Disease
was I None
evaluated I None
according I None
to I None
Billingham I None
( I None
in I None
Cancer I Disease
Treat I None
Rep I None
62(6):865 I None
- I None
872 I None
, I None
1978 I None
) I None
. I None
<eof> I None

<s> O None
Microscopic I None
evaluation I None
revealed I None
that I None
treatment I None
with I None
DOX I Chemical
alone I None
induced I None
significant I None
cardiac I Disease
damage O Disease
in I None
comparison I None
to I None
the I None
saline I None
control I None
group I None
( I None
P<0.001 I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
number I None
of I None
damaged I None
cardiomyocytes I None
was I None
9.6-fold I None
( I None
95 I None
% I None
CI I None
4.4 I None
- I None
21.0 I None
) I None
higher I None
in I None
mice I None
treated I None
with I None
DOX I Chemical
alone I None
than I None
that I None
in I None
animals I None
of I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
The I None
ratio I None
of I None
aberrant I None
cardiomyocytes I None
in I None
mice I None
treated I None
with I None
DOX I Chemical
preceded I None
by I None
monoHER I Chemical
and I None
those I None
in I None
mice I None
treated I None
with I None
saline I None
ranged I None
from I None
1.6 I None
to I None
2.8 I None
( I None
mean I None
2.2 I None
, I None
95 I None
% I None
CI I None
1.2 I None
- I None
4.1 I None
, I None
P=0.019 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
protective I None
effect I None
by I None
adding I None
monoHER I Chemical
before I None
DOX I Chemical
led I None
to I None
a I None
significant I None
4.4-fold I None
reduction I None
( I None
P<0.001 I None
, I None
95 I None
% I None
CI I None
2.3 I None
- I None
8.2 I None
) I None
of I None
abnormal I None
cardiomyocytes I None
. I None
<eof> I None

<s> O None
This I None
protective I None
effect I None
did I None
not I None
depend I None
on I None
the I None
time I None
interval I None
between I None
monoHER I Chemical
and I None
DOX I Chemical
administration I None
( I None
P=0.345 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
in I None
an I None
outpatient I None
clinical I None
setting I None
monoHER I Chemical
may I None
be I None
administered I None
shortly I None
before I None
DOX I Chemical
. I None
<eof> I None

<s> O None
Clinical I None
evaluation I None
of I None
adverse I None
effects I None
during I None
bepridil I Chemical
administration I None
for I None
atrial I None
fibrillation I None
and I None
flutter I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Bepridil I Chemical
hydrochloride O Chemical
<eof> I None

<s> O None
( I None
Bpd I Chemical
) I None
has I None
attracted I None
attention I None
as I None
an I None
effective I None
drug I None
for I None
atrial I Disease
fibrillation O Disease
<eof> I None

<s> O None
( I None
AF I Disease
) I None
and I None
atrial I Disease
flutter O Disease
<eof> I None

<s> O None
( I None
AFL I Disease
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
serious I None
adverse I None
effects I None
, I None
including I None
torsade I Disease
de O Disease
pointes O Disease
<eof> I None

<s> O None
( I None
Tdp I Disease
) I None
, I None
have I None
been I None
reported I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
Adverse I None
effects I None
of I None
Bpd I Chemical
requiring I None
discontinuation I None
of I None
treatment I None
were I None
evaluated I None
. I None
<eof> I None

<s> O None
Bpd I Chemical
was I None
administered I None
to I None
459 I None
patients I None
( I None
361 I None
males I None
, I None
63+/-12 I None
years I None
old I None
) I None
comprising I None
378 I None
AF I Disease
and I None
81 I None
AFL I Disease
cases I None
. I None
<eof> I None

<s> O None
Mean I None
left I None
ventricular I None
ejection I None
fraction I None
and I None
atrial I None
dimension I None
( I None
LAD I None
) I None
were I None
66+/-11 I None
% I None
and I None
40+/-6 I None
mm I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Adverse I None
effects I None
were I None
observed I None
in I None
19 I None
patients I None
( I None
4 I None
% I None
) I None
during I None
an I None
average I None
follow I None
- I None
up I None
of I None
20 I None
months I None
. I None
<eof> I None

<s> O None
There I None
was I None
marked I None
<eof> I None

<s> O None
QT I Disease
prolongation O Disease
greater I None
than I None
0.55 I None
s I None
in I None
13 I None
patients I None
, I None
bradycardia I Disease
less I None
than I None
40 I None
beats I None
/ I None
min I None
in I None
6 I None
patients I None
, I None
dizziness I Disease
and I None
general I None
fatigue I Disease
in I None
1 I None
patient I None
each I None
. I None
<eof> I None

<s> O None
In I None
4 I None
of I None
13 I None
patients I None
with I None
QT I Disease
prolongation O Disease
, I None
Tdp I Disease
occurred I None
. I None
<eof> I None

<s> O None
The I None
major I None
triggering I None
factors I None
of I None
Tdp I Disease
were I None
hypokalemia I Disease
and I None
sudden I None
decrease I None
in I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
differences I None
in I None
the I None
clinical I None
backgrounds I None
of I None
the I None
patients I None
with I None
and I None
without I None
Tdp I Disease
other I None
than I None
LAD I None
and I None
age I None
, I None
which I None
were I None
larger I None
and I None
older I None
in I None
the I None
patients I None
with I None
Tdp I Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Careful I None
observation I None
of I None
serum I None
<eof> I None

<s> O None
potassium I Chemical
concentration I None
and I None
the I None
ECG I None
should I None
always I None
be I None
done I None
during I None
Bpd I Chemical
administration I None
, I None
particularly I None
in I None
elderly I None
patients I None
. I None
<eof> I None

<s> O None
Enhanced I None
<eof> I None

<s> O None
isoproterenol I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
hypertrophy O Disease
in I None
transgenic I None
rats I None
with I None
low I None
brain I None
angiotensinogen I None
. I None
<eof> I None

<s> O None
We I None
have I None
previously I None
shown I None
that I None
a I None
permanent I None
deficiency I None
in I None
the I None
brain I None
renin- I None
angiotensin I Chemical
system I None
( I None
RAS I None
) I None
may I None
increase I None
the I None
sensitivity I None
of I None
the I None
baroreflex I None
control I None
of I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
we I None
aimed I None
at I None
studying I None
the I None
involvement I None
of I None
the I None
brain I None
RAS I None
in I None
the I None
cardiac I None
reactivity I None
to I None
the I None
beta I None
- I None
adrenoceptor I None
( I None
beta I None
- I None
AR I None
) I None
agonist I None
isoproterenol I Chemical
<eof> I None

<s> O None
( I None
Iso I Chemical
) I None
. I None
<eof> I None

<s> O None
Transgenic I None
rats I None
with I None
low I None
brain I None
angiotensinogen I None
( I None
TGR I None
) I None
were I None
used I None
. I None
<eof> I None

<s> O None
In I None
isolated I None
hearts I None
, I None
Iso I Chemical
induced I None
a I None
significantly I None
greater I None
increase I None
in I None
left I None
ventricular I None
( I None
LV I None
) I None
pressure I None
and I None
maximal I None
contraction I None
( I None
+ I None
dP I None
/ I None
dt(max I None
) I None
) I None
in I None
the I None
TGR I None
than I None
in I None
the I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
rats I None
. I None
<eof> I None

<s> O None
LV I Disease
hypertrophy O Disease
induced I None
by I None
Iso I Chemical
treatment I None
was I None
significantly I None
higher I None
in I None
TGR I None
than I None
in I None
SD I None
rats I None
( I None
in I None
g I None
LV I None
wt/100 I None
g I None
body I None
wt I None
, I None
0.28 I None
+ I None
/- I None
<eof> I None

<s> O None
0.004 I None
vs. I None
0.24 I None
+ I None
/- I None
<eof> I None

<s> O None
0.004 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
greater I None
LV I Disease
hypertrophy O Disease
in I None
TGR I None
rats I None
was I None
associated I None
with I None
more I None
pronounced I None
downregulation I None
of I None
beta I None
- I None
AR I None
and I None
upregulation I None
of I None
LV I None
beta I None
- I None
AR I None
kinase-1 I None
<eof> I None

<s> O None
mRNA I None
levels I None
compared I None
with I None
those I None
in I None
SD I None
rats I None
. I None
<eof> I None

<s> O None
The I None
decrease I None
in I None
the I None
heart I None
rate I None
( I None
HR I None
) I None
induced I None
by I None
the I None
beta I None
- I None
AR I None
antagonist I None
metoprolol I Chemical
in I None
conscious I None
rats I None
was I None
significantly I None
attenuated I None
in I None
TGR I None
compared I None
with I None
SD I None
rats I None
( I None
-9.9 I None
+ I None
/- I None
<eof> I None

<s> O None
1.7 I None
% I None
vs. I None
-18.1 I None
<eof> I None

<s> O None
+ I None
/- I None
1.5 I None
% I None
) I None
, I None
whereas I None
the I None
effect I None
of I None
parasympathetic I None
blockade I None
by I None
atropine I Chemical
on I None
HR I None
was I None
similar I None
in I None
both I None
strains I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
TGR I None
are I None
more I None
sensitive I None
to I None
beta I None
- I None
AR I None
agonist I None
- I None
induced I None
cardiac I Disease
inotropic O Disease
response I None
and I None
hypertrophy I Disease
, I None
possibly I None
due I None
to I None
chronically I None
low I None
sympathetic I None
outflow I None
directed I None
to I None
the I None
heart I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
induced I None
long I Disease
QT O Disease
syndrome O Disease
in I None
injection I None
drug I None
users I None
receiving I None
methadone I Chemical
: I None
high I None
frequency I None
in I None
hospitalized I None
patients I None
and I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Drug I None
- I None
induced I None
<eof> I None

<s> O None
long I Disease
QT O Disease
syndrome O Disease
is I None
a I None
serious I None
adverse I None
drug I None
reaction I None
. I None
<eof> I None

<s> O None
Methadone I Chemical
prolongs I None
the I None
QT I None
interval I None
in I None
vitro I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
In I None
the I None
inpatient I None
setting I None
, I None
the I None
frequency I None
of I None
QT I Disease
interval O Disease
prolongation O Disease
with I None
methadone I Chemical
treatment I None
, I None
its I None
dose I None
dependence I None
, I None
and I None
the I None
importance I None
of I None
cofactors I None
such I None
as I None
drug I None
- I None
drug I None
interactions I None
remain I None
unknown I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
performed I None
a I None
systematic I None
, I None
retrospective I None
study I None
comparing I None
active I None
or I None
former I None
intravenous I None
drug I None
users I None
receiving I None
methadone I Chemical
and I None
those I None
not I None
receiving I None
methadone I Chemical
among I None
all I None
patients I None
hospitalized I None
over I None
a I None
5-year I None
period I None
in I None
a I None
tertiary I None
care I None
hospital I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
167 I None
patients I None
receiving I None
methadone I Chemical
fulfilled I None
the I None
inclusion I None
criteria I None
and I None
were I None
compared I None
with I None
a I None
control I None
group I None
of I None
80 I None
injection I None
drug I None
users I None
not I None
receiving I None
methadone I Chemical
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
methadone I Chemical
dose I None
, I None
15 I None
demographic I None
, I None
biological I None
, I None
and I None
pharmacological I None
variables I None
were I None
considered I None
as I None
potential I None
risk I None
factors I None
for I None
QT I Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Among I None
167 I None
methadone I Chemical
maintenance I None
patients I None
, I None
the I None
prevalence I None
of I None
QTc I None
prolongation I None
to I None
0.50 I None
second((1/2 I None
) I None
) I None
or I None
longer I None
was I None
16.2 I None
% I None
compared I None
with I None
0 I None
% I None
in I None
80 I None
control I None
subjects I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
( I None
3.6 I None
% I None
) I None
in I None
the I None
methadone I Chemical
group I None
presented I None
torsades I Disease
de O Disease
pointes O Disease
. I None
<eof> I None

<s> O None
QTc I None
length I None
was I None
weakly I None
but I None
significantly I None
associated I None
with I None
methadone I Chemical
<eof> I None

<s> O None
daily I None
dose I None
( I None
Spearman I None
rank I None
correlation I None
coefficient I None
, I None
0.20 I None
; I None
<eof> I None

<s> O None
P<.01 I None
) I None
. I None
<eof> I None

<s> O None
Multivariate I None
regression I None
analysis I None
allowed I None
attribution I None
of I None
31.8 I None
% I None
of I None
QTc I None
variability I None
to I None
methadone I Chemical
dose I None
, I None
cytochrome I None
P-450 I None
3A4 I None
drug I None
- I None
drug I None
interactions I None
, I None
hypokalemia I Disease
, I None
and I None
altered I None
liver I None
function I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
QT I Disease
interval O Disease
prolongation O Disease
in I None
methadone I Chemical
maintenance I None
patients I None
hospitalized I None
in I None
a I None
tertiary I None
care I None
center I None
is I None
a I None
frequent I None
finding I None
. I None
<eof> I None

<s> O None
Methadone I Chemical
dose I None
, I None
presence I None
of I None
cytochrome I None
P-450 I None
3A4 I None
inhibitors I None
, I None
potassium I Chemical
level I None
, I None
and I None
liver I None
function I None
contribute I None
to I None
QT I Disease
prolongation O Disease
. I None
<eof> I None

<s> O None
Long I Disease
QT O Disease
syndrome O Disease
can I None
occur I None
with I None
low I None
doses I None
of I None
methadone I Chemical
. I None
<eof> I None

<s> O None
Mechanisms I None
of I None
hypertension I Disease
induced I None
by I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
deficiency I None
: I None
focus I None
on I None
venous I None
function I None
. I None
<eof> I None

<s> O None
Loss I None
of I None
endothelial I None
cell I None
- I None
derived I None
nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
in I None
hypertension I Disease
is I None
a I None
hallmark I None
of I None
arterial I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Experimental I None
hypertension I Disease
created I None
by I None
the I None
removal I None
of I None
NO I Chemical
, I None
however I None
, I None
involves I None
mechanisms I None
in I None
addition I None
to I None
decreased I None
arterial I None
vasodilator I None
activity I None
. I None
<eof> I None

<s> O None
These I None
include I None
augmented I None
endothelin-1 I None
( I None
ET-1 I None
) I None
release I None
, I None
increased I None
sympathetic I None
nervous I None
system I None
activity I None
, I None
and I None
elevated I None
tissue I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
We I None
hypothesized I None
that I None
increased I None
venous I None
smooth I None
muscle I None
( I None
venomotor I None
) I None
tone I None
plays I None
a I None
role I None
in I None
Nomega I Chemical
- O Chemical
nitro O Chemical
- O Chemical
L O Chemical
- O Chemical
arginine O Chemical
<eof> I None

<s> O None
( I None
LNNA I Chemical
) I None
<eof> I None

<s> O None
hypertension I Disease
through I None
these I None
mechanisms I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
treated I None
with I None
the I None
NO I Chemical
synthase I None
inhibitor I None
LNNA I Chemical
<eof> I None

<s> O None
( I None
0.5 I None
g I None
/ I None
L I None
in I None
drinking I None
water I None
) I None
for I None
2 I None
weeks I None
. I None
<eof> I None

<s> O None
Mean I None
arterial I None
pressure I None
of I None
conscious I None
rats I None
was I None
119 I None
+ I None
/- I None
<eof> I None

<s> O None
2 I None
mm I None
Hg I None
in I None
control I None
and I None
194 I None
+ I None
/- I None
5 I None
mm I None
Hg I None
in I None
LNNA I Chemical
rats I None
( I None
P<0.05 I None
) I None
. I None
<eof> I None

<s> O None
Carotid I None
arteries I None
and I None
vena I None
cava I None
were I None
removed I None
for I None
measurement I None
of I None
isometric I None
contraction I None
. I None
<eof> I None

<s> O None
Maximal I None
contraction I None
to I None
norepinephrine I Chemical
was I None
modestly I None
reduced I None
in I None
arteries I None
from I None
LNNA I Chemical
compared I None
with I None
control I None
rats I None
whereas I None
the I None
maximum I None
contraction I None
to I None
ET-1 I None
was I None
significantly I None
reduced I None
( I None
54 I None
% I None
control I None
) I None
. I None
<eof> I None

<s> O None
Maximum I None
contraction I None
of I None
vena I None
cava I None
to I None
norepinephrine I Chemical
<eof> I None

<s> O None
( I None
37 I None
% I None
control I None
) I None
also I None
was I None
reduced I None
but I None
no I None
change I None
in I None
response I None
to I None
ET-1 I None
was I None
observed I None
. I None
<eof> I None

<s> O None
Mean I None
circulatory I None
filling I None
pressure I None
, I None
an I None
in I None
vivo I None
measure I None
of I None
venomotor I None
tone I None
, I None
was I None
not I None
elevated I None
in I None
LNNA I Chemical
hypertension I Disease
at I None
1 I None
or I None
2 I None
weeks I None
after I None
LNNA I Chemical
. I None
<eof> I None

<s> O None
The I None
superoxide I Chemical
scavenger I None
tempol I Chemical
<eof> I None

<s> O None
( I None
30 I None
, I None
100 I None
, I None
and I None
300 I None
micromol I None
kg(-1 I None
) I None
, I None
IV I None
) I None
did I None
not I None
change I None
arterial I None
pressure I None
in I None
control I None
rats I None
but I None
caused I None
a I None
dose I None
- I None
dependent I None
decrease I None
in I None
LNNA I Chemical
rats I None
( I None
-18 I None
+ I None
/- I None
8 I None
, I None
-26 I None
+ I None
/- I None
15 I None
, I None
and I None
-54 I None
+ I None
/- I None
11 I None
mm I None
Hg I None
) I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
ganglionic I None
blockade I None
with I None
hexamethonium I Chemical
caused I None
a I None
significantly I None
greater I None
fall I None
in I None
LNNA I Chemical
hypertensive I Disease
rats I None
( I None
76 I None
+ I None
/- I None
<eof> I None

<s> O None
9 I None
mm I None
Hg I None
) I None
compared I None
with I None
control I None
rats I None
( I None
35 I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
mm I None
Hg I None
) I None
. I None
<eof> I None

<s> O None
Carotid I None
arteries I None
, I None
vena I None
cava I None
, I None
and I None
sympathetic I None
ganglia I None
from I None
LNNA I Chemical
rats I None
had I None
higher I None
basal I None
levels I None
of I None
superoxide I Chemical
compared I None
with I None
those I None
from I None
control I None
rats I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
while I None
NO I Chemical
deficiency I None
increases I None
oxidative I None
stress I None
and I None
sympathetic I None
activity I None
in I None
both I None
arterial I None
and I None
venous I None
vessels I None
, I None
the I None
impact I None
on I None
veins I None
does I None
not I None
make I None
a I None
major I None
contribution I None
to I None
this I None
form I None
of I None
hypertension I Disease
. I None
<eof> I None

<s> O None
Association I None
of I None
DRD2 I None
polymorphisms I None
and I None
chlorpromazine I Chemical
-induced I None
extrapyramidal I Disease
syndrome O Disease
in I None
Chinese I None
schizophrenic I Disease
patients I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
Extrapyramidal I Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
EPS I Disease
) I None
is I None
most I None
commonly I None
affected I None
by I None
typical I None
antipsychotic I None
drugs I None
that I None
have I None
a I None
high I None
affinity I None
with I None
the I None
D2 I None
receptor I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
many I None
research I None
groups I None
have I None
reported I None
on I None
the I None
positive I None
relationship I None
between I None
the I None
genetic I None
variations I None
in I None
the I None
DRD2 I None
gene I None
and I None
the I None
therapeutic I None
response I None
in I None
schizophrenia I Disease
patients I None
as I None
a I None
result I None
of I None
the I None
role I None
of I None
variations I None
in I None
the I None
receptor I None
in I None
modulating I None
receptor I None
expression I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
evaluate I None
the I None
role I None
DRD2 I None
plays I None
in I None
chlorpromazine I Chemical
-induced I None
<eof> I None

<s> O None
EPS I Disease
in I None
schizophrenic I Disease
patients I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
identified I None
seven I None
SNP(single I None
nucleotide I None
polymorphism I None
) I None
<eof> I None

<s> O None
( I None
-141Cins I None
<eof> I None

<s> O None
> I None
del I None
, I None
TaqIB I None
, I None
TaqID I None
, I None
Ser311Cys I None
, I None
rs6275 I None
, I None
rs6277 I None
and I None
TaqIA I None
) I None
in I None
the I None
DRD2 I None
gene I None
in I None
146 I None
schizophrenic I Disease
inpatients I None
( I None
59 I None
with I None
EPS I Disease
and I None
87 I None
without I None
EPS I Disease
according I None
to I None
the I None
Simpson I None
- I None
Angus I None
Scale I None
) I None
treated I None
with I None
chlorpromazine I Chemical
after I None
8 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
alleles I None
of I None
all I None
loci I None
were I None
determined I None
by I None
PCR I None
( I None
polymerase I None
chain I None
reaction I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Polymorphisms I None
TaqID I None
, I None
Ser311Cys I None
and I None
rs6277 I None
were I None
not I None
polymorphic I None
in I None
the I None
population I None
recruited I None
in I None
the I None
present I None
study I None
. I None
<eof> I None

<s> O None
No I None
statistical I None
significance I None
was I None
found I None
in I None
the I None
allele I None
distribution I None
of I None
-141Cins I None
> I None
del I None
, I None
TaqIB I None
, I None
rs6275 I None
and I None
TaqIA I None
or I None
in I None
the I None
estimated I None
haplotypes I None
( I None
constituted I None
by I None
TaqIB I None
, I None
rs6275 I None
and I None
TaqIA I None
) I None
in I None
linkage I None
disequilibrium I None
between I None
the I None
two I None
groups I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Our I None
results I None
did I None
not I None
lend I None
strong I None
support I None
to I None
the I None
view I None
that I None
the I None
genetic I None
variation I None
of I None
the I None
DRD2 I None
gene I None
plays I None
a I None
major I None
role I None
in I None
the I None
individually I None
variable I None
adverse I None
effect I None
induced I None
by I None
chlorpromazine I Chemical
, I None
at I None
least I None
in I None
Chinese I None
patients I None
with I None
schizophrenia I Disease
. I None
<eof> I None

<s> O None
Our I None
results I None
confirmed I None
a I None
previous I None
study I None
on I None
the I None
relationship I None
between I None
DRD2 I None
and I None
EPS I Disease
in I None
Caucasians I None
. I None
<eof> I None

<s> O None
Physical I None
training I None
decreases I None
susceptibility I None
to I None
subsequent I None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Regular I None
motor I None
activity I None
has I None
many I None
benefits I None
for I None
mental I None
and I None
physical I None
condition I None
but I None
its I None
implications I None
for I None
epilepsy I Disease
are I None
still I None
controversial I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
elucidate I None
this I None
problem I None
, I None
we I None
have I None
studied I None
the I None
effect I None
of I None
long I None
- I None
term I None
physical I None
activity I None
on I None
susceptibility I None
to I None
subsequent I None
seizures I Disease
. I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
subjected I None
to I None
repeated I None
training I None
sessions I None
in I None
a I None
treadmill I None
and I None
swimming I None
pool I None
. I None
<eof> I None

<s> O None
Thereafter I None
, I None
seizures I Disease
were I None
induced I None
by I None
pilocarpine I Chemical
injections I None
in I None
trained I None
and I None
non I None
- I None
trained I None
control I None
groups I None
. I None
<eof> I None

<s> O None
During I None
the I None
acute I None
period I None
of I None
status I Disease
epilepticus O Disease
, I None
we I None
measured I None
: I None
( I None
1 I None
) I None
the I None
latency I None
of I None
the I None
first I None
motor I None
sign I None
, I None
( I None
2 I None
) I None
the I None
intensity I None
of I None
seizures I Disease
, I None
( I None
3 I None
) I None
the I None
time I None
when I None
it I None
occurred I None
within I None
the I None
6-h I None
observation I None
period I None
, I None
and I None
( I None
4 I None
) I None
the I None
time I None
when I None
the I None
acute I None
period I None
ended I None
. I None
<eof> I None

<s> O None
All I None
these I None
behavioral I None
parameters I None
showed I None
statistically I None
significant I None
changes I None
suggesting I None
that I None
regular I None
physical I None
exercises I None
decrease I None
susceptibility I None
to I None
subsequently I None
induced I None
seizures I Disease
and I None
ameliorate I None
the I None
course I None
of I None
experimentally I None
induced I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
Tonic I None
dopaminergic I None
stimulation I None
<eof> I None

<s> O None
impairs I Disease
associative O Disease
learning O Disease
in I None
healthy I None
subjects I None
. I None
<eof> I None

<s> O None
Endogenous I None
dopamine I Chemical
plays I None
a I None
central I None
role I None
in I None
salience I None
coding I None
during I None
associative I None
learning I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
the I None
dopamine I Chemical
precursor I None
levodopa I Chemical
enhances I None
learning I None
in I None
healthy I None
subjects I None
and I None
stroke I Disease
patients I None
. I None
<eof> I None

<s> O None
Because I None
levodopa I Chemical
increases I None
both I None
phasic I None
and I None
tonic I None
dopaminergic I None
neurotransmission I None
, I None
the I None
critical I None
mechanism I None
mediating I None
the I None
enhancement I None
of I None
learning I None
is I None
unresolved I None
. I None
<eof> I None

<s> O None
We I None
here I None
probed I None
how I None
selective I None
tonic I None
dopaminergic I None
stimulation I None
affects I None
associative I None
learning I None
. I None
<eof> I None

<s> O None
Forty I None
healthy I None
subjects I None
were I None
trained I None
in I None
a I None
novel I None
vocabulary I None
of I None
45 I None
concrete I None
nouns I None
over I None
the I None
course I None
of I None
5 I None
consecutive I None
training I None
days I None
in I None
a I None
prospective I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
design I None
. I None
<eof> I None

<s> O None
Subjects I None
received I None
the I None
tonically I None
stimulating I None
dopamine I Chemical
-receptor I None
agonist I None
<eof> I None

<s> O None
pergolide I Chemical
( I None
0.1 I None
mg I None
) I None
vs I None
placebo I None
120 I None
min I None
before I None
training I None
on I None
each I None
training I None
day I None
. I None
<eof> I None

<s> O None
The I None
dopamine I Chemical
agonist I None
significantly I None
impaired I Disease
novel O Disease
word O Disease
learning O Disease
compared I None
to I None
placebo I None
. I None
<eof> I None

<s> O None
This I None
learning I None
decrement I None
persisted I None
up I None
to I None
the I None
last I None
follow I None
- I None
up I None
4 I None
weeks I None
post I None
- I None
training I None
. I None
<eof> I None

<s> O None
Subjects I None
treated I None
with I None
pergolide I Chemical
also I None
showed I None
restricted I None
emotional I None
responses I None
compared I None
to I None
the I None
PLACEBO I None
group I None
. I None
<eof> I None

<s> O None
The I None
extent I None
of I None
' I None
flattened I None
' I None
affect I None
with I None
pergolide I Chemical
was I None
related I None
to I None
the I None
degree I None
of I None
learning I None
inhibition I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
tonic I None
occupation I None
of I None
dopamine I Chemical
receptors I None
impairs I None
learning I None
by I None
competition I None
with I None
phasic I None
dopamine I Chemical
signals I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
phasic I None
signaling I None
seems I None
to I None
be I None
the I None
critical I None
mechanism I None
by I None
which I None
dopamine I Chemical
enhances I None
associative I None
learning I None
in I None
healthy I None
subjects I None
and I None
stroke I Disease
patients I None
. I None
<eof> I None

<s> O None
Minocycline I Chemical
-induced I None
vasculitis I Disease
fulfilling I None
the I None
criteria I None
of I None
polyarteritis I Disease
nodosa O Disease
. I None
<eof> I None

<s> O None
A I None
47-year I None
- I None
old I None
man I None
who I None
had I None
been I None
taking I None
minocycline I Chemical
for I None
palmoplantar I Disease
pustulosis O Disease
developed I None
<eof> I None

<s> O None
fever I Disease
, I None
myalgias I Disease
, I None
polyneuropathy I Disease
, I None
and I None
testicular I Disease
pain O Disease
, I None
with I None
elevated I None
C I None
- I None
reactive I None
protein I None
( I None
CRP I None
) I None
. I None
<eof> I None

<s> O None
Neither I None
myeloperoxidase- I None
nor I None
proteinase-3-antineutrophil I None
cytoplasmic I None
antibody I None
was I None
positive I None
. I None
<eof> I None

<s> O None
These I None
manifestations I None
met I None
the I None
American I None
College I None
of I None
Rheumatology I None
1990 I None
criteria I None
for I None
the I None
classification I None
of I None
polyarteritis I Disease
nodosa O Disease
. I None
<eof> I None

<s> O None
Stopping I None
minocycline I Chemical
led I None
to I None
amelioration I None
of I None
symptoms I None
and I None
normalization I None
of I None
CRP I None
level I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
is I None
the I None
second I None
case I None
of I None
minocycline I Chemical
-induced I None
vasculitis I Disease
satisfying I None
the I None
criteria I None
. I None
<eof> I None

<s> O None
Differential I None
diagnosis I None
for I None
drug I None
- I None
induced I None
disease I None
is I None
invaluable I None
even I None
for I None
patients I None
with I None
classical I None
polyarteritis I Disease
nodosa O Disease
. I None
<eof> I None

<s> O None
Intramuscular I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
combined I None
with I None
lamivudine I Chemical
in I None
prevention I None
of I None
hepatitis I Disease
B O Disease
recurrence I None
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Combined I None
hepatitis I Disease
B O Disease
immune I None
globulin I None
( I None
HBIg I None
) I None
and I None
<eof> I None

<s> O None
lamivudine I Chemical
in I None
prophylaxis I None
of I None
the I None
recurrence I None
of I None
hepatitis I Disease
B O Disease
<eof> I None

<s> O None
after I None
liver I None
transplantation I None
has I None
significantly I None
improved I None
the I None
survival I None
of I None
HBsAg I Chemical
positive I None
patients I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
undertaken I None
to I None
evaluate I None
the I None
outcomes I None
of I None
liver I None
transplantation I None
for I None
patients I None
with I None
hepatitis I Disease
B O Disease
virus I None
( I None
HBV I None
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
retrospective I None
chart I None
analysis I None
and I None
a I None
review I None
of I None
the I None
organ I None
transplant I None
database I None
identified I None
51 I None
patients I None
( I None
43 I None
men I None
and I None
8 I None
women I None
) I None
transplanted I None
for I None
benign I None
HBV I None
- I None
related I None
cirrhotic I Disease
diseases O Disease
between I None
June I None
2002 I None
and I None
December I None
2004 I None
who I None
had I None
survived I None
more I None
than I None
3 I None
months I None
. I None
<eof> I None

<s> O None
HBIg I None
was I None
administered I None
intravenously I None
during I None
the I None
first I None
week I None
and I None
intramuscularly I None
thereafter I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
At I None
a I None
median I None
follow I None
- I None
up I None
of I None
14.1 I None
months I None
, I None
the I None
overall I None
recurrence I None
rate I None
in I None
the I None
51 I None
patients I None
was I None
3.9 I None
% I None
( I None
2/51 I None
) I None
. I None
<eof> I None

<s> O None
The I None
overall I None
patient I None
survival I None
was I None
88.3 I None
% I None
, I None
and I None
82.4 I None
% I None
after I None
1 I None
and I None
2 I None
years I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
A I None
daily I None
oral I None
dose I None
of I None
100 I None
mg I None
lamivudine I Chemical
for I None
2 I None
weeks I None
before I None
transplantation I None
for I None
10 I None
patients I None
enabled I None
57.1 I None
% I None
( I None
4/7 I None
) I None
and I None
62.5 I None
% I None
( I None
5/8 I None
) I None
of I None
HBV I None
- I None
DNA I None
and I None
HBeAg I Chemical
positive I None
patients I None
respectively I None
to I None
convert I None
to I None
be I None
negative I None
. I None
<eof> I None

<s> O None
Intramuscular I None
HBIg I None
was I None
well I None
tolerated I None
in I None
all I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Lamivudine I Chemical
combined I None
with I None
intramuscular I None
HBIg I None
can I None
effectively I None
prevent I None
allograft I None
from I None
the I None
recurrence I None
of I None
HBV I None
after I None
liver I None
transplantation I None
. I None
<eof> I None

<s> O None
Anticonvulsant I None
effect I None
of I None
eslicarbazepine I Chemical
acetate O Chemical
<eof> I None

<s> O None
( I None
BIA I Chemical
2 O Chemical
- O Chemical
093 O Chemical
) I None
on I None
seizures I Disease
induced I None
by I None
microperfusion I None
of I None
picrotoxin I Chemical
in I None
the I None
hippocampus I None
of I None
freely I None
moving I None
rats I None
. I None
<eof> I None

<s> O None
Eslicarbazepine I Chemical
acetate O Chemical
( I None
BIA I Chemical
2 O Chemical
- O Chemical
093 O Chemical
, I None
S-(-)-10-acetoxy-10,11-dihydro-5H I Chemical
- O Chemical
dibenzo O Chemical
/ O Chemical
b O Chemical
, O Chemical
f O Chemical
/ O Chemical
azepine-5-carboxamide O Chemical
) I None
is I None
a I None
novel I None
antiepileptic I None
drug I None
, I None
now I None
in I None
Phase I None
III I None
clinical I None
trials I None
, I None
designed I None
with I None
the I None
aim I None
of I None
improving I None
efficacy I None
and I None
safety I None
in I None
comparison I None
with I None
the I None
structurally I None
related I None
drugs I None
carbamazepine I Chemical
<eof> I None

<s> O None
( I None
CBZ I Chemical
) I None
and I None
oxcarbazepine I Chemical
<eof> I None

<s> O None
( I None
OXC I Chemical
) I None
. I None
<eof> I None

<s> O None
We I None
have I None
studied I None
the I None
effects I None
of I None
oral I None
treatment I None
with I None
eslicarbazepine I Chemical
acetate O Chemical
on I None
a I None
whole I None
- I None
animal I None
model I None
in I None
which I None
partial I None
seizures I Disease
can I None
be I None
elicited I None
repeatedly I None
on I None
different I None
days I None
without I None
changes I None
in I None
threshold I None
or I None
seizure I Disease
patterns I None
. I None
<eof> I None

<s> O None
In I None
the I None
animals I None
treated I None
with I None
threshold I None
doses I None
of I None
picrotoxin I Chemical
, I None
the I None
average I None
number I None
of I None
seizures I Disease
was I None
2.3+/-1.2 I None
, I None
and I None
average I None
seizure I Disease
duration I None
was I None
39.5+/-8.4s I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
treatment I None
with I None
a I None
dose I None
of I None
30 I None
mg I None
/ I None
kg I None
2h I None
before I None
picrotoxin I Chemical
microperfusion I None
prevented I None
<eof> I None

<s> O None
seizures I Disease
in I None
the I None
75 I None
% I None
of I None
the I None
rats I None
. I None
<eof> I None

<s> O None
Lower I None
doses I None
( I None
3 I None
and I None
10mg I None
/ I None
kg I None
) I None
did I None
not I None
suppress I None
seizures I Disease
, I None
however I None
, I None
after I None
administration I None
of I None
10mg I None
/ I None
kg I None
, I None
significant I None
reductions I None
in I None
seizures I Disease
duration I None
( I None
24.3+/-6.8s I None
) I None
and I None
seizure I Disease
number I None
( I None
1.6+/-0.34 I None
) I None
were I None
found I None
. I None
<eof> I None

<s> O None
No I None
adverse I None
effects I None
of I None
eslicarbazepine I Chemical
acetate O Chemical
were I None
observed I None
in I None
the I None
behavioral I None
/ I None
EEG I None
patterns I None
studied I None
, I None
including I None
sleep I None
/ I None
wakefulness I None
cycle I None
, I None
at I None
the I None
doses I None
studied I None
. I None
<eof> I None

<s> O None
Acute I Disease
renal O Disease
failure O Disease
associated I None
with I None
prolonged I None
intake I None
of I None
slimming I None
pills I None
containing I None
anthraquinones I Chemical
. I None
<eof> I None

<s> O None
Chinese I Chemical
herbal O Chemical
medicine I None
preparations I None
are I None
widely I None
available I None
and I None
often I None
regarded I None
by I None
the I None
public I None
as I None
natural I None
and I None
safe I None
remedies I None
for I None
a I None
variety I None
of I None
medical I None
conditions I None
. I None
<eof> I None

<s> O None
Nephropathy I Disease
caused I None
by I None
Chinese I Chemical
herbs O Chemical
has I None
previously I None
been I None
reported I None
, I None
usually I None
involving I None
the I None
use I None
of I None
aristolochic I Chemical
acids O Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
23-year I None
- I None
old I None
woman I None
who I None
developed I None
acute I Disease
renal O Disease
failure O Disease
following I None
prolonged I None
use I None
of I None
a I None
proprietary I None
Chinese I Chemical
herbal O Chemical
slimming I None
pill I None
that I None
contained I None
anthraquinone I Chemical
derivatives I None
, I None
extracted I None
from I None
Rhizoma I None
Rhei I None
( I None
rhubarb I None
) I None
. I None
<eof> I None

<s> O None
The I None
renal I Disease
injury O Disease
was I None
probably I None
aggravated I None
by I None
the I None
concomitant I None
intake I None
of I None
a I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drug I None
, I None
diclofenac I Chemical
. I None
<eof> I None

<s> O None
Renal I None
pathology I None
was I None
that I None
of I None
hypocellular I None
interstitial I None
fibrosis I Disease
. I None
<eof> I None

<s> O None
Spontaneous I None
renal I None
recovery I None
occurred I None
upon I None
cessation I None
of I None
the I None
slimming I None
pills I None
, I None
but I None
mild I None
interstitial I None
fibrosis I Disease
and I None
tubular I None
atrophy I Disease
was I None
still I None
evident I None
histologically I None
4 I None
months I None
later I None
. I None
<eof> I None

<s> O None
Although I None
a I None
causal I None
relationship I None
between I None
the I None
use I None
of I None
an I None
anthraquinone I Chemical
-containing I None
herbal I None
agent I None
and I None
renal I Disease
injury O Disease
remains I None
to I None
be I None
proven I None
, I None
phytotherapy I None
- I None
associated I None
interstitial I None
nephropathy I Disease
should I None
be I None
considered I None
in I None
patients I None
who I None
present I None
with I None
unexplained I None
renal I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Chloroacetaldehyde I Chemical
as I None
a I None
sulfhydryl I Chemical
reagent I None
: I None
the I None
role I None
of I None
critical I None
thiol I Chemical
groups I None
in I None
ifosfamide I Chemical
nephropathy I Disease
. I None
<eof> I None

<s> O None
Chloroacetaldehyde I Chemical
<eof> I None

<s> O None
( I None
CAA I Chemical
) I None
is I None
a I None
metabolite I None
of I None
the I None
alkylating I None
agent I None
ifosfamide I Chemical
<eof> I None

<s> O None
( I None
IFO I Chemical
) I None
and I None
putatively I None
responsible I None
for I None
renal I Disease
damage O Disease
following I None
anti- I None
tumor I Disease
therapy I None
with I None
IFO I Chemical
. I None
<eof> I None

<s> O None
Depletion I None
of I None
sulfhydryl I Chemical
<eof> I None

<s> O None
( I None
SH I Chemical
) I None
groups I None
has I None
been I None
reported I None
from I None
cell I None
culture I None
, I None
animal I None
and I None
clinical I None
studies I None
. I None
<eof> I None

<s> O None
In I None
this I None
work I None
the I None
effect I None
of I None
CAA I Chemical
on I None
human I None
proximal I None
tubule I None
cells I None
in I None
primary I None
culture I None
( I None
hRPTEC I None
) I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Toxicity I Disease
of I None
CAA I Chemical
was I None
determined I None
by I None
protein I None
content I None
, I None
cell I None
number I None
, I None
LDH I None
release I None
, I None
trypan I Chemical
blue O Chemical
exclusion I None
assay I None
and I None
caspase-3 I None
activity I None
. I None
<eof> I None

<s> O None
Free I None
thiols I Chemical
were I None
measured I None
by I None
the I None
method I None
of I None
Ellman I None
. I None
<eof> I None

<s> O None
CAA I Chemical
reduced I None
hRPTEC I None
cell I None
number I None
and I None
protein I None
, I None
induced I None
a I None
loss I None
in I None
free I None
intracellular I None
thiols I Chemical
and I None
an I None
increase I None
in I None
necrosis I Disease
markers I None
. I None
<eof> I None

<s> O None
CAA I Chemical
but I None
not I None
acrolein I Chemical
inhibited I None
the I None
cysteine I Chemical
proteases I None
caspase-3 I None
, I None
caspase-8 I None
and I None
cathepsin I None
B. I None
Caspase I None
activation I None
by I None
cisplatin I Chemical
was I None
inhibited I None
by I None
CAA I Chemical
. I None
<eof> I None

<s> O None
In I None
cells I None
stained I None
with I None
fluorescent I None
dyes I None
targeting I None
lysosomes I None
, I None
CAA I Chemical
induced I None
an I None
increase I None
in I None
lysosomal I None
size I None
and I None
lysosomal I None
leakage I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
CAA I Chemical
on I None
cysteine I Chemical
protease I None
activities I None
and I None
thiols I Chemical
could I None
be I None
reproduced I None
in I None
cell I None
lysate I None
. I None
<eof> I None

<s> O None
Acidification I None
, I None
which I None
slowed I None
the I None
reaction I None
of I None
CAA I Chemical
with I None
thiol I Chemical
donors I None
, I None
could I None
also I None
attenuate I None
effects I None
of I None
CAA I Chemical
on I None
necrosis I Disease
markers I None
, I None
thiol I Chemical
depletion I None
and I None
cysteine I Chemical
protease I None
inhibition I None
in I None
living I None
cells I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
CAA I Chemical
directly I None
reacts I None
with I None
cellular I None
protein I None
and I None
non I None
- I None
protein I None
thiols I Chemical
, I None
mediating I None
its I None
toxicity I Disease
on I None
hRPTEC I None
. I None
<eof> I None

<s> O None
This I None
effect I None
can I None
be I None
reduced I None
by I None
acidification I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
urinary I None
acidification I None
could I None
be I None
an I None
option I None
to I None
prevent I None
IFO I Chemical
nephropathy I Disease
in I None
patients I None
. I None
<eof> I None

<s> O None
Stereological I None
methods I None
reveal I None
the I None
robust I None
size I None
and I None
stability I None
of I None
ectopic I None
hilar I None
granule I None
cells I None
after I None
<eof> I None

<s> O None
pilocarpine I Chemical
-induced I None
status I Disease
epilepticus O Disease
in I None
the I None
adult I None
rat I None
. I None
<eof> I None

<s> O None
Following I None
<eof> I None

<s> O None
status I Disease
epilepticus O Disease
in I None
the I None
rat I None
, I None
dentate I None
granule I None
cell I None
neurogenesis I None
increases I None
greatly I None
, I None
and I None
many I None
of I None
the I None
new I None
neurons I None
appear I None
to I None
develop I None
ectopically I None
, I None
in I None
the I None
hilar I None
region I None
of I None
the I None
hippocampal I None
formation I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
suggested I None
that I None
the I None
ectopic I None
hilar I None
granule I None
cells I None
could I None
contribute I None
to I None
the I None
spontaneous I None
seizures I Disease
that I None
ultimately I None
develop I None
after I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
population I None
has I None
never I None
been I None
quantified I None
, I None
so I None
it I None
is I None
unclear I None
whether I None
it I None
is I None
substantial I None
enough I None
to I None
have I None
a I None
strong I None
influence I None
on I None
epileptogenesis I None
. I None
<eof> I None

<s> O None
To I None
quantify I None
this I None
population I None
, I None
the I None
total I None
number I None
of I None
ectopic I None
hilar I None
granule I None
cells I None
was I None
estimated I None
using I None
unbiased I None
stereology I None
at I None
different I None
times I None
after I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
hilar I None
neurons I None
immunoreactive I None
for I None
Prox-1 I None
, I None
a I None
granule I None
- I None
cell I None
- I None
specific I None
marker I None
, I None
was I None
estimated I None
using I None
the I None
optical I None
fractionator I None
method I None
. I None
<eof> I None

<s> O None
The I None
results I None
indicate I None
that I None
the I None
size I None
of I None
the I None
hilar I None
ectopic I None
granule I None
cell I None
population I None
after I None
status I Disease
epilepticus O Disease
is I None
substantial I None
, I None
and I None
stable I None
over I None
time I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
the I None
size I None
of I None
the I None
population I None
appears I None
to I None
be I None
correlated I None
with I None
the I None
frequency I None
of I None
behavioral I None
seizures I Disease
, I None
because I None
animals I None
with I None
more I None
ectopic I None
granule I None
cells I None
in I None
the I None
hilus I None
have I None
more I None
frequent I None
behavioral I None
seizures I Disease
. I None
<eof> I None

<s> O None
The I None
hilar I None
ectopic I None
granule I None
cell I None
population I None
does I None
not I None
appear I None
to I None
vary I None
systematically I None
across I None
the I None
septotemporal I None
axis I None
, I None
although I None
it I None
is I None
associated I None
with I None
an I None
increase I None
in I None
volume I None
of I None
the I None
hilus I None
. I None
<eof> I None

<s> O None
The I None
results I None
provide I None
new I None
insight I None
into I None
the I None
potential I None
role I None
of I None
ectopic I None
hilar I None
granule I None
cells I None
in I None
the I None
pilocarpine I Chemical
model I None
of I None
temporal I Disease
lobe O Disease
epilepsy O Disease
. I None
<eof> I None

<s> O None
A I None
prospective I None
, I None
open I None
- I None
label I None
trial I None
of I None
galantamine I Chemical
in I None
autistic I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
Post I None
- I None
mortem I None
studies I None
have I None
reported I None
abnormalities I None
of I None
the I None
cholinergic I None
system I None
in I None
autism I Disease
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
assess I None
the I None
use I None
of I None
galantamine I Chemical
, I None
an I None
acetylcholinesterase I None
inhibitor I None
and I None
nicotinic I None
receptor I None
modulator I None
, I None
in I None
the I None
treatment I None
of I None
interfering I None
behaviors I None
in I None
children I None
with I None
autism I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Thirteen I None
medication I None
- I None
free I None
children I None
with I None
autism I Disease
<eof> I None

<s> O None
( I None
mean I None
age I None
, I None
8.8 I None
+ I None
/- I None
<eof> I None

<s> O None
3.5 I None
years I None
) I None
participated I None
in I None
a I None
12-week I None
, I None
open I None
- I None
label I None
trial I None
of I None
galantamine I Chemical
. I None
<eof> I None

<s> O None
Patients I None
were I None
rated I None
monthly I None
by I None
parents I None
on I None
the I None
Aberrant I None
Behavior I None
Checklist I None
( I None
ABC I None
) I None
and I None
the I None
Conners I None
' I None
Parent I None
Rating I None
Scale I None
- I None
Revised I None
, I None
and I None
by I None
a I None
physician I None
using I None
the I None
Children I None
's I None
Psychiatric I None
Rating I None
Scale I None
and I None
the I None
Clinical I None
Global I None
Impressions I None
scale I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Patients I None
showed I None
a I None
significant I None
reduction I None
in I None
parent I None
- I None
rated I None
irritability I Disease
and I None
social I None
withdrawal I None
on I None
the I None
ABC I None
as I None
well I None
as I None
significant I None
improvements I None
in I None
emotional I None
lability I None
and I None
inattention I None
on I None
the I None
Conners I None
' I None
Parent I None
Rating I None
Scale I None
-- I None
Revised I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
clinician I None
ratings I None
showed I None
reductions I None
in I None
the I None
anger I None
subscale I None
of I None
the I None
Children I None
's I None
Psychiatric I None
Rating I None
Scale I None
. I None
<eof> I None

<s> O None
Eight I None
of I None
13 I None
participants I None
were I None
rated I None
as I None
responders I None
on I None
the I None
basis I None
of I None
their I None
improvement I None
scores I None
on I None
the I None
Clinical I None
Global I None
Impressions I None
scale I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
galantamine I Chemical
was I None
well I None
- I None
tolerated I None
, I None
with I None
no I None
significant I None
adverse I None
effects I None
apart I None
from I None
headaches I Disease
in I None
one I None
patient I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
this I None
open I None
trial I None
, I None
galantamine I Chemical
was I None
well I None
- I None
tolerated I None
and I None
appeared I None
to I None
be I None
beneficial I None
for I None
the I None
treatment I None
of I None
interfering I None
behaviors I None
in I None
children I None
with I None
autism I Disease
, I None
particularly I None
aggression I Disease
, I None
behavioral I Disease
dyscontrol O Disease
, I None
and I None
inattention I Disease
. I None
<eof> I None

<s> O None
Further I None
controlled I None
trials I None
are I None
warranted I None
. I None
<eof> I None

<s> O None
Randomized I None
comparison I None
of I None
olanzapine I Chemical
versus I None
risperidone I Chemical
for I None
the I None
treatment I None
of I None
first I None
- I None
episode I None
schizophrenia I Disease
: I None
4-month I None
outcomes I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
The I None
authors I None
compared I None
4-month I None
treatment I None
outcomes I None
for I None
olanzapine I Chemical
versus I None
risperidone I Chemical
in I None
patients I None
with I None
first I None
- I None
episode I None
schizophrenia I Disease
spectrum I None
disorders I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
One I None
hundred I None
twelve I None
subjects I None
( I None
70 I None
% I None
male I None
; I None
mean I None
age=23.3 I None
years I None
[ I None
SD I None
= I None
5.1 I None
] I None
) I None
with I None
first I None
- I None
episode I None
schizophrenia I Disease
( I None
75 I None
% I None
) I None
, I None
schizophreniform I Disease
disorder O Disease
( I None
17 I None
% I None
) I None
, I None
or I None
schizoaffective I Disease
disorder O Disease
( I None
8 I None
% I None
) I None
were I None
randomly I None
assigned I None
to I None
treatment I None
with I None
olanzapine I Chemical
<eof> I None

<s> O None
( I None
2.5 I None
- I None
20 I None
mg I None
/ I None
day I None
) I None
or I None
risperidone I Chemical
( I None
1 I None
- I None
6 I None
mg I None
/ I None
day I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Response I None
rates I None
did I None
not I None
significantly I None
differ I None
between I None
olanzapine I Chemical
<eof> I None

<s> O None
( I None
43.7 I None
% I None
, I None
95 I None
% I None
CI=28.8%-58.6 I None
% I None
) I None
and I None
risperidone I Chemical
( I None
54.3 I None
% I None
, I None
95 I None
% I None
CI=39.9%-68.7 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Among I None
those I None
responding I None
to I None
treatment I None
, I None
more I None
subjects I None
in I None
the I None
olanzapine I Chemical
group I None
( I None
40.9 I None
% I None
, I None
95 I None
% I None
CI=16.8%-65.0 I None
% I None
) I None
than I None
in I None
the I None
risperidone I Chemical
group I None
( I None
18.9 I None
% I None
, I None
95 I None
% I None
CI=0%-39.2 I None
% I None
) I None
had I None
subsequent I None
ratings I None
not I None
meeting I None
response I None
criteria I None
. I None
<eof> I None

<s> O None
Negative I None
symptom I None
outcomes I None
and I None
measures I None
of I None
parkinsonism I Disease
and I None
akathisia I Disease
did I None
not I None
differ I None
between I None
medications I None
. I None
<eof> I None

<s> O None
Extrapyramidal I Disease
symptom O Disease
severity I None
scores I None
were I None
1.4 I None
( I None
95 I None
% I None
CI=1.2 I None
- I None
1.6 I None
) I None
with I None
risperidone I Chemical
and I None
1.2 I None
( I None
95 I None
% I None
<eof> I None

<s> O None
CI=1.0 I None
- I None
1.4 I None
) I None
with I None
<eof> I None

<s> O None
olanzapine I Chemical
. I None
<eof> I None

<s> O None
Significantly I None
more I None
weight I Disease
gain O Disease
occurred I None
with I None
olanzapine I Chemical
than I None
with I None
risperidone I Chemical
: I None
the I None
increase I None
in I None
weight I None
at I None
4 I None
months I None
relative I None
to I None
baseline I None
weight I None
was I None
17.3 I None
% I None
( I None
95 I None
% I None
CI=14.2%-20.5 I None
% I None
) I None
with I None
<eof> I None

<s> O None
olanzapine I Chemical
and I None
11.3 I None
% I None
( I None
95 I None
% I None
CI=8.4%-14.3 I None
% I None
) I None
with I None
<eof> I None

<s> O None
risperidone I Chemical
. I None
<eof> I None

<s> O None
Body I None
mass I None
index I None
at I None
baseline I None
and I None
at I None
4 I None
months I None
was I None
24.3 I None
( I None
95 I None
% I None
CI=22.8 I None
- I None
25.7 I None
) I None
versus I None
28.2 I None
( I None
95 I None
% I None
CI=26.7 I None
- I None
29.7 I None
) I None
with I None
olanzapine I Chemical
and I None
23.9 I None
( I None
95 I None
% I None
CI=22.5 I None
- I None
25.3 I None
) I None
versus I None
26.7 I None
( I None
95 I None
% I None
CI=25.2 I None
- I None
28.2 I None
) I None
with I None
risperidone I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Clinical I None
outcomes I None
with I None
risperidone I Chemical
were I None
equal I None
to I None
those I None
with I None
olanzapine I Chemical
, I None
and I None
response I None
may I None
be I None
more I None
stable I None
. I None
<eof> I None

<s> O None
Olanzapine I Chemical
may I None
have I None
an I None
advantage I None
for I None
motor I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Both I None
medications I None
caused I None
substantial I None
rapid I None
weight I Disease
gain O Disease
, I None
but I None
weight I Disease
gain O Disease
was I None
greater I None
with I None
olanzapine I Chemical
. I None
<eof> I None

<s> O None
Early I None
paracentral I None
<eof> I None

<s> O None
visual I Disease
field O Disease
loss O Disease
in I None
patients I None
taking I None
hydroxychloroquine I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
review I None
the I None
natural I None
history I None
and I None
ocular I None
and I None
systemic I None
adverse I None
effects I None
of I None
patients I None
taking I None
hydroxychloroquine I Chemical
sulfate O Chemical
who I None
attended I None
an I None
ophthalmic I None
screening I None
program I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Retrospective I None
study I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Records I None
of I None
262 I None
patients I None
who I None
were I None
taking I None
hydroxychloroquine I Chemical
and I None
screened I None
in I None
the I None
Department I None
of I None
Ophthalmology I None
were I None
reviewed I None
. I None
<eof> I None

<s> O None
Of I None
the I None
262 I None
patients I None
, I None
14 I None
( I None
18 I None
% I None
) I None
of I None
76 I None
who I None
had I None
stopped I None
treatment I None
at I None
the I None
time I None
of I None
the I None
study I None
experienced I None
documented I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Systemic I None
adverse I None
effects I None
occurred I None
in I None
8 I None
patients I None
( I None
10.5 I None
% I None
) I None
and I None
ocular I None
adverse I None
effects I None
, I None
in I None
5 I None
( I None
6.5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
five I None
patients I None
( I None
13.4 I None
% I None
) I None
had I None
visual I Disease
field O Disease
abnormalities O Disease
, I None
which I None
were I None
attributed I None
to I None
hydroxychloroquine I Chemical
treatment I None
in I None
4 I None
patients I None
( I None
1.5 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Three I None
of I None
the I None
4 I None
patients I None
were I None
taking I None
less I None
than I None
6.5 I None
mg I None
/ I None
kg I None
per I None
day I None
and I None
all I None
patients I None
had I None
normal I None
renal I None
and I None
liver I None
function I None
test I None
results I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
current I None
study I None
used I None
a I None
protocol I None
of I None
visual I None
acuity I None
and I None
color I None
vision I None
assessment I None
, I None
funduscopy I None
, I None
and I None
Humphrey I None
10 I None
- I None
2 I None
visual I None
field I None
testing I None
and I None
shows I None
that I None
visual I Disease
field O Disease
defects O Disease
appeared I None
before I None
any I None
corresponding I None
changes I None
in I None
any I None
other I None
tested I None
clinical I None
parameters I None
; I None
the I None
defects I None
were I None
reproducible I None
and I None
the I None
test I None
parameters I None
were I None
reliable I None
. I None
<eof> I None

<s> O None
Patients I None
taking I None
hydroxychloroquine I Chemical
can I None
demonstrate I None
a I None
toxic I None
reaction I None
in I None
the I None
retina I None
despite I None
the I None
absence I None
of I None
known I None
risk I None
factors I None
. I None
<eof> I None

<s> O None
Screening I None
, I None
including I None
Humphrey I None
10 I None
- I None
2 I None
visual I None
field I None
assessment I None
, I None
is I None
recommended I None
2 I None
years I None
after I None
the I None
initial I None
baseline I None
and I None
yearly I None
thereafter I None
. I None
<eof> I None

<s> O None
Peri I None
- I None
operative I None
<eof> I None

<s> O None
atrioventricular I Disease
block O Disease
as I None
a I None
result I None
of I None
chemotherapy I None
with I None
epirubicin I Chemical
and I None
paclitaxel I Chemical
. I None
<eof> I None

<s> O None
A I None
47-year I None
- I None
old I None
woman I None
presented I None
for I None
mastectomy I None
and I None
immediate I None
latissimus I None
dorsi I None
flap I None
reconstruction I None
having I None
been I None
diagnosed I None
with I None
carcinoma I Disease
of O Disease
the O Disease
breast O Disease
6 I None
months I None
previously I None
. I None
<eof> I None

<s> O None
In I None
the I None
preceding I None
months I None
she I None
had I None
received I None
neo I None
- I None
adjuvant I None
chemotherapy I None
with I None
epirubicin I Chemical
, I None
paclitaxel I Chemical
<eof> I None

<s> O None
( I None
Taxol I Chemical
) I None
and I None
cyclophosphamide I Chemical
. I None
<eof> I None

<s> O None
This I None
had I None
been I None
apparently I None
uncomplicated I None
and I None
she I None
had I None
maintained I None
a I None
remarkably I None
high I None
level I None
of I None
physical I None
activity I None
. I None
<eof> I None

<s> O None
She I None
was I None
found I None
to I None
be I None
bradycardic I Disease
<eof> I None

<s> O None
at I None
pre I None
- I None
operative I None
assessment I None
but I None
had I None
no I None
cardiac I None
symptoms I None
. I None
<eof> I None

<s> O None
Second I None
degree I None
Mobitz I None
type I None
II I None
atrioventricular I Disease
block O Disease
was I None
diagnosed I None
on I None
electrocardiogram I None
, I None
and I None
temporary I None
transvenous I None
ventricular I None
pacing I None
instituted I None
in I None
the I None
peri I None
- I None
operative I None
period I None
. I None
<eof> I None

<s> O None
We I None
discuss I None
how I None
evidence I None
- I None
based I None
guidelines I None
would I None
not I None
have I None
been I None
helpful I None
in I None
this I None
case I None
, I None
and I None
how I None
chemotherapy I None
can I None
exhibit I None
substantial I None
cardiotoxicity I Disease
that I None
may I None
develop I None
over I None
many I None
years I None
. I None
<eof> I None

<s> O None
We I None
suggest I None
that I None
patients I None
who I None
have I None
received I None
chemotherapy I None
at I None
any I None
time I None
should I None
have I None
a I None
pre I None
- I None
operative I None
electrocardiogram I None
even I None
if I None
they I None
are I None
asymptomatic I None
. I None
<eof> I None

<s> O None
Risks I None
and I None
benefits I None
of I None
COX-2 I Chemical
inhibitors O Chemical
vs I None
non I None
- I None
selective I None
NSAIDs I None
: I None
does I None
their I None
cardiovascular I None
risk I None
exceed I None
their I None
gastrointestinal I None
benefit I None
? I None
<eof> I None

<s> O None
A I None
retrospective I None
cohort I None
study I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
risk I None
of I None
acute I Disease
myocardial O Disease
infarction O Disease
<eof> I None

<s> O None
( I None
AMI I Disease
) I None
with I None
<eof> I None

<s> O None
COX-2 I Chemical
inhibitors O Chemical
may I None
offset I None
their I None
gastrointestinal I None
( I None
GI I None
) I None
benefit I None
compared I None
with I None
non I None
- I None
selective I None
( I None
NS I None
) I None
non I Chemical
- O Chemical
steroidal O Chemical
anti O Chemical
- O Chemical
inflammatory O Chemical
drugs O Chemical
( I None
NSAIDs I None
) I None
. I None
<eof> I None

<s> O None
We I None
aimed I None
to I None
compare I None
the I None
risks I None
of I None
hospitalization I None
for I None
AMI I Disease
and I None
GI I Disease
bleeding O Disease
among I None
elderly I None
patients I None
using I None
COX-2 I Chemical
inhibitors O Chemical
, I None
NS I None
- I None
NSAIDs I None
and I None
acetaminophen I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
conducted I None
a I None
retrospective I None
cohort I None
study I None
using I None
administrative I None
data I None
of I None
patients I None
> I None
or I None
= I None
65 I None
years I None
of I None
age I None
who I None
filled I None
a I None
prescription I None
for I None
NSAID I None
or I None
acetaminophen I Chemical
during I None
1999 I None
- I None
2002 I None
. I None
<eof> I None

<s> O None
Outcomes I None
were I None
compared I None
using I None
Cox I None
regression I None
models I None
with I None
time I None
- I None
dependent I None
exposures I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Person I None
- I None
years I None
of I None
exposure I None
among I None
non I None
- I None
users I None
of I None
aspirin I Chemical
were I None
: I None
75,761 I None
to I None
acetaminophen I Chemical
, I None
42,671 I None
to I None
rofecoxib I Chemical
65,860 I None
to I None
celecoxib I Chemical
, I None
and I None
37,495 I None
to I None
NS I None
- I None
NSAIDs I None
. I None
<eof> I None

<s> O None
Among I None
users I None
of I None
aspirin I Chemical
, I None
they I None
were I None
: I None
14,671 I None
to I None
rofecoxib I Chemical
, I None
22,875 I None
to I None
celecoxib I Chemical
, I None
9,832 I None
to I None
NS I None
- I None
NSAIDs I None
and I None
38,048 I None
to I None
acetaminophen I Chemical
. I None
<eof> I None

<s> O None
Among I None
non I None
- I None
users I None
of I None
aspirin I Chemical
, I None
the I None
adjusted I None
hazard I None
ratios I None
( I None
95 I None
% I None
confidence I None
interval I None
) I None
of I None
hospitalization I None
for I None
AMI I Disease
/GI I None
vs I None
the I None
acetaminophen I Chemical
( I None
with I None
no I None
aspirin I Chemical
) I None
group I None
were I None
: I None
<eof> I None

<s> O None
rofecoxib I Chemical
1.27 I None
( I None
1.13 I None
, I None
1.42 I None
) I None
, I None
<eof> I None

<s> O None
celecoxib I Chemical
0.93 I None
( I None
0.83 I None
, I None
1.03 I None
) I None
, I None
naproxen I Chemical
1.59 I None
<eof> I None

<s> O None
( I None
1.31 I None
, I None
1.93 I None
) I None
, I None
<eof> I None

<s> O None
diclofenac I Chemical
1.17 I None
( I None
0.99 I None
, I None
1.38 I None
) I None
and I None
ibuprofen I Chemical
1.05 I None
( I None
0.74 I None
, I None
1.51 I None
) I None
. I None
<eof> I None

<s> O None
Among I None
users I None
of I None
aspirin I Chemical
, I None
they I None
were I None
: I None
rofecoxib I Chemical
1.73 I None
( I None
1.52 I None
, I None
1.98 I None
) I None
, I None
<eof> I None

<s> O None
celecoxib I Chemical
1.34 I None
( I None
1.19 I None
, I None
1.52 I None
) I None
, I None
ibuprofen I Chemical
1.51 I None
( I None
0.95 I None
, I None
2.41 I None
) I None
, I None
diclofenac I Chemical
1.69 I None
( I None
1.35 I None
, I None
2.10 I None
) I None
, I None
naproxen I Chemical
1.35 I None
<eof> I None

<s> O None
( I None
0.97 I None
, I None
1.88 I None
) I None
and I None
acetaminophen I Chemical
1.29 I None
( I None
1.17 I None
, I None
1.42 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Among I None
non I None
- I None
users I None
of I None
aspirin I Chemical
, I None
naproxen I Chemical
seemed I None
to I None
carry I None
the I None
highest I None
risk I None
for I None
AMI I Disease
/ I None
GI I Disease
bleeding O Disease
. I None
<eof> I None

<s> O None
The I None
AMI I Disease
/GI I None
<eof> I None

<s> O None
toxicity I Disease
of I None
celecoxib I Chemical
was I None
similar I None
to I None
that I None
of I None
acetaminophen I Chemical
and I None
seemed I None
to I None
be I None
better I None
than I None
those I None
of I None
rofecoxib I Chemical
and I None
NS I None
- I None
NSAIDs I None
. I None
<eof> I None

<s> O None
Among I None
users I None
of I None
aspirin I Chemical
, I None
both I None
celecoxib I Chemical
and I None
naproxen I Chemical
seemed I None
to I None
be I None
the I None
least I None
toxic I None
. I None
<eof> I None

<s> O None
Quinine I Chemical
-induced I None
arrhythmia I Disease
in I None
a I None
patient I None
with I None
severe I Disease
malaria O Disease
. I None
<eof> I None

<s> O None
It I None
was I None
reported I None
that I None
there I None
was I None
a I None
case I None
of I None
severe I Disease
malaria O Disease
patient I None
with I None
jaundice I Disease
who I None
presented I None
with I None
arrhythmia I Disease
<eof> I None

<s> O None
( I None
premature I Disease
ventricular O Disease
contraction O Disease
) I None
while I None
getting I None
quinine I Chemical
infusion I None
was I None
reported I None
. I None
<eof> I None

<s> O None
A I None
man I None
, I None
25 I None
years I None
old I None
, I None
was I None
admitted I None
to I None
hospital I None
with I None
high I None
fever I Disease
, I None
chill I Disease
, I None
vomiting I Disease
, I None
jaundice I Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
fully I None
conscious I None
, I None
blood I None
pressure I None
120/80 I None
<eof> I None

<s> O None
mmHg I None
, I None
pulse I None
rate I None
100 I None
x I None
/ I None
minute I None
, I None
regular I None
. I None
<eof> I None

<s> O None
On I None
admission I None
, I None
laboratory I None
examination I None
showed I None
Plasmodium I None
falciparum I None
( I None
+ I None
+ I None
+ I None
+ I None
) I None
, I None
total I None
bilirubin I Chemical
8.25 I None
mg I None
/ I None
dL I None
, I None
conjugated I None
bilirubin I Chemical
4.36 I None
mg I None
/ I None
dL I None
, I None
unconjugated I None
bilirubin I Chemical
3.89 I None
mg I None
/ I None
dL I None
, I None
potassium I Chemical
3.52 I None
meq I None
/ I None
L I None
Patient I None
was I None
diagnosed I None
as I None
severe I Disease
malaria O Disease
with I None
jaundice I Disease
and I None
got I None
quinine I Chemical
infusion I None
in I None
<eof> I None

<s> O None
dextrose I Chemical
5 I None
% I None
500 I None
mg/8 I None
hour I None
. I None
<eof> I None

<s> O None
On I None
the I None
second I None
day I None
the I None
patient I None
had I None
vomitus I Disease
, I None
diarrhea I Disease
, I None
tinnitus I Disease
, I None
loss I Disease
of O Disease
hearing O Disease
. I None
<eof> I None

<s> O None
After I None
30 I None
hours I None
of I None
quinine I Chemical
infusion I None
the I None
patient I None
felt I None
palpitation I Disease
and I None
electrocardiography I None
( I None
ECG I None
) I None
recording I None
showed I None
premature I Disease
ventricular O Disease
contraction O Disease
<eof> I None

<s> O None
( I None
PVC I Disease
) I None
<eof> I None

<s> O None
> I None
5 I None
x I None
/ I None
minute I None
, I None
trigemini I None
, I None
constant I None
type-- I None
sinoatrial I Disease
block O Disease
, I None
positive I None
U I None
wave I None
. I None
<eof> I None

<s> O None
He I None
was I None
treated I None
with I None
lidocaine I Chemical
<eof> I None

<s> O None
50 I None
mg I None
intravenously I None
followed I None
by I None
infusion I None
1500 I None
mg I None
in I None
dextrose I Chemical
<eof> I None

<s> O None
5%/24 I None
hour I None
and I None
potassium I Chemical
aspartate O Chemical
tablet I None
. I None
<eof> I None

<s> O None
Quinine I Chemical
infusion I None
was I None
discontinued I None
and I None
changed I None
with I None
sulfate I None
quinine I Chemical
tablets I None
. I None
<eof> I None

<s> O None
Three I None
hours I None
later I None
the I None
patient I None
felt I None
better I None
, I None
the I None
frequency I None
of I None
PVC I Disease
reduced I None
to I None
4 I None
- I None
5 I None
x I None
/ I None
minute I None
and I None
on I None
the I None
third I None
day I None
ECG I None
was I None
normal I None
, I None
potassium I Chemical
level I None
was I None
3.34 I None
meq I None
/ I None
L. I None
<eof> I None

<s> O None
He I None
was I None
discharged I None
on I None
7th I None
day I None
in I None
good I None
condition I None
. I None
<eof> I None

<s> O None
Quinine I Chemical
, I None
like I None
quinidine I Chemical
, I None
is I None
a I None
chincona I None
alkaloid I None
that I None
has I None
anti- I None
arrhythmic I Disease
property I None
, I None
although I None
it I None
also I None
pro- I None
<eof> I None

<s> O None
arrhythmic I Disease
that I None
can I None
cause I None
various I None
arrhythmias I Disease
, I None
including I None
severe I None
arrhythmia I Disease
such I None
as I None
multiple I None
PVC I Disease
. I None
<eof> I None

<s> O None
Administration I None
of I None
parenteral I None
quinine I Chemical
must I None
be I None
done I None
carefully I None
and I None
with I None
good I None
observation I None
because I None
of I None
its I None
pro- I None
arrhythmic I Disease
effect I None
, I None
especially I None
in I None
older I None
patients I None
who I None
have I None
heart I Disease
diseases O Disease
or I None
patients I None
with I None
electrolyte I Disease
disorder O Disease
<eof> I None

<s> O None
( I None
hypokalemia I Disease
) I None
which I None
frequently I None
occurs I None
due I None
to I None
vomiting I Disease
and I None
or I None
diarrhea I Disease
in I None
malaria I Disease
cases I None
. I None
<eof> I None

<s> O None
Penicillamine I Chemical
-related I None
lichenoid I Disease
dermatitis O Disease
and I None
utility I None
of I None
zinc I Chemical
acetate O Chemical
in I None
a I None
Wilson I Disease
disease O Disease
patient I None
with I None
hepatic I None
presentation I None
, I None
anxiety I Disease
and I None
SPECT I None
abnormalities I None
. I None
<eof> I None

<s> O None
Wilson I Disease
's O Disease
disease O Disease
is I None
an I None
autosomal I None
recessive I None
disorder I None
of I None
hepatic I None
copper I Chemical
metabolism I None
with I None
consequent I None
copper I Chemical
accumulation I None
and I None
toxicity I Disease
in I None
many I None
tissues I None
and I None
consequent I None
hepatic I None
, I None
neurologic I None
and I None
psychiatric I None
disorders I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
Wilson I Disease
's O Disease
disease O Disease
with I None
chronic I Disease
liver O Disease
disease O Disease
; I None
moreover I None
, I None
in I None
our I None
patient I None
, I None
presenting I None
also I None
with I None
high I None
levels I None
of I None
state I None
anxiety I Disease
without I None
depression I Disease
, I None
99mTc I None
- I None
ECD I None
- I None
SPECT I None
showed I None
cortical I None
hypoperfusion I None
in I None
frontal I None
lobes I None
, I None
more I None
marked I None
on I None
the I None
left I None
frontal I None
lobe I None
. I None
<eof> I None

<s> O None
During I None
the I None
follow I None
- I None
up I None
of I None
our I None
patient I None
, I None
penicillamine I Chemical
was I None
interrupted I None
after I None
the I None
appearance I None
of I None
a I None
lichenoid I Disease
dermatitis O Disease
, I None
and I None
zinc I Chemical
acetate O Chemical
permitted I None
to I None
continue I None
the I None
successful I None
treatment I None
of I None
the I None
patient I None
without I None
side I None
- I None
effects I None
. I None
<eof> I None

<s> O None
In I None
our I None
case I None
the I None
therapy I None
with I None
zinc I Chemical
acetate O Chemical
represented I None
an I None
effective I None
treatment I None
for I None
a I None
Wilson I Disease
's O Disease
disease O Disease
patient I None
in I None
which I None
penicillamine I Chemical
-related I None
side I None
effects I None
appeared I None
. I None
<eof> I None

<s> O None
The I None
safety I None
of I None
the I None
zinc I Chemical
acetate O Chemical
allowed I None
us I None
to I None
avoid I None
other I None
potentially I None
toxic I None
chelating I None
drugs I None
; I None
this I None
observation I None
is I None
in I None
line I None
with I None
the I None
growing I None
evidence I None
on I None
the I None
efficacy I None
of I None
the I None
drug I None
in I None
the I None
treatment I None
of I None
Wilson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
Since I None
most I None
of I None
Wilson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
penicillamine I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
do I None
not I None
seem I None
to I None
develop I None
this I None
skin I Disease
lesion O Disease
, I None
it I None
could I None
be I None
conceivable I None
that I None
a I None
specific I None
genetic I None
factor I None
is I None
involved I None
in I None
drug I None
response I None
. I None
<eof> I None

<s> O None
Further I None
studies I None
are I None
needed I None
for I None
a I None
better I None
clarification I None
of I None
Wilson I Disease
's O Disease
disease O Disease
therapy I None
, I None
and I None
in I None
particular I None
to I None
differentiate I None
specific I None
therapies I None
for I None
different I None
Wilson I Disease
's O Disease
disease O Disease
phenotypes I None
. I None
<eof> I None

<s> O None
A I None
dramatic I None
drop I Disease
in O Disease
blood O Disease
pressure O Disease
following I None
prehospital I None
GTN I Chemical
administration I None
. I None
<eof> I None

<s> O None
A I None
male I None
in I None
his I None
sixties I None
with I None
no I None
history I None
of I None
cardiac I None
chest I Disease
pain O Disease
awoke I None
with I None
chest I Disease
pain O Disease
following I None
an I None
afternoon I None
sleep I None
. I None
<eof> I None

<s> O None
The I None
patient I None
did I None
not I None
self I None
medicate I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
observations I None
were I None
within I None
normal I None
limits I None
, I None
he I None
was I None
administered I None
<eof> I None

<s> O None
oxygen I Chemical
via I None
a I None
face I None
mask I None
and I None
glyceryl I Chemical
trinitrate O Chemical
<eof> I None

<s> O None
( I None
GTN I Chemical
) I None
. I None
<eof> I None

<s> O None
Several I None
minutes I None
after I None
the I None
GTN I Chemical
the I None
patient I None
experienced I None
a I None
sudden I None
drop I Disease
in O Disease
blood O Disease
pressure O Disease
and I None
heart I None
rate I None
, I None
this I None
was I None
rectified I None
by I None
atropine I Chemical
sulphate O Chemical
and I None
a I None
fluid I None
challenge I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
further I None
deterioration I None
in I None
the I None
patient I None
's I None
condition I None
during I None
transport I None
to I None
hospital I None
. I None
<eof> I None

<s> O None
There I None
are I None
very I None
few I None
documented I None
case I None
like I None
this I None
in I None
the I None
prehospital I None
scientific I None
literature I None
. I None
<eof> I None

<s> O None
The I None
cause I None
appears I None
to I None
be I None
the I None
Bezold I None
- I None
Jarish I None
reflex I None
, I None
stimulation I None
of I None
the I None
ventricular I None
walls I None
which I None
in I None
turn I None
decreases I None
sympathetic I None
outflow I None
from I None
the I None
vasomotor I None
centre I None
. I None
<eof> I None

<s> O None
Prehospital I None
care I None
providers I None
who I None
are I None
managing I None
any I None
patient I None
with I None
a I None
syncopal I Disease
episode O Disease
that I None
fails I None
to I None
recover I None
within I None
a I None
reasonable I None
time I None
frame I None
should I None
consider I None
the I None
Bezold I None
- I None
Jarisch I None
reflex I None
as I None
the I None
cause I None
and I None
manage I None
the I None
patient I None
accordingly I None
. I None
<eof> I None

<s> O None
Acute I Disease
encephalopathy O Disease
and I None
cerebral I Disease
vasospasm O Disease
after I None
multiagent I None
chemotherapy I None
including I None
PEG I Chemical
- O Chemical
asparaginase O Chemical
and I None
intrathecal I None
cytarabine I Chemical
for I None
the I None
treatment I None
of I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
. I None
<eof> I None

<s> O None
A I None
7-year I None
- I None
old I None
girl I None
with I None
an I None
unusual I None
reaction I None
to I None
induction I None
chemotherapy I None
for I None
precursor I None
B I None
- I None
cell I None
acute I Disease
lymphoblastic O Disease
leukemia O Disease
<eof> I None

<s> O None
( I None
ALL I Disease
) I None
is I None
described I None
. I None
<eof> I None

<s> O None
The I None
patient I None
developed I None
<eof> I None

<s> O None
acute I Disease
encephalopathy O Disease
evidenced I None
by I None
behavioral I None
changes I None
, I None
aphasia I Disease
, I None
incontinence I Disease
, I None
visual I Disease
hallucinations O Disease
, I None
and I None
right I None
- I None
sided I None
<eof> I None

<s> O None
weakness I Disease
with I None
diffuse I None
cerebral I Disease
vasospasm O Disease
on I None
magnetic I None
resonance I None
angiography I None
after I None
the I None
administration I None
of I None
intrathecal I None
cytarabine I Chemical
. I None
<eof> I None

<s> O None
Vincristine I Chemical
, I None
dexamethasone I Chemical
, I None
and I None
polyethylene I Chemical
glycol O Chemical
- O Chemical
asparaginase O Chemical
were I None
also I None
administered I None
before I None
the I None
episode I None
as I None
part I None
of I None
induction I None
therapy I None
. I None
<eof> I None

<s> O None
Neurologic I None
status I None
returned I None
to I None
baseline I None
within I None
10 I None
days I None
of I None
the I None
acute I None
event I None
, I None
and I None
magnetic I None
resonance I None
angiography I None
findings I None
returned I None
to I None
normal I None
4 I None
months I None
later I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
valsartan I Chemical
/ I None
hydrochlorothiazide I Chemical
combination I None
therapy I None
at I None
doses I None
up I None
to I None
320/25 I None
mg I None
versus I None
monotherapy I None
: I None
a I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
study I None
followed I None
by I None
long I None
- I None
term I None
combination I None
therapy I None
in I None
hypertensive I Disease
adults I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
One I None
third I None
of I None
patients I None
treated I None
for I None
hypertension I Disease
attain I None
adequate I None
blood I None
pressure I None
( I None
BP I None
) I None
control I None
, I None
and I None
multidrug I None
regimens I None
are I None
often I None
required I None
. I None
<eof> I None

<s> O None
Given I None
the I None
lifelong I None
nature I None
of I None
hypertension I Disease
, I None
there I None
is I None
a I None
need I None
to I None
evaluate I None
the I None
long I None
- I None
term I None
efficacy I None
and I None
tolerability I None
of I None
higher I None
doses I None
of I None
combination I None
anti- I None
hypertensive I Disease
therapies I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
the I None
efficacy I None
and I None
tolerability I None
of I None
valsartan I Chemical
<eof> I None

<s> O None
( I None
VAL I Chemical
) I None
or I None
hydrochlorothiazide I Chemical
<eof> I None

<s> O None
( I None
HCTZ I Chemical
) I None
<eof> I None

<s> O None
-monotherapy I None
and I None
higher I None
- I None
dose I None
combinations I None
in I None
patients I None
with I None
essential I Disease
hypertension O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
first I None
part I None
of I None
this I None
study I None
was I None
an I None
8-week I None
, I None
multicenter I None
, I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
controlled I None
, I None
parallel I None
- I None
group I None
trial I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
essential I Disease
hypertension O Disease
<eof> I None

<s> O None
( I None
mean I None
sitting I None
diastolic I None
BP I None
[ I None
MSDBP I None
] I None
, I None
> I None
or I None
= I None
95 I None
mm I None
Hg I None
and I None
< I None
110 I None
mm I None
Hg I None
) I None
were I None
randomized I None
to I None
1 I None
of I None
8 I None
treatment I None
groups I None
: I None
VAL I Chemical
160 I None
or I None
320 I None
mg I None
; I None
HCTZ I Chemical
12.5 I None
or I None
25 I None
mg I None
; I None
VAL I Chemical
/ I None
HCTZ I Chemical
160/12.5 I None
, I None
320/12.5 I None
, I None
or I None
320/25 I None
mg I None
; I None
or I None
placebo I None
. I None
<eof> I None

<s> O None
Mean I None
changes I None
in I None
MSDBP I None
and I None
mean I None
sitting I None
systolic I None
BP I None
( I None
MSSBP I None
) I None
were I None
analyzed I None
at I None
the I None
8-week I None
core I None
study I None
end I None
point I None
. I None
<eof> I None

<s> O None
VAL I Chemical
/ I None
HCTZ I Chemical
320/12.5 I None
and I None
320/25 I None
mg I None
were I None
further I None
investigated I None
in I None
a I None
54-week I None
, I None
open I None
- I None
label I None
extension I None
. I None
<eof> I None

<s> O None
Response I None
was I None
defined I None
as I None
MSDBP I None
< I None
90 I None
mm I None
Hg I None
or I None
a I None
> I None
or I None
= I None
10 I None
mm I None
Hg I None
decrease I None
compared I None
to I None
baseline I None
. I None
<eof> I None

<s> O None
Control I None
was I None
defined I None
as I None
MSDBP I None
< I None
90 I None
mm I None
Hg I None
compared I None
with I None
baseline I None
. I None
<eof> I None

<s> O None
Tolerability I None
was I None
assessed I None
by I None
monitoring I None
adverse I None
events I None
at I None
randomization I None
and I None
all I None
subsequent I None
study I None
visits I None
and I None
regular I None
evaluation I None
of I None
hematology I None
and I None
blood I None
chemistry I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
1346 I None
patients I None
were I None
randomized I None
into I None
the I None
8-week I None
core I None
study I None
( I None
734 I None
men I None
, I None
612 I None
women I None
; I None
924 I None
white I None
, I None
291 I None
black I None
, I None
23 I None
Asian I None
, I None
108 I None
other I None
; I None
mean I None
age I None
, I None
52.7 I None
years I None
; I None
mean I None
weight I None
, I None
92.6 I None
kg I None
) I None
. I None
<eof> I None

<s> O None
All I None
active I None
treatments I None
were I None
associated I None
with I None
significantly I None
reduced I None
MSSBP I None
and I None
MSDBP I None
during I None
the I None
core I None
8-week I None
study I None
, I None
with I None
each I None
monotherapy I None
significantly I None
contributing I None
to I None
the I None
overall I None
effect I None
of I None
combination I None
therapy I None
( I None
VAL I Chemical
and I None
HCTZ I Chemical
, I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
Each I None
combination I None
was I None
associated I None
with I None
significantly I None
greater I None
reductions I None
in I None
MSSBP I None
and I None
MSDBP I None
compared I None
with I None
the I None
monotherapies I None
and I None
placebo I None
( I None
all I None
, I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
reduction I None
in I None
MSSBP I None
/ I None
MSDBP I None
with I None
VAL I Chemical
/ I None
HCTZ I Chemical
<eof> I None

<s> O None
320/25 I None
mg I None
was I None
24.7/16.6 I None
mm I None
Hg I None
, I None
compared I None
with I None
5.9/7.0 I None
mm I None
Hg I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
The I None
reduction I None
in I None
MSSBP I None
was I None
significantly I None
greater I None
with I None
VAL I Chemical
/ I None
HCTZ I Chemical
<eof> I None

<s> O None
320/25 I None
mg I None
compared I None
with I None
VAL I Chemical
/ I None
HCTZ I Chemical
<eof> I None

<s> O None
160/12.5 I None
mg I None
( I None
P I None
< I None
0.002 I None
) I None
. I None
<eof> I None

<s> O None
Rates I None
of I None
response I None
and I None
BP I None
control I None
were I None
significantly I None
higher I None
in I None
the I None
groups I None
that I None
received I None
combination I None
treatment I None
compared I None
with I None
those I None
that I None
received I None
monotherapy I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
hypokalemia I Disease
was I None
lower I None
with I None
VAL I Chemical
/ I None
HCTZ I Chemical
combinations I None
( I None
1.8%-6.1 I None
% I None
) I None
than I None
with I None
HCTZ I Chemical
monotherapies I None
( I None
7.1%-13.3 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
majority I None
of I None
adverse I None
events I None
in I None
the I None
core I None
study I None
were I None
of I None
mild I None
to I None
moderate I None
severity I None
. I None
<eof> I None

<s> O None
The I None
efficacy I None
and I None
tolerability I None
of I None
VAL I Chemical
/ I None
HCTZ I Chemical
combinations I None
were I None
maintained I None
during I None
the I None
extension I None
( I None
797 I None
patients I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
In I None
this I None
study I None
population I None
, I None
combination I None
therapies I None
with I None
VAL I Chemical
/ I None
HCTZ I Chemical
were I None
associated I None
with I None
significantly I None
greater I None
BP I None
reductions I None
compared I None
with I None
either I None
monotherapy I None
, I None
were I None
well I None
tolerated I None
, I None
and I None
were I None
associated I None
with I None
less I None
hypokalemia I Disease
than I None
HCTZ I Chemical
alone I None
. I None
<eof> I None

<s> O None
Succimer I Chemical
chelation I None
improves I None
learning I None
, I None
attention I None
, I None
and I None
arousal I None
regulation I None
in I None
lead I Chemical
<eof> I None

<s> O None
-exposed I None
rats I None
but I None
produces I None
lasting I None
cognitive I Disease
impairment O Disease
in I None
the I None
absence I None
of I None
lead I Chemical
exposure I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
There I None
is I None
growing I None
pressure I None
for I None
clinicians I None
to I None
prescribe I None
chelation I None
therapy I None
at I None
only I None
slightly I None
elevated I None
blood I None
lead I Chemical
levels I None
. I None
<eof> I None

<s> O None
However I None
, I None
very I None
few I None
studies I None
have I None
evaluated I None
whether I None
chelation I None
improves I None
cognitive I None
outcomes I None
in I None
Pb I Chemical
<eof> I None

<s> O None
-exposed I None
children I None
, I None
or I None
whether I None
these I None
agents I None
have I None
adverse I None
effects I None
that I None
may I None
affect I None
brain I None
development I None
in I None
the I None
absence I None
of I None
Pb I Chemical
exposure I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
designed I None
to I None
answer I None
these I None
questions I None
, I None
using I None
a I None
rodent I None
model I None
of I None
early I None
childhood I None
Pb I Chemical
exposure I None
and I None
treatment I None
with I None
succimer I Chemical
, I None
a I None
widely I None
used I None
chelating I None
agent I None
for I None
the I None
treatment I None
of I None
Pb I Disease
poisoning O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Pb I Chemical
exposure I None
produced I None
lasting I None
impairments I None
in I None
learning I None
, I None
attention I None
, I None
inhibitory I None
control I None
, I None
and I None
arousal I None
regulation I None
, I None
paralleling I None
the I None
areas I None
of I None
dysfunction I None
seen I None
in I None
Pb I Chemical
<eof> I None

<s> O None
-exposed I None
children I None
. I None
<eof> I None

<s> O None
Succimer I Chemical
treatment I None
of I None
the I None
Pb I Chemical
-exposed I None
rats I None
significantly I None
improved I None
learning I None
, I None
attention I None
, I None
and I None
arousal I None
regulation I None
, I None
although I None
the I None
efficacy I None
of I None
the I None
treatment I None
varied I None
as I None
a I None
function I None
of I None
the I None
Pb I Chemical
exposure I None
level I None
and I None
the I None
specific I None
functional I None
deficit I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
succimer I Chemical
treatment I None
of I None
rats I None
not I None
previously I None
exposed I None
to I None
Pb I Chemical
<eof> I None

<s> O None
produced I None
lasting I None
and I None
pervasive I None
cognitive I None
and I None
affective I None
dysfunction I None
comparable I None
in I None
magnitude I None
to I None
that I None
produced I None
by I None
the I None
higher I None
Pb I Chemical
exposure I None
regimen I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
are I None
the I None
first I None
data I None
, I None
to I None
our I None
knowledge I None
, I None
to I None
show I None
that I None
treatment I None
with I None
any I None
chelating I None
agent I None
can I None
alleviate I None
cognitive I Disease
deficits O Disease
due I None
to I None
Pb I Chemical
exposure I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
it I None
may I None
be I None
possible I None
to I None
identify I None
a I None
succimer I Chemical
treatment I None
protocol I None
that I None
improves I None
cognitive I None
outcomes I None
in I None
Pb I Chemical
-exposed I None
children I None
. I None
<eof> I None

<s> O None
However I None
, I None
they I None
also I None
suggest I None
that I None
succimer I Chemical
treatment I None
should I None
be I None
strongly I None
discouraged I None
for I None
children I None
who I None
do I None
not I None
have I None
elevated I None
tissue I None
levels I None
of I None
Pb I Chemical
or I None
other I None
heavy I None
metals I None
. I None
<eof> I None

<s> O None
Caffeine I Chemical
challenge I None
test I None
in I None
panic I Disease
disorder O Disease
and I None
depression I Disease
with I None
panic I Disease
attacks O Disease
. I None
<eof> I None

<s> O None
Our I None
aim I None
was I None
to I None
observe I None
if I None
patients I None
with I None
panic I Disease
disorder O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
and I None
patients I None
with I None
major I Disease
depression O Disease
with I None
panic I Disease
attacks O Disease
<eof> I None

<s> O None
( I None
MDP I Disease
) I None
<eof> I None

<s> O None
( I None
Diagnostic I None
and I None
Statistical I None
Manual I None
of I None
Mental I Disease
Disorders O Disease
, I None
Fourth I None
Edition I None
criteria I None
) I None
respond I None
in I None
a I None
similar I None
way I None
to I None
the I None
induction I None
of I None
panic I Disease
attacks O Disease
by I None
an I None
oral I None
caffeine I Chemical
challenge I None
test I None
. I None
<eof> I None

<s> O None
We I None
randomly I None
selected I None
29 I None
patients I None
with I None
PD I Disease
, I None
27 I None
with I None
MDP I Disease
, I None
25 I None
with I None
major I Disease
depression O Disease
without I None
panic I Disease
attacks O Disease
<eof> I None

<s> O None
( I None
MD I Disease
) I None
, I None
and I None
28 I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
The I None
patients I None
had I None
no I None
psychotropic I None
drug I None
for I None
at I None
least I None
a I None
4-week I None
period I None
. I None
<eof> I None

<s> O None
In I None
a I None
randomized I None
double I None
- I None
blind I None
experiment I None
performed I None
in I None
2 I None
occasions I None
7 I None
days I None
apart I None
, I None
480 I None
mg I None
caffeine I Chemical
and I None
a I None
caffeine I Chemical
-free I None
<eof> I None

<s> O None
( I None
placebo I None
) I None
solution I None
were I None
administered I None
in I None
a I None
coffee I None
form I None
and I None
<eof> I None

<s> O None
anxiety I Disease
scales I None
were I None
applied I None
before I None
and I None
after I None
each I None
test I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
58.6 I None
% I None
( I None
n I None
= I None
17 I None
) I None
of I None
patients I None
with I None
PD I Disease
, I None
44.4 I None
% I None
( I None
n I None
= I None
12 I None
) I None
of I None
patients I None
with I None
MDP I Disease
, I None
12.0 I None
% I None
( I None
n I None
= I None
3 I None
) I None
of I None
patients I None
with I None
MD I Disease
, I None
and I None
7.1 I None
% I None
( I None
n= I None
2 I None
) I None
of I None
control I None
subjects I None
had I None
a I None
panic I Disease
attack O Disease
after I None
the I None
480-mg I None
caffeine I Chemical
challenge I None
test I None
( I None
chi(2)(3 I None
) I None
= I None
<eof> I None

<s> O None
16.22 I None
, I None
P I None
= I None
.001 I None
) I None
. I None
<eof> I None

<s> O None
The I None
patients I None
with I None
PD I Disease
and I None
MDP I Disease
were I None
more I None
sensitive I None
to I None
caffeine I Chemical
than I None
were I None
patients I None
with I None
MD I Disease
and I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
No I None
panic I Disease
attack O Disease
was I None
observed I None
after I None
the I None
caffeine I Chemical
-free I None
solution I None
intake I None
. I None
<eof> I None

<s> O None
The I None
patients I None
with I None
MD I Disease
had I None
a I None
lower I None
heart I None
rate I None
response I None
to I None
the I None
test I None
than I None
all I None
the I None
other I None
groups I None
( I None
2-way I None
analysis I None
of I None
variance I None
, I None
group I None
by I None
time I None
interaction I None
with I None
Greenhouse I None
- I None
Geisser I None
correction I None
: I None
F(3,762 I None
) I None
= I None
2.85 I None
, I None
P I None
= I None
.026 I None
) I None
. I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
there I None
is I None
an I None
association I None
between I None
panic I Disease
attacks O Disease
, I None
no I None
matter I None
if I None
associated I None
with I None
PD I Disease
or I None
MDP I Disease
, I None
and I None
hyperreactivity I None
to I None
an I None
oral I None
caffeine I Chemical
challenge I None
test I None
. I None
<eof> I None

<s> O None
Mitral I None
annuloplasty I None
as I None
a I None
ventricular I None
restoration I None
method I None
for I None
the I None
failing I Disease
left O Disease
ventricle O Disease
: I None
a I None
pilot I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
AND I None
AIM I None
OF I None
THE I None
STUDY I None
: I None
<eof> I None

<s> O None
Undersized I None
mitral I None
annuloplasty I None
( I None
MAP I None
) I None
is I None
effective I None
in I None
patients I None
with I None
dilated I Disease
cardiomyopathy O Disease
and I None
functional I None
mitral I Disease
regurgitation O Disease
<eof> I None

<s> O None
( I None
MR I Disease
) I None
since I None
, I None
as I None
well I None
as I None
addressing I None
the I None
MR I Disease
, I None
the I None
MAP I None
may I None
also I None
reshape I None
the I None
dilated I None
left I None
ventricular I None
( I None
LV I None
) I None
base I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
direct I None
benefits I None
of I None
this I None
possible I None
reshaping I None
on I None
LV I None
function I None
in I None
the I None
absence I None
of I None
underlying I None
MR I Disease
remain I None
incompletely I None
understood I None
. I None
<eof> I None

<s> O None
The I None
study I None
aim I None
was I None
to I None
identify I None
these I None
benefits I None
in I None
a I None
canine I None
model I None
of I None
acute I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Six I None
dogs I None
underwent I None
MAP I None
with I None
a I None
prosthetic I None
band I None
on I None
the I None
posterior I None
mitral I None
annulus I None
, I None
using I None
four I None
mattress I None
sutures I None
. I None
<eof> I None

<s> O None
The I None
sutures I None
were I None
passed I None
individually I None
through I None
four I None
tourniquets I None
and I None
exteriorized I None
untied I None
via I None
the I None
left I None
atriotomy I None
. I None
<eof> I None

<s> O None
Sonomicrometry I None
crystals I None
were I None
implanted I None
around I None
the I None
mitral I None
annulus I None
and I None
left I None
ventricle I None
to I None
measure I None
geometry I None
and I None
regional I None
function I None
. I None
<eof> I None

<s> O None
Acute I None
heart I Disease
failure O Disease
was I None
induced I None
by I None
propranolol I Chemical
and I None
volume I None
loading I None
after I None
weaning I None
from I None
cardiopulmonary I None
bypass I None
; I None
an I None
absence I None
of I None
MR I Disease
was I None
confirmed I None
by I None
echocardiography I None
. I None
<eof> I None

<s> O None
MAP I None
was I None
accomplished I None
by I None
cinching I None
the I None
tourniquets I None
. I None
<eof> I None

<s> O None
Data I None
were I None
acquired I None
at I None
baseline I None
, I None
after I None
induction I None
of I None
acute I None
heart I Disease
failure O Disease
, I None
and I None
after I None
MAP I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
MAP I None
decreased I None
mitral I None
annular I None
dimensions I None
in I None
both I None
commissure I None
- I None
commissure I None
and I None
septal I None
- I None
lateral I None
directions I None
. I None
<eof> I None

<s> O None
Concomitantly I None
, I None
the I None
diastolic I None
diameter I None
of I None
the I None
LV I None
base I None
and I None
LV I None
sphericity I None
decreased I None
( I None
i.e. I None
, I None
improved I None
) I None
from I None
37.4 I None
+ I None
/- I None
9.3 I None
to I None
35.9 I None
+ I None
/- I None
<eof> I None

<s> O None
10 I None
mm I None
( I None
p I None
= I None
0.063 I None
) I None
, I None
and I None
from I None
67.9 I None
+ I None
/- I None
18.6 I None
% I None
to I None
65.3 I None
+ I None
/- I None
18.9 I None
% I None
( I None
p I None
= I None
0.016 I None
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Decreases I None
were I None
evident I None
in I None
both I None
LV I None
end I None
- I None
diastolic I None
pressure I None
( I None
from I None
17 I None
+ I None
/- I None
7 I None
to I None
15 I None
+ I None
/- I None
<eof> I None

<s> O None
6 I None
mmHg I None
, I None
p I None
= I None
0.0480 I None
and I None
Tau I None
( I None
from I None
48 I None
+ I None
/- I None
8 I None
to I None
45 I None
+ I None
/- I None
<eof> I None

<s> O None
8 I None
ms I None
, I None
p I None
< I None
0.01 I None
) I None
, I None
while I None
fractional I None
shortening I None
at I None
the I None
LV I None
base I None
increased I None
from I None
7.7 I None
+ I None
/- I None
4.5 I None
% I None
to I None
9.4 I None
+ I None
/- I None
<eof> I None

<s> O None
4.5 I None
% I None
( I None
p I None
= I None
0.045 I None
) I None
. I None
<eof> I None

<s> O None
After I None
MAP I None
, I None
increases I None
were I None
identified I None
in I None
both I None
cardiac I None
output I None
( I None
from I None
1.54 I None
+ I None
/- I None
0.57 I None
to I None
1.65 I None
+ I None
/- I None
0.57 I None
1/min I None
) I None
and I None
Emax I None
( I None
from I None
1.86 I None
+ I None
/- I None
0.9 I None
to I None
2.41 I None
+ I None
/- I None
<eof> I None

<s> O None
1.31 I None
mmHg I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
<eof> I None

<s> O None
: I None
The I None
data I None
acquired I None
suggest I None
that I None
isolated I None
MAP I None
may I None
have I None
certain I None
benefits I None
on I None
LV I None
dimension I None
/ I None
function I None
in I None
acute I None
heart I Disease
failure O Disease
, I None
even I None
in I None
the I None
absence I None
of I None
MR I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
further I None
investigations I None
are I None
warranted I None
in I None
a I None
model I None
of I None
chronic I None
heart I Disease
failure O Disease
. I None
<eof> I None

<s> O None
Piperacillin I Chemical
/ O Chemical
tazobactam O Chemical
-induced I None
seizure I Disease
rapidly I None
reversed I None
by I None
high I None
flux I None
hemodialysis I None
in I None
a I None
patient I None
on I None
peritoneal I None
dialysis I None
. I None
<eof> I None

<s> O None
Despite I None
popular I None
use I None
of I None
piperacillin I Chemical
, I None
the I None
dire I None
neurotoxicity I Disease
associated I None
with I None
piperacillin I Chemical
still I None
goes I None
unrecognized I None
, I None
leading I None
to I None
a I None
delay I None
in I None
appropriate I None
management I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
57-year I None
- I None
old I None
woman I None
with I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
receiving I None
continuous I None
ambulatory I None
peritoneal I None
dialysis I None
( I None
CAPD I None
) I None
, I None
who I None
developed I None
slurred I None
speech I None
, I None
tremor I Disease
, I None
bizarre I None
behavior I None
, I None
progressive I None
mental I None
confusion I Disease
, I None
and I None
2 I None
episodes I None
of I None
generalized I None
tonic I Disease
- O Disease
clonic O Disease
seizure O Disease
<eof> I None

<s> O None
( I None
GTCS I Disease
) I None
after I None
5 I None
doses I None
of I None
piperacillin I Chemical
/ O Chemical
tazobactam O Chemical
<eof> I None

<s> O None
( I None
2 I None
g/250 I None
mg I None
) I None
were I None
given I None
for I None
bronchiectasis I Disease
with I None
secondary I Disease
infection O Disease
. I None
<eof> I None

<s> O None
The I None
laboratory I None
data I None
revealed I None
normal I None
plasma I None
electrolyte I None
and I None
ammonia I Chemical
levels I None
but I None
leukocytosis I Disease
. I None
<eof> I None

<s> O None
Neurologic I None
examinations I None
showed I None
dysarthria I Disease
and I None
bilateral I None
Babinski I None
sign I None
. I None
<eof> I None

<s> O None
Computed I None
tomography I None
of I None
brain I None
and I None
electroencephalogram I None
were I None
unremarkable I None
. I None
<eof> I None

<s> O None
Despite I None
the I None
use I None
of I None
antiepileptic I None
agents I None
, I None
another I None
GTCS I Disease
episode I None
recurred I None
after I None
the I None
sixth I None
dose I None
of I None
piperacillin I Chemical
/ O Chemical
tazobactam O Chemical
. I None
<eof> I None

<s> O None
Brain I None
magnetic I None
resonance I None
imaging I None
did I None
not I None
demonstrate I None
acute I None
infarction I Disease
and I None
organic I Disease
brain O Disease
lesions O Disease
. I None
<eof> I None

<s> O None
Initiation I None
of I None
high I None
- I None
flux I None
hemodialysis I None
rapidly I None
reversed I None
the I None
neurologic I None
symptoms I None
within I None
4 I None
hours I None
. I None
<eof> I None

<s> O None
Piperacillin I Chemical
-induced I None
<eof> I None

<s> O None
encephalopathy I Disease
should I None
be I None
considered I None
in I None
any I None
uremic I Disease
patients I None
with I None
unexplained I None
neurological I None
manifestations I None
. I None
<eof> I None

<s> O None
CAPD I None
is I None
inefficient I None
in I None
removing I None
piperacillin I Chemical
, I None
whereas I None
hemodialysis I None
can I None
rapidly I None
terminate I None
the I None
piperacillin I Chemical
-induced I None
encephalopathy I Disease
. I None
<eof> I None

<s> O None
Frequency I None
of I None
transient I None
ipsilateral I None
vocal I Disease
cord O Disease
paralysis O Disease
in I None
patients I None
undergoing I None
carotid I None
endarterectomy I None
under I None
local I None
anesthesia I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Especially I None
because I None
of I None
improvements I None
in I None
clinical I None
neurologic I None
monitoring I None
, I None
<eof> I None

<s> O None
carotid I None
endarterectomy I None
done I None
under I None
local I None
anesthesia I None
has I None
become I None
the I None
technique I None
of I None
choice I None
in I None
several I None
centers I None
. I None
<eof> I None

<s> O None
Temporary I None
ipsilateral I None
vocal I Disease
nerve O Disease
palsies O Disease
due I None
to I None
local I None
anesthetics I None
have I None
been I None
described I None
, I None
however I None
. I None
<eof> I None

<s> O None
Such I None
complications I None
are I None
most I None
important I None
in I None
situations I None
where I None
there I None
is I None
a I None
pre I None
- I None
existing I None
contralateral I None
paralysis I Disease
. I None
<eof> I None

<s> O None
We I None
therefore I None
examined I None
the I None
effect I None
of I None
local I None
anesthesia I None
on I None
vocal I None
cord I None
function I None
to I None
better I None
understand I None
its I None
possible I None
consequences I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
This I None
prospective I None
study I None
included I None
28 I None
patients I None
undergoing I None
carotid I None
endarterectomy I None
under I None
local I None
anesthesia I None
. I None
<eof> I None

<s> O None
Vocal I None
cord I None
function I None
was I None
evaluated I None
before I None
, I None
during I None
, I None
and I None
after I None
surgery I None
( I None
postoperative I None
day I None
1 I None
) I None
using I None
flexible I None
laryngoscopy I None
. I None
<eof> I None

<s> O None
Anesthesia I None
was I None
performed I None
by I None
injecting I None
20 I None
to I None
40 I None
mL I None
of I None
a I None
mixture I None
of I None
long I None
- I None
acting I None
( I None
ropivacaine I Chemical
) I None
and I None
short I None
- I None
acting I None
( I None
prilocaine I Chemical
) I None
anesthetic I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
All I None
patients I None
had I None
normal I None
vocal I None
cord I None
function I None
preoperatively I None
. I None
<eof> I None

<s> O None
Twelve I None
patients I None
( I None
43 I None
% I None
) I None
were I None
found I None
to I None
have I None
intraoperative I None
ipsilateral I None
vocal I Disease
cord O Disease
paralysis O Disease
. I None
<eof> I None

<s> O None
It I None
resolved I None
in I None
all I None
cases I None
< I None
or I None
= I None
24 I None
hours I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
significant I None
differences I None
in I None
operating I None
time I None
or I None
volume I None
or I None
frequency I None
of I None
anesthetic I None
administration I None
in I None
patients I None
with I None
temporary I None
vocal I Disease
cord O Disease
paralysis O Disease
compared I None
with I None
those I None
without I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Local I None
anesthesia I None
led I None
to I None
temporary I None
ipsilateral I None
vocal I Disease
cord O Disease
paralysis O Disease
in I None
almost I None
half I None
of I None
these I None
patients I None
. I None
<eof> I None

<s> O None
Because I None
pre I None
- I None
existing I None
paralysis I Disease
is I None
of I None
a I None
relevant I None
frequency I None
( I None
up I None
to I None
3 I None
% I None
) I None
, I None
a I None
preoperative I None
evaluation I None
of I None
vocal I None
cord I None
function I None
before I None
carotid I None
endarterectomy I None
under I None
local I None
anesthesia I None
is I None
recommended I None
to I None
avoid I None
intraoperative I None
bilateral I None
paralysis I Disease
. I None
<eof> I None

<s> O None
In I None
patients I None
with I None
preoperative I None
contralateral I None
vocal I Disease
cord O Disease
paralysis O Disease
, I None
surgery I None
under I None
general I None
anesthesia I None
should I None
be I None
considered I None
. I None
<eof> I None

<s> O None
Neuroprotective I None
effects I None
of I None
melatonin I Chemical
upon I None
the I None
offspring I None
cerebellar I None
cortex I None
in I None
the I None
rat I None
model I None
of I None
BCNU I Chemical
<eof> I None

<s> O None
-induced I None
cortical I Disease
dysplasia O Disease
. I None
<eof> I None

<s> O None
Cortical I Disease
dysplasia O Disease
is I None
a I None
malformation I None
characterized I None
by I None
defects I None
in I None
proliferation I None
, I None
migration I None
and I None
maturation I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
designed I None
to I None
evaluate I None
the I None
alterations I None
in I None
offspring I None
rat I None
cerebellum I None
induced I None
by I None
maternal I None
exposure I None
to I None
carmustine I Chemical
- I None
[ I None
1,3-bis I Chemical
( O Chemical
2-chloroethyl)-1-nitrosoure O Chemical
] I None
<eof> I None

<s> O None
( I None
BCNU I Chemical
) I None
and I None
to I None
investigate I None
the I None
effects I None
of I None
exogenous I None
melatonin I Chemical
upon I None
cerebellar I None
BCNU I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cortical I Disease
dysplasia O Disease
, I None
using I None
histological I None
and I None
biochemical I None
analyses I None
. I None
<eof> I None

<s> O None
Pregnant I None
Wistar I None
rats I None
were I None
assigned I None
to I None
five I None
groups I None
: I None
intact I None
- I None
control I None
, I None
saline I None
- I None
control I None
, I None
melatonin I Chemical
-treated I None
, I None
BCNU I Chemical
-exposed I None
and I None
BCNU I Chemical
-exposed I None
plus I None
melatonin I Chemical
. I None
<eof> I None

<s> O None
Rats I None
were I None
exposed I None
to I None
BCNU I Chemical
on I None
embryonic I None
day I None
15 I None
and I None
melatonin I Chemical
was I None
given I None
until I None
delivery I None
. I None
<eof> I None

<s> O None
Immuno I None
/ I None
histochemistry I None
and I None
electron I None
microscopy I None
were I None
carried I None
out I None
on I None
the I None
offspring I None
cerebellum I None
, I None
and I None
levels I None
of I None
malondialdehyde I Chemical
and I None
superoxide I Chemical
dismutase I None
were I None
determined I None
. I None
<eof> I None

<s> O None
Histopathologically I None
, I None
typical I None
findings I None
were I None
observed I None
in I None
the I None
cerebella I None
from I None
the I None
control I None
groups I None
, I None
but I None
the I None
findings I None
consistent I None
with I None
early I None
embryonic I None
development I None
were I None
noted I None
in I None
BCNU I Chemical
-exposed I None
cortical I Disease
dysplasia O Disease
group I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
marked I None
increase I None
in I None
the I None
number I None
of I None
TUNEL I None
positive I None
cells I None
and I None
nestin I None
positive I None
cells I None
in I None
BCNU I Chemical
-exposed I None
group I None
, I None
but I None
a I None
decreased I None
immunoreactivity I None
to I None
glial I None
fibrillary I None
acidic I None
protein I None
, I None
synaptophysin I None
and I None
transforming I None
growth I None
factor I None
beta1 I None
was I None
observed I None
, I None
indicating I None
a I None
delayed I None
maturation I None
, I None
and I None
melatonin I Chemical
significantly I None
reversed I None
these I None
changes I None
. I None
<eof> I None

<s> O None
Malondialdehyde I Chemical
level I None
in I None
<eof> I None

<s> O None
BCNU I Chemical
-exposed I None
group I None
was I None
higher I None
than I None
those I None
in I None
control I None
groups I None
and I None
melatonin I Chemical
decreased I None
malondialdehyde I Chemical
levels I None
in I None
BCNU I Chemical
group I None
( I None
P<0.01 I None
) I None
, I None
while I None
there I None
were I None
no I None
significant I None
differences I None
in I None
the I None
superoxide I Chemical
dismutase I None
levels I None
between I None
these I None
groups I None
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
exposure I None
of I None
animals I None
to I None
BCNU I Chemical
during I None
pregnancy I None
leads I None
to I None
delayed I None
maturation I None
of I None
offspring I None
cerebellum I None
and I None
melatonin I Chemical
protects I None
the I None
cerebellum I None
against I None
the I None
effects I None
of I None
BCNU I Chemical
. I None
<eof> I None

<s> O None
Myo I Chemical
- O Chemical
inositol-1-phosphate O Chemical
<eof> I None

<s> O None
( I None
MIP I Chemical
) I None
synthase I None
inhibition I None
: I None
in I None
- I None
vivo I None
study I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
and I None
valproate I Chemical
are I None
the I None
prototypic I None
mood I None
stabilizers I None
and I None
have I None
diverse I None
structures I None
and I None
targets I None
. I None
<eof> I None

<s> O None
Both I None
drugs I None
influence I None
inositol I Chemical
metabolism I None
. I None
<eof> I None

<s> O None
Lithium I Chemical
inhibits I None
IMPase I None
and I None
valproate I Chemical
inhibits I None
<eof> I None

<s> O None
MIP I Chemical
synthase I None
. I None
<eof> I None

<s> O None
This I None
study I None
shows I None
that I None
MIP I Chemical
synthase I None
inhibition I None
does I None
not I None
replicate I None
or I None
augment I None
the I None
effects I None
of I None
lithium I Chemical
in I None
the I None
inositol I Chemical
sensitive I None
<eof> I None

<s> O None
pilocarpine I Chemical
-induced I None
<eof> I None

<s> O None
seizures I Disease
model I None
. I None
<eof> I None

<s> O None
This I None
lack I None
of I None
effects I None
may I None
stem I None
from I None
the I None
low I None
contribution I None
of I None
de I None
- I None
novo I None
synthesis I None
to I None
cellular I None
inositol I Chemical
supply I None
or I None
to I None
the I None
inhibition I None
of I None
the I None
de I None
- I None
novo I None
synthesis I None
by I None
lithium I Chemical
itself I None
. I None
<eof> I None

<s> O None
Non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
- I None
associated I None
acute I None
interstitial I Disease
nephritis O Disease
with I None
granular I None
tubular I None
basement I None
membrane I None
deposits I None
. I None
<eof> I None

<s> O None
Acute I Disease
tubulo O Disease
- O Disease
interstitial O Disease
nephritis O Disease
<eof> I None

<s> O None
( I None
ATIN I Disease
) I None
is I None
an I None
important I None
cause I None
of I None
acute I Disease
renal O Disease
failure O Disease
resulting I None
from I None
a I None
variety I None
of I None
insults I None
, I None
including I None
immune I None
complex I None
- I None
mediated I None
tubulo I Disease
- O Disease
interstitial O Disease
injury O Disease
, I None
but I None
drugs I None
such I None
as I None
non I None
- I None
steroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
are I None
a I None
far I None
more I None
frequent I None
cause I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
as I None
an I None
entity I None
, I None
ATIN I Disease
remains I None
under I None
- I None
diagnosed I None
, I None
as I None
symptoms I None
resolve I None
spontaneously I None
if I None
the I None
medication I None
is I None
stopped I None
. I None
<eof> I None

<s> O None
We I None
report I None
on I None
a I None
14-year I None
- I None
old I None
boy I None
who I None
developed I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
2 I None
weeks I None
after I None
aortic I None
valve I None
surgery I None
. I None
<eof> I None

<s> O None
He I None
was I None
put I None
on I None
aspirin I Chemical
following I None
surgery I None
and I None
took I None
ibuprofen I Chemical
for I None
fever I Disease
for I None
nearly I None
a I None
week I None
prior I None
to I None
presentation I None
. I None
<eof> I None

<s> O None
He I None
then I None
presented I None
to I None
the I None
emergency I None
department I None
feeling I None
quite I None
ill I None
and I None
was I None
found I None
to I None
have I None
a I None
blood I Chemical
urea O Chemical
nitrogen O Chemical
<eof> I None

<s> O None
( I None
BUN I Chemical
) I None
concentration I None
of I None
of I None
147 I None
mg I None
/ I None
dl I None
, I None
creatinine I Chemical
of I None
15.3 I None
mg I None
/ I None
dl I None
and I None
serum I None
potassium I Chemical
of I None
8.7 I None
mEq I None
/ I None
l I None
. I None
<eof> I None

<s> O None
Dialysis I None
was I None
immediately I None
initiated I None
. I None
<eof> I None

<s> O None
A I None
kidney I None
biopsy I None
showed I None
inflammatory I None
infiltrate I None
consistent I None
with I None
ATIN I Disease
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
the I None
tubular I None
basement I None
membrane I None
( I None
TBM I None
) I None
, I None
very I None
intense I None
granular I None
deposits I None
of I None
polyclonal I None
IgG I None
and I None
C3 I None
were I None
noted I None
. I None
<eof> I None

<s> O None
He I None
needed I None
dialysis I None
for I None
2 I None
weeks I None
and I None
was I None
treated I None
successfully I None
with I None
steroids I Chemical
for I None
6 I None
months I None
. I None
<eof> I None

<s> O None
His I None
renal I None
recovery I None
and I None
disappearance I None
of I None
proteinuria I Disease
took I None
a I None
year I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
this I None
is I None
a I None
first I None
report I None
of I None
NSAIDs I None
- I None
associated I None
ATIN I Disease
, I None
showing I None
deposits I None
of I None
granular I None
immune I None
complex I None
present I None
only I None
in I None
the I None
TBM I None
and I None
not I None
in I None
the I None
glomeruli I None
. I None
<eof> I None

<s> O None
Rifampicin I Chemical
-associated I None
segmental I None
necrotizing I None
glomerulonephritis I Disease
in I None
staphylococcal I None
endocarditis I None
. I None
<eof> I None

<s> O None
Segmental I None
necrotising I None
<eof> I None

<s> O None
glomerulonephritis I Disease
has I None
been I None
reported I None
as I None
complication I None
of I None
rifampicin I Chemical
therapy I None
in I None
patients I None
receiving I None
treatment I None
for I None
tuberculosis I Disease
. I None
<eof> I None

<s> O None
Changing I None
epidemiology I None
of I None
infections I Disease
such I None
as I None
infective I Disease
endocarditis O Disease
<eof> I None

<s> O None
( I None
IE I Disease
) I None
has I None
led I None
to I None
an I None
increase I None
in I None
the I None
use I None
of I None
rifampicin I Chemical
for I None
Staphylococcal I Disease
infections O Disease
. I None
<eof> I None

<s> O None
We I None
describe I None
a I None
case I None
of I None
a I None
patient I None
with I None
Staphylococcal I None
IE I None
who I None
developed I None
acute I Disease
renal O Disease
failure O Disease
secondary I None
to I None
a I None
segmental I None
necrotising I None
glomerulonephritis I Disease
while I None
being I None
treated I None
with I None
rifampicin I Chemical
, I None
and I None
review I None
the I None
literature I None
regarding I None
this I None
complication I None
of I None
rifampicin I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Rate I None
of I None
YMDD I None
motif I None
mutants I None
in I None
lamivudine I Chemical
<eof> I None

<s> O None
-untreated I None
Iranian I None
patients I None
with I None
chronic I Disease
hepatitis O Disease
B O Disease
virus O Disease
infection O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Lamivudine I Chemical
is I None
used I None
for I None
the I None
treatment I None
of I None
chronic I Disease
hepatitis O Disease
B O Disease
patients I None
. I None
<eof> I None

<s> O None
Recent I None
studies I None
show I None
that I None
the I None
YMDD I None
motif I None
mutants I None
( I None
resistant I None
hepatitis I Disease
B O Disease
virus I None
) I None
occur I None
as I None
natural I None
genome I None
variability I None
in I None
lamivudine I Chemical
-untreated I None
chronic I Disease
hepatitis O Disease
B O Disease
patients I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
we I None
aimed I None
to I None
determine I None
the I None
rate I None
of I None
YMDD I None
motif I None
mutants I None
in I None
lamivudine I Chemical
-untreated I None
chronic I Disease
hepatitis O Disease
B O Disease
patients I None
in I None
Iran I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
77 I None
chronic I Disease
hepatitis O Disease
B O Disease
patients I None
who I None
had I None
not I None
been I None
treated I None
with I None
lamivudine I Chemical
were I None
included I None
in I None
the I None
study I None
. I None
<eof> I None

<s> O None
Serum I None
samples I None
from I None
patients I None
were I None
tested I None
by I None
polymerase I None
chain I None
reaction I None
- I None
restriction I None
fragment I None
length I None
polymorphism I None
( I None
PCR I None
- I None
RFLP I None
) I None
for I None
detection I None
of I None
YMDD I None
motif I None
mutants I None
. I None
<eof> I None

<s> O None
All I None
patients I None
were I None
also I None
tested I None
for I None
liver I None
enzymes I None
, I None
anti I None
- I None
HCV I None
, I None
HBeAg I Chemical
, I None
and I None
anti I None
- I None
HBe I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Of I None
the I None
77 I None
patients I None
enrolled I None
in I None
the I None
study I None
, I None
73 I None
% I None
were I None
male I None
and I None
27 I None
% I None
were I None
female I None
. I None
<eof> I None

<s> O None
Mean I None
ALT I None
and I None
AST I None
levels I None
were I None
124.4+/-73.4 I None
and I None
103.1+/-81 I None
IU I None
/ I None
l I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
HBeAg I Chemical
was I None
positive I None
in I None
40 I None
% I None
and I None
anti I None
- I None
HBe I None
in I None
60 I None
% I None
of I None
the I None
patients I None
. I None
<eof> I None

<s> O None
Anti I None
- I None
HCV I None
was I None
negative I None
in I None
all I None
of I None
them I None
. I None
<eof> I None

<s> O None
YMDD I None
motif I None
mutants I None
were I None
not I None
detected I None
in I None
any I None
of I None
the I None
patients I None
despite I None
the I None
liver I None
enzyme I None
levels I None
and I None
the I None
presence I None
of I None
HBeAg I Chemical
or I None
anti I None
- I None
HBe I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Although I None
the I None
natural I None
occurrence I None
of I None
YMDD I None
motif I None
mutants I None
in I None
lamivudine I Chemical
-untreated I None
patients I None
with I None
chronic I Disease
hepatitis O Disease
B O Disease
has I None
been I None
reported I None
, I None
these I None
mutants I None
were I None
not I None
detected I None
in I None
Iranian I None
lamivudine I Chemical
-untreated I None
chronic I Disease
hepatitis O Disease
B O Disease
patients I None
. I None
<eof> I None

<s> O None
Branch I None
retinal I Disease
vein O Disease
occlusion O Disease
and I None
fluoxetine I Chemical
. I None
<eof> I None

<s> O None
A I None
case I None
of I None
branch I None
retinal I Disease
vein O Disease
occlusion O Disease
associated I None
with I None
fluoxetine I Chemical
-induced I None
<eof> I None

<s> O None
secondary I None
hypertension I Disease
is I None
described I None
. I None
<eof> I None

<s> O None
Although I None
an I None
infrequent I None
complication I None
of I None
selective I None
serotonin I Chemical
reuptake I None
inhibitor I None
therapy I None
, I None
it I None
is I None
important I None
that I None
ophthalmologists I None
are I None
aware I None
that I None
these I None
agents I None
can I None
cause I None
hypertension I Disease
because I None
this I None
class I None
of I None
drugs I None
is I None
widely I None
prescribed I None
. I None
<eof> I None

<s> O None
The I None
differential I None
effects I None
of I None
bupivacaine I Chemical
and I None
lidocaine I Chemical
on I None
prostaglandin I Chemical
E2 O Chemical
release I None
, I None
cyclooxygenase I None
gene I None
expression I None
and I None
pain I Disease
in I None
a I None
clinical I None
pain I Disease
model I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
In I None
addition I None
to I None
blocking I None
nociceptive I None
input I None
from I None
surgical I None
sites I None
, I None
long I None
- I None
acting I None
local I None
anesthetics I None
might I None
directly I None
modulate I None
inflammation I Disease
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
describe I None
the I None
proinflammatory I None
effects I None
of I None
bupivacaine I Chemical
on I None
local I None
prostaglandin I Chemical
E2 O Chemical
( I None
PGE2 I Chemical
) I None
production I None
and I None
cyclooxygenase I None
( I None
COX I None
) I None
gene I None
expression I None
that I None
increases I None
postoperative I Disease
pain O Disease
in I None
human I None
subjects I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Subjects I None
( I None
n I None
= I None
114 I None
) I None
undergoing I None
extraction I None
of I None
impacted I None
third I None
molars I None
received I None
either I None
2 I None
% I None
lidocaine I Chemical
or I None
0.5 I None
% I None
bupivacaine I Chemical
before I None
surgery I None
and I None
either I None
rofecoxib I Chemical
<eof> I None

<s> O None
50 I None
mg I None
or I None
placebo I None
orally I None
90 I None
min I None
before I None
surgery I None
and I None
for I None
the I None
following I None
48 I None
h. I None
Oral I None
mucosal I None
biopsies I None
were I None
taken I None
before I None
surgery I None
and I None
48 I None
h I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
After I None
extraction I None
, I None
a I None
microdialysis I None
probe I None
was I None
placed I None
at I None
the I None
surgical I None
site I None
for I None
PGE2 I Chemical
and I None
thromboxane I Chemical
B2 O Chemical
<eof> I None

<s> O None
( I None
TXB2 I Chemical
) I None
measurements I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
bupivacaine I Chemical
/ I None
rofecoxib I Chemical
group I None
reported I None
significantly I None
less I None
pain I Disease
, I None
as I None
assessed I None
by I None
a I None
visual I None
analog I None
scale I None
, I None
compared I None
with I None
the I None
other I None
three I None
treatment I None
groups I None
over I None
the I None
first I None
4 I None
<eof> I None

<s> O None
h. I None
However I None
, I None
the I None
bupivacaine I Chemical
/placebo I None
group I None
reported I None
significantly I None
more I None
pain I Disease
at I None
24 I None
h I None
and I None
PGE2 I Chemical
levels I None
during I None
the I None
first I None
4 I None
h I None
were I None
significantly I None
higher I None
than I None
the I None
other I None
three I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
bupivacaine I Chemical
significantly I None
increased I None
COX-2 I None
gene I None
expression I None
at I None
48 I None
h I None
as I None
compared I None
with I None
the I None
lidocaine I Chemical
/placebo I None
group I None
. I None
<eof> I None

<s> O None
Thromboxane I Chemical
levels I None
were I None
not I None
significantly I None
affected I None
by I None
any I None
of I None
the I None
treatments I None
, I None
indicating I None
that I None
the I None
effects I None
seen I None
were I None
attributable I None
to I None
inhibition I None
of I None
COX-2 I None
, I None
but I None
not I None
COX-1 I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
bupivacaine I Chemical
stimulates I None
COX-2 I None
gene I None
expression I None
after I None
tissue I Disease
injury O Disease
, I None
which I None
is I None
associated I None
with I None
higher I None
PGE2 I Chemical
production I None
and I None
pain I Disease
after I None
the I None
local I None
anesthetic I None
effect I None
dissipates I None
. I None
<eof> I None

<s> O None
p75NTR I None
expression I None
in I None
rat I None
urinary I None
bladder I None
sensory I None
neurons I None
and I None
spinal I None
cord I None
with I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cystitis I Disease
. I None
<eof> I None

<s> O None
A I None
role I None
for I None
nerve I None
growth I None
factor I None
( I None
NGF I None
) I None
in I None
contributing I None
to I None
increased I None
voiding I None
frequency I None
and I None
altered I None
sensation I None
from I None
the I None
urinary I None
bladder I None
has I None
been I None
suggested I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
have I None
examined I None
the I None
expression I None
and I None
regulation I None
of I None
tyrosine I Chemical
kinase I None
receptors I None
( I None
Trks I None
) I None
in I None
micturition I None
reflexes I None
with I None
urinary I Disease
bladder O Disease
inflammation O Disease
. I None
<eof> I None

<s> O None
The I None
present I None
studies I None
examine I None
the I None
expression I None
and I None
regulation I None
of I None
another I None
receptor I None
known I None
to I None
bind I None
NGF I None
, I None
p75(NTR I None
) I None
, I None
after I None
various I None
durations I None
of I None
bladder I Disease
inflammation O Disease
induced I None
by I None
cyclophosphamide I Chemical
<eof> I None

<s> O None
( I None
CYP I Chemical
) I None
. I None
<eof> I None

<s> O None
CYP I Chemical
-induced I None
<eof> I None

<s> O None
cystitis I Disease
increased I None
( I None
P I None
< I None
or I None
= I None
0.001 I None
) I None
p75(NTR I None
) I None
expression I None
in I None
the I None
superficial I None
lateral I None
and I None
medial I None
dorsal I None
horn I None
in I None
L1-L2 I None
and I None
L6-S1 I None
spinal I None
segments I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
p75(NTR)-immunoreactive I None
( I None
-IR I None
) I None
cells I None
in I None
the I None
lumbosacral I None
dorsal I None
root I None
ganglia I None
( I None
DRG I None
) I None
also I None
increased I None
( I None
P I None
< I None
or I None
= I None
0.05 I None
) I None
with I None
<eof> I None

<s> O None
CYP I Chemical
-induced I None
<eof> I None

<s> O None
cystitis I Disease
( I None
acute I None
, I None
intermediate I None
, I None
and I None
chronic I None
) I None
. I None
<eof> I None

<s> O None
Quantitative I None
, I None
real I None
- I None
time I None
polymerase I None
chain I None
reaction I None
also I None
demonstrated I None
significant I None
increases I None
( I None
P I None
< I None
or I None
= I None
0.01 I None
) I None
in I None
p75(NTR I None
) I None
<eof> I None

<s> O None
mRNA I None
in I None
DRG I None
with I None
intermediate I None
and I None
chronic I None
CYP I Chemical
-induced I None
cystitis I Disease
. I None
<eof> I None

<s> O None
Retrograde I None
dye I None
- I None
tracing I None
techniques I None
with I None
Fastblue I None
were I None
used I None
to I None
identify I None
presumptive I None
bladder I None
afferent I None
cells I None
in I None
the I None
lumbosacral I None
DRG I None
. I None
<eof> I None

<s> O None
In I None
bladder I None
afferent I None
cells I None
in I None
DRG I None
, I None
p75(NTR)-IR I None
was I None
also I None
increased I None
( I None
P I None
< I None
or I None
= I None
0.01 I None
) I None
with I None
cystitis I Disease
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
increases I None
in I None
p75(NTR)-IR I None
in I None
DRG I None
cell I None
bodies I None
, I None
increases I None
( I None
P I None
< I None
or I None
= I None
0.001 I None
) I None
in I None
pericellular I None
( I None
encircling I None
DRG I None
cells I None
) I None
<eof> I None

<s> O None
p75(NTR)-IR I None
in I None
DRG I None
also I None
increased I None
. I None
<eof> I None

<s> O None
Confocal I None
analyses I None
demonstrated I None
that I None
pericellular I None
<eof> I None

<s> O None
p75(NTR)-IR I None
was I None
not I None
colocalized I None
with I None
the I None
glial I None
marker I None
, I None
glial I None
fibrillary I None
acidic I None
protein I None
( I None
GFAP I None
) I None
. I None
<eof> I None

<s> O None
These I None
studies I None
demonstrate I None
that I None
p75(NTR I None
) I None
expression I None
in I None
micturition I None
reflexes I None
is I None
present I None
constitutively I None
and I None
modified I None
by I None
bladder I Disease
inflammation O Disease
. I None
<eof> I None

<s> O None
The I None
functional I None
significance I None
of I None
p75(NTR I None
) I None
expression I None
in I None
micturition I None
reflexes I None
remains I None
to I None
be I None
determined I None
. I None
<eof> I None

<s> O None
Azathioprine I Chemical
-induced I None
suicidal I None
erythrocyte I None
death I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Azathioprine I Chemical
is I None
widely I None
used I None
as I None
an I None
immunosuppressive I None
drug I None
. I None
<eof> I None

<s> O None
The I None
side I None
effects I None
of I None
azathioprine I Chemical
include I None
anemia I Disease
, I None
which I None
has I None
been I None
attributed I None
to I None
bone I None
marrow I None
suppression I None
. I None
<eof> I None

<s> O None
Alternatively I None
, I None
anemia I Disease
could I None
result I None
from I None
accelerated I None
suicidal I None
erythrocyte I None
death I None
or I None
eryptosis I None
, I None
which I None
is I None
characterized I None
by I None
exposure I None
of I None
phosphatidylserine I Chemical
<eof> I None

<s> O None
( I None
PS I Chemical
) I None
at I None
the I None
erythrocyte I None
surface I None
and I None
by I None
cell I None
shrinkage I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
The I None
present I None
experiments I None
explored I None
whether I None
azathioprine I Chemical
influences I None
eryptosis I None
. I None
<eof> I None

<s> O None
According I None
to I None
annexin I None
V I None
binding I None
, I None
erythrocytes I None
from I None
patients I None
indeed I None
showed I None
a I None
significant I None
increase I None
of I None
PS I Chemical
exposure I None
within I None
1 I None
week I None
of I None
treatment I None
with I None
azathioprine I Chemical
. I None
<eof> I None

<s> O None
In I None
a I None
second I None
series I None
, I None
cytosolic I None
Ca I Chemical
2 I None
+ I None
activity I None
( I None
Fluo3 I Chemical
fluorescence I None
) I None
, I None
cell I None
volume I None
( I None
forward I None
scatter I None
) I None
, I None
and I None
<eof> I None

<s> O None
PS I Chemical
-exposure I None
<eof> I None

<s> O None
( I None
annexin I None
V I None
binding I None
) I None
were I None
determined I None
by I None
FACS I None
analysis I None
in I None
erythrocytes I None
from I None
healthy I None
volunteers I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Exposure I None
to I None
azathioprine I Chemical
<eof> I None

<s> O None
( I None
> I None
or I None
= I None
2 I None
microg I None
/ I None
mL I None
) I None
for I None
48 I None
hours I None
increased I None
cytosolic I None
Ca I Chemical
2 I None
+ I None
activity I None
and I None
annexin I None
V I None
binding I None
and I None
decreased I None
forward I None
scatter I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
azathioprine I Chemical
on I None
both I None
annexin I None
V I None
<eof> I None

<s> O None
binding I None
and I None
forward I None
scatter I None
<eof> I None

<s> O None
was I None
significantly I None
blunted I None
in I None
the I None
nominal I None
absence I None
of I None
extracellular I None
Ca I Chemical
2 I None
+ I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Azathioprine I Chemical
triggers I None
suicidal I None
erythrocyte I None
death I None
, I None
an I None
effect I None
presumably I None
contributing I None
to I None
azathioprine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
anemia I Disease
. I None
<eof> I None

<s> O None
Clinical I None
comparison I None
of I None
cardiorespiratory I None
effects I None
during I None
unilateral I None
and I None
conventional I None
spinal I None
anaesthesia I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Spinal I None
anaesthesia I None
is I None
widely I None
employed I None
in I None
clinical I None
practice I None
but I None
has I None
the I None
main I None
drawback I None
of I None
post I None
- I None
spinal I None
block I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Efforts I None
must I None
therefore I None
continue I None
to I None
be I None
made I None
to I None
obviate I None
this I None
setback I None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
evaluate I None
the I None
cardiovascular I None
and I None
respiratory I None
changes I None
during I None
unilateral I None
and I None
conventional I None
spinal I None
anaesthesia I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
With I None
ethical I None
approval I None
, I None
we I None
studied I None
74 I None
American I None
Society I None
of I None
Anesthesiologists I None
( I None
ASA I None
) I None
, I None
physical I None
status I None
class I None
1 I None
and I None
2 I None
patients I None
scheduled I None
for I None
elective I None
unilateral I None
lower I None
limb I None
surgery I None
. I None
<eof> I None

<s> O None
Patients I None
were I None
randomly I None
allocated I None
into I None
one I None
of I None
two I None
groups I None
: I None
lateral I None
and I None
conventional I None
spinal I None
anaesthesia I None
groups I None
. I None
<eof> I None

<s> O None
In I None
the I None
lateral I None
position I None
with I None
operative I None
side I None
down I None
, I None
patients I None
recived I None
10 I None
mg I None
( I None
2mls I None
) I None
of I None
0.5 I None
% I None
hyperbaric I None
bupivacaine I Chemical
through I None
a I None
25-gauge I None
spinal I None
needle I None
. I None
<eof> I None

<s> O None
Patients I None
in I None
the I None
unilateral I None
group I None
were I None
maintained I None
in I None
the I None
lateral I None
position I None
for I None
15 I None
minutes I None
following I None
spinal I None
injection I None
while I None
those I None
in I None
the I None
conventional I None
group I None
were I None
turned I None
supine I None
immediately I None
after I None
injection I None
. I None
<eof> I None

<s> O None
Blood I None
pressure I None
, I None
heart I None
rate I None
, I None
respiratory I None
rate I None
and I None
oxygen I Chemical
saturation I None
were I None
monitored I None
over I None
1 I None
hour I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Three I None
patients I None
( I None
8.1 I None
% I None
) I None
in I None
the I None
unilateral I None
group I None
and I None
5 I None
( I None
13.5 I None
% I None
) I None
in I None
the I None
conventional I None
group I None
developed I None
<eof> I None

<s> O None
hypotension I Disease
, I None
P= I None
0.71 I None
. I None
<eof> I None

<s> O None
Four I None
( I None
10.8 I None
% I None
) I None
<eof> I None

<s> O None
patients I None
in I None
the I None
conventional I None
group I None
and I None
1 I None
( I None
2.7 I None
% I None
) I None
in I None
the I None
unilateral I None
group I None
, I None
P= I None
0.17 I None
required I None
epinephrine I Chemical
infusion I None
to I None
treat I None
hypotension I Disease
. I None
<eof> I None

<s> O None
Patients I None
in I None
the I None
conventional I None
group I None
had I None
statistically I None
significant I None
greater I None
fall I None
in I None
the I None
systolic I None
blood I None
pressures I None
at I None
15 I None
, I None
30 I None
and I None
45 I None
minutes I None
when I None
compared I None
to I None
the I None
baseline I None
( I None
P= I None
0.003 I None
, I None
0.001 I None
and I None
0.004 I None
) I None
. I None
<eof> I None

<s> O None
The I None
mean I None
respiratory I None
rate I None
and I None
oxygen I Chemical
saturations I None
in I None
the I None
two I None
groups I None
were I None
similar I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Compared I None
to I None
conventional I None
spinal I None
anaesthesia I None
, I None
unilateral I None
spinal I None
anaesthesia I None
was I None
associated I None
with I None
fewer I None
cardiovascular I None
perturbations I None
. I None
<eof> I None

<s> O None
Also I None
, I None
the I None
type I None
of I None
spinal I None
block I None
instituted I None
affected I None
neither I None
the I None
respiratory I None
rate I None
nor I None
the I None
arterial I None
oxygen I Chemical
saturation I None
. I None
<eof> I None

<s> O None
Spectrum I None
of I None
adverse I None
events I None
after I None
generic I None
HAART I None
in I None
southern I None
Indian I None
HIV I Disease
- O Disease
infected O Disease
patients I None
. I None
<eof> I None

<s> O None
To I None
determine I None
the I None
incidence I None
of I None
clinically I None
significant I None
adverse I None
events I None
after I None
long I None
- I None
term I None
, I None
fixed I None
- I None
dose I None
, I None
generic I None
highly I None
active I None
antiretroviral I None
therapy I None
( I None
HAART I None
) I None
use I None
among I None
HIV I Disease
- O Disease
infected O Disease
individuals I None
in I None
South I None
India I None
, I None
we I None
examined I None
the I None
experiences I None
of I None
3154 I None
HIV I Disease
- O Disease
infected O Disease
individuals I None
who I None
received I None
a I None
minimum I None
of I None
3 I None
months I None
of I None
generic I None
HAART I None
between I None
February I None
1996 I None
and I None
December I None
2006 I None
at I None
a I None
tertiary I None
HIV I None
care I None
referral I None
center I None
in I None
South I None
India I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
regimens I None
were I None
3TC I Chemical
+ I None
d4 I Chemical
T O Chemical
+ I None
nevirapine I Chemical
<eof> I None

<s> O None
( I None
NVP I Chemical
) I None
( I None
54.8 I None
% I None
) I None
, I None
zidovudine I Chemical
<eof> I None

<s> O None
( I None
AZT I Chemical
) I None
+ I None
3TC I Chemical
+ I None
<eof> I None

<s> O None
NVP I Chemical
( I None
14.5 I None
% I None
) I None
, I None
3TC I Chemical
+ I None
d4 I Chemical
T O Chemical
+ I None
efavirenz I Chemical
<eof> I None

<s> O None
( I None
EFV I Chemical
) I None
( I None
20.1 I None
% I None
) I None
, I None
and I None
AZT I Chemical
+ I None
3TC I Chemical
+ I None
EFV I Chemical
( I None
5.4 I None
% I None
) I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
adverse I None
events I None
and I None
median I None
CD4 I None
at I None
time I None
of I None
event I None
were I None
rash I Disease
<eof> I None

<s> O None
( I None
15.2 I None
% I None
; I None
CD4 I None
, I None
285 I None
cells I None
/ I None
microL I None
) I None
and I None
peripheral I Disease
neuropathy O Disease
( I None
9.0 I None
% I None
and I None
348 I None
cells I None
/ I None
microL I None
) I None
. I None
<eof> I None

<s> O None
Clinically I None
significant I None
anemia I Disease
<eof> I None

<s> O None
( I None
hemoglobin I None
< I None
7 I None
g I None
/ I None
dL I None
) I None
was I None
observed I None
in I None
5.4 I None
% I None
of I None
patients I None
( I None
CD4 I None
, I None
165 I None
cells I None
/ I None
microL I None
) I None
and I None
hepatitis I Disease
( I None
clinical I None
jaundice I Disease
with I None
alanine I Chemical
aminotransferase I None
> I None
5 I None
times I None
upper I None
limits I None
of I None
normal I None
) I None
in I None
3.5 I None
% I None
of I None
patients I None
( I None
CD4 I None
, I None
260 I None
cells I None
/ I None
microL I None
) I None
. I None
<eof> I None

<s> O None
Women I None
were I None
significantly I None
more I None
likely I None
to I None
experience I None
lactic I Disease
acidosis O Disease
, I None
while I None
men I None
were I None
significantly I None
more I None
likely I None
to I None
experience I None
immune I Disease
reconstitution O Disease
syndrome O Disease
<eof> I None

<s> O None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Among I None
the I None
patients I None
with I None
1 I None
year I None
of I None
follow I None
- I None
up I None
, I None
NVP I Chemical
therapy I None
was I None
significantly I None
associated I None
with I None
developing I None
rash I Disease
and I None
d4 I Chemical
T O Chemical
therapy I None
with I None
developing I None
peripheral I Disease
neuropathy O Disease
<eof> I None

<s> O None
( I None
p I None
< I None
0.05 I None
) I None
. I None
<eof> I None

<s> O None
Anemia I Disease
and I None
hepatitis I Disease
often I None
occur I None
within I None
12 I None
weeks I None
of I None
initiating I None
generic I None
HAART I None
. I None
<eof> I None

<s> O None
Frequent I None
and I None
early I None
monitoring I None
for I None
these I None
toxicities I Disease
is I None
warranted I None
in I None
developing I None
countries I None
where I None
generic I None
HAART I None
is I None
increasingly I None
available I None
. I None
<eof> I None

<s> O None
Thalidomide I Chemical
and I None
sensory I Disease
neurotoxicity O Disease
: I None
a I None
neurophysiological I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Recent I None
studies I None
confirmed I None
a I None
high I None
incidence I None
of I None
sensory I Disease
axonal O Disease
neuropathy O Disease
in I None
patients I None
treated I None
with I None
different I None
doses I None
of I None
thalidomide I Chemical
. I None
<eof> I None

<s> O None
The I None
study I None
's I None
aims I None
were I None
to I None
measure I None
variations I None
in I None
sural I None
nerve I None
sensory I None
action I None
potential I None
( I None
SAP I None
) I None
amplitude I None
in I None
patients I None
with I None
refractory I None
cutaneous I Disease
lupus O Disease
erythematosus O Disease
<eof> I None

<s> O None
( I None
CLE I Disease
) I None
treated I None
with I None
thalidomide I Chemical
and I None
use I None
these I None
findings I None
to I None
identify I None
the I None
neurotoxic I Disease
potential I None
of I None
thalidomide I Chemical
and I None
the I None
recovery I None
capacity I None
of I None
sensory I None
fibres I None
after I None
discontinuation I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
PATIENTS I None
AND I None
METHODS I None
: I None
Clinical I None
and I None
electrophysiological I None
data I None
in I None
12 I None
female I None
patients I None
with I None
CLE I Disease
during I None
treatment I None
with I None
thalidomide I Chemical
and I None
up I None
to I None
47 I None
months I None
after I None
discontinuation I None
of I None
treatment I None
were I None
analysed I None
. I None
<eof> I None

<s> O None
Sural I None
nerve I None
SAP I None
amplitude I None
reduction I None
> I None
or I None
= I None
40 I None
% I None
was I None
the I None
criteria I None
for I None
discontinuing I None
therapy I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
During I None
treatment I None
, I None
11 I None
patients I None
showed I None
a I None
reduction I None
in I None
sural I None
nerve I None
SAP I None
amplitude I None
compared I None
to I None
baseline I None
values I None
( I None
9 I None
with I None
a I None
reduction I None
> I None
or I None
= I None
50 I None
% I None
and I None
2 I None
< I None
50 I None
% I None
) I None
. I None
<eof> I None

<s> O None
One I None
patient I None
showed I None
no I None
changes I None
in I None
SAP I None
amplitude I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
complained I None
of I None
paresthesias I Disease
and I None
leg I None
cramps I Disease
. I None
<eof> I None

<s> O None
After I None
thalidomide I Chemical
treatment I None
, I None
sural I None
SAP I None
amplitude I None
recovered I None
in I None
3 I None
patients I None
. I None
<eof> I None

<s> O None
At I None
detection I None
of I None
reduction I None
in I None
sural I None
nerve I None
SAP I None
amplitude I None
, I None
the I None
median I None
thalidomide I Chemical
<eof> I None

<s> O None
cumulative I None
dose I None
was I None
21.4 I None
g. I None
<eof> I None

<s> O None
The I None
threshold I None
neurotoxic I Disease
dosage I None
is I None
lower I None
than I None
previously I None
reported I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Sural I None
nerve I None
SAP I None
amplitude I None
reduction I None
is I None
a I None
reliable I None
and I None
sensitive I None
marker I None
of I None
degeneration I None
and I None
recovery I None
of I None
sensory I None
fibres I None
. I None
<eof> I None

<s> O None
This I None
electrophysiological I None
parameter I None
provides I None
information I None
about I None
subclinical I None
neurotoxic I Disease
potential I None
of I None
thalidomide I Chemical
but I None
is I None
not I None
helpful I None
in I None
predicting I None
the I None
appearance I None
of I None
sensory I None
symptoms I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
-related I None
pulmonary I Disease
mass O Disease
and I None
unique I None
membranous I Disease
glomerulonephritis O Disease
in I None
a I None
patient I None
with I None
valvular I Disease
heart O Disease
disease O Disease
: I None
<eof> I None

<s> O None
Diagnostic I None
pitfall I None
and I None
new I None
findings I None
. I None
<eof> I None

<s> O None
Amiodarone I Chemical
is I None
an I None
anti- I None
arrhythmic I Disease
drug I None
for I None
life I None
- I None
threatening I None
tachycardia I Disease
, I None
but I None
various I None
adverse I None
effects I None
have I None
been I None
reported I None
. I None
<eof> I None

<s> O None
Reported I None
herein I None
is I None
an I None
autopsy I None
case I None
of I None
valvular I Disease
heart O Disease
disease O Disease
, I None
in I None
a I None
patient I None
who I None
developed I None
a I None
lung I Disease
mass O Disease
( I None
1.5 I None
cm I None
in I None
diameter I None
) I None
and I None
proteinuria I Disease
( I None
2.76 I None
g I None
/ I None
day I None
) I None
after I None
treatment I None
with I None
amiodarone I Chemical
for I None
a I None
long I None
time I None
. I None
<eof> I None

<s> O None
The I None
lung I Disease
mass O Disease
was I None
highly I None
suspected I None
to I None
be I None
lung I Disease
cancer O Disease
on I None
CT I None
and I None
positron I None
emission I None
tomography I None
, I None
but I None
histologically I None
the I None
lesion I None
was I None
composed I None
of I None
lymphoplasmacytic I None
infiltrates I None
in I None
alveolar I None
walls I None
and I None
intra I None
- I None
alveolar I None
accumulation I None
of I None
foamy I None
macrophages I None
containing I None
characteristic I None
myelinoid I None
bodies I None
, I None
indicating I None
that I None
it I None
was I None
an I None
amiodarone I Chemical
-related I None
lesion I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
lung I None
tissue I None
had I None
unevenly I None
distributed I None
hemosiderin I Disease
deposition I None
, I None
and I None
abnormally I None
tortuous I None
capillaries I None
were I None
seen I None
in I None
the I None
mass I None
and I None
in I None
heavily I None
hemosiderotic I Disease
lung I None
portions I None
outside I None
the I None
mass I None
. I None
<eof> I None

<s> O None
In I None
the I None
kidneys I None
, I None
glomeruli I None
had I None
membrane I None
spikes I None
, I None
prominent I None
swelling I None
of I None
podocytes I None
and I None
subepithelial I None
deposits I None
, I None
which I None
were I None
sometimes I None
large I None
and I None
hump I None
- I None
like I None
. I None
<eof> I None

<s> O None
Autoimmune I Disease
diseases O Disease
, I None
viral I Disease
hepatitis O Disease
, I None
malignant I None
neoplasms I Disease
or I None
other I None
diseases I None
with I None
a I None
known I None
relationship I None
to I None
membranous I Disease
glomerulonephritis O Disease
were I None
not I None
found I None
. I None
<eof> I None

<s> O None
The I None
present I None
case I None
highlights I None
the I None
possibility I None
that I None
differential I None
diagnosis I None
between I None
an I None
<eof> I None

<s> O None
amiodarone I Chemical
-related I None
<eof> I None

<s> O None
pulmonary I Disease
lesion O Disease
and I None
a I None
neoplasm I Disease
can I None
be I None
very I None
difficult I None
radiologically I None
, I None
and I None
suggests I None
that I None
membranous I Disease
glomerulonephritis O Disease
might I None
be I None
another I None
possible I None
complication I None
of I None
amiodarone I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Risk I None
of I None
coronary I Disease
artery O Disease
disease O Disease
associated I None
with I None
initial I None
sulphonylurea I Chemical
treatment I None
of I None
patients I None
with I None
type I Disease
2 O Disease
diabetes O Disease
: I None
a I None
matched I None
case I None
- I None
control I None
study I None
. I None
<eof> I None

<s> O None
AIMS I None
: I None
<eof> I None

<s> O None
This I None
study I None
sought I None
to I None
assess I None
the I None
risk I None
of I None
developing I None
coronary I Disease
artery O Disease
disease O Disease
<eof> I None

<s> O None
( I None
CAD I Disease
) I None
associated I None
with I None
initial I None
treatment I None
of I None
type I Disease
2 O Disease
diabetes O Disease
with I None
different I None
sulphonylureas I Chemical
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
In I None
type I Disease
2 O Disease
diabetic O Disease
patients I None
, I None
cases I None
who I None
developed I None
CAD I Disease
were I None
compared I None
retrospectively I None
with I None
controls I None
that I None
did I None
not I None
. I None
<eof> I None

<s> O None
The I None
20-year I None
risk I None
of I None
CAD I Disease
at I None
diagnosis I None
of I None
diabetes I Disease
, I None
using I None
the I None
UKPDS I None
risk I None
engine I None
, I None
was I None
used I None
to I None
match I None
cases I None
with I None
controls I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
76 I None
cases I None
of I None
CAD I Disease
were I None
compared I None
with I None
152 I None
controls I None
. I None
<eof> I None

<s> O None
The I None
hazard I None
of I None
developing I None
CAD I Disease
<eof> I None

<s> O None
( I None
95 I None
% I None
CI I None
) I None
associated I None
with I None
initial I None
treatment I None
increased I None
by I None
2.4-fold I None
( I None
1.3 I None
- I None
4.3 I None
, I None
P=0.004 I None
) I None
with I None
glibenclamide I Chemical
; I None
2-fold I None
( I None
0.9 I None
- I None
4.6 I None
, I None
P=0.099 I None
) I None
with I None
glipizide I Chemical
; I None
2.9-fold I None
( I None
1.6 I None
- I None
5.1 I None
, I None
P=0.000 I None
) I None
with I None
either I None
, I None
and I None
was I None
unchanged I None
with I None
metformin I Chemical
. I None
<eof> I None

<s> O None
The I None
hazard I None
decreased I None
0.3-fold I None
<eof> I None

<s> O None
( I None
0.7 I None
- I None
1.7 I None
, I None
P=0.385 I None
) I None
with I None
glimepiride I Chemical
, I None
0.4-fold I None
( I None
0.7 I None
- I None
1.3 I None
, I None
P=0.192 I None
) I None
with I None
gliclazide I Chemical
, I None
and I None
0.4-fold I None
( I None
0.7 I None
- I None
1.1 I None
, I None
P=0.09 I None
) I None
with I None
either I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Initiating I None
treatment I None
of I None
type I Disease
2 O Disease
diabetes O Disease
with I None
glibenclamide I Chemical
or I None
glipizide I Chemical
is I None
associated I None
with I None
increased I None
risk I None
of I None
CAD I Disease
in I None
comparison I None
to I None
gliclazide I Chemical
or I None
glimepiride I Chemical
. I None
<eof> I None

<s> O None
If I None
confirmed I None
, I None
this I None
may I None
be I None
important I None
because I None
most I None
Indian I None
patients I None
receive I None
the I None
cheaper I None
older I None
sulphonylureas I Chemical
, I None
and I None
present I None
guidelines I None
do I None
not I None
distinguish I None
between I None
individual I None
agents I None
. I None
<eof> I None

<s> O None
Reduced I None
progression I None
of I None
adriamycin I Chemical
nephropathy I Disease
in I None
spontaneously I None
hypertensive I Disease
rats I None
treated I None
by I None
losartan I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
study I None
was I None
to I None
investigate I None
the I None
antihypertensive I None
effects I None
of I None
angiotensin I Chemical
II O Chemical
type-1 I None
receptor I None
blocker I None
, I None
losartan I Chemical
, I None
and I None
its I None
potential I None
in I None
slowing I None
down I None
renal I Disease
disease O Disease
progression I None
in I None
spontaneously I None
hypertensive I Disease
rats I None
( I None
SHR I None
) I None
with I None
adriamycin I Chemical
<eof> I None

<s> O None
( I None
ADR I Chemical
) I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Six I None
- I None
month I None
- I None
old I None
female I None
SHR I None
were I None
randomly I None
selected I None
in I None
six I None
groups I None
. I None
<eof> I None

<s> O None
Two I None
control I None
groups I None
( I None
SH(6 I None
) I None
, I None
SH(12 I None
) I None
) I None
received I None
vehicle I None
. I None
<eof> I None

<s> O None
Groups I None
ADR I Chemical
( I None
6 I None
) I None
, I None
ADR I Chemical
+ I None
LOS I Chemical
<eof> I None

<s> O None
( I None
6 I None
) I None
and I None
ADR I Chemical
( I None
12 I None
) I None
, I None
and I None
ADR I Chemical
+ I None
LOS I Chemical
<eof> I None

<s> O None
( I None
12 I None
) I None
received I None
ADR I Chemical
<eof> I None

<s> O None
( I None
2 I None
mg I None
/ I None
kg I None
/ I None
b.w I None
. I None
i.v I None
. I None
) I None
<eof> I None

<s> O None
twice I None
in I None
a I None
3-week I None
interval I None
. I None
<eof> I None

<s> O None
Group I None
ADR I Chemical
+ I None
LOS I Chemical
( I None
6 I None
) I None
received I None
losartan I Chemical
<eof> I None

<s> O None
( I None
10 I None
mg I None
/ I None
kg I None
/ I None
b.w./day I None
by I None
gavages I None
) I None
for I None
6 I None
weeks I None
and I None
group I None
ADR I Chemical
+ I None
LOS I Chemical
<eof> I None

<s> O None
( I None
12 I None
) I None
for I None
12 I None
weeks I None
after I None
second I None
injection I None
of I None
ADR I Chemical
. I None
<eof> I None

<s> O None
Animals I None
were I None
killed I None
after I None
6 I None
or I None
12 I None
weeks I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Haemodynamic I None
measurements I None
were I None
performed I None
on I None
anaesthetized I None
animals I None
, I None
blood I None
and I None
urine I None
samples I None
were I None
taken I None
for I None
biochemical I None
analysis I None
and I None
the I None
left I None
kidney I None
was I None
processed I None
for I None
morphological I None
studies I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Short I None
- I None
term I None
losartan I Chemical
treatment I None
, I None
besides I None
antihypertensive I None
effect I None
, I None
improved I None
glomerular I None
filtration I None
rate I None
and I None
ameliorated I None
<eof> I None

<s> O None
glomerulosclerosis I Disease
resulting I None
in I None
decreased I None
proteinuria I Disease
. I None
<eof> I None

<s> O None
Prolonged I None
treatment I None
with I None
losartan I Chemical
showed I None
further I None
reduction I None
of I None
glomerulosclerosis I Disease
associated I None
with I None
reduced I None
progression I None
of I None
tubular I None
atrophy I Disease
and I None
interstitial I Disease
fibrosis O Disease
, I None
thus I None
preventing I None
heavy I None
proteinuria I Disease
and I None
chronic I Disease
renal O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Losartan I Chemical
reduced I None
<eof> I None

<s> O None
uraemia I Disease
and I None
increased I None
urea I Chemical
clearance I None
in I None
advanced I None
ADR I Chemical
nephropathy I Disease
in I None
SHR I None
. I None
<eof> I None

<s> O None
Histological I None
examination I None
showed I None
that I None
losartan I Chemical
could I None
prevent I None
tubular I None
atrophy I Disease
, I None
interstitial I None
infiltration I None
and I None
fibrosis I Disease
in I None
ADR I Chemical
nephropathy I Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Losartan I Chemical
reduces I None
the I None
rate I None
of I None
progression I None
of I None
ADR I Chemical
-induced I None
<eof> I None

<s> O None
focal I Disease
segmental O Disease
glomerulosclerosis O Disease
to I None
end I Disease
- O Disease
stage O Disease
renal O Disease
disease O Disease
in I None
SHR I None
. I None
<eof> I None

<s> O None
The I None
risks I None
of I None
aprotinin I None
and I None
tranexamic I Chemical
acid O Chemical
in I None
cardiac I None
surgery I None
: I None
a I None
one I None
- I None
year I None
follow I None
- I None
up I None
of I None
1188 I None
consecutive I None
patients I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Our I None
aim I None
was I None
to I None
investigate I None
postoperative I None
complications I None
and I None
mortality I None
after I None
administration I None
of I None
aprotinin I None
compared I None
to I None
tranexamic I Chemical
acid O Chemical
in I None
an I None
unselected I None
, I None
consecutive I None
cohort I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Perioperative I None
data I None
from I None
consecutive I None
cardiac I None
surgery I None
patients I None
were I None
prospectively I None
collected I None
between I None
September I None
2005 I None
and I None
June I None
2006 I None
in I None
a I None
university I None
- I None
affiliated I None
clinic I None
( I None
n I None
= I None
1188 I None
) I None
. I None
<eof> I None

<s> O None
During I None
the I None
first I None
5 I None
mo I None
, I None
596 I None
patients I None
received I None
aprotinin I None
( I None
Group I None
A I None
) I None
; I None
in I None
the I None
next I None
5 I None
mo I None
, I None
592 I None
patients I None
were I None
treated I None
with I None
tranexamic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
Group I None
T I None
) I None
. I None
<eof> I None

<s> O None
Except I None
for I None
antifibrinolytic I None
therapy I None
, I None
the I None
anesthetic I None
and I None
surgical I None
protocols I None
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
pre- I None
and I None
intraoperative I None
variables I None
were I None
comparable I None
between I None
the I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Postoperatively I None
, I None
a I None
significantly I None
higher I None
incidence I None
of I None
seizures I Disease
was I None
found I None
in I None
Group I None
T I None
( I None
4.6 I None
% I None
vs I None
1.2 I None
% I None
, I None
P I None
< I None
0.001 I None
) I None
. I None
<eof> I None

<s> O None
This I None
difference I None
was I None
also I None
significant I None
in I None
the I None
primary I None
valve I None
surgery I None
and I None
the I None
high I None
risk I None
surgery I None
subgroups I None
( I None
7.9 I None
% I None
vs I None
1.2 I None
% I None
, I None
P I None
= I None
0.003 I None
; I None
7.3 I None
% I None
vs I None
2.4 I None
% I None
, I None
P I None
= I None
0.035 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Persistent I None
atrial I None
fibrillation I None
( I None
7.9 I None
% I None
vs I None
2.3 I None
% I None
, I None
P I None
= I None
0.020 I None
) I None
and I None
renal I Disease
failure O Disease
( I None
9.7 I None
% I None
vs I None
1.7 I None
% I None
, I None
P I None
= I None
0.002 I None
) I None
were I None
also I None
more I None
common I None
in I None
Group I None
T I None
, I None
in I None
the I None
primary I None
valve I None
surgery I None
subgroup I None
. I None
<eof> I None

<s> O None
On I None
the I None
contrary I None
, I None
among I None
primary I None
coronary I None
artery I None
bypass I None
surgery I None
patients I None
, I None
there I None
were I None
more I None
acute I None
myocardial I Disease
infarctions O Disease
and I None
renal I Disease
dysfunction O Disease
in I None
Group I None
A I None
( I None
5.8 I None
% I None
vs I None
2.0 I None
% I None
, I None
P I None
= I None
0.027 I None
; I None
22.5 I None
% I None
vs I None
15.2 I None
% I None
, I None
P I None
= I None
0.036 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
1-yr I None
mortality I None
was I None
significantly I None
higher I None
after I None
aprotinin I None
treatment I None
in I None
the I None
high I None
risk I None
surgery I None
group I None
( I None
17.7 I None
% I None
vs I None
9.8 I None
% I None
, I None
P I None
= I None
0.034 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Both I None
antifibrinolytic I None
drugs I None
bear I None
the I None
risk I None
of I None
adverse I None
outcome I None
depending I None
on I None
the I None
type I None
of I None
cardiac I None
surgery I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
aprotinin I None
should I None
be I None
avoided I None
in I None
coronary I None
artery I None
bypass I None
graft I None
and I None
high I None
risk I None
patients I None
, I None
whereas I None
administration I None
of I None
tranexamic I Chemical
acid O Chemical
is I None
not I None
recommended I None
in I None
valve I None
surgery I None
. I None
<eof> I None

<s> O None
The I None
biological I None
properties I None
of I None
the I None
optical I None
isomers I None
of I None
propranolol I Chemical
and I None
their I None
effects I None
on I None
cardiac I Disease
arrhythmias O Disease
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
optical I None
isomers I None
of I None
propranolol I Chemical
have I None
been I None
compared I None
for I None
their I None
beta I None
- I None
blocking I None
and I None
antiarrhythmic I None
activities.2 I None
. I None
<eof> I None

<s> O None
In I None
blocking I None
the I None
positive I None
inotropic I None
and I None
chronotropic I None
responses I None
to I None
isoprenaline I Chemical
, I None
( I None
+ I None
) I None
- I None
propranolol I Chemical
had I None
less I None
than I None
one I None
hundredth I None
the I None
potency I None
of I None
( I None
-)- I None
propranolol I Chemical
. I None
<eof> I None

<s> O None
At I None
dose I None
levels I None
of I None
( I None
+ I None
) I None
- I None
propranolol I Chemical
which I None
attenuated I None
the I None
responses I None
to I None
isoprenaline I Chemical
, I None
there I None
was I None
a I None
significant I None
prolongation I None
of I None
the I None
PR I None
interval I None
of I None
the I None
electrocardiogram.3 I None
. I None
<eof> I None

<s> O None
The I None
metabolic I None
responses I None
to I None
isoprenaline I Chemical
in I None
dogs I None
( I None
an I None
increase I None
in I None
circulating I None
<eof> I None

<s> O None
glucose I Chemical
, I None
lactate I Chemical
and I None
free I None
fatty I Chemical
acids O Chemical
) I None
were I None
all I None
blocked I None
by I None
( I None
<eof> I None

<s> O None
-)- I None
propranolol I Chemical
. I None
<eof> I None

<s> O None
( I None
+ I None
) I None
- I None
Propranolol I Chemical
had I None
no I None
effect I None
on I None
fatty I Chemical
acid O Chemical
mobilization I None
but I None
significantly I None
reduced I None
the I None
increments I None
in I None
both I None
lactate I Chemical
and I None
glucose I Chemical
.4 I None
. I None
<eof> I None

<s> O None
Both I None
isomers I None
of I None
propranolol I Chemical
possessed I None
similar I None
depressant I None
potency I None
on I None
isolated I None
atrial I None
muscle I None
taken I None
from I None
guinea I None
- I None
pigs.5 I None
. I None
<eof> I None

<s> O None
The I None
isomers I None
of I None
propranolol I Chemical
exhibited I None
similar I None
local I None
anaesthetic I None
potencies I None
on I None
an I None
isolated I None
frog I None
nerve I None
preparation I None
at I None
a I None
level I None
approximately I None
three I None
times I None
that I None
of I None
procaine I Chemical
. I None
<eof> I None

<s> O None
The I None
racemic I None
compound I None
was I None
significantly I None
less I None
potent I None
than I None
either I None
isomer.6 I None
. I None
<eof> I None

<s> O None
Both I None
isomers I None
of I None
propranolol I Chemical
were I None
capable I None
of I None
preventing I None
adrenaline I Chemical
-induced I None
<eof> I None

<s> O None
cardiac I Disease
arrhythmias O Disease
in I None
cats I None
anaesthetized I None
with I None
halothane I Chemical
, I None
but I None
the I None
mean I None
dose I None
of I None
( I None
-)- I None
propranolol I Chemical
was I None
0.09+/-0.02 I None
mg I None
/ I None
kg I None
whereas I None
that I None
of I None
( I None
+ I None
) I None
- I None
propranolol I Chemical
was I None
4.2+/-1.2 I None
mg I None
/ I None
kg I None
. I None
<eof> I None

<s> O None
At I None
the I None
effective I None
dose I None
level I None
of I None
( I None
+ I None
) I None
- I None
propranolol I Chemical
there I None
was I None
a I None
significant I None
prolongation I None
of I None
the I None
PR I None
interval I None
of I None
the I None
electrocardiogram I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
<eof> I None

<s> O None
arrhythmias I Disease
with I None
both I None
isomers I None
was I None
surmountable I None
by I None
increasing I None
the I None
dose I None
of I None
adrenaline I Chemical
.7 I None
. I None
<eof> I None

<s> O None
Both I None
isomers I None
of I None
propranolol I Chemical
were I None
also I None
capable I None
of I None
reversing I None
ventricular I Disease
tachycardia O Disease
caused I None
by I None
ouabain I Chemical
in I None
anaesthetized I None
cats I None
and I None
dogs I None
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
( I None
-)- I None
propranolol I Chemical
was I None
significantly I None
smaller I None
than I None
that I None
of I None
( I None
+ I None
) I None
- I None
propranolol I Chemical
in I None
both I None
species I None
but I None
much I None
higher I None
than I None
that I None
required I None
to I None
produce I None
evidence I None
of I None
beta I None
- I None
blockade.8 I None
. I None
<eof> I None

<s> O None
The I None
implications I None
of I None
these I None
results I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Topotecan I Chemical
in I None
combination I None
with I None
radiotherapy I None
in I None
unresectable I None
glioblastoma I Disease
: I None
a I None
phase I None
2 I None
study I None
. I None
<eof> I None

<s> O None
Improving I None
glioblastoma I Disease
multiforme O Disease
<eof> I None

<s> O None
( I None
GBM I Disease
) I None
treatment I None
with I None
radio I None
- I None
chemotherapy I None
remains I None
a I None
challenge I None
. I None
<eof> I None

<s> O None
Topotecan I Chemical
is I None
an I None
attractive I None
option I None
as I None
it I None
exhibits I None
growth I None
inhibition I None
of I None
human I None
glioma I Disease
as I None
well I None
as I None
brain I None
penetration I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
assessed I None
the I None
combination I None
of I None
radiotherapy I None
( I None
60 I None
Gy/30 I None
fractions/40 I None
days I None
) I None
and I None
topotecan I Chemical
( I None
0.9 I None
mg I None
/ I None
m(2)/day I None
on I None
days I None
1 I None
- I None
5 I None
on I None
weeks I None
1 I None
, I None
3 I None
and I None
5 I None
) I None
in I None
50 I None
adults I None
with I None
histologically I None
proven I None
and I None
untreated I None
GBM I Disease
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
non I None
- I None
hematological I None
toxicities I Disease
was I None
low I None
and I None
grade I None
3 I None
- I None
4 I None
hematological I None
<eof> I None

<s> O None
toxicities I Disease
were I None
reported I None
in I None
20 I None
patients I None
( I None
mainly I None
lymphopenia I Disease
and I None
neutropenia I Disease
) I None
. I None
<eof> I None

<s> O None
Partial I None
response I None
and I None
stabilization I None
rates I None
were I None
2 I None
% I None
and I None
32 I None
% I None
, I None
respectively I None
, I None
with I None
an I None
overall I None
time I None
to I None
progression I None
of I None
12 I None
weeks I None
. I None
<eof> I None

<s> O None
One I None
- I None
year I None
overall I None
survival I None
( I None
OS I None
) I None
rate I None
was I None
42 I None
% I None
, I None
with I None
a I None
median I None
OS I None
of I None
40 I None
weeks I None
. I None
<eof> I None

<s> O None
Topotecan I Chemical
in I None
combination I None
with I None
radiotherapy I None
was I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
However I None
, I None
while I None
response I None
and I None
stabilization I None
concerned I None
one I None
- I None
third I None
of I None
the I None
patients I None
, I None
the I None
study I None
did I None
not I None
show I None
increased I None
benefits I None
in I None
terms I None
of I None
survival I None
in I None
patients I None
with I None
unresectable I None
GBM I Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
<eof> I None

<s> O None
lithium I Chemical
therapy I None
leading I None
to I None
hyperparathyroidism I Disease
: I None
a I None
case I None
report I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
This I None
paper I None
reviews I None
the I None
effect I None
of I None
chronic I None
lithium I Chemical
therapy I None
on I None
serum I None
calcium I Chemical
level I None
and I None
parathyroid I None
glands I None
, I None
its I None
pathogenesis I None
, I None
and I None
treatment I None
options I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
case I None
of I None
a I None
lithium I Chemical
-treated I None
patient I None
who I None
had I None
recurrent I None
hypercalcemia I Disease
to I None
better I None
understand I None
the I None
disease I None
process I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Primary I Disease
hyperparathyroidism O Disease
is I None
a I None
rare I None
but I None
potentially I None
life I None
- I None
threatening I None
side I None
effect I None
of I None
long I None
- I None
term I None
lithium I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Careful I None
patient I None
selection I None
and I None
long I None
- I None
term I None
follow I None
- I None
up I None
can I None
reduce I None
morbidity I None
. I None
<eof> I None

<s> O None
PRACTICAL I None
IMPLICATIONS I None
: I None
As I None
much I None
as I None
15 I None
% I None
of I None
<eof> I None

<s> O None
lithium I Chemical
<eof> I None

<s> O None
-treated I None
patients I None
become I None
hypercalcemic I Disease
. I None
<eof> I None

<s> O None
By I None
routinely I None
monitoring I None
serum I None
calcium I Chemical
levels I None
, I None
healthcare I None
providers I None
can I None
improve I None
the I None
quality I None
of I None
life I None
of I None
this I None
patient I None
group I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
laryngeal I None
mask I None
with I None
endotracheal I None
tube I None
for I None
anesthesia I None
in I None
endoscopic I None
sinus I None
surgery I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
compare I None
surgical I None
conditions I None
, I None
including I None
the I None
amount I None
of I None
intraoperative I None
bleeding I Disease
as I None
well I None
as I None
intraoperative I None
blood I None
pressure I None
, I None
during I None
functional I None
endoscopic I None
sinus I None
surgery I None
( I None
FESS I None
) I None
using I None
flexible I None
reinforced I None
laryngeal I None
mask I None
airway I None
( I None
FRLMA I None
) I None
versus I None
endotracheal I None
tube I None
( I None
ETT I None
) I None
in I None
maintaining I None
controlled I None
hypotension I Disease
anesthesia I None
induced I None
by I None
propofol I Chemical
- I None
remifentanil I Chemical
total I None
i.v I None
. I None
anesthesia I None
( I None
TIVA I None
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Sixty I None
normotensive I None
American I None
Society I None
of I None
Anesthesiologists I None
I I None
- I None
II I None
adult I None
patients I None
undergoing I None
FESS I None
under I None
controlled I None
hypotension I Disease
anesthesia I None
caused I None
by I None
propofol I Chemical
- I None
remifentanil I Chemical
-TIVA I None
were I None
randomly I None
assigned I None
into I None
two I None
groups I None
: I None
group I None
I I None
, I None
FRLMA I None
; I None
group I None
II I None
, I None
ETT I None
. I None
<eof> I None

<s> O None
Hemorrhage I Disease
was I None
measured I None
and I None
the I None
visibility I None
of I None
the I None
operative I None
field I None
was I None
evaluated I None
according I None
to I None
a I None
six I None
- I None
point I None
scale I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Controlled I None
<eof> I None

<s> O None
hypotension I Disease
was I None
achieved I None
within I None
a I None
shorter I None
period I None
using I None
laryngeal I None
mask I None
using I None
lower I None
rates I None
of I None
remifentanil I Chemical
infusion I None
and I None
lower I None
total I None
dose I None
of I None
remifentanil I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
summary I None
, I None
our I None
results I None
indicate I None
that I None
airway I None
management I None
using I None
FRLMA I None
during I None
controlled I None
hypotension I Disease
anesthesia I None
provided I None
better I None
surgical I None
conditions I None
in I None
terms I None
of I None
quality I None
of I None
operative I None
field I None
and I None
blood I None
loss I None
and I None
allowed I None
for I None
convenient I None
induced I None
hypotension I Disease
with I None
low I None
doses I None
of I None
remifentanil I Chemical
during I None
TIVA I None
in I None
patients I None
undergoing I None
FESS I None
. I None
<eof> I None

<s> O None
Nonalcoholic I Disease
fatty O Disease
liver O Disease
disease O Disease
during I None
valproate I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Valproic I Chemical
acid O Chemical
<eof> I None

<s> O None
( I None
VPA I Chemical
) I None
is I None
effective I None
for I None
the I None
treatment I None
of I None
many I None
types I None
of I None
epilepsy I Disease
, I None
but I None
its I None
use I None
can I None
be I None
associated I None
with I None
an I None
increase I None
in I None
body I None
weight I None
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
nonalcoholic I Disease
fatty O Disease
liver O Disease
disease O Disease
<eof> I None

<s> O None
( I None
NAFLD I Disease
) I None
arising I None
in I None
a I None
child I None
who I None
developed I None
obesity I Disease
during I None
VPA I Chemical
treatment I None
. I None
<eof> I None

<s> O None
Laboratory I None
data I None
revealed I None
hyperinsulinemia I Disease
with I None
insulin I Disease
resistance O Disease
. I None
<eof> I None

<s> O None
After I None
the I None
withdrawal I None
of I None
VPA I Chemical
therapy I None
, I None
our I None
patient I None
showed I None
a I None
significant I None
weight I Disease
loss O Disease
, I None
a I None
decrease I None
of I None
body I None
mass I None
index I None
, I None
and I None
normalization I None
of I None
metabolic I None
and I None
endocrine I None
parameters I None
; I None
moreover I None
, I None
ultrasound I None
measurements I None
showed I None
a I None
complete I None
normalization I None
. I None
<eof> I None

<s> O None
The I None
present I None
case I None
suggests I None
that I None
obesity I Disease
, I None
hyperinsulinemia I Disease
, I None
insulin I Disease
resistance O Disease
, I None
and I None
long I None
- I None
term I None
treatment I None
with I None
VPA I Chemical
may I None
be I None
all I None
associated I None
with I None
the I None
development I None
of I None
NAFLD I Disease
; I None
this I None
side I None
effect I None
is I None
reversible I None
after I None
VPA I Chemical
withdrawal I None
. I None
<eof> I None

<s> O None
Carbimazole I Chemical
induced I None
<eof> I None

<s> O None
ANCA I Disease
positive O Disease
vasculitis O Disease
. I None
<eof> I None

<s> O None
Anti I Chemical
- O Chemical
thyroid O Chemical
drugs O Chemical
, I None
like I None
carbimazole I Chemical
and I None
propylthiouracil I Chemical
<eof> I None

<s> O None
( I None
PTU I Chemical
) I None
are I None
commonly I None
prescribed I None
for I None
the I None
treatment I None
of I None
hyperthyroidism I Disease
. I None
<eof> I None

<s> O None
One I None
should I None
be I None
aware I None
of I None
the I None
side I None
effects I None
of I None
antithyroid I Chemical
medications O Chemical
. I None
<eof> I None

<s> O None
Antineutrophil I Disease
cytoplasmic O Disease
antibody O Disease
( O Disease
ANCA)--associated O Disease
vasculitis O Disease
is I None
a I None
potentially I None
life I None
- I None
threatening I None
adverse I None
effect I None
of I None
antithyroidmedications I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
patient I None
with I None
Graves I Disease
' O Disease
disease O Disease
who I None
developed I None
ANCA I None
positive I None
carbimazole I Chemical
induced I None
vasculitis I Disease
. I None
<eof> I None

<s> O None
The I None
episode I None
was I None
characterized I None
by I None
a I None
vasculitic I Disease
skin I Disease
rash O Disease
associated I None
with I None
large I None
joint I None
arthritis I Disease
, I None
pyrexia I Disease
and I None
parotiditis I Disease
but I None
no I None
renal I None
or I None
pulmonary I None
involvement I None
. I None
<eof> I None

<s> O None
He I None
was I None
referred I None
to I None
us I None
for I None
neurological I None
evaluation I None
because I None
he I None
had I None
difficulty I None
in I None
getting I None
up I None
from I None
squatting I None
position I None
and I None
was I None
suspected I None
to I None
have I None
myositis I Disease
. I None
<eof> I None

<s> O None
Carbimazole I Chemical
and I None
methimazole I Chemical
have I None
a I None
lower I None
incidence I None
of I None
reported I None
ANCA I None
positive I None
side I None
effects I None
than I None
PUT I None
. I None
<eof> I None

<s> O None
To I None
the I None
best I None
of I None
our I None
knowledge I None
this I None
is I None
the I None
first I None
ANCA I None
positive I None
carbimazole I Chemical
induced I None
vasculitis I Disease
case I None
reported I None
from I None
India I None
. I None
<eof> I None

<s> O None
Aspirin I Chemical
for I None
the I None
primary I None
prevention I None
of I None
cardiovascular I None
events I None
: I None
an I None
update I None
of I None
the I None
evidence I None
for I None
the I None
U.S. I None
Preventive I None
Services I None
Task I None
Force I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Coronary I Disease
heart O Disease
disease O Disease
and I None
cerebrovascular I Disease
disease O Disease
are I None
leading I None
causes I None
of I None
death I None
in I None
the I None
United I None
States I None
. I None
<eof> I None

<s> O None
In I None
2002 I None
, I None
the I None
U.S. I None
Preventive I None
Services I None
Task I None
Force I None
( I None
USPSTF I None
) I None
strongly I None
recommended I None
that I None
clinicians I None
discuss I None
aspirin I Chemical
with I None
adults I None
who I None
are I None
at I None
increased I None
risk I None
for I None
coronary I Disease
heart O Disease
disease O Disease
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
determine I None
the I None
benefits I None
and I None
harms I None
of I None
taking I None
aspirin I Chemical
for I None
the I None
primary I None
prevention I None
of I None
myocardial I Disease
infarctions O Disease
, I None
strokes I Disease
, I None
and I None
death I None
. I None
<eof> I None

<s> O None
DATA I None
SOURCES I None
: I None
MEDLINE I None
and I None
Cochrane I None
Library I None
( I None
search I None
dates I None
, I None
1 I None
January I None
2001 I None
to I None
28 I None
August I None
2008 I None
) I None
, I None
recent I None
systematic I None
reviews I None
, I None
reference I None
lists I None
of I None
retrieved I None
articles I None
, I None
and I None
suggestions I None
from I None
experts I None
. I None
<eof> I None

<s> O None
STUDY I None
SELECTION I None
: I None
<eof> I None

<s> O None
English I None
- I None
language I None
randomized I None
, I None
controlled I None
trials I None
( I None
RCTs I None
) I None
; I None
case I None
- I None
control I None
studies I None
; I None
meta I None
- I None
analyses I None
; I None
and I None
systematic I None
reviews I None
of I None
aspirin I Chemical
versus I None
control I None
for I None
the I None
primary I None
prevention I None
of I None
cardiovascular I Disease
disease O Disease
<eof> I None

<s> O None
( I None
CVD I Disease
) I None
were I None
selected I None
to I None
answer I None
the I None
following I None
questions I None
: I None
Does I None
aspirin I Chemical
decrease I None
coronary I None
heart I None
events I None
, I None
strokes I Disease
, I None
death I None
from I None
coronary I None
heart I None
events I None
or I None
stroke I Disease
, I None
or I None
all I None
- I None
cause I None
mortality I None
in I None
adults I None
without I None
known I None
CVD I Disease
? I None
<eof> I None

<s> O None
Does I None
aspirin I Chemical
increase I None
<eof> I None

<s> O None
gastrointestinal I Disease
bleeding O Disease
or I None
hemorrhagic I None
strokes I None
? I None
<eof> I None

<s> O None
DATA I None
EXTRACTION I None
: I None
<eof> I None

<s> O None
All I None
studies I None
were I None
reviewed I None
, I None
abstracted I None
, I None
and I None
rated I None
for I None
quality I None
by I None
using I None
predefined I None
USPSTF I None
criteria I None
. I None
<eof> I None

<s> O None
DATA I None
SYNTHESIS I None
: I None
<eof> I None

<s> O None
New I None
evidence I None
from I None
1 I None
good I None
- I None
quality I None
RCT I None
, I None
1 I None
good I None
- I None
quality I None
meta I None
- I None
analysis I None
, I None
and I None
2 I None
fair I None
- I None
quality I None
subanalyses I None
of I None
RCTs I None
demonstrates I None
that I None
aspirin I Chemical
use I None
reduces I None
the I None
number I None
of I None
CVD I Disease
events I None
in I None
patients I None
without I None
known I None
CVD I Disease
. I None
<eof> I None

<s> O None
Men I None
in I None
these I None
studies I None
experienced I None
fewer I None
myocardial I Disease
infarctions O Disease
and I None
women I None
experienced I None
fewer I None
ischemic I None
strokes I Disease
. I None
<eof> I None

<s> O None
Aspirin I Chemical
does I None
not I None
seem I None
to I None
affect I None
CVD I Disease
mortality I None
or I None
all I None
- I None
cause I None
mortality I None
in I None
either I None
men I None
or I None
women I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
aspirin I Chemical
for I None
primary I None
prevention I None
increases I None
the I None
risk I None
for I None
major I None
bleeding I Disease
events I None
, I None
primarily I None
gastrointestinal I Disease
bleeding O Disease
events I None
, I None
in I None
both I None
men I None
and I None
women I None
. I None
<eof> I None

<s> O None
Men I None
have I None
an I None
increased I None
risk I None
for I None
hemorrhagic I None
strokes I None
with I None
aspirin I Chemical
use I None
. I None
<eof> I None

<s> O None
A I None
new I None
RCT I None
and I None
meta I None
- I None
analysis I None
suggest I None
that I None
the I None
risk I None
for I None
hemorrhagic I None
strokes I None
in I None
women I None
is I None
not I None
statistically I None
significantly I None
increased I None
. I None
<eof> I None

<s> O None
LIMITATIONS I None
: I None
<eof> I None

<s> O None
New I None
evidence I None
on I None
aspirin I Chemical
for I None
the I None
primary I None
prevention I None
of I None
CVD I Disease
is I None
limited I None
. I None
<eof> I None

<s> O None
The I None
dose I None
of I None
aspirin I Chemical
used I None
in I None
the I None
RCTs I None
varied I None
, I None
which I None
prevented I None
the I None
estimation I None
of I None
the I None
most I None
appropriate I None
dose I None
for I None
primary I None
prevention I None
. I None
<eof> I None

<s> O None
Several I None
of I None
the I None
RCTs I None
were I None
conducted I None
within I None
populations I None
of I None
health I None
professionals I None
, I None
which I None
potentially I None
limits I None
generalizability I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Aspirin I Chemical
reduces I None
the I None
risk I None
for I None
myocardial I Disease
infarction O Disease
in I None
men I None
and I None
strokes I Disease
in I None
women I None
. I None
<eof> I None

<s> O None
Aspirin I Chemical
use I None
increases I None
the I None
risk I None
for I None
serious I None
bleeding I Disease
events I None
. I None
<eof> I None

<s> O None
Reducing I None
harm I None
associated I None
with I None
anticoagulation I None
: I None
practical I None
considerations I None
of I None
argatroban I Chemical
therapy I None
in I None
heparin I Chemical
-induced I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
Argatroban I Chemical
is I None
a I None
hepatically I None
metabolized I None
, I None
direct I None
thrombin I None
inhibitor I None
used I None
for I None
prophylaxis I None
or I None
treatment I None
of I None
thrombosis I Disease
in I None
<eof> I None

<s> O None
heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
<eof> I None

<s> O None
( I None
HIT I Disease
) I None
and I None
for I None
patients I None
with I None
or I None
at I None
risk I None
of I None
HIT I Disease
undergoing I None
percutaneous I None
coronary I None
intervention I None
( I None
PCI I None
) I None
. I None
<eof> I None

<s> O None
The I None
objective I None
of I None
this I None
review I None
is I None
to I None
summarize I None
practical I None
considerations I None
of I None
argatroban I Chemical
therapy I None
in I None
HIT I Disease
. I None
<eof> I None

<s> O None
The I None
US I None
FDA I None
- I None
recommended I None
argatroban I Chemical
dose I None
in I None
<eof> I None

<s> O None
HIT I Disease
is I None
2 I None
microg I None
/ I None
kg I None
/ I None
min I None
( I None
reduced I None
in I None
patients I None
with I None
hepatic I Disease
impairment O Disease
and I None
in I None
paediatric I None
patients I None
) I None
, I None
adjusted I None
to I None
achieve I None
activated I None
partial I None
thromboplastin I None
times I None
( I None
aPTTs I None
) I None
1.5 I None
- I None
3 I None
times I None
baseline I None
( I None
not I None
> I None
100 I None
seconds I None
) I None
. I None
<eof> I None

<s> O None
Contemporary I None
experiences I None
indicate I None
that I None
reduced I None
doses I None
are I None
also I None
needed I None
in I None
patients I None
with I None
conditions I None
associated I None
with I None
hepatic I None
hypoperfusion I None
, I None
e.g. I None
heart I Disease
failure O Disease
, I None
yet I None
are I None
unnecessary I None
for I None
renal I Disease
dysfunction O Disease
, I None
adult I None
age I None
, I None
sex I None
, I None
race I None
/ I None
ethnicity I None
or I None
obesity I Disease
. I None
<eof> I None

<s> O None
Argatroban I Chemical
0.5 I None
- I None
1.2 I None
microg I None
/ I None
kg I None
/ I None
min I None
typically I None
supports I None
therapeutic I None
aPTTs I None
. I None
<eof> I None

<s> O None
The I None
FDA I None
- I None
recommended I None
dose I None
during I None
PCI I None
is I None
25 I None
microg I None
/ I None
kg I None
/ I None
min I None
( I None
350 I None
microg I None
/ I None
kg I None
initial I None
bolus I None
) I None
, I None
adjusted I None
to I None
achieve I None
activated I None
clotting I None
times I None
( I None
ACTs I None
) I None
of I None
300 I None
- I None
450 I None
sec I None
. I None
<eof> I None

<s> O None
For I None
PCI I None
, I None
argatroban I Chemical
has I None
not I None
been I None
investigated I None
in I None
hepatically I None
impaired I None
patients I None
; I None
dose I None
adjustment I None
is I None
unnecessary I None
for I None
adult I None
age I None
, I None
sex I None
, I None
race I None
/ I None
ethnicity I None
or I None
obesity I Disease
, I None
and I None
lesser I None
doses I None
may I None
be I None
adequate I None
with I None
concurrent I None
glycoprotein I None
IIb I None
/ I None
IIIa I None
inhibition I None
. I None
<eof> I None

<s> O None
Argatroban I Chemical
prolongs I None
the I None
International I None
Normalized I None
Ratio I None
, I None
and I None
published I None
approaches I None
for I None
monitoring I None
the I None
argatroban I Chemical
-to- I None
warfarin I Chemical
transition I None
should I None
be I None
followed I None
. I None
<eof> I None

<s> O None
Major I None
bleeding I Disease
with I None
argatroban I Chemical
is I None
0 I None
- I None
10 I None
% I None
in I None
the I None
non I None
- I None
interventional I None
setting I None
and I None
0 I None
- I None
5.8 I None
% I None
periprocedurally I None
. I None
<eof> I None

<s> O None
Argatroban I Chemical
has I None
no I None
specific I None
antidote I None
, I None
and I None
if I None
excessive I None
anticoagulation I None
occurs I None
, I None
argatroban I Chemical
infusion I None
should I None
be I None
stopped I None
or I None
reduced I None
. I None
<eof> I None

<s> O None
Improved I None
familiarity I None
of I None
healthcare I None
professionals I None
with I None
argatroban I Chemical
therapy I None
in I None
HIT I Disease
, I None
including I None
in I None
special I None
populations I None
and I None
during I None
PCI I None
, I None
may I None
facilitate I None
reduction I None
of I None
harm I None
associated I None
with I None
HIT I Disease
<eof> I None

<s> O None
( I None
e.g. I None
fewer I None
thromboses I None
) I None
or I None
its I None
treatment I None
( I None
e.g. I None
fewer I None
argatroban I Chemical
medication I None
errors I None
) I None
. I None
<eof> I None

<s> O None
Rhabdomyolysis I Disease
and I None
brain I None
ischemic I Disease
stroke O Disease
in I None
a I None
heroin I Chemical
-dependent I None
male I None
under I None
methadone I Chemical
maintenance I None
therapy I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
There I None
are I None
several I None
complications I None
associated I None
with I None
heroin I Disease
abuse O Disease
, I None
some I None
of I None
which I None
are I None
life I None
- I None
threatening I None
. I None
<eof> I None

<s> O None
Methadone I Chemical
may I None
aggravate I None
this I None
problem I None
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
A I None
clinical I None
case I None
description I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
33-year I None
- I None
old I None
man I None
presented I None
with I None
rhabdomyolysis I Disease
and I None
cerebral I None
ischemic I Disease
stroke O Disease
after I None
intravenous I None
heroin I Chemical
. I None
<eof> I None

<s> O None
He I None
had I None
used I None
heroin I Chemical
since I None
age I None
20 I None
, I None
and I None
had I None
used I None
150 I None
mg I None
methadone I Chemical
daily I None
for I None
6 I None
months I None
. I None
<eof> I None

<s> O None
He I None
was I None
found I None
<eof> I None

<s> O None
unconsciousness I Disease
at I None
home I None
and I None
was I None
sent I None
to I None
our I None
hospital I None
. I None
<eof> I None

<s> O None
In I None
the I None
ER I None
, I None
his I None
opiate I None
level I None
was I None
4497 I None
ng I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
In I None
the I None
ICU I None
, I None
we I None
found I None
rhabdomyolysis I Disease
, I None
acute I Disease
renal O Disease
failure O Disease
and I None
acute I None
respiratory I Disease
failure O Disease
. I None
<eof> I None

<s> O None
After I None
transfer I None
to I None
an I None
internal I None
ward I None
, I None
we I None
noted I None
aphasia I Disease
and I None
weakness I Disease
of I None
his I None
left I None
limbs I None
. I None
<eof> I None

<s> O None
After I None
MRI I None
, I None
we I None
found I None
cerebral I Disease
ischemic O Disease
infarction O Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
Those I None
using I None
methadone I Chemical
and I None
heroin I Chemical
simultaneously I None
may I None
increase I None
risk I None
of I None
rhabdomyolysis I Disease
and I None
ischemic I Disease
stroke O Disease
. I None
<eof> I None

<s> O None
Patients I None
under I None
methadone I Chemical
<eof> I None

<s> O None
maintenance I None
therapy I None
should I None
be I None
warned I None
regarding I None
these I None
serious I None
adverse I None
events I None
. I None
<eof> I None

<s> O None
Hypotheses I None
of I None
heroin I Chemical
-related I None
<eof> I None

<s> O None
rhabdomyolysis I Disease
and I None
stroke I Disease
in I None
heroin I Chemical
abusers I None
are I None
discussed I None
. I None
<eof> I None

<s> O None
Increased I None
vulnerability I None
to I None
6-hydroxydopamine I Chemical
lesion I None
and I None
reduced I None
development I None
of I None
dyskinesias I Disease
in I None
mice I None
lacking I None
CB1 I None
cannabinoid I None
receptors I None
. I None
<eof> I None

<s> O None
Motor I None
impairment I None
, I None
dopamine I Chemical
<eof> I None

<s> O None
( I None
DA I Chemical
) I None
neuronal I None
activity I None
and I None
proenkephalin I Chemical
( I None
PENK I Chemical
) I None
gene I None
expression I None
in I None
the I None
caudate I None
- I None
putamen I None
( I None
CPu I None
) I None
were I None
measured I None
in I None
6-OHDA I Chemical
-lesioned I None
and I None
treated I None
( I None
L I Chemical
- O Chemical
DOPA+benserazide O Chemical
) I None
<eof> I None

<s> O None
CB1 I None
KO I None
and I None
WT I None
mice I None
. I None
<eof> I None

<s> O None
A I None
lesion I None
induced I None
by I None
6-OHDA I Chemical
produced I None
more I None
severe I None
motor I None
deterioration I None
in I None
CB1 I None
KO I None
mice I None
accompanied I None
by I None
more I None
loss I None
of I None
DA I Chemical
neurons I None
and I None
increased I None
PENK I Chemical
gene I None
expression I None
in I None
the I None
CPu I None
. I None
<eof> I None

<s> O None
Oxidative I None
/ I None
nitrosative I None
and I None
neuroinflammatory I None
parameters I None
were I None
estimated I None
in I None
the I None
CPu I None
and I None
cingulate I None
cortex I None
( I None
Cg I None
) I None
. I None
<eof> I None

<s> O None
CB1 I None
KO I None
mice I None
exhibited I None
higher I None
MDA I Chemical
levels I None
and I None
iNOS I None
protein I None
expression I None
in I None
the I None
CPu I None
and I None
Cg I None
compared I None
to I None
WT I None
mice I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
L I Chemical
- O Chemical
DOPA+benserazide O Chemical
<eof> I None

<s> O None
( I None
12 I None
weeks I None
) I None
resulted I None
in I None
less I None
severe I None
dyskinesias I Disease
in I None
CB1 I None
KO I None
than I None
in I None
WT I None
mice I None
. I None
<eof> I None

<s> O None
The I None
results I None
revealed I None
that I None
the I None
lack I None
of I None
cannabinoid I None
CB1 I None
receptors I None
increased I None
the I None
severity I None
of I None
motor I None
impairment I None
and I None
DA I Chemical
lesion I None
, I None
and I None
reduced I None
<eof> I None

<s> O None
L I Chemical
- O Chemical
DOPA O Chemical
-induced I None
<eof> I None

<s> O None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
activation I None
of I None
CB1 I None
receptors I None
offers I None
neuroprotection I None
against I None
dopaminergic I None
lesion I None
and I None
the I None
development I None
of I None
L I Chemical
- O Chemical
DOPA O Chemical
-induced I None
dyskinesias I Disease
. I None
<eof> I None

<s> O None
Animal I None
model I None
of I None
mania I Disease
induced I None
by I None
ouabain I Chemical
: I None
<eof> I None

<s> O None
Evidence I None
of I None
oxidative I None
stress I None
in I None
submitochondrial I None
particles I None
of I None
the I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
The I None
intracerebroventricular I None
( I None
ICV I None
) I None
administration I None
of I None
ouabain I Chemical
<eof> I None

<s> O None
( I None
a I None
Na I Chemical
( I None
+ I None
) I None
<eof> I None

<s> O None
/ I None
K I Chemical
( I None
+ I None
) I None
-ATPase I None
inhibitor I None
) I None
in I None
rats I None
has I None
been I None
suggested I None
to I None
mimic I None
some I None
symptoms I None
of I None
human I None
bipolar I Disease
mania O Disease
. I None
<eof> I None

<s> O None
Clinical I None
studies I None
have I None
shown I None
that I None
bipolar I Disease
disorder O Disease
may I None
be I None
related I None
to I None
mitochondrial I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
investigated I None
the I None
behavioral I None
and I None
biochemical I None
effects I None
induced I None
by I None
the I None
ICV I None
administration I None
of I None
ouabain I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
To I None
achieve I None
this I None
aim I None
, I None
the I None
effects I None
of I None
ouabain I Chemical
injection I None
immediately I None
after I None
and I None
7 I None
days I None
following I None
a I None
single I None
ICV I None
administration I None
( I None
at I None
concentrations I None
of I None
10(-2 I None
) I None
and I None
10(-3)M I None
) I None
on I None
locomotion I None
was I None
measured I None
using I None
the I None
open I None
- I None
field I None
test I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
thiobarbituric I Chemical
acid O Chemical
reactive I None
substances I None
( I None
TBARSs I None
) I None
and I None
superoxide I Chemical
production I None
were I None
measured I None
in I None
submitochondrial I None
particles I None
of I None
the I None
prefrontal I None
cortex I None
, I None
hippocampus I None
, I None
striatum I None
and I None
amygdala I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
demonstrated I None
that I None
ouabain I Chemical
at I None
10(-2 I None
) I None
and I None
10(-3)M I None
induced I None
hyperlocomotion I Disease
in I None
rats I None
, I None
and I None
this I None
response I None
remained I None
up I None
to I None
7 I None
days I None
following I None
a I None
single I None
ICV I None
injection I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
observed I None
that I None
the I None
persistent I None
increase I None
in I None
the I None
rat I None
spontaneous I None
locomotion I None
is I None
associated I None
with I None
increased I None
TBARS I None
levels I None
and I None
superoxide I Chemical
generation I None
in I None
submitochondrial I None
particles I None
in I None
the I None
prefrontal I None
cortex I None
, I None
striatum I None
and I None
amygdala I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
ouabain I Chemical
-induced I None
<eof> I None

<s> O None
mania I Disease
-like I None
behavior I None
may I None
provide I None
a I None
useful I None
animal I None
model I None
to I None
test I None
the I None
hypothesis I None
of I None
the I None
involvement I None
of I None
oxidative I None
stress I None
in I None
bipolar I Disease
disorder O Disease
. I None
<eof> I None

<s> O None
Intraoperative I None
dialysis I None
during I None
liver I None
transplantation I None
with I None
citrate I Chemical
dialysate I None
. I None
<eof> I None

<s> O None
Liver I None
transplantation I None
for I None
acutely I None
ill I None
patients I None
with I None
fulminant I Disease
liver O Disease
failure O Disease
carries I None
high I None
intraoperative I None
and I None
immediate I None
postoperative I None
risks I None
. I None
<eof> I None

<s> O None
These I None
are I None
increased I None
with I None
the I None
presence I None
of I None
concomitant I None
acute I Disease
kidney O Disease
injury O Disease
( I None
AKI I Disease
) I None
and I None
intraoperative I None
dialysis I None
is I None
sometimes I None
required I None
to I None
allow I None
the I None
transplant I None
to I None
proceed I None
. I None
<eof> I None

<s> O None
The I None
derangements I None
in I None
the I None
procoagulant I None
and I None
anticoagulant I None
pathways I None
during I None
fulminant I Disease
liver O Disease
failure O Disease
can I None
lead I None
to I None
difficulties I None
with I None
anticoagulation I None
during I None
dialysis I None
, I None
especially I None
when I None
continued I None
in I None
the I None
operating I None
room I None
. I None
<eof> I None

<s> O None
Systemic I None
anticoagulation I None
is I None
unsafe I None
and I None
regional I None
citrate I Chemical
anticoagulation I None
in I None
the I None
absence I None
of I None
a I None
functional I None
liver I None
carries I None
the I None
risk I None
of I None
citrate I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Citrate I Chemical
dialysate I None
, I None
a I None
new I None
dialysate I None
with I None
citric I Chemical
acid O Chemical
can I None
be I None
used I None
for I None
anticoagulation I None
in I None
patients I None
who I None
can I None
not I None
tolerate I None
heparin I Chemical
or I None
regional I None
citrate I Chemical
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
a I None
40-year I None
- I None
old I None
female I None
with I None
acetaminophen I Chemical
-induced I None
fulminant I Disease
liver O Disease
failure O Disease
with I None
associated I None
AKI I Disease
who I None
underwent I None
intraoperative I None
dialytic I None
support I None
during I None
liver I None
transplantation I None
anticoagulated I None
with I None
citrate I Chemical
dialysate I None
during I None
the I None
entire I None
procedure I None
. I None
<eof> I None

<s> O None
The I None
patient I None
tolerated I None
the I None
procedure I None
well I None
without I None
any I None
signs I None
of I None
citrate I Chemical
toxicity I Disease
and I None
maintained I None
adequate I None
anticoagulation I None
for I None
patency I None
of I None
the I None
dialysis I None
circuit I None
. I None
<eof> I None

<s> O None
Citrate I Chemical
<eof> I None

<s> O None
dialysate I None
is I None
a I None
safe I None
alternative I None
for I None
intradialytic I None
support I None
of I None
liver I None
transplantation I None
in I None
fulminant I Disease
liver O Disease
failure O Disease
. I None
<eof> I None

<s> O None
Delirium I Disease
in I None
a I None
patient I None
with I None
toxic I None
flecainide I Chemical
plasma I None
concentrations I None
: I None
the I None
role I None
of I None
a I None
pharmacokinetic I None
drug I None
interaction I None
with I None
paroxetine I Chemical
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
describe I None
a I None
case I None
of I None
flecainide I Chemical
-induced I None
delirium I Disease
associated I None
with I None
a I None
pharmacokinetic I None
drug I None
interaction I None
with I None
paroxetine I Chemical
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
69-year I None
- I None
old I None
white I None
female I None
presented I None
to I None
the I None
emergency I None
department I None
with I None
a I None
history I None
of I None
confusion I Disease
and I None
paranoia I Disease
over I None
the I None
past I None
several I None
days I None
. I None
<eof> I None

<s> O None
On I None
admission I None
the I None
patient I None
was I None
taking I None
<eof> I None

<s> O None
carvedilol I Chemical
12 I None
mg I None
twice I None
daily I None
, I None
warfarin I Chemical
2 I None
mg I None
/ I None
day I None
, I None
folic I Chemical
acid O Chemical
1 I None
mg I None
/ I None
day I None
, I None
levothyroxine I Chemical
100 I None
microg I None
/ I None
day I None
, I None
pantoprazole I Chemical
40 I None
mg I None
/ I None
day I None
, I None
paroxetine I Chemical
40 I None
mg I None
/ I None
day I None
, I None
and I None
flecainide I Chemical
100 I None
mg I None
twice I None
daily I None
. I None
<eof> I None

<s> O None
Flecainide I Chemical
had I None
been I None
started I None
2 I None
weeks I None
prior I None
for I None
atrial I Disease
fibrillation O Disease
. I None
<eof> I None

<s> O None
Laboratory I None
test I None
findings I None
on I None
admission I None
were I None
notable I None
only I None
for I None
a I None
flecainide I Chemical
plasma I None
concentration I None
of I None
1360 I None
microg I None
/ I None
L I None
( I None
reference I None
range I None
200 I None
- I None
1000 I None
) I None
. I None
<eof> I None

<s> O None
A I None
metabolic I None
drug I None
interaction I None
between I None
flecainide I Chemical
and I None
paroxetine I Chemical
, I None
which I None
the I None
patient I None
had I None
been I None
taking I None
for I None
more I None
than I None
5 I None
years I None
, I None
was I None
considered I None
. I None
<eof> I None

<s> O None
Paroxetine I Chemical
was I None
discontinued I None
and I None
the I None
dose I None
of I None
<eof> I None

<s> O None
flecainide I Chemical
was I None
reduced I None
to I None
50 I None
mg I None
twice I None
daily I None
. I None
<eof> I None

<s> O None
Her I None
<eof> I None

<s> O None
delirium I Disease
resolved I None
3 I None
days I None
later I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Flecainide I Chemical
and I None
pharmacologically I None
similar I None
agents I None
that I None
interact I None
with I None
sodium I Chemical
channels I None
may I None
cause I None
delirium I Disease
in I None
susceptible I None
patients I None
. I None
<eof> I None

<s> O None
A I None
MEDLINE I None
search I None
( I None
1966-January I None
2009 I None
) I None
revealed I None
one I None
in I None
vivo I None
pharmacokinetic I None
study I None
on I None
the I None
interaction I None
between I None
flecainide I Chemical
, I None
a I None
CYP2D6 I None
substrate I None
, I None
and I None
paroxetine I Chemical
, I None
a I None
CYP2D6 I None
inhibitor I None
, I None
as I None
well I None
as I None
3 I None
case I None
reports I None
of I None
flecainide I Chemical
<eof> I None

<s> O None
-induced I None
delirium I Disease
. I None
<eof> I None

<s> O None
According I None
to I None
the I None
Naranjo I None
probability I None
scale I None
, I None
flecainide I Chemical
was I None
the I None
probable I None
cause I None
of I None
the I None
patient I None
's I None
delirium I Disease
; I None
the I None
Horn I None
Drug I None
Interaction I None
Probability I None
Scale I None
indicates I None
a I None
possible I None
pharmacokinetic I None
drug I None
interaction I None
between I None
flecainide I Chemical
and I None
paroxetine I Chemical
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Supratherapeutic I None
flecainide I Chemical
<eof> I None

<s> O None
plasma I None
concentrations I None
may I None
cause I None
delirium I Disease
. I None
<eof> I None

<s> O None
Because I None
toxicity I Disease
may I None
occur I None
when I None
flecainide I Chemical
is I None
prescribed I None
with I None
paroxetine I Chemical
and I None
other I None
potent I None
CYP2D6 I None
inhibitors I None
, I None
flecainide I Chemical
plasma I None
concentrations I None
should I None
be I None
monitored I None
closely I None
with I None
commencement I None
of I None
CYP2D6 I None
inhibitors I None
. I None
<eof> I None

<s> O None
Efficacy I None
of I None
everolimus I Chemical
<eof> I None

<s> O None
( I None
RAD001 I Chemical
) I None
in I None
patients I None
with I None
advanced I None
NSCLC I Disease
previously I None
treated I None
with I None
chemotherapy I None
alone I None
or I None
with I None
chemotherapy I None
and I None
EGFR I None
inhibitors I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Treatment I None
options I None
are I None
scarce I None
in I None
pretreated I None
advanced I None
non I Disease
- O Disease
small O Disease
- O Disease
cell O Disease
lung O Disease
cancer O Disease
<eof> I None

<s> O None
( I None
NSCLC I Disease
) I None
patients I None
. I None
<eof> I None

<s> O None
RAD001 I Chemical
, I None
an I None
oral I None
inhibitor I None
of I None
the I None
mammalian I None
target I None
of I None
rapamycin I Chemical
<eof> I None

<s> O None
( I None
mTOR I None
) I None
, I None
has I None
shown I None
phase I None
I I None
efficacy I None
in I None
NSCLC I Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Stage I None
IIIb I None
or I None
IV I None
NSCLC I Disease
patients I None
, I None
with I None
two I None
or I None
fewer I None
prior I None
chemotherapy I None
regimens I None
, I None
one I None
platinum I Chemical
<eof> I None

<s> O None
based I None
( I None
stratum I None
1 I None
) I None
or I None
both I None
chemotherapy I None
and I None
epidermal I None
growth I None
factor I None
receptor I None
tyrosine I Chemical
kinase I None
inhibitors I None
( I None
stratum I None
2 I None
) I None
, I None
received I None
RAD001 I Chemical
<eof> I None

<s> O None
10 I None
mg I None
/ I None
day I None
until I None
progression I None
or I None
unacceptable I None
toxicity I Disease
. I None
<eof> I None

<s> O None
Primary I None
objective I None
was I None
overall I None
response I None
rate I None
( I None
ORR I None
) I None
. I None
<eof> I None

<s> O None
Analyses I None
of I None
markers I None
associated I None
with I None
the I None
mTOR I None
pathway I None
were I None
carried I None
out I None
on I None
archival I None
tumor I Disease
from I None
a I None
subgroup I None
using I None
immunohistochemistry I None
( I None
IHC I None
) I None
and I None
direct I None
mutation I None
sequencing I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Eighty I None
- I None
five I None
patients I None
were I None
enrolled I None
, I None
42 I None
in I None
stratum I None
1 I None
and I None
43 I None
in I None
stratum I None
. I None
<eof> I None

<s> O None
ORR I None
was I None
4.7 I None
% I None
( I None
7.1 I None
% I None
stratum I None
1 I None
; I None
2.3 I None
% I None
stratum I None
2 I None
) I None
. I None
<eof> I None

<s> O None
Overall I None
disease I None
control I None
rate I None
was I None
47.1 I None
% I None
. I None
<eof> I None

<s> O None
Median I None
progression I None
- I None
free I None
survivals I None
( I None
PFSs I None
) I None
were I None
2.6 I None
( I None
stratum I None
1 I None
) I None
and I None
2.7 I None
months I None
( I None
stratum I None
2 I None
) I None
. I None
<eof> I None

<s> O None
Common I None
> I None
or I None
= I None
grade I None
3 I None
events I None
were I None
fatigue I Disease
, I None
dyspnea I Disease
, I None
stomatitis I Disease
, I None
anemia I Disease
, I None
and I None
thrombocytopenia I Disease
. I None
<eof> I None

<s> O None
Pneumonitis I Disease
, I None
probably I None
or I None
possibly I None
related I None
, I None
mainly I None
grade I None
1/2 I None
, I None
occurred I None
in I None
25 I None
% I None
. I None
<eof> I None

<s> O None
Cox I None
regression I None
analysis I None
of I None
IHC I None
scores I None
found I None
that I None
only I None
phospho I None
AKT I None
( I None
pAKT I None
) I None
was I None
a I None
significant I None
independent I None
predictor I None
of I None
worse I None
PFS I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
RAD001 I Chemical
10 I None
mg I None
/ I None
day I None
was I None
well I None
tolerated I None
, I None
showing I None
modest I None
clinical I None
activity I None
in I None
pretreated I None
NSCLC I Disease
. I None
<eof> I None

<s> O None
Evaluation I None
of I None
RAD001 I Chemical
plus I None
standard I None
therapy I None
for I None
metastatic I None
NSCLC I Disease
continues I None
. I None
<eof> I None

<s> O None
Posttransplant I None
anemia I Disease
: I None
the I None
role I None
of I None
sirolimus I Chemical
. I None
<eof> I None

<s> O None
Posttransplant I None
anemia I Disease
is I None
a I None
common I None
problem I None
that I None
may I None
hinder I None
patients I None
' I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
It I None
occurs I None
in I None
12 I None
to I None
76 I None
% I None
of I None
patients I None
, I None
and I None
is I None
most I None
common I None
in I None
the I None
immediate I None
posttransplant I None
period I None
. I None
<eof> I None

<s> O None
A I None
variety I None
of I None
factors I None
have I None
been I None
identified I None
that I None
increase I None
the I None
risk I None
of I None
posttransplant I None
anemia I Disease
, I None
of I None
which I None
the I None
level I None
of I None
renal I None
function I None
is I None
most I None
important I None
. I None
<eof> I None

<s> O None
Sirolimus I Chemical
, I None
a I None
mammalian I None
target I None
of I None
rapamycin I Chemical
inhibitor I None
, I None
has I None
been I None
implicated I None
as I None
playing I None
a I None
special I None
role I None
in I None
posttransplant I None
anemia I Disease
. I None
<eof> I None

<s> O None
This I None
review I None
considers I None
<eof> I None

<s> O None
anemia I Disease
associated I None
with I None
sirolimus I Chemical
, I None
including I None
its I None
presentation I None
, I None
mechanisms I None
, I None
and I None
management I None
. I None
<eof> I None

<s> O None
Coronary I None
computerized I None
tomography I None
angiography I None
for I None
rapid I None
discharge I None
of I None
low I None
- I None
risk I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Most I None
patients I None
presenting I None
to I None
emergency I None
departments I None
( I None
EDs I None
) I None
with I None
cocaine I Chemical
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
are I None
admitted I None
for I None
at I None
least I None
12 I None
hours I None
and I None
receive I None
a I None
" I None
rule I None
out I None
acute I Disease
coronary O Disease
syndrome O Disease
" I None
protocol I None
, I None
often I None
with I None
noninvasive I None
testing I None
prior I None
to I None
discharge I None
. I None
<eof> I None

<s> O None
In I None
patients I None
without I None
cocaine I Chemical
use I None
, I None
coronary I None
computerized I None
tomography I None
angiography I None
( I None
CTA I None
) I None
has I None
been I None
shown I None
to I None
be I None
useful I None
for I None
identifying I None
a I None
group I None
of I None
patients I None
at I None
low I None
risk I None
for I None
cardiac I None
events I None
who I None
can I None
be I None
safely I None
discharged I None
. I None
<eof> I None

<s> O None
It I None
is I None
unclear I None
whether I None
a I None
coronary I None
CTA I None
strategy I None
would I None
be I None
efficacious I None
in I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
, I None
as I None
coronary I Disease
vasospasm O Disease
may I None
account I None
for I None
some I None
of I None
the I None
ischemia I Disease
. I None
<eof> I None

<s> O None
We I None
studied I None
whether I None
a I None
negative I None
coronary I None
CTA I None
in I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
could I None
identify I None
a I None
subset I None
safe I None
for I None
discharge I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
prospectively I None
evaluated I None
the I None
safety I None
of I None
coronary I None
CTA I None
for I None
low I None
- I None
risk I None
patients I None
who I None
presented I None
to I None
the I None
ED I None
with I None
cocaineassociated I None
chest I Disease
pain O Disease
<eof> I None

<s> O None
( I None
self I None
- I None
reported I None
or I None
positive I None
urine I None
test I None
) I None
. I None
<eof> I None

<s> O None
Consecutive I None
patients I None
received I None
either I None
immediate I None
coronary I None
CTA I None
in I None
the I None
ED I None
( I None
without I None
serial I None
markers I None
) I None
or I None
underwent I None
coronary I None
CTA I None
after I None
a I None
brief I None
observation I None
period I None
with I None
serial I None
cardiac I None
marker I None
measurements I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
negative I None
coronary I None
CTA I None
( I None
maximal I None
stenosis I Disease
less I None
than I None
50 I None
% I None
) I None
were I None
discharged I None
. I None
<eof> I None

<s> O None
The I None
main I None
outcome I None
was I None
30-day I None
cardiovascular I None
death I None
or I None
myocardial I Disease
infarction O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
59 I None
patients I None
with I None
cocaine I Chemical
<eof> I None

<s> O None
-associated I None
<eof> I None

<s> O None
chest I Disease
pain O Disease
were I None
evaluated I None
. I None
<eof> I None

<s> O None
Patients I None
had I None
a I None
mean I None
age I None
of I None
45.6 I None
+ I None
/- I None
<eof> I None

<s> O None
6.6 I None
yrs I None
and I None
were I None
86 I None
% I None
black I None
, I None
66 I None
% I None
male I None
. I None
<eof> I None

<s> O None
Seventy I None
- I None
nine I None
percent I None
had I None
a I None
normal I None
or I None
nonspecific I None
ECG I None
and I None
85 I None
% I None
had I None
a I None
TIMI I None
score I None
< I None
2 I None
. I None
<eof> I None

<s> O None
Twenty I None
patients I None
received I None
coronary I None
CTA I None
immediately I None
in I None
the I None
ED I None
, I None
18 I None
of I None
whom I None
were I None
discharged I None
following I None
CTA I None
( I None
90 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Thirty I None
- I None
nine I None
received I None
coronary I None
CTA I None
after I None
a I None
brief I None
observation I None
period I None
, I None
with I None
37 I None
discharged I None
home I None
following I None
CTA I None
( I None
95 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Six I None
patients I None
had I None
coronary I Disease
stenosis O Disease
<eof> I None

<s> O None
> I None
<eof> I None

<s> O None
or=50 I None
% I None
. I None
<eof> I None

<s> O None
During I None
the I None
30-day I None
follow I None
- I None
up I None
period I None
, I None
no I None
patients I None
died I None
of I None
a I None
cardiovascular I None
event I None
( I None
0 I None
% I None
; I None
95 I None
% I None
CI I None
, I None
0 I None
- I None
6.1 I None
% I None
) I None
and I None
no I None
patient I None
sustained I None
a I None
nonfatal I None
myocardial I Disease
infarction O Disease
<eof> I None

<s> O None
( I None
0 I None
% I None
; I None
95 I None
% I None
CI I None
, I None
0 I None
- I None
6.1 I None
% I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Although I None
cocaine I Chemical
-associated I None
myocardial I Disease
ischemia O Disease
can I None
result I None
from I None
coronary I None
vasoconstriction I None
, I None
patients I None
with I None
cocaine I Chemical
associated I None
chest I Disease
pain O Disease
, I None
a I None
non- I None
ischemic I Disease
ECG I None
, I None
and I None
a I None
TIMI I None
risk I None
score I None
< I None
2 I None
may I None
be I None
safely I None
discharged I None
from I None
the I None
ED I None
after I None
a I None
negative I None
coronary I None
CTA I None
with I None
a I None
low I None
risk I None
of I None
30-day I None
adverse I None
events I None
. I None
<eof> I None

<s> O None
Late I None
fulminant I None
posterior I Disease
reversible O Disease
encephalopathy O Disease
syndrome O Disease
after I None
liver I None
transplant I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
Posterior I Disease
leukoencephalopathy O Disease
due I None
to I None
calcineurin I None
- I None
inhibitor I None
- I None
related I None
neurotoxicity I Disease
is I None
a I None
rare I None
but I None
severe I None
complication I None
that I None
results I None
from I None
treatment I None
with I None
immunosuppressive I None
agents I None
( I None
primarily I None
those I None
administered I None
after I None
a I None
liver I None
or I None
kidney I None
transplant I None
) I None
. I None
<eof> I None

<s> O None
The I None
pathophysiologic I None
mechanisms I None
of I None
that I None
disorder I None
remain I None
unknown I None
. I None
<eof> I None

<s> O None
CASE I None
: I None
<eof> I None

<s> O None
We I None
report I None
the I None
case I None
of I None
a I None
46-year I None
- I None
old I None
woman I None
who I None
received I None
a I None
liver I None
transplant I None
in I None
our I None
center I None
as I None
treatment I None
for I None
alcoholic I Disease
cirrhosis O Disease
and I None
in I None
whom I None
either I None
a I None
fulminant I None
course I None
of I None
posterior I Disease
leukoencephalopathy O Disease
or I None
posterior I Disease
reversible O Disease
encephalopathy O Disease
syndrome O Disease
developed I None
110 I None
days I None
after I None
transplant I None
. I None
<eof> I None

<s> O None
After I None
an I None
initially I None
uneventful I None
course I None
after I None
the I None
transplant I None
, I None
the I None
patient I None
rapidly I None
fell I None
into I None
deep I None
coma I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Cerebral I None
MRI I None
scan I None
showed I None
typical I None
signs I None
of I None
enhancement I None
in I None
the I None
pontine I None
and I None
posterior I None
regions I None
. I None
<eof> I None

<s> O None
Switching I None
the I None
immunosuppressive I None
regimen I None
from I None
tacrolimus I Chemical
to I None
cyclosporine I Chemical
did I None
not I None
improve I None
the I None
clinical I None
situation I None
. I None
<eof> I None

<s> O None
The I None
termination I None
of I None
treatment I None
with I None
any I None
calcineurin I None
inhibitor I None
resulted I None
in I None
a I None
complete I None
resolution I None
of I None
that I None
complication I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Posterior I Disease
reversible O Disease
encephalopathy O Disease
syndrome O Disease
after I None
liver I None
transplant I None
is I None
rare I None
. I None
<eof> I None

<s> O None
We I None
recommend I None
a I None
complete I None
cessation I None
of I None
any I None
calcineurin I None
inhibitor I None
rather I None
than I None
a I None
dose I None
reduction I None
. I None
<eof> I None

<s> O None
Prolonged I None
hypothermia I Disease
as I None
a I None
bridge I None
to I None
recovery I None
for I None
cerebral I Disease
edema O Disease
and I None
intracranial I Disease
hypertension O Disease
associated I None
with I None
fulminant I Disease
hepatic O Disease
failure O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
To I None
review I None
evidence I None
- I None
based I None
treatment I None
options I None
in I None
patients I None
with I None
cerebral I Disease
edema O Disease
<eof> I None

<s> O None
complicating I None
fulminant I Disease
hepatic O Disease
failure O Disease
<eof> I None

<s> O None
( I None
FHF I Disease
) I None
and I None
discuss I None
the I None
potential I None
applications I None
of I None
hypothermia I Disease
. I None
<eof> I None

<s> O None
METHOD I None
: I None
<eof> I None

<s> O None
Case I None
- I None
based I None
observations I None
from I None
a I None
medical I None
intensive I None
care I None
unit I None
( I None
MICU I None
) I None
in I None
a I None
tertiary I None
care I None
facility I None
in I None
a I None
27-year I None
- I None
old I None
female I None
with I None
FHF I Disease
from I None
acetaminophen I Chemical
and I None
resultant I None
cerebral I Disease
edema O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Our I None
patient I None
was I None
admitted I None
to I None
the I None
MICU I None
after I None
being I None
found I None
unresponsive I None
with I None
presumed I None
toxicity I Disease
from I None
acetaminophen I Chemical
which I None
was I None
ingested I None
over I None
a I None
2-day I None
period I None
. I None
<eof> I None

<s> O None
The I None
patient I None
had I None
depressed I None
of I None
mental I None
status I None
lasting I None
at I None
least I None
24 I None
h I None
prior I None
to I None
admission I None
. I None
<eof> I None

<s> O None
Initial I None
evaluation I None
confirmed I None
FHF I Disease
from I None
acetaminophen I Chemical
and I None
cerebral I Disease
edema O Disease
. I None
<eof> I None

<s> O None
The I None
patient I None
was I None
treated I None
with I None
hyperosmolar I None
therapy I None
, I None
hyperventilation I Disease
, I None
sedation I None
, I None
and I None
chemical I None
paralysis I Disease
. I None
<eof> I None

<s> O None
Her I None
intracranial I None
pressure I None
remained I None
elevated I None
despite I None
maximal I None
medical I None
therapy I None
. I None
<eof> I None

<s> O None
We I None
then I None
initiated I None
therapeutic I None
hypothermia I Disease
which I None
was I None
continued I None
for I None
5 I None
days I None
. I None
<eof> I None

<s> O None
At I None
re I None
- I None
warming I None
, I None
patient I None
had I None
resolution I None
of I None
her I None
cerebral I Disease
edema O Disease
and I None
intracranial I Disease
hypertension O Disease
. I None
<eof> I None

<s> O None
At I None
discharge I None
, I None
she I None
had I None
complete I None
recovery I None
of I None
neurological I None
and I None
hepatic I None
functions I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
patients I None
with I None
FHF I Disease
and I None
cerebral I Disease
edema O Disease
from I None
acetaminophen I Chemical
<eof> I None

<s> O None
overdose I Disease
, I None
prolonged I None
therapeutic I None
hypothermia I Disease
could I None
potentially I None
be I None
used I None
as I None
a I None
life I None
saving I None
therapy I None
and I None
a I None
bridge I None
to I None
hepatic I None
and I None
neurological I None
recovery I None
. I None
<eof> I None

<s> O None
A I None
clinical I None
trial I None
of I None
hypothermia I Disease
in I None
patients I None
with I None
this I None
condition I None
is I None
warranted I None
. I None
<eof> I None

<s> O None
Binasal I Disease
visual O Disease
field O Disease
defects O Disease
are I None
not I None
specific I None
to I None
vigabatrin I Chemical
. I None
<eof> I None

<s> O None
This I None
study I None
investigated I None
the I None
visual I Disease
defects O Disease
associated I None
with I None
the I None
antiepileptic I None
drug I None
vigabatrin I Chemical
<eof> I None

<s> O None
( I None
VGB I Chemical
) I None
. I None
<eof> I None

<s> O None
Two I None
hundred I None
four I None
people I None
with I None
epilepsy I Disease
were I None
grouped I None
on I None
the I None
basis I None
of I None
antiepileptic I None
drug I None
therapy I None
( I None
current I None
, I None
previous I None
, I None
or I None
no I None
exposure I None
to I None
VGB I Chemical
) I None
. I None
<eof> I None

<s> O None
Groups I None
were I None
matched I None
with I None
respect I None
to I None
age I None
, I None
gender I None
, I None
and I None
seizure I Disease
frequency I None
. I None
<eof> I None

<s> O None
All I None
patients I None
underwent I None
objective I None
assessment I None
of I None
electrophysiological I None
function I None
( I None
wide I None
- I None
field I None
multifocal I None
electroretinography I None
) I None
and I None
conventional I None
visual I None
field I None
testing I None
( I None
static I None
perimetry I None
) I None
. I None
<eof> I None

<s> O None
Bilateral I None
visual I None
field I None
constriction I None
was I None
observed I None
in I None
59 I None
% I None
of I None
patients I None
currently I None
taking I None
VGB I Chemical
, I None
43 I None
% I None
of I None
patients I None
who I None
previously I None
took I None
VGB I Chemical
, I None
and I None
24 I None
% I None
of I None
patients I None
with I None
no I None
exposure I None
to I None
VGB I Chemical
. I None
<eof> I None

<s> O None
Assessment I None
of I None
retinal I None
function I None
revealed I None
abnormal I None
responses I None
in I None
48 I None
% I None
of I None
current I None
VGB I Chemical
users I None
and I None
22 I None
% I None
of I None
prior I None
VGB I Chemical
users I None
, I None
but I None
in I None
none I None
of I None
the I None
patients I None
without I None
previous I None
exposure I None
to I None
VGB I Chemical
. I None
<eof> I None

<s> O None
Bilateral I Disease
visual O Disease
field O Disease
abnormalities O Disease
are I None
common I None
in I None
the I None
treated I None
epilepsy I Disease
population I None
, I None
irrespective I None
of I None
drug I None
history I None
. I None
<eof> I None

<s> O None
Assessment I None
by I None
conventional I None
static I None
perimetry I None
may I None
neither I None
be I None
sufficiently I None
sensitive I None
nor I None
specific I None
to I None
reliably I None
identify I None
retinal I Disease
toxicity O Disease
associated I None
with I None
VGB I Chemical
. I None
<eof> I None

<s> O None
Smoking I None
of I None
crack I Chemical
cocaine O Chemical
as I None
a I None
risk I None
factor I None
for I None
HIV I Disease
infection O Disease
among I None
people I None
who I None
use I None
injection I None
drugs I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Little I None
is I None
known I None
about I None
the I None
possible I None
role I None
that I None
smoking I None
<eof> I None

<s> O None
crack I Chemical
cocaine O Chemical
has I None
on I None
the I None
incidence I None
of I None
HIV I Disease
infection O Disease
. I None
<eof> I None

<s> O None
Given I None
the I None
increasing I None
use I None
of I None
crack I Chemical
cocaine O Chemical
, I None
we I None
sought I None
to I None
examine I None
whether I None
use I None
of I None
this I None
illicit I None
drug I None
has I None
become I None
a I None
risk I None
factor I None
for I None
HIV I Disease
infection O Disease
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
included I None
data I None
from I None
people I None
participating I None
in I None
the I None
Vancouver I None
Injection I None
Drug I None
Users I None
Study I None
who I None
reported I None
injecting I None
illicit I None
drugs I None
at I None
least I None
once I None
in I None
the I None
month I None
before I None
enrolment I None
, I None
lived I None
in I None
the I None
greater I None
Vancouver I None
area I None
, I None
were I None
HIV I None
- I None
negative I None
at I None
enrolment I None
and I None
completed I None
at I None
least I None
1 I None
follow I None
- I None
up I None
study I None
visit I None
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
the I None
risk I None
of I None
HIV I Disease
seroconversion O Disease
among I None
daily I None
smokers I None
of I None
crack I Chemical
cocaine O Chemical
changed I None
over I None
time I None
, I None
we I None
used I None
Cox I None
proportional I None
hazards I None
regression I None
and I None
divided I None
the I None
study I None
into I None
3 I None
periods I None
: I None
May I None
1 I None
, I None
1996-Nov I None
. I None
<eof> I None

<s> O None
30 I None
, I None
1999 I None
( I None
period I None
1 I None
) I None
, I None
Dec. I None
1 I None
, I None
1999-Nov I None
. I None
<eof> I None

<s> O None
30 I None
, I None
2002 I None
( I None
period I None
2 I None
) I None
, I None
and I None
Dec. I None
1 I None
, I None
2002-Dec I None
. I None
<eof> I None

<s> O None
30 I None
, I None
2005 I None
( I None
period I None
3 I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Overall I None
, I None
1048 I None
eligible I None
injection I None
drug I None
users I None
were I None
included I None
in I None
our I None
study I None
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
137 I None
acquired I None
<eof> I None

<s> O None
HIV I Disease
infection O Disease
during I None
follow I None
- I None
up I None
. I None
<eof> I None

<s> O None
The I None
mean I None
proportion I None
of I None
participants I None
who I None
reported I None
daily I None
smoking I None
of I None
crack I Chemical
cocaine O Chemical
increased I None
from I None
11.6 I None
% I None
in I None
period I None
1 I None
to I None
39.7 I None
% I None
in I None
period I None
3 I None
. I None
<eof> I None

<s> O None
After I None
adjusting I None
for I None
potential I None
confounders I None
, I None
we I None
found I None
that I None
the I None
risk I None
of I None
HIV I Disease
seroconversion O Disease
among I None
participants I None
who I None
were I None
daily I None
smokers I None
of I None
crack I Chemical
cocaine O Chemical
increased I None
over I None
time I None
( I None
period I None
1 I None
: I None
hazard I None
ratio I None
[ I None
HR I None
] I None
1.03 I None
, I None
95 I None
% I None
confidence I None
interval I None
[ I None
CI I None
] I None
0.57 I None
- I None
1.85 I None
; I None
period I None
2 I None
: I None
HR I None
1.68 I None
, I None
95 I None
% I None
CI I None
1.01 I None
- I None
2.80 I None
; I None
and I None
period I None
3 I None
: I None
HR I None
2.74 I None
, I None
95 I None
% I None
CI I None
1.06 I None
- I None
7.11 I None
) I None
. I None
<eof> I None

<s> O None
INTERPRETATION I None
: I None
<eof> I None

<s> O None
Smoking I None
of I None
crack I Chemical
cocaine O Chemical
was I None
found I None
to I None
be I None
an I None
independent I None
risk I None
factor I None
for I None
HIV I Disease
seroconversion O Disease
among I None
people I None
who I None
were I None
injection I None
drug I None
users I None
. I None
<eof> I None

<s> O None
This I None
finding I None
points I None
to I None
the I None
urgent I None
need I None
for I None
evidence I None
- I None
based I None
public I None
health I None
initiatives I None
targeted I None
at I None
people I None
who I None
smoke I None
crack I Chemical
cocaine O Chemical
. I None
<eof> I None

<s> O None
Fluoxetine I Chemical
improves I None
the I None
memory I Disease
deficits O Disease
caused I None
by I None
the I None
chemotherapy I None
agent I None
5-fluorouracil I Chemical
. I None
<eof> I None

<s> O None
Cancer I Disease
patients I None
who I None
have I None
been I None
treated I None
with I None
systemic I None
adjuvant I None
chemotherapy I None
have I None
described I None
experiencing I None
deteriorations I None
in I None
cognition I None
. I None
<eof> I None

<s> O None
A I None
widely I None
used I None
chemotherapeutic I None
agent I None
, I None
5-fluorouracil I Chemical
<eof> I None

<s> O None
( I None
5-FU I Chemical
) I None
, I None
readily I None
crosses I None
the I None
blood I None
- I None
brain I None
barrier I None
and I None
so I None
could I None
have I None
a I None
direct I None
effect I None
on I None
brain I None
function I None
. I None
<eof> I None

<s> O None
In I None
particular I None
this I None
anti I None
mitotic I None
drug I None
could I None
reduce I None
cell I None
proliferation I None
in I None
the I None
neurogenic I None
regions I None
of I None
the I None
adult I None
brain I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
reports I None
indicate I None
that I None
hippocampal I None
dependent I None
neurogenesis I None
and I None
cognition I None
are I None
enhanced I None
by I None
the I None
SSRI I Chemical
antidepressant I None
Fluoxetine I Chemical
. I None
<eof> I None

<s> O None
In I None
this I None
investigation I None
the I None
behavioural I None
effects I None
of I None
chronic I None
( I None
two I None
week I None
) I None
treatment I None
with I None
5-FU I Chemical
and I None
<eof> I None

<s> O None
( I None
three I None
weeks I None
) I None
with I None
Fluoxetine I Chemical
either I None
separately I None
or I None
in I None
combination I None
with I None
5-FU I Chemical
were I None
tested I None
on I None
adult I None
Lister I None
hooded I None
rats I None
. I None
<eof> I None

<s> O None
Behavioural I None
effects I None
were I None
tested I None
using I None
a I None
context I None
dependent I None
conditioned I None
emotional I None
response I None
test I None
( I None
CER I None
) I None
which I None
showed I None
that I None
animals I None
treated I None
with I None
5-FU I Chemical
had I None
a I None
significant I None
reduction I None
in I None
freezing I None
time I None
compared I None
to I None
controls I None
. I None
<eof> I None

<s> O None
A I None
separate I None
group I None
of I None
animals I None
was I None
tested I None
using I None
a I None
hippocampal I None
dependent I None
spatial I None
working I None
memory I None
test I None
, I None
the I None
object I None
location I None
recognition I None
test I None
( I None
OLR I None
) I None
. I None
<eof> I None

<s> O None
Animals I None
treated I None
only I None
with I None
5-FU I Chemical
showed I None
significant I None
deficits I None
in I None
their I None
ability I None
to I None
carry I None
out I None
the I None
OLR I None
task I None
but I None
co I None
administration I None
of I None
Fluoxetine I Chemical
improved I None
their I None
performance I None
. I None
<eof> I None

<s> O None
5-FU I Chemical
chemotherapy I None
caused I None
a I None
significant I None
reduction I None
in I None
the I None
number I None
of I None
proliferating I None
cells I None
in I None
the I None
sub I None
granular I None
zone I None
of I None
the I None
dentate I None
gyrus I None
compared I None
to I None
controls I None
. I None
<eof> I None

<s> O None
This I None
reduction I None
was I None
eliminated I None
when I None
Fluoxetine I Chemical
was I None
co I None
administered I None
with I None
5-FU I Chemical
. I None
<eof> I None

<s> O None
Fluoxetine I Chemical
on I None
its I None
own I None
had I None
no I None
effect I None
on I None
proliferating I None
cell I None
number I None
or I None
behaviour I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
5-FU I Chemical
can I None
negatively I None
affect I None
both I None
cell I None
proliferation I None
and I None
hippocampal I None
dependent I None
working I None
memory I None
and I None
that I None
these I None
deficits I None
can I None
be I None
reversed I None
by I None
the I None
simultaneous I None
administration I None
of I None
the I None
antidepressant I None
Fluoxetine I Chemical
. I None
<eof> I None

<s> O None
Liver I None
- I None
specific I None
ablation I None
of I None
integrin I None
- I None
linked I None
kinase I None
in I None
mice I None
results I None
in I None
enhanced I None
and I None
prolonged I None
cell I None
proliferation I None
and I None
hepatomegaly I Disease
after I None
phenobarbital I Chemical
administration I None
. I None
<eof> I None

<s> O None
We I None
have I None
recently I None
demonstrated I None
that I None
disruption I None
of I None
extracellular I None
matrix I None
( I None
ECM)/integrin I None
signaling I None
via I None
elimination I None
of I None
integrin I None
- I None
linked I None
kinase I None
( I None
ILK I None
) I None
in I None
hepatocytes I None
interferes I None
with I None
signals I None
leading I None
to I None
termination I None
of I None
liver I None
regeneration I None
. I None
<eof> I None

<s> O None
This I None
study I None
investigates I None
the I None
role I None
of I None
ILK I None
in I None
liver I None
enlargement I None
induced I None
by I None
phenobarbital I Chemical
<eof> I None

<s> O None
( I None
PB I Chemical
) I None
. I None
<eof> I None

<s> O None
Wild I None
- I None
type I None
( I None
WT I None
) I None
and I None
ILK I None
: I None
<eof> I None

<s> O None
liver-/- I None
mice I None
were I None
given I None
PB I Chemical
( I None
0.1 I None
% I None
in I None
drinking I None
water I None
) I None
for I None
10 I None
days I None
. I None
<eof> I None

<s> O None
Livers I None
were I None
harvested I None
on I None
2 I None
, I None
5 I None
, I None
and I None
10 I None
days I None
during I None
PB I Chemical
administration I None
. I None
<eof> I None

<s> O None
In I None
the I None
hepatocyte I None
- I None
specific I None
ILK I None
/ I None
liver-/- I None
mice I None
, I None
the I None
liver I None
: I None
body I None
weight I None
ratio I None
was I None
more I None
than I None
double I None
as I None
compared I None
to I None
0 I None
h I None
at I None
day I None
2 I None
( I None
2.5 I None
times I None
) I None
, I None
while I None
at I None
days I None
5 I None
and I None
10 I None
, I None
it I None
was I None
enlarged I None
three I None
times I None
. I None
<eof> I None

<s> O None
In I None
the I None
WT I None
mice I None
, I None
the I None
increase I None
was I None
as I None
expected I None
from I None
previous I None
literature I None
( I None
1.8 I None
times I None
) I None
and I None
seems I None
to I None
have I None
leveled I None
off I None
after I None
day I None
2 I None
. I None
<eof> I None

<s> O None
There I None
were I None
slightly I None
increased I None
proliferating I None
cell I None
nuclear I None
antigen I None
- I None
positive I None
cells I None
in I None
the I None
ILK I None
/ I None
liver-/- I None
animals I None
at I None
day I None
2 I None
as I None
compared I None
to I None
WT I None
after I None
PB I Chemical
administration I None
. I None
<eof> I None

<s> O None
In I None
the I None
WT I None
animals I None
, I None
the I None
proliferative I None
response I None
had I None
come I None
back I None
to I None
normal I None
by I None
days I None
5 I None
and I None
10 I None
. I None
<eof> I None

<s> O None
Hepatocytes I None
of I None
the I None
ILK I None
/ I None
liver-/- I None
mice I None
continued I None
to I None
proliferate I None
up I None
until I None
day I None
10 I None
. I None
<eof> I None

<s> O None
ILK I None
/ I None
liver-/- I None
mice I None
also I None
showed I None
increased I None
expression I None
of I None
key I None
genes I None
involved I None
in I None
hepatocyte I None
proliferation I None
at I None
different I None
time I None
points I None
during I None
PB I Chemical
administration I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
ECM I None
proteins I None
communicate I None
with I None
the I None
signaling I None
machinery I None
of I None
dividing I None
cells I None
via I None
ILK I None
to I None
regulate I None
hepatocyte I None
proliferation I None
and I None
termination I None
of I None
the I None
proliferative I None
response I None
. I None
<eof> I None

<s> O None
Lack I None
of I None
ILK I None
in I None
the I None
hepatocytes I None
imparts I None
prolonged I None
proliferative I None
response I None
not I None
only I None
to I None
stimuli I None
related I None
to I None
liver I None
regeneration I None
but I None
also I None
to I None
xenobiotic I None
chemical I None
mitogens I None
, I None
such I None
as I None
PB I Chemical
. I None
<eof> I None

<s> O None
Decreased I None
Expression I None
of I None
Na I Chemical
<eof> I None

<s> O None
/ I None
K I Chemical
-ATPase I None
, I None
NHE3 I None
, I None
NBC1 I None
, I None
AQP1 I None
and I None
OAT I None
in I None
Gentamicin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
Nephropathy I Disease
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
was I None
aimed I None
to I None
determine I None
whether I None
there I None
is I None
an I None
altered I None
regulation I None
of I None
tubular I None
transporters I None
in I None
gentamicin I Chemical
-induced I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
Sprague I None
- I None
Dawley I None
male I None
rats I None
( I None
200~250 I None
g I None
) I None
were I None
subcutaneously I None
injected I None
with I None
gentamicin I Chemical
<eof> I None

<s> O None
( I None
100 I None
mg I None
/ I None
kg I None
per I None
day I None
) I None
for I None
7 I None
days I None
, I None
and I None
the I None
expression I None
of I None
tubular I None
transporters I None
was I None
determined I None
by I None
immunoblotting I None
and I None
immunohistochemistry I None
. I None
<eof> I None

<s> O None
The I None
mRNA I None
and I None
protein I None
expression I None
of I None
OAT I None
was I None
also I None
determined I None
. I None
<eof> I None

<s> O None
Gentamicin I Chemical
<eof> I None

<s> O None
-treated I None
rats I None
exhibited I None
significantly I None
decreased I None
creatinine I Chemical
clearance I None
along I None
with I None
increased I None
plasma I None
creatinine I Chemical
levels I None
. I None
<eof> I None

<s> O None
Accordingly I None
, I None
the I None
fractional I None
excretion I None
of I None
sodium I Chemical
increased I None
. I None
<eof> I None

<s> O None
Urine I None
volume I None
was I None
increased I None
, I None
while I None
urine I None
osmolality I None
and I None
free I None
water I None
reabsorption I None
were I None
decreased I None
. I None
<eof> I None

<s> O None
Immunoblotting I None
and I None
immunohistochemistry I None
revealed I None
decreased I None
expression I None
of I None
Na I Chemical
<eof> I None

<s> O None
( I None
+ I None
) I None
/ I None
K I Chemical
( I None
+ I None
) I None
<eof> I None

<s> O None
-ATPase I None
, I None
NHE3 I None
, I None
NBC1 I None
, I None
and I None
AQP1 I None
in I None
the I None
kidney I None
of I None
<eof> I None

<s> O None
gentamicin I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
OAT1 I None
and I None
OAT3 I None
was I None
also I None
decreased I None
. I None
<eof> I None

<s> O None
Gentamicin I Chemical
-induced I None
<eof> I None

<s> O None
nephropathy I Disease
may I None
at I None
least I None
in I None
part I None
be I None
causally I None
related I None
with I None
a I None
decreased I None
expression I None
of I None
Na I Chemical
( I None
+ I None
) I None
<eof> I None

<s> O None
/ I None
K I Chemical
( I None
+ I None
) I None
-ATPase I None
, I None
NHE3 I None
, I None
NBC1 I None
, I None
AQP1 I None
and I None
OAT I None
. I None
<eof> I None

<s> O None
Longitudinal I None
association I None
of I None
alcohol I Chemical
use I None
with I None
HIV I Disease
disease O Disease
progression I None
and I None
psychological I None
health I None
of I None
women I None
with I None
HIV I None
. I None
<eof> I None

<s> O None
We I None
evaluated I None
the I None
association I None
of I None
alcohol I Chemical
consumption I None
and I None
depression I Disease
, I None
and I None
their I None
effects I None
on I None
HIV I Disease
disease O Disease
progression I None
among I None
women I None
with I None
HIV I None
. I None
<eof> I None

<s> O None
The I None
study I None
included I None
871 I None
women I None
with I None
HIV I None
who I None
were I None
recruited I None
from I None
1993 I None
- I None
1995 I None
in I None
four I None
US I None
cities I None
. I None
<eof> I None

<s> O None
The I None
participants I None
had I None
physical I None
examination I None
, I None
medical I None
record I None
extraction I None
, I None
and I None
venipuncture I None
, I None
CD4+T I None
- I None
cell I None
counts I None
determination I None
, I None
measurement I None
of I None
depression I Disease
symptoms I None
( I None
using I None
the I None
self I None
- I None
report I None
Center I None
for I None
Epidemiological I None
Studies- I None
<eof> I None

<s> O None
Depression I Disease
Scale I None
) I None
, I None
and I None
alcohol I Chemical
use I None
assessment I None
at I None
enrollment I None
, I None
and I None
semiannually I None
until I None
March I None
2000 I None
. I None
<eof> I None

<s> O None
Multilevel I None
random I None
coefficient I None
ordinal I None
models I None
as I None
well I None
as I None
multilevel I None
models I None
with I None
joint I None
responses I None
were I None
used I None
in I None
the I None
analysis I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
significant I None
association I None
between I None
level I None
of I None
alcohol I Chemical
use I None
and I None
CD4 I None
+ I None
T I None
- I None
cell I None
counts I None
. I None
<eof> I None

<s> O None
When I None
participants I None
were I None
stratified I None
by I None
antiretroviral I None
therapy I None
( I None
ART I None
) I None
use I None
, I None
the I None
association I None
between I None
alcohol I Chemical
and I None
CD4 I None
+ I None
T I None
- I None
cell I None
did I None
not I None
reach I None
statistical I None
significance I None
. I None
<eof> I None

<s> O None
The I None
association I None
between I None
alcohol I Chemical
consumption I None
and I None
depression I Disease
was I None
significant I None
( I None
p<0.001 I None
) I None
. I None
<eof> I None

<s> O None
Depression I Disease
had I None
a I None
significant I None
negative I None
effect I None
on I None
CD4 I None
+ I None
T I None
- I None
cell I None
counts I None
over I None
time I None
regardless I None
of I None
ART I None
use I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
suggest I None
that I None
alcohol I Chemical
consumption I None
has I None
a I None
direct I None
association I None
with I None
depression I Disease
. I None
<eof> I None

<s> O None
Moreover I None
, I None
depression I Disease
is I None
associated I None
with I None
HIV I Disease
disease O Disease
progression I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
have I None
implications I None
for I None
the I None
provision I None
of I None
alcohol I Chemical
use I None
interventions I None
and I None
psychological I None
resources I None
to I None
improve I None
the I None
health I None
of I None
women I None
with I None
HIV I None
. I None
<eof> I None

<s> O None
Chemokine I None
CCL2 I None
and I None
its I None
receptor I None
CCR2 I None
are I None
increased I None
in I None
the I None
hippocampus I None
following I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
status I Disease
epilepticus O Disease
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Neuroinflammation I Disease
occurs I None
after I None
seizures I Disease
and I None
is I None
implicated I None
in I None
epileptogenesis I None
. I None
<eof> I None

<s> O None
CCR2 I None
is I None
a I None
chemokine I None
receptor I None
for I None
CCL2 I None
and I None
their I None
interaction I None
mediates I None
monocyte I None
infiltration I None
in I None
the I None
neuroinflammatory I Disease
cascade I None
triggered I None
in I None
different I None
brain I None
pathologies I None
. I None
<eof> I None

<s> O None
In I None
this I None
work I None
CCR2 I None
and I None
CCL2 I None
expression I None
were I None
examined I None
following I None
status I Disease
epilepticus O Disease
<eof> I None

<s> O None
( I None
SE I Disease
) I None
induced I None
by I None
pilocarpine I Chemical
injection I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
SE I Disease
was I None
induced I None
by I None
pilocarpine I Chemical
injection I None
. I None
<eof> I None

<s> O None
Control I None
rats I None
were I None
injected I None
with I None
saline I None
instead I None
of I None
pilocarpine I Chemical
. I None
<eof> I None

<s> O None
Five I None
days I None
after I None
SE I Disease
, I None
CCR2 I None
staining I None
in I None
neurons I None
and I None
glial I None
cells I None
was I None
examined I None
using I None
imunohistochemical I None
analyses I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
CCR2 I None
positive I None
cells I None
was I None
determined I None
using I None
stereology I None
probes I None
in I None
the I None
hippocampus I None
. I None
<eof> I None

<s> O None
CCL2 I None
expression I None
in I None
the I None
hippocampus I None
was I None
examined I None
by I None
molecular I None
assay I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Increased I None
CCR2 I None
was I None
observed I None
in I None
the I None
hippocampus I None
after I None
SE I Disease
. I None
<eof> I None

<s> O None
Seizures I Disease
also I None
resulted I None
in I None
alterations I None
to I None
the I None
cell I None
types I None
expressing I None
CCR2 I None
. I None
<eof> I None

<s> O None
Increased I None
numbers I None
of I None
neurons I None
that I None
expressed I None
CCR2 I None
was I None
observed I None
following I None
SE I Disease
. I None
<eof> I None

<s> O None
Microglial I None
cells I None
were I None
more I None
closely I None
apposed I None
to I None
the I None
CCR2-labeled I None
cells I None
in I None
SE I Disease
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
rats I None
that I None
experienced I None
SE I Disease
exhibited I None
CCR2-labeling I None
in I None
populations I None
of I None
hypertrophied I Disease
astrocytes I None
, I None
especially I None
in I None
CA1 I None
and I None
dentate I None
gyrus I None
. I None
<eof> I None

<s> O None
These I None
CCR2 I None
+ I None
astroctytes I None
were I None
not I None
observed I None
in I None
control I None
rats I None
. I None
<eof> I None

<s> O None
Examination I None
of I None
CCL2 I None
expression I None
showed I None
that I None
it I None
was I None
elevated I None
in I None
the I None
hippocampus I None
following I None
SE I Disease
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
The I None
data I None
show I None
that I None
CCR2 I None
and I None
CCL2 I None
are I None
up I None
- I None
regulated I None
in I None
the I None
hippocampus I None
after I None
pilocarpine I Chemical
<eof> I None

<s> O None
-induced I None
SE I Disease
. I None
<eof> I None

<s> O None
Seizures I Disease
also I None
result I None
in I None
changes I None
to I None
CCR2 I None
receptor I None
expression I None
in I None
neurons I None
and I None
astrocytes I None
. I None
<eof> I None

<s> O None
These I None
changes I None
might I None
be I None
involved I None
in I None
detrimental I None
neuroplasticity I None
and I None
neuroinflammatory I Disease
changes I None
that I None
occur I None
following I None
seizures I Disease
. I None
<eof> I None

<s> O None
Metallothionein I Chemical
induction I None
reduces I None
caspase-3 I None
activity I None
and I None
TNFalpha I None
levels I None
with I None
preservation I None
of I None
cognitive I None
function I None
and I None
intact I None
hippocampal I None
neurons I None
in I None
carmustine I Chemical
-treated I None
rats I None
. I None
<eof> I None

<s> O None
Hippocampal I None
integrity I None
is I None
essential I None
for I None
cognitive I None
functions I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
induction I None
of I None
metallothionein I Chemical
<eof> I None

<s> O None
( I None
MT I Chemical
) I None
by I None
<eof> I None

<s> O None
ZnSO(4 I Chemical
) O Chemical
and I None
its I None
role I None
in I None
neuroprotection I None
has I None
been I None
documented I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
aimed I None
to I None
explore I None
the I None
effect I None
of I None
MT I Chemical
induction I None
on I None
carmustine I Chemical
<eof> I None

<s> O None
( I None
BCNU I Chemical
) I None
-induced I None
hippocampal I None
cognitive I Disease
dysfunction O Disease
in I None
rats I None
. I None
<eof> I None

<s> O None
A I None
total I None
of I None
60 I None
male I None
Wistar I None
albino I None
rats I None
were I None
randomly I None
divided I None
into I None
four I None
groups I None
( I None
15/group I None
) I None
: I None
The I None
control I None
group I None
injected I None
with I None
single I None
doses I None
of I None
normal I None
saline I None
( I None
i.c.v I None
) I None
followed I None
24 I None
h I None
later I None
by I None
BCNU I Chemical
solvent I None
( I None
i.v I None
) I None
. I None
<eof> I None

<s> O None
The I None
second I None
group I None
administered I None
<eof> I None

<s> O None
ZnSO(4 I Chemical
) O Chemical
( I None
0.1 I None
micromol/10 I None
microl I None
normal I None
saline I None
, I None
i.c.v I None
, I None
once I None
) I None
then I None
BCNU I Chemical
solvent I None
( I None
i.v I None
) I None
after I None
24 I None
h. I None
Third I None
group I None
received I None
BCNU I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
, I None
i.v I None
, I None
once I None
) I None
24 I None
h I None
after I None
injection I None
with I None
normal I None
saline I None
( I None
i.c.v I None
) I None
. I None
<eof> I None

<s> O None
Fourth I None
group I None
received I None
a I None
single I None
dose I None
of I None
ZnSO(4 I Chemical
) O Chemical
<eof> I None

<s> O None
( I None
0.1 I None
micromol/10 I None
microl I None
<eof> I None

<s> O None
normal I None
saline I None
, I None
i.c.v I None
) I None
then I None
BCNU I Chemical
<eof> I None

<s> O None
( I None
20 I None
mg I None
/ I None
kg I None
, I None
i.v I None
, I None
once I None
) I None
after I None
24 I None
h. I None
<eof> I None

<s> O None
The I None
obtained I None
data I None
revealed I None
that I None
BCNU I Chemical
administration I None
resulted I None
in I None
deterioration I None
of I None
learning I None
and I None
short I None
- I None
term I None
memory I None
( I None
STM I None
) I None
, I None
as I None
measured I None
by I None
using I None
radial I None
arm I None
water I None
maze I None
, I None
accompanied I None
with I None
decreased I None
hippocampal I None
glutathione I Chemical
reductase I None
( I None
GR I None
) I None
activity I None
and I None
reduced I None
glutathione I Chemical
<eof> I None

<s> O None
( I None
GSH I Chemical
) I None
content I None
. I None
<eof> I None

<s> O None
Also I None
, I None
BCNU I Chemical
administration I None
increased I None
serum I None
tumor I Disease
necrosis I Disease
factor I None
- I None
alpha I None
( I None
TNFalpha I None
) I None
, I None
hippocampal I None
MT I Chemical
and I None
malondialdehyde I Chemical
<eof> I None

<s> O None
( I None
MDA I Chemical
) I None
contents I None
as I None
well I None
as I None
caspase-3 I None
activity I None
in I None
addition I None
to I None
histological I None
alterations I None
. I None
<eof> I None

<s> O None
ZnSO(4 I Chemical
) O Chemical
pretreatment I None
counteracted I None
<eof> I None

<s> O None
BCNU I Chemical
-induced I None
inhibition I None
of I None
GR I None
and I None
depletion I None
of I None
GSH I Chemical
and I None
resulted I None
in I None
significant I None
reduction I None
in I None
the I None
levels I None
of I None
MDA I Chemical
and I None
TNFalpha I None
as I None
well I None
as I None
the I None
activity I None
of I None
caspase-3 I None
. I None
<eof> I None

<s> O None
The I None
histological I None
features I None
were I None
improved I None
in I None
hippocampus I None
of I None
rats I None
treated I None
with I None
ZnSO(4 I Chemical
) O Chemical
+ I None
BCNU I Chemical
compared I None
to I None
only I None
BCNU I Chemical
-treated I None
animals I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
MT I Chemical
induction I None
halts I None
BCNU I Chemical
-induced I None
hippocampal I None
toxicity I Disease
as I None
it I None
prevented I None
GR I None
inhibition I None
and I None
GSH I Chemical
depletion I None
and I None
counteracted I None
the I None
increased I None
levels I None
of I None
TNFalpha I None
, I None
MDA I Chemical
and I None
caspase-3 I None
activity I None
with I None
subsequent I None
preservation I None
of I None
cognition I None
. I None
<eof> I None

<s> O None
Fatal I None
carbamazepine I Chemical
induced I None
fulminant I Disease
eosinophilic O Disease
<eof> I None

<s> O None
( I None
hypersensitivity I Disease
) I None
myocarditis I Disease
: I None
emphasis I None
on I None
anatomical I None
and I None
histological I None
characteristics I None
, I None
mechanisms I None
and I None
genetics I None
of I None
drug I Disease
hypersensitivity O Disease
and I None
differential I None
diagnosis I None
. I None
<eof> I None

<s> O None
The I None
most I None
severe I None
adverse I None
reactions I None
to I None
carbamazepine I Chemical
have I None
been I None
observed I None
in I None
the I None
haemopoietic I None
system I None
, I None
the I None
liver I None
and I None
the I None
cardiovascular I None
system I None
. I None
<eof> I None

<s> O None
A I None
frequently I None
fatal I None
, I None
although I None
exceptionally I None
rare I None
side I None
effect I None
of I None
carbamazepine I Chemical
is I None
necrotizing I None
eosinophilic I None
( I None
hypersensitivity I Disease
) I None
myocarditis I Disease
. I None
<eof> I None

<s> O None
We I None
report I None
a I None
case I None
of I None
hypersensitivity I Disease
myocarditis I Disease
secondary I None
to I None
administration I None
of I None
carbamazepine I Chemical
. I None
<eof> I None

<s> O None
Acute I None
hypersensitivity I Disease
myocarditis I Disease
was I None
not I None
suspected I None
clinically I None
, I None
and I None
the I None
diagnosis I None
was I None
made I None
post I None
- I None
mortem I None
. I None
<eof> I None

<s> O None
Histology I None
revealed I None
diffuse I None
infiltration I None
of I None
the I None
myocardium I None
by I None
eosinophils I None
and I None
lymphocytes I None
with I None
myocyte I None
damage I None
. I None
<eof> I None

<s> O None
Clinically I None
, I None
death I None
was I None
due I None
to I None
cardiogenic I Disease
shock O Disease
. I None
<eof> I None

<s> O None
To I None
best I None
of I None
our I None
knowledge I None
this I None
is I None
the I None
second I None
case I None
of I None
fatal I None
carbamazepine I Chemical
induced I None
myocarditis I Disease
reported I None
in I None
English I None
literature I None
. I None
<eof> I None

<s> O None
Neuropsychiatric I None
behaviors I None
in I None
the I None
MPTP I Chemical
<eof> I None

<s> O None
marmoset I None
model I None
of I None
Parkinson I Disease
's O Disease
disease O Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
<eof> I None

<s> O None
Neuropsychiatric I None
symptoms I None
are I None
increasingly I None
recognised I None
as I None
a I None
significant I None
problem I None
in I None
patients I None
with I None
Parkinson I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
PD I Disease
) I None
. I None
<eof> I None

<s> O None
These I None
symptoms I None
may I None
be I None
due I None
to I None
' I None
sensitisation I None
' I None
following I None
repeated I None
levodopa I Chemical
treatment I None
or I None
a I None
direct I None
effect I None
of I None
dopamine I Chemical
on I None
the I None
disease I None
state I None
. I None
<eof> I None

<s> O None
The I None
levodopa I Chemical
-treated I None
MPTP I Chemical
-lesioned I None
marmoset I None
was I None
used I None
as I None
a I None
model I None
of I None
neuropsychiatric I Disease
symptoms O Disease
in I None
PD I Disease
patients I None
. I None
<eof> I None

<s> O None
Here I None
we I None
compare I None
the I None
time I None
course I None
of I None
levodopa I Chemical
-induced I None
motor I None
fluctuations I None
and I None
neuropsychiatric I Disease
- O Disease
like O Disease
behaviors O Disease
to I None
determine I None
the I None
relationship I None
between I None
duration I None
of I None
treatment I None
and I None
onset I None
of I None
symptoms I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
<eof> I None

<s> O None
Marmosets I None
were I None
administered I None
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine I Chemical
<eof> I None

<s> O None
( I None
2.0 I None
mg I None
/ I None
kg I None
s.c I None
. I None
) I None
<eof> I None

<s> O None
for I None
five I None
days I None
, I None
resulting I None
in I None
stable I None
parkinsonism I Disease
. I None
<eof> I None

<s> O None
Levodopa I Chemical
( I None
15 I None
mg I None
/ I None
kg I None
and I None
benserazide I Chemical
, I None
3.75 I None
mg I None
/ I None
kg I None
) I None
p.o I None
. I None
<eof> I None

<s> O None
b.i.d I None
, I None
was I None
administered I None
for I None
30 I None
days I None
. I None
<eof> I None

<s> O None
Animals I None
were I None
evaluated I None
for I None
parkinsonian I Disease
disability O Disease
, I None
dyskinesia I Disease
and I None
on I None
- I None
time I None
( I None
motor I None
fluctuations I None
) I None
and I None
neuropsychiatric I Disease
- O Disease
like O Disease
behaviors O Disease
on I None
Day I None
0 I None
( I None
prior I None
to I None
levodopa I Chemical
) I None
and I None
on I None
Days I None
1 I None
, I None
7 I None
, I None
13 I None
, I None
27 I None
and I None
30 I None
of I None
treatment I None
using I None
post I None
hoc I None
DVD I None
analysis I None
by I None
a I None
trained I None
rater I None
, I None
blind I None
to I None
the I None
treatment I None
day I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
neuropsychiatric I Disease
- O Disease
like O Disease
behavior O Disease
rating I None
scale I None
demonstrated I None
high I None
interrater I None
reliability I None
between I None
three I None
trained I None
raters I None
of I None
differing I None
professional I None
backgrounds I None
. I None
<eof> I None

<s> O None
As I None
anticipated I None
, I None
animals I None
exhibited I None
a I None
progressive I None
increase I None
in I None
levodopa I Chemical
-induced I None
motor I None
fluctuations I None
, I None
<eof> I None

<s> O None
dyskinesia I Disease
and I None
wearing I None
- I None
off I None
, I None
that I None
correlated I None
with I None
the I None
duration I None
of I None
levodopa I Chemical
therapy I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
levodopa I Chemical
-induced I None
<eof> I None

<s> O None
neuropsychiatric I Disease
- O Disease
like O Disease
behaviors O Disease
were I None
present I None
on I None
Day I None
1 I None
of I None
levodopa I Chemical
treatment I None
and I None
their I None
severity I None
did I None
not I None
correlate I None
with I None
duration I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
data I None
suggest I None
that I None
neuropsychiatric I Disease
disorders O Disease
in I None
PD I Disease
are I None
more I None
likely I None
an I None
interaction I None
between I None
levodopa I Chemical
and I None
the I None
disease I None
state I None
than I None
a I None
consequence I None
of I None
sensitisation I None
to I None
repeated I None
dopaminergic I None
therapy I None
. I None
<eof> I None

<s> O None
Contrast I Chemical
medium O Chemical
<eof> I None

<s> O None
nephrotoxicity I Disease
after I None
renal I None
artery I None
and I None
coronary I None
angioplasty I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Renal I Disease
dysfunction O Disease
induced I None
by I None
iodinated I None
contrast I Chemical
medium O Chemical
<eof> I None

<s> O None
( I None
CM I Chemical
) I None
administration I None
can I None
minimize I None
the I None
benefit I None
of I None
the I None
interventional I None
procedure I None
in I None
patients I None
undergoing I None
renal I None
angioplasty I None
( I None
PTRA I None
) I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
<eof> I None

<s> O None
To I None
compare I None
the I None
susceptibility I None
to I None
nephrotoxic I Disease
effect I None
of I None
CM I Chemical
in I None
patients I None
undergoing I None
PTRA I None
with I None
that I None
of I None
patients I None
submitted I None
to I None
percutaneous I None
coronary I None
intervention I None
( I None
PCI I None
) I None
. I None
<eof> I None

<s> O None
MATERIAL I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
A I None
total I None
of I None
33 I None
patients I None
successfully I None
treated I None
with I None
PTRA I None
( I None
PTRA I None
group I None
, I None
mean I None
age I None
70+/-12 I None
years I None
, I None
23 I None
female I None
, I None
basal I None
creatinine I Chemical
<eof> I None

<s> O None
1.46+/-0.79 I None
, I None
range I None
0.7 I None
- I None
4.9 I None
mg I None
/ I None
dl I None
) I None
were I None
compared I None
with I None
33 I None
patients I None
undergoing I None
successful I None
PCI I None
( I None
PCI I None
group I None
) I None
, I None
matched I None
for I None
basal I None
creatinine I Chemical
<eof> I None

<s> O None
( I None
1.44+/-0.6 I None
, I None
range I None
0.7 I None
- I None
3.4 I None
mg I None
/ I None
dl I None
) I None
, I None
gender I None
, I None
and I None
age I None
. I None
<eof> I None

<s> O None
In I None
both I None
groups I None
postprocedural I None
( I None
48 I None
h I None
) I None
serum I None
creatinine I Chemical
was I None
measured I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Postprocedural I None
creatinine I Chemical
level I None
decreased I None
nonsignificantly I None
in I None
the I None
PTRA I None
group I None
( I None
1.46+/-0.8 I None
vs. I None
1.34+/-0.5 I None
mg I None
/ I None
dl I None
, I None
P I None
= I None
NS I None
) I None
and I None
increased I None
significantly I None
in I None
the I None
PCI I None
group I None
( I None
1.44+/-0.6 I None
vs. I None
1.57+/-0.7 I None
mg I None
/ I None
dl I None
, I None
P<0.02 I None
) I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
serum I None
creatinine I Chemical
after I None
intervention I None
( I None
after I None
- I None
before I None
) I None
were I None
significantly I None
different I None
between I None
the I None
PTRA I None
and I None
PCI I None
groups I None
<eof> I None

<s> O None
( I None
-0.12+/-0.5 I None
vs. I None
0.13+/-0.3 I None
, I None
P=0.014 I None
) I None
. I None
<eof> I None

<s> O None
This I None
difference I None
was I None
not I None
related I None
to I None
either I None
a I None
different I None
clinical I None
risk I None
profile I None
or I None
to I None
the I None
volume I None
of I None
CM I Chemical
administered I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
In I None
this I None
preliminary I None
study I None
patients I None
submitted I None
to I None
PTRA I None
showed I None
a I None
lower I None
susceptibility I None
to I None
renal I Disease
damage O Disease
induced I None
by I None
CM I Chemical
administration I None
than I None
PCI I None
patients I None
. I None
<eof> I None

<s> O None
The I None
effectiveness I None
of I None
PTRA I None
on I None
renal I None
function I None
seems I None
to I None
be I None
barely I None
influenced I None
by I None
CM I Chemical
toxicity I Disease
. I None
<eof> I None

<s> O None
Medical I None
and I None
psychiatric I None
outcomes I None
for I None
patients I None
transplanted I None
for I None
acetaminophen I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
acute I Disease
liver O Disease
failure O Disease
: I None
a I None
case I None
- I None
control I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
hepatotoxicity I Disease
is I None
the I None
most I None
common I None
cause I None
of I None
acute I Disease
liver O Disease
failure O Disease
<eof> I None

<s> O None
( I None
ALF I Disease
) I None
in I None
the I None
UK I None
. I None
<eof> I None

<s> O None
Patients I None
often I None
consume I None
the I None
drug I None
with I None
suicidal I None
intent I None
or I None
with I None
a I None
background I None
of I None
substance I None
dependence I None
. I None
<eof> I None

<s> O None
AIMS I None
AND I None
METHODS I None
: I None
<eof> I None

<s> O None
We I None
compared I None
the I None
severity I None
of I None
pretransplant I None
illness I None
, I None
psychiatric I None
co I None
- I None
morbidity I None
, I None
medical I None
and I None
psychosocial I None
outcomes I None
of I None
all I None
patients I None
who I None
had I None
undergone I None
liver I None
transplantation I None
( I None
LT I None
) I None
emergently I None
between I None
1999 I None
- I None
2004 I None
for I None
<eof> I None

<s> O None
acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
ALF I Disease
<eof> I None

<s> O None
( I None
n=36 I None
) I None
with I None
age- I None
and I None
sex I None
- I None
matched I None
patients I None
undergoing I None
emergent I None
LT I None
for I None
non- I None
acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
ALF I Disease
( I None
n=35 I None
) I None
and I None
elective I None
LT I None
for I None
chronic I Disease
liver O Disease
disease O Disease
<eof> I None

<s> O None
( I None
CLD I Disease
, I None
n=34 I None
) I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
ALF I Disease
patients I None
undergoing I None
LT I None
had I None
a I None
greater I None
severity I None
of I None
pre I None
- I None
LT I None
illness I None
reflected I None
by I None
higher I None
Acute I None
Physiology I None
and I None
Chronic I None
Health I None
Evaluation I None
II I None
scores I None
and I None
requirement I None
for I None
organ I None
support I None
compared I None
with I None
the I None
other I None
two I None
groups I None
. I None
<eof> I None

<s> O None
Twenty I None
( I None
56 I None
% I None
) I None
acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
ALF I Disease
patients I None
had I None
a I None
formal I None
psychiatric I None
diagnosis I None
before I None
LT I None
( I None
non- I None
acetaminophen I Chemical
-induced I None
ALF I Disease
= I None
0/35 I None
, I None
CLD I Disease
= I None
2/34 I None
; I None
P<0.01 I None
for I None
all I None
) I None
and I None
nine I None
( I None
25 I None
% I None
) I None
had I None
a I None
previous I None
suicide I None
attempt I None
. I None
<eof> I None

<s> O None
During I None
follow I None
- I None
up I None
( I None
median I None
5 I None
years I None
) I None
, I None
there I None
were I None
no I None
significant I None
differences I None
in I None
rejection I None
( I None
acute I None
and I None
chronic I None
) I None
, I None
graft I None
failure I None
or I None
survival I None
between I None
the I None
groups I None
( I None
acetaminophen I Chemical
-induced I None
ALF I Disease
1 I None
year I None
87 I None
% I None
, I None
5 I None
years I None
75 I None
% I None
; I None
non- I None
acetaminophen I Chemical
-induced I None
ALF I Disease
88 I None
% I None
, I None
78 I None
% I None
; I None
CLD I Disease
93 I None
% I None
, I None
82 I None
% I None
: I None
P>0.6 I None
log I None
rank I None
) I None
. I None
<eof> I None

<s> O None
Two I None
acetaminophen I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
ALF I Disease
patients I None
reattempted I None
suicide I None
post I None
- I None
LT I None
( I None
one I None
died I None
8 I None
years I None
post I None
- I None
LT I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Despite I None
a I None
high I None
prevalence I None
of I None
psychiatric I None
disturbance I None
, I None
outcomes I None
for I None
patients I None
transplanted I None
emergently I None
for I None
acetaminophen I Chemical
-induced I None
<eof> I None

<s> O None
ALF I Disease
were I None
comparable I None
to I None
those I None
transplanted I None
for I None
non- I None
acetaminophen I Chemical
-induced I None
ALF I Disease
and I None
electively I None
for I None
CLD I Disease
. I None
<eof> I None

<s> O None
Multidisciplinary I None
approaches I None
with I None
long I None
- I None
term I None
psychiatric I None
follow I None
- I None
up I None
may I None
contribute I None
to I None
low I None
post I None
- I None
transplant I None
suicide I None
rates I None
seen I None
and I None
low I None
rates I None
of I None
graft I None
loss I None
because I None
of I None
non I None
- I None
compliance I None
. I None
<eof> I None

<s> O None
Studies I None
of I None
synergy I None
between I None
morphine I Chemical
and I None
a I None
novel I None
sodium I Chemical
channel I None
blocker I None
, I None
CNSB002 I Chemical
, I None
in I None
rat I None
models I None
of I None
inflammatory I None
and I None
neuropathic I Disease
pain O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
This I None
study I None
determined I None
the I None
antihyperalgesic I None
effect I None
of I None
CNSB002 I Chemical
, I None
a I None
sodium I Chemical
channel I None
blocker I None
with I None
antioxidant I None
properties I None
given I None
alone I None
and I None
in I None
combinations I None
with I None
morphine I Chemical
in I None
rat I None
models I None
of I None
inflammatory I None
and I None
neuropathic I Disease
pain O Disease
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
<eof> I None

<s> O None
Dose I None
response I None
curves I None
for I None
nonsedating I None
doses I None
of I None
morphine I Chemical
and I None
CNSB002 I Chemical
given I None
intraperitoneally I None
alone I None
and I None
together I None
in I None
combinations I None
were I None
constructed I None
for I None
antihyperalgesic I None
effect I None
using I None
paw I None
withdrawal I None
from I None
noxious I None
heat I None
in I None
two I None
rat I None
pain I Disease
models I None
: I None
carrageenan I Chemical
-induced I None
paw I None
inflammation I Disease
and I None
streptozotocin I Chemical
<eof> I None

<s> O None
( I None
STZ I Chemical
) I None
-induced I None
diabetic I Disease
neuropathy O Disease
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
The I None
maximum I None
nonsedating I None
doses I None
were I None
: I None
morphine I Chemical
, I None
3.2 I None
mg I None
/ I None
kg I None
; I None
CNSB002 I Chemical
10.0 I None
mg I None
/ I None
kg I None
; I None
5.0 I None
mg I None
/ I None
kg I None
CNSB002 I Chemical
with I None
morphine I Chemical
<eof> I None

<s> O None
3.2 I None
mg I None
/ I None
kg I None
in I None
combination I None
. I None
<eof> I None

<s> O None
The I None
doses I None
calculated I None
to I None
cause I None
50 I None
% I None
reversal I None
of I None
hyperalgesia I Disease
<eof> I None

<s> O None
( I None
ED50 I None
) I None
were I None
7.54 I None
( I None
1.81 I None
) I None
and I None
4.83 I None
( I None
1.54 I None
) I None
in I None
the I None
carrageenan I Chemical
model I None
and I None
44.18 I None
<eof> I None

<s> O None
( I None
1.37 I None
) I None
and I None
9.14 I None
( I None
1.24 I None
) I None
in I None
<eof> I None

<s> O None
the I None
STZ I Chemical
-induced I None
<eof> I None

<s> O None
neuropathy I Disease
model I None
for I None
CNSB002 I Chemical
and I None
morphine I Chemical
, I None
respectively I None
( I None
mg I None
/ I None
kg I None
; I None
mean I None
, I None
SEM I None
) I None
. I None
<eof> I None

<s> O None
These I None
values I None
were I None
greater I None
than I None
the I None
maximum I None
nonsedating I None
doses I None
. I None
<eof> I None

<s> O None
The I None
ED50 I None
values I None
for I None
morphine I Chemical
when I None
given I None
in I None
combination I None
with I None
CNSB002 I Chemical
<eof> I None

<s> O None
( I None
5 I None
mg I None
/ I None
kg I None
) I None
were I None
less I None
than I None
the I None
maximum I None
nonsedating I None
dose I None
: I None
0.56 I None
( I None
1.55 I None
) I None
in I None
the I None
carrageenan I Chemical
model I None
and I None
1.37 I None
( I None
1.23 I None
) I None
in I None
the I None
neuropathy I Disease
model I None
( I None
mg I None
/ I None
kg I None
; I None
mean I None
, I None
SEM I None
) I None
. I None
<eof> I None

<s> O None
The I None
antinociception I None
after I None
morphine I Chemical
<eof> I None

<s> O None
( I None
3.2 I None
mg I None
/ I None
kg I None
) I None
was I None
increased I None
by I None
co I None
- I None
administration I None
with I None
CNSB002 I Chemical
from I None
28.0 I None
and I None
31.7 I None
% I None
to I None
114.6 I None
and I None
56.9 I None
% I None
reversal I None
of I None
hyperalgesia I Disease
in I None
the I None
inflammatory I None
and I None
neuropathic I Disease
models I None
, I None
respectively I None
( I None
P I None
< I None
0.01 I None
; I None
<eof> I None

<s> O None
one I None
- I None
way I None
analysis I None
of I None
variance I None
- I None
significantly I None
greater I None
than I None
either I None
drug I None
given I None
alone I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
The I None
maximum I None
antihyperalgesic I None
effect I None
achievable I None
with I None
nonsedating I None
doses I None
of I None
<eof> I None

<s> O None
morphine I Chemical
may I None
be I None
increased I None
significantly I None
when I None
the I None
drug I None
is I None
used I None
in I None
combination I None
with I None
CNSB002 I Chemical
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
thrombocytopenia I Disease
: I None
a I None
practical I None
review I None
. I None
<eof> I None

<s> O None
Heparin I Chemical
-induced I None
<eof> I None

<s> O None
thrombocytopenia I Disease
<eof> I None

<s> O None
( I None
HIT I Disease
) I None
remains I None
under I None
- I None
recognized I None
despite I None
its I None
potentially I None
devastating I None
outcomes I None
. I None
<eof> I None

<s> O None
It I None
begins I None
when I None
heparin I Chemical
exposure I None
stimulates I None
the I None
formation I None
of I None
<eof> I None

<s> O None
heparin I Chemical
-platelet I None
factor I None
4 I None
antibodies I None
, I None
which I None
in I None
turn I None
triggers I None
the I None
release I None
of I None
procoagulant I None
platelet I None
particles I None
. I None
<eof> I None

<s> O None
Thrombosis I Disease
and I None
thrombocytopenia I Disease
<eof> I None

<s> O None
that I None
follow I None
comprise I None
the I None
2 I None
hallmark I None
traits I None
of I None
HIT I Disease
, I None
with I None
the I None
former I None
largely I None
responsible I None
for I None
significant I None
vascular I None
complications I None
. I None
<eof> I None

<s> O None
The I None
prevalence I None
of I None
HIT I Disease
varies I None
among I None
several I None
subgroups I None
, I None
with I None
greater I None
incidence I None
in I None
surgical I None
as I None
compared I None
with I None
medical I None
populations I None
. I None
<eof> I None

<s> O None
HIT I Disease
must I None
be I None
acknowledged I None
for I None
its I None
intense I None
predilection I None
for I None
thrombosis I Disease
and I None
suspected I None
whenever I None
thrombosis I Disease
occurs I None
after I None
heparin I Chemical
exposure I None
. I None
<eof> I None

<s> O None
Early I None
recognition I None
that I None
incorporates I None
the I None
clinical I None
and I None
serologic I None
clues I None
is I None
paramount I None
to I None
timely I None
institution I None
of I None
treatment I None
, I None
as I None
its I None
delay I None
may I None
result I None
in I None
catastrophic I None
outcomes I None
. I None
<eof> I None

<s> O None
The I None
treatment I None
of I None
HIT I Disease
mandates I None
an I None
immediate I None
cessation I None
of I None
all I None
heparin I Chemical
exposure I None
and I None
the I None
institution I None
of I None
an I None
antithrombotic I None
therapy I None
, I None
most I None
commonly I None
using I None
a I None
direct I Chemical
thrombin O Chemical
inhibitor O Chemical
. I None
<eof> I None

<s> O None
Current I None
" I None
diagnostic I None
" I None
tests I None
, I None
which I None
primarily I None
include I None
functional I None
and I None
antigenic I None
assays I None
, I None
have I None
more I None
of I None
a I None
confirmatory I None
than I None
diagnostic I None
role I None
in I None
the I None
management I None
of I None
HIT I Disease
. I None
<eof> I None

<s> O None
Special I None
attention I None
must I None
be I None
paid I None
to I None
cardiac I None
patients I None
who I None
are I None
often I None
exposed I None
to I None
heparin I Chemical
multiple I None
times I None
during I None
their I None
course I None
of I None
treatment I None
. I None
<eof> I None

<s> O None
Direct I Chemical
thrombin O Chemical
inhibitors O Chemical
are I None
appropriate I None
, I None
evidence I None
- I None
based I None
alternatives I None
to I None
heparin I Chemical
in I None
patients I None
with I None
a I None
history I None
of I None
HIT I Disease
, I None
who I None
need I None
to I None
undergo I None
percutaneous I None
coronary I None
intervention I None
. I None
<eof> I None

<s> O None
As I None
heparin I Chemical
remains I None
one I None
of I None
the I None
most I None
frequently I None
used I None
medications I None
today I None
with I None
potential I None
for I None
HIT I Disease
with I None
every I None
heparin I Chemical
exposure I None
, I None
a I None
close I None
vigilance I None
of I None
platelet I None
counts I None
must I None
be I None
practiced I None
whenever I None
heparin I Chemical
is I None
initiated I None
. I None
<eof> I None

<s> O None
Abductor I None
paralysis I Disease
after I None
botox I Chemical
injection I None
for I None
adductor I Disease
spasmodic O Disease
dysphonia O Disease
. I None
<eof> I None

<s> O None
OBJECTIVES I None
/ I None
HYPOTHESIS I None
: I None
<eof> I None

<s> O None
Botulinum I None
toxin I None
( I None
Botox I Chemical
) I None
injections I None
into I None
the I None
thyroarytenoid I None
muscles I None
are I None
the I None
current I None
standard I None
of I None
care I None
for I None
adductor I Disease
spasmodic O Disease
dysphonia O Disease
<eof> I None

<s> O None
( I None
ADSD I Disease
) I None
. I None
<eof> I None

<s> O None
Reported I None
adverse I None
effects I None
include I None
a I None
period I None
of I None
breathiness I None
, I None
throat I Disease
pain O Disease
, I None
and I None
difficulty I None
with I None
swallowing I None
liquids I None
. I None
<eof> I None

<s> O None
Here I None
we I None
report I None
multiple I None
cases I None
of I None
bilateral I None
abductor I None
paralysis I Disease
following I None
Botox I Chemical
injections I None
for I None
ADSD I Disease
, I None
a I None
complication I None
previously I None
unreported I None
. I None
<eof> I None

<s> O None
STUDY I None
DESIGN I None
: I None
<eof> I None

<s> O None
Retrospective I None
case I None
series I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Patients I None
that I None
received I None
Botox I Chemical
injections I None
for I None
spasmodic I Disease
dysphonia O Disease
between I None
January I None
2000 I None
and I None
October I None
2009 I None
were I None
evaluated I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
ADSD I Disease
were I None
identified I None
. I None
<eof> I None

<s> O None
The I None
number I None
of I None
treatments I None
received I None
and I None
adverse I None
effects I None
were I None
noted I None
. I None
<eof> I None

<s> O None
For I None
patients I None
with I None
bilateral I None
abductor I None
paralysis I Disease
, I None
age I None
, I None
sex I None
, I None
paralytic I None
Botox I Chemical
dose I None
, I None
prior I None
Botox I Chemical
dose I None
, I None
and I None
course I None
following I None
paralysis I Disease
were I None
noted I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
From I None
a I None
database I None
of I None
452 I None
patients I None
receiving I None
Botox I Chemical
, I None
352 I None
patients I None
had I None
been I None
diagnosed I None
with I None
ADSD I Disease
. I None
<eof> I None

<s> O None
Of I None
these I None
352 I None
patients I None
, I None
eight I None
patients I None
suffered I None
bilateral I None
abductor I None
paralysis I Disease
, I None
and I None
two I None
suffered I None
this I None
complication I None
twice I None
. I None
<eof> I None

<s> O None
All I None
affected I None
patients I None
were I None
females I None
over I None
the I None
age I None
of I None
50 I None
years I None
. I None
<eof> I None

<s> O None
Most I None
patients I None
had I None
received I None
treatments I None
prior I None
to I None
abductor I None
paralysis I Disease
and I None
continued I None
receiving I None
after I None
paralysis I Disease
. I None
<eof> I None

<s> O None
Seven I None
patients I None
recovered I None
after I None
a I None
brief I None
period I None
of I None
activity I None
restrictions I None
, I None
and I None
one I None
underwent I None
a I None
tracheotomy I None
. I None
<eof> I None

<s> O None
The I None
incidence I None
of I None
abductor I None
paralysis I Disease
after I None
Botox I Chemical
injection I None
for I None
ADSD I Disease
was I None
0.34 I None
% I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
Bilateral I None
abductor I None
<eof> I None

<s> O None
paralysis I Disease
is I None
a I None
rare I None
complication I None
of I None
Botox I Chemical
injections I None
for I None
ADSD I Disease
, I None
causing I None
difficulty I None
with I None
breathing I None
upon I None
exertion I None
. I None
<eof> I None

<s> O None
The I None
likely I None
mechanism I None
of I None
paralysis I Disease
is I None
diffusion I None
of I None
Botox I Chemical
around I None
the I None
muscular I None
process I None
of I None
the I None
arytenoid I None
to I None
the I None
posterior I None
cricoarytenoid I None
muscles I None
. I None
<eof> I None

<s> O None
The I None
paralysis I Disease
is I None
temporary I None
, I None
and I None
watchful I None
waiting I None
with I None
restriction I None
of I None
activity I None
is I None
the I None
recommended I None
management I None
. I None
<eof> I None

<s> O None
Mitochondrial I Disease
impairment O Disease
contributes I None
to I None
cocaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiac I Disease
dysfunction O Disease
: I None
<eof> I None

<s> O None
Prevention I None
by I None
the I None
targeted I None
antioxidant I None
MitoQ I Chemical
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
this I None
study I None
was I None
to I None
assess I None
mitochondrial I None
function I None
and I None
ROS I None
production I None
in I None
an I None
experimental I None
model I None
of I None
cocaine I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
cardiac I Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
We I None
hypothesized I None
that I None
cocaine I Disease
abuse O Disease
may I None
lead I None
to I None
altered I None
mitochondrial I None
function I None
that I None
in I None
turn I None
may I None
cause I None
left I Disease
ventricular O Disease
dysfunction O Disease
. I None
<eof> I None

<s> O None
Seven I None
days I None
of I None
cocaine I Chemical
administration I None
to I None
rats I None
led I None
to I None
an I None
increased I None
oxygen I Chemical
consumption I None
detected I None
in I None
cardiac I None
fibers I None
, I None
specifically I None
through I None
complex I None
I I None
and I None
complex I None
III I None
. I None
<eof> I None

<s> O None
ROS I None
levels I None
were I None
increased I None
, I None
specifically I None
in I None
interfibrillar I None
mitochondria I None
. I None
<eof> I None

<s> O None
In I None
parallel I None
there I None
was I None
a I None
decrease I None
in I None
ATP I Chemical
synthesis I None
, I None
whereas I None
no I None
difference I None
was I None
observed I None
in I None
subsarcolemmal I None
mitochondria I None
. I None
<eof> I None

<s> O None
This I None
uncoupling I None
effect I None
on I None
oxidative I None
phosphorylation I None
was I None
not I None
detectable I None
after I None
short I None
- I None
term I None
exposure I None
to I None
cocaine I Chemical
, I None
suggesting I None
that I None
these I None
mitochondrial I Disease
abnormalities O Disease
were I None
a I None
late I None
rather I None
than I None
a I None
primary I None
event I None
in I None
the I None
pathological I None
response I None
to I None
cocaine I Chemical
. I None
<eof> I None

<s> O None
MitoQ I Chemical
, I None
a I None
mitochondrial I None
- I None
targeted I None
antioxidant I None
, I None
was I None
shown I None
to I None
completely I None
prevent I None
these I None
mitochondrial I Disease
abnormalities O Disease
as I None
well I None
as I None
cardiac I Disease
dysfunction O Disease
characterized I None
here I None
by I None
a I None
diastolic I Disease
dysfunction O Disease
studied I None
with I None
a I None
conductance I None
catheter I None
to I None
obtain I None
pressure I None
- I None
volume I None
data I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
results I None
extend I None
previous I None
studies I None
and I None
demonstrate I None
that I None
cocaine I Chemical
-induced I None
cardiac I Disease
dysfunction O Disease
may I None
be I None
due I None
to I None
a I None
mitochondrial I Disease
defect O Disease
. I None
<eof> I None

<s> O None
Trimethoprim I Chemical
-induced I None
immune I None
hemolytic I Disease
anemia O Disease
in I None
a I None
pediatric I None
oncology I None
patient I None
presenting I None
as I None
an I None
acute I None
hemolytic I None
transfusion I None
reaction I None
. I None
<eof> I None

<s> O None
A I None
10-year I None
- I None
old I None
male I None
with I None
acute I Disease
leukemia O Disease
presented I None
with I None
post I None
- I None
chemotherapy I None
anemia I Disease
. I None
<eof> I None

<s> O None
During I None
red I None
cell I None
transfusion I None
, I None
he I None
developed I None
hemoglobinuria I Disease
. I None
<eof> I None

<s> O None
Transfusion I None
reaction I None
workup I None
was I None
negative I None
. I None
<eof> I None

<s> O None
Drug I None
- I None
induced I None
immune I None
hemolytic I Disease
anemia O Disease
was I None
suspected I None
because I None
of I None
positive I None
direct I None
antiglobulin I None
test I None
, I None
negative I None
eluate I None
, I None
and I None
microspherocytes I None
on I None
smear I None
pre- I None
and I None
post I None
- I None
transfusion I None
. I None
<eof> I None

<s> O None
Drug I None
studies I None
using I None
the I None
indirect I None
antiglobulin I None
test I None
were I None
strongly I None
positive I None
with I None
trimethoprim I Chemical
and I None
trimethoprim I Chemical
- O Chemical
sulfamethoxazole O Chemical
but I None
negative I None
with I None
sulfamethoxazole I Chemical
. I None
<eof> I None

<s> O None
The I None
patient I None
recovered I None
after I None
discontinuing I None
the I None
drug I None
, I None
with I None
no I None
recurrence I None
in I None
2 I None
years I None
. I None
<eof> I None

<s> O None
Other I None
causes I None
of I None
anemia I Disease
should I None
be I None
considered I None
in I None
patients I None
with I None
worse I None
- I None
than I None
- I None
expected I None
anemia I Disease
after I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
hemolysis I Disease
during I None
transfusion I None
is I None
not I None
always I None
a I None
transfusion I None
reaction I None
. I None
<eof> I None

<s> O None
Blockade I None
of I None
endothelial I None
- I None
mesenchymal I None
transition I None
by I None
a I None
Smad3 I None
inhibitor I None
delays I None
the I None
early I None
development I None
of I None
streptozotocin I Chemical
-induced I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
A I None
multicenter I None
, I None
controlled I None
trial I None
showed I None
that I None
early I None
blockade I None
of I None
the I None
renin- I None
angiotensin I Chemical
system I None
in I None
patients I None
with I None
type I Disease
1 O Disease
diabetes O Disease
and I None
normoalbuminuria I None
did I None
not I None
retard I None
the I None
progression I None
of I None
nephropathy I Disease
, I None
suggesting I None
that I None
other I None
mechanism(s I None
) I None
are I None
involved I None
in I None
the I None
pathogenesis I None
of I None
early I None
diabetic I Disease
nephropathy O Disease
<eof> I None

<s> O None
( I None
diabetic I Disease
nephropathy O Disease
) I None
. I None
<eof> I None

<s> O None
We I None
have I None
previously I None
demonstrated I None
that I None
endothelial I None
- I None
mesenchymal I None
- I None
transition I None
( I None
EndoMT I None
) I None
contributes I None
to I None
the I None
early I None
development I None
of I None
renal I None
interstitial I None
fibrosis I Disease
independently I None
of I None
microalbuminuria I None
in I None
mice I None
with I None
streptozotocin I Chemical
<eof> I None

<s> O None
( I None
STZ I Chemical
) I None
-induced I None
diabetes I Disease
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
hypothesized I None
that I None
blocking I None
EndoMT I None
reduces I None
the I None
early I None
development I None
of I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
RESEARCH I None
DESIGN I None
AND I None
METHODS I None
<eof> I None

<s> O None
: I None
EndoMT I None
was I None
induced I None
in I None
a I None
mouse I None
pancreatic I None
microvascular I None
endothelial I None
cell I None
line I None
( I None
MMEC I None
) I None
in I None
the I None
presence I None
of I None
advanced I None
glycation I None
end I None
products I None
( I None
AGEs I None
) I None
and I None
in I None
the I None
endothelial I None
lineage I None
- I None
traceble I None
mouse I None
line I None
Tie2-Cre;Loxp I None
- I None
EGFP I None
by I None
administration I None
of I None
AGEs I None
, I None
with I None
nonglycated I None
mouse I None
albumin I None
serving I None
as I None
a I None
control I None
. I None
<eof> I None

<s> O None
Phosphorylated I None
Smad3 I None
was I None
detected I None
by I None
immunoprecipitation I None
/ I None
Western I None
blotting I None
and I None
confocal I None
microscopy I None
. I None
<eof> I None

<s> O None
Blocking I None
studies I None
using I None
receptor I None
for I None
AGE I None
siRNA I None
and I None
a I None
specific I None
inhibitor I None
of I None
Smad3 I None
( I None
SIS3 I None
) I None
were I None
performed I None
in I None
MMECs I None
and I None
in I None
<eof> I None

<s> O None
STZ I Chemical
-induced I None
<eof> I None

<s> O None
diabetic I Disease
nephropathy O Disease
in I None
Tie2-Cre;Loxp I None
- I None
EGFP I None
mice I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
<eof> I None

<s> O None
Confocal I None
microscopy I None
and I None
real I None
- I None
time I None
PCR I None
demonstrated I None
that I None
AGEs I None
induced I None
EndoMT I None
in I None
MMECs I None
and I None
in I None
Tie2-Cre;Loxp I None
- I None
EGFP I None
mice I None
. I None
<eof> I None

<s> O None
Immunoprecipitation I None
/ I None
Western I None
blotting I None
showed I None
that I None
Smad3 I None
was I None
activated I None
by I None
AGEs I None
but I None
was I None
inhibited I None
by I None
SIS3 I None
in I None
MMECs I None
and I None
in I None
<eof> I None

<s> O None
STZ I Chemical
-induced I None
<eof> I None

<s> O None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
Confocal I None
microscopy I None
and I None
real I None
- I None
time I None
PCR I None
further I None
demonstrated I None
that I None
SIS3 I None
abrogated I None
EndoMT I None
, I None
reduced I None
renal I None
fibrosis I Disease
, I None
and I None
retarded I None
progression I None
of I None
nephropathy I Disease
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
EndoMT I None
is I None
a I None
novel I None
pathway I None
leading I None
to I None
early I None
development I None
of I None
diabetic I Disease
nephropathy O Disease
. I None
<eof> I None

<s> O None
Blockade I None
of I None
EndoMT I None
by I None
SIS3 I None
may I None
provide I None
a I None
new I None
strategy I None
to I None
retard I None
the I None
progression I None
of I None
diabetic I Disease
nephropathy O Disease
and I None
other I None
diabetes I Disease
complications O Disease
. I None
<eof> I None

<s> O None
Cytostatic I None
and I None
anti I None
- I None
angiogenic I None
effects I None
of I None
temsirolimus I Chemical
in I None
refractory I None
mantle I Disease
cell O Disease
lymphoma O Disease
. I None
<eof> I None

<s> O None
Mantle I Disease
cell O Disease
lymphoma O Disease
<eof> I None

<s> O None
( I None
MCL I Disease
) I None
is I None
a I None
rare I None
and I None
aggressive I None
type I None
of I None
B I Disease
- O Disease
cell O Disease
non O Disease
- O Disease
Hodgkin O Disease
's O Disease
lymphoma O Disease
. I None
<eof> I None

<s> O None
Patients I None
become I None
progressively I None
refractory I None
to I None
conventional I None
chemotherapy I None
, I None
and I None
their I None
prognosis I None
is I None
poor I None
. I None
<eof> I None

<s> O None
However I None
, I None
a I None
38 I None
% I None
remission I None
rate I None
has I None
been I None
recently I None
reported I None
in I None
refractory I None
<eof> I None

<s> O None
MCL I Disease
treated I None
with I None
temsirolimus I Chemical
, I None
a I None
mTOR I None
inhibitor I None
. I None
<eof> I None

<s> O None
Here I None
we I None
had I None
the I None
opportunity I None
to I None
study I None
a I None
case I None
of I None
refractory I None
MCL I Disease
who I None
had I None
<eof> I None

<s> O None
tumor I Disease
regression I None
two I None
months I None
after I None
temsirolimus I Chemical
treatment I None
, I None
and I None
a I None
progression I None
- I None
free I None
survival I None
of I None
10 I None
months I None
. I None
<eof> I None

<s> O None
In I None
this I None
case I None
, I None
lymph I None
node I None
biopsies I None
were I None
performed I None
before I None
and I None
six I None
months I None
after I None
temsirolimus I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
two I None
biopsies I None
showed I None
that I None
temsirolimus I Chemical
inhibited I None
tumor I Disease
cell I None
proliferation I None
through I None
cell I None
cycle I None
arrest I None
, I None
but I None
did I None
not I None
induce I None
any I None
change I None
in I None
the I None
number I None
of I None
apoptotic I None
tumor I Disease
cells I None
. I None
<eof> I None

<s> O None
Apart I None
from I None
this I None
cytostatic I None
effect I None
, I None
temsirolimus I Chemical
had I None
an I None
antiangiogenic I None
effect I None
with I None
decrease I None
of I None
tumor I Disease
microvessel I None
density I None
and I None
of I None
VEGF I None
expression I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
numerous I None
patchy I None
, I None
well I None
- I None
limited I None
fibrotic I None
areas I None
, I None
compatible I None
with I None
post- I None
necrotic I Disease
tissue I None
repair I None
, I None
were I None
found I None
after I None
6-month I None
temsirolimus I Chemical
therapy I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
temsirolimus I Chemical
reduced I None
tumor I Disease
burden I None
through I None
associated I None
cytostatic I None
and I None
anti I None
- I None
angiogenic I None
effects I None
. I None
<eof> I None

<s> O None
This I None
dual I None
effect I None
of I None
temsirolimus I Chemical
on I None
tumor I Disease
tissue I None
could I None
contribute I None
to I None
its I None
recently I None
reported I None
efficiency I None
in I None
refractory I None
MCL I Disease
resistant I None
to I None
conventional I None
chemotherapy I None
. I None
<eof> I None

<s> O None
Syncope I Disease
caused I None
by I None
hyperkalemia I Disease
during I None
use I None
of I None
a I None
combined I None
therapy I None
with I None
the I None
angiotensin I Chemical
-converting I None
enzyme I None
inhibitor I None
and I None
spironolactone I Chemical
. I None
<eof> I None

<s> O None
A I None
76 I None
year I None
- I None
old I None
woman I None
with I None
a I None
history I None
of I None
coronary I None
artery I None
bypass I None
grafting I None
and I None
prior I None
myocardial I Disease
infarction O Disease
was I None
transferred I None
to I None
the I None
emergency I None
room I None
with I None
loss I Disease
of O Disease
consciousness O Disease
due I None
to I None
marked I None
bradycardia I Disease
caused I None
by I None
hyperkalemia I Disease
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
serum I None
potassium I Chemical
was I None
high I None
, I None
and I None
normal I None
sinus I None
rhythm I None
was I None
restored I None
after I None
correction I None
of I None
the I None
serum I None
potassium I Chemical
level I None
. I None
<eof> I None

<s> O None
The I None
cause I None
of I None
hyperkalemia I Disease
was I None
considered I None
to I None
be I None
several I None
doses I None
of I None
spiranolactone I Chemical
, I None
an I None
aldosterone I Chemical
antagonist I None
, I None
in I None
addition I None
to I None
the I None
long I None
- I None
term I None
intake I None
of I None
ramipril I Chemical
, I None
an I None
ACE I None
inhibitor I None
. I None
<eof> I None

<s> O None
This I None
case I None
is I None
a I None
good I None
example I None
of I None
electrolyte I None
imbalance I None
causing I None
acute I None
life I None
- I None
threatening I None
cardiac I None
events I None
. I None
<eof> I None

<s> O None
Clinicians I None
should I None
be I None
alert I None
to I None
the I None
possibility I None
of I None
hyperkalemia I Disease
, I None
especially I None
in I None
elderly I None
patients I None
using I None
ACE I None
/ I None
ARB I None
in I None
combination I None
with I None
potassium I Chemical
sparing I None
agents I None
and I None
who I None
have I None
mild I None
renal I Disease
disturbance O Disease
. I None
<eof> I None

<s> O None
Diffuse I None
skeletal I None
pain I Disease
after I None
administration I None
of I None
alendronate I Chemical
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
<eof> I None

<s> O None
Osteoporosis I Disease
is I None
caused I None
by I None
bone I None
resorption I None
in I None
excess I None
of I None
bone I None
formation I None
, I None
and I None
bisphosphonates I Chemical
, I None
are I None
used I None
to I None
inhibit I None
bone I None
resorption I None
. I None
<eof> I None

<s> O None
Alendronate I Chemical
, I None
a I None
biphosphonate I Chemical
, I None
is I None
effective I None
for I None
both I None
the I None
treatment I None
and I None
prevention I None
of I None
osteoporosis I Disease
in I None
postmenopausal I None
women I None
. I None
<eof> I None

<s> O None
Side I None
effects I None
are I None
relatively I None
few I None
and I None
prominently I None
gastrointestinal I None
. I None
<eof> I None

<s> O None
Musculoskeletal I Disease
pain O Disease
may I None
be I None
an I None
important I None
side I None
effect I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
We I None
presented I None
a I None
patient I None
admitted I None
to I None
our I None
out I None
- I None
patient I None
clinic I None
with I None
diffuse I None
skeletal I None
pain I Disease
after I None
three I None
consecutive I None
administration I None
of I None
alendronate I Chemical
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
patients I None
with I None
osteoporosis I Disease
can I None
report I None
pain I Disease
, I None
and I None
bisphosphonate I Chemical
-related I None
<eof> I None

<s> O None
pain I Disease
should I None
also I None
be I None
considered I None
before I None
ascribing I None
this I None
complaint I None
to I None
osteoporosis I Disease
. I None
<eof> I None

<s> O None
Cerebrospinal I None
fluid I None
penetration I None
of I None
high I None
- I None
dose I None
daptomycin I Chemical
in I None
suspected I None
Staphylococcus I None
aureus I None
meningitis I Disease
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
<eof> I None

<s> O None
To I None
report I None
a I None
case I None
of I None
methicillin I Chemical
-sensitive I None
Staphylococcus I None
aureus I None
( I None
MSSA I None
) I None
<eof> I None

<s> O None
bacteremia I Disease
with I None
suspected I None
MSSA I None
meningitis I Disease
treated I None
with I None
high I None
- I None
dose I None
daptomycin I Chemical
assessed I None
with I None
concurrent I None
serum I None
and I None
cerebrospinal I None
fluid I None
( I None
CSF I None
) I None
concentrations I None
. I None
<eof> I None

<s> O None
CASE I None
SUMMARY I None
: I None
<eof> I None

<s> O None
A I None
54-year I None
- I None
old I None
male I None
presented I None
to I None
the I None
emergency I None
department I None
with I None
generalized I None
weakness I Disease
and I None
presumed I None
health I None
- I None
care I None
- I None
associated I None
pneumonia I Disease
shown I None
on I None
chest I None
radiograph I None
. I None
<eof> I None

<s> O None
Treatment I None
was I None
empirically I None
initiated I None
with I None
vancomycin I Chemical
, I None
levofloxacin I Chemical
, I None
and I None
piperacillin I Chemical
/ I None
tazobactam I Chemical
. I None
<eof> I None

<s> O None
Blood I None
cultures I None
revealed I None
S. I None
aureus I None
susceptible I None
to I None
oxacillin I Chemical
. I None
<eof> I None

<s> O None
Empiric I None
antibiotic I None
treatment I None
was I None
narrowed I None
to I None
nafcillin I Chemical
on I None
day I None
4 I None
. I None
<eof> I None

<s> O None
On I None
day I None
8 I None
, I None
the I None
patient I None
developed I None
acute I Disease
renal O Disease
failure O Disease
<eof> I None

<s> O None
( I None
serum I None
<eof> I None

<s> O None
creatinine I Chemical
1.9 I None
mg I None
/ I None
dL I None
, I None
increased I None
from I None
1.2 I None
mg I None
/ I None
dL I None
the I None
previous I None
day I None
and I None
0.8 I None
mg I None
/ I None
dL I None
on I None
admission I None
) I None
. I None
<eof> I None

<s> O None
The I None
patient I None
's I None
Glasgow I None
Coma I None
Score I None
was I None
3 I None
, I None
with I None
normal I None
findings I None
shown I None
on I None
computed I None
tomography I None
scan I None
of I None
the I None
head I None
72 I None
hours I None
following I None
an I None
episode I None
of I None
cardiac I Disease
arrest O Disease
on I None
day I None
10 I None
. I None
<eof> I None

<s> O None
The I None
patient I None
experienced I None
relapsing I None
MSSA I None
bacteremia I Disease
on I None
day I None
9 I None
, I None
increasing I None
the I None
suspicion I None
for I None
a I None
central I None
nervous I None
system I None
( I None
CNS I None
) I None
infection I Disease
. I None
<eof> I None

<s> O None
Nafcillin I Chemical
was I None
discontinued I None
and I None
daptomycin I Chemical
9 I None
mg I None
/ I None
kg I None
daily I None
was I None
initiated I None
for I None
suspected I None
meningitis I Disease
and I None
was I None
continued I None
until I None
the I None
patient I None
's I None
death I None
on I None
day I None
16 I None
. I None
<eof> I None

<s> O None
Daptomycin I Chemical
serum I None
and I None
CSF I None
trough I None
concentrations I None
were I None
11.21 I None
ug I None
/ I None
mL I None
and I None
0.52 I None
ug I None
/ I None
mL I None
, I None
respectively I None
, I None
prior I None
to I None
the I None
third I None
dose I None
. I None
<eof> I None

<s> O None
Lumbar I None
puncture I None
results I None
were I None
inconclusive I None
and I None
no I None
further I None
blood I None
cultures I None
were I None
positive I None
for I None
MSSA I None
. I None
<eof> I None

<s> O None
Creatine I Chemical
kinase I None
levels I None
were I None
normal I None
prior I None
to I None
daptomycin I Chemical
therapy I None
and I None
were I None
not I None
reassessed I None
. I None
<eof> I None

<s> O None
DISCUSSION I None
: I None
<eof> I None

<s> O None
Daptomycin I Chemical
was I None
initiated I None
in I None
our I None
patient I None
secondary I None
to I None
possible I None
<eof> I None

<s> O None
nafcillin I Chemical
-induced I None
acute I None
interstitial I Disease
nephritis O Disease
and I None
relapsing I None
bacteremia I Disease
. I None
<eof> I None

<s> O None
At I None
a I None
dose I None
of I None
9 I None
mg I None
/ I None
kg I None
, I None
resultant I None
penetration I None
of I None
5 I None
% I None
was I None
higher I None
than I None
in I None
previous I None
reports I None
, I None
more I None
consistent I None
with I None
inflamed I None
meninges I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
<eof> I None

<s> O None
High I None
- I None
dose I None
<eof> I None

<s> O None
daptomycin I Chemical
may I None
be I None
an I None
alternative I None
option I None
for I None
MSSA I None
bacteremia I Disease
with I None
or I None
without I None
a I None
CNS I None
source I None
in I None
patients I None
who I None
have I None
failed I None
or I None
can I None
not I None
tolerate I None
standard I None
therapy I None
. I None
<eof> I None

<s> O None
Further I None
clinical I None
evaluation I None
in I None
patients I None
with I None
confirmed I None
<eof> I None

<s> O None
meningitis I Disease
is I None
warranted I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
nitric I Chemical
oxide O Chemical
in I None
convulsions I Disease
induced I None
by I None
lindane I Chemical
in I None
rats I None
. I None
<eof> I None

<s> O None
Lindane I Chemical
is I None
an I None
organochloride I None
pesticide I None
and I None
scabicide I None
. I None
<eof> I None

<s> O None
It I None
evokes I None
<eof> I None

<s> O None
convulsions I Disease
mainly I None
trough I None
the I None
blockage I None
of I None
GABA I Chemical
( I None
A I None
) I None
receptors I None
. I None
<eof> I None

<s> O None
Nitric I Chemical
oxide O Chemical
<eof> I None

<s> O None
( I None
NO I Chemical
) I None
, I None
gaseous I None
neurotransmitter I None
, I None
has I None
contradictor I None
role I None
in I None
epileptogenesis I None
due I None
to I None
opposite I None
effects I None
of I None
L I Chemical
- O Chemical
arginine O Chemical
, I None
precursor I None
of I None
NO I Chemical
syntheses I None
( I None
NOS I None
) I None
, I None
and I None
L I Chemical
- O Chemical
NAME O Chemical
( I None
NOS I None
inhibitor I None
) I None
observed I None
in I None
different I None
epilepsy I Disease
models I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
current I None
study I None
was I None
to I None
determine I None
the I None
effects I None
of I None
NO I Chemical
on I None
the I None
behavioral I None
and I None
EEG I None
characteristics I None
of I None
lindane I Chemical
-induced I None
epilepsy I Disease
in I None
male I None
Wistar I None
albino I None
rats I None
. I None
<eof> I None

<s> O None
The I None
administration I None
of I None
L I Chemical
- O Chemical
arginine O Chemical
<eof> I None

<s> O None
( I None
600 I None
, I None
800 I None
and I None
1000 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
<eof> I None

<s> O None
in I None
dose I None
- I None
dependent I None
manner I None
significantly I None
increased I None
convulsion I Disease
incidence I None
and I None
severity I None
and I None
shortened I None
latency I None
time I None
to I None
first I None
<eof> I None

<s> O None
convulsion I Disease
elicited I None
by I None
lower I None
lindane I Chemical
dose I None
( I None
4 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
On I None
the I None
contrary I None
, I None
pretreatment I None
with I None
L I Chemical
- O Chemical
NAME O Chemical
<eof> I None

<s> O None
( I None
500 I None
, I None
700 I None
and I None
900 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
decreased I None
convulsion I Disease
<eof> I None

<s> O None
incidence I None
and I None
severity I None
and I None
prolonged I None
latency I None
time I None
to I None
convulsion I Disease
following I None
injection I None
with I None
a I None
convulsive I Disease
dose I None
of I None
lindane I Chemical
<eof> I None

<s> O None
( I None
8 I None
mg I None
/ I None
kg I None
, I None
i.p I None
. I None
) I None
. I None
<eof> I None

<s> O None
EEG I None
analyses I None
showed I None
increase I None
of I None
number I None
and I None
duration I None
of I None
ictal I None
periods I None
in I None
EEG I None
of I None
rats I None
receiving I None
l I Chemical
- O Chemical
arginine O Chemical
prior I None
to I None
lindane I Chemical
and I None
decrease I None
of I None
this I None
number I None
in I None
rats I None
pretreated I None
with I None
L I Chemical
- O Chemical
NAME O Chemical
. I None
<eof> I None

<s> O None
These I None
results I None
support I None
the I None
conclusion I None
that I None
NO I Chemical
plays I None
a I None
role I None
of I None
endogenous I None
convulsant I None
in I None
rat I None
model I None
of I None
lindane I Chemical
seizures I Disease
. I None
<eof> I None

<s> O None
Long I None
- I None
term I None
oral I None
galactose I Chemical
<eof> I None

<s> O None
treatment I None
prevents I None
<eof> I None

<s> O None
cognitive I Disease
deficits O Disease
in I None
male I None
Wistar I None
rats I None
treated I None
intracerebroventricularly I None
with I None
streptozotocin I Chemical
. I None
<eof> I None

<s> O None
Basic I None
and I None
clinical I None
research I None
has I None
demonstrated I None
that I None
dementia I Disease
of I None
sporadic I None
Alzheimer I Disease
's O Disease
disease O Disease
<eof> I None

<s> O None
( I None
sAD I None
) I None
type I None
is I None
associated I None
with I None
dysfunction I None
of I None
the I None
insulin I None
- I None
receptor I None
( I None
IR I None
) I None
system I None
followed I None
by I None
decreased I None
glucose I Chemical
transport I None
via I None
glucose I Chemical
<eof> I None

<s> O None
transporter I None
GLUT4 I None
and I None
decreased I None
glucose I Chemical
metabolism I None
in I None
brain I None
cells I None
. I None
<eof> I None

<s> O None
An I None
alternative I None
source I None
of I None
energy I None
is I None
d I Chemical
- O Chemical
galactose O Chemical
<eof> I None

<s> O None
( I None
the I None
C-4-epimer I None
of I None
d I Chemical
- O Chemical
glucose O Chemical
) I None
which I None
is I None
transported I None
into I None
the I None
brain I None
by I None
insulin I None
- I None
independent I None
GLUT3 I None
transporter I None
where I None
it I None
might I None
be I None
metabolized I None
to I None
glucose I Chemical
via I None
the I None
Leloir I None
pathway I None
. I None
<eof> I None

<s> O None
Exclusively I None
parenteral I None
daily I None
injections I None
of I None
galactose I Chemical
induce I None
memory I Disease
deterioration O Disease
in I None
rodents I None
and I None
are I None
used I None
to I None
generate I None
animal I None
aging I None
model I None
, I None
but I None
the I None
effects I None
of I None
oral I None
galactose I Chemical
treatment I None
on I None
cognitive I None
functions I None
have I None
never I None
been I None
tested I None
. I None
<eof> I None

<s> O None
We I None
have I None
investigated I None
the I None
effects I None
of I None
continuous I None
daily I None
oral I None
galactose I Chemical
<eof> I None

<s> O None
( I None
200 I None
mg I None
/ I None
kg I None
/ I None
day I None
) I None
treatment I None
on I None
cognitive I Disease
deficits O Disease
in I None
streptozotocin I Chemical
<eof> I None

<s> O None
-induced I None
<eof> I None

<s> O None
( I None
STZ I Chemical
-icv I None
) I None
rat I None
model I None
of I None
sAD I None
, I None
tested I None
by I None
Morris I None
Water I None
Maze I None
and I None
Passive I None
Avoidance I None
test I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
One I None
month I None
of I None
oral I None
galactose I Chemical
treatment I None
initiated I None
immediately I None
after I None
the I None
STZ I Chemical
-icv I None
administration I None
, I None
successfully I None
prevented I None
development I None
of I None
the I None
STZ I Chemical
-icv I None
- I None
induced I None
cognitive I Disease
deficits O Disease
. I None
<eof> I None

<s> O None
Beneficial I None
effect I None
of I None
oral I None
galactose I Chemical
was I None
independent I None
of I None
the I None
rat I None
age I None
and I None
of I None
the I None
galactose I Chemical
dose I None
ranging I None
from I None
100 I None
to I None
300 I None
mg I None
/ I None
kg I None
/ I None
day I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
oral I None
galactose I Chemical
administration I None
led I None
to I None
the I None
appearance I None
of I None
galactose I Chemical
in I None
the I None
blood I None
. I None
<eof> I None

<s> O None
The I None
increase I None
of I None
galactose I Chemical
concentration I None
in I None
the I None
cerebrospinal I None
fluid I None
was I None
several I None
times I None
lower I None
after I None
oral I None
than I None
after I None
parenteral I None
administration I None
of I None
the I None
same I None
galactose I Chemical
dose I None
. I None
<eof> I None

<s> O None
Oral I None
galactose I Chemical
exposure I None
might I None
have I None
beneficial I None
effects I None
on I None
learning I None
and I None
memory I None
ability I None
and I None
could I None
be I None
worth I None
investigating I None
for I None
improvement I None
of I None
cognitive I Disease
deficits O Disease
associated I None
with I None
glucose I Disease
hypometabolism O Disease
in I None
AD I Disease
. I None
<eof> I None

